<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004415.pub2" GROUP_ID="SKIN" ID="713102100409244764" MERGED_FROM="" MODIFIED="2016-06-08 12:39:38 +0100" MODIFIED_BY="Helen Scott" REVIEW_NO="#34" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2016-06-08 12:39:29 +0100" MODIFIED_BY="Helen Scott">
<TITLE>Interventions for actinic keratoses</TITLE>
<CONTACT MODIFIED="2016-06-08 12:39:29 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="16358" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aditya</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Gupta</LAST_NAME><EMAIL_1>agupta@execulink.com</EMAIL_1><ADDRESS><ORGANISATION>Mediprobe Research Inc.</ORGANISATION><ADDRESS_1>645 Windermere Road</ADDRESS_1><CITY>London</CITY><ZIP>N5X 2P1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519-657-4222 ext. 277</PHONE_1><PHONE_2>519-851-9715</PHONE_2><FAX_1>519-657-4233</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-06-08 12:39:29 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="16358" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aditya</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Gupta</LAST_NAME><EMAIL_1>agupta@execulink.com</EMAIL_1><ADDRESS><ORGANISATION>Mediprobe Research Inc.</ORGANISATION><ADDRESS_1>645 Windermere Road</ADDRESS_1><CITY>London</CITY><ZIP>N5X 2P1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519-657-4222 ext. 277</PHONE_1><PHONE_2>519-851-9715</PHONE_2><FAX_1>519-657-4233</FAX_1></ADDRESS></PERSON><PERSON ID="47805678948582174452110324113102" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maryse</FIRST_NAME><LAST_NAME>Paquet</LAST_NAME><POSITION>Medical Writer</POSITION><ADDRESS><ORGANISATION>Mediprobe Research Inc.</ORGANISATION><ADDRESS_1>645 Windermere Road</ADDRESS_1><CITY>London</CITY><ZIP>N5X 2P1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>(519)657-4222</PHONE_1><FAX_1>(519)657-4233</FAX_1></ADDRESS></PERSON><PERSON ID="5057" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elmer</FIRST_NAME><LAST_NAME>Villanueva</LAST_NAME><SUFFIX>MD ScM FRIPH</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>Elmer.Villanueva@xjtlu.edu.cn</EMAIL_1><EMAIL_2>Elmer.Villanueva@xjtlu.edu.cn</EMAIL_2><ADDRESS><DEPARTMENT>Department of Public Health</DEPARTMENT><ORGANISATION>Xi'an Jiaotong-Liverpool University</ORGANISATION><ADDRESS_1>111 Ren'ai Road, Dushu Lake Higher Education Town</ADDRESS_1><ADDRESS_2>Suzhou Industrial Park</ADDRESS_2><CITY>Suzhou</CITY><REGION>Jiangsu</REGION><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="95179493249384946695100812183950" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>William</FIRST_NAME><LAST_NAME>Brintnell</LAST_NAME><POSITION>Senior Clinical Research Scientist</POSITION><ADDRESS><ORGANISATION>Mediprobe Research Inc.</ORGANISATION><ADDRESS_1>645 Windermere Road</ADDRESS_1><CITY>London</CITY><ZIP>N5X 2P1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>519-657-4222 x 293</PHONE_1><FAX_1>519-657-4233</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-06-08 12:24:25 +0100" MODIFIED_BY="Helen Scott">
<UP_TO_DATE>
<DATE DAY="23" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="3" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="3" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="12" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2016-06-08 12:31:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-08 12:31:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>This review is going to be updated. We have written a published note to say that because the scope of the review has been reduced to make it more manageable a new protocol and then a new review will be written.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-11-09 00:51:17 +0000" MODIFIED_BY="Finola M Delamere">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-09 00:51:17 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Change in authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-14 14:29:30 +0100" MODIFIED_BY="Finola M Delamere">
<DATE DAY="11" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="9" MONTH="1" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-06-08 12:32:08 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-11-09 09:22:57 +0000" MODIFIED_BY="Maryse Paquet">
<TITLE MODIFIED="2011-11-09 15:47:58 +0000" MODIFIED_BY="[Empty name]">Interventions for actinic keratoses</TITLE>
<SUMMARY_BODY MODIFIED="2012-11-09 09:22:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>Actinic keratoses are a skin disease caused by long-term sun exposure. Damaged skin shows small, red, rough, scaly, flat spots called actinic keratoses or lesions, which feel like patches of dry skin. Symptoms such as bleeding and pain can be associated with actinic keratoses. Moreover, actinic keratoses have the potential to develop into skin cancer if left untreated. The reasons for treatment may include cosmetic appearance, relief of symptoms, or prevention of skin cancer. Treatment can be directed either at individual lesions or to larger areas of the skin where several visible and less visible lesions occur (field-directed treatment).</P>
<P>This systematic review included results from 83 randomised controlled clinical trials evaluating 24 treatments, with a total of 10,036 participants diagnosed with actinic keratosis. We included 18 topical creams or gels applied to a skin area by the participants: adapalene gel, aretinoid methyl sulfone (Ro 14-9706), betulin-based oleogel, calcipotriol (vitamin D), colchicine, diclofenac, 2-(difluoromethyl)-dl-ornithine (DFMO), 5-fluorouracil, ß-1,3-D-glucan, imiquimod, ingenol mebutate (PEP005), isotretinoin, masoprocol, nicotinamide, resiquimod, sunscreen, DL-&#945;-tocopherol (vitamin E), and tretinoin. One treatment, etretinate, was taken orally. Clinical staff administered two mechanical treatments (carbon dioxide and Er:YAG laser resurfacing) on a skin area, and they administered three chemical treatments: cryotherapy on individual lesions, photodynamic therapy on individual lesions or a skin area, and trichloroacetic acid peel on a skin area.</P>
<P>The clinical effects resulting from the treatment of actinic keratoses were reported differently from one study to another. In spite of this inconsistency, it can be concluded that several good treatment options exist for the treatment of actinic keratoses. Actinic keratoses were successfully treated with cryotherapy, diclofenac, 5-fluorouracil, imiquimod, ingenol mebutate, photodynamic therapy, resurfacing, and trichloroacetic acid peel. These different treatments were generally comparably effective. Skin irritation was associated with some of these treatments, such as diclofenac and 5-fluorouracil, but other side-effects were uncommon. The final cosmetic appearance varies from one treatment to another. Imiquimod treatment and photodynamic therapy resulted in better cosmetic appearance than treatment with cryotherapy and 5-fluorouracil.</P>
<P>Treatment with photodynamic therapy gives better therapeutic and cosmetic results than cryotherapy for individual lesions. For field-directed treatments, diclofenac, 5-fluorouracil, imiquimod, and ingenol mebutate are good options associated with different side-effects and cosmetic results. Thus, the choice of treatment option for actinic keratosis depends on the number of lesions, the individual's desired results, and tolerance to the treatments.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-09 01:04:14 +0000" MODIFIED_BY="Maryse Paquet">
<ABS_BACKGROUND MODIFIED="2012-10-31 10:02:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>Actinic keratoses are a skin disease caused by long-term sun exposure, and their lesions have the potential to develop into squamous cell carcinoma. Treatments for actinic keratoses are sought for cosmetic reasons, for the relief of associated symptoms, or for the prevention of skin cancer development. Detectable lesions are often associated with alteration of the surrounding skin (field) where subclinical lesions might be present. The interventions available for the treatment of actinic keratoses include individual lesion-based (e.g. cryotherapy) or field-directed (e.g. topical) treatments. These might vary in terms of efficacy, safety, and cosmetic outcomes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-04-03 15:02:13 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of topical, oral, mechanical, and chemical interventions for actinic keratosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-31 10:03:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>We searched the following databases up to March 2011: the Cochrane Skin Group Specialised Register, CENTRAL in <I>The Cochrane Library</I>, MEDLINE (from 2005), EMBASE (from 2010), and LILACS (from 1982). We also searched trials registers, conference proceedings, and grey literature sources.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-10-31 10:03:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>Randomised controlled trials (RCTs) comparing the treatment of actinic keratoses with either placebo, vehicle, or another active therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-10-31 10:04:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>At least two authors independently abstracted data, which included adverse events, and assessed the quality of evidence. We performed meta-analysis to calculate a weighted treatment effect across trials, and we expressed the results as risk ratios (RR) and 95% confidence intervals (CI) for dichotomous outcomes (e.g. participant complete clearance rates), and mean difference (MD) and 95% CI for continuous outcomes (e.g. mean reduction in lesion counts).<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-11-09 01:04:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>We included 83 RCTs in this review, with a total of 10,036 participants. The RCTs covered 18 topical treatments, 1 oral treatment, 2 mechanical interventions, and 3 chemical interventions, including photodynamic therapy (PDT). Most of the studies lacked descriptions of some methodological details, such as the generation of the randomisation sequence or allocation concealment, and half of the studies had a high risk of reporting bias. Study comparison was difficult because of the multiple parameters used to report efficacy and safety outcomes, as well as statistical limitations. We found no data on the possible reduction of squamous cell carcinoma.</P>
<P>The primary outcome 'participant complete clearance' significantly favoured four field-directed treatments compared to vehicle or placebo: 3% diclofenac in 2.5% hyaluronic acid (RR 2.46, 95% CI 1.66 to 3.66; 3 studies with 420 participants), 0.5% 5-fluorouracil (RR 8.86, 95% CI: 3.67 to 21.44; 3 studies with 522 participants), 5% imiquimod (RR 7.70, 95% CI 4.63 to 12.79; 9 studies with1871 participants), and 0.025% to 0.05% ingenol mebutate (RR 4.50, 95% CI 2.61 to 7.74; 2 studies with 456 participants).</P>
<P>It also significantly favoured the treatment of individual lesions with photodynamic therapy (PDT) compared to placebo-PDT with the following photosensitisers: aminolevulinic acid (ALA) (blue light: RR 6.22, 95% CI 2.88 to 13.43; 1 study with 243 participants, aminolevulinic acid (ALA) (red light: RR 5.94, 95% CI 3.35 to 10.54; 3 studies with 422 participants), and methyl aminolevulinate (MAL) (red light: RR 4.46, 95% CI 3.17 to 6.28; 5 studies with 482 participants). ALA-PDT was also significantly favoured compared to cryotherapy (RR 1.31, 95% CI 1.05 to 1.64).</P>
<P>The corresponding comparative risks in terms of number of participants completely cleared per 1000 were as follows: 313 with 3% diclofenac compared to 127 with 2.5% hyaluronic acid; 136 with 0.5% 5-fluorouracil compared to 15 with placebo; 371 with 5% imiquimod compared to 48 with placebo; 331 with ingenol mebutate compared to 73 with vehicle; 527 to 656 with ALA/MAL-PDT treatment compared to 89 to 147 for placebo-PDT; and 580 with ALA-PDT compared to 443 with cryotherapy.</P>
<P>5% 5-fluorouracil efficacy was not compared to placebo, but it was comparable to 5% imiquimod (RR 1.85, 95% Cl 0.41 to 8.33).</P>
<P>A significant number of participants withdrew because of adverse events with 144 participants affected out of 1000 taking 3% diclofenac in 2.5% hyaluronic acid, compared to 40 participants affected out of 1000 taking 2.5% hyaluronic acid alone, and 56 participants affected out of 1000 taking 5% imiquimod compared to 21 participants affected out of 1000 taking placebo.</P>
<P>Based on investigator and participant evaluation, imiquimod treatment and photodynamic therapy resulted in better cosmetic outcomes than cryotherapy and 5-fluorouracil. <I>
<BR/>
</I>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-11 14:14:10 +0100" MODIFIED_BY="Maryse Paquet">
<P>For individual lesions, photodynamic therapy appears more effective and has a better cosmetic outcome than cryotherapy. For field-directed treatments, diclofenac, 5-fluorouracil, imiquimod, and ingenol mebutate had similar efficacy, but their associated adverse events and cosmetic outcomes are different. More direct comparisons between these treatments are needed to determine the best therapeutic approach.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-13 10:30:38 +0000" MODIFIED_BY="Maryse Paquet">
<BACKGROUND MODIFIED="2012-11-09 12:05:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2012-11-09 12:05:30 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="3">Disease definition</HEADING>
<P>Actinic keratoses are scaly lesions on the skin resulting from abnormal growth of atypical epidermal keratinocytes. They are localised at the surface of the skin on the sun-exposed parts of the face or hands, particularly among older fair-skinned individuals. Actinic keratoses are markers for increased rate of non-melanoma skin cancer (<LINK REF="REF-Ramsay-2003" TYPE="REFERENCE">Ramsay 2003</LINK>) and shows the morphological and histological features of squamous cell carcinoma (<LINK REF="REF-Cockerell-2000" TYPE="REFERENCE">Cockerell 2000</LINK>; <LINK REF="REF-Feldman-2011" TYPE="REFERENCE">Feldman 2011</LINK>). An actinic keratosis could be considered a precancerous lesion or carcinoma in situ based on the fact that the majority of invasive squamous cell carcinomas arise from actinic keratoses. Actinic keratoses are confined to the epidermis, whereas squamous cell carcinoma extends more deeply into the dermis. Thus, to limit the morbidity and mortality associated with squamous cell carcinoma, treatment of actinic keratoses is strongly recommended.</P>
<P>Actinic keratosis is also known as solar keratosis, senile keratosis, senile hyperkeratosis, keratoma senile, keratosis senilis, and actinic cheilitis (actinic keratosis on the lip) (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>; <LINK REF="REF-Rigel--2008" TYPE="REFERENCE">Rigel 2008</LINK>; <LINK REF="REF-Schwartz-1997" TYPE="REFERENCE">Schwartz 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical Features</HEADING>
<P>The conventional clinical actinic keratosis lesion is a pink, red, or brown scaly patch on the skin, less than one centimetre in diameter (<LINK REF="REF-Roewert_x002d_Huber-2007" TYPE="REFERENCE">Roewert-Huber 2007</LINK>). Often, the scaliness of a lesion can be felt before it can be seen; this may progress into thickened or hypertrophic (increased bulk, due to an increase in lesion size) lesions. Actinic keratoses can be clinically graded with grade 1, slightly palpable; grade 2, moderately thick and visible; and grade 3, very thick and hyperkeratotic (<LINK REF="REF-Cockerell-2000" TYPE="REFERENCE">Cockerell 2000</LINK>; <LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>). Accurate clinical diagnosis requires careful observation under adequate lighting conditions and palpation of the lesion texture (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>). Actinic keratoses are diagnosed histologically with a skin biopsy (<LINK REF="REF-Cockerell-2000" TYPE="REFERENCE">Cockerell 2000</LINK>; <LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>). Detectable actinic keratosis lesions are often associated with field change where the surrounding skin is also altered, and subclinical lesions may be present (<LINK REF="REF-Vatve-2007" TYPE="REFERENCE">Vatve 2007</LINK>).</P>
<P>There are different classifications based on the clinical appearance of actinic keratoses: atrophic, hyperkeratotic, bowenoid, acantholytic, lichenoid, and pigmented (<LINK REF="REF-Rigel--2008" TYPE="REFERENCE">Rigel 2008</LINK>; <LINK REF="REF-Roewert_x002d_Huber-2007" TYPE="REFERENCE">Roewert-Huber 2007</LINK>). Atrophic actinic keratoses are dry, scaly-appearing lesions on a reddened base (due to dilated blood capillaries) without distinct margins. Hyperkeratotic actinic keratoses are papules and plaques with scale or scale-crust that also possibly have cutaneous horns or conical masses. Bowenoid actinic keratoses are scaling red plaques with sharply-established borders that simulate Bowen's Disease (a solitary red plaque with distinct borders) in that the abnormal cells are found throughout the depth of the epidermis. Acantholytic actinic keratoses have focal acantholysis (separation from other cells) occasionally accompanied by clefts. Lichenoid actinic keratoses show dense band-like infiltration of lymphocytes in the papillary dermis and vacuolar alteration at the dermoepidermal junction. Pigmented actinic keratoses have a hyperpigmented or reticulated appearance. Differential diagnosis of actinic keratosis includes Bowen's disease, squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, seborrhoeic keratosis, and lentigo maligna (<LINK REF="REF-Holmes--2007" TYPE="REFERENCE">Holmes 2007</LINK>).</P>
<P>Symptoms of actinic keratosis include tenderness, itchiness, burning, and a sandpaper-like texture. Over time, lesions may remain unchanged, proliferate, regress, reappear, or develop into squamous cell carcinoma. Microscopically, actinic keratosis lesions show abnormal tissue development (dysplasia) in the skin cells (keratinocytes). During early development of a lesion, the lower layers of the epidermis show the most dysplastic keratinocytes. As a lesion develops, the dysplastic cells permeate the epidermis and form conical-shaped scales when the surface of the epidermis is reached. Acceleration of growth of the epidermal layer and abnormal cellular maturation leads to excessive production of immature adherent scales with a sandpaper or gritty feel (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>). The lower skin layer (dermis) undergoes patchy inflammation as seen by an increased number of white blood cells (lymphocytes) noted in the dermis (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pathogenesis and epidemiology</HEADING>
<P>The anatomical distribution of actinic keratosis lesions correlates with areas of the body that receive the most long-term, chronic, and intense exposure to ultraviolet radiation in sunlight (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>; <LINK REF="REF-Schwartz-1997" TYPE="REFERENCE">Schwartz 1997</LINK>). More than 80% of the lesions occur on the head, neck, back of the hands, and forearms (<LINK REF="REF-Salasche-2000" TYPE="REFERENCE">Salasche 2000</LINK>). Chronic exposure to ultraviolet (UV) radiation, mainly UVB (290 to 320 nm), is the major agent leading to mutagenesis (disordered regulation of growth) in keratinocytes (<LINK REF="REF-Callen-1997" TYPE="REFERENCE">Callen 1997</LINK>). In fact, mutations in the p53 tumour suppressor gene have been found in 53% of those with actinic keratoses and 69% of squamous cell carcinoma biopsies (<LINK REF="REF-Nelson-1994" TYPE="REFERENCE">Nelson 1994</LINK>). Ultraviolet radiation can also contribute to suppression of the immune system, resulting in a decreased ability to eliminate over-proliferating cells (<LINK REF="REF-Holmes--2007" TYPE="REFERENCE">Holmes 2007</LINK>). Moreover, UV light could directly activate human papillomavirus replication. The virus, in turn, degrades a proapoptotic protein BAk, also preventing elimination of tumour cells (<LINK REF="REF-Holmes--2007" TYPE="REFERENCE">Holmes 2007</LINK>). Thus, sunlight initiates and promotes the formation of non-melanoma skin cancer.</P>
<P>The cause of actinic keratosis involves an interaction between skin colour (melanin protects by absorbing UVB radiation); advancing age (cumulative sun exposure and decrease in the effectiveness of the immune system); gender (actinic keratosis is more prevalent in men); history of severe sunburn in childhood; and sun exposure, which is influenced by latitude and the integrity of the ozone layer (<LINK REF="REF-Holmes--2007" TYPE="REFERENCE">Holmes 2007</LINK>; <LINK REF="REF-Lebwohl-2003" TYPE="REFERENCE">Lebwohl 2003</LINK>; <LINK REF="REF-Salasche-2000" TYPE="REFERENCE">Salasche 2000</LINK>). Other factors may include occupation (working outdoors), socioeconomic status, and diet (<LINK REF="REF-Lebwohl-2003" TYPE="REFERENCE">Lebwohl 2003</LINK>; <LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>; <LINK REF="REF-Salasche-2000" TYPE="REFERENCE">Salasche 2000</LINK>; <LINK REF="REF-Schwartz-1997" TYPE="REFERENCE">Schwartz 1997</LINK>). Immunosuppressive therapy, e.g. in organ transplant recipients, and exhibition of genetic diseases of skin hypopigmentation (low pigmentation), such as xeroderma pigmentosum or albinism (<LINK REF="REF-Holmes--2007" TYPE="REFERENCE">Holmes 2007</LINK>; <LINK REF="REF-Moy-2000" TYPE="REFERENCE">Moy 2000</LINK>), are also risk factors.</P>
<P>The first National Health and Nutrition Examination Survey (<LINK REF="REF-NHANES-I" TYPE="REFERENCE">NHANES I</LINK>) found that in healthy white people in the US, the age-adjusted prevalence rate for actinic keratoses was 6.5%. This increases significantly with advancing age: In 65- to 74 year-old men with high sun exposure, the prevalence rate was 55.4% and 18.5% for low sun exposure (<LINK REF="REF-Engel-1988" TYPE="REFERENCE">Engel 1988</LINK>). In Australia, where prevalence of actinic keratosis is the highest, as many as 40% of white adults may have an actinic keratosis. For younger adults, aged 30 to 39 years, the rate was 22% for men and 8% for women. In older adults aged 60 to 69 years, 83% of men and 64% of women have an actinic keratosis. For this population of adults, 42% developed at least 1 new lesion within the year (<LINK REF="REF-Frost-2000" TYPE="REFERENCE">Frost 2000</LINK>). Although known to be precancerous, the probability of a lesion undergoing malignant transformation to a squamous cell carcinoma is not clear, but ranges from 0.025% to 16% per year (<LINK REF="REF-Glogau-2000" TYPE="REFERENCE">Glogau 2000</LINK>; <LINK REF="REF-Jeffes-2000" TYPE="REFERENCE">Jeffes 2000</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2012-11-09 09:39:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>An actinic keratosis may potentially become cancerous; therefore, monitoring is advised. Because of the prevalence of actinic keratoses among an ageing population, treatment has been sought by an increasing number of people (<LINK REF="REF-Warino-2006" TYPE="REFERENCE">Warino 2006</LINK>). Reasons for treatment include prevention of cancer development; relief of symptoms, such as bleeding; and improvement of cosmetic appearance. Interventions for actinic keratoses could be divided into individual treatment of lesion and field-directed treatment, i.e. applied to an area of sun-damaged skin where there may be multiple lesions. Individual lesion treatment (spot) might relieve symptoms or cosmetic concerns, whereas field-directed treatment might be more appropriate for prevention of transformation into squamous cell carcinoma. Most of the field-directed treatments are topical treatments where efficacy depends on patient compliance.</P>
<P>Behaviour modifications, including limiting sun exposure between 10am and 4pm, the use of sunscreens with a SPF (sun protection factor) rating of at least 15, and the use of protective clothing, are the best methods for the prevention of actinic keratosis and will help reduce the need for treatment (<LINK REF="REF-Schwartz-1997" TYPE="REFERENCE">Schwartz 1997</LINK>; <LINK REF="REF-Wilkerson-1984" TYPE="REFERENCE">Wilkerson 1984</LINK>).</P>
<P>Various strategies for the treatment of actinic keratoses have been developed; these include physician-administered cryotherapy for a few lesions, and topical 5-fluorouracil, topical imiquimod, topical masoprocol, topical diclofenac in 2.5% hyaluronic acid gel, and photodynamic therapy for large numbers of lesions. Salicylic acid may also be used for early lesions, while dermabrasion and laser resurfacing are beneficial when there is coexistent photodamage or multiple recalcitrant lesions. Excision (removal of the lesion, often using a scalpel blade) and chemical peels (use of a caustic agent that causes the lesion to slough off) are both appropriate for hyperkeratotic or recalcitrant lesions. Interferon and oral retinoids are uncommon treatments, and they are still under development. These treatments have varying efficacies and adverse effect profiles (<LINK REF="REF-Dinehart-2000" TYPE="REFERENCE">Dinehart 2000</LINK>; <LINK REF="REF-Ibrahim-2009" TYPE="REFERENCE">Ibrahim 2009</LINK>; <LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>; <LINK REF="REF-Wilkerson-1984" TYPE="REFERENCE">Wilkerson 1984</LINK>).</P>
<P>Thus, the factors to consider when making decisions about treatment include efficacy, tolerability, number of lesions to treat, spot or field-directed treatment, compliance, history of skin cancer, immunosuppression, previous treatment history, and cosmetic appearance.</P>
</INTERVENTION>
<THEORY MODIFIED="2012-11-09 12:05:47 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="3">Topical Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Diclofenac gel</HEADING>
<P>One topical treatment for actinic keratoses is the non-steroidal anti-inflammatory drug (NSAID) diclofenac in 2.5% hyaluronic acid gel. The hyaluronic acid vehicle contributes to the success of this treatment by delivering and then retaining diclofenac at the epidermis, protecting against UV radiation and its cosmetic properties (<LINK REF="REF-Brown-2005" TYPE="REFERENCE">Brown 2005</LINK>). Although the precise mechanisms of action are not clear, diclofenac is thought to target several aspects of actinic keratosis pathophysiology. One mechanism that has been proposed is the inhibition of cyclooxygenase 2 (COX-2) (<LINK REF="REF-Hemmi-2002" TYPE="REFERENCE">Hemmi 2002</LINK>), which leads to a reduction in prostaglandin synthesis (<LINK REF="REF-Rivers-2004" TYPE="REFERENCE">Rivers 2004</LINK>). This COX-2 inhibition or other mechanisms may be responsible for diclofenac&#8217;s inhibition of cell differentiation in vitro, induction of apoptosis in vitro and in vivo, alteration of cell proliferation, and inhibition of angiogenesis (<LINK REF="REF-Adamson-2002" TYPE="REFERENCE">Adamson 2002</LINK>; <LINK REF="REF-Alam-1995" TYPE="REFERENCE">Alam 1995</LINK>; <LINK REF="REF-Lu-1995" TYPE="REFERENCE">Lu 1995</LINK>; <LINK REF="REF-Seed-1997" TYPE="REFERENCE">Seed 1997</LINK>). Diclofenac has also been shown to activate the nuclear hormone receptors, peroxisome proliferator-activated receptors (PPARs), in vitro; these receptors are involved in many cellular functions including cell differentiation and apoptosis (<LINK REF="REF-Adamson-2002" TYPE="REFERENCE">Adamson 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5-Fluorouracil (5-FU)</HEADING>
<P>This topical agent causes a decrease in cell proliferation and an induction of cell death, particularly in cells with high mitotic (cell division) rates. This occurs through the inhibition of thymidylate synthetase, which blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby, interfering with DNA and RNA synthesis (<LINK REF="REF-Berman-2006" TYPE="REFERENCE">Berman 2006</LINK>; <LINK REF="REF-Chakrabarty-2004" TYPE="REFERENCE">Chakrabarty 2004</LINK>; <LINK REF="REF-Eaglstein-1970" TYPE="REFERENCE">Eaglstein 1970</LINK>; <LINK REF="REF-Robins-2002b" TYPE="REFERENCE">Robins 2002b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Imiquimod</HEADING>
<P>This topical treatment for actinic keratoses is a synthetic compound belonging to the imidazoquinolone family of drugs (<LINK REF="REF-Hemmi-2002" TYPE="REFERENCE">Hemmi 2002</LINK>). It acts as an immune modulator by activating toll-like receptors, ultimately resulting in the modulation of the mRNA expression of many immunomodulatory genes, which induces the production of cytokines by monocytes, macrophages, and epidermal keratinocytes (<LINK REF="REF-Correale-2002" TYPE="REFERENCE">Correale 2002</LINK>; <LINK REF="REF-Stanley-1999" TYPE="REFERENCE">Stanley 1999</LINK>). This has the effect of enhancing innate and acquired immune responses, which leads to strong antiviral and antitumoural activity (<LINK REF="REF-Vidal-2006" TYPE="REFERENCE">Vidal 2006</LINK>). Imiquimod also induces pro-apoptotic pathways through a variety of mechanisms (<LINK REF="REF-Amini-2010" TYPE="REFERENCE">Amini 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Chemical Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cryotherapy</HEADING>
<P>Cryotherapy is often the treatment of choice for individual actinic keratosis lesions (<LINK REF="REF-Goldberg-2010" TYPE="REFERENCE">Goldberg 2010</LINK>). It uses liquid nitrogen to freeze and destroy the epidermis containing actinic keratoses (<LINK REF="REF-Goldberg-2010" TYPE="REFERENCE">Goldberg 2010</LINK>), with efficacy increasing as a function of freezing duration (<LINK REF="REF-Thai-2004" TYPE="REFERENCE">Thai 2004</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Photodynamic therapy (PDT)</HEADING>
<P>Photodynamic therapy involves the selective accumulation of a photosensitising agent in premalignant or malignant cells (<LINK REF="REF-Gold-2008" TYPE="REFERENCE">Gold 2008</LINK>; <LINK REF="REF-Juarranz-2008" TYPE="REFERENCE">Juarranz 2008</LINK>). This is achieved by the application of 5-aminolevulinic acid (5-ALA) or MAL (ALA methyl ester), which are precursors to protoporphyrin IX (PpIX), a potent photosensitiser (<LINK REF="REF-Fink_x002d_Puches-1997" TYPE="REFERENCE">Fink-Puches 1997</LINK>). This causes an excess of PpIX, which selectively accumulates in neoplastic cells. Subsequently, the photosensitiser is activated by visible light, causing the generation of reactive oxygen species in the presence of oxygen. These reactive oxygen species [mainly singlet oxygen (&#712;O&#8322;)] start a cascade of biochemical events that induce damage and the death of neoplastic cells through an apoptotic mechanism (<LINK REF="REF-Juzeniene-2007" TYPE="REFERENCE">Juzeniene 2007</LINK>; <LINK REF="REF-Moan-1991" TYPE="REFERENCE">Moan 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2011-11-02 17:03:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>The existing evidence for use of the various treatment agents for actinic keratoses is varied, and there are concerns regarding adverse events and cosmetic outcomes. It is vital to critically assess data in terms of the benefits as well as the risks associated with treatment.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-11-06 17:37:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>To assess the effects of interventions for actinic keratoses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-09 11:10:02 +0000" MODIFIED_BY="Maryse Paquet">
<SELECTION_CRITERIA MODIFIED="2012-11-09 10:07:13 +0000" MODIFIED_BY="Maryse Paquet">
<CRIT_STUDIES MODIFIED="2012-10-31 10:57:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>This review included randomised controlled trials comparing the treatment of actinic keratoses to either placebo, vehicle, other current therapies, or variation in treatment conditions (e.g. different concentrations of the active ingredient or types of light sources for phototherapy). We included cross-over trials and parallel and intraindividual (e.g. left- or right-side comparison) studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-10-31 11:02:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>We included participants with clinical signs of actinic keratoses as assessed by a medical practitioner or histological diagnosis. Diagnostic criteria, such as the Marks definition (<LINK REF="REF-Marks-1993" TYPE="REFERENCE">Marks 1993</LINK>) or the Salasche or Schwartz characterisation (<LINK REF="REF-Salasche-2000" TYPE="REFERENCE">Salasche 2000</LINK>; <LINK REF="REF-Schwartz-1997" TYPE="REFERENCE">Schwartz 1997</LINK>), were acceptable, as was the diagnosis of actinic keratoses by a dermatologist using the terms 'actinic keratosis', 'solar keratosis', 'senile keratosis', 'senile hyperkeratosis', 'keratoma senile', or 'keratosis senilis'. We included studies with immunocompetent and immunosuppressed participants.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-31 11:03:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>We considered the following interventions:</P>
<UL>
<LI>prescription-based topical treatments, e.g. diclofenac in hyaluronic gel, 5-fluorouracil, or imiquimod;</LI>
<LI>prescription-based oral drugs, e.g. oral retinoids;</LI>
<LI>mechanical interventions, e.g. curettage, dermabrasion, or resurfacing;</LI>
<LI>chemical interventions, e.g. chemical peels, cryotherapy, or photodynamic therapy; and</LI>
<LI>combinations of topical and oral treatments with mechanical or chemical interventions.</LI>
</UL>
<P>The comparators were vehicle, placebo, another active compound or intervention, or a variation of the treatment (duration, concentration, etc).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-11-09 10:07:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>For actinic keratoses, the outcomes can be expressed per lesion or per participant. Because the participants or body parts of the participants (intraindividual design), not the lesions, were generally randomised, only per-participant outcomes could be included in meta-analyses. Thus, the included outcomes in this review were outcomes reported per participant.</P>
<P>Efficacy outcomes for studies on actinic keratoses are generally based on the clearance of individual lesions. Lesions present at baseline are generally identified, graded (grade I: slightly palpable, better felt than seen; grade II: moderately thick, easily seen and felt; and grade 3: very thick, hyperkeratotic, or both), and mapped. Use of transparencies and photography might help with this process. Sometimes distinction is made between lesions present at the baseline and new lesions appearing during the study. At the end of the study, the assessors evaluate the clearance, or not, of the lesions.</P>
<P>Ideally, complete clearance of actinic keratosis lesions at follow-up would be measured (i.e. number of participants with 100% clearance of target (present at baseline) or all actinic keratosis lesions).</P>
<P>A second outcome measurement, such as partial clearance, is also often used. The definition of partial clearance is subjective but frequently indicates the number of participants with 75% or more of actinic keratosis lesions being completely cleared, i.e. a reduction in the number of lesions by at least 75%.</P>
<P>Alternatively, the mean reduction of total number of lesions at baseline per participant is also used, i.e. the difference between the mean number of lesions at baseline and the mean number of lesions at assessment. The results are then presented as absolute mean or mean percentage of reduction in lesion counts compared to baseline.</P>
<P>We only included outcomes expressed as number of participants experiencing adverse events in this review.</P>
<P>Cosmetic outcomes are really varied from global assessment to individual characteristics, such as changes in pigmentation. We only included outcomes expressed as number of participants or mean per participant in this review.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-11-06 18:02:01 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="5">Efficacy outcomes</HEADING>
<OL>
<LI>Subjective assessment: global degree of improvement in symptoms or signs as rated by a medical practitioner or participant, or global improvement indices (GII) for completely improved or cleared.</LI>
<LI>Objective assessment: participant complete (100%) or partial (<U>&gt;</U> 75%) clearance.</LI>
<LI>Objective assessment: mean reduction in lesion counts (absolute number or percentage).</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-10-31 11:08:27 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="5">Safety and cosmetic outcomes</HEADING>
<OL>
<LI>Withdrawal due to adverse events.</LI>
<LI>Skin irritation.</LI>
<LI>Minor adverse events excluding skin irritation.</LI>
<LI>Cosmetic outcomes: cosmetic changes, including pigmentation and scarring.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-11-09 10:11:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-10-31 11:11:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>We searched the following databases up to 23 March 2011:</P>
<UL>
<LI>the Cochrane Skin Group Specialised Register using the terms: ((actinic or solar or senile) and keratos*) or hyperkeratos*;</LI>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>using the search strategy in <A HREF="http://archie.cochrane.org/sections/documents/view?document=205602041915453638&amp;format=REVMAN#APP-01">Appendix 1</A>:</LI>
<LI>PUBMED/MEDLINE via OVID (from 2005) using the strategy in <A HREF="http://archie.cochrane.org/sections/documents/view?document=205602041915453638&amp;format=REVMAN#APP-02">Appendix 2</A>;</LI>
<LI>EMBASE via OVID (from 2010) using the strategy in <A HREF="http://archie.cochrane.org/sections/documents/view?document=205602041915453638&amp;format=REVMAN#APP-03">Appendix 3</A>; and</LI>
<LI>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</LI>
</UL>
<P>The UK and US Cochrane Centres have an ongoing project to systematically search MEDLINE and EMBASE for reports of trials, which are then included in the Cochrane Central Register of Controlled Trials. Searching has currently been completed in MEDLINE from inception to 2004 and in EMBASE from inception to 2009. Further searches of these two databases were undertaken for this review by the Cochrane Skin Group to cover the years not searched by the UK and US Cochrane Centres for CENTRAL.</P>
<P>A final prepublication search for this review was undertaken on 4 April 2012. Although it has not been possible to incorporate RCTs identified through this search within this review, relevant references are listed under '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>'. They will be incorporated into the next update of the review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trials Registers</HEADING>
<P>We searched the following trials registers on 10 March 2011 using the search terms ((actinic, senile, or solar) and keratos) or hyperkeratos.</P>
<UL>
<LI>The metaRegister of Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>).</LI>
<LI>The US National Institutes of Health Ongoing Trials Register (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>).</LI>
<LI>The Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au/">www.anzctr.org.au</A>).</LI>
<LI>The World Health Organisation International Clinical Trials Registry platform (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>).</LI>
<LI>The Ongoing Skin Trials Register (<A HREF="http://www.nottingham.ac.uk/ongoingskintrials">www.nottingham.ac.uk/ongoingskintrials</A>).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-11-09 10:11:06 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="4">Unpublished literature</HEADING>
<P>We conducted online searches (via pharmaceutical company websites, the U.S. Food and Drug Administration (FDA) website, or both) for the following products and drug companies:<BR/>
</P>
<UL>
<LI>3M/Graceway Pharmaceuticals (imiquimod, Aldara, or Zyclara);</LI>
<LI>Actavis Mid-Atlantic LLC (imiquimod);</LI>
<LI>Allergan (5-fluorouracil, Fluoroplex);</LI>
<LI>Apotex (imiquimod);</LI>
<LI>Dermik/Sanofi Aventis (5-fluorouracil, Carac);</LI>
<LI>DUSA Pharmaceuticals (aminolevulinic acid, Levulan Kerastick);</LI>
<LI>Galderma (adapelene, Differin);</LI>
<LI>ICN (5-fluorouracil, Efudex);</LI>
<LI>Leo Pharmaceuticals (calcipotriol, Dovonex, or Daivonex);</LI>
<LI>Mochida Pharmaceuticals (imiquimod, Beselna);</LI>
<LI>PharmaDerm/NycoMed US (diclofenac, Solaraze);</LI>
<LI>Pharmacia &amp; Upjohn (5-fluorouracil);</LI>
<LI>Photocure ASA/Galderma (methyl aminolevulinate, Metvix, or Metvixia);</LI>
<LI>Roche (etretinate, Tegison);</LI>
<LI>Stiefel/GlaxoSmithKline (isotretinoin, Isotrex, or Isotrexin); and</LI>
<LI>URL Pharma (colchicine, Colcrys).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference proceedings</HEADING>
<P>We scanned the conference proceedings of the British Association of Dermatologists and the European Academy of Dermatology from 2007 to 2011 for further references to relevant trials. We examined the conference proceedings for 2009 and 2010 of the Annual Meeting of the American Academy of Dermatology, the Annual Meeting of the European Society for Dermatological Research, the Congress of the European Association of Dermatol-Oncology, the Annual Meeting of the British Association of Dermatologists, and the Annual Meeting of the Australasian College of Dermatologists. We scanned the conference proceedings for the 2012 Annual meeting of the American Academy of Dermatology.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Language restrictions</HEADING>
<P>We imposed no language restrictions when we searched for publications. We electronically translated articles published in languages other than English.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>We did not perform a separate search for adverse effects of interventions for actinic keratoses. We looked at reports of adverse events or side-effects in the RCTs identified as a result of our searches, as part of our secondary outcomes.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-09 11:10:02 +0000" MODIFIED_BY="Maryse Paquet">
<STUDY_SELECTION MODIFIED="2012-10-31 11:20:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>At least two authors (WB and MP) independently checked titles and abstracts identified from the searches. We obtained the full text of all studies of possible relevance for independent assessment by two authors (MP and WB). The authors decided which trials fit the inclusion criteria and recorded their methodological quality (MP and WB). They resolved any disagreement by discussion between the authors and a third party arbitrator (AG). Previous contributors also participated in this process in earlier versions of the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-31 11:33:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>At least two authors extracted and summarised, using data collection forms, the details of eligible trials. One author (MP) double-checked and entered data. The authors were not blinded to the names of the trial authors, journals, or institutions.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-31 11:35:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>Assessment of risk of bias included the Review Manager 5.1 'Risk of bias' assessment tool shown in the 'Risk of bias' tables. In addition, GradePro "quality of evidence" was also used for selected outcomes, and the results are shown in the overview tables for five selected interventions.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-11-09 10:13:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>We performed a meta-analysis for each treatment comparison to calculate a weighted treatment effect across trials. We expressed the results as a risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes, and a mean difference (MD) with 95% CI for continuous outcomes. We calculated the number needed to treat (NNT) for significantly different dichotomous outcomes using the following formula: NNT = &#921; 1/ ACR * (1-RR)&#921; where the risk ratios (RR) from the meta-analysis and the moderate assumed control risk (ACR) calculated in GRADEpro was used. For ACR, a mean baseline risk from the study was used for analysis with only one study; and low, median, or high control-group risk were used based on the variation in the included studies in meta-analysis. This previous method would not be applicable to outcomes with an ACR of 0%, i.e. no event in the control group, because of the numerical problems that would ensue.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-11-09 11:10:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>The unit of analysis was the participant. We analysed cross-over trials using data from the first phase only and pooled, where possible, with parallel-design studies. We divided results from withinparticipant trials (intraindividual, e.g. split face) into 2 categories: 1) outcomes expressed as number of participants (e.g. participant complete clearance), which could not be included in meta-analyses, were only reported in the text; and 2) outcomes expressed as mean with standard deviation (e.g. mean reduction in lesion counts = mean of reductions observed in each participant), which could be included in meta-analyses using the inverse-variance method. We combined together data from studies with multiple treatments when appropriate (e.g. "all treatment groups" versus "placebo"), or we split the data from the shared group. If studies were using more than one outcome included in this review, we included all outcomes in the analyses.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-11-09 10:15:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>We assessed heterogeneity using an I² statistic value expressed as a percentage. We excluded results from meta-analyses with an I² statistic value of 80% or higher. We explored reasons for heterogeneity in studies, and if necessary, sensitivity analyses examined the effects of excluding a study, e.g. those studies with lower methodological quality.</P>
<P>Many studies do not distinguish between the physical location of actinic keratosis lesions on the body. This can introduce heterogeneity, as actinic keratoses of the face and scalp are often more effectively treated by certain topical formulations than lesions located elsewhere. In some studies, pretreatment of lesions to remove hyperkeratosis essentially negated the differences encountered by lesion location, as lower response has been associated with greater hyperkeratosis. Most of the studies included limited their investigation to grade one or two lesions, i.e. minimally to moderate thick lesions. However, when comparing efficacy results from two separate studies using the same treatment, studies incorporating pretreatment of any kind may have accounted for different efficacy rates.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-31 12:06:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>A random-effects model was prespecified for all meta-analyses. The Mantel-Haenszel method was used for dichotomous outcomes (e.g. cure rates), and an inverse variance model was used for continuous outcomes (e.g. mean reduction in lesion counts).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-31 12:07:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>Where appropriate, we undertook subgroup analysis (subgroups of participants) in an attempt to decrease heterogeneity between studies (for example, when different dosing regimens were used or to keep information separated, i.e. when blue or red light was used for photodynamic therapy). In addition, if data were presented for several assessment time points or anatomical locations, we performed subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-13 10:30:38 +0000" MODIFIED_BY="Maryse Paquet">
<STUDY_DESCRIPTION MODIFIED="2012-11-09 12:19:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>', '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>', and '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>'.</P>
<SEARCH_RESULTS MODIFIED="2012-11-09 12:19:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>We identified 1001 references from searching bibliographic and trials databases, as well as 28 references through other sources. After removing duplicate references and ongoing studies without results, we had 469 records to screen. We excluded 318 records based on titles and abstracts as they did not meet our eligibility criteria (non-randomised studies, reviews, not interventions to cure). We assessed the full texts of the remaining 151 records. We then excluded a further 55 records, leaving 96 studies. We included 83 of these in our qualitative analysis; 12 are listed under studies awaiting classification, and 1 is an ongoing study. We included 75 studies in our meta-analysis.</P>
<P>The PRISMA study flow chart in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> summarises the results of the search for studies.</P>
<P>(Please note that in all tables in the results section, the "X" means that the associated outcome was reported, and when there was no participant withdrawal it is specified between parentheses.)</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-11-09 10:42:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>We included 83 randomised studies in the review, encompassing 10,036 participants in total.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>We only included the randomised (participants or right/left side in intraindividual studies) clinical trials if the interventions were covered by this review and if they reported numerical results for at least one of the review outcomes. This criterion excluded the outcome 'withdrawal due to adverse events', which is generally reported in all studies.</P>
<P>Some studies had more than one design. The design of the studies is summarised in the following table.</P>
<TABLE COLS="3" ROWS="3">
<TR>
<TD ALIGN="CENTER">
<P/>
</TD>
<TH ALIGN="CENTER">
<P>Placebo/vehicle-controlled</P>
</TH>
<TH ALIGN="CENTER">
<P>Active-</P>
<P>controlled<B>
<SUP>1</SUP>
</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Parallel groups</P>
</TH>
<TD ALIGN="CENTER">
<P>46 studies</P>
<P>(including part I of 1 cross-over study)</P>
</TD>
<TD ALIGN="CENTER">
<P>17 studies</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Intraindividual<SUP>2</SUP>
</P>
</TH>
<TD ALIGN="CENTER">
<P>12 studies</P>
</TD>
<TD ALIGN="CENTER">
<P>10 studies</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1. Active-controlled = compared to another treatment, which could be a different treatment or the same treatment at a different concentration, duration, or types of light used for photodynamic therapy.</SUP>
</P>
<P>
<SUP>2. Intraindividual = within-patients, i.e. different body parts of the same participant received different treatments in parallel (not sequentially).</SUP>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>Studies ranged in sample size from 4 to 492 participants (124 <U>+</U> 127, mean <U>+</U> SD).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The interventions assessed in the studies included the following.</P>
<SUBSECTION>
<HEADING LEVEL="5">Topical treatments</HEADING>
<UL>
<LI>Adapalene gel</LI>
<LI>Aretinoid methyl sulfone (Ro 14-9706)</LI>
<LI>Betulin-based oleogel</LI>
<LI>Calcipotriol (vitamin D)</LI>
<LI>Colchicine</LI>
<LI>Diclofenac</LI>
<LI>2-(Difluoromethyl)-dl-ornithine (DFMO)</LI>
<LI>5-fluorouracil (5-FU)</LI>
<LI>ß-1,3-D-glucan</LI>
<LI>Imiquimod</LI>
<LI>Ingenol mebutate (PEP005)</LI>
<LI>Isotretinoin</LI>
<LI>Masoprocol</LI>
<LI>Nicotinamide</LI>
<LI>Resiquimod</LI>
<LI>Sunscreen</LI>
<LI>DL-&#945;-tocopherol (vitamin E)</LI>
<LI>Tretinoin</LI>
</UL>
<P>A total of 60 studies investigated topical treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oral treatments</HEADING>
<UL>
<LI>Etretinate</LI>
</UL>
<P>One study investigated oral treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mechanical interventions</HEADING>
<UL>
<LI>Resurfacing (carbon dioxide and Er:YAG lasers)</LI>
</UL>
<P>Two studies investigated mechanical interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Chemical interventions</HEADING>
<UL>
<LI>Cryotherapy</LI>
<LI>Photodynamic therapy (using a variety of different parameters)</LI>
<LI>Chemical peel (trichloroacetic acid)</LI>
</UL>
<P>A total of 37 studies investigated chemical interventions.</P>
<P>Interventions in the included studies could also be segregated based on clinical (e.g. PDT or cryotherapy) or participant (e.g. topical cream) administration, as well as treatments for individual lesions (e.g. cryotherapy) or field-directed treatments (e.g. topical cream).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Participants in the studies were generally in good health, but a few studies specifically recruited participants with a history of non-melanoma skin cancer. We included studies with organ transplant recipients (immunosuppressed), but these were analysed separately. Responsiveness to immunomodulators may decrease with increasing age, so the age of participants might influence the efficacy of treatments using them. In the included studies, most of the participants were men with mean ages of 60 to 70 years. Lesions were generally grade I (slightly palpable, better felt than seen) or II (moderately thick, easily seen and felt). The location of actinic keratosis lesions, i.e. lesions difficult to access for cream application, could also influence participant compliance and ultimately the efficacy of participant-administered treatments. Lesions were located on the head only (i.e. face, forehead, temples, cheeks, scalp, ear, lips, and neck) in 59 studies, on only non-head locations (upper and lower extremities, legs, arms, elbow, forearms, hands, dorsa of hands, shoulder, décolleté, chest, trunk, and back) in 9 studies, and on both head and non-head locations (including the term "other") in 22 studies. One study did not specify the location of the lesions. In general, lesions were more often located on the face and scalp, which are easy to reach.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy outcomes</HEADING>
<P>The included studies reported several efficacy outcomes. A lot of the studies did not specify if only target (baseline) lesions or all lesions [i.e. target and subclinical lesions (new lesions appearing during the study)] were included in their analysis. Most of the studies reported more than one outcome. Some of these outcomes corresponded to our primary outcomes or could be transformed into our primary outcomes, whereas others did not meet our criteria for this review. We have summarised the primary and other outcomes in the following table.</P>
<TABLE COLS="3" ROWS="22">
<TR>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER">
<P>Equivalence or transformed into outcome</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>
<B>Primary outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>Global improvement indices expressed per participant</P>
<P>(Investigator, participant, or both)</P>
</TD>
<TD ALIGN="LEFT">
<P>Physician global assessment improvement, global therapeutic response or treated area, investigator assessment scale, investigator global assessment, overall response</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant complete clearance (number of participants, rate, proportion, percentages)</P>
</TD>
<TD>
<P>Complete responders, total clearance, response to treatment, proportion of participants achieving total clearance, field complete clearance, complete remission, complete response of lesional area, participant's complete resolution, complete clearing, number of participants with 100% clearance, complete participant response, target lesion number score = 0, complete healing, cumulative lesion number score = 0, 100% lesions cleared, percentage of participants who experienced 100% clearance of all target lesions, number of participants with all cleared lesions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance (number of participants, rate, proportion, percentages)</P>
</TD>
<TD>
<P>At least 75% reduction in the number of lesions, at least 75% of lesions cleared, percentage of participants who experienced 75% or greater clearance of all target lesions, therapy responders with at least 75% of clearing of the lesions, participant partial (&gt; 80%) clearance rates</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>50</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean reduction in lesion counts (absolute values or percentages)</P>
</TD>
<TD>
<P>Mean reduction in the number of actinic keratoses, mean changes of lesion counts, mean numbers of lesions at baseline and assessment time point, mean percentage reduction in the number of actinic keratoses, average changes in lesion counts, mean per cent changes from baseline for all actinic keratoses, mean per cent lesions cleared</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>
<B>Other outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>Global improvement indices expressed as scores</P>
</TD>
<TD>
<P>Physician global assessment, global improvement score</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>29</P>
</TD>
<TD ALIGN="CENTER">
<P>Lesion complete response (per lesions)</P>
</TD>
<TD>
<P>Reduction rate in number of actinic keratoses, clearance of individual lesions, rate of totally healed lesions, number of lesions with 0% of remaining area, complete clinical clearance rate on lesion basis, complete clearance rate of lesions, individual lesion clearance, lesion counts at baseline and assessment, percentage lesion reduction, proportion of baseline lesions cleared at the end of treatment, lesions remitted, total lesion counts</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>Median per cent reduction of baseline lesions</P>
</TD>
<TD>
<P>Median per cent changes from baseline for all actinic keratoses</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant histological clearance</P>
</TD>
<TD>
<P>Histological clearance, histological confirmation</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>Recurrence</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant partial</P>
<P>(<U>&gt;</U> 50%) clearance</P>
</TD>
<TD>
<P>Participant with 50% or greater reduction, clearance = resolution of &gt; 50% of the lesions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>Reduction in lesion size</P>
</TD>
<TD>
<P>Overall reduction in lesion area, partial remission (50% size reduction of 75% of lesions), mean diameter of target lesion at baseline and assessment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Median number of lesions at baseline and assessment time point</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant partial</P>
<P>(<U>&gt;</U> 66%) clearance</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant partial</P>
<P>(% not specified) clearance</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Total lesion number score (0 = 0 lesions, 1 = 1 to 3 lesions, 2 = 2 to 4 lesions, 3 = &gt; 6 lesions)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Negative predictive value, i.e. ratio between histological and clinical clearance</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant's perception of efficacy</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Efficacy on a visual analogue scale for field-directed treatment</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Relapse</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Safety outcomes</HEADING>
<P>There was a lot of variability in the safety outcomes reported by the included studies. Some studies provided briefly qualitative observations on adverse events, whereas others gave detailed quantitative description of adverse events. Intraparticipant studies have limitations in assessing adverse events other than application site and local skin reactions. Adverse events might influence a participant's compliance as well as the maintenance of the blinding. In turn, poor compliance and unblinding could compromise the evaluation of the treatment efficacy. Moreover, adverse events are an important factor in a physician's decision about appropriate treatment for their patients, and a more standardised report of adverse events would be beneficial. The safety outcomes that were our prespecified secondary outcomes found in the included studies, as well as other outcomes, are summarised in the following table.</P>
<TABLE COLS="3" ROWS="35">
<TR>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER">
<P>Equivalence or transformed into outcome</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Secondary outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>77</P>
</TD>
<TD ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
</TD>
<TD>
<P>None lost = all participants completed the trial/study, or lost participants were all justified by other reasons</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>Skin irritation (per participant)</P>
</TD>
<TD>
<P>Application site irritation, local irritation, facial irritation, graphical representation of irritation, number of participants reporting relative irritation between treatments</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>31</P>
</TD>
<TD ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation (number or percentages of participants)</P>
</TD>
<TD>
<P>Most frequent adverse events, number of participants reporting individual adverse events, participants with eye irritation, percentages of participants reporting adverse events for only 1 treatment arm or pooled data, specific treatment-related adverse events</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Other outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>Application site reactions in general</P>
<P>(number or percentages of participants experiencing reactions in general)</P>
</TD>
<TD ALIGN="LEFT">
<P>Adverse events at treatment sites</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>Application site reactions for specific reactions</P>
<P>(number or percentages of participants experiencing specific reactions)</P>
</TD>
<TD>
<P>Adverse events at treatment sites</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>All = 6</P>
<P>Severe = 3</P>
</TD>
<TD ALIGN="CENTER">
<P>Local skin/adverse reactions - in general</P>
<P>(number of percentages of participants)</P>
</TD>
<TD>
<P>Local adverse events</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>All = 33</P>
<P>Severe = 12</P>
</TD>
<TD ALIGN="CENTER">
<P>Local skin/adverse reactions for specific reactions</P>
<P>(number of percentages of participants)</P>
</TD>
<TD>
<P>Local skin reactions reported for only 1 treatment arm or pooled data, graphical representation of local skin reactions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>Participants experiencing at least 1 adverse event</P>
<P>(number or percentages of participants)</P>
</TD>
<TD>
<P>Number or percentage of participants reporting adverse events, graphical representation of percentages of participants experiencing adverse events</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment-related adverse events in general (number or percentages of participants)</P>
</TD>
<TD ALIGN="LEFT">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>31</P>
</TD>
<TD ALIGN="CENTER">
<P>Serious adverse events (treatment-related or not)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>Serious adverse events-detection of basal cell carcinoma (presence or not per participant)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>Serious adverse events - detection of squamous cell carcinoma (presence or not per participant)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>Clinical laboratory tests</P>
</TD>
<TD ALIGN="LEFT">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Incidences of application site reactions</P>
<P>(number of events)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Application site reactions reported per lesions</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="CENTER">
<P>Local tolerability (severe, moderate, mild, absent)</P>
</TD>
<TD ALIGN="LEFT">
<P>Severity of local skin reactions, global severity rating of local reactions, side-effects (skin reactions) on a scale, irritation severity, severity of facial irritation, severity of local adverse events, grading of individual local reactions, physician's grading of erythema</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of reports of skin irritations</P>
</TD>
<TD>
<P>Incidence of local skin reactions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of participants with strong, moderate, weak, or no inflammatory reaction</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Local phototoxic reactions</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of treatment-related adverse events (incidence)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Qualitative report on treatment-related adverse events</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>Qualitative report on skin irritation (types and severity)</P>
</TD>
<TD>
<P>Comparison of severity of adverse events between treatments</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of reports of adverse events (incidences)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of reports of serious adverse events</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>New actinic keratosis lesions</P>
</TD>
<TD>
<P>Subclinical lesions, increase in number of lesions during the study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>Pain score</P>
</TD>
<TD>
<P>Mean visual analogue scale for pain</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Skin discomfort on a visual analogue scale</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Duration of discomfort</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Erythema measured by skin reflectance meter</P>
</TD>
<TD ALIGN="LEFT">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Graft rejection</P>
<P>(organ transplant participants)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Detection of Bowen's disease</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Incidence of new non-melanoma skin cancer</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<P>The evaluation of the 'skin irritation' outcome was restricted, as only 15 studies had outcomes containing explicitly the term 'irritation'. Several studies reported application site, local skin reactions, or both, which generally included signs and symptoms of skin irritation, such as burning/stinging, erythema, oedema, pruritus, and scaling. We could have included these skin irritation signs and symptoms as more specific 'skin irritation' outcomes if a universal definition of skin irritation existed. Because of the exclusion of skin irritation in the 'minor adverse events' outcome, these reactions as well as the number of participants reporting at least one adverse event, related or not to the treatment (which could include skin irritation), could not be included in any of our secondary outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cosmetic outcomes</HEADING>
<P>Only a few studies reported cosmetic outcomes and were varied. In general, cosmetic evaluation was performed on cleared lesions. The cosmetic outcomes that were our prespecified secondary outcomes found in the included studies, as well as other outcomes, are summarised in the following table.</P>
<TABLE COLS="3" ROWS="14">
<TR>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER">
<P>Equivalence or transformed into outcome</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Cosmetic outcomes reported per participant</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>Changes in pigmentation</P>
</TD>
<TD>
<P>Hypopigmentation, hyperpigmentation</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>Global cosmetic outcome of "good", "very good", or "excellent"</P>
</TD>
<TD ALIGN="LEFT">
<P>Final cosmetic results, overall cosmetic outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Cosmetic appearance score</P>
</TD>
<TD ALIGN="LEFT">
<P>Total score for cosmetic appearance (erythema, desquamation, induration), cosmetic appearance scores by participant and investigator on a 7-point scale (-3 = much worse to +3 = much better)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>Skin quality</P>
</TD>
<TD>
<P>Decrease in roughness/dryness/scaliness of the skin, normal skin surface, decrease of scarring</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>Improvement in photodamage or photoageing score</P>
</TD>
<TD>
<P>Investigator global integrated photodamage, photodamage score (fine lines, mottled pigmentation, tactile roughness, sallowness), photoageing score (global appearance, fine wrinkles, mottled hyperpigmentation, coarse wrinkles, rosy glow)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Significantly - or much- improved cosmetic outcome</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Decreased infiltration and disappearance of crust</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Proportion of participants with improvement of surface with actinic damage</P>
</TD>
<TD>
<P>Note: the number of participants was not given and could not be included in the analysis</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Other outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>Cosmetic outcomes per cleared lesions</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Total thickness score</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Changes in pigmentation per lesions</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>The studies sometimes reported additional outcomes, and they are summarised in the following table. They rarely reported important outcomes, such as compliance, (7 studies) compared to the number of studies investigating participant-administered treatments (63 studies, including 3 daylight photodynamic therapy studies).</P>
<TABLE COLS="2" ROWS="11">
<TR>
<TH ALIGN="CENTER">
<P>Number of studies</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant's satisfaction</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>Rest periods or temporary interruption during treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>Compliance</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>Participant's preference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>Biological and immunological outcomes</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Skin concentrations of drug and products due to its mechanism of action</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator's preference</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Lesion severity index</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Quality of life on a visual analogue scale</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Number of spray cooling for photodynamic therapy</P>
</TD>
</TR>
</TABLE>
<P>In 2011, we contacted the following authors to get clarification on the studies included.</P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Author</P>
</TH>
<TH>
<P>Topic</P>
</TH>
<TH ALIGN="CENTER">
<P>Clarification</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Kurt Gebauer</P>
</TD>
<TD>
<P>Type of analysis used in the study <LINK REF="STD-Gebauer-2003" TYPE="STUDY">Gebauer 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Intention-to-treat</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Joseph Jorizzo</P>
</TD>
<TD>
<P>Type of analysis used in the studies <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> and <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>The type of analysis could not be confirmed</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Iraji Fariba</P>
</TD>
<TD>
<P>Outcome presented was 'lesions complete response' or 'participant complete clearance' in the study <LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>No response received</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Emil Tanghetti</P>
</TD>
<TD>
<P>Type of analysis used in the study <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Intention-to-treat</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-11-08 15:43:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>Generally, we excluded studies if they were not randomised clinical trials on interventions to cure actinic keratosis lesions (actinic keratoses). In addition, we excluded some randomised studies for the reasons cited in the tables of excluded studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' section. The following table summarises the main reasons for the exclusion of these studies.</P>
<TABLE COLS="6" ROWS="2">
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Data not separated for actinic keratoses</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Did not meet review criteria for outcomes</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Unacceptable or unclear randomisation</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>No numerical values, graphical data, or not enough information</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Prevention of actinic keratosis lesions</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Follow-up reports on included studies</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Alberts-2004" TYPE="STUDY">Alberts 2004</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Green-1998" TYPE="STUDY">Green 1998</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Humphreys-1996" TYPE="STUDY">Humphreys 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Apalla-2010b" TYPE="STUDY">Apalla 2010b</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Babilas-2007" TYPE="STUDY">Babilas 2007</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Babilas-2008" TYPE="STUDY">Babilas 2008</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Bartels-2009" TYPE="STUDY">Bartels 2009</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Biecha_x002d_Thalharnmer-2003" TYPE="STUDY">Biecha-Thalharnmer 2003</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Braathen-2009" TYPE="STUDY">Braathen 2009</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Dirschka-2010" TYPE="STUDY">Dirschka 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Edwards-1986" TYPE="STUDY">Edwards 1986</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Epstein-2006" TYPE="STUDY">Epstein 2006</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Ericson-2004" TYPE="STUDY">Ericson 2004</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Jury-2005" TYPE="STUDY">Jury 2005</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Kurwa-1999" TYPE="STUDY">Kurwa 1999</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Morales-2010" TYPE="STUDY">Morales 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Puizina_x002d_Ivic-2008a" TYPE="STUDY">Puizina-Ivic 2008a</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Radakovic_x002d_Fijan-2005" TYPE="STUDY">Radakovic-Fijan 2005</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Shuttleworth-1989" TYPE="STUDY">Shuttleworth 1989</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Sotiriou-2011" TYPE="STUDY">Sotiriou 2011</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Wulf-2006" TYPE="STUDY">Wulf 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Alexiades_x002d_Armenakas-2003" TYPE="STUDY">Alexiades-Armenakas 2003</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Babilas-2006" TYPE="STUDY">Babilas 2006</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Berlin-2008" TYPE="STUDY">Berlin 2008</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Gold-2006" TYPE="STUDY">Gold 2006</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Goldman-2003" TYPE="STUDY">Goldman 2003</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Griffin-1991" TYPE="STUDY">Griffin 1991</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Grima_x00ee_tre-2000" TYPE="STUDY">Grimaître 2000</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Marrero-1998" TYPE="STUDY">Marrero 1998</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Tsoukas-2010" TYPE="STUDY">Tsoukas 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Valeant-2004" TYPE="STUDY">Valeant 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Apalla-2010a" TYPE="STUDY">Apalla 2010a</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Breza-1976" TYPE="STUDY">Breza 1976</LINK>
</P>
<P/>
<P>
<LINK REF="STD-de-S_x00e9_vaux-2003" TYPE="STUDY">de Sévaux 2003</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Dermik-2003" TYPE="STUDY">Dermik 2003</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Gupta-2004" TYPE="STUDY">Gupta 2004</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Robins-2002a" TYPE="STUDY">Robins 2002a</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Rosen-2010" TYPE="STUDY">Rosen 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Simmonds-1973" TYPE="STUDY">Simmonds 1973</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Spencer-2010" TYPE="STUDY">Spencer 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Touma-2004" TYPE="STUDY">Touma 2004</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Weinstock-2010" TYPE="STUDY">Weinstock 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Yamauchi-2002" TYPE="STUDY">Yamauchi 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Apalla-2010c" TYPE="STUDY">Apalla 2010c</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Elmets-2010" TYPE="STUDY">Elmets 2010</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Naylor-1995" TYPE="STUDY">Naylor 1995</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Wennberg-2008" TYPE="STUDY">Wennberg 2008</LINK>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fowler-2002" TYPE="STUDY">Fowler 2002</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Hanke-2011" TYPE="STUDY">Hanke 2011</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Stockfleth-2004" TYPE="STUDY">Stockfleth 2004</LINK>
</P>
<P/>
<P>
<LINK REF="STD-Szeimies-2010a" TYPE="STUDY">Szeimies 2010a</LINK>
</P>
</TD>
</TR>
</TABLE>
<P>In 2011, we tried to contact the following author to get clarification on the studies excluded.</P>
<TABLE COLS="3" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Author</P>
</TH>
<TH>
<P>Topic</P>
</TH>
<TH ALIGN="CENTER">
<P>Clarification</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Barbara A. Gilchrest</P>
</TD>
<TD>
<P>1) Number of treatment arms and number of participants allocated</P>
<P/>
<P>2) Mean numbers of lesions and their standard error of the mean (SEM) for the 3 groups, i.e. 1, 2, and 3 hours</P>
</TD>
<TD ALIGN="LEFT">
<P>1) 3 groups of 6 participants each incubated for 1, 2, or 3 hours</P>
<P/>
<P>2) not received</P>
</TD>
</TR>
</TABLE>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-11-09 14:00:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>Please refer to the 'Risk of bias' tables for each included study, which are part of the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables, and the summary figure, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> ('Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies).</P>
<ALLOCATION MODIFIED="2012-11-09 10:44:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>Ffity studies were judged to be at low risk of bias with regard to the method used to generate the randomisation sequence, which were stratification (<LINK REF="STD-Alberts-2000" TYPE="STUDY">Alberts 2000</LINK>; <LINK REF="STD-Foote-2009" TYPE="STUDY">Foote 2009</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>; <LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>; <LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>; <LINK REF="STD-Thompson-1993" TYPE="STUDY">Thompson 1993</LINK>), computer-generated randomisation schedule (<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>; <LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>; <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>; <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>; <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>; <LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>; <LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; <LINK REF="STD-Loven-2002" TYPE="STUDY">Loven 2002</LINK>; <LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>; <LINK REF="STD-Ostertag-2006" TYPE="STUDY">Ostertag 2006</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>; <LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK>; <LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>; <LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>), permuted block randomisation (<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>; <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK>; <LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>; <LINK REF="STD-Moloney-2010" TYPE="STUDY">Moloney 2010</LINK>; <LINK REF="STD-Szeimies-2008" TYPE="STUDY">Szeimies 2008</LINK>; <LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>), shuffling of envelopes or drawing of lots (<LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>; <LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>), and random digits table or number generator (<LINK REF="STD-Seckin-2009" TYPE="STUDY">Seckin 2009</LINK>; <LINK REF="STD-Shaffelburg-2009" TYPE="STUDY">Shaffelburg 2009</LINK>).</P>
<P>Only 16 studies stated the methods used for allocation concealment before the treatments were assigned, and we judged these studies at low risk of bias. Eight studies used opaque sealed envelopes (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Moloney-2010" TYPE="STUDY">Moloney 2010</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>; <LINK REF="STD-Tarstedt-2005" TYPE="STUDY">Tarstedt 2005</LINK>; <LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>; <LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>; <LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>). Two studies assigned the next sequential number (<LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>; <LINK REF="STD-Shaffelburg-2009" TYPE="STUDY">Shaffelburg 2009</LINK>). An external person (pharmacist, sponsor, or CRO) handled the randomisation process in six studies (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>; <LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>; <LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>; <LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>; <LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>; <LINK REF="STD-Van-der-Geer-2009" TYPE="STUDY">Van der Geer 2009</LINK>).<I>
<BR/>
</I>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-11-09 14:00:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>Double-blind or assessor-blind were used in 58 and 10 studies, respectively. Nine studies were open. In some of these studies, blinding was difficult because of the nature of the treatments being compared (e.g. surgical treatment versus topical treatment). Some authors also reported that adverse events, such as the local skin reactions associated with some treatments, might have compromised the blinding. In these cases, different investigators could have been involved in the treatment/safety assessment and the efficacy assessment in order to keep the part of the assessment blinded. Additionally, the use of photography in the evaluation process could help to keep the assessor blinded. The evaluation of the risk of bias for participants, personnel and assessors took into consideration the type of blinding, and when possible, the possibility of unblinding. Of our 83 included studies, we judged 48 as at low risk of bias for both these domains, 19 studies, at high risk of bias, and 3, as unclear for both domains.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-11-09 14:00:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>Three studies used intention-to-treat (ITT) analyses, and 25 studies used per-protocol (PP) analyses. Nine studies used both types of analysis. The type of analysis was undetermined in 12 studies. Most studies adequately recorded characteristics of participants not completing the study. We considered studies where <U>&lt;</U> 20% of enrolled participants dropped out as acceptable, and only three studies (<LINK REF="STD-Alirezai-1994" TYPE="STUDY">Alirezai 1994</LINK>; <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>; <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>) exceeded 20%. For the meta-analyses, we favoured data from ITT analyses over PP analyses, and we converted PP data to ITT data when possible. The evaluation of the risk of bias took into consideration the type of analysis, the number of dropouts, if the reasons for the dropouts were given, and possible discrepancy in the data presented.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-11-09 10:46:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>We judged 14 studies as at low risk of bias based on the following criteria: 1) The study protocols were available, and all the prespecified outcomes were presented; 2) the same data were presented in different formats (abstract, protocol with data, product insert, and published report); or 3) non-significant outcomes were reported.</P>
<P>We judged 42 studies as at high risk of bias based on the following criteria: 1) Not all prespecified outcomes in the protocol or methods section were presented (e.g. the percentage in mean reduction in lesion counts was stated, but only absolute counts were presented); or 2) when the outcomes were incompletely reported and could not be entered in meta-analysis (e.g. the standard deviations associated with mean reduction in lesion counts were not reported and the statistical significance between treatments was impossible to determine). We encountered this last example frequently. A few studies only gave data for only one treatment arm or pooled together for different treatment arms. For example, they did not always report adverse events separately for the different treatments. Of course, separate reports were impossible for studies using intraindividual study design.</P>
<P>Twenty-seven studies reported unclear risk of bias. We refer the readers to the 'Risk of bias' tables for each included study for additional information on possible publication bias.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-13 10:30:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>We presented the data and analyses of the included studies in two sections.</P>
<P>A) Overviews of the results with five selected outcomes (three primary and two secondary outcomes) expressed as comparative risks and risk ratios (RR) for five selected interventions in immunocompetent participants.</P>
<P>B) Results expressed as risk ratios (RR), number needed to treat (NNT), and mean difference (MD) presented for all interventions and all reported primary and secondary outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">A) Overviews of selected interventions</HEADING>
<P>Because of the variety of data presented for the different outcomes, we made a selection based on the data most frequently presented. For example, 'participant complete clearance' has been reported for target, subclinical, and all lesions, but most of the included studies reported data for all lesions. Thus, to be able to compare the different treatments and keep the summary table simple, we only included 'participant complete clearance' for all lesions. When data were presented for different cycles of treatments, only data for one cycle were included. Selections specific for one treatment are described in the comments section of the overview tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Diclofenac in 2.5% hyaluronic acid</HEADING>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> is an overview for 3% diclofenac in 2.5% hyaluronic acid.</P>
<P>In summary, diclofenac was significantly more efficacious than its vehicle, 2.5% hyaluronic acid. It was also associated with more adverse events, based on the number of participants who withdrew because of adverse events and the number of participants who experienced skin irritation. Diclofenac treatment in 2.5% hyaluronic acid combined with ALA-PDT might increase the long-term efficacy compared to ALA-PDT with 2.5% hyaluronic acid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5-fluorouracil (5-FU)</HEADING>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> is an overview for 5-fluorouracil.</P>
<P>In summary, 0.5% and 5% 5-fluorouracil treatments resulted in similar efficacy and safety based on 1 study comparing them directly. 5-Fluorouracil was significantly more efficacious than vehicle and cryotherapy, but similar to ALA-PDT (see PDT overview table: <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) and carbon dioxide laser resurfacing. More studies are needed to confirm its superiority to masoprocol and imiquimod and its long-term inferiority to Er:YAG laser resurfacing. In 1 study, additional treatment with 5-fluorouracil increased the efficacy of cryotherapy with vehicle, but the efficacy (illustrative comparative risks) of cryotherapy alone in this study seemed much lower than other studies investigating cryotherapy (see cryotherapy overview table: <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). On the other hand, additional treatment with tretinoin did not improve the efficacy of 5-fluorouracil. In general, 5-fluorouracil treatment did not lead to withdrawal because of adverse events; however, substantial skin irritation was associated with this intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Imiquimod</HEADING>
<P>
<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> is an overview for imiquimod.</P>
<P>In summary, imiquimod was significantly more efficacious than vehicle, but similar to cryotherapy and 3% diclofenac in 2.5% hyaluronic acid (based on another efficacy outcome presented below). More studies are needed to confirm its inferiority to 5% 5-fluorouracil. Additional treatment with 3.75%, but not 5%, imiquimod increased the efficacy of cryotherapy, but the efficacy (illustrative comparative risks) of cryotherapy with vehicle in this study seemed much lower than other studies investigating cryotherapy alone (see cryotherapy overview table: <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). More data are needed to be able to compare 5% imiquimod to photodynamic therapy, and additional treatment with imiquimod did not improve the efficacy of photodynamic therapy. Treatment with 5% imiquimod resulted in a larger number of participant withdrawals due to adverse events than treatment with 2.5% and 3.75% imiquimod.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cryotherapy</HEADING>
<P>
<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> is an overview for cryotherapy.</P>
<P>In summary, cryotherapy had similar efficacy to betulin-based oleogel and imiquimod. Cryotherapy was significantly inferior to 5-fluorouracil and ALA-PDT. No conclusion could be made on its efficacy compared to MAL-PDT based on our primary outcomes. Additional treatment with 5-fluorouracil or imiquimod might increase the efficacy of cryotherapy, but these studies had generally lower efficacy associated with cryotherapy with vehicle treatment than the other studies with cryotherapy alone. Cryotherapy was generally not associated with withdrawal due to adverse events and had less skin irritation than ALA-PDT3.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Photodynamic therapy (PDT)</HEADING>
<P>
<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> is an overview for photodynamic therapy.</P>
<P>In summary, similar efficacy was obtained for the two photosensitising agents, ALA and MAL, under similar photodynamic therapy conditions. The use of ALA/MAL with blue or red light PDT resulted in similar results, which were significantly different than vehicle with blue or red light PDT. Longer incubation (4 hours [h]) with ALA resulted in better results compared to shorter incubation time (0.5, 1, and 2 hours). Consequently, 4-hour incubation with ALA followed by PDT was significantly more efficacious than cryotherapy, but 1-hour incubation with ALA followed by PDT (blue light or pulsed dye laser) was not significantly different than 0.5% 5-fluorouracil. Additional treatment with 5% imiquimod did not improve the efficacy of ALA-PDT. With MAL-PDT, similar efficacy was observed for red light, broad visible light with water-filtered infrared A, and daylight. With daylight PDT, no difference was found between 16% and 8% MAL or between 2-hour and 3-hour incubation with MAL before daylight exposure. Based on our primary outcomes, no conclusion could be made on MAL-red light PDT efficacy compared to cryotherapy or the benefit of multiple versus single treatment. Photodynamic therapy generally did not lead to withdrawal because of adverse events. Based on the only two studies reporting skin irritation, incubation with ALA might cause skin irritation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">B) All interventions</HEADING>
<P>This section is addressed as planned in '<LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>' and '<LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK>':</P>
<P>(1) Prescription-based topical treatments<BR/>(2) Prescription-based oral drugs<BR/>(3) Mechanical interventions<BR/>(4) Chemical interventions<BR/>(5) Combinations of topical and oral treatments with mechanical or chemical interventions</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Prescription-based topical treatments</HEADING>
<P>Prescription-based topical treatments, which are generally field-directed treatments, were addressed in alphabetical order: adapalene gel, aretinoid methyl sulfone (Ro 14-9706), betulin-based oleogel, calcipotriol, colchicine, diclofenac, 2-(Difluoromethyl)-dl-ornithine (DFMO), 5-fluorouracil (5-FU), &#946;-1,3-D-glucan, imiquimod, ingenol mebutate (PEP005), isotretinoin, masoprocol, nicotinamide, resiquimod, sunscreen, DL-&#945;-tocopherol (vitamin E), and tretinoin.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adapalene gel</HEADING>
<P>This intervention was addressed by only 1 study (<LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK>), which compared the efficacy of 0.1% adapalene gel, 0.3% adapalene gel, and vehicle gel for the treatment of actinic keratoses on the face, ears, scalp, arms, and back of the hands. Participants were treated with adapalene gel or placebo daily for four weeks, followed by twice-daily applications for up to nine months. The assessment was performed at the end of treatment. There was no major source of possible bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 90 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 90 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>With regard to the outcome 'global Improvement Indices (investigator): completely improved or cleared', we detected no significant difference in efficacy between adapalene and placebo treatments (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), or between 0.1% and 0.3% adapalene (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The proportion of participants who had positive outcomes (clear, marked, moderate, or slight improvements) was higher in participants treated with adapalene (52/60) than those treated with placebo (21/30), and the proportion of participants graded unchanged or worse was higher in those treated with placebo (9/30) than those that were adapalene-treated (8/60) (<LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK>).</P>
<P>Mean changes [reduction (-) for adapalene and increase (+) for placebo] in the number of actinic keratoses from baseline were the means of measuring efficacy. Compared to placebo, both 0.1% and 0.3% adapalene gel resulted in a significant reduction in mean lesion counts [0.1% = MD -2.00, 95% CI -2.73 to -1.27, and 0.3% = MD -4.00, 95% CI -4.73 to -3.27; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>]. The 0.3% adapalene gel was significantly more efficient than 0.1% adapalene gel in reducing the number of lesions [MD -2.00, 95% CI -2.46 to -1.54; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 90 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 90 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 42 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>Graph</P>
</TD>
</TR>
</TABLE>
<P>Three participants in the 0.3% adapalene group had to withdraw because of these adverse events: skin irritation, dermatitis, and eye dryness. This number of participants was not significantly different from the placebo group (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) or the 0.1% adapalene treated-group (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>Dermatitis was the only minor adverse event reported quantitatively. Dermatitis was significantly more frequent in the participants treated with adapalene (20/60) than with placebo (3/30) [RR 3.33, 95% CI 1.08 to 10.34; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>], corresponding to a NNT for an additional harmful outcome of 4.3. In contrast, the number of participants experiencing dermatitis was similar in the 0.1% and 0.3% adapalene-treated groups (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>
<LINK REF="STD-Kang-2003" TYPE="STUDY">Kang 2003</LINK> graphically reported improvements in the following clinical features of photoageing of the skin: mottled hyperpigmentation, fine wrinkles, coarse wrinkles, and rosy glow. The authors stated that a significant difference between adapalene and placebo was detected for global appearance, mottled hyperpigmentation, fine wrinkles, and rosy glow, but not for coarse wrinkles. The exact percentages of participants with improvement in mottled hyperpigmentation were given (55% in the 0.1% group, 65% in the 0.3%, and 25% in the placebo group), but only a subpopulation of participants were evaluated, and the number of participants for each treatment group was not given. Thus, no statistical analysis was performed on this data.</P>
<P>To summarise, adapalene gel was more efficient than placebo in treating actinic keratoses. In addition, 0.3% adapalene gel gave better results than 0.1% adapalene gel, based on the mean reduction in lesion counts without an increase in adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aretinoid methyl sulfone (Ro 14-9706)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Ro 14-9706 versus 0.05% tretinoin</I>
</HEADING>
<P>This intervention was addressed by only 1 intraindividual study (<LINK REF="STD-Misiewicz-1991" TYPE="STUDY">Misiewicz 1991</LINK>), which compared the efficacy of 0.05% Ro 14-9706 and 0.05% tretinoin applied twice-daily for 16 weeks for the treatment of facial actinic keratoses. Assessment was performed at the end of the 16-week treatment. There was no major source of possible bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 25 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 25 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Misiewicz-1991" TYPE="STUDY">Misiewicz 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>Because of the study design, i.e. intraindividual study, the data for 'global improvement indices' for participants receiving the two different interventions could not be included in a meta-analysis, but is presented in the following table.</P>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Number of participants with the following improvements</P>
</TH>
<TH>
<P>Ro14-9706</P>
</TH>
<TH ALIGN="CENTER">
<P>Tretinoin</P>
</TH>
</TR>
<TR>
<TD>
<P>Complete response</P>
</TD>
<TD>
<P>0/25</P>
</TD>
<TD>
<P>2/25</P>
</TD>
</TR>
<TR>
<TD>
<P>Partial response</P>
</TD>
<TD>
<P>12/25</P>
</TD>
<TD>
<P>10/25</P>
</TD>
</TR>
<TR>
<TD>
<P>No response</P>
</TD>
<TD>
<P>13/25</P>
</TD>
<TD>
<P>11/25</P>
</TD>
</TR>
<TR>
<TD>
<P>Worsening</P>
</TD>
<TD>
<P>0/25</P>
</TD>
<TD>
<P>2/25</P>
</TD>
</TR>
</TABLE>
<P>Areas treated with tretinoin cream showed an initial increase in the number of lesions (weeks 3 to 9), which eventually decreased after week 10. Ro 14-9706 showed no initial increase in number of actinic keratoses lesions, but a gradual decline over time. The resulting mean percentage of reduction in lesion counts was significantly higher in the group treated with Ro 14-9706 than the group treated with tretinoin (MD 7.50, 95% CI 6.57 to 8.43; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>
<LINK REF="STD-Misiewicz-1991" TYPE="STUDY">Misiewicz 1991</LINK> reported none of our secondary outcomes.</P>
<P>To summarise, Ro 14-9706 treatment showed better overall reduction in lesion counts, whereas tretinoin treatment, which showed an initial increase in lesions, resulted in more participants with complete response.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Betulin-based oleogel</HEADING>
<P>Studies using betulin-based oleogel used this treatment as a comparator for cryotherapy. The results will be discussed in the cryotherapy section below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcipotriol (vitamin D)</HEADING>
<P>This intervention was addressed by only one study (<LINK REF="STD-Seckin-2009" TYPE="STUDY">Seckin 2009</LINK>), which compared the efficacy of calcipotriol (vitamin D) to placebo treatment for actinic keratoses on the face and scalp. One treatment was applied on 1 randomised side of the face, and the other treatment on the other side twice daily for 12 weeks. Assessment was performed at the end of the 12-week treatment. There was possible attrition and reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 8 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Seckin-2009" TYPE="STUDY">Seckin 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values, percentages</P>
</TD>
</TR>
</TABLE>
<P>Mean changes [reduction (-) for calcipotriol and increase (+) for placebo] in the number of actinic keratoses from baseline were the means of measuring efficacy. In contrast to placebo, calcipotriol reduced the number of lesions; however, the overall effect was not statistically different (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). In addition, no statistical difference in the mean percentage of reduction in lesion counts was detected by the authors (<LINK REF="STD-Seckin-2009" TYPE="STUDY">Seckin 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 8 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 8 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Seckin-2009" TYPE="STUDY">Seckin 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The reduction of the total score for cosmetic appearance, which rated erythema, desquamation, and induration of a target lesion, was not different between the calcipotriol and placebo groups (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>To summarise, the data available for treatment of actinic keratoses with calcipotriol could not demonstrate its superiority for efficacy or cosmetic outcomes compared to placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Colchicine</HEADING>
<P>This intervention was addressed by only 1 study (<LINK REF="STD-Akar-2001" TYPE="STUDY">Akar 2001</LINK>), which compared the efficacy of 1% colchicine to 0.5% colchicine for actinic keratosis lesions. Both 0.5% and 1% colchicine were applied twice daily for 10 days on the face, scalp, and upper extremities. Assessment was performed at four weeks. There was no major source of possible bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 16 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 16 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Akar-2001" TYPE="STUDY">Akar 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>In general, 0.5% and 1% colchicine treatments resulted in similar efficacy, with 7/8 and 6/8 participants completely cleared (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) and similar mean reduction in lesion counts for all lesions (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) or by anatomical locations (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 16 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Akar-2001" TYPE="STUDY">Akar 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>The final cosmetic results in successful cases were good for both colchicine concentrations, as supported by the quantitative analysis of the number of participants with decreased infiltration and disappearance of crust at one month (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>), which showed no difference between the two treatments.</P>
<P>To summarise, 0.5% and 1% colchicine had similar efficacy and cosmetic outcomes and showed high efficacy (81% of participants completely cleared); however, these conclusions were based on a small sample size.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diclofenac</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Diclofenac versus vehicle</I>
</HEADING>
<P>This intervention was addressed by 7 studies (<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>; <LINK REF="STD-Gebauer-2003" TYPE="STUDY">Gebauer 2003</LINK>; <LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>; <LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>; <LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>; <LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>; <LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>) comparing 3% diclofenac in 2.5% hyaluronic acid gel to 2.5% hyaluronic acid gel, for the treatment of actinic keratoses. The characteristics of these studies are presented in the following table. There was possible attrition bias (<LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>; <LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>), reporting bias (<LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>; <LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>), and other bias (<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>; <LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>).</P>
<TABLE COLS="8" ROWS="7">
<TR>
<TH ALIGN="CENTER">
<P>Characteristic</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2003" TYPE="STUDY">Gebauer 2003</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Study design</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel-group</P>
</TD>
</TR>
<TR>
<TD>
<P>Anatomical locations</P>
</TD>
<TD>
<P>Face, scalp, ear, neck, lower arm/elbow, hand, lower leg/knee</P>
</TD>
<TD>
<P>Forehead, central face, scalp, arms, hands</P>
</TD>
<TD>
<P>Forehead, central face, scalp, dorsum of hands</P>
</TD>
<TD>
<P>Face, scalp, forehead, arm, forearm, back of hands</P>
</TD>
<TD>
<P>Head/neck, hands, or arms</P>
</TD>
<TD>
<P>Face or scalp</P>
</TD>
<TD>
<P>Face, scalp, hands</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Diclofenac concentration (%)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Frequency of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
<TD ALIGN="CENTER">
<P>Twice daily</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Duration given (days)</P>
</TD>
<TD ALIGN="CENTER">
<P>56 to 168</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>30, 60</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD ALIGN="CENTER">
<P>112</P>
</TD>
</TR>
<TR>
<TD>
<P>Assessment</P>
</TD>
<TD>
<P>At the end of 24-week treatment</P>
</TD>
<TD>
<P>4 weeks after the end of treatment</P>
</TD>
<TD>
<P>4 weeks after the end of treatment</P>
</TD>
<TD>
<P>4 weeks after the end of treatment</P>
</TD>
<TD>
<P>At the end of 12-week treatment and 4 weeks after the end of treatment</P>
</TD>
<TD>
<P>At the end of 12-week treatment</P>
</TD>
<TD>
<P>At the end of 16-week treatment</P>
</TD>
</TR>
</TABLE>
<P>In <LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>, participants were immunosuppressed (organ transplant patients). Three of the included studies (<LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>; <LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>; <LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>) were part of the Solaraze product insert, and the number of participants experiencing at least one adverse event was pooled and reported in the <LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="8">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 312 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 490 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 28 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 345 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator and participant</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator and participant</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2003" TYPE="STUDY">Gebauer 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>Efficacy measurements using investigator and participant global improvement indices for the outcome 'completely improved' showed the superiority of the 3% diclofenac in 2.5% hyaluronic acid gel over 2.5% hyaluronic acid gel alone for 60-day treatment [investigator: RR 3.06, 95% CI 1.21 and 7.77, NNT= 4.8; participant: RR 2.86, 95% CI 1.12 to 7.32, NNT = 5.3] and 90-day treatment [investigator: RR 2.50, 95% CI 1.37 to 4.55, NNT = 3.6; participant: RR 2.44, 95% CI 1.28 to 4.64], but not for 30-day treatment [investigator and participant: RR 4.00, 95% CI 0.89 to 17.89] (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
<P>We performed seven meta-analyses for the outcome 'participant complete clearance'.</P>
<OL>
<LI>Analysis for efficacy assessment at the end of treatment: The 2 studies that reported the efficacy assessment at the end of treatment used a treatment period longer than 30 days and showed the superiority of the diclofenac treatment over 2.5% hyaluronic acid gel alone [RR 1.95, 95% CI 1.21 to 3.13, NNT = 7.1] (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</LI>
<LI>Analysis for efficacy assessment after a 30-day follow-up for target lesions, i.e. present at baseline: This was similar to the global improvement indices for completely improved 60- and 90-day treatments, but not 30-day treatment. Diclofenac/hyaluronic acid showed superiority over the vehicle for target lesions [(60 days: RR 3.27, 95% CI 1.30 to 8.21, NNT = 4.3) (90 days: RR 2.87, 95% CI 1.84 to 4.48, NNT = 3.4) (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>)].</LI>
<LI>Analysis for efficacy assessment after a 30-day follow-up for all lesions, i.e. target and new lesions: Again, participant complete clearance was significantly different for 60-day therapy (RR 3.83, 95% CI 1.37 to 10.71, NNT = 4.3) and 90-day therapy (RR 2.20, 95% CI 1.40 to 3.44, NNT = 4.5), but not after 30 days of therapy (RR 3.50, 95% CI 0.76 to 16.01). The pooled RR was 2.46 (95% CI 1.66 to 3.66, NNT = 5.4) (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>). The small sample sizes resulted in no significant difference in the RRs for participant complete clearance between the different anatomical locations.</LI>
<LI>Analysis for 30-day treatment with subgroups by anatomical locations (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>).</LI>
<LI>Analysis for 60-day treatment with subgroups by anatomical locations (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>).</LI>
<LI>Analysis for 90-day treatment with subgroups by anatomical locations: In contrast to locations on the face or forehead, the RRs for scalp, arm/forearms, and back of the hands did not favour diclofenac for 90-day treatment over vehicle, because of the variability between studies (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>).</LI>
<LI>Analysis of immunosuppressed participants with efficacy assessment after a 30-day follow-up (<LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>): In immunosuppressed participants, statistically significant superiority of 16-week treatment with diclofenac over placebo could not be demonstrated despite a large effect for participant complete clearance (RR 5.78, 95% CI 0.38 to 87.35; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>) or partial (&gt; 75%) clearance (RR 3.55, 95% CI 0.57 to 21.94; <LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>). This was probably due to the small number of participants involved in this single study. Further studies are needed to be able to conclude on the efficacy of diclofenac in immunosuppressed participants.</LI>
</OL>
<P>The healing properties of diclofenac seem to continue after treatment. There was no significant difference in the mean reduction of lesion counts at the end of 60- to 90-day treatment between diclofenac and vehicle (2.5% hyaluronic acid gel) (<LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>). In contrast, a significantly better reduction in lesion counts was achieved by the diclofenac treatment compared to 2.5% hyaluronic acid gel alone after a 30-day follow-up (MD of at least 2.00; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>). For the immunosuppressed participants, a mean reduction of 53% in the lesion counts was observed for diclofenac, whereas a mean increase of 17% was observed for 2.5% hyaluronic acid gel alone. A statistical analysis could not be performed because standard deviations were not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="8">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 644 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 462 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 32 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-McEwan-1997" TYPE="STUDY">McEwan 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>In general (excluding dermatology because it could include skin irritation) and specific adverse events based on body system</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2003" TYPE="STUDY">Gebauer 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (intraindividual)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>None of the participants (N = 20) in the intraindividual study by <LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK> withdrew because of adverse events. In contrast, significantly more participants withdrew because of adverse events in the 3% diclofenac in 2.5% hyaluronic acid group compared to the 2.5% hyaluronic acid group for the other studies (RR 3.59, 95% CI 1.92 to 6.70; <LINK REF="CMP-006.13" TYPE="ANALYSIS">Analysis 6.13</LINK>), corresponding to a NNT of 9.4 for an additional harmful outcome. In the immunosuppressed participants, 2 out of 24 participants in the diclofenac with 2.5% hyaluronic acid group withdrew because of adverse events, whereas none of the 8 participants receiving 2.5% hyaluronic acid alone withdrew.</P>
<P>
<LINK REF="STD-Fariba-2006" TYPE="STUDY">Fariba 2006</LINK> reported irritation only on the side treated with diclofenac in 8 of 20 participants.</P>
<P>Minor adverse events were reported for several body systems, and only the number of participants experiencing minor adverse events related to metabolic and nutritional disorders was significantly higher for diclofenac/hyaluronic acid (RR 5.09, 95% CI 1.16 to 22.22; <LINK REF="CMP-006.28" TYPE="ANALYSIS">Analysis 6.28</LINK>), corresponding to a NNT of 7.2 for an additional harmful outcome. Unfortunately, the authors of the study (<LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>) did not give the details of the adverse events related to metabolic and nutritional disorders. A large number of specific minor adverse events have been reported by only one study, and none of them were significantly different between the two groups. One of the minor adverse events reported by the three studies was dry skin. Dry skin was significantly more frequent in the diclofenac/hyaluronic acid group (RR 2.40, 95% CI 1.20 to 4.78; <LINK REF="CMP-006.20" TYPE="ANALYSIS">Analysis 6.20</LINK>), corresponding to a NNT of 4.4 for an additional harmful outcome. Two studies reported two adverse events related to the nervous system, hyperaesthesia and paraesthesia, which were localised to treatment sites by <LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002.</LINK> The number of participants experiencing both neurological adverse events were not different between the two treatment groups.</P>
<P>
<LINK REF="STD-Ulrich-2010" TYPE="STUDY">Ulrich 2010</LINK> mentioned that all immunosuppressed participants on the diclofenac treatment group had "cosmetically appealing results" four weeks after the end of the study, but did not mention anything about the hyaluronic acid (vehicle) group.</P>
<P>To summarise, diclofenac was in general significantly more effective than hyaluronic acid alone, but it was associated with significantly more withdrawals due to adverse events. Unfortunately, the data reported by the included studies did not allow comparison of efficacy and safety between immunosuppressed and immunocompetent participants.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Diclofenac versus imiquimod</I>
</HEADING>
<P>This intervention was addressed by 1 open-label study (<LINK REF="STD-Kose-2008" TYPE="STUDY">Kose 2008</LINK>), which compared the efficacy of 3% diclofenac in 2.5% hyaluronic acid (once daily for 12 weeks) and 5% imiquimod (3 times per week for 12 weeks) for the treatment of actinic keratoses on the face and scalp. Assessment was performed at the end of the 12-week treatment. There was possible performance, detection, and reporting bias in this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 49 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kose-2008" TYPE="STUDY">Kose 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigators and participants</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>No significant difference was found between diclofenac or imiquimod either by the investigator global improvement indices (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>) or by the participant global improvement indices (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 49 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kose-2008" TYPE="STUDY">Kose 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, diclofenac and imiquimod treatments were equivalent.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other comparisons</HEADING>
<P>The efficacy of diclofenac in combination with photodynamic therapy will be discussed in the phototherapy section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2-(Difluoromethyl)-dl-ornithine (DFMO)</HEADING>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Alberts-2000" TYPE="STUDY">Alberts 2000</LINK>), which compared the efficacy of 10% 2-(Difluoromethyl)-dl-ornithine (DFMO) with placebo for the treatment of actinic keratosis. The creams were applied to the randomised forearms twice daily for six months. Assessment was performed at the end of the 24-week treatment. There was possible reporting bias in this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 42 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alberts-2000" TYPE="STUDY">Alberts 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>The mean numbers of lesions at baseline were high [DFMO-treated arms: 28.1 <U>+</U> 17.1 (SD); placebo-treated arms: 29.2 <U>+ </U>18.7], and the reduction rates of lesion counts were relatively low: 23.5% for DFMO and 2.4% for placebo. Moreover, because of the large variability associated with this efficacy outcome, the mean difference (MD) of the absolute mean reduction in lesion counts did not reach statistical significance (MD 5.90, 95% CI -3.84 to 15.64; <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 42 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alberts-2000" TYPE="STUDY">Alberts 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Two participants for this intraindividual study withdrew because of adverse events.</P>
<P>To summarise, with severe actinic keratosis, DFMO had limited efficacy and is associated with severe inflammatory reactions.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5-Fluorouracil (5-FU)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>5-Fluorouracil versus placebo</I>
</HEADING>
<P>This intervention was addressed by 3 studies (<LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002;</LINK> <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>; <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK>). <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> and <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK> compared 0.5% 5-fluorouracil to vehicle cream applied daily for 1, 2, or 4 weeks on lesions located on the face or frontal scalp, and the data were part of the Carac product insert. <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK> reported results from an assessment 4 weeks after 1 week of treatment with either 0.5% 5-fluorouracil or vehicle cream prior to cryotherapy treatment on lesions on the face, scalp, ears, neck, and lips. Assessment was performed at four weeks after the end of treatment. There was possible performance, detection, attrition, and reporting bias associated with <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> and <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK> studies. The latter also has other possible sources of bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 351 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 528 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 528 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Scores (not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Scores (not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>The data for participant complete clearance from these studies was separated into subgroups based on duration of treatment. Subgroup analyses (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>) showed that treatment with 0.5% 5-fluorouracil treatment resulted in a significantly higher number of completely cleared participants than the placebo cream when applied for 1 week (NNT = 15.4), 2 weeks (NNT = 7.1), and 4 weeks (NNT = 3.2), resulting in an overall significantly better efficacy for 5-fluorouracil (RR 8.86, 95% CI 3.67 to 21.40, NNT = 8.5; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). When participant complete clearance for the different treatment durations were compared, daily application of 0.5% 5-fluorouracil for 4 weeks was found to have significantly higher efficacy than treatment for 1 week and 2 weeks (RR 0.39, 95% CI 0.19 to 0.81 and RR 0.56, 95% CI 0.36 to 0.87, respectively; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>). No difference was found between treatment for one week and treatment for two weeks. We must be cautious in our interpretation of these results because the design of the studies did not blind the participants and assessor for the treatment duration.</P>
<P>Mean reduction in lesion counts was presented as absolute values, percentages, or both. In <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK>, only the percentages without the associated standard deviations were presented, as shown in the following table. <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK> presented both absolute values and percentages (table) with their associated standard deviation. Analysis of the absolute values showed a significant reduction in lesion counts with 1 week of 5-fluorouracil compared to placebo (MD 5.40, 95% CI 2.94 to 7.86; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>). Finally, <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK> presented the absolute values (placebo: 2.7, 1 week: 8.8, 2 weeks: 11.7, and 4 weeks: 11.1) and percentages (table) without their associated standard deviations. In all studies, the mean percentages of reduction in lesion counts were higher in the 5-fluorouracil-treated groups than placebo.</P>
<TABLE COLS="6" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Mean percentage of reduction in lesion counts</P>
</TH>
<TH ALIGN="CENTER">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER">
<P>5-fluorouracil</P>
<P>(1 week)</P>
</TH>
<TH ALIGN="CENTER">
<P>5-fluorouracil</P>
<P>(2 weeks)</P>
</TH>
<TH ALIGN="CENTER">
<P>5-fluorouracl</P>
<P>(4 weeks)</P>
</TH>
<TH ALIGN="CENTER">
<P>5-fluorouracl</P>
<P>(pooled)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> (N = 207 participants)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.6%</P>
</TD>
<TD ALIGN="CENTER">
<P>69.5%</P>
</TD>
<TD ALIGN="CENTER">
<P>86.1%</P>
</TD>
<TD ALIGN="CENTER">
<P>91.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>82.4%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK> (N = 144 participants)</P>
</TD>
<TD ALIGN="CENTER">
<P>28.8%</P>
<P>
<U>+</U> 32.6% (SD)</P>
</TD>
<TD ALIGN="CENTER">
<P>62.4%</P>
<P>
<U>+</U> 32.6% (SD)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>62.4%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK> (N = 177 participants)</P>
</TD>
<TD ALIGN="CENTER">
<P>34.4%</P>
</TD>
<TD ALIGN="CENTER">
<P>78.5%</P>
</TD>
<TD ALIGN="CENTER">
<P>83.6%</P>
</TD>
<TD ALIGN="CENTER">
<P>88.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>83.6%</P>
</TD>
</TR>
</TABLE>
<P>
<SUB>N/A = not available</SUB>
</P>
<P>Based on the data from <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>, the mean percentage of reduction in lesion counts for 1 week of treatment with 0.5% 5-fluorouracil compared to vehicle was statistically significant in favour of 5-fluorouracil (MD 33.60, 95% CI 22.88 to 44.32; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>Because the safety analysis in <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK> included cryotherapy treatment, this study was excluded from this section. All the safety outcomes, except 'skin irritation' in general, were pooled together in the Carac product insert and were reported as in the <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> study.</P>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 384 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 384 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 384 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>In general (excluding dermatology because it could include skin irritation) and specific adverse events based on body system</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>In general (excluding dermatology because it could include skin irritation) and specific adverse events based on body system</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Analysis of data reported by <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK> showed that the number of participants who withdrew because of adverse events had a tendency to be higher in the 5-fluorouracil-treated group compared to the placebo-treated group (<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>). The number of withdrawals due to adverse events had a tendency to increase with longer treatment with 5-fluorouracil (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>), but this was not statistically significant. Similar to <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK>, <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> had 4 treatments arms (1, 2, and 4 weeks of 5-fluorouracil and placebo). In this study, a total of 24 participants out of 207 withdrew because of adverse events, but the authors only mentioned that 12 of them (50%) were in the 4-week group (N = 45). Together, these data suggest that severe adverse events are indeed associated with 4-week treatment with 5-fluorouracil.</P>
<P>Similarly, the number of participants experiencing facial irritation was significantly higher in the 5-fluorouracil-treated group than in the group treated with placebo (RR 1.45, 95% CI 1.27 to 1.65, NNT = 3; <LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>) without any difference between treatment durations (<LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>). The number of participants experiencing skin irritation was slightly lower in the 1-week group than the 2 other 5-fluorouracil groups, i.e. 2 and 4 weeks of treatments. Irritation related to treatment was mostly of mild to moderate severity.</P>
<P>None of the analyses for our outcome 'minor adverse events' resulted in significant differences between 5-fluorouracil and vehicle-treated participants (<LINK REF="CMP-009.06" TYPE="ANALYSIS">Analysis 9.6</LINK>; <LINK REF="CMP-009.07" TYPE="ANALYSIS">Analysis 9.7</LINK>; <LINK REF="CMP-009.08" TYPE="ANALYSIS">Analysis 9.8</LINK>; <LINK REF="CMP-009.09" TYPE="ANALYSIS">Analysis 9.9</LINK>; <LINK REF="CMP-009.10" TYPE="ANALYSIS">Analysis 9.10</LINK>; <LINK REF="CMP-009.11" TYPE="ANALYSIS">Analysis 9.11</LINK>; <LINK REF="CMP-009.12" TYPE="ANALYSIS">Analysis 9.12</LINK>; <LINK REF="CMP-009.13" TYPE="ANALYSIS">Analysis 9.13</LINK>; <LINK REF="CMP-009.14" TYPE="ANALYSIS">Analysis 9.14</LINK>; <LINK REF="CMP-009.15" TYPE="ANALYSIS">Analysis 9.15</LINK>; <LINK REF="CMP-009.16" TYPE="ANALYSIS">Analysis 9.16</LINK>). Moreover, no difference was detected between the different 5-fluorouracil treatment durations (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>; <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>; <LINK REF="CMP-010.06" TYPE="ANALYSIS">Analysis 10.6</LINK>; <LINK REF="CMP-010.07" TYPE="ANALYSIS">Analysis 10.7</LINK>; <LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>; <LINK REF="CMP-010.09" TYPE="ANALYSIS">Analysis 10.9</LINK>; <LINK REF="CMP-010.10" TYPE="ANALYSIS">Analysis 10.10</LINK>; <LINK REF="CMP-010.11" TYPE="ANALYSIS">Analysis 10.11</LINK>; <LINK REF="CMP-010.12" TYPE="ANALYSIS">Analysis 10.12</LINK>).</P>
<P>To summarise, 5-fluorouracil was more efficient than vehicle to treat actinic keratoses. Four-week treatment gave better results than one- and two-week treatments, which were comparable. Treatment with 0.5% 5-fluorouracil for 4 weeks could lead to more adverse events as shown by the number of withdrawals due to adverse events. Significant facial irritation was associated with 0.5% 5-fluorouracil treatment<I>.</I>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Different concentrations of 5-fluorouracil</I>
</HEADING>
<P>This intervention was addressed by one study (<LINK REF="STD-Loven-2002" TYPE="STUDY">Loven 2002</LINK>), which used a right/left withinparticipant design (intraindividual) to compare the efficacy of 0.5% to 5% 5-fluorouracil cream or the treatment of actinic keratoses on the face, anterior bald scalp, or forehead. The creams were applied once daily on 1 side of the face with 0.5% cream and twice daily on the other side with 5% cream for 4 weeks. Assessment was performed at 4 weeks after the end of treatment. There was possible performance and reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 21 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 21 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Loven-2002" TYPE="STUDY">Loven 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>Due to the intraindividual design of the study, no analysis could be performed for the participant-based outcome 'participant complete clearance'; however, a similar total clearance rate was obtained for the 2 treatments, i.e. approximately 43% (9/21) (<LINK REF="STD-Loven-2002" TYPE="STUDY">Loven 2002</LINK>).</P>
<P>After treatment with 0.5% 5-fluorouracil, participants had a mean reduction of 8.8 lesions, corresponding to 67%, and after 5% 5-fluorouracil, the mean reduction was 6.1 (47%). The authors reported a significant difference (P = 0.044) between the 2 treatments for the absolute mean reduction in lesion counts and graphically represented the standard deviations associated with lesion counts at baseline and week 8. An analysis could not be performed because the numerical values of the standard deviations were not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 21 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 21 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 21 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Loven-2002" TYPE="STUDY">Loven 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Sixteen of 21 participants discontinued treatment but did not withdraw from the study, because of irritation: 4 participants discontinued because of treatment with 0.5% 5-fluorouracil cream, 8 because of 5% cream, and 4 because of both creams.</P>
<P>All participants reported facial irritation in association with both creams.</P>
<P>Eye irritation was reported in 5 out of 21 participants and nasal congestion in 3 out of 21 participants. It was not mentioned if these events were associated with a particular treatment side.</P>
<P>To summarise, 0.5% 5-fluorouracil cream might be more efficient than the 5% cream and is associated with similar skin irritation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>5-fluorouracil with tretinoin</I>
</HEADING>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Bercovitch-1987" TYPE="STUDY">Bercovitch 1987</LINK>) comparing 5% fluorouracil treatment combined with 0.05% tretinoin and 5% fluorouracil treatment combined with placebo for treatment of actinic keratoses. 5% fluorouracil was applied twice daily on both forearms and hands, and 0.05% tretinoin cream was applied nightly on a randomised forearm/hand and placebo on the other forearm/hand up to 12 weeks. Assessment was performed at the end of the 12-week treatment. There was possible reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 20 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Bercovitch-1987" TYPE="STUDY">Bercovitch 1987</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>The additional treatment with tretinoin did not make any difference in the mean reduction of lesion counts by 5% fluorouracil (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Bercovitch-1987" TYPE="STUDY">Bercovitch 1987</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x (relative)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Twelve participants experienced more irritation on the side treated with tretinoin cream, four on the side treated with placebo, and three had equal irritation. One participant withdrew from the study due to irritation, but it was not mentioned if it was due to one treatment in particular.</P>
<P>To summarise, additional treatment with tretinoin did not improve the efficacy of the 5-fluorouracil treatment and was associated with more skin irritation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>5-fluorouracil versus imiquimod</I>
</HEADING>
<P>This comparison is discussed in the imiquimod section below, and the results presented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> correspond to <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>5-fluorouracil versus masoprocol</I>
</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Kulp_x002d_Shorten-1993" TYPE="STUDY">Kulp-Shorten 1993</LINK>), comparing 5% 5-fluorouracil and 10% masoprocol for the treatment of actinic keratoses. Both creams were applied twice daily for four weeks on the head or neck. Assessment was performed four weeks after the end of treatment. There was possible bias (other) associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 57 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 49 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kulp_x002d_Shorten-1993" TYPE="STUDY">Kulp-Shorten 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>Analysis of 'investigator global improvement indices' for cleared participants showed a strong and significant risk ratio favouring 5-fluorouracil over masoprocol treatments (RR 3.60, 95% CI 1.57 to 8.26; <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>). Two (NTT = 2.1) participants need to be treated to result in 1 clearance with 5-fluorouracil, whereas a larger number would be needed for masoprocol.</P>
<P>No significant difference was detected with the absolute values for mean reduction in lesion counts (<LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>). In contrast, the mean percentages were significantly different and supported the superiority of 5-fluorouracil in the treatment of actinic keratoses (MD 20.00, 95% CI 11.82 to 28.18; <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 57 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 57 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kulp_x002d_Shorten-1993" TYPE="STUDY">Kulp-Shorten 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Graph</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Only 1 participant in the 5-fluorouracil group withdrew because of adverse events (<LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>).</P>
<P>Minor adverse events were presented graphically based on their severity as percentages of participants experiencing different adverse events, such as necrosis and contact dermatitis. Based on these data and the incidences of these events, the authors concluded that masoprocol treatment was better tolerated than the 5-fluorouracil treatment, and they made a correlation with the number of participants that failed to complete 28 days of treatment. Indeed, a significantly higher percentage (65.5%) of participants treated with 5-fluorouracil failed to complete 28 days of treatment than participants treated with masoprocol (16%).</P>
<P>To summarise, 2 out of 3 efficacy outcome measurements supported the superiority of 5% 5-fluorouracil treatment over 10% masoprocol treatments for actinic keratosis. Masoprocol treatment may be associated with better tolerability.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Other comparisons</I>
</HEADING>
<P>The comparisons between 5-fluorouracil and cryotherapy, photodynamic therapy, resurfacing, and chemical peel are discussed in their respective sections. The results presented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> correspond to the following analyses:<BR/>1) cryotherapy (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>);<BR/>2) photodynamic therapy (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>);<BR/>3) carbon dioxide laser resurfacing (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>; <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>);<BR/>4) Er:YAG laser resurfacing (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>; <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>); and<BR/>5) trichloroacetic acid peel (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">&#946;-1,3-D-glucan</HEADING>
<P>This intervention was addressed by one study (<LINK REF="STD-Tong-1996" TYPE="STUDY">Tong 1996</LINK>), which compared &#946;-1,3-D-glucan with placebo for the treatment of solar keratoses. &#946;-1,3-D-glucan was applied twice daily for 7 days to 1 arm with placebo on the other arm. Assessment was performed seven weeks after the end of treatment. There was possible reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 20 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tong-1996" TYPE="STUDY">Tong 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>The mean number of lesions at baseline were respectively 22.5 and 23.9, and the mean reductions after 8 weeks were 5.7 and 8.3 for &#946;-1,3-D-glucan and placebo treatment. Based on the graphical representation of the data (means and standard deviations) over time provided by the authors, &#946;-1,3-D-glucan treatment was not more effective than placebo at reducing actinic keratosis lesions. A statistical analysis was not possible because the numerical values of the standard deviations were not given by the authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tong-1996" TYPE="STUDY">Tong 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The participants did not report any minor adverse events.</P>
<P>To summarise, &#946;-1,3-D-glucan treatment showed no benefits in treating solar keratoses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Imiquimod cream</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Imiquimod versus placebo</I>
</HEADING>
<P>This intervention was addressed by 18 studies (<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>; <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>; <LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>; <LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>; <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>; <LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>; <LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; <LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>; <LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>; <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>; <LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>; <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>; <LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>; <LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>; <LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>; <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>) comparing 2.5% to 5% imiquimod cream and placebo in the treatment of actinic keratoses. Two studies had an intraindividual design (<LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>; <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>), whereas all the other studies had a parallel design. In only one study the participants were immunosuppressed (organ transplant patients, <LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>). Dosing regimens were varied and included 2.5%, 3.75%, and 5% imiquimod and 8 dosing regimens with and without repetition of the treatment schedule, which are summarised in the following table. There were possible performance (<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>; <LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>; <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>), detection (<LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>; <LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>; <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>), attrition (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>; <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>), reporting (<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>; <LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>; <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>; <LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>; <LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>; <LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>), and other (<LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>) biases.</P>
<TABLE COLS="7" ROWS="19">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Anatomical locations</P>
</TH>
<TH ALIGN="CENTER">
<P>Imiquimod percentage</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of doses/week</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of weeks</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of doses</P>
</TH>
<TH ALIGN="CENTER">
<P>Time of assessment</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, arms, legs</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>8 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>24 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, scalp, forehead, dorsal forearm, neck, back of hands</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>12 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>36 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>At the end of the 12-week treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, forehead and temples, cheeks</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3 or 6</P>
</TD>
<TD ALIGN="CENTER">
<P>9 or 18</P>
</TD>
<TD ALIGN="CENTER">
<P>4 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>16 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>32 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>16 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>48 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>48</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Scalp, extremities, or upper trunk</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>16 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>48 or less</P>
</TD>
<TD ALIGN="CENTER">
<P>At the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>4 or 8</P>
</TD>
<TD ALIGN="CENTER">
<P>12 or 24</P>
</TD>
<TD ALIGN="CENTER">
<P>4 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Head</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>4 or 8</P>
</TD>
<TD ALIGN="CENTER">
<P>12 or 24</P>
</TD>
<TD ALIGN="CENTER">
<P>4 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, forehead, or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>48</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Dorsal of 1 or both forearms and hands</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>2,3,5,7</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>16,24,40,56</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Head</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>4 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>2.5, 3.75</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>6 (3 on, 3 off, 3 on)</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face</P>
</TD>
<TD ALIGN="CENTER">
<P>3.75</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2 on, 2 off, 2 on)</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD ALIGN="CENTER">
<P>20 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Head (bald scalp or face)</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>8 (4 on, 4 off, 4 on)</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>At week 20 (6 weeks after the end of treatment)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>2.5, 3.75</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2 on, 2 off, 2 on)</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Aldara" TYPE="STUDY">NCT00828568 Aldara</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of treatment</P>
</TD>
</TR>
</TABLE>
<P>Three types of subgroup analyses were performed: 1) by number of doses (from 9 to 56 doses) for 5% imiquimod (in the Analyses 19); 2) by imiquimod concentrations (in the Analyses 20); and 3) by frequency of application, i.e. number per week (in the Analyses 21).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="19">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 20 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 3637 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 2914 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
<P>(N = 315 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Aldara" TYPE="STUDY">NCT00828568 Aldara</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Only one intraindividual study, <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>, presented the number of participants with global improvement indices for complete clearance. One participant out of 15 was completely cleared on the imiquimod-treated side, whereas none of the participants showed complete clearance on the placebo-treated side. Thus, this dosing regimen was not very effective.</P>
<P>Overall, the risk ratio for participant complete clearance favoured 5% imiquimod treatment over placebo for immunocompetent (RR 6.91, 95% CI 4.25 to 11.26; <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>) as well as in immunosuppressed participants (RR 18.50, 95% CI 1.19 to 286.45; <LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>). Eight immunocompetent participants (NNT = 7.7) must be treated with 5% imiquimod to obtain 1 complete clearance. No immunosuppressed participant in the control group was completely cleared, so the corresponding number, i.e. NNT could not be calculated for this population.</P>
<P>However, 5% imiquimod was not statistically favoured in 4 of the 8 dosing regimens: 9 or 18 doses (3 times/week for 3 weeks on, 4 weeks off), 24 doses (3 times/week for 8 weeks), 40 doses (5 times/week for 8 weeks), and 56 doses (7 times/week for 8 weeks). Increasing the number of doses did not result in an increase in the values of the RRs, suggesting that the number of doses might not be a determining factor for the efficacy of imiquimod. Despite these subgroup analyses, substantial heterogeneity was associated with most of the subgroups of pooled studies. The heterogeneity was particularly high (I² statistic = 91%) for the 2 studies, with 1 or 2 courses 3 times/week for 4 weeks on, 4 weeks off, 4 weeks on (<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>; <LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>). The two studies were similar in design. <LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK> was performed in Europe and included participants with five to nine lesions, whereas <LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK> was performed in North America and included participants with four to eight lesions. In the European study, 47/126 participants were cleared after 1 course and did not receive a second course, compared to 32/121 in the American study. This difference might explain the heterogeneity associated with these studies.</P>
<P>Slightly different results were obtained for participant partial (<U>&gt;</U> 75%) clearance (<LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>). One additional dosing regimen did not reach significant difference (12 or 24 doses, 4 weeks on, 4 weeks off). In immunosuppressed participants, the results for partial clearance (RR 23.50, 95% CI 1.53 to 360.94; <LINK REF="CMP-019.04" TYPE="ANALYSIS">Analysis 19.4</LINK>) were similar to complete clearance (<LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>).</P>
<P>The number of participants with complete clearance was significantly higher in the imiquimod-treated group than the placebo-treated group for the 3 concentrations, i.e. 2.5% (RR 4.49, 95% CI 2.40 to 8.39, NNT = 4.6), 3.75% (RR 6.45, 95% CI 3.87 to 10.73, NNT = 3.7), and 5% (RR 7.70, 95% CI 4.63 to 12.79, NTT = 4.7). Based on the result for the subgroup difference test (P = 0.42; <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>), the efficacy of the 3 concentrations compared to placebo was not significantly different despite the fact that the magnitude of the effect increased with the concentration of imiquimod used to treat the actinic keratoses. In contrast, the analysis of the participant partial clearance, which included fewer studies, showed a significant difference between the concentrations of imiquimod (test for subgroup differences: P = 0.01; <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>). It is also worth noting that the two studies (<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>; <LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>) not including lesions on the face did not favour imiquimod (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>).</P>
<P>The amplitude of the clearance effect increased when the frequency of application was increased from 2 to 3 times per week for both complete clearance (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>) from (RR 5.36, 95% CI 2.03 to 14.16) to (RR 8.38, 95% CI 3.79 to 18.52) and for partial clearance (<LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>) from (RR 4.99, 95% CI 3.43 to 7.26) to (RR 7.65, 95% CI 2.51 to 23.32), but the difference between the RRs between 2 and 3 times were not significantly different.</P>
<P>Also, no correlation was found for the subgroup analysis of the number of weeks of treatment (not shown).</P>
<P>A funnel plot (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) for all the studies reporting 'participant complete clearance' suggests that there was no publication bias for this outcome.</P>
<P>Two studies (<LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>; <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>) with 24 doses of 5% imiquimod or placebo presented mean reduction in lesion counts as absolute values. <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>, but not <LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>, provided the associated standard deviations allowing statistical analysis. The mean reduction in lesion counts were similar for the imiquimod group (2.8 <U>+</U> 2.1 and 3.9) and for the placebo group (0.6 <U>+</U> 2.6 and 0.5), but the RR did not significantly favour imiquimod based on <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK> alone (<LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>). In contrast, the mean percentage of reduction in lesion counts provided by <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> with 3.75% imiquimod supported the superiority of imiquimod over placebo for treatment of actinic keratoses (MD 46.90, 95% CI 36.68 to 57.12; <LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>In the <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> study, some lesions also had cryotherapy treatment, and safety outcomes were only reported for the comparison between cryotherapy with and without imiquimod treatment. Thus, this study was not included in the secondary outcomes presented in this section.</P>
<TABLE COLS="5" ROWS="18">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 3444 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 1677 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 700 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 1691 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Persaud-2002" TYPE="STUDY">Persaud 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost -</P>
<P>intraindividual not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x (imiquimod, not included)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alomar-2007" TYPE="STUDY">Alomar 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2007" TYPE="STUDY">Jorizzo 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ulrich-2007" TYPE="STUDY">Ulrich 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
<P>(imiquimod only, not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>x (qualitative, not included)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost -</P>
<P>intraindividual not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>Qualitative (not included)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00828568-Taro" TYPE="STUDY">NCT00828568 Taro</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>All of the studies reported the number of participants who withdrew because of adverse events. Six out of 17 studies reported that no participants withdrew due to adverse events (i.e. "none lost" in the previous table), which are not included in the pooled risk ratio of meta-analysis because of the absence of events. All these studies used 5% imiquimod applied 3 times per week and had a very small sample size (&lt; 50 participants) compared to the other studies. Thus, we have to be careful about the interpretation of the analysed data. When comparing 5% imiquimod application to placebo, there was no significant difference in withdrawals due to adverse effects except at 48 doses. At 48 doses, when 2 studies were combined, there was a significant difference in favour of placebo (RR 2.69, 95% CI 1.48 to 4.90, NNT=16.7; <LINK REF="CMP-019.06" TYPE="ANALYSIS">Analysis 19.6</LINK>).</P>
<P>When 8 of the studies using 5% imiquimod were pooled together (imiquimod N = 1338, placebo N = 952), the number of participant withdrawals due to adverse events was significantly higher in the 5% imiquimod-treated group than the placebo-treated group (RR 2.59, 95% CI 1.59 to 4.23, NNT = 27; <LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>). The 4 studies with a parallel design (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Ooi-2006" TYPE="STUDY">Ooi 2006</LINK>; <LINK REF="STD-Ortonne-2010" TYPE="STUDY">Ortonne 2010</LINK>; <LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>), not included in the calculation of the pooled RR because of the lack of event, represented only 79 participants in the imiquimod group and 31 participants in the placebo group. Thus, we could conclude that 5% imiquimod treatment results in a higher number of participants withdrawn because of adverse events compared to placebo. In contrast, there was no significant difference for 3.75% and 2.5% imiquimod compared to placebo (<LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>).</P>
<P>For all frequencies of weekly application, there was a tendency to have more participants withdraw because of adverse events in the imiquimod group; a significant difference (RR 2.47, 95% CI 1.42 to 4.30, NTT = 27.2; <LINK REF="CMP-021.03" TYPE="ANALYSIS">Analysis 21.3</LINK>) was reached in the 3 times per week group. Five studies (imiquimod N = 670, placebo N = 649) were included in the calculation of the pooled risk ratio, but 4 smaller studies were not included because of absence of withdrawal in the intervention and control arms (imiquimod N = 79, placebo N = 31). Finally, there was no difference in the number of participants who withdrew because of adverse events in the immunosuppressed participants (<LINK REF="CMP-019.07" TYPE="ANALYSIS">Analysis 19.7</LINK>).</P>
<P>In the studies reporting skin irritation, no significant difference was observed for the separate analysis of the different concentrations. However, the pooled risk ratio did favour placebo, i.e. more participants treated with imiquimod experienced skin irritation compared to participants treated with placebo (RR 3.93, 95% CI 1.56 to 9.88, NNT = 60; <LINK REF="CMP-020.06" TYPE="ANALYSIS">Analysis 20.6</LINK>). In the intraindividual study <LINK REF="STD-Zeichner-2009" TYPE="STUDY">Zeichner 2009</LINK>, the participants experienced similar mild irritation with 5% imiquimod and placebo.</P>
<P>Only one study, <LINK REF="STD-Gebauer-2009" TYPE="STUDY">Gebauer 2009</LINK>, reported the number of participants experiencing 'minor adverse events excluding skin irritation' in general for different body systems, i.e. body as a whole, digestive system, and nervous system. None of the data were significantly different between the 5% imiquimod- and placebo-treated groups. Few studies reported the number of participants experiencing specific minor adverse events. The following adverse events affecting the body as a whole (pyrexia), the haemic and lymphatic system (lymphadenopathy), the musculoskeletal system (myalgia), the nervous system (fatigue), the respiratory system (cough, sinusitis, and upper respiratory tract infection), and the urogenital system (urinary tract infection) were not different between imiquimod and placebo groups. The number of participants treated with imiquimod experiencing "flu" or "cold"-like symptoms or "headache" was generally not different from placebo-treated participants except for application 7 times per week reported in 1 study by <LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK> (RR 19.68, 95% CI 1.20 to 323.89; <LINK REF="CMP-021.05" TYPE="ANALYSIS">Analysis 21.5</LINK>).</P>
<P>Only a few studies gave quantitative cosmetic outcomes (<LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; <LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>); a significant decrease in roughness, dryness, and scaliness of the skin was associated with 5% imiquimod treatment compared to placebo (RR 3.23, 95% CI 1.86 to 5.58, NNT = 2.6; <LINK REF="CMP-019.13" TYPE="ANALYSIS">Analysis 19.13</LINK>). In addition, overall cosmetic outcomes were significantly or much improved with 2.5% (RR 2.25, 95% CI 1.62 to 3.14, NNT = 3.1) and 3.75% (RR 2.71, 95% CI 2.05 to 3.58, NNT = 2.3) imiquimod compared to placebo (<LINK REF="CMP-020.16" TYPE="ANALYSIS">Analysis 20.16</LINK>).</P>
<P>To summarise, the efficacy of imiquimod compared to placebo was significantly better based on the participant complete and partial clearance as well as the mean percentage of reduction in lesion counts, but not for the absolute mean reduction in lesion counts. The amplitude of the effect was independent of the number of doses of 5% imiquimod, imiquimod concentrations, or frequency of application on a weekly basis. The number of withdrawals due to adverse events in the imiquimod group compared to placebo was statistically significant in the 48-dose group (although not in the 56-dose group) compared with the lower doses and in the 5% compared to the 2.5% and 3.75% imiquimod concentrations. Significantly better cosmetic outcomes were obtained with imiquimod treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Imiquimod versus diclofenac</I>
</HEADING>
<P>This comparison was reported in the diclofenac section above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Imiquimod versus 5-fluorouracil</I>
</HEADING>
<P>This intervention, which was addressed by 2 studies, 1 assessor-blinded (<LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>) and 1 open study (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>), compared the efficacy of 5% imiquimod and 5% 5-fluorouracil for the treatment of actinic keratoses. In <LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>, imiquimod was applied on the head, neck, or décolleté 3 times per week for 4 weeks on and 4 weeks off, once or twice, and 5-fluorouracil was applied twice daily for 4 weeks. Assessment was performed 4 and 8 weeks after the end of treatment for 5-fluorouracil and imiquimod, respectively. <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK> applied imiquimod on the face, forehead, or scalp twice weekly for 16 weeks and 5-fluorouracil twice daily for 2 to 4 weeks. Assessment was performed at 8 weeks after the end of treatment. There were possible performance (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>; <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>), detection (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>), and reporting (<LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>) biases.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 89 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
<P>(N = 50 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>With regard to the outcome 'participant complete clearance', no pooled RR can be calculated because of the high heterogeneity (I² statistic = 93%; <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>) associated with the 2 studies. The data from <LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>, which had no blinding specified, did not favour any treatment (RR 0.88, 95% CI 0.73 to 1.06). In contrast, the data from <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>, which was assessor-blinded, significantly favoured 5-fluorouracil (RR 0.31, 95% CI 0.14 to 0.67). The variability in the dosing regimen might explain the considerable heterogeneity associated with participant complete clearance. <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK> also supported 5-fluorouracil superiority by reporting the mean percentage of reduction in lesion counts of 94% and 66% for 5-fluorouracil and imiquimod, respectively. However, the authors did not provide the standard deviation associated with these values to determine statistically the significance of this difference between the treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 89 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 50 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The percentage of participants with a general cosmetic outcome assessed as excellent by the investigator was clearly better for imiquimod (21/26 = 81%) than 5-fluorouracil (1/24 = 4%) (RR 19.38, 95% CI 2.82 to 133.26, NNT = 1.3; <LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>). Moreover, the skin quality was better in the imiquimod group than the 5-fluorouracil group (RR 1.45, 95% CI 1.00 to 2.11, NNT = 3.8; <LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK>).</P>
<P>To summarise, the superiority of 5-fluorouracil over imiquimod in treating actinic keratoses needs to be supported by additional data. Imiquimod treatment seemed to result in better cosmetic outcomes than 5-fluorouracil.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Other comparisons</I>
</HEADING>
<P>The efficacy of imiquimod compared with cryotherapy will be discussed in the cryotherapy section below, and the results presented in the additional <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> correspond to <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>. Similarly, comparison with photodynamic therapy will be discussed in the phototherapy section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ingenol mebutate (PEP005)</HEADING>
<P>This intervention was addressed by three studies (<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>; <LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>; <LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>). These three studies investigated the efficacy of ingenol mebutate applied once daily for two to three consecutive days or once weekly for two weeks, i.e. two days one week apart (<LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>), compared to vehicle for the treatment of actinic keratoses. Treatments were applied to the arms, shoulder, chest, and scalp in both <LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK> and <LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>. In addition, the treatments were also applied to the back in <LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK> and the face in <LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>, whereas only non-head locations were investigated in <LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>. Assessment was performed 8 (<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>; <LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>) and 12 (<LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>) weeks after the first day of treatment. There was possible reporting (<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>) and other (<LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>) bias.</P>
<P>Because different concentrations (0.025%, 0.01%, and 0.05%) of ingenol mebutate and dosing regimens were used in these studies, subgroup analyses were performed for the different ingenol mebutate concentrations (in the Analyses 25) and the number of applications for 0.05% ingenol mebutate (i.e. number of doses or days, in the Analyses 26). Analyses of pooled data were also performed (in the Analyses 24).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 477 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 285 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x (percentage not specified and data not included in analysis)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Participant complete clearance was evaluated for target lesions (i.e. present at baseline) as well as for all lesions (i.e. target and new lesions). For both, the number of participants completely cleared was significantly higher in the ingenol mebutate group compared to vehicle (target: RR 3.61, 95% CI 1.86 to 7.02, NNT = 2.9; <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>) (all lesions: RR 4.50, 95% CI 2.61 to 7.74, NNT = 3.4; <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>), which corresponds to 383 per 1000 participants for ingenol mebutate and 73 per 1000 participants for vehicle achieving complete clearance.The amplitude of the effect had a tendency to increase with the concentration of ingenol mebutate (<LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>; <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>), but not with the number of applications of 0.05% ingenol mebutate (<LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>; <LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>).</P>
<P>Similar results were obtained for participant partial clearance with a RR of 2.88, 95% CI 1.81 to 4.58 (<LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK>), corresponding to a NNT of 2.8. A possible dependence on the ingenol mebutate concentration (<LINK REF="CMP-025.03" TYPE="ANALYSIS">Analysis 25.3</LINK>), but not on the number of applications for 0.05% ingenol mebutate (<LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>), was also observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 540 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 222 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 540 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>No withdrawal due to adverse events was reported in <LINK REF="STD-Anderson-2009" TYPE="STUDY">Anderson 2009</LINK> and <LINK REF="STD-Siller-2009" TYPE="STUDY">Siller 2009</LINK>. However, in <LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK>, 1 out of 255 participants withdrew because of an adverse event (pain), but the associated treatment was not specified.</P>
<P>No statistical analyses were performed for minor adverse events because only one participant experienced the individual minor adverse events reported, as shown in the following table, and no statistical significance could be reached. However, based on the incidences, more reports of minor adverse events were associated with the 0.05% ingenol mebutate.</P>
<TABLE COLS="6" ROWS="16">
<TR>
<TH ALIGN="CENTER">
<P>Body system</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse event</P>
</TH>
<TH ALIGN="CENTER">
<P>Placebo (N = 60)</P>
</TH>
<TH ALIGN="CENTER">
<P>0.025% ingenol mebutate for 3 days (N = 50)</P>
</TH>
<TH ALIGN="CENTER">
<P>0.05% ingenol mebutate for 3 days (N = 57)</P>
</TH>
<TH ALIGN="CENTER">
<P>0.05% ingenol mebutate for 2 days (N = 55)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Body as a whole</P>
</TD>
<TD ALIGN="CENTER">
<P>Chills</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Body as a whole</P>
</TD>
<TD ALIGN="CENTER">
<P>Fever</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Body as a whole</P>
</TD>
<TD ALIGN="CENTER">
<P>Flu or cold</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Dermatologic</P>
</TD>
<TD ALIGN="CENTER">
<P>Contact dermatitis</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Dermatologic</P>
</TD>
<TD ALIGN="CENTER">
<P>Impetigo</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Hemic and lymphatic</P>
</TD>
<TD ALIGN="CENTER">
<P>Traumatic hematoma</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Metabolic and nutritional disorders</P>
</TD>
<TD ALIGN="CENTER">
<P>Increase in creatine phosphokinase</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Musculoskeletal and connective tissue</P>
</TD>
<TD ALIGN="CENTER">
<P>Muscle spasms</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Nervous system</P>
</TD>
<TD ALIGN="CENTER">
<P>Headache</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Renal and urogenital</P>
</TD>
<TD ALIGN="CENTER">
<P>Proteinuria</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Respiratory</P>
</TD>
<TD ALIGN="CENTER">
<P>Nasal congestion</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="6">
<P>Incidences</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" COLSPAN="2">
<P>Each treatment arm</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" COLSPAN="3">
<P>3 days versus 2 days</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" COLSPAN="3">
<P>0.025% versus 0.05%</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>10</P>
</TD>
</TR>
</TABLE>
<P>There was no scarring, but some pigmentation changes occurred in some participants treated with ingenol mebutate. These changes were not significantly different compared to vehicle (<LINK REF="CMP-024.04" TYPE="ANALYSIS">Analysis 24.4</LINK>).</P>
<P>To summarise, ingenol mebutate was significantly more efficient than vehicle in treating actinic keratoses. When a higher concentration was used (i.e. 0.05%), ingenol mebutate generally resulted in better efficacy. Increasing the number of applications from two to three times did not result in an increase in the number of participants cleared. No significant difference was observed between ingenol mebutate and placebo for adverse events. Thus, ingenol mebutate treatment was relatively safe and efficient for actinic keratosis treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Isotretinoin</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Alirezai-1994" TYPE="STUDY">Alirezai 1994</LINK>) comparing the efficacy and safety of 0.1% isotretinoin and vehicle cream applied twice daily for 24 weeks for the treatment of actinic keratoses of the face, scalp, and upper extremities. Assessment was performed at the end of treatment. There was possible attrition and other bias in this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 100 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction (changes) in lesion counts</P>
<P>(N = 100 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alirezai-1994" TYPE="STUDY">Alirezai 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>The number of participants experiencing complete clearance, partial clearance, no clearance, and worsening were determined by an investigator global evaluation at the end of treatment. The numbers of participants with complete clearance were low with both isotretinoin and placebo for the three anatomical locations, and the associated risk ratios did not favour any treatment (<LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>).</P>
<P>The mean reduction of lesion counts for lesions on the face (MD 2.20, 95% CI 1.97 to 2.43) and upper extremities (MD 1.90, 95% CI 1.28 to 2.52), but not on the scalp, did favour isotretinoin over placebo (<LINK REF="CMP-027.02" TYPE="ANALYSIS">Analysis 27.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 100 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 92 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alirezai-1994" TYPE="STUDY">Alirezai 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x (in general and severe)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Two of 50 participants in the isotretinoin group withdrew because of adverse events, but it was not statistically different compared to the placebo group (0/50) (<LINK REF="CMP-027.03" TYPE="ANALYSIS">Analysis 27.3</LINK>).</P>
<P>Local irritation on the face, but not on the scalp or upper extremities (<LINK REF="STD-Alirezai-1994" TYPE="STUDY">Alirezai 1994</LINK>), was significantly more frequent for the isotretinoin-treated group than for the placebo-treated group for all intensities (RR 1.57, 95% CI 1.23 to 2.01, NNT = 3.0; <LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>) as well as severe irritation (RR 17.09, 95% CI 2.35 to 124.10, NNT = 3.1; <LINK REF="CMP-027.05" TYPE="ANALYSIS">Analysis 27.5</LINK>).</P>
<P>To summarise, 0.1% isotretinoin with the dosing regimen used was able to significantly reduce actinic keratoses counts on the face or upper extremities but was not sufficient to result in significant participant complete clearance. Isotretinoin treatment was associated with significant local irritation on the face.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Masoprocol</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Masoprocol versus vehicle</I>
</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>) comparing 10% masoprocol cream to vehicle cream for the treatment of actinic keratoses. Masoprocol or placebo creams were applied on the head and neck once or twice daily for a maximum of 28 days and follow-up assessment was done at 4 weeks after the last application of the study drug. There was possible attrition and other bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 154 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
<P>(N = 154 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>Masoprocol-treated participants had a complete cure rate of 12/113 (11%), which was similar to the cure rate of the vehicle cream; 2/41 (5%), as globally assessed by the investigator. Thus, the RR associated with investigator global improvement indices for cured participant did not significantly favour masoprocol.</P>
<P>In contrast, mean reduction in lesion counts was significantly higher for masoprocol than for vehicle-treated groups (MD 7.30, 95% CI 5.77 to 8.83; <LINK REF="CMP-028.02" TYPE="ANALYSIS">Analysis 28.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 176 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Two of 131 participants in the masoprocol group withdrew because of adverse events, but it was not statistically different to the placebo group (0/45) (<LINK REF="CMP-028.03" TYPE="ANALYSIS">Analysis 28.3</LINK>).</P>
<P>To summarise, 10% masoprocol with the dosing regimen used was able to significantly reduce actinic keratoses counts but was not sufficient to result in significant participant complete clearance as globally assessed by the investigator. Substantial local skin reactions were also associated with masoprocol treatment compared to vehicle.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Masoprocol versus 5-fluorouracil</I>
</HEADING>
<P>This comparison was presented in the 5-fluorouracil section above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Nicotinamide</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Moloney-2010" TYPE="STUDY">Moloney 2010</LINK>) investigating the efficacy of 1% nicotinamide twice daily compared to placebo for the treatment of non-hyperkeratotic actinic keratoses on the face, scalp, and upper limbs. Assessment was performed at three and six months after the beginning of the treatment. There was possible reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
<P>(N = 30 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moloney-2010" TYPE="STUDY">Moloney 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>Mean percentage of reduction in lesion counts was assessed at three and six months. At 3 months, the associated RR favoured nicotinamide that reduced by 21.8 <U>+</U> 10% the number of lesions compared to 10 <U>+</U> 12% for placebo (MD 11.80, 95% CI 3.92 to 19.68; <LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>). The superiority of nicotinamide was lost at six months (<LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moloney-2010" TYPE="STUDY">Moloney 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>None of the 13 participants in the nicotinamide group withdrew because of adverse events; it was not statistically different to the placebo group, which had 2 withdrawals out of 17 participants (<LINK REF="CMP-029.02" TYPE="ANALYSIS">Analysis 29.2</LINK>).</P>
<P>In summary, 1% nicotinamide had very limited short-term efficacy at the dosing regimen used.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Resiquimod</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Szeimies-2008" TYPE="STUDY">Szeimies 2008</LINK>) investigating different concentrations (0.01%, 0.03%, 0.06%, and 0.1%) of resiquimod for the treatment of actinic keratoses on the face or bald scalp. The cream was applied once daily three times per week for four weeks on and eight weeks off, once or twice, i.e. one or two treatment cycles depending on the participant response to treatment. Assessment was performed at eight weeks after the end of treatment. There was possible other bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 132 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 132 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2008" TYPE="STUDY">Szeimies 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Results from individual analyses of participant complete and partial clearance for pairs of resiquimod concentrations are summarised in the following table.</P>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Higher versus lower resiquimod concentrations</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(after 1 cycle)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(after 1 or 2 cycles)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial clearance</P>
<P>(after 1 or 2 cycles)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.06%</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.03% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>&lt; : significantly inferior, <U>&lt;</U> : tendency to be inferior, = : equal, <U>&gt;</U>: tendency to be superior, &gt; : significantly superior, vs = versus</SUP>
</P>
<P>For participant complete clearance, the efficacy of 0.1% resiquimod was generally superior to the other lower concentrations after 1 treatment cycle (0.1% vs 0.01%: RR 2.45, 95% CI 1.64 to 3.65, NNT = 1.7; <LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>) (0.1% vs 0.03%: RR 1.34, 95% CI 1.09 to 1.66, NNT = 4.0; <LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>) (0.1% vs 0.06%: RR 1.76, 95% CI 1.30 to 2.38, NNT = 2.3; <LINK REF="CMP-032.01" TYPE="ANALYSIS">Analysis 32.1</LINK>). After the second cycle of treatment, the differences between resiquimod concentrations were lost.</P>
<P>No significant difference was detected between the resiquimod concentrations used with the outcome 'participant partial clearance' (<LINK REF="CMP-030.02" TYPE="ANALYSIS">Analysis 30.2</LINK>; <LINK REF="CMP-031.02" TYPE="ANALYSIS">Analysis 31.2</LINK>; <LINK REF="CMP-032.02" TYPE="ANALYSIS">Analysis 32.2</LINK>; <LINK REF="CMP-033.02" TYPE="ANALYSIS">Analysis 33.2</LINK>; <LINK REF="CMP-034.02" TYPE="ANALYSIS">Analysis 34.2</LINK>; <LINK REF="CMP-035.02" TYPE="ANALYSIS">Analysis 35.2</LINK>).</P>
<P>In general, higher concentrations had a tendency to be more effective. The results obtained with 0.03% and 0.06% resiquimod suggest that these 2 concentrations might have been "switched" or "mislabelled" (<LINK REF="CMP-034.01" TYPE="ANALYSIS">Analysis 34.1</LINK>; <LINK REF="CMP-034.02" TYPE="ANALYSIS">Analysis 34.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 132 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 132 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2008" TYPE="STUDY">Szeimies 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>In general by body system and individual adverse event</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were significantly more participants in the 0.1% resiquimod group who withdrew because of adverse events compared to those in the 0.01% (RR 27.77, 95% CI 1.72 to 449.47, NNT = not applicable; <LINK REF="CMP-030.03" TYPE="ANALYSIS">Analysis 30.3</LINK>) and 0.03% (RR 2.96, 95% CI 1.08 to 8.13, NNT = 4.0; <LINK REF="CMP-031.03" TYPE="ANALYSIS">Analysis 31.3</LINK>) resiquimod groups. A significant difference was also found between 0.06% and 0.01% resiquimod (RR 22.91, 95% CI 1.40 to 375.77, NNT = not applicable; <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>).</P>
<P>Results from individual analyses of minor adverse events excluding skin irritation for pairs of resiquimod concentrations are summarised in the following table.</P>
<TABLE COLS="8" ROWS="17">
<TR>
<TH ALIGN="CENTER" COLSPAN="8">
<P>Minor adverse events excluding skin irritation</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" COLSPAN="8">
<P>Higher versus lower resiquimod concentrations</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Musculoskeletal and connective tissue</P>
<P>(in general)</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Nervous system</P>
<P>(in general)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin and subcutaneous tissue disorders</P>
<P>(in general)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.06%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>=</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.03% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="4">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="2">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Body as a whole</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Musculoskeletal and connective tissue</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Nervous system</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Fatigue</P>
</TH>
<TH ALIGN="CENTER">
<P>Rigors</P>
</TH>
<TH ALIGN="CENTER">
<P>Arthralgia</P>
</TH>
<TH ALIGN="CENTER">
<P>Myalgia</P>
</TH>
<TH ALIGN="CENTER">
<P>Headache</P>
</TH>
<TH ALIGN="CENTER">
<P>Lethargy</P>
</TH>
<TH ALIGN="CENTER">
<P>Psychiatric disorders</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.1% vs 0.06%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt;</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.06% vs 0.03%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&lt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>0.03% vs 0.01%</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>=</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<U>&gt;</U>
</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>&lt; : significantly less participants, <U>&lt;</U> : tendency to have less participants, = : equal number of participants, <U>&gt;</U> : tendency to have more participants, &gt; : significantly more participants</SUP>
</P>
<P>The numbers of participants experiencing adverse events related to musculoskeletal, connective tissue, and skin and subcutaneous tissue disorders, were similar between the different resiquimod concentrations. In contrast, the numbers of participants with adverse events associated with the nervous system in general were significantly lower in the 0.01% resiquimod group compared to all the other groups, which had similar number of participants (0.03%: RR 9.03, 95% CI 1.20 to 68.22, NNT = 4.3; <LINK REF="CMP-035.09" TYPE="ANALYSIS">Analysis 35.9</LINK>) (0.06%: RR 10.94, 95% CI 1.48 to 80.73, NNT = 3.5; <LINK REF="CMP-033.09" TYPE="ANALYSIS">Analysis 33.9</LINK>) (0.1%: RR 10.29, 95% CI 1.39 to 76.12, NNT = 3.7; <LINK REF="CMP-030.09" TYPE="ANALYSIS">Analysis 30.9</LINK>). Headache, the only individual adverse event with significant difference between 2 resiquimod concentrations (0.06% vs 0.01%: RR 18.55, 95% CI 1.11 to 308.90, NNT = not applicable; <LINK REF="CMP-033.10" TYPE="ANALYSIS">Analysis 33.10</LINK>), is a main contributor to the nervous system-related adverse events in this study, with 6/8 participants in the 0.03% group, 8/10 in the 0.06% group, and 7/10 in the 0.1% group suffering from it.</P>
<P>To summarise, 0.1% resiquimod was more effective than the other lower concentrations only if the participants were treated with 1 cycle, i.e. once per day 3 times per week for 4 weeks on and 8 weeks off. Treatment with 0.01% resiquimod was generally associated with less adverse events compared to the other 3 concentrations used.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sunscreen</HEADING>
<P>Sunscreen is not generally a treatment for actinic keratosis, but it is a means of preventing actinic keratoses. However, one study investigated the role of sunscreen in the cure of existing lesions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Sunscreen SPF 17 (8% 2-ethyl-hexyl p-methoxycinnamate/2% 4-tert-butyl-4-methoxy-4-dibenzoylmethane) versus placebo</I>
</HEADING>
<P>This intervention was addressed by one study (<LINK REF="STD-Thompson-1993" TYPE="STUDY">Thompson 1993</LINK>) comparing sunscreen or placebo creams applied as needed daily for seven months to treat solar keratoses on the head, neck, forearms, and hands. Assessment was performed at the end of the seven-month treatment. There was possible attrition bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 431 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Thompson-1993" TYPE="STUDY">Thompson 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>Mean changes [reduction (-) or increase (+)] in lesion counts (<LINK REF="CMP-036.01" TYPE="ANALYSIS">Analysis 36.1</LINK>) were assessed at the end of treatment. The sunscreen-treated group showed a small mean decrease in lesion counts (-0.6 <U>+</U> 4.34, SD), whereas the placebo-treated group showed a mean increase in lesion counts (1 <U>+</U> 4.46, SD), demonstrating that sunscreen application could not only prevent but also treat actinic keratoses. The resulting mean difference of -1.60 (95% CI -2.43 to -0.77) favoured the use of sunscreen.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 588 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Thompson-1993" TYPE="STUDY">Thompson 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>The authors of the <LINK REF="STD-Thompson-1993" TYPE="STUDY">Thompson 1993</LINK> study mentioned that 28 and 32 participants in the placebo and sunscreen groups, respectively, withdrew from the study because of skin reactions. We were unable to perform statistical analysis as the participants who withdrew were not grouped by individual reason, and some participants had multiple reasons. Because the number of participants in each treatment group was similar for withdrawal due to skin reactions, withdrawal in general, and who completed the study, we can assume that there was no significant difference in the number of participants who withdrew because of adverse events between the placebo and sunscreen groups.</P>
<P>To summarise, sunscreen might help to treat actinic keratoses in addition to its preventive role, but the efficacy was limited.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DL-&#945;-tocopherol (vitamin E)</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Foote-2009" TYPE="STUDY">Foote 2009</LINK>) comparing 12.5% DL-&#945;-tocopherol (vitamin E) and placebo applied twice daily for 6 months on the right/left arms for treatment of actinic keratoses. Assessment was performed at the end of the six-month treatment. There was possible other bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 42 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Foote-2009" TYPE="STUDY">Foote 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>No significant difference in mean reduction in lesion counts (<LINK REF="CMP-037.01" TYPE="ANALYSIS">Analysis 37.1</LINK>) was observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 48 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Foote-2009" TYPE="STUDY">Foote 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>In this intraindividual study, 2 of the 48 participants withdrew from the study because of unrelated illness.</P>
<P>To summarise, vitamin E at the dosing regimen used was not more efficient than placebo to treat actinic keratoses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tretinoin</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Tretinoin with 5-fluorouracil</I>
</HEADING>
<P>This comparison was presented in the 5-fluorouracil section above.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Tretinoin versus arotinoid methyl sulfone (Ro 14-9706)</I>
</HEADING>
<P>This comparison was presented in the arotinoid methyl sulfone section above</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Prescription-based oral drugs</HEADING>
<P>Only one intervention for the treatment of actinic keratoses was given orally: etretinate.</P>
<SUBSECTION>
<HEADING LEVEL="5">Etretinate</HEADING>
<P>This intervention was addressed by one study (<LINK REF="STD-Moriarty-1982" TYPE="STUDY">Moriarty 1982</LINK>) investigating the efficacy of etretinate for the treatment of actinic keratoses by comparing it to placebo treatment. Two parts were involved in this double-blind cross-over study, and only the first part is presented in this review. The first part involved oral etretinate, a 225 mg tablet 3 times daily for 2 months for 1 group, and the other group taking placebo with the same regimen. Assessment was performed at the end of the two-month treatment. The anatomical locations of the lesions analysed were not specified. There was possible attrition bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 50 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moriarty-1982" TYPE="STUDY">Moriarty 1982</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Complete remission rates (converted to participant complete clearance) after part 1 were better in the etretinate group (5/25 = 20%) compared to placebo (0/25 = 0%), but it was not statistically significant (RR 11.00, 95% CI 0.64 to 188.95; <LINK REF="CMP-038.01" TYPE="ANALYSIS">Analysis 38.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 50 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 50 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moriarty-1982" TYPE="STUDY">Moriarty 1982</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (maybe)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Five (etretinate = 3, placebo = 2) participants out of 50 dropped out of the study, but the reasons were not specified.</P>
<P>Because the adverse events were reported for both parts of the study, the quantitative data were not included in this review. Adverse effects were consistent with vitamin A-type side-effects (i.e. dry mouth, skin rash, desquamation, etc) and were experienced within the first three to four weeks of starting treatment by a large number of participants, but were reversed by reducing dosage. Many participants (17/44 = 39%, at the end of the 2 parts of the cross-over study) required reduction in dosage due to toxicity of etretinate (hepatotoxicity), but response was still maintained when dosage was reduced. Hyperlipidaemia (raised serum lipid levels) associated with etretinate was not assessed in this study.</P>
<P>To summarise, etretinate at the dosing regimen used was not statistically more efficient than placebo to treat actinic keratoses and was associated with adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Mechanical interventions</HEADING>
<P>The only mechanical intervention reported in the included studies was laser resurfacing, and the different types of laser resurfacing are presented in alphabetical order: carbon dioxide and Er:YAG laser resurfacing. Both interventions are field-directed treatments.</P>
<SUBSECTION>
<HEADING LEVEL="5">Carbon dioxide laser resurfacing</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>) comparing the efficacy of 2 passes of carbon dioxide laser resurfacing with 5-fluorouracil applied twice daily for 3 weeks and with trichloroacetic acid peel in the treatment of actinic keratoses on the face. Assessment was performed at 12 weeks after the end of the treatment. There was possible performance, detection, and attrition bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 27 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>The mean percentage of reduction in lesion counts showed a tendency to favour resurfacing compared to 5-fluorouracil treatment (<LINK REF="CMP-039.01" TYPE="ANALYSIS">Analysis 39.1</LINK>) or trichloroacetic acid peel (<LINK REF="CMP-040.01" TYPE="ANALYSIS">Analysis 40.1</LINK>), but the differences were not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 27 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 27 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>Two of 8 participants in the carbon dioxide laser resurfacing group withdrew because of adverse events (incomplete treatment due to intolerance), whereas no participants withdrew in the trichloroacetic acid peel (0/10) and 5-fluorouracil (0/9) groups. However, there was no statistically significant difference (<LINK REF="CMP-039.02" TYPE="ANALYSIS">Analysis 39.2</LINK>; <LINK REF="CMP-040.02" TYPE="ANALYSIS">Analysis 40.2</LINK>) between the treatments.</P>
<P>No postinflammatory pigmentary alteration or scarring was noted in the three treatment arms.</P>
<P>To summarise, the small sample size used in this study did not allow us to conclude on the superiority for efficacy or safety of carbon dioxide laser resurfacing over fluorouracil or trichloroacetic acid peel.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Er:YAG laser resurfacing</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Ostertag-2006" TYPE="STUDY">Ostertag 2006</LINK>) comparing the efficacy of Er:YAG laser resurfacing and 5% 5-fluorouracil applied twice daily for 4 to 7 weeks for the treatment of actinic keratoses on the face, scalp, or both. Assessments were performed at 3, 6, and 12 months after the end of treatment. There was possible reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 55 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ostertag-2006" TYPE="STUDY">Ostertag 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>A statistical analysis could not be performed because the associated standard deviations were not provided with the mean reductions. The means in <LINK REF="CMP-041.01" TYPE="ANALYSIS">Analysis 41.1</LINK> suggested that the 2 treatments were equally efficient at reducing actinic keratosis lesions, whereas the mean percentages in <LINK REF="CMP-041.02" TYPE="ANALYSIS">Analysis 41.2</LINK> suggested better efficacy for laser resurfacing at 6 and 12 months. A statistical significance was stated by the authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 55 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 55 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 55 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 55 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ostertag-2006" TYPE="STUDY">Ostertag 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>Overtime</P>
</TD>
<TD ALIGN="CENTER">
<P>Overtime</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>One participant withdrew due to an adverse event (death) in the 5-fluorouracil-treated group, which was not significantly different to the Er:YAG laser resurfacing group (<LINK REF="CMP-041.03" TYPE="ANALYSIS">Analysis 41.3</LINK>).</P>
<P>The adverse events (skin irritation and minor adverse events) could be categorised into 3 groups:<BR/>1) adverse events present only after treatment;<BR/>2) adverse events developing after the treatment, i.e. during the follow-up period; and<BR/>3) adverse events present after the treatment and at follow-up. Infection was present only at the end of the treatment.</P>
<P>The number of participants who developed an infection was not significantly different between the two treatments but was higher at most time points with laser resurfacing. Acne and milia developed during the follow-up period. The number of participants with acne or milia was higher in the laser resurfacing group. The exception was acne at 12 months, which was similar between the two groups. The number of participants experiencing pain, crustea, and irritation tended to be higher in the fluorouracil treated-group at the end of treatment, but it became higher in the laser resurfacing group during follow-up. Only the number of participants with crustea was significantly different at the end of treatment (RR 0.46, 95% CI 0.27 to 0.79, NNT = 2.4; <LINK REF="CMP-041.06" TYPE="ANALYSIS">Analysis 41.6</LINK>).</P>
<P>In terms of cosmetic outcomes, hypopigmentation got worse over time for laser resurfacing, significantly favouring 5-fluorouracil at 12 months (RR 11.57, 95% CI 1.61 to 83.00; <LINK REF="CMP-041.10" TYPE="ANALYSIS">Analysis 41.10</LINK>), corresponding to a NNT of 2.6 for an additional harmful outcome with laser re-surfacing. Scarring was seen only in the laser resurfacing group but was not significantly different than in the fluorouracil group. In contrast, significantly more participants improved on the photoageing score with the laser resurfacing at 6 months (RR 1.57, 95% CI 1.01 to 2.43, NNT = 3.5) and 12 months (RR 1.70, 95% CI 1.01 to 2.88, NNT = 3.3) (<LINK REF="CMP-041.12" TYPE="ANALYSIS">Analysis 41.12</LINK>) based on evaluation by 2 blinded investigators.</P>
<P>To summarise, the superiority of Er:YAG laser resurfacing over 5-fluorouracil still needs to be demonstrated. More adverse events were associated with Er:YAG laser resurfacing compared to 5-fluorouracil; however, overall ageing scores were better with Er:YAG laser resurfacing.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Chemical interventions</HEADING>
<P>Chemical interventions included studies on cryotherapy, photodynamic therapy, and trichloroacetic acid peel, which are presented in alphabetical order.</P>
<SUBSECTION>
<HEADING LEVEL="5">Cryotherapy</HEADING>
<P>Cryotherapy was either compared with or combined with topical treatments or other chemical interventions, e.g. photodynamic therapy. Thus, the results are presented in two corresponding sections. Within each section, the comparisons are presented in alphabetical order of the comparison treatment. Cryotherapy is a lesion-directed treatment for detectable lesions, whereas topical treatments are generally field-directed treatments, which treat both detectable and subclinical lesions. Photodynamic therapy can be used for single lesion or field-directed treatments. Cryotherapy and photodynamic therapy are provider-administered, whereas topical treatments are administered by participants, and their efficacy is highly dependent on the compliance of the participants. These factors might influence the treatment efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Comparisons with topical treatments</I>
</HEADING>
<P>
<U>Cryotherapy compared to betulin-based oleogel</U>
</P>
<P>This intervention was addressed by one study (<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>) comparing cryotherapy with liquid nitrogen to betulin-based oleogel alone on the face, scalp, or other locations. Cryotherapy of participant lesions was performed once on lesions on the face and twice on lesions on the rest of the body, whereas betulin-based oleogel was applied twice daily for an unspecified duration. Assessment was performed at three months after the beginning of the treatment. There was possible performance and detection bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Similar participant complete or partial (<U>&gt;</U> 75%) clearance rates were observed for the 2 treatments (<LINK REF="CMP-042.01" TYPE="ANALYSIS">Analysis 42.1</LINK>; <LINK REF="CMP-042.02" TYPE="ANALYSIS">Analysis 42.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, the regimens used in this study for cryotherapy with liquid nitrogen and betulin-based oleogel had similar efficacy for the treatment of actinic keratoses.</P>
<P>
<U>Cryotherapy compared to 5-fluorouracil</U>
</P>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>) comparing cryotherapy with liquid nitrogen performed once or twice with 2-week intervals to 5% 5-fluorouracil applied twice daily for 4 weeks on the head, neck, and décolleté. Assessment was performed at 4 (5-fluorouracil) or 6 (cryotherapy) weeks after the end of treatment and at 1-year follow-up. There was possible performance and detection bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 49 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>5% 5-fluorouracil was significantly more effective than cryotherapy to completely clear participants of lesions after the treatment (RR 0.71, 95% CI 0.54 to 0.94, NNT = 3.6) as well as at 12-month follow-up (RR 0.12, 95% CI 0.02 to 0.89, NNT = 3.4; <LINK REF="CMP-043.01" TYPE="ANALYSIS">Analysis 43.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 49 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 49 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The same percentage (4%) of the participants in the 5% 5-fluorouracil group and cryotherapy group showed excellent cosmetic outcome as assessed by the investigator. Significantly more participants in the 5-fluorouracil group had better skin appearance (RR 0.27, 95% CI 0.11 to 0.72, NNT = 2.3; <LINK REF="CMP-043.03" TYPE="ANALYSIS">Analysis 43.3</LINK>).</P>
<P>To summarise, cryotherapy was less efficacious than 5% 5-fluorouracil at treating actinic keratoses.</P>
<P>
<U>Cryotherapy compared to imiquimod</U>
</P>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>) comparing cryotherapy and 5% imiquimod. Cryotherapy was performed once or twice with a 2-week interval, whereas imiquimod was applied 3 times per week for 4 weeks followed by 4 weeks rest, and repeated if needed. There was possible performance and detection bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 51 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>No significant difference was found in the number of participants completely cleared between 5% imiquimod applied for a total of 4 weeks and cryotherapy treatments, but there were more participants with clearance with imiquimod (22//26 compared with 17/25 on cryotherapy), which may have been due to the additional treatment of subclinical lesions (RR 0.80, 95% CI 0.59 to 1.10; <LINK REF="CMP-044.01" TYPE="ANALYSIS">Analysis 44.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 51 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 51 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Krawtchenko-2007" TYPE="STUDY">Krawtchenko 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>Assessment by the investigator showed that 4% and 81% of the participants had excellent cosmetic outcomes for cryotherapy and imiquimod treatments, respectively (RR 0.05, 95% CI 0.01 to 0.34, NNT = 1.3; <LINK REF="CMP-044.02" TYPE="ANALYSIS">Analysis 44.2</LINK>). In particular, the skin quality was better with imiquimod treatment (RR 0.19, 95% CI 0.08 to 0.47, NNT = 1.5; <LINK REF="CMP-044.03" TYPE="ANALYSIS">Analysis 44.3</LINK>).</P>
<P>To summarise, cryotherapy and 5% imiquimod had similar efficacy, but imiquimod had significantly better cosmetic outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Comparisons with photodynamic treatments</I>
</HEADING>
<P>
<U>Cryotherapy versus 5-aminolaevulinic acid (ALA)- photodynamic therapy (PDT)</U>
</P>
<P>This intervention was addressed by one open study (<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>) comparing cryotherapy with photodynamic therapy (PDT) using red light and auto-adhesive ALA patches. Both interventions treated participant individual lesions on the head once, and no prior lesion preparation was performed. Assessment was performed 12 weeks after the end of treatment. There was possible performance, detection, attrition, and reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 255 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Analysis of participant complete clearance clearly favoured the ALA-PDT treatment over cryotherapy (RR 0.76, 95% CI 0.61 to 0.96, NNT = 7.2; <LINK REF="CMP-046.01" TYPE="ANALYSIS">Analysis 46.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 297 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 297 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>Qualitative</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>Significantly more participants treated with ALA-PDT experienced skin irritation during (RR 0.63, 95% CI 0.54 to 0.74, NNT = 3.2) and 1 day after (RR 0.27, 95% CI 0.16 to 0.46, NNT = 3.7) treatment compared to cryotherapy (<LINK REF="CMP-046.02" TYPE="ANALYSIS">Analysis 46.2</LINK>).</P>
<P>The minor adverse events reported in the cryotherapy group were eyelid oedema and swollen face, whereas pyoderma and emotional distress were documented for ALA-PDT group. Headaches were reported in both groups.</P>
<P>In summary, in this single study, ALA-PDT treatment was superior to cryotherapy for efficacy outcomes, but more skin irritation was associated with ALA-PDT.</P>
<P>
<U>Cryotherapy versus methyl aminolevulinate (MAL)-photodynamic therapy (PDT)</U>
</P>
<P>This intervention was addressed by 4 studies (<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>; <LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>; <LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>) comparing cryotherapy and PDT with 16% MAL for the treatment of actinic keratoses. All studies were open and used red light PDT. Characteristics of the studies are presented in the following table. There was possible performance, detection, and reporting bias for all studies, attrition bias for all studies except <LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>, and other bias for <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK> and <LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>.</P>
<TABLE COLS="5" ROWS="14">
<TR>
<TH ALIGN="CENTER">
<P>Characteristic</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Study design</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Anatomical locations</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, scalp,</P>
<P>others (&lt; 10%)</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Upper and lower extremities (98%), trunk, neck</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Prior preparation of lesions (scale and crust removal)</P>
</TD>
<TD ALIGN="CENTER">
<P>Cryotherapy: yes</P>
<P>PDT: yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Cryotherapy: no</P>
<P>PDT: yes</P>
</TD>
<TD ALIGN="CENTER">
<P>PDT: yes</P>
</TD>
<TD ALIGN="CENTER">
<P>PDT: yes (except mild lesions = 12%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of treatment cycle</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (face and scalp) or 2 (other locations)</P>
</TD>
<TD ALIGN="CENTER">
<P>Cryotherapy : 1</P>
<P>PDT: 2</P>
</TD>
<TD ALIGN="CENTER">
<P>1 or 2</P>
</TD>
<TD ALIGN="CENTER">
<P>1 or 2</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of weeks between treatments</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of freeze-thaw cycles per treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Total freezing time (sec)</P>
</TD>
<TD ALIGN="CENTER">
<P>24 <U>+</U> 18</P>
</TD>
<TD ALIGN="CENTER">
<P>12 to 26</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD ALIGN="CENTER">
<P>20 <U>+</U> 14</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Individual lesion or field-directed treatment (MAL)</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Occlusion time with 16% MAL (hour)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT intensity</P>
<P>(mW/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>70 to 200</P>
</TD>
<TD ALIGN="CENTER">
<P>50 to 250</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT dose</P>
<P>(J/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Type of light source</P>
</TD>
<TD ALIGN="CENTER">
<P>Non-coherent light</P>
</TD>
<TD ALIGN="CENTER">
<P>(CureLIght)</P>
</TD>
<TD ALIGN="CENTER">
<P>LED (Aktilite CL 128 lamp)</P>
</TD>
<TD ALIGN="CENTER">
<P>LED (Aktilite CL 128 lamp)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Time of assessment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<P>Most of the studies presented 'lesion complete response' as an efficacy outcome, which was not included in this review.</P>
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 240 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>
<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK> and <LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK> presented the percentages without the associated standard deviations. Thus, no statistical analysis could be performed. Based on these percentages presented in <LINK REF="CMP-045.01" TYPE="ANALYSIS">Analysis 45.1</LINK> and the data presented in the overview tables for cryotherapy and photodynamic therapy, the two treatments seem to have similar efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 619 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(see table below)</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Only for MAL-PDT and not included in the analysis</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual study not included in meta-analysis</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual study not included in meta-analysis</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>In the parallel-group studies, there was no difference in the number of participants who withdrew because of adverse events (<LINK REF="CMP-045.02" TYPE="ANALYSIS">Analysis 45.2</LINK>). In the intraindividual studies, 4 of 119 (<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>) and 2 of 121 (<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>) participants withdrew because of adverse events and 1 of them was related to MAL-PDT treatment.</P>
<P>
<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK> mentioned that the types of adverse events observed were mainly photosensitivity reaction (43% of 121 participants) and cold exposure injury (62% of 121 participants) for the MAL-PDT and cryotherapy groups, respectively. Similar qualitative observation was mentioned by <LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK> (N = 119).</P>
<P>The types of cosmetic outcomes reported by the four studies are summarised in the following table.</P>
<TABLE COLS="5" ROWS="6">
<TR>
<TH ALIGN="CENTER">
<P>Parameter</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK>
</P>
<P>(N = 122 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
<P>( N = ? participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Morton-2006" TYPE="STUDY">Morton 2006</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Kaufmann-2008" TYPE="STUDY">Kaufmann 2008</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Evaluation by investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Evaluation by participant</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Outcome</P>
</TD>
<TD ALIGN="LEFT">
<P>1) excellent or good</P>
<P>2) fair or poor</P>
<P/>
</TD>
<TD ALIGN="LEFT">
<P>Excellent</P>
</TD>
<TD ALIGN="LEFT">
<P>1) excellent</P>
<P>2) good</P>
<P>3) fair</P>
<P>4) poor</P>
</TD>
<TD ALIGN="LEFT">
<P>1) excellent</P>
<P>2) good</P>
<P>3) fair</P>
<P>4) poor</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Reported per participant</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
<P>(only for participants with</P>
<P>
<U>&gt;</U> 75% reduction of total lesions)</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
<P>(only for participants with</P>
<P>100% reduction of total lesions)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Reported per lesion</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
</TABLE>
<P>Because participants or right/left sides were randomised and not the lesions, only the data reported by participants were analysed. <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK> reported the percentages of completely cleared participants with excellent cosmetic outcome, but the number of participants completely cleared was not specified and the standard deviations associated with the percentages were not provided. Thus, no statistical analysis could be performed on these data. Similar percentages were obtained for investigator and participant assessments for MAL-PDT (83% vs 76%) and cryotherapy (51% vs 56%). The authors reported significant differences between MAL-PDT and cryotherapy groups. The investigator (RR 0.84, 95% CI 0.74 to 0.95, NNT = 6.5; <LINK REF="CMP-045.03" TYPE="ANALYSIS">Analysis 45.3</LINK>) and participant (RR 0.93, 95% CI 0.86 to 1.01, NNT = 14.6; <LINK REF="CMP-045.04" TYPE="ANALYSIS">Analysis 45.4</LINK>) evaluations in the <LINK REF="STD-Szeimies-2002" TYPE="STUDY">Szeimies 2002</LINK> study also supported a better cosmetic outcome in the MAL-PDT group.</P>
<P>To summarise, because most of the efficacy outcomes reported could not be included in our analyses, it is difficult to determine the relative efficacy of MAL-PDT and cryotherapy. Data from one study suggested equivalence between the two treatments. MAL-PDT treatment seems to result in better cosmetic outcomes than cryotherapy.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Photodynamic therapy</HEADING>
<P>Photodynamic therapy employs light sources and photosensitising agents that may differ between studies. As this is a relatively new treatment method, testing different combinations of variables is necessary to attempt to identify the optimal PDT treatment form and regimen. Light sources vary from polychromatic to pulsed laser. Photosensitising agents aminolevulinic acid (ALA) and newer methyl-aminolevulinic acid (MAL) were both used, depending on the study. Thus, results are presented in two sections: photodynamic therapy with ALA and photodynamic therapy with MAL. Within these sections, the results are presented in the following order: 1) comparisons between ALA or MAL and placebo, 2) comparisons with different photodynamic therapy variables, and 3) comparisons with other treatments. Photodynamic therapy could be used to treat individual lesions or a field.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA)</I>
</HEADING>
<P>
<U>ALA-PDT versus placebo-PDT</U>
</P>
<P>This intervention was addressed by five studies (<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>; <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>; <LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>) investigating the use of aminolevulinic acid (ALA) and photodynamic therapy (PDT) compared to placebo-PDT to treat actinic keratoses. Characteristics of the studies are presented in the following table. There was possible performance (<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>; <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>), detection (<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>), attrition (<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>), reporting (<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>), and other (<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>) bias.</P>
<TABLE COLS="5" ROWS="15">
<TR>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Blue light</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Red light</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Characteristic</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>
</P>
<P>and</P>
<P>
<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Study design</P>
</TD>
<TD ALIGN="CENTER">
<P>Assessor-blinded</P>
<P>intraindividual</P>
</TD>
<TD ALIGN="CENTER">
<P>Assessor-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Anatomical locations</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Head</P>
</TD>
<TD ALIGN="CENTER">
<P>Face, bald scalp, or both</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Prior preparation of lesions (e.g. scale and crust removal)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>No</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of treatment cycle</P>
</TD>
<TD ALIGN="CENTER">
<P>1 or 2</P>
</TD>
<TD ALIGN="CENTER">
<P>1 or 2</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1 or 2</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of weeks between treatments</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Individual lesion or field-directed treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>ALA formulation</P>
</TD>
<TD ALIGN="CENTER">
<P>20% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>20% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>Patch containing 8 mg</P>
</TD>
<TD ALIGN="CENTER">
<P>BF-200 gel</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Occlusion time (hour)</P>
</TD>
<TD ALIGN="CENTER">
<P>14 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>14 to 18</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT intensity</P>
<P>(mW/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>3, 5, 10</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>Aktilite: 50-70</P>
<P>PhotoDyn 750: 196</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT dose</P>
<P>(J/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>2, 5,10</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
<TD ALIGN="CENTER">
<P>Aktilite: 37</P>
<P>PhotoDyn 750: 170</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Illumination time (seconds)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>1000</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>Aktilite: N/A</P>
<P>PhotoDyn 750: 900</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Type of light source</P>
</TD>
<TD ALIGN="CENTER">
<P>Non-laser fluorescent</P>
<P>(Dusa BLU-417)</P>
</TD>
<TD ALIGN="CENTER">
<P>visible</P>
<P>(Blu-U)</P>
</TD>
<TD ALIGN="CENTER">
<P>LED</P>
<P>(Aktilite CL 128 lamp or Omnilux)</P>
</TD>
<TD ALIGN="CENTER">
<P>LED</P>
<P>(Aktilite CL 128 lamp)</P>
<P>or incoherent (PhotoDyn 750)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Time of assessment</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of each treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>8 weeks after the end of each treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of each treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of each treatment</P>
</TD>
</TR>
</TABLE>
<P>Subgroup analyses were performed to compare blue and red light photodynamic therapies. In addition, one study (<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>) provided efficacy data for individual anatomical locations, i.e. face or scalp, allowing additional subgroup analysis for blue light ALA or placebo with photodynamic treatment.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 701 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 243 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>intraindividual and not included in meta-analysis</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Most of the studies gave a second treatment to uncured lesions after the first treatment, and they provided efficacy outcomes 8 to 12 weeks after the first treatment (1 treatment) and after 4 to 12 weeks after the last treatment (1 or 2 treatments). Thus, separate comparisons were performed for the number of treatments received.</P>
<P>In <LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>, lesions treated with ALA were completely cleared in 45.7% (16/35) of the participants after 1 treatment using blue light PDT, whereas lesions treated with placebo were completely cleared in only 5.7% (2/35). Similarly, the number of participants with complete clearance was significantly higher in the ALA-PDT group than placebo-PDT group for both blue and red light after one treatment (<LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>). The amplitude of the effect was similar between blue (RR 6.22, 95% CI 2.88 to 13.43, NNT = 2.0; <LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>) and red light (RR 5.94, 95% CI 3.35 to 10.54, NNT = 2.0; <LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>), but a larger increase in the RR associated with blue light treatment following an additional treatment on uncured lesions was observed (blue light: RR 9.33, 95% CI 3.59 to 24.26, NNT = 1.8; and red light: RR 6.20, 95% CI 2.40 to 15.99, NNT = 2.0; <LINK REF="CMP-047.02" TYPE="ANALYSIS">Analysis 47.2</LINK>). This difference might be explained by the fact that only one study with red light performed a second treatment: <LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK> used two light sources to reflect more medical practices. A lower efficacy was obtained with the ALA/PhotoDyn 750 lamp (26/49 = 53%) than with ALA/Aktilite CL 128 (27/31 = 87%). The PhotoDyn lamp was used in 60% of the ALA and placebo participants, resulting in lower efficacy than the other 2 studies using only the Aktilite lamp after the first treatment.</P>
<P>Similar results were obtained with participant partial clearance for blue light ALA-PDT with a RR of 4.38, 95% CI 2.47 to 7.79, NNT = 1.8 for 1 treatment (<LINK REF="CMP-047.04" TYPE="ANALYSIS">Analysis 47.4</LINK>) and a RR of 6.51, 95% CI 3.22 to 13.15, NNT = 1.6 for 1 or 2 treatments (<LINK REF="CMP-047.05" TYPE="ANALYSIS">Analysis 47.5</LINK>). There was no difference in the RRs for participants completely (<LINK REF="CMP-047.03" TYPE="ANALYSIS">Analysis 47.3</LINK>) or partially (<LINK REF="CMP-047.06" TYPE="ANALYSIS">Analysis 47.6</LINK>) cleared of lesions on the face or scalp. For both outcomes and both sites, ALA-PDT was significantly better than placebo-PDT.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="5">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 701 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 300 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 543 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(see table below)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>
</P>
<P>
<LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual study not included in meta-analysis</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The number of participants experiencing skin irritation was significantly higher in the ALA-PDT group compared to placebo-PDT during illumination (RR 8.94, 95% CI 4.62 to 17.31, NNT = 1.3; <LINK REF="CMP-047.07" TYPE="ANALYSIS">Analysis 47.7</LINK>) and after the treatment (RR 59.72, 95% CI 3.75 to 952.48, NNT = not applicable; <LINK REF="CMP-047.07" TYPE="ANALYSIS">Analysis 47.7</LINK>).</P>
<P>None of the adverse events reported for blue light photodynamic therapy [injury (<LINK REF="CMP-047.08" TYPE="ANALYSIS">Analysis 47.8</LINK>), hypertension (<LINK REF="CMP-047.09" TYPE="ANALYSIS">Analysis 47.9</LINK>), skin hypertrophy (<LINK REF="CMP-047.11" TYPE="ANALYSIS">Analysis 47.11</LINK>) and headache (<LINK REF="CMP-047.12" TYPE="ANALYSIS">Analysis 47.12</LINK>)] were significantly different between the two treatments. For red light photodynamic therapy, <LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK> and <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK> reported skin discolouration in one participant in the ALA group, which was not significantly different between ALA and placebo-treated participants (<LINK REF="CMP-047.10" TYPE="ANALYSIS">Analysis 47.10</LINK>).</P>
<P>The types of cosmetic outcomes reported by the five studies are summarised in the following table.</P>
<TABLE COLS="5" ROWS="6">
<TR>
<TH ALIGN="CENTER">
<P>Parameter</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Jeffes-2001" TYPE="STUDY">Jeffes 2001</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK>
</P>
<P>(N = 114 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Evaluation by investigator</P>
</TD>
<TD ALIGN="CENTER">
<P>x (not specified)</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Evaluation by participant</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Outcome</P>
</TD>
<TD ALIGN="LEFT">
<P/>
<P>Changes in pigmentation</P>
<P/>
</TD>
<TD ALIGN="LEFT">
<P>Changes in pigmentation</P>
</TD>
<TD ALIGN="LEFT">
<P>1) excellent</P>
<P>2) good</P>
<P>3) fair</P>
<P>4) poor</P>
</TD>
<TD ALIGN="LEFT">
<P>General outcome:</P>
<P>1) very good or good</P>
<P>2) unsatisfactory/impaired outcome</P>
<P>Skin quality (qualitative)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Reported per participant</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Reported per lesion</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x (cleared lesions only)</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
</TR>
</TABLE>
<P>Cosmetic outcomes were reported by all studies, but only <LINK REF="STD-Szeimies-2010b" TYPE="STUDY">Szeimies 2010b</LINK> reported its outcome per participant. The cosmetic outcomes assessed by the investigator were very good or good in 49% of ALA-PDT and 27% in placebo-PDT groups, which was significantly different (RR 1.83, 95% CI 1.03 to 3.25, NNT = 4.5; <LINK REF="CMP-047.13" TYPE="ANALYSIS">Analysis 47.13</LINK>).</P>
<P>To summarise, ALA-PDT was more effective than placebo-PDT, and the efficacy is similar for blue or red light photodynamic therapy. For red light photodynamic therapy, using Aktilite CL 128 lamp gave better results than PhotoDyn 750 lamp. ALA treatment was generally associated with more skin irritation than placebo; however, ALA-PDT resulted in better cosmetic outcomes.</P>
<P>
<U>ALA-PDT: comparison between types of light source</U>
</P>
<P>This intervention was addressed by one study (<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>) investigating ALA with one hour incubation followed by illumination with blue light or pulsed dye laser (PDL) for field-directed treatment on the face or scalp, twice with a month interval. Assessment was performed at four weeks after the end of treatment. There was possible performance, detection, and reporting bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 24 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 24 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>More participants receiving ALA-blue light PDT compared to ALA-PDL had complete (6/12 compared to 1/12) (<LINK REF="CMP-048.01" TYPE="ANALYSIS">Analysis 48.1</LINK>) or partial (&gt;75%) (9/12 compared to 5/12) (<LINK REF="CMP-048.02" TYPE="ANALYSIS">Analysis 48.2</LINK>) clearance, respectively; however, this was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 24 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 24 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>None of the three cosmetic outcomes reported, i.e. improvements in global response, tactile roughness, and mottled hyperpigmentation, were significantly different between the two light sources (<LINK REF="CMP-048.03" TYPE="ANALYSIS">Analysis 48.3</LINK>; <LINK REF="CMP-048.04" TYPE="ANALYSIS">Analysis 48.4</LINK>; <LINK REF="CMP-048.05" TYPE="ANALYSIS">Analysis 48.5</LINK>).</P>
<P>To summarise, insufficient data were provided to determine the superiority of one source of light over the other for field-directed treatment of actinic keratoses with ALA-PDT.</P>
<P>
<U>ALA-PDT: comparison for different incubation times with ALA</U>
</P>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Hauschild-2009c" TYPE="STUDY">Hauschild 2009c</LINK>) comparing the efficacy of self-adhesive ALA patch treating individual lesions for different incubation times (0.5, 1, 2, and 4 hours) before PDT (red light) treatment to treat actinic keratoses on the head and face. Assessments were performed at 4 and 8 weeks after the end of treatment. There was possible attrition and reporting bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 140 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009c" TYPE="STUDY">Hauschild 2009c</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Efficacy was assessed at four (<LINK REF="CMP-049.01" TYPE="ANALYSIS">Analysis 49.1</LINK>) and eight weeks (<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>), and participant complete clearance was analysed for subgroups of the different combinations between shorter and longer incubation times. At 4 weeks, analyses of participant complete clearance did not favour shorter or longer times except for comparison between the shortest (0.5 hours) and the longest (4 hours), which favoured the longest incubation time (RR 0.50, 95% CI 0.26 to 0.95, NNT = 3.8). In contrast, all comparisons favoured the longer incubation times with the exception of 1 hour versus 2 hours at week 8 (<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>). Thus, a longer incubation with ALA gave better long-term results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 149 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 149 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hauschild-2009c" TYPE="STUDY">Hauschild 2009c</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (maybe)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Of 149 participants, 9 were not included in the final efficacy analysis and 3 of them terminated the study prematurely; however, the authors did not give more details about the reasons or associated treatments.</P>
<P>Five of 149 participants experienced adverse events related to treatment, which were 3 headaches (1 in each of the 0.5-, 2-, and 4-hour groups), 1 nose bleed (in the 4-hour group), and a mild increase in alanine transaminase (1 in the 0.5-hour group). None of these adverse events were significantly associated with the incubation time (mild increase in alanine transaminase: <LINK REF="CMP-049.03" TYPE="ANALYSIS">Analysis 49.3;</LINK> headache: <LINK REF="CMP-049.04" TYPE="ANALYSIS">Analysis 49.4;</LINK> and nose bleed: <LINK REF="CMP-049.05" TYPE="ANALYSIS">Analysis 49.5</LINK>). Other adverse events were reported but not in relation to the incubation groups.</P>
<P>To summarise, longer incubation with ALA resulted in an increase in long-term efficacy.</P>
<P>
<U>ALA-PDT versus 5-fluorouracil</U>
</P>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>) comparing ALA-PDT field-directed treatment (twice with a 1-month interval) using 2 different types of light sources (blue light and pulse dye laser) with 0.5% fluorouracil applied once or twice daily for 4 weeks on the face or scalp (field-directed treatment). Assessment was performed four weeks after the end of treatment. There was possible performance, detection, and reporting bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 36 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 36 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Analyses of participant complete (<LINK REF="CMP-050.01" TYPE="ANALYSIS">Analysis 50.1</LINK>) and partial (&gt; 75%) (<LINK REF="CMP-050.02" TYPE="ANALYSIS">Analysis 50.2</LINK>) clearance showed that the PDT treatments with blue light and the pulse dye laser (PDL) were comparable to 5-fluorouracil. However, a tendency to favour 5-fluorouracil over ALA-PDT with pulsed dye laser could be observed for both outcomes (complete: RR 0.17, 95% CI 0.02 to 1.18; partial: RR 0.56, 95% CI 0.26 to 1.17), but this was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 36 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 36 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>One of 12 participants in the 5-fluorouracil group withdrew because of adverse events compared to none of the 24 participants in the ALA-PDT groups, which was not significantly different (<LINK REF="CMP-050.03" TYPE="ANALYSIS">Analysis 50.3</LINK>).</P>
<P>None of the 3 cosmetic outcomes reported improvements in global response (RR 0.74, 95% CI 0.44 to 1.25; <LINK REF="CMP-050.04" TYPE="ANALYSIS">Analysis 50.4</LINK>). Tactile roughness (RR 0.92, 95% CI 0.52 to 1.61; <LINK REF="CMP-050.05" TYPE="ANALYSIS">Analysis 50.5</LINK>) and mottled hyperpigmentation (RR 0.65, 95% CI 0.34 to 1.26; <LINK REF="CMP-050.06" TYPE="ANALYSIS">Analysis 50.6</LINK>) were significantly different between 5-fluorouracil and ALA-PDT administered with the 2 light sources, but there was a general tendency to favour 5-fluorouracil treatment. However, this was not statistically significant.</P>
<P>To summarise, no statistical difference could be observed between 5-fluorouracil treatments and ALA with photodynamic therapy because of the small sample of this study. However, 5-fluorouracil treatment had a tendency to result in better outcomes.</P>
<P>
<U>ALA-PDT and imiquimod</U>
</P>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Sotiriou-2009" TYPE="STUDY">Sotiriou 2009</LINK>) comparing 2 treatments of ALA-red light PDT performed at a 15-day interval on individual lesions and a dosing cycle of 5% imiquimod once per day 3 times per week for 4 weeks on, 4 weeks off, repeated if needed on the dorsal side of the hands and forearms (field-directed treatment). Assessments were performed 4 and 24 weeks after the end of treatment. There was possible performance and detection bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Sotiriou-2009" TYPE="STUDY">Sotiriou 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>The study by <LINK REF="STD-Sotiriou-2009" TYPE="STUDY">Sotiriou 2009</LINK> reported "lesion complete response" as an efficacy outcome, which was not one of our primary outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 30 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Sotiriou-2009" TYPE="STUDY">Sotiriou 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>The authors of the <LINK REF="STD-Sotiriou-2009" TYPE="STUDY">Sotiriou 2009</LINK> study reported no significant difference in the investigator-assessed excellent cosmetic outcome for lesions in the two treatment groups.</P>
<P>To summarise, the efficacy of ALA-PDT and imiquimod could not be compared.</P>
<P>
<U>ALA-PDT versus cryotherapy</U>
</P>
<P>This comparison was discussed in the cryotherapy section above, and the results presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> correspond to <LINK REF="CMP-051.01" TYPE="ANALYSIS">Analysis 51.1</LINK> and <LINK REF="CMP-051.02" TYPE="ANALYSIS">Analysis 51.2</LINK> .</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Photodynamic therapy (PDT) with methyl-aminolevulinic (MAL)</I>
</HEADING>
<P>
<U>MAL-PDT versus placebo-PDT</U>
</P>
<P>This intervention was addressed by seven studies (<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>; <LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>; <LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>; <LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK>) investigating the use of methyl-aminolevulinic (MAL) and photodynamic therapy (PDT) compared to placebo-PDT to treat actinic keratoses. The <LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK> study was performed with immunocompromised participants (organ transplants recipients). Characteristics of the studies are presented in the following table. There was possible performance (<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>), detection (<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>), attrition (<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>; <LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>), reporting (<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>; <LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>), and other (<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>) biases.</P>
<TABLE COLS="7" ROWS="15">
<TR>
<TH ALIGN="CENTER">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="6">
<P>Red light</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Characteristic</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Study design</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>intraindividual</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
<TD ALIGN="CENTER">
<P>Double-blinded</P>
<P>parallel</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Anatomical locations</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp, neck, extremities</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Face and scalp, hand (&lt; 1%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Prior preparation of lesions (e.g. scale and crust removal)</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
<TD ALIGN="CENTER">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of treatment cycle</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Number of weeks between treatments</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Individual lesion or field-directed treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Field-directed treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
<TD ALIGN="CENTER">
<P>Individual lesions</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>MAL formulation</P>
</TD>
<TD ALIGN="CENTER">
<P>16% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>16% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>16.8% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>16.8% cream</P>
</TD>
<TD ALIGN="CENTER">
<P>16% cream</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Occlusion time (hour)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>2.5 to 4</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT intensity</P>
<P>(mW/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>50 to 250</P>
</TD>
<TD ALIGN="CENTER">
<P>50 to 200</P>
</TD>
<TD ALIGN="CENTER">
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>56 to 83</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>PDT dose</P>
<P>(J/cm²)</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
<TD ALIGN="CENTER">
<P>37</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Illumination time (seconds)</P>
</TD>
<TD ALIGN="CENTER">
<P>600</P>
</TD>
<TD ALIGN="CENTER">
<P>480</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>N/A</P>
</TD>
<TD ALIGN="CENTER">
<P>480</P>
</TD>
<TD ALIGN="CENTER">
<P>540</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Type of light source</P>
</TD>
<TD ALIGN="CENTER">
<P>Broadband</P>
<P>(CureLight)</P>
</TD>
<TD ALIGN="CENTER">
<P>Broadband non-coherent light</P>
</TD>
<TD ALIGN="CENTER">
<P>Broadband non-coherent</P>
<P>(Waldmann PDT 1200)</P>
</TD>
<TD ALIGN="CENTER">
<P>Broadband</P>
<P>(CureLight)</P>
</TD>
<TD ALIGN="CENTER">
<P>Light-emitting diode (LED)</P>
<P>(Aktilite CL 128)</P>
</TD>
<TD ALIGN="CENTER">
<P>Light-emitting diode (LED)</P>
<P>(Aktilite CL 128)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Time of assessment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>16 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>12 weeks after the end of treatment</P>
</TD>
</TR>
</TABLE>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 499 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 191 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>;</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK> reported only lesion complete response, which is not included in this review.</P>
<P>In immunocompetent participants, pooled RR for participant complete clearance favoured MAL/red light PDT (RR 4.46, 95% CI 3.17 to 6.28, NNT = 1.9; <LINK REF="CMP-052.01" TYPE="ANALYSIS">Analysis 52.1</LINK>). Similarly, pooled RR (<LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>) for participant partial (<U>&gt;</U> 75%) clearance also favoured MAL-PDT over placebo-PDT (RR 3.28, 95% CI 1.73 to 6.23, NNT = 1.8; <LINK REF="CMP-052.02" TYPE="ANALYSIS">Analysis 52.2</LINK>). In immunosuppressed participants, 13 out of 17 participants were completely cleared on the MAL-PDT-treated side and none on the placebo-PDT-treated side, supporting the superiority of MAL photodynamic therapy in these organ transplants patients.</P>
<P>No publication bias was detected for the studies with immunocompetent participants based on the funnel plot (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 402 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 115 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(see text below)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Dragieva-2004a" TYPE="STUDY">Dragieva 2004a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Photocure_x002d_Australian-2004" TYPE="STUDY">Photocure-Australian 2004</LINK>; <LINK REF="STD-Photocure_x002d_US-2004" TYPE="STUDY">Photocure-US 2004</LINK>;</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Pariser-2008" TYPE="STUDY">Pariser 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>The pooled risk ratio for two of the studies showed no significant difference in the number of participants who withdrew because of adverse events between MAL-PDT- and placebo-PDT-treated groups (<LINK REF="CMP-052.03" TYPE="ANALYSIS">Analysis 52.3</LINK>). In addition, two other studies had no withdrawals due to adverse events in both treatment groups. These data together suggest that there is no difference between the two groups.</P>
<P>
<LINK REF="STD-Szeimies-2009" TYPE="STUDY">Szeimies 2009</LINK> reported one event of headache (one participant; <LINK REF="CMP-052.04" TYPE="ANALYSIS">Analysis 52.4</LINK>) and three events of eyelid oedema in the MAL-PDT group.</P>
<P>Excellent cosmetic outcomes were observed for MAL-PDT in 81% to 93% of participants completely cleared [<LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK> (N = the number of participants evaluated was not given); <LINK REF="STD-Pariser-2003" TYPE="STUDY">Pariser 2003</LINK> (N = 32)], but in the absence of data reported for placebo-PDT, these values could not be compared. No significant difference was observed for hyperpigmentation (N = 191; <LINK REF="CMP-052.05" TYPE="ANALYSIS">Analysis 52.5</LINK>).</P>
<P>To summarise, MAL-PDT was clearly more efficient than placebo-PDT to treat actinic keratoses.</P>
<P>
<U>MAL-PDT: comparisons between types of light source</U>
</P>
<P>This intervention was addressed by two studies (<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>; <LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>). <LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK> compared field-directed treatment using MAL-PDT with light-emitting diode (LED) red light and field-directed treatment using MAL-PDT with daylight (sun) on the face or scalp (field-directed treatment). After removal of crust and hyperkeratoses, MAL cream was applied for three hours. After 30 minutes occlusion, the daylight-treated side was exposed to outside daylight for 2.5 hours, and then the red light side, which stayed under occlusion for 3 hours, was treated with a LED lamp. <LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK> compared individual lesion treatment (one or two treatments) using MAL-PDT with red light LED or a broadband visible plus water-filtered infrared A on the face or scalp. Each treatment group was further separated into two subgroups: with and without cooling spray during illumination. Assessments were performed at 12 (<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>; <LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>), 24 (<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>), and 48 weeks (<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>). There was possible performance (<LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>) and attrition (<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>) bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 80 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 80 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 30 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>No difference in the mean reduction in lesion counts was found between red (8.0 <U>+</U> 5.6, mean <U>+</U> SD, 71%) and daylight (8.4 <U>+</U> 5.4, 79%) (<LINK REF="CMP-054.01" TYPE="ANALYSIS">Analysis 54.1</LINK>).</P>
<P>At 12 months, the number of participants with complete (RR 1.50, 95% CI 0.90 to 2.51; <LINK REF="CMP-053.01" TYPE="ANALYSIS">Analysis 53.1</LINK>) clearance had a tendency to be higher in the MAL-PDT using red light LED as the illumination source, although this was not statistically significant, compared to broadband visible plus water-filtered infrared A. In contrast, no tendency could be observed for partial clearance (RR 1.03, 95% CI 0.85 to 1.25; <LINK REF="CMP-053.02" TYPE="ANALYSIS">Analysis 53.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 110 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-von-Felbert-2010" TYPE="STUDY">von Felbert 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>It is worth noting that the authors of the <LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK> study reported a pain score significantly lower during daylight exposure than red light exposure. The adverse events were more severe in the sun-exposed side for 42% of the participants and more severe in the red light side for 21% following treatment (<LINK REF="STD-Wiegell-2008" TYPE="STUDY">Wiegell 2008</LINK>).</P>
<P>To summarise, performing MAL-PDT with daylight exposure resulted in similar efficacy to MAL-PDT with red light treatment. However, a tendency for better results with red light LED compared to broad visible light with water filtered infrared A was observed.</P>
<P>
<U>MAL-PDT: comparison for different incubation times with MAL</U>
</P>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>) comparing the efficacy of field-directed treatment MAL-PDT for different illumination times with daylight in the presence of 16% MAL cream. Sunscreen was applied for 15 minutes to the treatment area on the face and scalp, and crusts and scales were gently removed before MAL application. After 30 minutes occlusion with MAL, participants were exposed to the sun for 1.5 or 2.5 hours, resulting in exposure to MAL for 2 and 3 hours. All lesions present in the area were treated, but only grade 1 lesions were included in the data analysis by the authors of the study. Assessment was performed 12 weeks after the end of treatment. There was possible performance bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt; </U>75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 120 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>No difference was found between 2 and 3 hours MAL incubation with daylight PDT for mean reduction of lesion counts (MD 0.10, 95% CI -3.17 to 3.37; <LINK REF="CMP-055.01" TYPE="ANALYSIS">Analysis 55.1</LINK>) or mean percentage reduction in lesion counts (MD 2.60, 95% CI -6.46 to 11.66; <LINK REF="CMP-055.02" TYPE="ANALYSIS">Analysis 55.2</LINK>). The latter had a tendency to favour the shortest incubation time, but this was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 120 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2011a" TYPE="STUDY">Wiegell 2011a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, similar efficacy was obtained for 2- or 3-hour incubation with 16% MAL with sun exposure for 1.5 and 2.5 hours, respectively.</P>
<P>
<U>MAL-PDT: comparison for different concentrations of MAL</U>
</P>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>) comparing the efficacy of field-directed treatment with MAL-PDT for different MAL concentrations (16% versus 8%) with daylight PDT for actinic keratoses on the face or scalp. Sunscreen was applied for 15 minutes to the treatment area, and crusts and scales were gently removed before MAL application. The participants were then instructed to spend as much time as possible outside for the rest of the day and wash off the cream at bedtime. The light dose was measured by a dosimeter. Assessment was performed 12 weeks after the end of treatment. There was possible reporting bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 29 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>Similar efficacy was obtained for the 2 concentrations of MAL, i.e. mean reduction in lesion counts of 14.8 <U>+</U> 8.2 (mean <U>+</U> SD, 76.9%) for 16% MAL and 14.5 <U>+</U> 7.6 (79.5%) for 8% MAL (<LINK REF="CMP-056.01" TYPE="ANALYSIS">Analysis 56.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>One of 30 participants withdrew because of unrelated adverse events (terminal illness).</P>
<P>To summarise, 8% and 16% MAL treatments gave similar results with daylight photodynamic therapy to treat actinic keratoses.</P>
<P>
<U>MAL-PDT: comparison between single and multiple MAL-PDT treatment</U>
</P>
<P>This intervention was addressed by one study (<LINK REF="STD-Tarstedt-2005" TYPE="STUDY">Tarstedt 2005</LINK>) comparing the efficacy of one MAL-PDT treatment with red light and three-hour incubation compared to the efficacy of multiple MAL-PDT treatments, which involved two treatment sessions one week apart, on individual lesions on the face and scalp. Lesions not cleared after 12 weeks were retreated. Assessment was performed 12 weeks after the end of each cycle of treatment. There was possible performance, detection, and attrition bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 211 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Wiegell-2009" TYPE="STUDY">Wiegell 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>The number of participants achieving complete clearance was significantly higher in the single MAL-PDT treatment group compared to the multiple MAL-PDT treatment (RR 1.17, 95% CI 1.03 to 1.33; <LINK REF="CMP-057.01" TYPE="ANALYSIS">Analysis 57.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 211 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tarstedt-2005" TYPE="STUDY">Tarstedt 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Per lesion (not included in analysis)</P>
</TD>
</TR>
</TABLE>
<P>The number of participants who withdrew because of adverse events was not significantly different between single MAL-PDT and multiple MAL-PDT (<LINK REF="CMP-057.02" TYPE="ANALYSIS">Analysis 57.2</LINK>).</P>
<P>To summarise, multiple MAL-PDT treatments were associated with more adverse events and were less efficacious than a single treatment.</P>
<P>
<U>MAL-PDT versus cryotherapy</U>
</P>
<P>This comparison was discussed in the cryotherapy section above and the results presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> correspond to <LINK REF="CMP-045.01" TYPE="ANALYSIS">Analysis 45.1</LINK> and <LINK REF="CMP-058.01" TYPE="ANALYSIS">Analysis 58.1</LINK>.</P>
<P>
<U>ALA-PDT versus MAL-PDT</U>
</P>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Moloney-2007" TYPE="STUDY">Moloney 2007</LINK>) comparing 20% ALA incubated for 5 hours and 20% MAL incubated for 3 hours before PDT under identical conditions for field-directed treatment of extensive actinic keratoses on the scalp. Assessment was performed four weeks after the end of treatment. There was possible reporting bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 16 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 15 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moloney-2007" TYPE="STUDY">Moloney 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Field complete clearance</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>Because of the intraindividual design of the <LINK REF="STD-Moloney-2007" TYPE="STUDY">Moloney 2007</LINK> study, participant complete clearance could not be included in meta-analysis, but there was no significant difference between the effectiveness of the 2 treatments in curing actinic keratosis lesions based on participant complete clearance (ALA: 6/16 and MAL: 7/16) and mean reduction in lesion counts (<LINK REF="CMP-059.01" TYPE="ANALYSIS">Analysis 59.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 16 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Moloney-2007" TYPE="STUDY">Moloney 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, there was no significant difference between the effectiveness of MAL and ALA treatments to treat extensive actinic keratoses.</P>
<P>
<U>MAL-PDT versus 5-fluorouracil</U>
</P>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Perrett-2007" TYPE="STUDY">Perrett 2007</LINK>) comparing 3-hour incubation with MAL followed by red light PDT with 5% 5-fluorouracil twice daily for 3 weeks for treatment of individual actinic keratosis lesions and carcinoma in situ on the forearms and hands of organ transplant participants (immunosuppressed). Assessments were performed at 4, 12, and 24 weeks after the end of treatment. Data for efficacy but not safety outcomes were available separately for actinic keratoses. There was possible performance and detection bias associated with this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 4 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Perrett-2007" TYPE="STUDY">Perrett 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Because of the intraindividual design of the study, the data for the participant complete clearance could not be included in a meta-analysis. Thus, the efficacy results at one, three, and six months after treatments are presented in the following table.</P>
<TABLE COLS="3" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Assessment at (months)</P>
</TH>
<TH ALIGN="CENTER">
<P>MAL-PDT</P>
</TH>
<TH ALIGN="CENTER">
<P>5-fluorouracil</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>4/4</P>
</TD>
<TD ALIGN="CENTER">
<P>0/4</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>4/4</P>
</TD>
<TD ALIGN="CENTER">
<P>1/4</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>4/4</P>
</TD>
<TD ALIGN="CENTER">
<P>1/4</P>
</TD>
</TR>
</TABLE>
<P>Based on this small sample size study, MAL-PDT seemed to be more effective at treating actinic keratoses in organ transplant participants than 5-fluorouracil under the conditions used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>Because of the pooled data for carcinoma in situ and actinic keratoses, none of our secondary outcomes could be taken from the study by <LINK REF="STD-Perrett-2007" TYPE="STUDY">Perrett 2007</LINK>.</P>
<P>To summarise, despite the small sample size used in <LINK REF="STD-Perrett-2007" TYPE="STUDY">Perrett 2007</LINK>, efficacy data suggested that MAL-PDT was more efficacious than 5-fluorouracil to treat actinic keratoses in immunosuppressed participants</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trichloroacetic acid peel</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Trichloroacetic acid peel versus 5-fluorouracil</I>
</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>) comparing trichloroacetic acid peel with 5% 5-fluorouracil applied twice daily for 3 weeks on the face. Assessment was performed 12 weeks after the end of treatment. There was possible performance and detection bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 18 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>Analysis of mean percentage of reduction in lesion counts did not significantly favour any treatment, but there was a tendency to favour the chemical peel (MD 5.80, 95% CI -3.78 to 15.38; <LINK REF="CMP-060.01" TYPE="ANALYSIS">Analysis 60.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 19 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Hantash-2006" TYPE="STUDY">Hantash 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, additional data are needed to confirm the superiority of the trichloroacetic acid chemical peel over 5-fluorouracil to treat actinic keratoses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Trichloroacetic acid peel versus carbon dioxide laser resurfacing</I>
</HEADING>
<P>This comparison was presented in the laser resurfacing section above.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Combinations of topical and oral treatments with mechanical or chemical interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cryotherapy combined with betulin-based oleogel</HEADING>
<P>This intervention was addressed by one study (<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>) comparing cryotherapy with liquid nitrogen to cryotherapy combined with betulin-based oleogel on the face, scalp, or other locations. Cryotherapy of participant lesions was performed once on lesions on the face and twice on lesions on the rest of the body, whereas betulin-based oleogel was applied twice daily for an unspecified duration. Assessment was performed at three months after the beginning of the treatment. There was possible performance and detection bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>Additional treatment with betulin-based oleogel did not significantly change participant complete (<LINK REF="CMP-061.01" TYPE="ANALYSIS">Analysis 61.1</LINK>) or partial (<U>&gt;</U> 75%) clearance rates (<LINK REF="CMP-061.02" TYPE="ANALYSIS">Analysis 61.2</LINK>) obtained with cryotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 30 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Huyke-2009" TYPE="STUDY">Huyke 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, the use of betulin-based oleogel after cryotherapy did not improve the efficacy of the cryotherapy.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cryotherapy combined with 5-fluorouracil</HEADING>
<P>This intervention was addressed by 2 studies (<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>; <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>) comparing 0.5% 5-fluorouracil or placebo applied daily to lesions on the face, scalp, ears, neck, and lips for 7 days combined with cryotherapy at week 4 for uncured lesions for 1 (<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>) to 3 (<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>) cycles. Assessment was performed at 4 weeks after the end of treatment. There was possible reporting (<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>) and other (<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>) bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 144 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 144 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>Pretreatment with 0.5% 5-fluorouracil before cryotherapy for 1 (RR 4.08, 95% CI 1.63 to 10.23, NNT = 4.6) or 2 (RR 3.27, 95% CI 1.82 to 5.88, NNT = 2.8), but not for 3 cycles, resulted in higher participant complete clearance (<LINK REF="CMP-062.01" TYPE="ANALYSIS">Analysis 62.1</LINK>) compared to placebo combined with cryotherapy.</P>
<P>The absolute mean reduction in lesion counts and their associated standard deviations were calculated from the mean lesion counts at baseline and the end of the 3 different treatment cycles. The standard deviation associated with the mean percentage of reduction in lesion counts was only reported for the first treatment cycle in <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>. Thus, statistical analysis of this outcome could not be performed. This difference in efficacy between 0.5% 5-fluorouracil with cryotherapy and vehicle with cryotherapy was supported by the mean percentage of reduction in lesion counts presented in the following table and the significant mean difference for the first cycle (MD 21.40, 95% CI 5.10 to 37.70; <LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>), but not by the analysis of mean reduction of lesion counts (<LINK REF="CMP-062.02" TYPE="ANALYSIS">Analysis 62.2</LINK>).</P>
<TABLE COLS="4" ROWS="5">
<TR>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Mean percentage of reduction in lesion counts</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Number of cycles</P>
</TH>
<TH ALIGN="CENTER">
<P>Vehicle + cryotherapy</P>
<P>(mean <U>+</U> SD)</P>
</TH>
<TH ALIGN="CENTER">
<P>5-FU + cryotherapy</P>
<P>(mean <U>+</U> SD)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>45.6% <U>+</U> 54.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>67% <U>+</U> 43.6%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>57.8%</P>
</TD>
<TD ALIGN="CENTER">
<P>86.3%</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>65.7%</P>
</TD>
<TD ALIGN="CENTER">
<P>77.8%</P>
</TD>
</TR>
</TABLE>
<P>The results presented in the additional <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> comparing vehicle with cryotherapy and 5-FU with cryotherapy correspond to <LINK REF="CMP-063.01" TYPE="ANALYSIS">Analysis 63.1</LINK>, <LINK REF="CMP-063.02" TYPE="ANALYSIS">Analysis 63.2</LINK>, and <LINK REF="CMP-063.03" TYPE="ANALYSIS">Analysis 63.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="3">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 144 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 144 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x (eye irritation)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x (including <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>In the first treatment cycle of the <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK> and <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK> study, there were no participant withdrawals due to adverse events. Insufficient information was provided to determine how many participants were lost due to adverse events for the whole study.</P>
<P>None of the adverse events reported were significantly different between cryotherapy alone and cryotherapy combined with 5-fluorouracil. In general, eye irritation (<LINK REF="CMP-062.10" TYPE="ANALYSIS">Analysis 62.10</LINK>) and conjunctivitis (<LINK REF="CMP-062.09" TYPE="ANALYSIS">Analysis 62.9</LINK>) were the most commonly-reported adverse reactions for both groups and the same numbers of participants in each group experiencing it.</P>
<P>To summarise, the efficacy of cryotherapy could be increased with pretreatment with 0.5% 5-fluorouracil if used for 1 or 2, but not 3, cycles.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cryotherapy combined with imiquimod</HEADING>
<P>This intervention was addressed by three studies (<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>; <LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>; <LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>). The studies compared cryotherapy followed by vehicle and cryotherapy followed with imiquimod treatment. In <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>, 4 to 14 lesions were treated with cryotherapy, and 5 lesions were left untreated before randomisation. The method used to select which lesions were treated with cryotherapy was not specified. Thus, the data from this study comparing cryotherapy with imiquimod and imiquimod alone could not be used in our analyses. <LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK> had an intraindividual study design, whereas all the other studies had a parallel-group design. The anatomical locations, dosing regimens, and assessment time are presented in the following table. There was possible performance (<LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>), attrition (<LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>), reporting (<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>; <LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>; <LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>), and other (<LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>) biases.</P>
<TABLE COLS="6" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Anatomical locations</P>
</TH>
<TH ALIGN="CENTER">
<P>Cryotherapy (followed or not with placebo)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cryotherapy followed by imiquimod</P>
</TH>
<TH ALIGN="CENTER">
<P>Imiquimod alone</P>
</TH>
<TH ALIGN="CENTER">
<P>Time of assessment</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Once</P>
</TD>
<TD ALIGN="CENTER">
<P>5% imiquimod</P>
<P>2 times/week</P>
<P>for 8 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>No</P>
</TD>
<TD ALIGN="CENTER">
<P>4 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face</P>
</TD>
<TD ALIGN="CENTER">
<P>Once</P>
</TD>
<TD ALIGN="CENTER">
<P>3.75% imiquimod</P>
<P>3 times/week for 2 weeks on/2 weeks off/2 weeks on</P>
</TD>
<TD ALIGN="CENTER">
<P>3.75 %imiquimod</P>
<P>3 times/week for 2 weeks on/ 2 weeks off/2 weeks on</P>
</TD>
<TD ALIGN="CENTER">
<P>20 weeks after the end of treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Face or bald scalp</P>
</TD>
<TD ALIGN="CENTER">
<P>Once</P>
</TD>
<TD ALIGN="CENTER">
<P>5% imiquimod</P>
<P>3 times/week</P>
<P>for 4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>No</P>
</TD>
<TD ALIGN="CENTER">
<P>4 to 8 weeks after the end of treatment</P>
</TD>
</TR>
</TABLE>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 339 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 274 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Intraindividual study</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Percentages</P>
</TD>
</TR>
</TABLE>
<P>The primary outcomes were further divided into 3 outcomes: 1) for target lesions, i.e. cryotherapy-treated lesions visible at baseline; 2) for subclinical lesions, i.e. lesions not visible at baseline but visible during the study; and 3) all lesions, i.e. target and subclinical lesions.</P>
<P>More participants had complete clearance on the cryotherapy combined with imiquimod side (8/27 = 30%) than the side that had cryotherapy alone (5/27 = 19%) in the intraindividual study. Cryotherapy combined with imiquimod had a tendency (but this was not statistically significant) to result in more participants with target lesions (cryotherapy-treated: RR 0.62, 95% CI 0.36 to 1.04; <LINK REF="CMP-064.02" TYPE="ANALYSIS">Analysis 64.2</LINK>) or subclinical lesions (RR 0.57, 95% CI 0.33 to 1.01; <LINK REF="CMP-064.03" TYPE="ANALYSIS">Analysis 64.3</LINK>) completely cured compared to cryotherapy. By contrast, there was statistically significant complete clearance of all lesions in participants in <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> (RR 0.20, 95% CI 0.05 to 0.73; <LINK REF="CMP-064.01" TYPE="ANALYSIS">Analysis 64.1</LINK>); however, this could be due to the fact that the analysis in <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> included the 5 lesions untreated with cryotherapy.</P>
<P>The combined cryotherapy with 3.75% imiquimod therapy was also significantly favoured compared with the cryotherapy-only treated side for mean percentages of reduction for all lesions (MD -34.10, 95% CI -41.38, to -26.82; <LINK REF="CMP-064.04" TYPE="ANALYSIS">Analysis 64.4</LINK>) but not when 5.0% imiquimod was used (MD -11.20, 95% CI -26.53 to 4.13; <LINK REF="CMP-064.04" TYPE="ANALYSIS">Analysis 64.4</LINK>). The results from the 2 studies could not be pooled due to the high heterogeneity between the 2 studies (I² statistic = 86%). It is worth noting that the study favouring the combined therapy had a parallel design, whereas the study not favouring the combined therapy was an intraindividual study. Only the study with 3.75% imiquimod reported the mean percentage of reduction for target lesions only (MD -10.80, 95% CI -17.37 to -4.23; <LINK REF="CMP-064.05" TYPE="ANALYSIS">Analysis 64.5</LINK>), which favoured the combined therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="4">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 339 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
<P>(N = 312 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
<P>(N = 312 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P>(N = 274 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>x (only for 2 groups: cryotherapy with placebo and cryotherapy with imiquimod)</P>
</TD>
<TD ALIGN="CENTER">
<P>x (only for 2 groups: cryotherapy with placebo and cryotherapy with imiquimod)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Pooled data not included</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
</TR>
</TABLE>
<P>In the intraindividual study, <LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK>, there were no participant withdrawals due to adverse events. The pooled risk ratio for <LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK> and <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> showed no difference between cryotherapy with vehicle and cryotherapy with imiquimod groups (RR 0.93, 95% CI 0.28 to 3.07; <LINK REF="CMP-064.06" TYPE="ANALYSIS">Analysis 64.6</LINK>).</P>
<P>The number of participants experiencing skin irritation had a tendency to be higher in the group receiving additional treatment with imiquimod compared to cryotherapy alone (RR 0.39, 95% CI 0.10 to 1.54; <LINK REF="CMP-064.07" TYPE="ANALYSIS">Analysis 64.7</LINK>).</P>
<P>The number of participants experiencing fatigue (RR 0.09, 95% CI 0.01 to 1.69; <LINK REF="CMP-064.08" TYPE="ANALYSIS">Analysis 64.8</LINK>), nausea (RR 0.09, 95% CI 0.01 to 1.69; <LINK REF="CMP-064.09" TYPE="ANALYSIS">Analysis 64.9</LINK>), and myalgia (RR 0.21, 95% CI 0.02 to 1.76; <LINK REF="CMP-064.10" TYPE="ANALYSIS">Analysis 64.10</LINK>) tended to be higher with additional imiquimod treatment, whereas the 3 respiratory adverse events, upper respiratory tract infection (RR 1.34, 95% CI 0.51 to 3.48; <LINK REF="CMP-064.11" TYPE="ANALYSIS">Analysis 64.11</LINK>), bronchitis (RR 5.21, 95% CI 0.62 to 43.92; <LINK REF="CMP-064.12" TYPE="ANALYSIS">Analysis 64.12</LINK>), and sinusitis (RR 11.45, 95% CI 0.64 to 204.88; <LINK REF="CMP-064.13" TYPE="ANALYSIS">Analysis 64.13</LINK>) tended to be higher in the cryotherapy alone group. None of the minor adverse events were statistically significant. One case of skin infection due to cryotherapy had been reported by <LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>, but the treatment group (i.e. placebo or imiquimod) was not specified.</P>
<P>Additional imiquimod treatment with cryotherapy significantly improved the cosmetic outcome compared to cryotherapy alone in all individual cosmetic outcomes reported by <LINK REF="STD-Jorizzo-2010" TYPE="STUDY">Jorizzo 2010</LINK> (fine lines, tactile roughness, mottled pigmentation, and sallowness) as well as global photoageing score (RR 0.37, 95% CI 0.25 to 0.56, NNT = 3.1; <LINK REF="CMP-064.15" TYPE="ANALYSIS">Analysis 64.15</LINK>). Cosmetic outcome assessments by participant and investigator in <LINK REF="STD-NCT00774787" TYPE="STUDY">NCT00774787</LINK> showed similar results for the additional use of imiquimod with cryotherapy. In this study, analysis of participant assessment favoured the additional use of imiquimod, whereas analysis of investigator assessment did not favour its use. This could be explained by the fact that no placebo was used in this study reporting this cosmetic outcome, making the participants unblinded to the treatment and maybe biased towards the additional treatment with imiquimod; in contrast, the assessor was blinded.</P>
<P>The results presented in the additional <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> for imiquimod comparisons correspond to <LINK REF="CMP-065.01" TYPE="ANALYSIS">Analysis 65.1</LINK>, <LINK REF="CMP-065.02" TYPE="ANALYSIS">Analysis 65.2,</LINK> <LINK REF="CMP-065.03" TYPE="ANALYSIS">Analysis 65.3,</LINK> and <LINK REF="CMP-065.04" TYPE="ANALYSIS">Analysis 65.4</LINK>.</P>
<P>To summarise, combination of cryotherapy and imiquimod treatments resulted in significantly better efficacy compared to the cryotherapy alone. Use of imiquimod cream after cryotherapy increased in general the number of participants experiencing adverse events, but resulted in significantly better cosmetic outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ALA-PDT combined with diclofenac in 2.5% hyaluronic acid gel pretreatment</HEADING>
<P>This intervention was addressed by 1 study (<LINK REF="STD-Van-der-Geer-2009" TYPE="STUDY">Van der Geer 2009</LINK>) investigating the efficacy of field-directed treatment of ALA-red light PDT on lesions on the dorsal side of the hands pretreated with diclofenac in 2.5% hyaluronic acid gel or 2.5% hyaluronic acid gel, twice daily for 4 weeks. Two weeks after diclofenac treatment, ALA was incubated for 4 hours then PDT with red light fractions at 80 J/cm² was performed for 16 minutes. Assessments were performed 6 weeks, and 6 and 12 months after the end of treatment. There was possible reporting bias associated with this study.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global Improvement indices for completely improved or cleared</P>
<P>(N = 9 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 9 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Van-der-Geer-2009" TYPE="STUDY">Van der Geer 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Mean scores</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values</P>
</TD>
</TR>
</TABLE>
<P>The values provided for mean reduction in lesion counts at 6 weeks, 6 and 12 months (<LINK REF="CMP-066.02" TYPE="ANALYSIS">Analysis 66.2</LINK>), and mean global improvement indices scores at 6 months (<LINK REF="CMP-066.01" TYPE="ANALYSIS">Analysis 66.1</LINK>) were all lower in the vehicle group. The authors stated there was a significant difference in the mean number of lesions at 12 months (P = 0.017), but not in the mean reduction of lesion counts (P = 0.34) between the diclofenac and vehicle groups. However, it was impossible to test if these differences were statistically significant because measurement of variability, i.e. standard deviations or standard errors of the mean, were not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 9 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Van-der-Geer-2009" TYPE="STUDY">Van der Geer 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>x (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, pretreatment with diclofenac in 2.5% hyaluronic acid gel did not increase the efficacy of ALA-PDT treatment of actinic keratoses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ALA-PDT combined with imiquimod</HEADING>
<P>This intervention was addressed by 1 intraindividual study (<LINK REF="STD-Shaffelburg-2009" TYPE="STUDY">Shaffelburg 2009</LINK>) investigating 2 ALA-blue light PDT treatments with an interval of 4 weeks directed to a field of lesions.This was followed after another 4 weeks by 5% imiquimod or placebo applied once per day on the face (field-directed treatment), on 2 days per week for 16 weeks [ALA-blue light PDT followed with imiquimod versus ALA-blue PDT followed with placebo]. Assessments were performed at baseline and months 1, 2, 3, 4, 6, and 12 of the study. There was possible reporting bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Global improvement indices for completely improved or cleared</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant complete clearance</P>
<P>(N = 25 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Participant partial (<U>&gt;</U> 75%) clearance</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean (changes) reduction in lesion counts</P>
<P>(N = 25 participants)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Shaffelburg-2009" TYPE="STUDY">Shaffelburg 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>x</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Absolute values and percentages</P>
</TD>
</TR>
</TABLE>
<P>The participant complete clearance was similar with (2/25) or without (2/25) additional imiquimod treatment after ALA-PDT. The mean reduction in lesion counts was 19.9 (86.7%) for the imiquimod-treated group and 16.0 (73.1%) for the placebo group. However, in the absence of standard deviations or standard errors of the mean values, no statistical analysis was possible to determine the significance of these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<TABLE COLS="5" ROWS="2">
<TR>
<TH ALIGN="CENTER">
<P>Study</P>
</TH>
<TH ALIGN="CENTER">
<P>Withdrawal due to adverse events</P>
<P>(N = 25 participants)</P>
</TH>
<TH ALIGN="CENTER">
<P>Skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Minor adverse events excluding skin irritation</P>
</TH>
<TH ALIGN="CENTER">
<P>Cosmetic outcome</P>
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Shaffelburg-2009" TYPE="STUDY">Shaffelburg 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X (none lost)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<P>There were no participant withdrawals due to adverse events.</P>
<P>To summarise, an additional treatment with imiquimod after ALA-PDT did not improve the efficacy of the treatment for actinic keratosis.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-09 12:07:52 +0000" MODIFIED_BY="Maryse Paquet">
<SUMMARY_OF_RESULTS MODIFIED="2012-11-09 12:07:52 +0000" MODIFIED_BY="Maryse Paquet">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>Actinic keratoses remain unchanged, proliferate, regress, reappear, or develop into squamous cell carcinoma. Thus, comparison to a placebo control group gives a better estimate of the efficacy of an intervention for actinic keratoses. Significant estimate effects compared to vehicle or placebo were obtained for the following interventions.</P>
<P>1) For all reported efficacy outcomes: diclofenac (3/3 outcomes, number of studies (n) = 6, number of participants (N) = 723), 5-fluorouracil (3/3 outcomes, n = 3, N = 528), ingenol mebutate (2/2 outcomes, n = 3, N = 540), sunscreen (1/1 outcome, n = 1, N = 588), ALA-PDT (2/2 outcomes, n = 4, N = 814), and MAL-PDT (2/2 outcomes, n = 5, N = 486).</P>
<P>2) For 50% or more of the reported efficacy outcomes: adapalene (1/2 outcomes, n = 1, N = 90), imiquimod (3/5 outcomes, n = 17, N = 3417), isotretinoin (1/2 outcomes, n = 1, N = 100), and masoprocol (1/2 outcomes, n = 1, N = 176).</P>
<P>3) For none of the reported efficacy outcomes: calcipotriol (vitamin D, 0/2 outcomes, n = 1, N = 9), DFMO (0/1 outcome, n = 1, N = 48), &#946;-1,3-D-glucan (0/1 outcome, n = 1, N = 20), nicotinamide (0/1 outcome, n = 1, N = 30), DL-&#945;-tocopherol (vitamin E, 0/1 outcome, n = 1, N = 48), and etretinate (0/1 outcome, n = 1, N = 50).</P>
<P>Studies that compare the different concentrations of an intervention were included in our analysis. These studies were conducted for adapalene, colchicine, 5-fluorouracil, imiquimod, ingenol mebutate, and MAL. Adalpene was the only intervention to demonstrate a difference in efficacy as a result of different concentrations.  </P>
<P>The photosensitiser incubation time and light source were variables that were considered by several studies conducted on photodynamic therapy. One study comparing 0.5-, 1-, 2-, and 4-hour incubations with ALA showed that longer incubation before the photodynamic therapy resulted in better efficacy than a shorter incubation for 4 of the 6 possible comparisons between the different incubation times (see overview for photodynamic therapy in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). In contrast, a similar efficacy was found for two- and three-hour incubation with MAL before photodynamic therapy using daylight. No difference in efficacy was detected between the different light sources for photodynamic therapy (ALA: blue vs red light, blue light vs pulsed dye laser, and MAL: red light LED vs daylight, red light vs broadband visible plus water-filtered infrared A).</P>
<P>We analysed interventions that investigated the efficacy of combined interventions, which generally combined field-directed therapy with treatment for individual lesions. Pretreatment with 0.5% 5-fluorouracil before cryotherapy and imiquimod after cryotherapy significantly improved the efficacy of cryotherapy (see overview for cryotherapy in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). In contrast, no improvement in efficacy was detected when the following interventions were combined: additional tretinoin treatment to 5-fluorouracil, additional betulin-based oleogel to cryotherapy, pretreatment with diclofenac before ALA-PDT, and imiquimod treatment after MAL-PDT.</P>
<P>Several studies compared the efficacy of two different interventions. These interventions may be field-directed treatments applied to a large area of clinical and subclinical lesions (topical creams, resurfacing, field-directed photodynamic therapy, and chemical peel), or treatments that specifically target clinical lesions, (cryotherapy and individual lesion-directed photodynamic therapy). Topical aretinoid methyl sulfone (Ro 14-9706) was significantly more efficacious than topical tretinoin for only 1 of 2 outcomes reported by one study. Topical 5-fluorouracil was more efficacious than topical masoprocol (2/3 outcomes, n = 1, N = 49) and cryotherapy (1/1 outcome, n = 1, N = 49), but had similar efficacy to topical imiquimod (2/2, n = 2, N = 89), carbon dioxide laser resurfacing (1/1 outcome, n = 1, N = 14), Er:YAG laser resurfacing (2/2 outcomes, n = 1, N = 55), ALA-PDT for individual lesions (2/2 outcomes, n = 1, N = 36), and trichloroacetic acid peel (1/1 outcome, n = 1, N = 18) based on the data provided. However, more data are needed to be able to conclude on the difference in efficacy between 5-fluorouracil and MAL-PDT. Topical imiquimod efficacy was also similar to topical diclofenac (1/1 outcome, n = 1, N = 49) and cryotherapy (1/1 outcome, n = 1, N = 51) efficacies, but more data are needed to be able to compare imiquimod to ALA-PDT for individual lesions. Betulin-based oleogel and cryotherapy had similar efficacy (2/2 outcomes, n = 1, N = 28).  Cryotherapy showed lower efficacy compared to ALA-PDT for individual lesions (1/1 outcome, n = 1, N = 72), but more data are needed for the comparison with MAL-PDT for individual lesions. However, field-directed treatments with ALA-PDT and MAL-PDT had similar efficacy (2/2 outcomes, n = 1, N = 15). Based on these comparisons, these interventions could be ranked based on their relative efficacy as follows: (5-fluorouracil = imiquimod = carbon dioxide laser resurfacing = Er:YAG laser resurfacing = ALA-PDT = MAL-PDT = trichloroacetic acid peel = diclofenac ) &gt; masoprocol (cryotherapy = betulin-based oleogel). The relative efficacy between masoprocol and cryotherapy was not investigated in any of the studies included. In summary, the comparisons of different interventions showed that these interventions were generally comparable.</P>
<P>In our review, carbon dioxide laser resurfacing has been shown to have a similar efficacy to 5-fluorouracil and trichloroacetic acid peel to treat actinic keratosis. However, the efficiency of carbon dioxide laser resurfacing to prevent short-term (within 12 months) recurrence of actinic keratoses has been questioned (<LINK REF="REF-Fulton-1999" TYPE="REFERENCE">Fulton 1999</LINK>). Because recurrence, prophylaxis of actinic keratoses, or both, were not in the prespecified outcomes of our review, we will not further discuss this matter, but there might be a need for a future review on the subject.</P>
<P>The relative efficacy of the interventions on various anatomical locations was poorly reported. The majority of studies that investigated different regions of the skin grouped the locations together for each outcome. The only significant difference was reported between lesions on the face and upper extremities during isotretinoin treatment. There was also a decreased tendency to favour imiquimod for the lesions on the face. In summary, there was insufficient data to determine the difference in the lesions' location in this meta-analysis.</P>
<P>For three interventions, the efficacy relative to vehicle/placebo was investigated in immunosuppressed participants. Data from only one study with a small sample was usually included for immunosuppressed participants in the analyses, whereas data from several studies was generally pooled for immunocompetent participants. Thus, it is difficult to compare directly the calculated risk ratios and their 95% CI between studies including immunocompetent versus immunosuppressed participants. A comparison of the unweighted 'participant complete clearance' rates suggests that a similar efficacy is achieved for the two populations. In immunocompetent participants, diclofenac resulted in a 32% (67/208) complete clearance, whereas vehicle had a 13% (27/212) clearance. In immunosuppressed participants the same rates were 41% (9/66) for diclofenac and 0% (0/6) for vehicle. Imiquimod (5%) resulted in 42% (694/1649) vs 62% (18/29) complete clearance, whereas vehicle resulted in 5% (62/1231) and 0% (0/14) for the immunocompetent and immunosuppressed groups, respectively. In PDT, 76% (13/17) of immunosuppressed participants and 74% (204/278) of immunocompetent participants were completely cleared with MAL-PDT compared to 14% (30/204) and 0% (0/17) for placebo-PDT. In summary, the treatments were equally efficacious in immunosuppressed and immunocompetent participants. One ongoing study (<LINK REF="STD-NCT01525329" TYPE="STUDY">NCT01525329</LINK>) is comparing treatment with MAL-PDT alone and in combination with 5% 5-fluorouracil in both immunocompetent and immunosuppressed participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>In general, the number of participants withdrawn because of adverse events was not significantly different between interventions. The only exceptions were the following:</P>
<OL>
<LI>3% diclofenac in 2.5% hyaluronic acid compared to 2.5% hyaluronic acid (see overview for diclofenac in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>),</LI>
<LI>5% imiquimod compared to placebo (see overview for imiquimod <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>), and</LI>
<LI>0.06% to 0.1% resiquimod compared to 0.01% to 0.03% resiquimod.  </LI>
</OL>
<P>The studies reporting skin irritation indicate that diclofenac (see overview for diclofenac in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), 5-fluorouracil (see overview for 5-fluorouracil in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), tretinoin, isotretinoin, and ALA (see overview for photodynamic therapy in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) treatments are associated with significant skin irritation. Topical treatments were associated with different adverse effects than photodynamic therapy and cryotherapy. Topical treatments were associated with "flu" or "cold" symptoms, headache, and conjunctivitis or eye irritation. Photodynamic therapy and cryotherapy were associated with photosensitivity reaction and cold exposure injury, respectively. Most of the minor adverse events that were quantitatively reported were not significantly different between the two interventions that were compared. The only exceptions were the dermatitis associated with adapalene, the metabolic and nutritional disorder and dry skin associated with diclofenac, the "flu" or "cold" symptoms and headache with daily application of imiquimod, and the headache associated with concentrations of resiquimod superior to 0.01%.</P>
<P>Finally, the included studies reported varied cosmetic outcomes. In general, it could be concluded that imiquimod treatment and photodynamic therapy resulted in better cosmetic outcomes than cryotherapy and 5-fluorouracil.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-11-08 15:44:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>The physician's decision about which treatment to prescribe will depend on each patient's case and their treatment aims. Different interventions might be more effective for cosmetic outcomes, symptom relief, or prevention of squamous cell carcinoma. In addition, the efficacy, cost, adverse events, length of treatment, ease of treatment, personal preference of the participant, participant compliance, severity of actinic damage, past treatment experiences, and other factors must all be taken into consideration, and the most appropriate treatment will vary from person to person. The completeness of this review will be discussed based on these factors influencing the choice of an intervention for treating actinic keratoses.</P>
<P>Several of these factors (cost, ease of treatment, participant preference, participant compliance, past treatment experiences) were not included in this review. Some of these factors were presented as outcomes in a few studies, and these are summarised in a table in the <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> section under 'other outcomes'.</P>
<P>This review included several efficacy outcomes. However, the exclusion of an important efficacy outcome, such as 'lesion complete response', limited the evaluation of the relative efficacy of several interventions because some studies only reported this efficacy outcome (see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>).  </P>
<P>Adverse event reporting was complicated by the use of the generic "skin irritation" outcome. Many studies chose to use categories such as "application site reactions" and "local skin/adverse reactions" instead of "skin irritation".</P>
<P>The interventions could also be compared based on their length of treatment. A wide variety of treatment options are available for actinic keratosis. Treatments such as cryotherapy or photodynamic therapy are performed once or twice by clinical staff, whereas the duration of topical treatments administered by patients varies from two applications within a few days for ingenol mebutate to daily application for seven months with sunscreen. A decision based on patient compliance and preference could easily be made. The effect of changing the length of a specific treatment was reported in this review where the information was available, but we did not compare different interventions based on their length of treatment. We did not compare continuous therapy with interval/pulse/cycle therapy. The readers are referred to a recent review (<LINK REF="REF-Martin-2011" TYPE="REFERENCE">Martin 2011</LINK>), which discusses the efficacy of short-course and interval/pulse/cycle therapies for 5-fluorouracil, imiquimod, and ALA/MAL-PDT. Outcomes reported over time showed differences between the assessments, but variations in the time of the assessment (follow-up period) were generally not taken into consideration in our evaluation of the relative efficacy between interventions. Long-term  (&gt; one year) outcomes were not included in our meta-analysis, but references to these studies were included in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables. </P>
<P>The severity of the lesions at baseline was not accounted for in our analysis. The studies reported the severity of lesions in different terms; some used the lesion grade, whereas others reported the number of lesions. In some studies, the number of lesions was a criterion for inclusion or exclusion of participants. This information can be found for the individual studies in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables in the 'participants' sections.</P>
<P>Many patients wish to have their actinic keratoses treated in order to prevent their development into squamous cell carcinoma. The detection of squamous cell carcinoma, basal cell carcinoma, or Bowen's disease was not included in our outcomes, and little is known about their prevention by treating actinic keratoses. This outcome should be addressed in the future. One ongoing study (<LINK REF="STD-NCT01453179" TYPE="STUDY">NCT01453179</LINK>) will evaluate this issue for 5% imiquimod and 3% diclofenac in hyaluronic acid.  However, it is worth noting that the studies included in our analysis did not specify if cancerous lesions were present in the treatment area. This makes the interpretation of this data difficult.<BR/>
</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-11-08 16:15:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>The quality of the evidence presented in this review was evaluated in the 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and the 'Risk of bias' tables associated with each included study. The major factors decreasing the quality of evidence from the studies on interventions for actinic keratoses are as follows:</P>
<OL>
<LI>lack of reporting the methods used for allocation sequence generation and allocation concealment;</LI>
<LI>blinding of studies comparing physically-distinct interventions;</LI>
<LI>the use of per-protocol (PP) analysis instead of intention-to-treat (ITT) analysis (but PP data were converted as much as possible to ITT for meta-analyses); and</LI>
<LI>incomplete reporting of an outcome.</LI>
</OL>
<P>We also noticed another issue with reporting the diagnosis criteria for inclusion of the participants (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables). Many studies did not specify whether a clinical or histological diagnosis was used to include the participants in the clinical trials.</P>
<P>There were two major limitations in our assessment of the effects of interventions for actinic keratoses. The first was that data from numerous intraindividual studies could not be included in the meta-analyses. The second was the frequent omission of standard deviations in the reporting of the outcome "mean reduction in lesion counts" for both absolute values and percentages, which prevented the statistical analysis of the data.  Without the standard deviations, it is difficult to determine if there is a difference between the intervention and the control intervention.</P>
<P>The studies included in the different meta-analyses were generally very consistent, and only a few examples of high heterogeneity were observed. Many of the analyses only included data from an individual study; this included 76% of the efficacy outcomes, 91% of the safety outcomes, and 87% of the cosmetic outcomes.</P>
<P>The frequency of high-quality studies varied based on treatment. Our inclusion criteria fit more studies on imiquimod than 5-fluorouracil or cryotherapy. In contrast, 5-fluorouracil and cryotherapy have been compared to more interventions than imiquimod. The nature of cryotherapy does not allow for double-blinded prospective trials, with the exception of studies investigating the combined therapy with a topical treatment, which resulted in lower quality evidence (see overview for cryotherapy in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>There were several biases that affected the quality of the evidence. Certain treatments incurred adverse skin reactions (e.g. imiquimod, 5-fluorouracil, ALA, etc) that may indirectly introduce bias into the clinical assessment. Moreover, when comparing self-administered and clinically-administered interventions, such as 5-fluorouracil and photodynamic therapy, the compliance of the participants could have an influence on the outcomes and could introduce selection bias if participants were included or excluded based on their compliance. Reporting bias could also result from the method used to assess efficacy outcomes. Several studies reported the observation of new actinic keratoses during the clinical trial, and most of the studies did not specify whether they were studying all lesions or a specific subpopulation of clinical, subclinical, or new lesions.  </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-11-05 11:17:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This review included a broad variety of interventions for actinic keratoses and a large number of outcomes. The search for corresponding studies resulted in a large number of studies, which produced a considerable amount of information. Data extraction sheets were really useful tools for the organisation of this information. However, important details for comparison between studies could have been missed or overlooked in this process. The amount of information presented meant that we were unable to evaluate all of the factors influencing the outcomes, including the methods used for assessment. We searched multiple databases as well as websites and grey literature for randomised clinical trials on all interventions (not prophylaxis) for actinic keratoses in any language. We also contacted pharmaceutical companies to request additional information, but this correspondence was not always successful. There is a possibility that studies may be missing. For example, a study on comparison between 5% 5-fluorouracil and placebo for solar keratoses was registered in the metaRegister of Controlled Trials (mRCT) in 2001 to 2002, but no publication of this study was found.</P>
<P>Our analysis only included randomised controlled trials due to the large scope of this review; all other trial designs were excluded. The randomised clinical trials were only included if all the interventions were covered by this review and if they reported numerical results for at least one of the review outcomes. This criterion excluded the outcome 'Withdrawal due to adverse events', which is generally reported in all the studies. Because the terminology used for the different outcomes was not always consistent in the studies (see the <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> section under 'Outcomes'), the interpretation of the outcomes' definitions could have introduced some bias in the review process.</P>
<P>Inconsistency in terminology could also have led to misinterpretation during the data extraction process. Some of the review outcomes have been redefined to try to avoid this problem. However, a more precise definition of some outcomes was not always possible. There does not seem to be a common definition of "skin irritation", and many studies included adverse event outcomes that included irritation, symptoms of irritation, or both. The lack of consensus on which symptoms constitute "skin irritation" and the potential for different interpretations by the authors of the studies has resulted in our decision to only include outcomes with the word "irritation" in the label. This adverse event category may also include a pooling of different outcomes, as the skin irritation was not identified by the site (application site vs local irritation). </P>
<P>We separated the studies into two populations of participants: immunocompetent and immunosuppressed. We considered participants to be immunocompetent by default if the studies did not specifically include immunosuppressed participants.  However, in 40% of these studies, immunosuppressed participants could have been enrolled based on the inclusion and exclusion criteria reported. It is possible that the immunocompetent population included few immunosuppressed participants.</P>
<P>Data from intention-to-treat analysis was used in the analysis for the review whenever possible to reduce the attrition bias and increase consistency between studies included in the same meta-analysis. The information provided in the studies did not always allow for the conversion of data from per-protocol analysis to intention-to-treat analysis. In some studies, the authors did not observe a significant difference in the outcomes when analysis was conducted with per-protocol analysis, as opposed to intention-to-treat analysis. Thus, the estimated effect size calculated in the meta-analyses should not be affected and our conclusions should remain unchanged. Several studies presented data in a graphical format that was not included in our analysis, either because of unsuccessful correspondence with the authors, time limitations, or both. Statistical limitations due to outcome without event, such as exclusion from meta-analysis or calculation for number needed to treat (NNT) based on assumed control risk (ACR), also restricted our analyses and conclusions.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-11-08 16:15:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>In a systematic review of randomised controlled trials using 0.5% and 5% 5-fluorouracil for treatment of actinic keratoses, 9 studies were identified (<LINK REF="REF-Kaur-2010" TYPE="REFERENCE">Kaur 2010</LINK>). We included seven of these studies in our review and excluded two because there was no clear mention of randomisation of the treatments in the published reports. Despite this difference, the authors arrived at a similar conclusion to our review about the participant complete clearance of the 2 concentrations of 5-fluorouracil. In another systematic review (<LINK REF="REF-Askew-2009" TYPE="REFERENCE">Askew 2009</LINK>), the authors estimated that about 500 of 1000 of participants receiving 5-fluorouracil for treatment of actinic keratoses could expect complete clearance. An average of our illustrative comparative risks based on study population for 0.5% and 5% 5-fluorouracil treatments (see overview for 5-fluorouracil in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) resulted in 577 of 1000 participants with complete clearance. A similar conclusion was reached by using different methodologies.</P>
<P>A meta-analysis of 5 full journal publications of randomised double-blind clinical trials comparing 5% imiquimod to vehicle concluded that about 50% of participants (500 of 1000) treated with 5% imiquimod achieved complete clearance (<LINK REF="REF-Hadley-2006" TYPE="REFERENCE">Hadley 2006</LINK>). In this review, the method used to pool data was not specified (but the numbers given suggested that the numbers were added together without any weighting) and a fixed-effect model was used to calculate the relative risk. Our review calculated a lower percentage of 25% to 38% (253 to 382 of 1000; see overview for imiquimod in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>) based on 9 studies using a random-effects model to calculate the pooled risk ratio (RR). In contrast to our review, <LINK REF="REF-Hadley-2006" TYPE="REFERENCE">Hadley 2006</LINK> did not find any difference in the number of withdrawals due to adverse events between 5% imiquimod and vehicle, but a difference was detected for withdrawal in general, with significantly more in the imiquimod group. Hadley et al detected a greater proportion of local, treatment-related, and overall adverse effects in the 5% imiquimod group, but did not observe any differences in serious adverse events. Thus, 5% imiquimod treatment is generally associated with more adverse events than vehicle.</P>
<P>In a systematic review on photodynamic therapy in the treatment of pre-cancerous skin conditions and cancers (<LINK REF="REF-Fayter-2010" TYPE="REFERENCE">Fayter 2010</LINK>), the authors reached the following conclusions for the treatment of actinic keratosis: 1) "The only clear evidence of effectiveness" came from the comparison of ALA/MAL-PDT and placebo-PDT, and 2) "Uncertainties still exist around PDT&#8217;s effectiveness compared with other topical treatments." Our analyses led to similar conclusions (see the overview for photodynamic therapy in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).  </P>
<P>In our review, the efficacy of ALA-PDT was superior to cryotherapy based on 'participant complete clearance', but the efficacy of MAL-PDT compared to cryotherapy could not be assessed. A meta-analysis of 'lesion complete response' was performed in the <LINK REF="REF-Fayter-2010" TYPE="REFERENCE">Fayter 2010</LINK> review to compare MAL-PDT to cryotherapy. Unfortunately, this analysis included 4 studies with high heterogeneity (I² statistic = 88%), and no definitive conclusion could be made on their relative efficacy. The authors of this review also concluded that the improved cosmetic outcomes obtained for PDT compared to cryotherapy might be due to bias, because in most of the studies the assessors were not blinded.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-08 15:44:59 +0000" MODIFIED_BY="Maryse Paquet">
<IMPLICATIONS_PRACTICE MODIFIED="2012-11-08 15:44:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>The treatment of actinic keratoses is generally recommended to limit the morbidity and mortality of squamous cell carcinoma. Surprisingly, there was no evidence in the included studies that treating actinic keratoses prevented squamous cell carcinoma. Only a few studies reported the observation of squamous cell carcinoma, basal cell carcinoma, or both. In these studies, it was not specified if the cell carcinoma was observed in the treated area. Thus, it was impossible to correlate treatment of actinic keratoses with prevention of cell carcinoma. Of course, this lack of information on prevention of squamous cell carcinoma could have been a consequence of our criteria, which included interventions to treat actinic keratoses but not prophylaxis of cancers. As mentioned previously, this review did not cover long-term follow-up studies that could give useful information on recurrence of actinic keratoses as well as prevention of squamous cell carcinoma. We did include the recurrence rates, appearance of new actinic keratoses or incidence of cancer if they were provided in the tables of '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Because of the importance of this issue, a systematic review with these long-term outcomes must be performed, and we suggest that randomised clinical trials on interventions for actinic keratoses include observation of squamous cell carcinoma for a follow-up period of at least one year as an efficacy outcome. </P>
<P>Based on the evidence presented in this review, there are many effective options available for the treatment of actinic keratoses. The most effective treatment options were diclofenac, 5-fluorouracil, imiquimod, ingenol mebutate, laser resurfacing, trichloracetic acid peel, ALA-PDT, and MAL-PDT. Other treatment options should not be ruled out as they are still effective, and many have reduced side-effects, which may be preferable or better suited to certain patients.</P>
<P>Ultimately, the decision about which treatment option to use should be agreed upon by both the physician and the patient, based on which intervention suits the participant's specific situation. Certain treatments are better for treating diffuse actinic damage, while others are better for individual lesions. Moreover, the appropriate treatments would depend on the patient's wishes, whether it is cosmetic, symptom relief, or prevention of squamous cell carcinoma. If the risk associated with treatment is greater than the potential benefit, observation without treatment may also be an option.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-08 15:44:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>Our review did not directly compare the methodology used by the studies to evaluate the efficacy outcomes of the interventions for actinic keratoses. Some studies did not give any details on their methodology, whereas others described in detail how individual lesions were mapped, photographed, and followed throughout the study. Mapping of the lesions allowed the investigators to make a distinction between baseline lesions and new or subclinical lesions. For several studies, it was not clear if the efficacy assessment included only target (baseline) lesions or all lesions, which could greatly influence the final outcome. Thus, we recommend that the authors of studies describe in details the methodology used to evaluate the efficacy of the interventions investigated and specify which lesions (baseline/target, subclinical/new, or all lesions) are included in these evaluations.</P>
<P>A clear definition of the lesions being treated is particularly important when comparing individual lesion-based and field-directed treatments, as well as to show that new lesions appeared in response to some treatments. An increase in the number of lesions during treatment was observed for imiquimod (see the 'Notes' section of the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables for <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003;</LINK> <LINK REF="STD-Korman-2005" TYPE="STUDY">Korman 2005;</LINK> <LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>; and <LINK REF="STD-Tan-2007" TYPE="STUDY">Tan 2007</LINK>), 5-fluorouracil (<LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>; <LINK REF="STD-Tanghetti-2007" TYPE="STUDY">Tanghetti 2007</LINK>), and tretinoin (<LINK REF="STD-Misiewicz-1991" TYPE="STUDY">Misiewicz 1991</LINK>). This unmasking of lesions during treatment might have important implications for treatment of actinic keratoses and its associated recurrence. Long-term randomised clinical trials comparing lesion-based and field-directed treatments are needed to address this issue.</P>
<P>Diclofenac in 2.5% hyaluronic acid has been compared directly to 5% 5-fluorouracil (1 excluded study: <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>) and 5% imiquimod for the treatment for actinic keratosis. Diclofenac and 5% imiquimod are both associated with significant adverse events based on the related withdrawals, and 5-fluorouracil treatment is associated with significant skin irritation based on our analyses. It would be advantageous to perform randomised clinical trials comparing diclofenac with other interventions in order to clearly assess its safety outcomes. Similarly, the new treatment ingenol mebutate (PEP005) has only been compared to placebo, and comparison with other interventions for actinic keratosis is needed to evaluate its efficacy and safety compared to established therapy. As mentioned in the summary of main results, additional data are also needed to support or confirm the conclusion of some included studies.</P>
<P>Photodynamic therapy is a newer form of treatment that presents good results in clinical trials. Several studies tried to determine the optimal treatment regimen, output, and photosensitising agents, but most studies did not observe significant changes in efficacy in the variations studied. A few studies investigated the use of daylight for photodynamic therapy using the photosensitiser MAL, and one study showed an efficacy equivalent to MAL-red light PDT. This source of light could be more convenient, more cost effective and easily applicable as field-directed treatment. This is a good prospective area for further research. One ongoing study (<LINK REF="STD-NCT01475071" TYPE="STUDY">NCT01475071</LINK>) is comparing daylight PDT with conventional PDT.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-11-09 11:40:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>The Cochrane Skin Group editorial base wishes to thank Dedee Murrell who was the Key Editor for this review; Jo Leonardi-Bee and Philippa Middleton who were the Statistical and Methods Editors, respectively; the clinical referees, Hywel Williams and Stephen Keohane; and the consumer referee, Jack Tweed. </P>
<P>The following people contributed to earlier versions of this review; the authors would like to acknowledge their contribution: Kimberley Inniss, Robert Wainwright, Melody Chow, Elizabeth Cooper, Kristy Johnson, and Zbys Fedorowicz. The authors would also like to thank Chris Drummond-Main and Fiona C. Simpson for their input.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-11-09 11:41:42 +0000" MODIFIED_BY="Laura  Prescott">
<P>Dr Aditya Gupta, lead author of this review, participated in a clinical trial sponsored by DUSA in 2004, which was excluded from the review because it did not meet the inclusion criteria.</P>
<P>Dr Stephen Keohane, clinical referee for this review, states: "I have been paid for lectures and advisory boards by Galderma, Almirall, Intendis, Inc., Shire, and Bayer."</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-11-05 11:55:01 +0000" MODIFIED_BY="Maryse Paquet">
<P>We indicate below the contributions made by the reviewers.</P>
<UL>
<LI>Link with editorial base and coordinate contributions from co-reviewers (AG)</LI>
<LI>Draft protocol (AG, RW, with contributions from all)</LI>
<LI>Run search (AG, WB, and MP)</LI>
<LI>Identify relevant titles and abstracts from searches, i.e. broad screen (MP and WB)</LI>
<LI>Obtain full text copies of studies (WB and MP)</LI>
<LI>Select trials to include (WB, MP, and AG as arbitrator when necessary)</LI>
<LI>Extract data from trials (WB and MP)</LI>
<LI>Enter data into RevMan (MP)</LI>
<LI>Carry out the analysis (MP and EV)</LI>
<LI>Interpret the analysis (MP)</LI>
<LI>Draft final review (MP, WB, and AG)</LI>
<LI>Update the review (MP)</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-11-09 11:41:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>Authorship: </B>Since the publication of the Cochrane Protocol in 2009, the review has been updated by new authors.</P>
<P>
<B>Background:</B> This was updated as the protocol was published in 2003. The 'Disease definition' section was modified to emphasise the relationship between actinic keratosis and squamous cell carcinoma, and previous information about the differential diagnosis was moved to the 'Clinical features' section. The 'Epidemiology and causes' section title was changed to 'Pathogenesis and epidemiology' to reflect better the order of the information presented. Finally, a 'How the intervention might work' section was added to follow the recommendation in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>
<B>Methods:</B>
</P>
<P>
<U>Criteria for considering studies for this review:</U>  </P>
<P>
<I>Types of interventions</I>: The sentence on the comparators accepted was slightly modified to include any variation of the treatment (duration, concentration, etc) because several studies investigated the influences of these parameters on primary and secondary outcomes.</P>
<P>
<I>Types of outcome measures:</I> The rationale for selecting only per participant outcomes (i.e. randomisation per participant and not per lesion) was presented, as well as a description on the general method used to evaluate efficacy in the included studies.</P>
<P>Changes in the primary outcomes:</P>
<P>a) To make a distinction between "Global degree of improvement in symptoms and/or signs as rated by participant or medical practitioner" (subjective) and "Participant complete clearance" (objective), subjective assessment was added before the outcome description. Only global improvement indices for completely improved or cleared were considered for inclusion in meta-analysis.</P>
<P>b) "Lesion clearance rate of 100% and 75%" were changed for "participant complete (100%) or partial (<U>&gt;</U> 75%) clearance" to make a distinction between "lesion complete response" expressed per lesion, which is not included in our review, and the number of participants with the percentage of lesions cleared. "Participant complete clearance" and "Participant partial (<U>&gt;</U> 75%) clearance" were presented separately.</P>
<P>c) The outcomes reported in actinic keratoses studies that could be reported as "Improvement in quality of life" were cosmetic outcomes, which were reported separately as secondary outcomes. Thus, 'Improvement in quality of life' was removed from our primary outcomes.</P>
<P>The objective assessment, "Mean reduction in lesion counts" expressed as absolute values or percentages was included in the review because this per participant outcome was often reported, and it was the only efficacy outcome that could be analysed by meta-analysis for intraindividual studies. Thus, all primary outcomes became efficacy outcomes.</P>
<P>Changes in the secondary outcomes:</P>
<P>(a) "Severe adverse events, i.e. severe enough to require withdrawal of treatment" was changed to "Withdrawal due to adverse events" to avoid problems with the interpretation of data.</P>
<P>(c) "Minor patient-reported adverse events, not sufficient to require cessation of treatment, excluding skin irritation" was replaced by "Minor adverse events excluding skin irritation" because the source, reported by participant or investigator, was generally not specified.</P>
<P>To fulfil the requirement of a 'per participant' outcome for meta-analysis, all safety outcomes were the number of participants experiencing events in general or a specific event, and cosmetic outcomes were the number of participants with the different cosmetic measurement.</P>
<P>
<U>Search methods for identification of studies:</U>
</P>
<P>
<I>Electronic searches: </I>We updated all searches in March 2011, and the LILACs database was added, as well as different online ongoing trial registers.</P>
<P>
<I>Unpublished literature:</I> We searched additional companies, as well as the FDA website, for clinical trials in the product insert.</P>
<P>
<I>Conference proceedings:</I> We searched conference proceedings from additional associations.</P>
<P>
<U>Data collection and analysis:</U>
 
</P>
<P>
<I>Selection of studies/Data extraction and management:</I>
</P>
<P>Several collaborators contributed to this review over the years, and they shared different responsibilities in the study selection, data extraction, and data analysis. During a global revision of the manuscript undertaken in March 2011, the different roles were redistributed to the current authors, and they may differ from the protocol.</P>
<P>
<I>Assessment of risk of bias in included studies:</I>
</P>
<P>Cochrane methodology was changed for assessment of methodological quality. Thus, the quality of the data was assessed with two new tools: 1) the 'Risk of bias' tables included in RevMan 5.1, and 2) the quality of evidence by the GRADEpro software.</P>
<P>
<I>Analysis:</I>
</P>
<P>The section of the protocol on planed data analysis has been divided into the following sections: measures of treatment effect, unit of analysis issues, assessment of heterogeneity, data synthesis, and subgroup analysis and investigation of heterogeneity.</P>
<P>In 'Measures of treatment effect', the original protocol stated that the results will be expressed as odds ratios for dichotomous outcomes. However, the results were presented as risk ratios because they are easier to interpret.</P>
<P>In 'Unit of analysis issues', a strategy for analysis and reporting of data from intraindividual studies and studies with multiple treatments was added.</P>
<P>In 'Assessment of heterogeneity', a cut-off value of the I² statistic as a measure of heterogeneity was added.</P>
<P>In 'Data synthesis', no meta-analysis method was specified in the protocol, but a random-effects model was prespecified for all analyses.</P>
<P>In 'Subgroup analysis and investigation of heterogeneity', subgroup analysis in the protocol was referred to the different types of interventions (i.e. topical, oral, mechanical, etc), which were analysed in separate comparisons. Subgroup analysis in the review referred to subgroup analysis within a comparison.</P>
<P>Because of the large number of randomised studies included in this review, non-randomised controlled studies were not listed as mentioned in the protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-06-08 12:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>This review is being updated by way of a new protocol and then a review, because the scope of the review has been reduced to make it more manageable.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-06-08 12:39:38 +0100" MODIFIED_BY="Helen Scott">
<STUDIES MODIFIED="2012-10-02 14:48:11 +0100" MODIFIED_BY="Maryse Paquet">
<INCLUDED_STUDIES MODIFIED="2012-10-02 14:28:36 +0100" MODIFIED_BY="Maryse Paquet">
<STUDY DATA_SOURCE="PUB" ID="STD-Akar-2001" MODIFIED="2011-08-17 11:40:17 +0100" MODIFIED_BY="Liz Doney" NAME="Akar 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-08-17 11:40:17 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akar A, Tastan HB, Erbil H, Arca E, Kurumlu Z, Gur AR</AU>
<TI>Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>4</NO>
<PG>199-203</PG>
<IDENTIFIERS MODIFIED="2011-03-18 20:54:17 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736343"/><IDENTIFIER MODIFIED="2011-03-18 20:54:17 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12241628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736342"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alberts-2000" MODIFIED="2011-08-17 11:41:50 +0100" MODIFIED_BY="Liz Doney" NAME="Alberts 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-08-17 11:41:02 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, et al</AU>
<TI>Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1281-6</PG>
<IDENTIFIERS MODIFIED="2011-03-31 21:00:23 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736345"/><IDENTIFIER MODIFIED="2011-03-31 21:00:23 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11142412"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 11:41:50 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS</AU>
<TI>Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>1</NO>
<PG>149-55</PG>
<IDENTIFIERS MODIFIED="2011-04-05 18:41:46 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736346"/><IDENTIFIER MODIFIED="2011-04-05 18:41:46 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11801552 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736344"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alirezai-1994" MODIFIED="2011-11-24 16:52:53 +0000" MODIFIED_BY="Liz Doney" NAME="Alirezai 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-11-24 16:52:53 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alirezai M, Dupuy P, Amblard P, Kalis B, Souteyrand P, Frappaz A, et al</AU>
<TI>Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>3</NO>
<PG>447-51</PG>
<IDENTIFIERS MODIFIED="2011-11-24 16:52:53 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736348"/><IDENTIFIER MODIFIED="2011-11-24 16:52:53 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8113458"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736347"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alomar-2007" MODIFIED="2011-08-17 11:48:01 +0100" MODIFIED_BY="Liz Doney" NAME="Alomar 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-17 11:48:01 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alomar A, Bichel J, McRae S</AU>
<TI>Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>1</NO>
<PG>133-41</PG>
<IDENTIFIERS MODIFIED="2011-04-01 18:00:18 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736350"/><IDENTIFIER MODIFIED="2011-04-01 18:00:18 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17501955 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736349"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2009" MODIFIED="2011-12-13 13:35:38 +0000" MODIFIED_BY="Liz Doney" NAME="Anderson 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-10 19:33:54 +0000" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al</AU>
<TI>Randomized, double-blind, double-dummy, vehicle controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2009</YR>
<VL>60</VL>
<NO>6</NO>
<PG>934-43</PG>
<IDENTIFIERS MODIFIED="2011-04-05 16:19:37 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736352"/><IDENTIFIER MODIFIED="2011-04-05 16:19:37 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19467365 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:35:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00375739</AU>
<TI>Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00375739</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 13:34:45 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736353"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736351"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bercovitch-1987" MODIFIED="2011-08-17 11:55:29 +0100" MODIFIED_BY="Liz Doney" NAME="Bercovitch 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-08-17 11:55:29 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bercovitch L</AU>
<TI>Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study</TI>
<SO>British Journal of Dermatology</SO>
<YR>1987</YR>
<VL>116</VL>
<NO>4</NO>
<PG>549-52</PG>
<IDENTIFIERS MODIFIED="2011-04-01 23:21:04 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736355"/><IDENTIFIER MODIFIED="2011-04-01 23:21:04 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="3555597"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736354"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2011-08-17 11:57:08 +0100" MODIFIED_BY="Liz Doney" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-17 11:57:08 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen K, Yap LM, Marks R, Shumack S</AU>
<TI>Short-course therapy imiquimod 5% cream for solar keratoses: A randomized controlled trial</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>4</NO>
<PG>250-5</PG>
<IDENTIFIERS MODIFIED="2011-03-31 18:13:27 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736357"/><IDENTIFIER MODIFIED="2011-03-31 18:13:27 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="14616490"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736356"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dragieva-2004a" MODIFIED="2011-11-24 20:07:31 +0000" MODIFIED_BY="Maryse Paquet" NAME="Dragieva 2004a" YEAR="2004">
<REFERENCE MODIFIED="2011-11-24 18:12:50 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dragieva G, Prinz B, Hafner J, Dummer R, Burg G, Binswanger U, et al</AU>
<TI>Topical photodynamic therapy with MAL in the treatment of actinic keratoses in transplant recipients. [Abstract PD-16] The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK</TI>
<SO>British Journal of Dermatology</SO>
<YR>2005</YR>
<VL>153</VL>
<NO>Suppl 1</NO>
<PG>97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736359"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-24 16:54:05 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dregieva G, Prinz B, Hafner J, Dummer R, Burg G, Binswanger U et al</AU>
<TI>A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients</TI>
<SO>British Journal of Dermatology</SO>
<YR>2004</YR>
<VL>151</VL>
<NO>1</NO>
<PG>196-200</PG>
<IDENTIFIERS MODIFIED="2011-11-24 16:54:05 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736360"/><IDENTIFIER MODIFIED="2011-11-24 16:54:05 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15270891"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736358"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fariba-2006" MODIFIED="2011-11-24 20:07:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="Fariba 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 11:59:13 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA</AU>
<TI>Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study</TI>
<SO>Indian Journal of Dermatology, Venereology &amp; Leprology</SO>
<YR>2006</YR>
<VL>72</VL>
<NO>5</NO>
<PG>346-9</PG>
<IDENTIFIERS MODIFIED="2011-04-05 19:06:23 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736362"/><IDENTIFIER MODIFIED="2011-04-05 19:06:23 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17050927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736361"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foote-2009" MODIFIED="2011-08-17 12:02:21 +0100" MODIFIED_BY="Liz Doney" NAME="Foote 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-17 12:02:21 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foote JA, Ranger-Moore JR, Einspahr JG, Saboda K, Kenyon J, Warneke J, et al</AU>
<TI>Chemoprevention of human actinic keratoses by topical DL-&#945;-tocopherol</TI>
<SO>Cancer Prevention Research</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>4</NO>
<PG>394-400</PG>
<IDENTIFIERS MODIFIED="2011-03-24 13:15:29 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736364"/><IDENTIFIER MODIFIED="2011-03-24 13:15:29 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19336724"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736363"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Freeman-2003" MODIFIED="2011-11-24 16:55:18 +0000" MODIFIED_BY="Maryse Paquet" NAME="Freeman 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-17 15:27:33 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="OTHER">
<AU>Foley P, Freeman M, Vinciullo C, Spelman L, Murrell D, Weightman W, et al</AU>
<TI>Photodynamic therapy using methyl aminolaevulinate with cryotherapy in actinic keratosis: an Australian study. [Abstract P-31] The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK</TI>
<SO>British Journal of Dermatology</SO>
<YR>2005</YR>
<VL>153</VL>
<NO>Suppl 1</NO>
<PG>29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736366"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-24 16:55:18 +0000" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al</AU>
<TI>A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>99-106</PG>
<IDENTIFIERS MODIFIED="2011-11-24 16:55:18 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736367"/><IDENTIFIER MODIFIED="2011-11-24 16:55:18 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12775317"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-14 18:33:11 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736365"/><IDENTIFIER MODIFIED="2011-03-14 18:33:11 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12775317 "/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebauer-2003" MODIFIED="2011-12-13 14:56:07 +0000" MODIFIED_BY="Liz Doney" NAME="Gebauer 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-17 12:03:21 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebauer K, Brown P, Varigos G</AU>
<TI>Topical diclofenac in hyaluronan gel for the treatment of solar keratoses</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS MODIFIED="2011-03-22 15:33:34 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736369"/><IDENTIFIER MODIFIED="2011-03-22 15:33:34 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12581080 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 14:56:07 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="OTHER">
<AU>Paquet M</AU>
<TI>Confirmation of ITT analysis for efficacy [personal communication]</TI>
<SO>Email to: Dr Gebauer</SO>
<YR>27 March 2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736370"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736368"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebauer-2009" MODIFIED="2011-08-17 12:03:44 +0100" MODIFIED_BY="Liz Doney" NAME="Gebauer 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-17 12:03:44 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19545297&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:03:44 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebauer K, Shumack S, Cowen P S</AU>
<TI>Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>2009</YR>
<VL>161</VL>
<NO>4</NO>
<PG>897-903</PG>
<IDENTIFIERS MODIFIED="2011-04-05 20:08:54 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736372"/><IDENTIFIER MODIFIED="2011-04-05 20:08:54 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19545297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736371"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hanke-2010" MODIFIED="2011-12-13 13:44:51 +0000" MODIFIED_BY="Liz Doney" NAME="Hanke 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-17 12:20:48 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 20133012&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:20:48 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S</AU>
<TI>Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>4</NO>
<PG>573-81</PG>
<IDENTIFIERS MODIFIED="2011-04-19 14:57:04 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736374"/><IDENTIFIER MODIFIED="2011-04-19 14:57:04 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20133012"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:44:51 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00603798</AU>
<TI>Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (actinic keratoses)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00603798</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 13:44:51 +0000" MODIFIED_BY="Liz Doney"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736375"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736373"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hantash-2006" MODIFIED="2011-08-17 12:21:35 +0100" MODIFIED_BY="Liz Doney" NAME="Hantash 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 12:21:35 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM</AU>
<TI>Facial resurfacing for nonmelanoma skin cancer prophylaxis</TI>
<SO>Archives of Dermatology</SO>
<YR>2006</YR>
<VL>142</VL>
<NO>8</NO>
<PG>976-82</PG>
<IDENTIFIERS MODIFIED="2011-03-25 21:52:59 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736377"/><IDENTIFIER MODIFIED="2011-03-25 21:52:59 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16924046 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736376"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauschild-2009a" MODIFIED="2011-12-13 13:47:02 +0000" MODIFIED_BY="Maryse Paquet" NAME="Hauschild 2009a" YEAR="2009">
<REFERENCE MODIFIED="2011-11-24 16:56:14 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hauschild A, Stockfleth E, Popp G, Borrosch F, Bruning H, Dominicus R, et al</AU>
<TI>Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies</TI>
<SO>British Journal of Dermatology</SO>
<YR>2009</YR>
<VL>160</VL>
<NO>5</NO>
<PG>1066-74</PG>
<IDENTIFIERS MODIFIED="2011-03-30 15:57:30 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736379"/><IDENTIFIER MODIFIED="2011-03-30 15:57:30 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19222455"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:47:02 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00308854</AU>
<TI>PD P 506 A-PDT Versus Placebo-PDT for the treatment of actinic keratose</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00308854</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 13:46:01 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736380"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736378"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauschild-2009b" MODIFIED="2011-12-13 13:48:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="Hauschild 2009b" YEAR="2009">
<REFERENCE MODIFIED="2011-11-24 16:55:49 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hauschild A, Stockfleth E, Popp G, Borrosch F, Bruning H, Dominicus R, et al</AU>
<TI>Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies</TI>
<SO>British Journal of Dermatology</SO>
<YR>2009</YR>
<VL>160</VL>
<NO>5</NO>
<PG>1066-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736382"/><IDENTIFIER TYPE="PUBMED" VALUE="19222455"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:48:04 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00308867</AU>
<TI>PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of actinic keratose</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00308867</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 13:47:27 +0000" MODIFIED_BY="Liz Doney"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736383"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736381"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauschild-2009c" MODIFIED="2011-08-17 12:22:59 +0100" MODIFIED_BY="Liz Doney" NAME="Hauschild 2009c" YEAR="2009">
<REFERENCE MODIFIED="2011-08-17 12:22:59 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, Allergology and Venerology, University of Kiel, Kiel, Germany. ahauschild@dermatology.uni-kiel.deConnective Phrase: 18643849&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:22:59 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauschild A, Popp G, Stockfleth E, Meyer K G, Imberger D, Mohr P, et al</AU>
<TI>Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch</TI>
<SO>Experimental Dermatology</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>116-21</PG>
<IDENTIFIERS MODIFIED="2011-04-13 19:55:02 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736385"/><IDENTIFIER MODIFIED="2011-04-13 19:55:02 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18643849"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736384"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huyke-2009" MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" NAME="Huyke 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huyke C, Reuter J, Rodig M, Kersten A, Laszczyk M, Scheffler A, et al</AU>
<TI>Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, active-controlled pilot study</TI>
<SO>Journal Der Deutschen Dermatologischen Gesellschaft</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>2</NO>
<PG>128-133</PG>
<IDENTIFIERS MODIFIED="2011-03-28 19:36:32 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736387"/><IDENTIFIER MODIFIED="2011-03-28 19:36:32 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18808378"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736386"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeffes-2001" MODIFIED="2011-11-24 20:07:44 +0000" MODIFIED_BY="Maryse Paquet" NAME="Jeffes 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-08-17 12:23:35 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeffes E, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR</AU>
<TI>Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2001</YR>
<VL>45</VL>
<NO>1</NO>
<PG>96-104</PG>
<IDENTIFIERS MODIFIED="2011-03-18 21:34:34 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736389"/><IDENTIFIER MODIFIED="2011-03-18 21:34:34 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11423841"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736388"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jorizzo-2002" MODIFIED="2011-12-13 13:49:21 +0000" MODIFIED_BY="Maryse Paquet" NAME="Jorizzo 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-12-13 13:49:21 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Dermik Laboratories</AU>
<TI>Carac product insert</TI>
<SO>//products.sanofi.us/carac/carac.html</SO>
<YR>(accessed 24 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 12:24:03 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Email sent to Dr. Jorizzo on March 24 2011 for clarification on type of analysis for efficacy.&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:24:03 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P, et al</AU>
<TI>Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis</TI>
<SO>Cutis</SO>
<YR>2002</YR>
<VL>70</VL>
<NO>6</NO>
<PG>335-9</PG>
<IDENTIFIERS MODIFIED="2011-03-24 17:04:42 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736392"/><IDENTIFIER MODIFIED="2011-03-24 17:04:42 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12502122"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 12:24:21 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J</AU>
<TI>Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy?</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS MODIFIED="2011-04-06 19:22:06 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736393"/><IDENTIFIER MODIFIED="2011-04-06 19:22:06 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="14964743"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736390"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorizzo-2004" MODIFIED="2011-03-25 16:40:03 +0000" MODIFIED_BY="Maryse Paquet" NAME="Jorizzo 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-03-25 16:40:03 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J, Weiss J, Furst K, VandePol C, Levy S</AU>
<TI>Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial</TI>
<SO>Archives of Dermatology</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>813-6</PG>
<IDENTIFIERS MODIFIED="2011-03-25 16:40:03 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736395"/><IDENTIFIER MODIFIED="2011-03-25 16:40:03 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15262691"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736394"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorizzo-2006" MODIFIED="2011-08-17 12:25:03 +0100" MODIFIED_BY="Liz Doney" NAME="Jorizzo 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 12:25:03 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J, Weiss J, Vamvakias G</AU>
<TI>One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>133-9</PG>
<IDENTIFIERS MODIFIED="2011-03-25 17:52:17 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736397"/><IDENTIFIER MODIFIED="2011-03-25 17:52:17 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16485881 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736396"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorizzo-2007" MODIFIED="2011-08-17 12:26:13 +0100" MODIFIED_BY="Liz Doney" NAME="Jorizzo 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-17 12:26:13 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al</AU>
<TI>Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>2</NO>
<PG>265-8</PG>
<IDENTIFIERS MODIFIED="2011-03-25 18:42:46 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736399"/><IDENTIFIER MODIFIED="2011-03-25 18:42:46 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17512087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736398"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jorizzo-2010" MODIFIED="2011-12-13 13:51:51 +0000" MODIFIED_BY="Maryse Paquet" NAME="Jorizzo 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-17 12:27:18 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 20865842&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:27:18 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, et al</AU>
<TI>A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>9</NO>
<PG>1101-8</PG>
<IDENTIFIERS MODIFIED="2011-04-20 19:26:23 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736401"/><IDENTIFIER MODIFIED="2011-04-20 19:26:23 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20865842"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:51:51 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="OTHER">
<AU>Lee J, Jorizzo J, Lebwohl M, Markowitz O, Levy S</AU>
<TI>Cryosurgery followed by imiquimod 3.75% to treat actinic keratosis. 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States, February 2011</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>2 Suppl 1</NO>
<PG>AB2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736402"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 13:51:08 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>NCT00894647</AU>
<TI>Safety and effectiveness study of actinic keratosis treatment following cryosurgery</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00894647</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 13:50:19 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736403"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-19 18:56:08 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736400"/><IDENTIFIER MODIFIED="2011-04-19 18:56:08 +0100" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00894647"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2003" MODIFIED="2011-08-17 12:28:00 +0100" MODIFIED_BY="Liz Doney" NAME="Kang 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-17 12:28:00 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kang S, Goldfarb MT, Weiss JS, Metz RD, Hamilton TA, Voorhees JJ, et al</AU>
<TI>Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>1</NO>
<PG>83-90</PG>
<IDENTIFIERS MODIFIED="2011-03-23 16:27:36 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736405"/><IDENTIFIER MODIFIED="2011-03-23 16:27:36 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12833014 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaufmann-2008" MODIFIED="2011-11-24 16:58:03 +0000" MODIFIED_BY="Maryse Paquet" NAME="Kaufmann 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-24 16:58:03 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Johann-Wolfgang-Goethe-Universitat-Hautklinik, Frankfurt, GermanyConnective Phrase: 18341663&lt;/p&gt;" NOTES_MODIFIED="2011-11-24 16:58:03 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies R M, Verhaeghe E, et al</AU>
<TI>Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities</TI>
<SO>British Journal of Dermatology</SO>
<YR>2008</YR>
<VL>158</VL>
<NO>5</NO>
<PG>994-9</PG>
<IDENTIFIERS MODIFIED="2011-11-24 16:58:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736407"/><IDENTIFIER MODIFIED="2011-11-24 16:58:03 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18341663"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736406"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korman-2005" MODIFIED="2011-08-17 12:28:37 +0100" MODIFIED_BY="Liz Doney" NAME="Korman 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-08-17 12:28:37 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al</AU>
<TI>Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials</TI>
<SO>Archives of Dermatology</SO>
<YR>2005</YR>
<VL>141</VL>
<NO>4</NO>
<PG>467-73</PG>
<IDENTIFIERS MODIFIED="2011-03-21 19:55:20 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736409"/><IDENTIFIER MODIFIED="2011-03-21 19:55:20 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15837864 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736408"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kose-2008" MODIFIED="2011-08-17 12:29:14 +0100" MODIFIED_BY="Liz Doney" NAME="Kose 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-17 12:29:14 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18569272&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:29:14 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z</AU>
<TI>Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>3</NO>
<PG>159-63</PG>
<IDENTIFIERS MODIFIED="2011-04-07 16:17:09 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736411"/><IDENTIFIER MODIFIED="2011-04-07 16:17:09 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18569272 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krawtchenko-2007" MODIFIED="2011-03-30 20:43:34 +0100" MODIFIED_BY="Maryse Paquet" NAME="Krawtchenko 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-30 20:43:34 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E</AU>
<TI>A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>Suppl 2</NO>
<PG>34-40</PG>
<IDENTIFIERS MODIFIED="2011-03-30 20:43:19 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736413"/><IDENTIFIER MODIFIED="2011-03-30 20:43:19 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18067630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulp_x002d_Shorten-1993" MODIFIED="2011-02-15 19:07:00 +0000" MODIFIED_BY="Zbys Fedorowicz" NAME="Kulp-Shorten 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-15 19:07:00 +0000" MODIFIED_BY="Zbys Fedorowicz" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kulp-Shorten C, Konnikov N, Callen J</AU>
<TI>Comparative Evaluation of the efficacy and Safety of Masoprocol and 5-Fluorouracil Cream for the Treatment of Multiple Actinic Keratoses of the Head and Neck</TI>
<SO>Journal of Geriatric Dermatology</SO>
<YR>1993</YR>
<VL>1</VL>
<NO>4</NO>
<PG>161-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736415"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lebwohl-2004" MODIFIED="2011-12-13 13:54:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="Lebwohl 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 13:54:39 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Graceway Pharmaceuticals</AU>
<TI>Aldara product monograph</TI>
<SO>//www.gracewaypharma.com/sites/default/files/products/aldara_ppi.pdf</SO>
<YR>(accessed 24 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736417"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 12:30:06 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al</AU>
<TI>Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>5</NO>
<PG>714-21</PG>
<IDENTIFIERS MODIFIED="2011-03-21 17:38:24 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736418"/><IDENTIFIER MODIFIED="2011-03-21 17:38:24 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15097955"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736416"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loven-2002" MODIFIED="2011-11-24 20:07:51 +0000" MODIFIED_BY="Maryse Paquet" NAME="Loven 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-24 16:59:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loven K, Stein L, Furst K, Levy S</AU>
<TI>Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>6</NO>
<PG>990-1000</PG>
<IDENTIFIERS MODIFIED="2011-11-24 16:59:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736420"/><IDENTIFIER MODIFIED="2011-11-24 16:59:38 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12117087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736419"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEwan-1997" MODIFIED="2011-08-17 12:31:49 +0100" MODIFIED_BY="Liz Doney" NAME="McEwan 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-08-17 12:31:49 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEwan LE, Smith JG</AU>
<TI>Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>4</NO>
<PG>187-9</PG>
<IDENTIFIERS MODIFIED="2011-03-21 14:30:31 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736422"/><IDENTIFIER MODIFIED="2011-03-21 14:30:31 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="9431711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736421"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misiewicz-1991" MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" NAME="Misiewicz 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki BM, Jablonska S</AU>
<TI>Topical treatment of multiple actinic keratoses of the face with aretinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, active-controlled study</TI>
<SO>Journal of the American Academy Dermatology</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>3</NO>
<PG>448-51</PG>
<IDENTIFIERS MODIFIED="2011-03-17 14:41:35 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736424"/><IDENTIFIER MODIFIED="2011-03-17 14:41:35 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="2061443"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736423"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moloney-2007" MODIFIED="2011-08-17 12:32:25 +0100" MODIFIED_BY="Liz Doney" NAME="Moloney 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-17 12:32:25 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:32:25 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moloney FJ, Collins P</AU>
<TI>Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>1</NO>
<PG>87-91</PG>
<IDENTIFIERS MODIFIED="2011-04-08 17:41:38 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736426"/><IDENTIFIER MODIFIED="2011-04-08 17:41:38 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17501954 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moloney-2010" MODIFIED="2011-12-13 13:58:56 +0000" MODIFIED_BY="Liz Doney" NAME="Moloney 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 13:58:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12609000490279</AU>
<TI>Randomized, double-blind, placebo controlled study to assess efficacy of topical nicotinamide in the treatment and prevention of actinic keratosis.</TI>
<SO>anzctr.org.au/trial_view.aspx?ID=83879</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736428"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-10 20:15:13 +0000" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 20199551&lt;/p&gt;" NOTES_MODIFIED="2011-11-10 20:15:13 +0000" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Moloney F, Vestergaard M, Radojkovic B, Damian D</AU>
<TI>Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1138-9</PG>
<IDENTIFIERS MODIFIED="2011-04-21 18:05:22 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736429"/><IDENTIFIER MODIFIED="2011-04-21 18:05:22 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20199551"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-18 17:12:32 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736427"/><IDENTIFIER MODIFIED="2011-07-18 17:12:32 +0100" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE=""/><IDENTIFIER MODIFIED="2011-07-18 17:12:28 +0100" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE="ACTRN12607000428460"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moriarty-1982" MODIFIED="2011-08-17 12:33:47 +0100" MODIFIED_BY="Liz Doney" NAME="Moriarty 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-08-17 12:33:47 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moriarty M, Dunn J, Darragh A, Lambe R, Brick I</AU>
<TI>Etretinate in treatment of actinic keratosis: a double-blind crossover study</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>1</VL>
<NO>8268</NO>
<PG>364-5</PG>
<IDENTIFIERS MODIFIED="2011-03-17 18:53:19 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736431"/><IDENTIFIER MODIFIED="2011-03-17 18:53:19 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="6120350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736430"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-2006" MODIFIED="2012-10-02 14:24:59 +0100" MODIFIED_BY="Liz Doney" NAME="Morton 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-02 14:24:59 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, et al</AU>
<TI>Intraparticipant, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>155</VL>
<NO>5</NO>
<PG>1029-36</PG>
<IDENTIFIERS MODIFIED="2011-03-28 16:35:03 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736433"/><IDENTIFIER MODIFIED="2011-03-28 16:35:03 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17034536"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00774787" MODIFIED="2011-12-13 14:00:40 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00774787" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 14:00:40 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00774787</AU>
<TI>Topical imiquimod cream in combination with cryotherapy for the treatment of actinic keratoses</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00774787</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736435"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-19 18:32:47 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736434"/><IDENTIFIER MODIFIED="2011-04-19 18:32:47 +0100" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00774787"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00828568-Aldara" MODIFIED="2011-12-13 14:57:57 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00828568 Aldara" YEAR="2009">
<REFERENCE MODIFIED="2011-12-13 14:08:01 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00828568</AU>
<TI>A Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00828568</SO>
<YR>(accesssed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:07:46 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736437"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-19 14:03:13 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736436"/><IDENTIFIER MODIFIED="2011-04-19 14:03:13 +0100" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00828568"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00828568-Taro" MODIFIED="2011-12-13 14:58:11 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00828568 Taro" YEAR="2009">
<REFERENCE MODIFIED="2011-12-13 14:06:56 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00828568</AU>
<TI>A Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00828568</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:04:22 +0000" MODIFIED_BY="Liz Doney"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736439"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-19 14:02:42 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736438"/><IDENTIFIER MODIFIED="2011-04-19 14:02:42 +0100" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00828568"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-1991" MODIFIED="2011-08-17 12:35:31 +0100" MODIFIED_BY="Liz Doney" NAME="Olsen 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-08-17 12:35:31 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen EA, Abernethy ML, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al</AU>
<TI>A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>5 Pt 1</NO>
<PG>738-43</PG>
<IDENTIFIERS MODIFIED="2011-03-17 16:05:54 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736441"/><IDENTIFIER MODIFIED="2011-03-17 16:05:54 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="1869646"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736440"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ooi-2006" MODIFIED="2011-08-17 12:36:38 +0100" MODIFIED_BY="Liz Doney" NAME="Ooi 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 12:36:38 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, et al</AU>
<TI>Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>154</VL>
<NO>1</NO>
<PG>72-8</PG>
<IDENTIFIERS MODIFIED="2011-03-25 20:29:57 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736443"/><IDENTIFIER MODIFIED="2011-03-25 20:29:57 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16403097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortonne-2010" MODIFIED="2011-12-13 14:10:20 +0000" MODIFIED_BY="Maryse Paquet" NAME="Ortonne 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 14:10:20 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00294320</AU>
<TI>Evaluation of Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00294320</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:09:58 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736445"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 12:36:58 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Connective Phrase: PUBMED 20201959&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:36:58 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P</AU>
<TI>Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment</TI>
<SO>Experimental Dermatology</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>7</NO>
<PG>641-7</PG>
<IDENTIFIERS MODIFIED="2011-04-21 20:04:33 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736446"/><IDENTIFIER MODIFIED="2011-04-21 20:04:33 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20201959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736444"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ostertag-2006" MODIFIED="2011-08-17 12:37:39 +0100" MODIFIED_BY="Liz Doney" NAME="Ostertag 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 12:37:39 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="OTHER">
<AU>Ostertag JU, Quaedvlieg PJF, van der Geer S, Nelemans P, Christianen ME, Neumann MH, et al</AU>
<TI>A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses</TI>
<SO>Lasers in Surgery &amp; Medicine</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>8</NO>
<PG>731-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736448"/><IDENTIFIER TYPE="PUBMED" VALUE="16912977"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736447"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pariser-2003" MODIFIED="2011-11-24 18:08:35 +0000" MODIFIED_BY="Liz Doney" NAME="Pariser 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-24 18:08:35 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al</AU>
<TI>Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>2</NO>
<PG>227-32</PG>
<IDENTIFIERS MODIFIED="2011-11-24 18:08:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736450"/><IDENTIFIER MODIFIED="2011-11-24 18:08:35 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12582393"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pariser-2008" MODIFIED="2012-04-17 15:56:33 +0100" MODIFIED_BY="Maryse Paquet" NAME="Pariser 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-04-17 15:56:33 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Galderma</AU>
<TI>Metvixia product label</TI>
<SO>http://metvixia.com/pi/MetvixiaPI.pdf</SO>
<YR>(accessed on 26 April 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 14:11:53 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00306800</AU>
<TI>Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00306800</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:11:25 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736453"/><IDENTIFIER MODIFIED="2011-12-13 14:11:25 +0000" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE="NCT00306800"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 12:38:38 +0100" MODIFIED_BY="Liz Doney" NOTES="&lt;p&gt;Author Affiliation: Eastern Virginia Medical School, Division of Dermatology and Virginia Clinical Research Inc, Norfolk, Virginia 23507, USA. dpariser@pariserderm.comConnective Phrase: 18707799&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 12:38:38 +0100" NOTES_MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pariser D, Loss R, Jarratt M, Abramovits W, Spencer J, Geronemus R, et al</AU>
<TI>Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>4</NO>
<PG>569-76</PG>
<IDENTIFIERS MODIFIED="2011-04-14 19:40:06 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736454"/><IDENTIFIER MODIFIED="2011-04-14 19:40:06 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18707799 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrett-2007" MODIFIED="2011-11-24 20:08:02 +0000" MODIFIED_BY="Maryse Paquet" NAME="Perrett 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-08-30 20:47:14 +0100" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrett CM, McGregor JM, Warwick J, Karran P, Leigh IM, Proby CM, et al</AU>
<TI>Treatment of post-transplant premalignant skin disease: a randomized intrapatient active-controlled study of 5-fluorouracil cream and topical photodynamic therapy</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>156</VL>
<NO>2</NO>
<PG>320-8</PG>
<IDENTIFIERS MODIFIED="2011-04-08 19:53:00 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736456"/><IDENTIFIER MODIFIED="2011-04-08 19:53:00 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17223873 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Persaud-2002" MODIFIED="2011-11-24 20:08:07 +0000" MODIFIED_BY="Maryse Paquet" NAME="Persaud 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-08-17 12:39:21 +0100" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, et al</AU>
<TI>Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>4</NO>
<PG>553-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736458"/><IDENTIFIER TYPE="PUBMED" VALUE="12271300"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Photocure_x002d_Australian-2004" MODIFIED="2011-12-13 15:04:24 +0000" MODIFIED_BY="Maryse Paquet" NAME="Photocure-Australian 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 15:04:24 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Photocure ASA</AU>
<TI>Metvixia cream, 16.8%, product insert</TI>
<SO>Data on file</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736460"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Photocure_x002d_US-2004" MODIFIED="2011-12-13 15:05:00 +0000" MODIFIED_BY="Maryse Paquet" NAME="Photocure-US 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 15:05:00 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Photocure ASA</AU>
<TI>Metvixia cream 16.8%, product insert</TI>
<SO>Data on file</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736462"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Piacquadio-2004" MODIFIED="2011-12-13 14:14:03 +0000" MODIFIED_BY="Maryse Paquet" NAME="Piacquadio 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 14:14:03 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>DUSA</AU>
<TI>Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20%. Product monograph</TI>
<SO>accessdata.fda.gov/drugsatfda_docs/label/2010/020965s007lbl.pdf</SO>
<YR>(accessed 5 April 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736464"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-24 22:13:56 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fowler JF, Zax RH</AU>
<TI>Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment</TI>
<SO>Cutis</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>6 Suppl</NO>
<PG>2-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736465"/><IDENTIFIER TYPE="PUBMED" VALUE="12095067 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-27 15:38:16 +0100" MODIFIED_BY="Liz Doney" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Piacquadio DJ, Chen DM, Farber HF, Fowler JF, Glazer SD, Goodman JJ, et al</AU>
<TI>Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials</TI>
<SO>Archives of Dermatology</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>1</NO>
<PG>41-6</PG>
<IDENTIFIERS MODIFIED="2011-03-31 16:21:57 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736466"/><IDENTIFIER MODIFIED="2011-03-31 16:21:57 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="14732659"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rivers-2002" MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" NAME="Rivers 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-12-08 11:20:34 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y</AU>
<TI>Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronoan gel</TI>
<SO>British Journal of Dermatology</SO>
<YR>2002</YR>
<VL>146</VL>
<NO>1</NO>
<PG>94-100</PG>
<IDENTIFIERS MODIFIED="2011-03-22 13:30:22 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736468"/><IDENTIFIER MODIFIED="2011-03-22 13:30:22 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11841372"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<TI>Solaraze gel: Diclofenac Sodium 3% - package insert</TI>
<SO>www.solaraze.com/solaraze/pdf/solaraze_pi.pdf</SO>
<YR>(accessed January 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736469"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seckin-2009" MODIFIED="2011-12-08 11:21:18 +0000" MODIFIED_BY="Maryse Paquet" NAME="Seckin 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:21:18 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seckin D, Cerman AA, Yildiz A, Ergun T</AU>
<TI>Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>5</NO>
<PG>451-4</PG>
<IDENTIFIERS MODIFIED="2011-03-24 15:06:30 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736471"/><IDENTIFIER MODIFIED="2011-03-24 15:06:30 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19537367"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736470"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaffelburg-2009" MODIFIED="2011-12-08 11:21:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="Shaffelburg 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:21:39 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19180894&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:21:39 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaffelburg M</AU>
<TI>Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736473"/><IDENTIFIER TYPE="PUBMED" VALUE="19180894"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736472"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siller-2009" MODIFIED="2011-12-13 14:17:09 +0000" MODIFIED_BY="Maryse Paquet" NAME="Siller 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-13 14:17:09 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00107965</AU>
<TI>Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00107965</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:17:09 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736475"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:21:54 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:21:54 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM</AU>
<TI>PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:21:44 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736476"/><IDENTIFIER MODIFIED="2011-04-07 19:29:43 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19178487 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736474"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2003" MODIFIED="2011-12-08 11:22:14 +0000" MODIFIED_BY="Maryse Paquet" NAME="Smith 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-08 11:22:14 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R</AU>
<TI>Short incubation PDT versus 5-FU in treating actinic keratosis</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>6</NO>
<PG>629-35</PG>
<IDENTIFIERS MODIFIED="2011-03-28 15:26:00 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736478"/><IDENTIFIER MODIFIED="2011-03-28 15:26:00 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="14711141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Solaraze-study-2" MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" NAME="Solaraze study 2" YEAR="">
<REFERENCE MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="OTHER">
<TI>Solaraze gel: Diclofenac Sodium 3% - package insert</TI>
<SO>https://www.solaraze.com/solaraze/pdf/solaraze_pi.pdf</SO>
<YR>(accessed 24 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sotiriou-2009" MODIFIED="2011-12-08 11:23:24 +0000" MODIFIED_BY="Maryse Paquet" NAME="Sotiriou 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:23:24 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19470041&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:23:24 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sotiriou E, Apalla Z, Maliamani F, Zaparas N, Panagiotidou D, Ioannides D</AU>
<TI>Intraparticipant, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1061-5</PG>
<IDENTIFIERS MODIFIED="2011-04-18 14:44:47 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736482"/><IDENTIFIER MODIFIED="2011-04-18 14:44:47 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19470041 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stockfleth-2002" MODIFIED="2011-03-17 17:23:30 +0000" MODIFIED_BY="Maryse Paquet" NAME="Stockfleth 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-17 17:23:30 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stockfleth E, Meyer T, Benninghoff B, Salasche S, Paradoulos L, Ulrich C, et al</AU>
<TI>A randomized, double-blind, vehicle-controlled study to asses 5% imiquimod cream for the treatment of multiple actinic keratoses</TI>
<SO>Archives of Dermatology</SO>
<YR>2002</YR>
<VL>138</VL>
<NO>11</NO>
<PG>1498-502</PG>
<IDENTIFIERS MODIFIED="2011-03-17 17:23:30 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736484"/><IDENTIFIER MODIFIED="2011-03-17 17:23:30 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12437457"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Swanson-2010a" MODIFIED="2011-12-13 14:18:36 +0000" MODIFIED_BY="Maryse Paquet" NAME="Swanson 2010a" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 14:18:21 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Graceway Pharmaceuticals</AU>
<TI>Zyclara product monograph</TI>
<SO>http://www.gracewaypharma.com/sites/default/files/products/Zyclara%20Full%20PI.pdf</SO>
<YR>(accessed 26 April 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736486"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 14:18:36 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00605176</AU>
<TI>Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (actinic keratoses)</TI>
<SO>//clinicaltrials.gov/ct2/show/NCT00605176</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:18:36 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736487"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:28:46 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Connective Phrase: PUBMED 20133013&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:28:46 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S</AU>
<TI>Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>4</NO>
<PG>582-90</PG>
<IDENTIFIERS MODIFIED="2011-04-19 19:48:57 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736488"/><IDENTIFIER MODIFIED="2011-04-19 19:48:57 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20133013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Swanson-2010b" MODIFIED="2012-10-02 14:26:42 +0100" MODIFIED_BY="Maryse Paquet" NAME="Swanson 2010b" YEAR="">
<REFERENCE MODIFIED="2012-10-02 14:26:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B</AU>
<TI>Ingenol mebutate gel for actinic keratosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>11</NO>
<PG>1010-19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736490"/><IDENTIFIER TYPE="PUBMED" VALUE="22417254"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-15 11:31:39 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00742391</AU>
<TI>A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (actinic keratoses) on the Non Head Locations</TI>
<SO>//clinicaltrials.gov/ct2/show/NCT00742391</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-15 11:31:39 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736491"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 14:19:43 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="OTHER">
<AU>Swanson N</AU>
<TI>Multicenter, randomized, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on nonhead locations</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3 Suppl 1</NO>
<PG>AB2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736492"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736489"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szeimies-2002" MODIFIED="2011-12-08 11:34:20 +0000" MODIFIED_BY="[Empty name]" NAME="Szeimies 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-12-08 11:34:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, et al</AU>
<TI>Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>2</NO>
<PG>258-62</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:26:56 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736494"/><IDENTIFIER MODIFIED="2011-11-24 19:26:56 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12140473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736493"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szeimies-2004" MODIFIED="2011-12-08 11:34:47 +0000" MODIFIED_BY="Maryse Paquet" NAME="Szeimies 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-08 11:34:47 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al</AU>
<TI>Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology</TI>
<SO>Journal of the American Academy Dermatology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>4</NO>
<PG>547-55</PG>
<IDENTIFIERS MODIFIED="2011-03-21 15:24:38 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736496"/><IDENTIFIER MODIFIED="2011-03-21 15:24:38 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15389189"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736495"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szeimies-2008" MODIFIED="2011-12-08 11:35:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="Szeimies 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-08 11:35:04 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:35:04 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC</AU>
<TI>A phase II dose-ranging study of topical resiquimod to treat actinic keratosis</TI>
<SO>British Journal of Dermatology</SO>
<YR>2008</YR>
<VL>159</VL>
<NO>1</NO>
<PG>205-10</PG>
<IDENTIFIERS MODIFIED="2011-04-12 15:03:15 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736498"/><IDENTIFIER MODIFIED="2011-04-12 15:03:15 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18476957"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736497"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Szeimies-2009" MODIFIED="2011-12-13 14:20:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="Szeimies 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:36:32 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Galderma</AU>
<TI>Metvixia product label</TI>
<SO>http://metvixia.com/pi/MetvixiaPI.pdf</SO>
<YR>(accessed 26 April 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736500"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 14:20:39 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00304239</AU>
<TI>Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00304239</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:20:28 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:35:42 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies R, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klovekorn W, et al</AU>
<TI>Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study</TI>
<SO>Dermatologic Surgery</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>4</NO>
<PG>586-592</PG>
<IDENTIFIERS MODIFIED="2011-03-30 19:30:30 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736502"/><IDENTIFIER MODIFIED="2011-03-30 19:30:30 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19309347"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szeimies-2010b" MODIFIED="2011-12-08 11:38:11 +0000" MODIFIED_BY="Maryse Paquet" NAME="Szeimies 2010b" YEAR="2010">
<REFERENCE MODIFIED="2011-12-08 11:38:11 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, Regensburg University Hospital, Regensburg, GermanyConnective Phrase: 20518784&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:38:11 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn-Senftleben G, et al</AU>
<TI>Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>163</VL>
<NO>2</NO>
<PG>386-94</PG>
<IDENTIFIERS MODIFIED="2011-04-25 14:43:01 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736504"/><IDENTIFIER MODIFIED="2011-04-25 14:43:01 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20518784"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736503"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2007" MODIFIED="2011-12-13 14:20:56 +0000" MODIFIED_BY="Maryse Paquet" NAME="Tan 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-12-13 14:20:56 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00110682</AU>
<TI>Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00110682</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:20:56 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736506"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:39:29 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tan JK, Thomas DR, Poulin Y, Maddin F, Tang J</AU>
<TI>Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses</TI>
<SO>Journal of Cutaneous Medicine and Surgery</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>5</NO>
<PG>195-201</PG>
<IDENTIFIERS MODIFIED="2011-03-28 15:32:00 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736507"/><IDENTIFIER MODIFIED="2011-03-28 15:32:00 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18042331"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736505"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tanghetti-2007" MODIFIED="2012-01-04 10:22:16 +0000" MODIFIED_BY="Maryse Paquet" NAME="Tanghetti 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 10:22:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Paquet M</AU>
<TI>Tanghetti and Werschler 2007</TI>
<SO>Email to: E A Tanghetti</SO>
<YR>12 April 2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736509"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:40:01 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tanghetti E, Werschler P</AU>
<TI>Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>2</NO>
<PG>144-7</PG>
<IDENTIFIERS MODIFIED="2011-04-12 18:08:09 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736510"/><IDENTIFIER MODIFIED="2011-04-12 18:08:09 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17373172"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-12 18:05:17 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736508"/><IDENTIFIER MODIFIED="2011-04-12 18:05:17 +0100" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tarstedt-2005" MODIFIED="2011-12-08 11:44:38 +0000" MODIFIED_BY="Maryse Paquet" NAME="Tarstedt 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-12-08 11:43:19 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM</AU>
<TI>A Randomized Multicenter Study to Compare Two Treatment Regimens of Topical Methyl Aminolevulinate (Metvix)-PDT in Actinic Keratosis of the Face and Scalp</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2005</YR>
<VL>85</VL>
<NO>5</NO>
<PG>424-428</PG>
<IDENTIFIERS MODIFIED="2011-03-15 19:46:21 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736512"/><IDENTIFIER MODIFIED="2011-03-15 19:46:21 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16159735"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:44:38 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarstedt M, Wennberg A-M, Rosdahl I, Persson BE, Berne B, Bojs G, et al</AU>
<TI>A comparison of two treatment regimes using photodynamic therapy with Metvix in actinic keratosis [Abstract FC8-3]</TI>
<TO>The 12th Congress of the European Academy of Dermatology and Venerology. Barcelona, Spain 15-18th October 2003</TO>
<SO>Journal of the European Academy of Dermatology &amp; Venerology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>Suppl 3</NO>
<PG>126</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736513"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-15 19:39:25 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736511"/><IDENTIFIER MODIFIED="2011-03-15 19:39:25 +0000" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1993" MODIFIED="2011-12-08 11:44:58 +0000" MODIFIED_BY="Maryse Paquet" NAME="Thompson 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-12-08 11:44:58 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SC, Jolley D, Marks R</AU>
<TI>Reduction of solar keratoses by regular sunscreen use</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>16</NO>
<PG>1147-51</PG>
<IDENTIFIERS MODIFIED="2011-04-12 19:50:42 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736515"/><IDENTIFIER MODIFIED="2011-04-12 19:50:42 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="8377777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736514"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-1996" MODIFIED="2011-12-08 11:45:22 +0000" MODIFIED_BY="Maryse Paquet" NAME="Tong 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-08 11:45:22 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tong DW, Barnetson RS</AU>
<TI>Beta-1,3-D-glucan gel in the treatment of solar keratoses</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>3</NO>
<PG>137-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736517"/><IDENTIFIER TYPE="PUBMED" VALUE="8771866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulrich-2007" MODIFIED="2011-12-13 14:22:05 +0000" MODIFIED_BY="Maryse Paquet" NAME="Ulrich 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-12-13 14:22:05 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00189267</AU>
<TI>A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00189267</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:22:01 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736519"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:46:10 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, et al</AU>
<TI>Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>Suppl 2</NO>
<PG>25-31</PG>
<IDENTIFIERS MODIFIED="2011-03-29 18:34:40 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736520"/><IDENTIFIER MODIFIED="2011-03-29 18:34:40 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18067628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736518"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ulrich-2010" MODIFIED="2011-12-08 11:48:01 +0000" MODIFIED_BY="Maryse Paquet" NAME="Ulrich 2010" YEAR="">
<REFERENCE MODIFIED="2011-11-11 19:32:35 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Skin Cancer Centre Charite, Department of Dermatology, Charite Universitatsmedizin, Charite-Platz 1, 10117 Berlin, GermanyConnective Phrase: 20507841&lt;/p&gt;" NOTES_MODIFIED="2011-11-11 19:32:35 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E</AU>
<TI>Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses</TI>
<SO>European Journal of Dermatology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>4</NO>
<PG>482-8</PG>
<IDENTIFIERS MODIFIED="2011-04-25 16:11:48 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736522"/><IDENTIFIER MODIFIED="2011-04-25 16:11:48 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20507841"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:48:01 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Ulrich C</AU>
<TI>The efficacy and safety of diclofenac 3% gel treatment of multiple actinic keratoses in organ transplant patients: A double-blind, randomized, vehicle-controlled study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3 Suppl 1</NO>
<PG>AB107</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736523"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736521"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Geer-2009" MODIFIED="2011-12-08 11:48:28 +0000" MODIFIED_BY="Maryse Paquet" NAME="Van der Geer 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:48:28 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19370466&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:48:28 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Geer S, Krekels GA</AU>
<TI>Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>5</NO>
<PG>259-65</PG>
<IDENTIFIERS MODIFIED="2011-04-15 18:36:48 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736525"/><IDENTIFIER MODIFIED="2011-04-15 18:36:48 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19370466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Felbert-2010" MODIFIED="2011-11-11 19:34:20 +0000" MODIFIED_BY="Maryse Paquet" NAME="von Felbert 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-11 19:34:20 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, RWTH Aachen University, 52074 Aachen, Germany. vvonfelbert@ukaachen.deConnective Phrase: 20426780&lt;/p&gt;" NOTES_MODIFIED="2011-11-11 19:34:20 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Felbert V, Hoffmann G, Hoff-Lesch S, Abuzahra F, Renn C N, Braathen L R, et al</AU>
<TI>Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>163</VL>
<NO>3</NO>
<PG>607-15</PG>
<IDENTIFIERS MODIFIED="2011-04-25 17:58:28 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736527"/><IDENTIFIER MODIFIED="2011-04-25 17:58:28 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20426780"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736526"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Weiss-2002" MODIFIED="2012-01-04 10:28:00 +0000" MODIFIED_BY="Maryse Paquet" NAME="Weiss 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 10:28:00 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<TI>Carac® Cream, 0.5% - product insert</TI>
<SO>http://products.sanofi.us/carac/carac.html</SO>
<YR>(accessed January 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736529"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:49:07 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorizzo J</AU>
<TI>Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy?</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736530"/><IDENTIFIER TYPE="PUBMED" VALUE="14964743"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:49:46 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Second study included in Carqac product insert?  Different values presented, ITT analysis in Weiss 2002&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:49:46 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T,et al</AU>
<TI>Effective Treatment of Actinic Keratosis With 0.5% Fluorouracil Cream for 1, 2 or 4 Weeks</TI>
<SO>Cutis</SO>
<YR>2002</YR>
<VL>70</VL>
<NO>2 Suppl</NO>
<PG>22-9</PG>
<IDENTIFIERS MODIFIED="2011-03-23 14:29:39 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736531"/><IDENTIFIER MODIFIED="2011-03-23 14:29:39 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12353677"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736528"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiegell-2008" MODIFIED="2011-12-13 14:23:16 +0000" MODIFIED_BY="Maryse Paquet" NAME="Wiegell 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-13 14:23:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00432224</AU>
<TI>Treatment of Actinic Keratoses With Photodynamic Therapy Using Sunlight Versus Red Light</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00432224</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:23:12 +0000" MODIFIED_BY="Liz Doney"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736533"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 11:52:00 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC</AU>
<TI>Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2008</YR>
<VL>158</VL>
<NO>4</NO>
<PG>740-6</PG>
<IDENTIFIERS MODIFIED="2011-04-13 16:09:18 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736534"/><IDENTIFIER MODIFIED="2011-04-13 16:09:18 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18294318"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736532"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiegell-2009" MODIFIED="2012-10-02 14:28:19 +0100" MODIFIED_BY="Maryse Paquet" NAME="Wiegell 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:52:53 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiegell SR, Hædersdal M, Wulf H</AU>
<TI>Photodynamic therapy of actinic keratoses with two different concentrations of methylaminolevulinate and home-based daylight exposure &#8211; a randomized, controlled, double blinded study</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2008</YR>
<VL>128</VL>
<NO>S1</NO>
<PG>S204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736536"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:28:19 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wiegell SR, Haedersdal M, Eriksen P, Wulf HC</AU>
<TI>Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>2009</YR>
<VL>160</VL>
<NO>6</NO>
<PG>1308-14</PG>
<IDENTIFIERS MODIFIED="2011-03-28 18:31:21 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736537"/><IDENTIFIER MODIFIED="2011-03-28 18:31:21 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19416257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736535"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiegell-2011a" MODIFIED="2012-10-02 14:28:36 +0100" MODIFIED_BY="Maryse Paquet" NAME="Wiegell 2011a" YEAR="2011">
<REFERENCE MODIFIED="2011-12-13 14:23:51 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00711178</AU>
<TI>A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00711178</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:23:46 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736539"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:28:36 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiegell SR, Fabricius S, Stender IM, Berne B, Kroon S, Andersen BL, et al</AU>
<TI>A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp.</TI>
<SO>British Journal of Dermatology</SO>
<YR>2011</YR>
<VL>164</VL>
<NO>5</NO>
<PG>1083-90</PG>
<IDENTIFIERS MODIFIED="2011-04-25 18:58:48 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736540"/><IDENTIFIER MODIFIED="2011-04-25 18:58:48 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="21219287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-25 19:36:22 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736538"/><IDENTIFIER MODIFIED="2011-04-25 19:36:22 +0100" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00711178"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wolf-2001" MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" NAME="Wolf 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-01 19:04:42 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<TI>Solaraze gel: Diclofenac Sodium 3% - package insert</TI>
<SO>Doak Dermatologics</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736542"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-04 19:30:35 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolf JE, Taylor JR, Tschen E, Kang S</AU>
<TI>Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses</TI>
<SO>International Journal of Dermatology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>11</NO>
<PG>709-13</PG>
<IDENTIFIERS MODIFIED="2011-03-31 19:41:11 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736543"/><IDENTIFIER MODIFIED="2011-03-31 19:41:11 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11737438"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736541"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeichner-2009" MODIFIED="2011-12-08 11:55:14 +0000" MODIFIED_BY="Maryse Paquet" NAME="Zeichner 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-08 11:55:14 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:55:14 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeichner JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M</AU>
<TI>Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2009</YR>
<VL>60</VL>
<NO>1</NO>
<PG>59-62</PG>
<IDENTIFIERS MODIFIED="2011-04-18 16:33:34 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736545"/><IDENTIFIER MODIFIED="2011-04-18 16:33:34 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18937999 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736544"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-01-04 10:19:20 +0000" MODIFIED_BY="Maryse Paquet">
<STUDY DATA_SOURCE="PUB" ID="STD-Alberts-2004" MODIFIED="2011-12-08 11:55:42 +0000" MODIFIED_BY="Maryse Paquet" NAME="Alberts 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-08 11:55:42 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alberts D, Ranger-Moore J, Einsphahr J, Saboda K, Bozzo P, Liu Y, et al</AU>
<TI>Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1875-80</PG>
<IDENTIFIERS MODIFIED="2011-03-31 20:50:25 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736547"/><IDENTIFIER MODIFIED="2011-03-31 20:50:25 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15041701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736546"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexiades_x002d_Armenakas-2003" MODIFIED="2011-12-08 11:56:06 +0000" MODIFIED_BY="Maryse Paquet" NAME="Alexiades-Armenakas 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-08 11:56:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alexiades-Armenakas MR, Geronemus RG</AU>
<TI>Laser-mediated photodynamic therapy of actinic keratoses</TI>
<SO>Archives of Dermatology</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>10</NO>
<PG>1313-20</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:32:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736549"/><IDENTIFIER MODIFIED="2011-11-24 19:32:46 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14568836"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736548"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Apalla-2010a" MODIFIED="2011-12-08 11:56:23 +0000" MODIFIED_BY="Maryse Paquet" NAME="Apalla 2010a" YEAR="">
<REFERENCE MODIFIED="2011-12-08 11:56:23 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apalla Z, Panagiotidou D, Ioannides D, Sotiriou E</AU>
<TI>Does the fluence rate influence clinical outcome and pain experienced by the patients with actinic keratosis treated with PDT?</TI>
<SO>Melanoma Research</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>e-suppl</NO>
<PG>e73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736551"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736550"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Apalla-2010b" MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" NAME="Apalla 2010b" YEAR="2010">
<REFERENCE MODIFIED="2011-08-30 20:47:14 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apalla Z, Panagiotidou D, Ioannides D, Sotiriou E</AU>
<TI>Which light dose is the optimal for treating actinic keratosis with PDT? An intraindividual randomized active-controlled study. Abstracts of the 6th Congress of the European Association of Dermatologic Oncology [P70]</TI>
<SO>Melanoma Research</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>e-Suppl</NO>
<PG>e73-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736553"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736552"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apalla-2010c" MODIFIED="2011-11-11 19:42:12 +0000" MODIFIED_BY="Maryse Paquet" NAME="Apalla 2010c" YEAR="2010">
<REFERENCE MODIFIED="2011-11-11 19:42:12 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: First Dermatologic Clinic, Medical School, Aristotle University, Thessaloniki, GreeceConnective Phrase: 19863513&lt;/p&gt;" NOTES_MODIFIED="2011-11-11 19:42:12 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D</AU>
<TI>Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>162</VL>
<NO>1</NO>
<PG>171-5</PG>
<IDENTIFIERS MODIFIED="2011-04-20 17:39:09 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736555"/><IDENTIFIER MODIFIED="2011-04-20 17:39:09 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19863513"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736554"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Babilas-2006" MODIFIED="2011-12-08 11:57:06 +0000" MODIFIED_BY="Maryse Paquet" NAME="Babilas 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-08 11:57:06 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Babilas P, Kohl E, Maisch T, Backer H, Grob B, Branzan AL, et al</AU>
<TI>In vitro and in vivo comparison of two different light sources for topical photodynamic therapy</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>154</VL>
<NO>4</NO>
<PG>712-718</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736557"/><IDENTIFIER TYPE="PUBMED" VALUE="16536815 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736556"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Babilas-2007" MODIFIED="2011-08-26 21:58:17 +0100" MODIFIED_BY="Maryse Paquet" NAME="Babilas 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-08-26 21:58:17 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Babilas P, Knobler R, Hummel S, Gottschaller C, Maisch T, Koller M, et al</AU>
<TI>Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>1</NO>
<PG>111-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736559"/><IDENTIFIER TYPE="PUBMED" VALUE="17542980 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736558"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Babilas-2008" MODIFIED="2011-08-26 21:50:59 +0100" MODIFIED_BY="Maryse Paquet" NAME="Babilas 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-26 21:50:59 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Babilas P, Travnik R, Werner A, Landthaler M, Szeimies RM</AU>
<TI>Split-face-study using two different light sources for topical PDT of actinic keratoses:non-inferiority of the LED system</TI>
<SO>Journal der Deutschen Dermatologischen Gesellschaft</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>1</NO>
<PG>25-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736561"/><IDENTIFIER TYPE="PUBMED" VALUE="17995967 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736560"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartels-2009" MODIFIED="2011-04-13 18:25:55 +0100" MODIFIED_BY="Maryse Paquet" NAME="Bartels 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-13 18:25:55 +0100" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: College of Optical Sciences, University of Arizona, Tucson, Arizona 85724-5024, USA. hubertbartels@msn.comConnective Phrase: 20698351&lt;/p&gt;" NOTES_MODIFIED="2011-04-13 18:25:55 +0100" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartels P, Yozwiak M, Einspahr J, Saboda K, Liu Y, Brooks C, et al</AU>
<TI>Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry</TI>
<SO>Analytical &amp; Quantitative Cytology &amp; Histology</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>6</NO>
<PG>355-66</PG>
<IDENTIFIERS MODIFIED="2011-04-13 18:25:55 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736563"/><IDENTIFIER MODIFIED="2011-04-13 18:25:55 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20698351 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736562"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-2008" MODIFIED="2011-12-08 11:57:58 +0000" MODIFIED_BY="Maryse Paquet" NAME="Berlin 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-08 11:57:58 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Medium Designator: SR-SKINCODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:57:58 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JM, Rigel DS</AU>
<TI>Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>7</NO>
<PG>669-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736565"/><IDENTIFIER TYPE="PUBMED" VALUE="18664159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736564"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Biecha_x002d_Thalharnmer-2003" MODIFIED="2011-12-08 11:59:05 +0000" MODIFIED_BY="Maryse Paquet" NAME="Biecha-Thalharnmer 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-08 11:59:05 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Abstract&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 11:59:05 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Biecha-Thalharnmer U, Honigsmann H, Tanew A</AU>
<TI>Comparison of incoherent versus pulsed monochromatic light for photodynamic therapy of actinic keratoses. [Abstract FC13-3]. The 12th Congress of the European Academy of Dermatology and Venereology. Barcelona, Spain 15-18th October 2003</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>Suppl 3</NO>
<PG>143</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736567"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736566"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braathen-2009" MODIFIED="2011-10-27 18:52:02 +0100" MODIFIED_BY="Maryse Paquet" NAME="Braathen 2009" YEAR="2008">
<REFERENCE MODIFIED="2011-10-27 18:52:02 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braathen LR, Paredes BE, Saksela O, Gardio K, Morken T, Florich KW, et al</AU>
<TI>Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses</TI>
<SO>European Academy of Dermatology &amp; Venereology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>5</NO>
<PG>550-555</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736569"/><IDENTIFIER TYPE="PUBMED" VALUE="19415804"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736568"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breza-1976" MODIFIED="2011-12-08 11:59:31 +0000" MODIFIED_BY="Maryse Paquet" NAME="Breza 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-12-08 11:59:31 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breza T, Taylor JR, Eaglestein WH</AU>
<TI>Noninflammatory destruction of actinic keratoses by fluorouracil</TI>
<SO>Archives of Dermatology</SO>
<YR>1976</YR>
<VL>112</VL>
<NO>9</NO>
<PG>1256-8</PG>
<IDENTIFIERS MODIFIED="2011-04-04 18:18:39 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736571"/><IDENTIFIER MODIFIED="2011-04-04 18:18:39 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="999302"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dermik-2003" MODIFIED="2011-12-13 14:26:09 +0000" MODIFIED_BY="Maryse Paquet" NAME="Dermik 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-13 14:26:09 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="OTHER">
<AU>Dermik</AU>
<TI>Product monograph: Carac Cream 0.5% (fluorouracil cream)</TI>
<SO>carac.info/hcp/efficacy.aspx</SO>
<YR>(accessed 26 April 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 14:26:09 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736573"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736572"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-S_x00e9_vaux-2003" MODIFIED="2011-11-24 19:35:15 +0000" MODIFIED_BY="Maryse Paquet" NAME="de Sévaux 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-24 19:35:15 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Sévaux R, Smit J, de Jong E, van de Kerkhof P, Hoitsma A</AU>
<TI>Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: Clinical effects of a randomized trial comparing two doses of acitretin</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2003</YR>
<VL>49</VL>
<PG>407-12</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:35:15 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736575"/><IDENTIFIER MODIFIED="2011-11-24 19:35:15 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12963902"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736574"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dirschka-2010" MODIFIED="2011-12-08 12:01:26 +0000" MODIFIED_BY="Maryse Paquet" NAME="Dirschka 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-24 19:37:13 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dirschka T, Bierhoff E, Pflugfelder A, Garbe C</AU>
<TI>3.0% diclofenac in 2.5% hyaluronic acid inverts the process of cancerous transformation in actinic keratoses and maintains therapeutic response by prolongation of treatment</TI>
<SO>Melanoma Research</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>e-suppl</NO>
<PG>e39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736577"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-08 12:01:26 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19709346&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 12:01:26 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dirschka T, Bierhoff E, Pflugfelder A, Garbe C</AU>
<TI>Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>3</NO>
<PG>258-63</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:37:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736578"/><IDENTIFIER MODIFIED="2011-11-24 19:37:01 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19709346"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736576"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-DUSA-2009" MODIFIED="2011-12-13 14:26:43 +0000" MODIFIED_BY="Maryse Paquet" NAME="DUSA 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-13 14:26:43 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00865878</AU>
<TI>ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00865878</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736580"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-09 23:42:15 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736579"/><IDENTIFIER MODIFIED="2011-11-09 23:42:15 +0000" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00865878"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1986" MODIFIED="2011-12-08 12:03:30 +0000" MODIFIED_BY="Maryse Paquet" NAME="Edwards 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-12-08 12:03:30 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards L, Levine N, Weidner M, Piepkorn M, Smiles K</AU>
<TI>Effect of intralesional interferon on actinic keratoses</TI>
<SO>Archives of Dermatology</SO>
<YR>1986</YR>
<VL>122</VL>
<NO>7</NO>
<PG>779-82</PG>
<IDENTIFIERS MODIFIED="2011-04-05 18:33:52 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736582"/><IDENTIFIER MODIFIED="2011-04-05 18:33:52 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="3524471 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736581"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elmets-2010" MODIFIED="2011-12-08 12:03:44 +0000" MODIFIED_BY="Maryse Paquet" NAME="Elmets 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-08 12:03:44 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, 1530 3rd Ave South, EFH 414, University of Alabama at Birmingham, Birmingham, AL 35294, USA. celmets@uab.eduConnective Phrase: 21115882&lt;/p&gt;" NOTES_MODIFIED="2011-12-08 12:03:44 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al</AU>
<TI>Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2010</YR>
<VL>102</VL>
<NO>24</NO>
<PG>1835-44</PG>
<IDENTIFIERS MODIFIED="2011-04-20 19:00:52 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736584"/><IDENTIFIER MODIFIED="2011-04-20 19:00:52 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="21115882"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736583"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-2006" MODIFIED="2011-12-08 12:04:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="Epstein 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-08 12:04:04 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein E</AU>
<TI>Twice daily vs. four times daily 5-fluorouracil therapy for actinic keratoses: a split face study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2006</YR>
<VL>154</VL>
<NO>4</NO>
<PG>794-5</PG>
<IDENTIFIERS MODIFIED="2011-03-29 16:29:12 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736586"/><IDENTIFIER MODIFIED="2011-03-29 16:29:12 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16536841"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736585"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ericson-2004" MODIFIED="2011-08-25 22:27:23 +0100" MODIFIED_BY="Maryse Paquet" NAME="Ericson 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-08-25 22:27:23 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ericson M, Sandburg C, Stenquist B, Gudmundson F, Karlsson M, Ros AM, et al</AU>
<TI>Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome</TI>
<SO>British Journal of Dermatology</SO>
<YR>2004</YR>
<VL>151</VL>
<NO>6</NO>
<PG>1204-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736588"/><IDENTIFIER TYPE="PUBMED" VALUE="15606516"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fowler-2002" MODIFIED="2011-11-11 19:45:55 +0000" MODIFIED_BY="Maryse Paquet" NAME="Fowler 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-11 19:45:55 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fowler JF, Zax RH</AU>
<TI>Aminolevulinic acid hydrochloride with photodynamic therapy: efficacy outcomes and recurrence 4 years after treatment</TI>
<SO>Cutis</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>6</NO>
<PG>2-7</PG>
<IDENTIFIERS MODIFIED="2011-10-21 15:16:37 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736590"/><IDENTIFIER MODIFIED="2011-10-21 15:16:37 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12095067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736589"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-2006" MODIFIED="2011-12-08 12:04:38 +0000" MODIFIED_BY="Maryse Paquet" NAME="Gold 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-08 12:04:38 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA</AU>
<TI>Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage</TI>
<SO>Dermatologic Surgery</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>6</NO>
<PG>795-801</PG>
<IDENTIFIERS MODIFIED="2011-04-06 15:00:52 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736592"/><IDENTIFIER MODIFIED="2011-04-06 15:00:52 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16792644 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736591"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-2003" MODIFIED="2011-12-08 12:05:02 +0000" MODIFIED_BY="Maryse Paquet" NAME="Goldman 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-08 12:05:02 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldman MP, Atkin DH</AU>
<TI>ALA-PDT in the treatment of actinic keratosis: spot versus confluent therapy</TI>
<SO>Journal of Cosmetic &amp; Laser Therapy</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>107-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736594"/><IDENTIFIER TYPE="PUBMED" VALUE="12850802"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736593"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1998" MODIFIED="2011-12-08 12:05:37 +0000" MODIFIED_BY="Maryse Paquet" NAME="Green 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-12-08 12:05:37 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green C, Orchard G, Cerio R, Hawk JL</AU>
<TI>A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>4</NO>
<PG>162-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736596"/><IDENTIFIER TYPE="PUBMED" VALUE="9894360"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-1991" MODIFIED="2011-12-08 12:05:48 +0000" MODIFIED_BY="[Empty name]" NAME="Griffin 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-12-08 12:05:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin TD, Van Scott EJ</AU>
<TI>Use of pyruvic acid in the treatment of actinic keratoses: a clinical and histopathological study</TI>
<SO>Cutis</SO>
<YR>1991</YR>
<VL>47</VL>
<NO>5</NO>
<PG>325-9</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:39:37 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736598"/><IDENTIFIER MODIFIED="2011-11-24 19:39:37 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2070654"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736597"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grima_x00ee_tre-2000" MODIFIED="2011-12-08 12:06:02 +0000" MODIFIED_BY="Maryse Paquet" NAME="Grimaître 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-08 12:06:02 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimaitre M, Etienne A, Fathi M, Piletta PA, Saurat JH</AU>
<TI>Topical colchicine therapy for actinic keratoses</TI>
<SO>Dermatology</SO>
<YR>2000</YR>
<VL>200</VL>
<NO>4</NO>
<PG>346-8</PG>
<IDENTIFIERS MODIFIED="2011-04-06 16:39:34 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736600"/><IDENTIFIER MODIFIED="2011-04-06 16:39:34 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="10894974"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736599"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gupta-2004" MODIFIED="2011-12-08 12:06:33 +0000" MODIFIED_BY="Maryse Paquet" NAME="Gupta 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-08 12:06:33 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK</AU>
<TI>Single-blind, randomized controlled trial to evaluate the efficacy and safety of photodynamic therapy using aminolevulinic acid versus 5-fluorouracil in the management of actinic keratosis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>S3</NO>
<PG>P129</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736601"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanke-2011" MODIFIED="2011-12-08 12:06:52 +0000" MODIFIED_BY="Maryse Paquet" NAME="Hanke 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-12-08 12:06:52 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S</AU>
<TI>Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or2.5% cream</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>2</NO>
<PG>165-70</PG>
<IDENTIFIERS MODIFIED="2011-04-25 20:10:52 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736604"/><IDENTIFIER MODIFIED="2011-04-25 20:10:52 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="21283921"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736603"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Humphreys-1996" MODIFIED="2011-12-08 12:07:21 +0000" MODIFIED_BY="Maryse Paquet" NAME="Humphreys 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-08 12:07:21 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Humphreys TR, Werth V, Dzubow L, Kligman A</AU>
<TI>Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>4</NO>
<PG>638-44</PG>
<IDENTIFIERS MODIFIED="2011-04-06 18:32:32 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736606"/><IDENTIFIER MODIFIED="2011-04-06 18:32:32 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="8601654 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736605"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jury-2005" MODIFIED="2011-12-08 12:07:38 +0000" MODIFIED_BY="Maryse Paquet" NAME="Jury 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-12-08 12:07:38 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jury CS, Ramraka-Jones VS, Gudi V, Herd RM</AU>
<TI>A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment</TI>
<SO>British Journal of Dermatology</SO>
<YR>2005</YR>
<VL>153</VL>
<NO>4</NO>
<PG>808-810</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736608"/><IDENTIFIER TYPE="PUBMED" VALUE="16181465 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736607"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurwa-1999" MODIFIED="2011-12-13 09:32:44 +0000" MODIFIED_BY="Maryse Paquet" NAME="Kurwa 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-12-13 09:32:44 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ</AU>
<TI>A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1999</YR>
<VL>41</VL>
<NO>3 Pt 1</NO>
<PG>414-8</PG>
<IDENTIFIERS MODIFIED="2011-04-07 18:07:34 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736610"/><IDENTIFIER MODIFIED="2011-04-07 18:07:34 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="10459115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736609"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marrero-1998" MODIFIED="2011-12-13 09:33:08 +0000" MODIFIED_BY="Maryse Paquet" NAME="Marrero 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-12-13 09:33:08 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marrero GM, Katz BE</AU>
<TI>The new fluor-hydroxy pulse peel: a combination of 5-fluorouracil and glycolic acid</TI>
<SO>Dermatological Surgery</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>9</NO>
<PG>973-8</PG>
<IDENTIFIERS MODIFIED="2011-04-07 21:26:15 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736612"/><IDENTIFIER MODIFIED="2011-04-07 21:26:15 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="9754085 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736611"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-2010" MODIFIED="2011-08-05 16:29:58 +0100" MODIFIED_BY="Maryse Paquet" NAME="Morales 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-05 16:29:57 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales Toquero A, Ocampo Candiani J, Gomez Flores M, Gonzalez Gonzalez SE, Eguia Rodriguez R, Mendez Olvera NP, et al</AU>
<TI>Clinical and histological evaluation of 5% imiquimod cream vs 5% 5-fluorouracil ointment in patients with actinic keratosis on the face</TI>
<TO>Evaluación clínica e histológica de imiquimod a 5% en crema vs5-fluorouracilo a 5% en ungüento en pacientes con queratosisactínicas en la cara</TO>
<SO>Dermatologia Revista Mexicana</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>6</NO>
<PG>326-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736614"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736613"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naylor-1995" MODIFIED="2011-11-24 19:41:16 +0000" MODIFIED_BY="Maryse Paquet" NAME="Naylor 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-11-24 19:41:16 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH</AU>
<TI>High sun protection factor sunscreens in the suppression of actinic neoplasia</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>2</NO>
<PG>170-5</PG>
<IDENTIFIERS MODIFIED="2011-11-24 19:41:16 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736616"/><IDENTIFIER MODIFIED="2011-11-24 19:41:16 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7857113"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736615"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00005097" MODIFIED="2011-12-13 14:29:00 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00005097" YEAR="2000">
<REFERENCE MODIFIED="2011-12-13 14:28:41 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00005097</AU>
<TI>Green Tea Extract in Treating Patients With Actinic Keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00005097</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736618"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-09 23:38:22 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736617"/><IDENTIFIER MODIFIED="2011-11-09 23:38:22 +0000" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00005097"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puizina_x002d_Ivic-2008a" MODIFIED="2011-08-26 13:49:09 +0100" MODIFIED_BY="Maryse Paquet" NAME="Puizina-Ivic 2008a" YEAR="2008">
<REFERENCE MODIFIED="2011-08-26 13:49:03 +0100" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Clinic of Dermatovenerology, University Hospital Split, Split, Croatia. neira.puizina@kbsplit.hrConnective Phrase: 19138010&lt;/p&gt;" NOTES_MODIFIED="2011-08-26 13:49:03 +0100" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puizina-Ivic N, Zorc H, Vanjaka-Rogosic L, Miric L, Persin A</AU>
<TI>Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy</TI>
<SO>Collegium Antropologicum.</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>Suppl 2</NO>
<PG>67-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736620"/><IDENTIFIER TYPE="PUBMED" VALUE="19138010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736619"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radakovic_x002d_Fijan-2005" MODIFIED="2011-11-24 19:41:43 +0000" MODIFIED_BY="Maryse Paquet" NAME="Radakovic-Fijan 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-24 19:41:43 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radakovic-Fijan S, Blecha-Thalhammer U, Kittler H, Honigsmann H, Tanew A</AU>
<TI>Efficacy of 3 different light doses in the treatment of actinic keratoses with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2005</YR>
<VL>53</VL>
<PG>823-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736622"/><IDENTIFIER TYPE="PUBMED" VALUE="16243131 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736621"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robins-2002a" MODIFIED="2011-12-13 09:34:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="Robins 2002a" YEAR="2002">
<REFERENCE MODIFIED="2011-12-13 09:34:04 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robins P</AU>
<TI>Pulse therapy with 5-FU in eradication actinic keratoses with less than recommended dosage</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS MODIFIED="2011-04-08 22:10:11 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736624"/><IDENTIFIER MODIFIED="2011-04-08 22:10:11 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12847751"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rosen-2010" MODIFIED="2011-12-13 14:30:53 +0000" MODIFIED_BY="Maryse Paquet" NAME="Rosen 2010" YEAR="">
<REFERENCE MODIFIED="2011-12-13 14:30:53 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Rosen R</AU>
<TI>Clinical development of ingenol mebutate (PEP005) gel for actinic keratosis. 43rd Annual Scientific Meeting of the Australasian College of Dermatologists Darwin, NT Australia</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>Suppl 1</NO>
<PG>A5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736626"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736625"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuttleworth-1989" MODIFIED="2011-12-13 09:40:27 +0000" MODIFIED_BY="Maryse Paquet" NAME="Shuttleworth 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-12-13 09:40:27 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shuttleworth D, Marks R</AU>
<TI>A comparison of the effects of intralesional interferon a-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>2</NO>
<PG>65-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736627"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simmonds-1973" MODIFIED="2011-12-13 09:41:40 +0000" MODIFIED_BY="Liz Doney" NAME="Simmonds 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-12-13 09:41:40 +0000" MODIFIED_BY="Liz Doney" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simmonds WL</AU>
<TI>Double-blind investigation comparing a 1%-vs-5% 5-fluorouracil topical cream in patients with multiple actinic keratoses</TI>
<SO>Cutis</SO>
<YR>1973</YR>
<VL>12</VL>
<NO>4</NO>
<PG>615-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736629"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2006" MODIFIED="2011-12-13 14:31:18 +0000" MODIFIED_BY="Maryse Paquet" NAME="Smith 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-13 14:31:18 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SR, Morhenn VB, Piacquadio DJ</AU>
<TI>Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>156-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736632"/><IDENTIFIER TYPE="PUBMED" VALUE="16485883"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736631"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sotiriou-2011" MODIFIED="2011-12-13 14:40:07 +0000" MODIFIED_BY="Maryse Paquet" NAME="Sotiriou 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-12-13 14:40:07 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Sotiriou E, Apalla Z, Chovarda E, Goussi C, Trigoni A, Ioannides D</AU>
<TI>Single vs. fractionated photodynamic therapy for face and scalp actinic keratoses: a randomized, intraindividual comparison trial with 12-month follow-up</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2011 Mar 2 [Epub ahead of print]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736634"/><IDENTIFIER TYPE="PUBMED" VALUE="21366709"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736633"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-2010" MODIFIED="2011-12-13 09:36:16 +0000" MODIFIED_BY="Maryse Paquet" NAME="Spencer 2010" YEAR="">
<REFERENCE MODIFIED="2011-12-13 09:36:16 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Spencer J</AU>
<TI>Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3 Suppl 1</NO>
<PG>AB105</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736636"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736635"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stockfleth-2004" MODIFIED="2011-12-13 09:36:29 +0000" MODIFIED_BY="Maryse Paquet" NAME="Stockfleth 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 09:36:29 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stockfleth E, Christophers E, Benninghoff B, Sterry W</AU>
<TI>Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study</TI>
<SO>Archives of Dermatology</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>12</NO>
<PG>1542</PG>
<IDENTIFIERS MODIFIED="2011-03-24 14:33:04 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736638"/><IDENTIFIER MODIFIED="2011-03-24 14:33:04 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15611446 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736637"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szeimies-2010a" MODIFIED="2011-12-13 09:36:48 +0000" MODIFIED_BY="Maryse Paquet" NAME="Szeimies 2010a" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 09:36:48 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, Regensburg University Hospital, Franz Josef Strauss Allee 11, Regensburg, GermanyConnective Phrase: 19804593&lt;/p&gt;" NOTES_MODIFIED="2011-12-13 09:36:48 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szeimies RM, Stockfleth E, Popp G, Borrosch F, Bruning H, Dominicus R, et al</AU>
<TI>Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>162</VL>
<NO>2</NO>
<PG>410-4</PG>
<IDENTIFIERS MODIFIED="2011-04-25 14:26:20 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736640"/><IDENTIFIER MODIFIED="2011-04-25 14:26:20 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19804593"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736639"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Touma-2004" MODIFIED="2012-01-04 10:19:20 +0000" MODIFIED_BY="Maryse Paquet" NAME="Touma 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-04 10:19:20 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Paquet M</AU>
<TI>Touma et al. 2004 [personal communication]</TI>
<SO>Email to: BA Gilchrest</SO>
<YR>29 March 2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736642"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-13 09:44:43 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;sent email to authors to get more information on number of patients randomized to the different treatments.&lt;/p&gt;" NOTES_MODIFIED="2011-12-13 09:44:43 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest B</AU>
<TI>A Trial of Short Incubation, Broad-Area Photodynamic Therapy for Facial Actinic Keratoses and Diffuse Photodamage</TI>
<SO>Archives of Dermatology</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736643"/><IDENTIFIER TYPE="PUBMED" VALUE="14732657"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736641"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Tsoukas-2010" MODIFIED="2011-11-11 19:56:11 +0000" MODIFIED_BY="Maryse Paquet" NAME="Tsoukas 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-11 19:56:11 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsoukas M</AU>
<TI>Treatment of actinic keratosis with 5-ALA PDT versus topical imiquimod in healthy and immunosuppressed patients</TI>
<SO>Melanoma Research</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>e-suppl</NO>
<PG>e39-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736645"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valeant-2004" MODIFIED="2011-12-13 14:41:43 +0000" MODIFIED_BY="Maryse Paquet" NAME="Valeant 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 14:41:43 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="OTHER">
<AU>Valeant</AU>
<TI>Efudex topical solutions and cream (fluorouracil). Product monograph</TI>
<SO>valeant.com/fileRepository/products/PI/Efudex-40_Cream_5_Solution_2-5_PI_Apr04.pdf</SO>
<YR>(accessed 26 April 2011)</YR>
<IDENTIFIERS MODIFIED="2011-12-13 09:45:49 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736647"/><IDENTIFIER MODIFIED="2011-12-13 09:45:49 +0000" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Vbeam-2005" MODIFIED="2011-12-13 14:41:33 +0000" MODIFIED_BY="Maryse Paquet" NAME="Vbeam 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-12-13 14:41:33 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00524485</AU>
<TI>Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00524485</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736649"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-09 23:35:34 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736648"/><IDENTIFIER MODIFIED="2011-11-09 23:35:34 +0000" MODIFIED_BY="Maryse Paquet" TYPE="CTG" VALUE="NCT00524485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Weinstock-2010" MODIFIED="2011-12-13 09:47:27 +0000" MODIFIED_BY="Maryse Paquet" NAME="Weinstock 2010" YEAR="">
<REFERENCE MODIFIED="2011-12-13 09:47:27 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>Weinstock MA, Bingham SF</AU>
<TI>High-dose topical tretinoin for reducing multiplicity of actinic keratoses. 2010 Annual Meeting of the Society for Investigative Dermatology Atlanta, GA United States</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2010</YR>
<VL>Suppl 1</VL>
<NO>130</NO>
<PG>S63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736651"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736650"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wennberg-2008" MODIFIED="2011-12-13 09:51:12 +0000" MODIFIED_BY="Maryse Paquet" NAME="Wennberg 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-13 09:51:12 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;Author Affiliation: Department of Dermatology, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden. ann-marie.wennberg@vgregion.seConnective Phrase: 18698246&lt;/p&gt;" NOTES_MODIFIED="2011-12-13 09:51:12 +0000" NOTES_MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wennberg AM, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G, et al</AU>
<TI>Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study</TI>
<SO>Transplantation</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>3</NO>
<PG>423-9</PG>
<IDENTIFIERS MODIFIED="2011-04-18 16:15:55 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736653"/><IDENTIFIER MODIFIED="2011-04-18 16:15:55 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18698246"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736652"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wulf-2006" MODIFIED="2011-12-13 09:51:40 +0000" MODIFIED_BY="Maryse Paquet" NAME="Wulf 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-13 09:51:40 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA</AU>
<TI>Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1</NO>
<PG>25-8</PG>
<IDENTIFIERS MODIFIED="2011-03-31 19:36:28 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736655"/><IDENTIFIER MODIFIED="2011-03-31 19:36:28 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16585985"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736654"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamauchi-2002" MODIFIED="2011-12-13 09:53:50 +0000" MODIFIED_BY="Maryse Paquet" NAME="Yamauchi 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-12-13 09:53:50 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="YES" TYPE="OTHER">
<AU>Yamauchi PS, Lowe NJ, Lask GP, Patnaik R, Moore D, Foley P</AU>
<TI>Methyl aminolevulinate and photodynamic therapy in the treatment of actinic keratosis. [Abstract 804]. The 63rd annual meeting of the Society for Investigative Dermatology, 15-18 May, Los Angeles, USA</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2002</YR>
<VL>119</VL>
<NO>1</NO>
<PG>341</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736657"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736656"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-10-02 14:42:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akarsu-2011" MODIFIED="2012-10-02 14:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Akarsu 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:30:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akarsu S, Aktan S, Atahan A, Koc P, Ozkan S</AU>
<TI>Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>5</NO>
<PG>479-84</PG>
<IDENTIFIERS MODIFIED="2012-04-09 14:08:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736659"/><IDENTIFIER MODIFIED="2012-04-09 14:08:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21418281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-09 14:04:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736658"/><IDENTIFIER MODIFIED="2012-04-09 14:04:32 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apalla-2011" MODIFIED="2012-10-02 14:30:41 +0100" MODIFIED_BY="[Empty name]" NAME="Apalla 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:30:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apalla Z, Sotiriou E, Panagiotidou D, Lefaki I, Goussi C, Ioannides D</AU>
<TI>The impact of different fluence rates on pain and clinical outcome in patients with actinic keratoses treated with photodynamic therapy</TI>
<SO>Photodermatology, Photoimmunology &amp; Photomedicine</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>4</NO>
<PG>181-5</PG>
<IDENTIFIERS MODIFIED="2012-04-09 17:33:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736661"/><IDENTIFIER MODIFIED="2012-04-09 17:33:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21729165"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736660"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azimi-2012" MODIFIED="2012-04-13 22:05:09 +0100" MODIFIED_BY="[Empty name]" NAME="Azimi 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-04-13 22:05:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azimi H, Zadeh MG, Jaberian M, Omid M</AU>
<TI>Comparison of the efficacy of cryotherapy and 0.1% Acnalen gel vs. cryotherapy and placebo in the treatment of actinic keratoses</TI>
<SO>Pakistan Journal of Medical Sciences</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS MODIFIED="2012-04-09 17:43:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736663"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-09 17:39:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT201010104901N1</AU>
<TI>Comparison of the efficacy of cryotherapy and 0.1 % acnalen gel vs. cryotherapy alone in the treatment of actinic keratoses: a randomized, double-blind clinical trial</TI>
<SO>irct.ir/searchresult.php?id=4901&amp;number=1</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736664"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736662"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Damian-2011" MODIFIED="2012-10-02 14:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Damian 2011" YEAR="2009">
<REFERENCE MODIFIED="2012-04-09 18:57:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12609000490279</AU>
<TI>Randomized, double-blind, placebo controlled study to assess efficacy of oral nicotinamide in the treatment and prevention of actinic keratoses</TI>
<SO>anzctr.org.au/trial_view.aspx?ID=83879</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736666"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damian D, Surjana D, Martin A, Halliday G</AU>
<TI>Oral nicotinamide for skin cancer prevention. 41st Annual Meeting of the European Society for Dermatological Research, ESDR 2011 Barcelona Spain. 7-10 September 2011</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2011</YR>
<VL>131</VL>
<NO>Suppl 2</NO>
<PG>S99</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736667"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736665"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deonizio-2011" MODIFIED="2012-10-02 14:33:22 +0100" MODIFIED_BY="[Empty name]" NAME="Deonizio 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:33:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deonizio JM, Mulinari-Brenner FA</AU>
<TI>Cryopeeling for treatment of photodamage and actinic keratosis: liquid nitrogen versus portable system</TI>
<SO>Anais Brasileiros De Dermatologia</SO>
<YR>2011</YR>
<VL>86</VL>
<NO>3</NO>
<PG>440-4</PG>
<IDENTIFIERS MODIFIED="2012-04-09 19:35:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736669"/><IDENTIFIER MODIFIED="2012-04-09 19:35:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21738958"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736668"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dirschka-2012" MODIFIED="2012-10-02 14:33:42 +0100" MODIFIED_BY="[Empty name]" NAME="Dirschka 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:33:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dirschka T, Radny P, Dominicus R, Mensing H, Bruning H, Jenne L, et al</AU>
<TI>Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo</TI>
<SO>British Journal of Dermatology</SO>
<YR>2012</YR>
<VL>166</VL>
<NO>1</NO>
<PG>137-46</PG>
<IDENTIFIERS MODIFIED="2012-04-09 20:28:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736671"/><IDENTIFIER MODIFIED="2012-04-09 20:28:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21910711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galitzer-2011" MODIFIED="2012-04-13 22:08:01 +0100" MODIFIED_BY="[Empty name]" NAME="Galitzer 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-13 22:08:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galitzer BI</AU>
<TI>Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>10</NO>
<PG>1124-32</PG>
<IDENTIFIERS MODIFIED="2012-04-10 14:35:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736673"/><IDENTIFIER MODIFIED="2012-04-10 14:35:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21968662"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736672"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haddad-2011" MODIFIED="2012-10-02 14:34:07 +0100" MODIFIED_BY="[Empty name]" NAME="Haddad 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:34:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haddad A, Santos ID, Gragnani A, Ferreira LM</AU>
<TI>The effect of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light</TI>
<SO>Photomedicine &amp; Laser Surgery</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>6</NO>
<PG>427-32</PG>
<IDENTIFIERS MODIFIED="2012-04-10 17:21:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736675"/><IDENTIFIER MODIFIED="2012-04-10 17:21:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21631378"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736674"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lebwohl-2012" MODIFIED="2012-10-02 14:38:31 +0100" MODIFIED_BY="[Empty name]" NAME="Lebwohl 2012" YEAR="2009">
<REFERENCE MODIFIED="2012-10-02 14:35:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson L, Melgaard A, Schmeider G, Xu Z</AU>
<TI>Two-day topical treatment with ingenol mebutate gel, 0.05% for actinic keratoses on the trunk and extremities: Analysis of data pooled from two trials. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States, 16-20 March 2012</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4 Suppl</NO>
<PG>AB159</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736677"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:37:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman B, Melgaard A, Marmur E, Larsson T</AU>
<TI>Three-day topical treatment with ingenol mebutate gel, 0.015% for actinic keratoses on the face and scalp: analysis of data pooled from two trials. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States, 16-20 March 2012</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4 Suppl</NO>
<PG>AB3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736678"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:38:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebwohl M, Melgaard A, Kobayashi K, Swanson N</AU>
<TI>Local skin responses associated with ingenol mebutate gel for the treatment of actinic keratosis: Two analyses of pooled data, 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States, 16-20 March 2012</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4 Suppl</NO>
<PG>AB153</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-13 22:09:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B</AU>
<TI>Ingenol mebutate gel for actinic keratosis-online supplement</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>11</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736680"/><IDENTIFIER TYPE="PUBMED" VALUE="22417254"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-13 22:09:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B</AU>
<TI>Ingenol mebutate gel for actinic keratosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>11</NO>
<PG>1010-9</PG>
<IDENTIFIERS MODIFIED="2012-04-10 18:32:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736681"/><IDENTIFIER MODIFIED="2012-04-10 18:32:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22417254"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-17 16:10:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Leo Pharma</AU>
<TI>Picato product label information</TI>
<SO>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736682"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-10 18:26:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00915551</AU>
<TI>A multi-center study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, when used to treat actinic keratoses on the head (face or scalp)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00915551</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736683"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-10 18:27:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00916006</AU>
<TI>A multi-center study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, when used to treat actinic keratoses on the head (face or scalp)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00916006</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736684"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-10 18:28:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00942604</AU>
<TI>A multicenter study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel when used to treat actinic keratoses (AKs) on the non head locations</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00942604</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736676"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serra_x002d_Guillen-2012" MODIFIED="2012-10-02 14:40:43 +0100" MODIFIED_BY="[Empty name]" NAME="Serra-Guillen 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:40:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serra-Guillen C, Nagore E, Hueso L, Traves V, Messeguer F, Sanmartin O, et al</AU>
<TI>A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: Clinical and histologic outcomes</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4</NO>
<PG>e131-7</PG>
<IDENTIFIERS MODIFIED="2012-04-11 14:10:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736687"/><IDENTIFIER MODIFIED="2012-04-11 14:10:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22226430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736686"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stockfleth-2011" MODIFIED="2012-10-02 14:40:57 +0100" MODIFIED_BY="[Empty name]" NAME="Stockfleth 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-11 17:44:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00987246</AU>
<TI>Study on the efficacy of LAS41005 in the treatment of actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00987246ls.gov</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736689"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:40:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stockfleth E, Kerl H, Zwingers T, Willers C</AU>
<TI>Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results</TI>
<SO>British Journal of Dermatology</SO>
<YR>2011</YR>
<VL>165</VL>
<NO>5</NO>
<PG>1101-8</PG>
<IDENTIFIERS MODIFIED="2012-04-11 15:31:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736690"/><IDENTIFIER MODIFIED="2012-04-11 15:31:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21517801"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736688"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiegell-2011b" MODIFIED="2012-10-02 14:42:25 +0100" MODIFIED_BY="[Empty name]" NAME="Wiegell 2011b" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:41:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiegell SR, Heydenreich J, Fabricius S, Wulf HC</AU>
<TI>Continuous ultra-low-intensity artificial daylight is not as effective as red LED light in photodynamic therapy of multiple actinic keratoses</TI>
<SO>Photodermatology, Photoimmunology &amp; Photomedicine</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>6</NO>
<PG>280-5</PG>
<IDENTIFIERS MODIFIED="2012-04-11 18:24:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736692"/><IDENTIFIER MODIFIED="2012-04-11 18:24:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22092730"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-02 14:42:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willey A</AU>
<TI>Temperature-modulated photodynamic therapy for the treatment of actinic keratoses on the extremities. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States, 16-20 March 2012</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>4 Suppl</NO>
<PG>AB177</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736691"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2012-10-02 14:48:11 +0100" MODIFIED_BY="Maryse Paquet">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN12610000689077" MODIFIED="2012-04-17 15:59:15 +0100" MODIFIED_BY="Maryse Paquet" NAME="ACTRN12610000689077" YEAR="2010">
<REFERENCE MODIFIED="2012-04-17 15:59:15 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12610000689077</AU>
<TI>Effect of nicotinamide versus placebo on numbers of actinic keratoses</TI>
<SO>anzctr.org.au/trial_view.aspx?ID=335868</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736695"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736694"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00115154" MODIFIED="2011-12-13 11:33:46 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00115154" YEAR="5154">
<REFERENCE MODIFIED="2011-12-13 11:33:46 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00115154</AU>
<TI>Study to assess the safety and efficacy of imiquimod 5% cream for the treatment of actinic keratosis on the arms and hands</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00115154</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736697"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736696"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00204542" MODIFIED="2011-12-13 11:33:56 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00204542" YEAR="4542">
<REFERENCE MODIFIED="2011-12-13 11:33:56 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00204542</AU>
<TI>Comparison of the efficacy and tolerability of Solaraze for 3 versus 6 months in patients with mild to moderate actinic keratosis located on the face and head</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00204542</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736699"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736698"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00472459" MODIFIED="2011-12-13 11:36:07 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00472459" YEAR="2003">
<REFERENCE MODIFIED="2011-12-13 11:36:07 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00472459</AU>
<TI>PDT with Metvix® 160 mg/g cream in organ transplant recipients with non-melanoma skin cancer</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00472459</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736700"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00608634" MODIFIED="2011-12-13 11:34:06 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00608634" YEAR="2004">
<REFERENCE MODIFIED="2011-12-13 11:34:06 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00608634</AU>
<TI>Topical perillyl alcohol in treating patients with sun damaged skin and actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00608634</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736703"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736702"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00695578" MODIFIED="2011-12-13 11:34:14 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00695578" YEAR="2006">
<REFERENCE MODIFIED="2011-12-13 11:34:14 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00695578</AU>
<TI>Clinical trial to evaluate biafine cream versus standard care in subjects with actinic keratosis post cryotherapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00695578</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736705"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736704"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00700063" MODIFIED="2011-12-13 11:34:21 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00700063" YEAR="2008">
<REFERENCE MODIFIED="2011-12-13 11:34:21 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00700063</AU>
<TI>A multicenter study to evaluate the safety and efficacy of PEP005 topical gel when used to treat actinic keratoses on the head (face or scalp)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00700063</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736707"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736706"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00756288" MODIFIED="2012-04-17 16:14:58 +0100" MODIFIED_BY="Maryse Paquet" NAME="NCT00756288" YEAR="2008">
<REFERENCE MODIFIED="2012-04-17 16:14:58 +0100" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00756288</AU>
<TI>Photo-therapy with a topical retinoid versus photo-therapy alone for actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00756288</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736709"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736708"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00786994" MODIFIED="2011-12-13 11:34:46 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00786994" YEAR="2008">
<REFERENCE MODIFIED="2011-12-13 11:34:46 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00786994</AU>
<TI>The efficacy and tolerability of oleogel-S-10 in patients with actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00786994</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-07 19:51:20 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736710"/><IDENTIFIER MODIFIED="2011-11-07 19:51:20 +0000" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00859105" MODIFIED="2011-12-13 11:34:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00859105" YEAR="2008">
<REFERENCE MODIFIED="2011-12-13 11:34:39 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00859105</AU>
<TI>A randomized, double-blind, parallel-group, vehicle-controlled therapeutic equivalence study of three Imiquimod cream 5% treatments for patients with actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00859105</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736713"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736712"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00948428" MODIFIED="2011-12-13 11:41:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00948428" YEAR="8428">
<REFERENCE MODIFIED="2011-12-13 11:41:04 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00948428</AU>
<TI>Bioequivalence of generic imiquimod cream, 5% when compared to Aldara&#8482; (imiquimod) cream, 5% in the treatment of actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00948428</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736715"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736714"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00991861" MODIFIED="2011-12-13 11:43:52 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT00991861" YEAR="2009">
<REFERENCE MODIFIED="2011-12-13 11:43:52 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT00991861</AU>
<TI>Efficacy and safety study of LAS41007 in the treatment of actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00991861</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736717"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736716"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01203878" MODIFIED="2011-12-13 11:45:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT01203878" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 11:45:04 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01203878</AU>
<TI>Treatment of actinic keratoses of the face with imiquimod 3.75% cream followed by photodynamic therapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01203878</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736719"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736718"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01229319" MODIFIED="2011-12-13 11:46:31 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT01229319" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 11:46:31 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01229319</AU>
<TI>Imiquimod 3.75% cream in combination with cryotherapy in the treatment of hypertrophic actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01229319</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736720"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01260987" MODIFIED="2011-12-13 11:47:45 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT01260987" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 11:47:45 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01260987</AU>
<TI>Fractional CO2 laser assisted photodynamic therapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01260987</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736722"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01265602" MODIFIED="2011-12-13 11:48:49 +0000" MODIFIED_BY="Maryse Paquet" NAME="NCT01265602" YEAR="2010">
<REFERENCE MODIFIED="2011-12-13 11:48:49 +0000" MODIFIED_BY="Maryse Paquet" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01265602</AU>
<TI>Double-blind, randomized, vehicle- and comparator-controlled, multi-center trial to evaluate the efficacy and safety of LAS41007 in the treatment of actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01265602</SO>
<YR>(accessed 14 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01354717" MODIFIED="2012-10-02 14:48:11 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01354717" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:48:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01354717</AU>
<TI>Bioequivalence study of generic fluorouracil 0.5% cream and 0.5% Carac® and placebo</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01354717</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-13 14:09:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736726"/><IDENTIFIER MODIFIED="2012-04-13 14:09:29 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01354717"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01358851" MODIFIED="2012-10-02 14:48:03 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01358851" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:48:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01358851</AU>
<TI>LAS41005 in hyperkeratotic actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01358851</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 17:32:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736728"/><IDENTIFIER MODIFIED="2012-04-12 17:32:22 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01358851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01413763" MODIFIED="2012-10-02 14:47:57 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01413763" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01413763</AU>
<TI>Potential effect of topical imiquimod on atrial ectopy in patients with actinic aeratosis</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01413763</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736731"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 15:54:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736730"/><IDENTIFIER MODIFIED="2012-04-12 15:54:39 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01413763"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01453179" MODIFIED="2012-10-02 14:47:49 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01453179" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01453179</AU>
<TI>Long-term effects of imiquimod and diclofenac in actinic keratoses (LEIDA 2)</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01453179</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 17:58:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736732"/><IDENTIFIER MODIFIED="2012-04-12 17:58:13 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01453179"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01458587" MODIFIED="2012-10-02 14:47:40 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01458587" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01458587</AU>
<TI>Levulan PDT versus vehicle for extremity actinic keratoses (AK)</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01458587</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 19:30:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736734"/><IDENTIFIER MODIFIED="2012-04-12 19:30:27 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01458587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01459393" MODIFIED="2012-10-02 14:47:33 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01459393" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01459393</AU>
<TI>Comparison between 5-aminolevulinic acid photodynamic therapy versus cryotherapy for actinic keratosis treatment</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01459393</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 14:18:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736736"/><IDENTIFIER MODIFIED="2012-04-12 14:18:53 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01459393"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01475071" MODIFIED="2012-10-02 14:47:27 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01475071" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:47:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01475071</AU>
<TI>Intra-individual comparison of efficacy and safety of Metvix® natural daylight photodynamic therapy versus conventional Metvix® photodynamic therapy in subject with mild actinic keratoses (CoMet)</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01475071</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736739"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-13 13:51:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736738"/><IDENTIFIER MODIFIED="2012-04-13 13:51:33 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01475071"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01475955" MODIFIED="2012-10-02 14:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01475955" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01475955</AU>
<TI>Short-incubation Levulan photodynamic therapy versus vehicle for face/scalp actinic keratosis (AK)</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01475955</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736741"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 20:32:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736740"/><IDENTIFIER MODIFIED="2012-04-12 20:32:20 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01475955"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01481155" MODIFIED="2012-10-02 14:47:11 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01481155" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01481155</AU>
<TI>Comparative study of photodynamic therapy vs. CO2 laser therapy in treatment of actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01481155</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736743"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 15:38:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736742"/><IDENTIFIER MODIFIED="2012-04-12 15:38:39 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01481155"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01493921" MODIFIED="2012-10-02 14:47:05 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01493921" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:47:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01493921</AU>
<TI>Efficacy study &amp; safety evaluation of SR-T100 gel in actinic keratosis treatment</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01493921</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736745"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 15:15:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736744"/><IDENTIFIER MODIFIED="2012-04-12 15:15:25 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01493921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01502020" MODIFIED="2012-10-02 14:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01502020" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:46:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01502020</AU>
<TI>A bioequivalence study with clinical endpoints comparing generic imiquimod cream, 3.75% and Zyclara&#8482; (imiquimod) cream, 3.75% in subjects with actinic keratoses</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01502020</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736747"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 16:32:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736746"/><IDENTIFIER MODIFIED="2012-04-12 16:32:55 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01502020"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01516515" MODIFIED="2012-10-02 14:46:46 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01516515" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:46:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01516515</AU>
<TI>Efficacy and safety phase II dose-ranging study of SR-T100 to treat actinic keratosis</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01516515</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736749"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 16:09:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736748"/><IDENTIFIER MODIFIED="2012-04-12 16:09:37 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01516515"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01525329" MODIFIED="2012-10-02 14:46:39 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01525329" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:46:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01525329</AU>
<TI>Combination therapy with 5-FU and PDT for the treatment of post-transplant premalignant skin disease</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01525329</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736751"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 20:06:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736750"/><IDENTIFIER MODIFIED="2012-04-12 20:06:09 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01525329"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01538901" MODIFIED="2012-10-02 14:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01538901" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:43:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01538901</AU>
<TI>Imiquimod versus photodynamic therapy of actinic keratoses in organ transplant recipients</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01538901</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736753"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 14:49:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736752"/><IDENTIFIER MODIFIED="2012-04-12 14:49:15 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01538901"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01541228" MODIFIED="2012-10-02 14:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01541228" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:46:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01541228</AU>
<TI>Clinical effect of photodynamic treatment when treating actinic keratoses with different light doses</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01541228</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736755"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 13:40:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736754"/><IDENTIFIER MODIFIED="2012-04-12 13:40:25 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01541228"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01541553" MODIFIED="2012-10-02 14:45:54 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01541553" YEAR="2012">
<REFERENCE MODIFIED="2012-10-02 14:45:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01541553</AU>
<TI>A sequential treatment regimen of cryotherapy and Picato® for the treatment of actinic keratosis on the face and scalp</TI>
<SO>clinicaltrials.gov/ct2/results?term=NCT01541553</SO>
<YR>(accessed 5 April 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-04-12 18:38:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736756"/><IDENTIFIER MODIFIED="2012-04-12 18:38:12 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01541553"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Willey-2011" MODIFIED="2012-10-02 14:45:38 +0100" MODIFIED_BY="[Empty name]" NAME="Willey 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-02 14:45:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willey A, Sakamoto F</AU>
<TI>Temperature modulated photodynamic therapy for the treatment of actinic keratoses on the extremities. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States, 30/3-3/4 2011</TI>
<SO>Lasers in Surgery &amp; Medicine</SO>
<YR>2011</YR>
<VL>43</VL>
<NO>S23</NO>
<PG>957-958</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2736759"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2736758"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-11-05 12:06:36 +0000" MODIFIED_BY="Maryse Paquet">
<ADDITIONAL_REFERENCES MODIFIED="2012-11-05 12:06:36 +0000" MODIFIED_BY="Maryse Paquet">
<REFERENCE ID="REF-Adamson-2002" MODIFIED="2011-12-13 11:49:29 +0000" MODIFIED_BY="Maryse Paquet" NAME="Adamson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN</AU>
<TI>Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling</TI>
<SO>Molecular Pharmacology</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alam-1995" MODIFIED="2011-12-13 11:49:50 +0000" MODIFIED_BY="Maryse Paquet" NAME="Alam 1995" TYPE="JOURNAL_ARTICLE">
<AU>Alam CA, Seed MP, Willoughby DA</AU>
<TI>Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice</TI>
<SO>Journal of Pharmacy &amp; Phamacology</SO>
<YR>1995</YR>
<VL>47</VL>
<NO>5</NO>
<PG>407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amini-2010" MODIFIED="2011-12-13 11:50:16 +0000" MODIFIED_BY="Maryse Paquet" NAME="Amini 2010" TYPE="JOURNAL_ARTICLE">
<AU>Amini S, Viera MH, Valins W, Berman B</AU>
<TI>Nonsurgical innovations in the treatment of nonmelanoma skin cancer</TI>
<SO>The Journal of Clinical &amp; Aesthetic Dermatology</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>6</NO>
<PG>20-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Askew-2009" MODIFIED="2012-10-02 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NAME="Askew 2009" TYPE="JOURNAL_ARTICLE">
<AU>Askew DA, Mickan SM, Soyer HP, Wilkinson D</AU>
<TI>Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials</TI>
<SO>International Journal of Dermatology</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>5</NO>
<PG>453-63</PG>
<IDENTIFIERS MODIFIED="2011-10-28 18:32:15 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-10-28 18:32:15 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19416373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berman-2006" MODIFIED="2011-11-11 20:06:23 +0000" MODIFIED_BY="Maryse Paquet" NAME="Berman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Berman B, Villa AM, Ramirez CC</AU>
<TI>Mechanisms of action of new treatment modalities for actinic keratosis</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>167-73</PG>
<IDENTIFIERS MODIFIED="2011-05-04 20:58:10 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-05-04 20:58:10 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16485885"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2005" MODIFIED="2012-10-02 14:49:37 +0100" MODIFIED_BY="Maryse Paquet" NAME="Brown 2005" TYPE="JOURNAL_ARTICLE">
<AU>Brown MB, Jones SA</AU>
<TI>Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>308-18</PG>
<IDENTIFIERS MODIFIED="2011-09-09 17:39:06 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-09 17:39:06 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15857456"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Callen-1997" MODIFIED="2011-12-13 11:51:09 +0000" MODIFIED_BY="Liz Doney" NAME="Callen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Callen JP, Bickers DR, Moy RL</AU>
<TI>Actinic keratoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>4</NO>
<PG>650-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chakrabarty-2004" MODIFIED="2011-12-13 11:51:36 +0000" MODIFIED_BY="Maryse Paquet" NAME="Chakrabarty 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chakrabarty A, Geisse JK</AU>
<TI>Medical therapies for non-melanoma skin cancer</TI>
<SO>Clinics in Dermatology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>3</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockerell-2000" MODIFIED="2011-11-11 20:08:57 +0000" MODIFIED_BY="Maryse Paquet" NAME="Cockerell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cockerell CJ</AU>
<TI>Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis")</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<PG>S11-17</PG>
<IDENTIFIERS MODIFIED="2011-09-08 14:58:09 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 14:58:09 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="10607351"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Correale-2002" MODIFIED="2012-10-02 14:50:15 +0100" MODIFIED_BY="Maryse Paquet" NAME="Correale 2002" TYPE="JOURNAL_ARTICLE">
<AU>Correale CE</AU>
<TI>Actinic keratoses: new treatment options</TI>
<SO>Advances in Dermatology</SO>
<YR>2002</YR>
<VL>18</VL>
<PG>339-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dinehart-2000" MODIFIED="2011-12-13 11:52:33 +0000" MODIFIED_BY="Liz Doney" NAME="Dinehart 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dinehart SM</AU>
<TI>The treatment of actinic keratoses</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 2</NO>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eaglstein-1970" MODIFIED="2012-10-02 14:51:00 +0100" MODIFIED_BY="Maryse Paquet" NAME="Eaglstein 1970" TYPE="JOURNAL_ARTICLE">
<AU>Eaglstein WH, Weinstein GD, Frost P</AU>
<TI>Fluorouracil: mechanism of action in human skin and actinic keratoses. Effect on DNA synthesis in vivo</TI>
<SO>Archives of Dermatology</SO>
<YR>1970</YR>
<VL>101</VL>
<NO>2</NO>
<PG>132-9</PG>
<IDENTIFIERS MODIFIED="2011-05-04 21:02:03 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-05-04 21:02:03 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="5413250"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Engel-1988" MODIFIED="2011-12-13 11:53:49 +0000" MODIFIED_BY="[Empty name]" NAME="Engel 1988" TYPE="JOURNAL_ARTICLE">
<AU>Engel A, Johnson M, Haynes SG</AU>
<TI>Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974</TI>
<SO>Archives of Dermatology</SO>
<YR>1988</YR>
<VL>124</VL>
<NO>1</NO>
<PG>72-9</PG>
<IDENTIFIERS MODIFIED="2011-11-11 20:12:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-11-11 20:12:17 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3257372"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fayter-2010" MODIFIED="2011-12-13 11:54:04 +0000" MODIFIED_BY="Maryse Paquet" NAME="Fayter 2010" TYPE="JOURNAL_ARTICLE">
<AU>Fayter D, Corbett M, Heirs M, Fox D, Eastwood A</AU>
<TI>A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin</TI>
<SO>Health Technology Assessment</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>37</NO>
<PG>1-288</PG>
<IDENTIFIERS MODIFIED="2011-10-27 17:37:33 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-10-27 17:37:33 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20663420"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Feldman-2011" MODIFIED="2012-10-02 14:51:14 +0100" MODIFIED_BY="Maryse Paquet" NAME="Feldman 2011" TYPE="JOURNAL_ARTICLE">
<AU>Feldman SR, Fleischer AB</AU>
<TI>Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications</TI>
<SO>Cutis</SO>
<YR>2011</YR>
<VL>87</VL>
<PG>201-7</PG>
<IDENTIFIERS MODIFIED="2011-09-07 16:58:49 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-07 16:58:49 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="21644496"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fink_x002d_Puches-1997" MODIFIED="2012-10-02 14:52:00 +0100" MODIFIED_BY="Maryse Paquet" NAME="Fink-Puches 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fink-Puches R, Hofer A, Smolle J, Kerl H, Wolf P</AU>
<TI>Primary clinical responses and long-term follow-up of solar keratoses treated with topically applied 5-ALA and irradiation by different wavebands of light</TI>
<SO>Journal of Photochemistry &amp; Photobiology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>1-2</NO>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frost-2000" MODIFIED="2011-12-13 11:55:51 +0000" MODIFIED_BY="Liz Doney" NAME="Frost 2000" TYPE="JOURNAL_ARTICLE">
<AU>Frost C, Williams G, Green A</AU>
<TI>High incidence and regression rates of solar keratoses in a Queensland community</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2000</YR>
<VL>115</VL>
<NO>2</NO>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fulton-1999" MODIFIED="2011-12-13 11:57:23 +0000" MODIFIED_BY="Maryse Paquet" NAME="Fulton 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG</AU>
<TI>Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers</TI>
<SO>Dermatologic Surgery</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>9</NO>
<PG>729-732</PG>
<IDENTIFIERS MODIFIED="2011-10-31 13:53:34 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-10-31 13:53:34 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="10491067"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glogau-2000" MODIFIED="2011-12-13 11:57:46 +0000" MODIFIED_BY="Liz Doney" NAME="Glogau 2000" TYPE="JOURNAL_ARTICLE">
<AU>Glogau RG</AU>
<TI>The risk of progression to invasive disease</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 2</NO>
<PG>23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gold-2008" MODIFIED="2011-12-13 12:00:10 +0000" MODIFIED_BY="Maryse Paquet" NAME="Gold 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gold MH</AU>
<TI>Continuing medical education article-skin treatment: Photodynamic therapy: indications and treatment</TI>
<SO>Aesthetic Surgery Journal</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>5</NO>
<PG>545-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2010" MODIFIED="2011-12-13 12:01:00 +0000" MODIFIED_BY="Maryse Paquet" NAME="Goldberg 2010" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg LH, Kaplan B, Vergilis-Kalner I, Landau J</AU>
<TI>Liquid nitrogen: temperature control in the treatment of actinic keratosis</TI>
<SO>Dermatologic Surgery</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1956-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadley-2006" MODIFIED="2012-10-02 14:52:42 +0100" MODIFIED_BY="Maryse Paquet" NAME="Hadley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hadley G, Derry S, Moore RA</AU>
<TI>Imiquimod for actinic keratosis: systematic review and meta-analysis</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2006</YR>
<VL>126</VL>
<NO>6</NO>
<PG>1251-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hemmi-2002" MODIFIED="2011-12-13 12:02:55 +0000" MODIFIED_BY="Maryse Paquet" NAME="Hemmi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al</AU>
<TI>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway</TI>
<SO>Nature Immunology</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>2</NO>
<PG>196-200</PG>
<IDENTIFIERS MODIFIED="2011-05-04 21:12:33 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-05-04 21:12:33 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="11812998"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-11-05 12:06:34 +0000" MODIFIED_BY="Laura  Prescott" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holmes--2007" MODIFIED="2011-12-13 12:04:18 +0000" MODIFIED_BY="Maryse Paquet" NAME="Holmes  2007" TYPE="JOURNAL_ARTICLE">
<AU>Holmes C, Foley P, Freeman M, Chong AH</AU>
<TI>Solar keratosis: epidemiology, pathogenesis, presentation and treatment</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>2</NO>
<PG>67-76</PG>
<IDENTIFIERS MODIFIED="2011-09-08 13:31:55 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 13:31:55 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="17535191"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ibrahim-2009" MODIFIED="2012-10-02 14:53:04 +0100" MODIFIED_BY="Maryse Paquet" NAME="Ibrahim 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ibrahim SF, Brown MD</AU>
<TI>Actinic keratoses. A comprehensive update</TI>
<SO>Journal of Clinical &amp; Aesthetic Dermatology</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>7</NO>
<PG>43-8</PG>
<IDENTIFIERS MODIFIED="2011-09-08 20:30:25 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 20:30:25 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="20729970"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jeffes-2000" MODIFIED="2011-12-13 12:06:17 +0000" MODIFIED_BY="Liz Doney" NAME="Jeffes 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jeffes EW, Tang EH</AU>
<TI>Actinic keratoses. Current treatment options</TI>
<SO>American Journal of Clinical Dermatology</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>3</NO>
<PG>167-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juarranz-2008" MODIFIED="2011-12-13 12:07:21 +0000" MODIFIED_BY="Maryse Paquet" NAME="Juarranz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S</AU>
<TI>Photodynamic therapy of cancer. Basic principles and applications</TI>
<SO>Clinical &amp; Translational Oncology</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>3</NO>
<PG>148-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juzeniene-2007" MODIFIED="2011-12-13 12:08:28 +0000" MODIFIED_BY="Maryse Paquet" NAME="Juzeniene 2007" TYPE="JOURNAL_ARTICLE">
<AU>Juzeniene A, Peng Q, Moan J</AU>
<TI>Milestones in the development of photodynamic therapy and fluorescence diagnosis</TI>
<SO>Photochemical &amp; Photobiological Sciences</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>12</NO>
<PG>1234-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaur-2010" MODIFIED="2012-10-02 14:53:33 +0100" MODIFIED_BY="Maryse Paquet" NAME="Kaur 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kaur RR, Alikhan A, Maibach HI</AU>
<TI>Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>5</NO>
<PG>267-71</PG>
<IDENTIFIERS MODIFIED="2011-10-31 13:28:41 +0000" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-10-31 13:28:41 +0000" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="19878034"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lebwohl-2003" MODIFIED="2011-12-13 12:10:35 +0000" MODIFIED_BY="Maryse Paquet" NAME="Lebwohl 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lebwohl M</AU>
<TI>Actinic keratosis: epidemiology and progression to squamous cell carcinoma</TI>
<SO>British Journal of Dermatology</SO>
<YR>2003</YR>
<VL>149</VL>
<NO>Suppl 66</NO>
<PG>31-33</PG>
<IDENTIFIERS MODIFIED="2011-09-08 17:02:57 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 17:02:57 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="14616345"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2005" MODIFIED="2011-12-13 12:11:38 +0000" MODIFIED_BY="Maryse Paquet" NAME="Lee 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lee PK, Harwell WB, Loven KH, Phillips TJ, Whiting DA, Andres KL, et al</AU>
<TI>Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream</TI>
<SO>Dermatologic Surgery</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>6</NO>
<PG>659-63</PG>
<IDENTIFIERS MODIFIED="2011-04-07 18:25:44 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-04-07 18:25:44 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="15996416"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lu-1995" MODIFIED="2011-12-13 12:13:07 +0000" MODIFIED_BY="Maryse Paquet" NAME="Lu 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL</AU>
<TI>Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>17</NO>
<PG>7961-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marks-1993" MODIFIED="2011-09-09 13:38:40 +0100" MODIFIED_BY="Maryse Paquet" NAME="Marks 1993" TYPE="JOURNAL_ARTICLE">
<AU>Marks VJ</AU>
<TI>Actinic keratosis: a premalignant skin lesion</TI>
<SO>Otolaryngologic Clinics of North America</SO>
<YR>1993</YR>
<VL>26</VL>
<NO>1</NO>
<PG>23-35</PG>
<IDENTIFIERS MODIFIED="2011-09-09 13:38:40 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-09 13:38:40 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="8433840"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martin-2011" MODIFIED="2012-04-16 16:16:45 +0100" MODIFIED_BY="[Empty name]" NAME="Martin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Martin GM</AU>
<TI>Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2011</YR>
<VL>22</VL>
<PG>288-97</PG>
<IDENTIFIERS MODIFIED="2012-04-16 16:16:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-04-16 16:16:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20528483"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moan-1991" MODIFIED="2011-12-13 12:14:08 +0000" MODIFIED_BY="Maryse Paquet" NAME="Moan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Moan J, Berg K</AU>
<TI>The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen</TI>
<SO>Photochemistry &amp; Photobiology</SO>
<YR>1991</YR>
<VL>53</VL>
<NO>4</NO>
<PG>549-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moy-2000" MODIFIED="2011-12-13 12:16:08 +0000" MODIFIED_BY="Liz Doney" NAME="Moy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moy RL</AU>
<TI>Clinical presentation of actinic keratoses and squamous cell carcinoma</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 2</NO>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1994" MODIFIED="2011-12-13 12:17:17 +0000" MODIFIED_BY="Liz Doney" NAME="Nelson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nelson MA, Einspahr JG, Alberts DS, Balfour CA, Wymer JA, Welch KL, et al</AU>
<TI>Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers</TI>
<SO>Cancer Letters</SO>
<YR>1994</YR>
<VL>85</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHANES-I" MODIFIED="2012-10-02 17:28:57 +0100" MODIFIED_BY="[Empty name]" NAME="NHANES I" TYPE="OTHER">
<AU>Center for Disease Control and Prevention/ National Center for Health Statistics</AU>
<TI>National Health and Nutrition Examination Survay (NHANES I)</TI>
<SO>http://www.cdc.gov/nchs/nhanes/nhanesi.htm</SO>
<YR>(accessed 24 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-2003" MODIFIED="2012-10-02 14:55:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ramsay 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN</AU>
<TI>Factors associated with nonmelanoma skin cancer following renal transplantation in Quenssland Australia</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>3</NO>
<PG>397-406</PG>
<IDENTIFIERS MODIFIED="2012-04-05 20:28:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-04-05 20:28:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12963901"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rigel--2008" MODIFIED="2012-10-02 14:55:43 +0100" MODIFIED_BY="Maryse Paquet" NAME="Rigel  2008" TYPE="BOOK_SECTION">
<AU>Rigel DS, Cockerell CJ, Carucci J, Wharton J</AU>
<TI>Actinic keratosis, basal cell carcinoma and squamous cell carcinoma</TI>
<SO>Dermatology</SO>
<YR>2008</YR>
<VL>2</VL>
<PG>1641-59</PG>
<EN>2nd</EN>
<ED>Bolognia JL, Jorizzo JL, Rapini RP</ED>
<PB>Mosby Elsevier</PB>
<IDENTIFIERS MODIFIED="2011-09-09 15:21:33 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-09 15:21:33 +0100" MODIFIED_BY="Maryse Paquet" TYPE="OTHER" VALUE="ISBN 9781416029991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rivers-2004" MODIFIED="2011-12-13 12:36:14 +0000" MODIFIED_BY="Maryse Paquet" NAME="Rivers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rivers JK</AU>
<TI>Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses</TI>
<SO>Skin Therapy Letters</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robins-2002b" MODIFIED="2011-12-13 12:19:08 +0000" MODIFIED_BY="Maryse Paquet" NAME="Robins 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Robins P, Gupta AK</AU>
<TI>The use of topical fluorouracil to treat actinic keratosis</TI>
<SO>Cutis</SO>
<YR>2002</YR>
<VL>70</VL>
<NO>2 Suppl</NO>
<PG>4-7</PG>
<IDENTIFIERS MODIFIED="2011-05-04 21:05:30 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-05-04 21:05:30 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="12353679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roewert_x002d_Huber-2007" MODIFIED="2011-12-13 12:36:47 +0000" MODIFIED_BY="Maryse Paquet" NAME="Roewert-Huber 2007" TYPE="JOURNAL_ARTICLE">
<AU>Roewert-Huber J, Stockfleth E, Kerl H</AU>
<TI>Pathology and pathobiology of actinic (solar) keratosis - an update</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>Suppl 2</NO>
<PG>18-20</PG>
<IDENTIFIERS MODIFIED="2011-09-07 18:09:59 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-07 18:09:59 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18067626"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salasche-2000" MODIFIED="2011-12-13 12:19:56 +0000" MODIFIED_BY="Liz Doney" NAME="Salasche 2000" TYPE="JOURNAL_ARTICLE">
<AU>Salasche SJ</AU>
<TI>Epidemiology of actinic keratoses and squamous cell carcinoma</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1 Pt 2</NO>
<PG>4-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1997" MODIFIED="2011-12-13 12:20:36 +0000" MODIFIED_BY="Maryse Paquet" NAME="Schwartz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RA</AU>
<TI>The actinic keratosis: a perspective and update</TI>
<SO>Dermatologic Surgery</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1009-19</PG>
<IDENTIFIERS MODIFIED="2011-09-09 13:42:49 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-09 13:42:49 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="9391557"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seed-1997" MODIFIED="2011-12-13 12:22:00 +0000" MODIFIED_BY="Maryse Paquet" NAME="Seed 1997" TYPE="JOURNAL_ARTICLE">
<AU>Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, Willis D, et al</AU>
<TI>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</TI>
<SO>Cancer Research</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>9</NO>
<PG>1625-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanley-1999" MODIFIED="2011-12-13 12:24:18 +0000" MODIFIED_BY="Maryse Paquet" NAME="Stanley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stanley MA</AU>
<TI>Mechanism of action of imiquimod</TI>
<SO>Papillomavirus Rep</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>2</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thai-2004" MODIFIED="2011-12-13 12:25:46 +0000" MODIFIED_BY="Maryse Paquet" NAME="Thai 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, et al </AU>
<TI>A prospective study of the use of cryosurgery for the treatment of actinic keratoses</TI>
<SO>International Journal of Dermatology</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>9</NO>
<PG>687-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vatve-2007" MODIFIED="2011-12-13 12:26:39 +0000" MODIFIED_BY="Maryse Paquet" NAME="Vatve 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vatve M, Ortonne J-P, Birch-Machin MA, Gupta G</AU>
<TI>Management of field change in actinic keratosis</TI>
<SO>British Journal of Dermatology</SO>
<YR>2007</YR>
<VL>157</VL>
<NO>Suppl 2</NO>
<PG>21-24</PG>
<IDENTIFIERS MODIFIED="2011-09-08 14:33:36 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 14:33:36 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="18067627"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vidal-2006" MODIFIED="2011-12-13 12:27:32 +0000" MODIFIED_BY="Maryse Paquet" NAME="Vidal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vidal D</AU>
<TI>Topical imiquimod: mechanism of action and clinical applications</TI>
<SO>Mini-Reviews in Medicinal Chemistry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>5</NO>
<PG>499-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warino-2006" MODIFIED="2012-10-02 14:56:44 +0100" MODIFIED_BY="Maryse Paquet" NAME="Warino 2006" TYPE="JOURNAL_ARTICLE">
<AU>Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR</AU>
<TI>Frequency and cost of actinic keratosis treatment</TI>
<SO>Dermatologic Surgery</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>8</NO>
<PG>1045-49</PG>
<IDENTIFIERS MODIFIED="2011-09-08 20:07:28 +0100" MODIFIED_BY="Maryse Paquet"><IDENTIFIER MODIFIED="2011-09-08 20:07:28 +0100" MODIFIED_BY="Maryse Paquet" TYPE="PUBMED" VALUE="16918567"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilkerson-1984" NAME="Wilkerson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Wilkerson MG, Goldberg LH, Rapini RP</AU>
<TI>Actinic keratoses</TI>
<SO>American Family Physician</SO>
<YR>1984</YR>
<VL>30</VL>
<NO>1</NO>
<PG>103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-04-25 17:52:05 +0100" MODIFIED_BY="Maryse Paquet"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-11-13 10:45:08 +0000" MODIFIED_BY="Maryse Paquet">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-11-13 10:45:08 +0000" MODIFIED_BY="Maryse Paquet" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-11-09 11:42:37 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Akar-2001">
<CHAR_METHODS MODIFIED="2012-11-06 18:37:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, active-controlled, double-blind, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:43:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical and histological diagnoses</LI>
<LI>Anatomical locations: face, bald scalp, and dorsal forearms and hands</LI>
<LI>Single or multiple actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Topical agents within the last 3 months</LI>
<LI>More than 15 lesions or very extensive lesions</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>16 white participants</LI>
<LI>10 men, 6 women</LI>
<LI>Age: mean = 64; range = 50 to 82</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 12:25:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 1% colchicine cream twice daily for 10 days + 10 more days if weak response (N = 8 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 0.5% colchicine cream twice daily for 10 days + 10 more days if weak response (N = 8 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:42:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete healing (= participant complete clearance)</P>
<P>2) Reduction rate in number of actinic keratoses (= lesion complete response) at 1 month</P>
<P>3) Mean reduction of lesion counts at 1 month</P>
<P>4) Number of participants treated (pooled data) with strong, weak, or no inflammatory reaction</P>
<P>5) Minor adverse events (qualitative)</P>
<P>6) Number of participants with decreased infiltration and disappearance of crust (cosmetic) at 1 month</P>
<P>7) Clinical laboratory tests</P>
<P>8) Relapse at 6 months</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by counting visible and palpable actinic keratoses in each test area</P>
<P>Time points: at baseline; end of treatment; 1, 2, and 6 months post-treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. clinical examination, 2. routine laboratory tests (complete blood cell counts, urinalysis, and fasting chemistry)</P>
<P>Time points: 1. each study visit (clinical exam), 2. before and after treatment (laboratory tests)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-25 17:58:11 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was provided by Dr. F Frik Drug Company.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-22 20:03:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>Thick surface scales were removed by 10% salicylic acid 2 days before treatment. There were severe inflammation reactions in the majority of participants (11/16). In cases of inflammation, a weak antiseptic or antibiotic ointment was applied.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:43:46 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Alberts-2000">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 12:30:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Diagnosis by a dermatologist</LI>
<LI>Men or postmenopausal women, at least 30 years of age</LI>
<LI>Anatomical location: forearms</LI>
<LI>Moderate to severe (i.e. <U>&gt;</U> 10 actinic keratoses on the lateral surface)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Topical or systematic therapy within 3 months</LI>
<LI>Any topical medications within 30 days (excluding emollient and sunscreen)</LI>
<LI>Free of medication or disease that would cause even minor immunosuppression.</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>48 participants</LI>
<LI>32 men, 10 women</LI>
<LI>Age: mean = 69</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 12:30:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>A 1-month run-in was performed during which participants used a placebo formulation (hydrophilic ointment) twice daily on both right and left forearms.</P>
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 2-(Difluoromethyl)-dl-ornithine (DFMO) twice daily for 6 months (N = 48 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo twice daily for 6 months (N = 48 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:43:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Mean numbers of lesions at baseline and 6 months (the mean reduction in lesion counts was calculated)</P>
<P>2) Percentage reduction in the number of actinic keratoses</P>
<P>3) Skin concentrations of drug and products due to its mechanism of action at 6 months</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Tolerance (qualitative)</P>
<P>2) Compliance</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by circling and counting of individual lesions on each arm by a dermatologist and photography using a Nikon N5005 camera with a 60-mm Micor Nikkor lens, SB-21 Macro Speedlight, and Kodachrome ASA 64 film</P>
<P>Time points: at baseline and end of treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of clinical toxicity frequency and severity [scale 0 (none) to 3 (severe)] by the study dermatologist, 2. complete blood counts and serum chemistry panels (SMA20s)</P>
<P>Time points: 1. before the first application of the placebo ointment, at randomisation, and at each monthly visit (toxicity), 2. run-in and at the end of the study (laboratory tests)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 16:47:58 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by USPHS Grant PO1 CA27502.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-10-17 15:58:24 +0100" MODIFIED_BY="Maryse Paquet">
<P>There was no evidence of systemic toxicity.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:44:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Alirezai-1994">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 11:44:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Age 21 years and older</LI>
<LI>Anatomical locations: face, scalp, upper extremities</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>No topical retinoids or topical steroids in the 2 weeks before treatment</LI>
<LI>No topical 5-fluorouracil, systemic retinoids, or systemic steroids within 4 weeks before treatment</LI>
<LI>Pregnant, nursing women, PUVA therapy, skin cancer, or other condition that could interfere with the evaluation</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>100 randomised, 93 analysed, 79 completed (no other demographic information was presented)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 23:26:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: isotretinoin 0.1% cream twice daily for 24 weeks (N = 50 participants?)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo cream twice daily for 24 weeks (N = 50 participants?)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:44:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Investigators' evaluation of global therapeutic response (= global improvement indice-completely cleared)</P>
<P>2) Mean number of actinic keratosis lesions over time by anatomical area</P>
<P>3) Mean reduction of lesion counts by anatomical area at end of treatment</P>
<P>4) Number of participants with severe, moderate, mild, or no local irritation on the face (= skin irritation)</P>
<P>5) Minor adverse events (qualitative)</P>
<P>6) Serious adverse events (including basal and squamous cell carcinoma)</P>
<P>7) Clinical laboratory tests</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by lesion counting and photography</P>
<P>Time points: 1. at baseline and every 4 weeks (counting), 2. at baseline, week 12, and end of treatment (photography)</P>
<P>Definitions for the global evaluation: 1. worsening (increase in lesions in treated area), 2. partial response (between 30% &lt; 100% reduction in the number of lesions), and 3. complete response (total clearing)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. local tolerability was scored (absent to severe) by investigator, 2. clinical evaluation and reported adverse events, 3. routine laboratory tests</P>
<P>Time points: 1. at each visit (tolerability and adverse events), 2. before and after treatment (laboratory tests)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-05 13:16:05 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-05 13:16:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:46:22 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Alomar-2007">
<CHAR_METHODS MODIFIED="2012-11-05 13:38:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: December 2003</P>
<P>End date: December 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 13:22:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pre-study clinical diagnosis, 1 lesion confirmed histologically</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or balding scalp</LI>
<LI>5 to 9 actinic keratoses within 25 cm² area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Malignant tumours, dermatological disease, or condition in the treatment or surrounding area that could impede local skin assessments</LI>
<LI>Unstable cardiovascular, immunosuppressive, haematological, hepatic neurological, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>259 white participants</LI>
<LI>228 men, 31 women</LI>
<LI>Age: range = 44 to 94</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 13:24:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod once per day 3 times per week, 4 weeks on, 4 weeks off (repeated if not cleared) (N = 129 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once per day 3 times per week, 4 weeks on, 4 weeks off (repeated if not cleared) (N = 130 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:46:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at week 8 (1 treatment) and at week 16 (1or 2 treatments)</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates at week 16</P>
<P>2) Lesion complete response rates at weeks 8 and 16</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>2) Local skin reactions</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting and mapping with the use of a clear plastic template and photography, 2. histological confirmation using biopsy of a target lesion site</P>
<P>Time points: 1. at week 1, week 2, end of treatment (EOT) (week 4 for 1 treatment, week 12 for 2 treatments), and the 4-week post-treatment visit (week 8 for 1 treatment, week 16 form 2 treatments), 2. pretreatment and 8-week post-treatment visit (week 12 for 1 treatment, week 20 for 2 treatments) (biopsy)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of the presence and intensity of specific local skin reactions by the investigator and rating on a scale [0 (none) to 3 (severe)], 2. safety evaluations including clinical laboratory tests (haematology, blood chemistry, and urinalysis) and urine pregnancy tests for women of child-bearing potential, 3. physical examination including vital sign measurements, adverse events, and monitoring of concomitant medications</P>
<P>Time points: 1. each visit (local skin reactions, adverse events, and medication monitoring), 2. pre-study and poststudy (safety evaluations), 3. pre-study, week 4 and week 12 visits (physical exam)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 18:11:02 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 13:38:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>Rest periods were allowed in case of local skin reaction or treatment site adverse events. There were significant differences between imiquimod and vehicle groups in term of numbers and intensities of local skin reactions. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:47:33 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Anderson-2009">
<CHAR_METHODS MODIFIED="2012-11-05 13:39:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, double-dummy, vehicle-controlled, parallel-group study.</P>
<P>Start date: September 2006</P>
<P>End date: June 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical typical visible and discreet actinic keratoses</LI>
<LI>Men and postmenopausal women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: arm, shoulder, chest, back, scalp</LI>
<LI>4 to 8 actinic keratoses within 25 cm² area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women of child-bearing potential</LI>
<LI>Lesions on the face</LI>
<LI>Atypical-appearing lesions</LI>
<LI>Suspected cutaneous malignancy within the selected area</LI>
<LI>Lesion-directed therapy within 2 cm of the selected area within 4 weeks</LI>
<LI>Field-directed therapy within 2 cm within 24 months</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>222 participants</LI>
<LI>178 men, 44 women</LI>
<LI>Age: mean = 67; range = 43 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 23:13:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: once daily 0.025% ingenol mebutate gel (PEP005) for 3 days (N = 50 participants)</P>
<P>B: once daily 0.05% ingenol mebutate gel (PEP005) for 2 days (N = 55 participants)</P>
<P>C: once daily 0.05% ingenol mebutate gel (PEP005) for 3 days (N = 57 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>D: once daily vehicle for 3 days (N = 60 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:47:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Partial clearance rate (= participant partial clearance)</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Complete clearance rate (= participant complete clearance for all lesions)</P>
<P>2) Baseline clearance rate (= participant complete clearance for target lesions)</P>
<P>3) Median percentage reduction of target lesions</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions</P>
<P>2) Local skin reactions overtime (pooled ingenol mebutate data and no data for vehicle)</P>
<P>3) Global severity rating of local reactions</P>
<P>4) Minor adverse events</P>
<P>5) Treatment-related adverse events</P>
<P>6) Serious adverse events</P>
<P>7) Clinical laboratory tests</P>
<P>8) Cosmetic outcomes: pigmentation and scarring (pooled data)</P>
<P>9) Participants' satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of clinically-visible lesions in the selected treatment area (including baseline and new lesions)</P>
<P>Time points: at day 57 (end-of-study visit)</P>
<P>Definitions: 1. partial clearance rate (proportion of participants with <U>&gt;</U> 75% reduction in the number of lesions identified at baseline), 2. complete clearance rate (proportion of participants with no clinically-visible lesions in the selected treatment area - lesions present at baseline or emergent during the study period), 3. baseline clearance rate (proportion of participants with 100% reduction in the number of lesions identified at baseline), and 4. percentage reduction of the number of lesions (number of lesions present in the treatment area at baseline minus the number of lesions present at the end of the study divided by the number of lesions present at baseline)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of any local skin reactions and global severity rating, and monitoring of adverse events by a qualified dermatologist, 2. clinical laboratory tests<BR/>
</P>
<P>Time points: 1. at day 3, follow-up visits on days 8, 15, 29, and 57 (end-of-study visit); 2. at screening visit and on day 8 (laboratory tests)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: questionnaire with a 7-point Likert scale, in which a score of 1 is very negative, 4 is neutral, and 7 is very positive</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 18:12:00 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Peplin Ltd.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-05 23:21:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>Participants' satisfaction (P = 0.0005) and overall satisfaction (P &lt; 0.001) were higher in the treatments groups compared with vehicle. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:10:40 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Bercovitch-1987">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>The was a single-centre, randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-16 20:42:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical and histological diagnoses</LI>
<LI>Anatomical locations: forearms and hands</LI>
<LI>Multiple actinic keratoses</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>20 participants (no other demographic information was provided)</LI>
<LI>8 of 20 participants had history of squamous cell carcinoma</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 23:26:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% 5-fluorouracil twice daily on both arms for 2 to 4 weeks and 0.05% tretinoin nightly on 1 randomised arm for 2 to 4 weeks (N = 20 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 5% 5-fluorouracil twice daily on both arms for 2 to 4 weeks and placebo nightly on 1 randomised arm for 2 to 4 weeks (N = 20 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 23:26:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean number of actinic keratosis lesions at baseline and 3 months (mean reduction of lesion counts was calculated)</P>
<P>2) Relative irritation (skin irritation)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of residual actinic keratoses and biopsy of doubtful lesions</P>
<P>Time points: at baseline and week 12<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 20:54:57 +0000" MODIFIED_BY="[Empty name]">
<P>The treatments were provided by Ortho Pharmaceutical Corporation and Hoffman-LaRoche, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 15:10:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-05 23:30:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Chen-2003">
<CHAR_METHODS MODIFIED="2012-11-05 23:29:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: January 2002</P>
<P>End date: August 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 23:30:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical locations: face, forehead and temples, or both cheeks</LI>
<LI>5 to 15 actinic keratoses within 1 treatment area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Allergy to any products within the study cream</LI>
<LI>Pregnancy</LI>
<LI>Clinically significant and severe systemic disease</LI>
<LI>Treatment for actinic keratosis within the treatment area with cryotherapy within 6 weeks, with 5-fluorouracil, chemical peels, or dermabrasion within 6 months</LI>
<LI>Immunosuppressive or immunomodulating drugs including oral or topical corticosteroids within 4 weeks</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>34 participants</LI>
<LI>21 men,13 women</LI>
<LI>Age: mean = 64</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-05 23:29:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: imiquimod 5% cream once per day, 3 times per week for 3 weeks on, 4 weeks off (repeat once if 75% of lesions hadn't cleared)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo once per day, 3 times per week for 3 weeks on, 4 weeks off (repeat once if 75% of lesions hadn't cleared)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-05 23:30:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates at 14 weeks</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Mean number of actinic keratosis lesions overtime (graphical representation)</P>
<P>2) Participant complete clearance</P>
<P>3) Local skin reactions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of the number of lesions in the treatment area by the same investigator and photography</P>
<P>Time points: at each weekly visit</P>
<P>
<U>Safety</U>
</P>
<P>Methods: reporting of local skin reactions [severity on a 0 (none) to 3 (severe) scale] and adverse events</P>
<P>Time points: at each weekly visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 21:08:42 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-05 23:30:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>All adverse effects were gone at follow-up. An increase in the number of lesions during treatment was observed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:35:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Dragieva-2004a">
<CHAR_METHODS MODIFIED="2012-11-05 23:32:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>Start date: July 2001</P>
<P>End date: March 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-05 23:33:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Organ transplant participants (immunosuppressed)</LI>
<LI>Multiple mild to moderate actinic keratoses with histological confirmation</LI>
<LI>Both genders and over 18 years of age</LI>
<LI>Anatomical locations: face or scalp, neck, extremities</LI>
<LI>2 lesional areas (4 X 4 cm) for randomisation</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Porphyria</LI>
<LI>Known allergy to any of the compounds or excipients of the cream</LI>
<LI>Treatment for actinic keratosis within 1 month</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>17 participants</LI>
<LI>14 men, 3 women</LI>
<LI>Age: mean = 61; range = 44 to 76</LI>
<LI>Face or scalp (N = 107), neck (N = 1), extremities (N = 21) (N = number of lesions)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:35:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
<BR/>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 17 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 17 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts and scales removed by curettage</P>
<P>Cream concentration (%): --</P>
<P>Application of cream: 1 mm thick to lesional field and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: visible non-coherent light</P>
<P>Light source: Waldmann PDT 1200</P>
<P>Wavelength (nm): 600-730</P>
<P>Energy fluence (J/cm²): 75</P>
<P>inten (mW/cm²): 80</P>
<P>Exposure time: --</P>
<P>Others: Each participant received 1 g paracetamol orally 1 hour before illumination. Additionally, a fan was used to cool the treated area and to reduce discomfort during illumination.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:49:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete response rates of the lesional area (= participant complete clearance) at 16 weeks after 2nd treatment<BR/>2) Reduction in the number of lesions (= lesion complete response) at 16 weeks after 2nd treatment</P>
<P>3) Minor adverse events (qualitative)</P>
<P>4) Discomfort on a visual analogue scale (VAS)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by inspection, photography, and palpation of the lesional area</P>
<P>Time points: at 1, 4, 8, and 16 weeks after the 2nd treatment</P>
<P>Definitions: 1. complete response (complete clinical regression of all lesions within the treated area), 2. partial response (incomplete reduction in size or number of the lesions within the treated area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: reporting of adverse events including the local phototoxicity reactions</P>
<P>Time points: before and after illumination, and at 1, 4, 8, and 16 weeks after the 2nd treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-05 23:34:32 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-05 23:35:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>There was no quantification of adverse events, but discomfort was reported higher for MAL than placebo. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:50:15 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Fariba-2006">
<CHAR_METHODS MODIFIED="2012-11-05 23:36:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>Start date: 2003</P>
<P>End date: 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:14:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Individuals aged 30 years or older</LI>
<LI>General good health</LI>
<LI>Anatomical locations: face or scalp</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Lesions on lips</LI>
<LI>Non-postmenopausal women or not using contraception</LI>
<LI>History or suspected hypersensitivity to any of the ingredients of the active or placebo gel</LI>
<LI>History of allergy to aspirin or other NSAIDs</LI>
<LI>Current treatment with disallowed medication (5-fluorouracil, etretinate, cyclosporine, retinoids, topical steroids, or recent trichloroacetic acid or glycolic acid peels)</LI>
<LI>Unwillingness to discontinue the use of cosmetics or sunscreen on the designated site</LI>
<LI>Treatment with any other investigational drug or participation in another study within 60 days</LI>
<LI>Refusal to undergo a wash-out period</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>20 participants</LI>
<LI>14 men, 6 women</LI>
<LI>Age: mean = 55, range = 30 to 75</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-11 12:36:41 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac/2.5% hyaluronic acid twice daily for 90 days (N = 20 participants, 32 lesions)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 2.5% hyaluronic acid twice daily for 90 days (N = 20 participants, 32 lesions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:50:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates</P>
<P>2) Reduction in lesion size</P>
<P>3) Number of participants experiencing irritation (skin irritation)</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at the end of treatment</P>
<P>Definitions: 1. partial response (any reduction in the lesion size compared to baseline), 2. complete response (complete disappearance of the lesion)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 09:12:33 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 09:12:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 18:38:07 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Foote-2009">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 09:19:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Healthy volunteers with clinically diagnosable actinic keratoses</LI>
<LI>30 years of age or older</LI>
<LI>Anatomical locations: arms</LI>
<LI>
<U>&gt;</U> 10 actinic keratoses per forearm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Current cancer</LI>
<LI>Lateral forearm treatment for cancer or actinic keratosis within the past 30 days</LI>
<LI>Initial chemistry levels (SMA20) outside of normal limits</LI>
<LI>&gt; 75% compliance during 1-month run-in period</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>50 enrolled, 48 randomised participants</LI>
<LI>36 men, 6 women</LI>
<LI>Age: mean = 68</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 09:19:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 12.5% DL-&#945;-tocopherol (vitamin E) on right or left arm twice daily for 6 months (N = 48 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo on right or left arm twice daily for 6 months (N = 48 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 09:21:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Biochemical and immunological outcomes</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Mean reduction of lesion counts</P>
<P>
<B>
<U>Other outcome of the trial</U>
</B>
</P>
<P>1) Number of reports of symptoms (redness, itchiness, burning, dryness)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using circling of lesions and photographs, 2. shave biopsies by physician</P>
<P>Time points: before and at the end of treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. physical exams, 2. clinical staff inquired about adverse events (severity, date of onset, duration, and date of resolution)</P>
<P>Time points: 1. before treatment and at the end of treatment (physical exams), 2. at monthly visits (adverse events)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 22:39:40 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by NIH grants CA-27502 and CA-23074.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 09:21:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a phase IIb study. Vitamin E was well tolerated, i.e. only 14 reports for moderate and severe symptoms, which were similar for treatment and placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:23 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Freeman-2003">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, open, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 09:24:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clincial diagnosis</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>Mild-to-moderate non-pigmented actinic keratoses, suitable for cryotherapy with the largest diameter of each lesion being <U>&gt;</U> 5 mm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Grade 3 lesions (3 = severe, very thick, or obvious lesion)</LI>
<LI>Pigmented lesions</LI>
<LI>Recently-treated lesions</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>200 participants</LI>
<LI>119 men, 81 women</LI>
<LI>Age: range = 33 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 88 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: placebo -PDT: Placebo (N = 23 participants)</P>
<P>C: cryotherapy: no prior preparation, variable liquid nitrogen spray unit, 1 to 2 mm rim of frozen tissue beyond marked outline, a single timed freeze-thaw cycle; mean diameter &lt; 10 mm = mean freeze time of 12 <U>+</U> 13 seconds, 10 to 20 mm = 16 <U>+</U> 15 seconds, &gt; 20 mm = 26 <U>+</U> 11 seconds (N = 89 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts and scales removed by curettage</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source:</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 50 to 250</P>
<P>Exposure time: 10 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:51:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 3 months</P>
<P>2) Participants experiencing at least 1 adverse event</P>
<P>3) Local skin/adverse reactions</P>
<P>4) Minor adverse events (given only for MAL-PDT)</P>
<P>5) Cosmetic outcomes: overall and individual lesions at 3 months (MAL-PDT vs cryotherapy)</P>
<P>6) Participant satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using mapping with acetate sheets, marking of lesions and anatomical landmarks and Polaroid photography</P>
<P>Time points: at 3 months after the beginning of treatment</P>
<P>Definitions for lesion response: 1. complete response (complete disappearance of the lesion, both visually and by palpation), 2. non-complete response (incomplete disappearance of the lesion)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: adverse events reported by the participant or elicited through open (non-leading) questioning by the investigator</P>
<P>Time points: before, during, and after treatment; at 2 weeks by telephone contact; and at a final examination 3 months after treatment</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. overall cosmetic outcome of completely cleared participants (by investigator and participant), 2. individual lesion cosmetic outcome for completely cleared lesions (hypopigmentation, hyperpigmentation, scar formation and tissue defect rated as none, slight, or obvious)</P>
<P>Time points: at 3 months after the beginning of treatment</P>
<P>Definitions for overall outcome: 1. excellent (no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared with adjacent skin), 2. good (no scarring, atrophy or induration but moderate redness or change in pigmentation compared with adjacent skin), 3. fair (slight to moderate occurrence of scarring, atrophy, or induration), 4. poor (extensive occurrence of scarring, atrophy, or induration)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-16 22:59:13 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photocure ASA, Olso, Norway.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 09:26:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:53:34 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Gebauer-2003">
<CHAR_METHODS MODIFIED="2012-11-06 09:32:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: 1994</P>
<P>End date: 1995</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:53:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Solar keratoses</LI>
<LI>Over 18 years of age</LI>
<LI>Anatomical locations: head/neck, hands, or arms</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>History of hypersensitivity to non-steroidal anti-inflammatory drugs</LI>
<LI>Significant current illness</LI>
<LI>Abnormal liver/renal/haematological tests</LI>
<LI>Use of concomitant medication that would interfere with the study drug (systemic corticosteroids, antineoplastic, topical and systemic retinoids)</LI>
<LI>Presence of skin conditions that would confound the study (Bowen&#8217;s disease, basal cell carcinoma, squamous cell carcinoma)</LI>
<LI>Involvement in another clinical study in the previous 3 months</LI>
<LI>Unwillingness to discontinue use of cosmetics</LI>
<LI>Outdoor occupation or deliberate exposure of skin to sun or UV light</LI>
<LI>Pregnant women, breastfeeding, or without adequate contraception</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>150 participants</LI>
<LI>89 men, 61 women</LI>
<LI>Age: mean = 68</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-11 12:37:28 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 0.25 g of 3% diclofenac in 2.5% hyaluronic acid gel twice daily for 12 weeks (N = 73 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 2.5% hyaluronic acid gel alone twice daily for 12 weeks (N = 77 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 09:37:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction of lesion counts at end of treatment and at 30 days post-treatment<BR/>2) Participant complete resolution rates (= participant complete clearance) at end of treatment and at 30 days post-treatment<BR/>3) Participant with 50% or greater reduction rates at end of treatment and at 30 days post-treatment</P>
<P>4) Minor adverse events</P>
<P>5) Serious adverse events</P>
<P>6) Clinical laboratory tests</P>
<P>7) Compliance</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting by a single doctor in each centre throughout the entire study</P>
<P>Time points: at baseline, end of treatment (12 weeks), and at 16 weeks</P>
<P>Definitions: 1. complete clearance (proportion of participants with complete resolution of lesions), 2. partial clearance (proportion of participants with a <U>&gt;</U> 50% reduction in lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. medical history and physical examination (baseline only), 2. haematology and biochemistry testing, 3. adverse events were recorded in the case report form [type (serious or non-serious), onset date, severity (mild, moderate or severe), duration, any action taken, assumed relationship to treatment and outcome]</P>
<P>Time points: at baseline, week 12 , and week 16<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 15:08:42 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Hyal Pharmaceutical Corporation.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 09:36:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>The safety assessment showed no difference between groups. A high compliance was observed for both groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 12:08:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gebauer-2009">
<CHAR_METHODS MODIFIED="2012-11-06 09:46:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: April 2000</P>
<P>End date: December 2000</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 12:08:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinically typical actinic keratosis lesions and histological confirmation</LI>
<LI>Age 18 years and older</LI>
<LI>Anatomical locations: dorsal of 1 or both forearms and hands</LI>
<LI>10 to 50 lesions</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Dermatological condition in the treatment area that might be exacerbated by treatment or could impair study assessments</LI>
<LI>Allergy to imiquimod or any of the excipients</LI>
<LI>Chemical or alcohol dependency</LI>
<LI>Active malignancy</LI>
<LI>Clinically significant cardiovascular, immunosuppressive, haematological, hepatic, neurological, renal, endocrine, collagen-vascular or gastrointestinal disease or an unstable medical condition</LI>
<LI>Pregnancy or lactation</LI>
<LI>Enrolled in another clinical study</LI>
<LI>No prior treatment in the treatment area as follows:</LI>
</UL>
<UL>
<UL>
<LI>with imiquimod or systemic retinoids</LI>
<LI>within the last 2 years with topical retinoids</LI>
<LI>within the last 3 months with surgical excision</LI>
<LI>within the last 6 months with psoralen and UVA (PUVA), 5-fluorouracil, masoprocol, chemical peel, or dermabrasion</LI>
<LI>within the last 4 weeks with cryotherapy or curettage</LI>
<LI>within the last 24 hours with moisturisers, emollients, or oils</LI>
</UL>
</UL>
<UL>
<LI> No prior treatment outside the area of treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>with systemic retinoids</LI>
<LI>within the last 2 years with topical retinoids</LI>
<LI>within the last 6 months with psoralen and UVA (PUVA), 5-fluorouracil, masoprocol, chemical peel, or dermabrasion</LI>
<LI>within the last 1 week with &gt; 2 g daily fluorinated topical corticosteroids or equivalent</LI>
</UL>
</UL>
<UL>
<LI>No prior treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within the last 6 months with cancer chemotherapy</LI>
<LI>within the last 3 months with any treatment of SCC or basal cell carcinoma</LI>
<LI>within the last 4 weeks with interferon, interferon inducer, immunomodulators, cytotoxic drugs, investigational drugs, drugs with major organ toxicity, immunosuppressives, systemic corticosteroids, inhaled corticosteroids &gt; 1200 ug daily</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>149 participants</LI>
<LI>94 men, 54 women</LI>
<LI>Age: mean = 71</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-09 11:53:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: 5% imiquimod (2 times/week) for 8 weeks (N = 31 participants)</P>
<P>B: 5% imiquimod (3 times/week) for 8 weeks (N = 29 participants)</P>
<P>C: 5% imiquimod (5 times/week) for 8 weeks (N = 30 participants)</P>
<P>D: 5% imiquimod (7 times/week) for 8 weeks (N = 30 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>E: vehicle (2, 3, 5, 7 times/week) for 8 weeks (N = 29 participants, 7 to 8/dosing regimen pooled together)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:31:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at week 16</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participant partial (&gt; 75%) clearance rates at week 16</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions</P>
<P>2) Local skin reactions</P>
<P>3) Treatment-related adverse events</P>
<P>4) Serious adverse events</P>
<P>5) Clinical laboratory tests</P>
<P>6) Compliance</P>
<P>7) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counts within the target area performed by a qualified dermatologist using a transparent plastic template to track lesions, 2. qualitative assessment using lesion descriptions by investigator, i.e. degree of hyperkeratosis, size and confluence of the lesions, and degree of solar damage between lesions</P>
<P>Time points: at baseline, week 4, and end of study (week 16)</P>
<P>Definitions: 1. complete clearance rate (proportion of subjects at end of study with no lesions in the treatment area), 2. partial clearance rate (proportion of subjects at their last study visit with at least 75% reduction in lesions in the treatment area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of vital signs and adverse events, 2. assessment<BR/>of defined local skin reactions (erythema, oedema, induration, vesicles, erosion, excoriation &#8260;flaking, scabbing), 3. photography, 4. physical examination, 5. haematology and chemistry tests and pregnancy testing (adverse events were coded and summarised by body system and preferred term using a modified World Health Organization Adverse Reactions Terminology dictionary)</P>
<P>Time points: 1. at weeks 1, 2, 3, 4, 6, 8 (end of treatment), 12, and 16 (8 weeks post-treatment, end of study), 2. at baseline, end of treatment, and end of study (physical exam and laboratory tests)</P>
<P>Definitions for grading: 1. mild (subject is aware of the signs and symptoms, but the signs and symptoms are easily tolerated), 2. moderate (signs and symptoms are sufficient to restrict, but not prevent, usual daily activity for the subject), and 3. severe (signs and symptoms are such that the subject is unable to perform usual daily activity)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 15:22:47 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 09:50:29 +0000" MODIFIED_BY="[Empty name]">
<P>The number of local skin reactions and adverse events increased with dosing frequency. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:54:47 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hanke-2010">
<CHAR_METHODS MODIFIED="2012-11-06 09:58:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: January 2008</P>
<P>End date: July 2008</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 15:58:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Adults in general good health</LI>
<LI>Anatomical locations: face (70%) or balding scalp</LI>
<LI>5 to 20 visible and palpable actinic keratoses within 25 cm²</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Any condition in the treatment area that might impair evaluation</LI>
<LI>Atypical actinic keratoses</LI>
<LI>Pregnancy, lactation</LI>
<LI>Chemical or alcohol dependency</LI>
<LI>Known allergy to imiquimod or study cream excipients</LI>
<LI>No prior treatment with the following:</LI>
</UL>
<UL>
<UL>
<LI>within 1 year with imiquimod</LI>
<LI>within 90 days with interferon, interferon inducers, cytotoxic drugs, immunomodulators, immunosuppressants, oral or parenteral corticosteroids, topical corticosteroids more than 2 g/day, investigational drug or device use outside of the treatment area</LI>
<LI>within 30 days with imiquimod outside the treatment area, topical prescriptions drugs, and investigational drug or device within treatment</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>490 participants</LI>
<LI>386 men, 104 women</LI>
<LI>Age: mean = 65</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 10:00:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: 3.75% imiquimod, once daily for 3 weeks on, 3 weeks off, 3 weeks on (N = 162 participants)</P>
<P>B: 2.5% imiquimod, once daily for 3 weeks on, 3 weeks off, 3 weeks on (N = 164 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>C: placebo, once daily for 3 weeks on, 3 weeks off, 3 weeks on (N = 164 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:54:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at week 17</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates at week 17</P>
<P>2) Median percentage of changes in lesion counts</P>
<P>3) Local skin reactions</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>2) Application site reactions (including irritation)</P>
<P>3) Minor adverse events</P>
<P>4) Treatment-related adverse events</P>
<P>5) Serious adverse events</P>
<P>6) Clinical laboratory tests</P>
<P>7) Investigator global integrated photodamage (IGIP-cosmetic outcome)</P>
<P>8) Temporary treatment interruption</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of all visible or palpable lesions - baseline or new - in the treatment area by the investigator</P>
<P>Time points: baseline; at weeks 1, 2, 3 (end of cycle 1), 6 (beginning of cycle 2), 7, 8, 9 (end of cycle 2), 13, and 17 (end of study) (subjects who discontinued the study prematurely were requested to return for the end-of-study visit)</P>
<P>Definitions: 1. complete clearance rate (proportion of subjects at the end-of-study visit with a count of zero lesions in the treatment area), 2. partial clearance rates (proportion of subjects with 75% or greater reduction in lesion count in the treatment area at the end-of-study visit as compared with baseline), and 3. percentage of changes in lesion count (per cent change in lesion number at the end-of-study visit as compared with baseline)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. measurement of vital signs, 2. recording of adverse events, 3. investigator assessment of local skin reactions (erythema, edema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, and erosion/ulceration) graded as none, mild, moderate, or severe, 4. hematology, serum chemistry, urinalyses, and urine pregnancy tests (treatment-emergent adverse events were summarised for each treatment group by preferred term, intensity, and investigator assessment of relationship to study cream. The local skin reactions were summarised by the most intense score for each reaction and by the sum score at each visit and over the course of the study)</P>
<P>Time points: 1. baseline, at weeks 1, 2, 3 (end of cycle 1), 6 (beginning of cycle 2), 7, 8, 9 (end of cycle 2), 13, and 17 (end of study), 2. pre-study visit and end-of-study visit (laboratory tests)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: qualitative and quantitative assessment (IGIP score)</P>
<P>Time points: at end-of-study visit</P>
<P>Definition: IGIP score (overall assessment of the subject's photodamage change from baseline in the treatment area including an integrated assessment of fine wrinkling, coarse wrinkling, mottled pigmentation, roughness, sallowness, skin laxity, and telangiectasias) [the details on score were not provided, but both numerical results (score with standard deviation) and the number of participants with "significantly or much improved' cosmetic outcome were presented]</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 15:42:39 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Graceway Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 10:04:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>Data from 2 studies were pooled together. Temporary dosing interruptions could have been instructed by the investigator to manage local skin reactions and adverse events. 96% of subjects were compliant with dosing. A sample size calculation was provided. There was a follow-up study published (<LINK REF="STD-Hanke-2011" TYPE="STUDY">Hanke 2011</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:52:12 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hantash-2006">
<CHAR_METHODS MODIFIED="2012-11-06 10:07:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, active-controlled, parallel-group study.</P>
<P>Start date: October 1, 2000</P>
<P>End date: October 30, 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 10:09:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis confirmed by experienced dermatologist</LI>
<LI>Anatomical location: face</LI>
<LI>With a history of facial or scalp non-melanoma skin cancer and numerous actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Previous facial resurfacing (laser or chemical peel) within 5 years</LI>
<LI>Current non-melanoma skin cancer</LI>
<LI>Topical therapy or cryotherapy within 2 months</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>34 participants</LI>
<LI>33 men, 1 women</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-04 12:10:57 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 2 passes of carbon dioxide laser resurfacing (N = 8 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: 30% trichloroacetic acid peel (N = 10 participants)</P>
<P>C: 5% fluorouracil twice daily for 3 weeks (N = 9 participants)</P>
<P>D: not randomised control group without treatment (data not presented and not included in our review) (N = 5 participants, 2 participants not included and reasons were given)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:52:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean number of actinic keratosis lesions at baseline and 3 months (transformed to mean reduction in lesion counts)</P>
<P>2) Mean percentage of reduction of lesion counts at 3 months</P>
<P>3) Incidence of new non-melanoma skin cancer for 5 years (4 groups)</P>
<P>4) Minor adverse events (qualitative)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using the number and locations of existing lesions charted on a diagram of the head (at each visit, any lesions suggestive of basal or squamous cell carcinoma were biopsied. The VA Palo Alto Health Care System (VAPAHCS) medical and pathologic records were reviewed for each participant through June 30, 2005, to evaluate for any subsequent development of skin cancer in treated areas)</P>
<P>Time points: at enrolment and every 3 months for a minimum of 24 months (at the end of the 24-month study, participants continued routine general dermatology clinic surveillance)</P>
<P>Definitions for rates of cancer formation: 1. cancer incidence rates (ratio of the total number of cancers to the total number of participant-years followed in each group), 2. number of days from baseline/treatment to diagnosis of the first non-melanoma skin cancer</P>
<P>
<U>Safety</U>
</P>
<P>Methods: monitoring for any adverse events</P>
<P>Time points: at every 3 months for a minimum of 24 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 10:15:26 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-10-25 16:29:03 +0100" MODIFIED_BY="Maryse Paquet">
<P>Every 3 months, new or remaining lesions were treated with cryosurgery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:35 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hauschild-2009a">
<CHAR_METHODS MODIFIED="2012-11-06 10:18:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blinded, placebo-controlled, parallel-group study.</P>
<P>Start date: March 2006, End date: December 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>White men and women with actinic keratoses</LI>
<LI>Skin type I-IV</LI>
<LI>Age 18 years and older</LI>
<LI>Anatomical location: head</LI>
<LI>Mild to moderate grade actinic keratoses with a minimum diameter of 1.8 cm and an interlesional distance of at least 1 cm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women of child-bearing potential</LI>
<LI>Non-response to previous photodynamic therapy</LI>
<LI>Dermatological conditions that could influence the study arms</LI>
<LI>Porphyria</LI>
<LI>Clinically relevant immunosuppression or dementia</LI>
<LI>Topical treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 3 months with urea- and salicylic acid-containing preparations</LI>
<LI>within 4 weeks with systemic retinoids</LI>
<LI>within 2 weeks with treatment with cytostatic or radiation</LI>
<LI>within 3 months and during study, known intolerance to 1 or more ingredients of patches</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>103 participants</LI>
<LI>84 men,19 women</LI>
<LI>Age: range = 51 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3 to 8 self-adhesive patches of PD P506A (aminolevulinic acid - ALA)-photodynamic therapy (PDT) (N = 69 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 3 to 8 self-adhesive patches of placebo-PDT (N = 34 participants)</P>
<P>
<U>Characteristics of PDT intervention:</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: no</P>
<P>Cream concentration (%): patches containing 8 mg</P>
<P>Application of cream: self-adhesive patch</P>
<P>Incubation with cream: 4 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: Aktilite CL 128 or Omnilux</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 10:22:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Complete clinical clearance rates on lesion basis (= lesion complete response) at 12 weeks post-treatment</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 12 weeks post-treatment</P>
<P>2) Adverse reactions at the treatment site (= application site reactions) during and the day after the treatment</P>
<P>3) Local skin/adverse reactions (presented for ALA-PDT only)</P>
<P>4) Serious adverse events</P>
<P>5) Treatment-related adverse events</P>
<P>6) Participant and investigator cosmetic outcomes of cleared lesions</P>
<P>7) Participant satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: clinical diagnosis being regarded as usual procedure in dermatological practice</P>
<P>Time points: at 12 weeks post-treatment</P>
<P>Definitions: complete clinical clearance of a lesion (no visual evidence of persisting lesion on treated surface; no evidence of adherent scaling plaques on treated skin surface when palpated; lesions no longer perceptible to touch; and slight pink or red foci might be visible at lesion sides)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of local reactions by clinical staff, 2. a diary for the documentation of local reactions by participant during the 4 weeks after therapy, 3. blood samples for monitoring hepatic aminotransferases (alanine aminotransferase and aspartate aminotransferase) and &#611;-glutamyltransferase, 4. documentation of adverse events</P>
<P>Time points: 1. during patch application, illumination, and thereafter (local reactions), 2. before and day of treatment (blood tests), 3. each study visit (adverse events)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. participants' and investigators' assessment of the cosmetic outcome of cleared lesions ('excellent', 'good', 'fair', or 'poor'), 2. participants' overall satisfaction with the cosmetic outcome ('very satisfied', 'satisfied', 'poorly satisfied', 'not satisfied')</P>
<P>Time points: at 12 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 16:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photonamic GmbH &amp; Co. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-09 11:55:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>The manuscript included 2 independent phase III studies (AK03 and AK04). This study was AK03. Adverse events were given for individual studies and pooled for ALA-PDT, but pooled only for placebo-PDT. Thus, pooled data were used for analysis (under <LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>). A follow-up study was published (<LINK REF="STD-Szeimies-2010a" TYPE="STUDY">Szeimies 2010a</LINK>). Data for intention-to-treat analysis were used for the meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:38 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hauschild-2009b">
<CHAR_METHODS MODIFIED="2012-11-06 10:25:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open, parallel-group study.</P>
<P>Start date: March 2006</P>
<P>End date: November 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 11:56:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>White men and women with actinic keratoses</LI>
<LI>Skin type I-IV</LI>
<LI>Age18 years and older</LI>
<LI>Anatomical location: head</LI>
<LI>Mild to moderate grade actinic keratoses with a minimum diameter of 1.8 cm and an interlesional distance of at least 1 cm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women of child-bearing potential</LI>
<LI>Non-response to previous photodynamic therapy</LI>
<LI>Dermatological conditions which could influence the study arms</LI>
<LI>Porphyria</LI>
<LI>Clinically relevant immunosuppression or dementia</LI>
<LI>Topical treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 3 months with urea- and salicylic acid-containing preparations</LI>
<LI>within 4 weeks with systemic retinoids</LI>
<LI>within 2 weeks with treatment with cytostatic or radiation</LI>
<LI>within 3 months and during study a known intolerance to 1 or more ingredients of patches or cryosurgery</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>346 participants</LI>
<LI>248 men, 98 women</LI>
<LI>Age: mean = 70; range = 41 to 94</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 4 to 8 self-adhesive patches of PD P506A (aminolevulinic acid -ALA)- photodynamic therapy (PDT) (N = 148 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: 4 to 8 self-adhesive patches of placebo-PDT (N = 49 participants)</P>
<P>C: cryosurgery: nozzles of size C, 1 cycle and freeze time between 5 and 10 seconds (N = 149 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: no</P>
<P>Cream concentration (%): patches containing 8 mg</P>
<P>Application of cream: self-adhesive patch</P>
<P>Incubation with cream: 4 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: Aktilite CL 128 or Omnilux</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Complete clinical clearance rates on lesion basis (= lesion complete response) at 12 weeks post-treatment</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 12 weeks post-treatment</P>
<P>2) Adverse reactions at the treatment site (= application site reactions) during and the day after the treatment</P>
<P>3) Local skin/adverse reactions (presented for ALA-PDT only)</P>
<P>4) Serious adverse events</P>
<P>5) Treatment-related adverse events</P>
<P>6) Participant and investigator cosmetic outcomes of cleared lesions</P>
<P>7) Participant satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: clinical diagnosis being regarded as usual procedure in dermatological practice</P>
<P>Time points: at 12 weeks post-treatment</P>
<P>Definitions: complete clinical clearance of a lesion (no visual evidence of persisting lesion on treated surface; no evidence of adherent scaling plaques on treated skin surface when palpated; lesions no longer perceptible to touch; and slight pink or red foci might be visible at lesion sides)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of local reactions by clinical staff, 2. a diary for the documentation of local reactions by participant during the 4 weeks post-treatment, 3. blood samples for monitoring hepatic aminotransferases (alanine aminotransferase and aspartate aminotransferase) and &#611;-glutamyltransferase, 4. documentation of adverse events</P>
<P>Time points: 1. during patch application, illumination, and thereafter for PDT, and during the spraying procedure and thereafter for cryotherapy (local reactions), 2. before and day of treatment (blood tests), 3. each study visit (adverse events)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: participants' and investigators' assessment of the cosmetic outcome of cleared lesions ('excellent', 'good', 'fair', or 'poor')</P>
<P>Time points: at 12 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 16:38:32 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photonamic GmbH &amp; Co.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-09 11:57:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>The manuscript included 2 independent phase III studies (AK03 and AK04). This study was AK04. Adverse events were given for individual studies and pooled for ALA-PDT, but only pooled for placebo-PDT. Thus, pooled data were used for analysis for ALA-PDT vs placebo-PDT (under <LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>). A follow-up study was published (<LINK REF="STD-Szeimies-2010a" TYPE="STUDY">Szeimies 2010a</LINK>). Data for intention-to-treat analysis were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:40 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hauschild-2009c">
<CHAR_METHODS MODIFIED="2012-11-06 10:31:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, assessor-blinded, active-controlled, parallel group study.</P>
<P>Start date: January 2005</P>
<P>End date: July 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 18:51:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Histological diagnosis</LI>
<LI>White men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: head and face</LI>
<LI>3 to 4 actinic keratoses</LI>
<LI>Mild to moderate grade</LI>
<LI>With a maximum diameter of 1.8 cm and an interlesional distance of 1 cm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women of child-bearing potential</LI>
<LI>Known or suspected acute or chronic hepatic diseases or renal dysfunction</LI>
<LI>Dermatological conditions that could possibly influence the study aims</LI>
<LI>Porphyria</LI>
<LI>Immune system suppression</LI>
<LI>Severe concomitant diseases</LI>
<LI>Any topical treatment able to affect the disease status was not permitted within the last 4 weeks and during the study (3 months for systemic retinoids)</LI>
<LI>Urea and salicylic acid-containing dermatological preparations were not permitted within the last 2 weeks and during the study</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>149 randomised, 140 evaluable participants</LI>
<LI>103 men, 37 women</LI>
<LI>Age: mean = 71; range = 39 to 91</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 1 hour of PD P506A (aminolevulinic acid (ALA) self-adhesive patch)-photodynamic therapy (PDT) (N = 38 participants)</P>
<P>B: 2 hours of PD P506A-PDT (N = 34 participants)</P>
<P>C: 4 hours of PD P506A-PDT (N = 34 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>D: 0.5 hour of PD P506A-PDT (N = 34 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: no</P>
<P>Cream concentration (%): patches containing 8 mg</P>
<P>Application of cream: self-adhesive patch</P>
<P>Incubation with cream: 0.5 to 4 hours</P>
<P>Type of light: red light</P>
<P>Light source: Aktilite CL 128</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 4 and 8 weeks</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 4 and 8 weeks</P>
<P>2) Local skin reactions presented graphically for 3 periods (during ALA patch application, during illumination, and after illumination) as well as by severity of the reactions</P>
<P>3) Treatment-related adverse events (minor adverse events)</P>
<P>4) Minor adverse events (pooled)</P>
<P>5) Serious adverse events</P>
<P>6) Clinical laboratory tests</P>
<P>7) New actinic keratoses</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: clinical diagnosis, the usual procedure in dermatological practice</P>
<P>Time points: at 4 and 8 weeks after PDT</P>
<P>Definitions: complete clinical clearance of a lesion (no visual evidence of persisting lesions on treated surface, no evidence of adherent scaling plaques on treated skin surface when palpated, lesions no longer perceptible to touch, slight pink or red foci might be visible at lesion sides)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. inspection of study lesions for tolerability, 2. recording of local reactions and adverse events (local reactions were always assumed to be related to study therapy. For adverse events, the investigator judged the relation to the study therapy)</P>
<P>Time points: 1. at 1 day and 1 week after PDT (tolerability), 2. entire study duration (local reactions and adverse events)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 17:23:38 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photoamic.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 15:22:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>Percentages of participants with local skin reactions were given graphically. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:05:19 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Huyke-2009">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 10:39:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical or histological diagnosis</LI>
<LI>Healthy participants of both sexes older than 18 years with full contractual capability</LI>
<LI>Anatomical locations: face, scalp, and other</LI>
<LI>
<U>&lt;</U> 10 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Inflammatory skin diseases</LI>
<LI>Metabolic diseases</LI>
<LI>Consumption of any drugs except contraceptives</LI>
<LI>Alcohol consumption</LI>
<LI>Infections</LI>
<LI>Pregnancy, lactation</LI>
<LI>Impaired contractual capability as well as concomitant participation in other clinical studies</LI>
<LI>Pigmented skin lesions</LI>
<LI>Concomitant therapy with UV</LI>
<LI>Medication with immunomodulatory, antibiotic, or anti-inflammatory properties</LI>
<LI>Treatment for actinic keratosis within 4 weeks</LI>
<LI>No proper contraceptive method</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>45 participants</LI>
<LI>36 men, 9 women</LI>
<LI>Age: mean = 68; range = 50 to 92</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 10:39:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: betulin-based oleogel applied twice daily (N = 15)</P>
<P>B: combination therapy with initial cryotherapy followed by betulin-based oleogel twice daily (N = 15)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>C: cryotherapy in the form of a spray coat method with liquid nitrogen (20 to 40 seconds) (N = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:05:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete clearing (= participant complete clearance) rates at 3 months</P>
<P>2) Therapy responders with <U>&gt;</U> 75% of clearing of the lesions (= participant partial clearance) rates at 3 months</P>
<P>3) Histological analysis of biopsies before treatment and at the end of treatment</P>
<P>4) Minor adverse events (qualitative)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using documentation of visual and photographic evaluation in the case report forms, 2. punch biopsies from 4 participants out of the oleogel group, 2 participants out of the cryotherapy group and 2 participants out of the combination therapy group for evaluation of the degree of dysplasia, number of dyskeratoses and thickness of epidermis and stratum corneum</P>
<P>Time points: 1. at 1, 2, and 3 months after the beginning of treatment, 2. before treatment and at the end of treatment (biopsy)</P>
<P>Definitions: 1. responders [participants with complete (100 %) and with extensive (<U>&gt;</U> 75 %) total clearing of the lesions], and 2. non-responders (participants with disappearance of &lt; 75 % of the lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: assessment of the subjective parameters itching and stinging by a questionnaire and grading as follows: 0 = absent, 1 = mild, 2 = moderate, and 3 = severe<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 17:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Birken GmbH. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-10-18 18:24:33 +0100" MODIFIED_BY="Maryse Paquet">
<P>This study was a Phase II pilot study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:41 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jeffes-2001">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, assessor-blinded, vehicle-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:05:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinically typical actinic keratoses (scaly erythematous papules and plaques devoid of cystic pores or a papillomatous surface)</LI>
<LI>Grade 1 (mild, lesions slightly palpable, with lesions more readily felt than seen) or 2 (moderate, moderately thick lesions, easily seen and felt)</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>
<U>&gt;</U> 4 actinic keratoses (2/treatment group)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Grade 3 (severe, very thick, hypertrophic, or hyperkeratotic)</LI>
<LI>Previous treatment of target actinic keratoses</LI>
<LI>Concurrent use of photosensitising drug</LI>
<LI>Treatment with the following:</LI>
</UL>
<UL>
<UL>
<LI>within 1 week with non-steroidal anti-inflammatory drugs</LI>
<LI>within 2 weeks with topical steroids, retinoids (Retin A), or topical alpha hydroxy acids</LI>
<LI>within 4 weeks with systemic steroids</LI>
<LI>within 2 months with topical application of 5-fluorouracil, masoprocol, systemic chemotherapeutic agent, immunotherapy, or retinoids</LI>
</UL>
</UL>
<UL>
<LI>Pregnancy or nursing</LI>
<LI>History of cutaneous photosensitivity</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>36 participants</LI>
<LI>30 men, 6 women</LI>
<LI>Age: mean = 69; range = 38 to 100</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-photodynamic therapy (PDT) (N = 36 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle-PDT (N = 36 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2 (if complete response not achieved)</P>
<P>Interval between treatments: 8 weeks</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: 3 applications onto lesion and a rim of 2 to 4 mm, air dry between applications</P>
<P>Incubation with cream: 14 to 18 hours</P>
<P>Type of light: blue light</P>
<P>Light source: DUSA BLU-417</P>
<P>Wavelength (nm): 417</P>
<P>Energy fluence (J/cm²): 2, 5, or 10</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:51:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Clinical response of actinic keratosis lesions including completely cleared (= lesion complete response) rates for individual (at 8 weeks) and all (at 8 and 16 weeks) light doses</P>
<P>2) Number of participants with 0, 1, 2 (all) cleared lesions (= participant complete clearance) for individual (at 8 weeks) and all [at 8 (ALA and placebo) and 16 (ALA only) weeks] light doses</P>
<P>3) Application site reactions during (illumination) and after treatment reported per lesions</P>
<P>4) Clinical laboratory tests</P>
<P>5) Changes in pigmentation (cosmetic) per lesions</P>
<P>6) PpIX fluorescence</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at baseline; immediately after PDT; at 24 and 72 hours; and at weeks 1, 4, 8, 9 (retreated participants), 12, and 16</P>
<P>Definitions: 1. complete response (completely cleared with no evidence of adherent scale on the surface of the treated skin when palpated), 2. partial response (&#8805; 50% reduction in lesion size), and 3. no response (&lt; 50% reduction in lesion size)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. evaluation of objective changes in erythema, oedema, wheal, vesiculation, ulceration, haemorrhage, and necrosis on a graded scale (0: none; 1: minimal; 2: moderate; 3: severe), 2. subjective assessment of participant discomfort from pain, burning/stinging, and itching was graded (0: none; 1: minimal; 2: moderate; 3: severe), 3. standard hematologic and biochemical laboratory parameters, 4. reporting of adverse events</P>
<P>Time points: 1. at baseline; immediately after PDT; at 24 hours; at 72 hours; and at weeks 1, 4, 8, 9 (retreated participants), 12, and 16, 2. at baseline and again at 1 week post-treatment (laboratory tests)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 17:58:10 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by DUSA pharmaceuticals, Inc. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 18:53:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>Clinical response was dependant upon dose of light administered (5 or 10 J/cm² were more effective than 2 J/cm²). Visual detection of PpIX confirmed absence of cross contamination of treatment and placebo creams. Grade 1 (30/39 = 77%) lesions had better response than grade 2 (16/31 = 52%). PpIX fluorescence significantly correlated with clinical response (P &lt; 0.001). Only data from 8 week's visit was used, because data from 16 weeks included participants with or without additional treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:58:45 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jorizzo-2002">
<CHAR_METHODS MODIFIED="2012-11-09 11:58:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, open (treatment duration), vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 10:50:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or frontal scalp</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses  (<U>&gt;</U> 4 mm in diameter)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Confounding skin condition (basal cell carcinoma or squamous cell carcinoma)</LI>
<LI>History of facial skin irritation</LI>
<LI>Treatment of actinic keratoses within 1 month</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>207 participants</LI>
<LI>166 men, 41 women</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 18:54:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: 0.5% 5-fluorouracil, once daily for 1 week (N = 47 participants)</P>
<P>B: 0.5% 5-fluorouracil, once daily for 2 weeks (N = 46 participants)</P>
<P>C: 0.5% 5-fluorouracil, once daily for 4 weeks (N = 45 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>D: Vehicle, once daily for 1, 2, or 4 weeks (pooling not clear - see page 336 of the study) (N = 69 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:58:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Physician Global Assessment of Improvement (PGAI = Global improvement indices)</P>
<P>2) Per cent reduction of lesions (= mean percentage of reduction in lesion counts)</P>
<P>3) Absolute mean reduction in lesion counts</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Proportion of participants achieving total clearance (= participant complete clearance)<BR/>
</P>
<P>2) Skin irritation (percentages of participants, severity, overtime)</P>
<P>3) Application and local skin reactions and minor adverse events (pooled data from 2 studies included in Carac product insert, i.e. <LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK> and <LINK REF="STD-Weiss-2002" TYPE="STUDY">Weiss 2002</LINK>)</P>
<P>4) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting, 2. qualitative assessment (PGAI mean score, +5 = total clearance and -4 = much worse)</P>
<P>Time points: at baseline and 4 weeks post-treatment</P>
<P>
<U>Safety</U>
<BR/>Methods: 1. adverse events (including details of facial irritation): maximum severity,<BR/>symptoms, onset and overall duration, post-treatment duration, and summary by visit, 2. facial irritation graded as 0 = none, 1 = mild, 2 = moderate, or 3 = severe (to ensure that all facial irritation was recorded, the last observed value for facial irritation was carried forward if a participant discontinued treatment for any reason)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 18:16:40 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Dermik Laboratories.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 10:54:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>Data from this study were included in the Carac product insert.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 10:58:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jorizzo-2004">
<CHAR_METHODS MODIFIED="2012-11-06 10:55:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel group study.</P>
<P>Start date: October 2001</P>
<P>End date: February 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 10:55:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Age 18 years and older</LI>
<LI>Women were eligible if they were postmenopausal or using appropriate contraceptive methods and not pregnant or lactating</LI>
<LI>Anatomical locations: face, scalp, ears, neck, lips</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal or squamous cell carcinomas</LI>
<LI>Other potential confounding skin conditions</LI>
<LI>Known allergies to ingredients of the test drug formulation</LI>
<LI>Treatment for actinic keratosis within 5 months; cryosurgery within 4 weeks</LI>
<LI>Engaged in activities that involve excessive or prolonged exposure to sunlight</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>144 participants</LI>
<LI>119 men, 23 women</LI>
<LI>Age: mean = 63</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 10:56:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: topical 0.5% 5-fluorouracil, once daily for 7 days. At 4 weeks post-treatment, residual lesions treated with cryotherapy. (N = 72 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once daily for 7 days. At 4 weeks post-treatment, residual lesions treated with cryotherapy (N = 72 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 10:57:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Absolute and per cent of mean reduction in lesion counts at 4 weeks (topical only) and 6 months (topical + cryotherapy)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 4 weeks and 6 months</P>
<P>2) Application site reactions (also reported in <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>)</P>
<P>3) Eye irritation (= minor adverse events)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using the counting of visible or palpable lesions, or both, by the same evaluator</P>
<P>Time points: before initial treatment and at the 4-week and 6-month follow-up visits</P>
<P>
<U>Safety</U>
<BR/>Methods: 1. recording of severe application site reactions (erythema, edema, dryness, pain, erosion, burning, and pruritus), 2. eye irritation (burning, sensitivity, itching, stinging, and watering), 3. any other adverse events<BR/>Time points: at each visit<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 18:31:16 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Dermik Laboratories.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 10:58:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study (interim analysis) is part of a 3-cycle study published in <LINK REF="STD-Jorizzo-2006" TYPE="STUDY">Jorizzo 2006</LINK>, which was also included in this review. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:48:45 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jorizzo-2006">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 10:59:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Women were eligible if they were postmenopausal or using appropriate contraceptive methods and not pregnant or lactating</LI>
<LI>Anatomical locations: face, scalp, ears, neck, lips</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal or squamous cell carcinomas</LI>
<LI>Other potential confounding skin conditions</LI>
<LI>Known allergies to ingredients of the test drug formulation</LI>
<LI>Treatment for actinic keratosis within 5 months</LI>
<LI>Cryosurgery within 4 weeks</LI>
<LI>Engaged in activities that involve excessive or prolonged exposure to sunlight</LI>
<LI>Used a tanning parlour</LI>
<LI>Known dihydropyrimidine dehydrogenase enzyme deficiency</LI>
<LI>History of drug or alcohol abuse</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>144 participants</LI>
<LI>119 men, 23 women</LI>
<LI>Age: mean = 63</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:00:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 3 topical/cryosurgery cycles: topical 0.5% 5-fluorouracil, once daily for 7 days. At 4 weeks post-treatment, residual lesions were treated with cryosurgery (N = 72 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 3 topical/cryosurgery cycles: topical vehicle, once daily for 7 days. At 4 weeks post-treatment, residual lesions were treated with cryosurgery (N = 70 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Mean lesion counts at baseline and different treatment cycles (transformed to mean reduction in lesion counts)</P>
<P>2) Mean percentage of reduction in lesion counts</P>
<P>3) Participant complete clearance rates at 3 topical/cryosurgery cycles (before cryosurgery)</P>
<P>4) New involvement of actinic keratosis lesions</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions (severe)</P>
<P>2) Treatment-related adverse events (= minor adverse events)</P>
<P>3) Serious adverse events including basal and squamous cell carcinoma</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using the counting of visible or palpable actinic keratoses, or both, by the same evaluator</P>
<P>Time points: before initial treatment and at the follow-up visits</P>
<P>Definitions: 1. actinic keratosis reduction (number of lesions present at the 4-week follow-up visit for each topical/cryosurgery cycle minus the number of baseline lesions for that cycle), 2. clearance (complete lack of lesions in the treatment area at the 4-week follow-up visit for each topical/cryosurgery cycle), 3. new involvement [presence of new lesions in the treatment area at the start of topical/cryosurgery cycle 2 (week 26) or 3 (week 52)]</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring the incidence, onset, duration, and severity of adverse events observed, 2. participants reporting the occurrence of any adverse event, and study personnel questioned participants during study visits to monitor safety, 3. all adverse events were categorised by the investigator as serious or not<BR/>Time points: from time of enrolment to the end of the follow-up period</P>
<P>Definitons: serious adverse events [adverse events resulting in death, life threatening; required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or incapacity, those described as important medical events (e.g. diagnosis cancer during the course of treatment)]</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 18:53:06 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Dermik Laboratories.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:03:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>More participants in the vehicle group had cryosurgery. New actinic keratosis lesions were observed over time in both groups, but a lower percentage of participants in the 5-fluorouracil group than the vehicle group was obtained. The number of participants based on ITT analyses were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 11:59:52 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jorizzo-2007">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 11:05:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinically typical visible actinic keratoses</LI>
<LI>Age 18 years and older</LI>
<LI>Anatomical locations: balding scalp or face</LI>
<LI>4 to 8 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>246 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:05:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod, once per day, 3 days per week for 4 weeks on, 4 weeks off, 1 or 2 courses (N = 123 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle: once per day, 3 days per week for 4 weeks on, 4 weeks off, 1 or 2 courses (N = 123 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 11:59:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Recurrence at 1 year</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete and partial (<U>&gt;</U> 75%) clearance rates after course 1 or overall</P>
<P>2) Individual lesion clearance (= lesion complete response) rates after course 1 or overall</P>
<P>3) Minor adverse events (qualitative)</P>
<P>4) Clinical laboratory tests</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting</P>
<P>Time points: at week 8, 16, and 1 year follow-up (relapse for participants achieving complete clearance)</P>
<P>Definitions: 1. complete clearance rate (proportion of participants who cleared all lesions in the treatment area), 2. partial clearance rate (proportion of participants with at least a 75% reduction in baseline lesions)<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring for adverse events and local skin reactions, 2. clinical laboratory tests (hematology and chemistry blood tests, and urinalysis), 3. culture of suggested skin infections<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 19:21:28 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:06:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>1-year recurrence rate of 39% and 57% were respectively found for imiquimod and vehicle.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 12:00:27 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jorizzo-2010">
<CHAR_METHODS MODIFIED="2012-11-06 11:08:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel group study.</P>
<P>Start date: May 2009</P>
<P>End date: February 2010</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 11:10:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Adults in general good health</LI>
<LI>Anatomical location: face</LI>
<LI>&#8805;10 typical visible or palpable actinic keratoses (<U>&lt;</U> 1 cm² in area and &lt; 1 mm in height)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Atypical actinic keratoses (e.g. hyperkeratotic actinic keratoses &gt; 1 cm² in area or &gt; 1 mm in height, or both) in the treatment area (face)</LI>
<LI>Conditions in the facial area that might impair evaluation</LI>
<LI>Pregnancy or lactation</LI>
<LI>Chemical or alcohol dependency</LI>
<LI>Allergy to imiquimod or study cream excipients</LI>
<LI>The treatment area could not have been treated with the following: within 1 year with imiquimod; within 90 days with dermatologic procedures or surgeries, any actinic keratosis therapy, or investigational drug or device; within 30 days with any topical prescription drug</LI>
<LI>Exclusive of the treatment area, subjects could not have received treatment with interferon, interferon inducers, cytotoxic drugs, immunomodulators, immunosuppressants, oral or parenteral corticosteroids, topical corticosteroids &gt; 2 g/day within 90 days, or an investigational drug or device within 30 days</LI>
<LI>Usage of any of these treatments was also prohibited throughout the study.</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>247 participants</LI>
<LI>214 men, 33 women</LI>
<LI>Age: mean = 67</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-09 12:00:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: cryotherapy followed by 3.75% imiquimod, daily for 2 weeks on, 2 weeks off, 2 weeks on (N = 126 participants)</P>
<P>B: no cryotherapy followed by 3.75% imiquimod, daily for 2 weeks on, 2 weeks off, 2 weeks on (N = 126 participants)</P>
<P>
<B>
<U>Control interventions</U>
</B>
</P>
<P>C: cryotherapy followed by placebo, daily for 2 weeks on, 2 weeks off, 2 weeks on (N =121 participants)</P>
<P>D: no cryotherapy followed by placebo, daily for 2 weeks on, 2 weeks off, 2 weeks on (N =121 participants)</P>
<P>Randomisation was performed for imiquimod or placebo treatment, but the method used to select which lesions were treated with or without cryotherapy was not specified. At least 5 lesions were not treated with cryosurgery, and 5 to 14 actinic keratoses were treated with cryosurgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 12:00:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Mean and median per cent changes from baseline for all lesions (= mean percentage of reduction in lesion counts) at week 26</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates for all lesions at week 26</P>
<P>2) Local skin reactions (severe)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions including irritation</P>
<P>2) Treatment-related adverse events (= minor adverse events)</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events including basal and squamous cell carcinoma</P>
<P>5) Cosmetic outcomes (photodamage)</P>
<P>6) Rest periods</P>
<P>7) Participant satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting and mapping on a facial diagram, including lesions that were initially treated with cryosurgery</P>
<P>Time points: 1. at each visit (counting), 2. baseline and end of study at week 26 (mapping)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: investigator assessment of local skin reactions (erythema, oedema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, and erosion/ulceration) graded as none, mild, moderate, or severe and summarised by the most intense score for each reaction, 2. recording of adverse events coded using MedORA® (Medical Dictionary for Regulatory Activities), Version 12.0 (treatment-emergent AEs were summarised for each treatment group by preferred term, intensity, and investigator assessment of relationship to study cream), 3. serious adverse events and discontinuations due to adverse events</P>
<P>Time points: at each clinic visit</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of facial photodamage by the investigator using previously published 5-point scales that rated fine lines, mottled pigmentation, tactile roughness, sallowness, and global photoageing</P>
<P>Time points: at baseline (prior to cryosurgery) and at weeks 10, 14, 20, and 26/end of study</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 19:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Graceway Pharmaceuticals, LLC. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:11:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 12:01:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Kang-2003">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, placebo-controlled, active-controlled, assessor-blinded, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:03:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Between 18 and 85 years of age</LI>
<LI>Anatomical locations: face above the jawline, ear, and scalp, sometimes arms and back of hands</LI>
<LI>5 to 25 visible actinic keratoses at least 2 mm diameter but target lesions (maximum of 3 lesions) were at least 5 mm diameter</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Treatment within the last 6 months with topical retinoids, alpha hydroxy acids, or 5-fluorouracil; within 1 year with systemic retinoids, dermabrasion, or cosmetic operation; within 2 months with oral psoralen-UVA therapy; within 1 month with cryotherapy; within 2 weeks with topical steroids</LI>
<LI>Dark skin (phototypes V and VI)</LI>
<LI>Pregnant or lactating women</LI>
<LI>History of skin cancer in the previous 3 years</LI>
<LI>Any condition that could interfere with the study evaluation</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>90 participants</LI>
<LI>69 men, 21 women</LI>
<LI>Age: mean = 63; range = 43 to 83</LI>
<LI>White, 79% with skin phototypes I and II</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:26:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: 0.1% adapalene gel, once daily for 4 weeks; twice daily from 4 weeks to 36 weeks (N = 30 participants)</P>
<P>B: 0.3% adapalene gel, once daily for 4 weeks; twice daily from 4 weeks to 36 weeks (N = 30 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>C: placebo, once daily for 4 weeks; twice daily from 4 weeks to 36 weeks (N = 30 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 12:01:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction/changes of lesion counts</P>
<P>2) Morphological changes of target lesions</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Physician global assessment improvement (PGAI) from worse to clear (= Global Improvement Indices)</P>
<P>2) Histological analysis of biopsies before and after treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Tolerability (= local skin reactions)</P>
<P>2) Minor adverse events</P>
<P>3) Serious adverse events</P>
<P>4) Photoaging characteristic improvement (cosmetic outcome)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using total lesion counts, 2. assessment of morphologic changes in target actinic keratoses (induration, scaling, and erythema evaluated on a scale of 0 [none] to 3 [severe]), 3. qualitative assessment of improvement (PGAI) as clear, marked, moderate, slight, no change, or worse, 4. biopsy specimens evaluated in a blinded manner by a board-certified dermatopathologist at 1 centre (University of Michigan, Ann Arbor, Michigan)</P>
<P>Time points: at week 2, 4, 12, 18, 24, 30, and 36</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: standardised photographs were taken of 45 participants by a professional photographer at 1 centre (University of Michigan). [The photographs were evaluated retrospectively in a randomised, blinded fashion to assess the effects of the 3 treatments on photoageing characteristics (mottled hyperpigmentation, fine wrinkles, coarse wrinkles, rosy glow-healthy pink complexion, and global photoageing severity). Each parameter was graded for improvement on a scale of 0 to 6. If there was no difference or worsening between before- and after-treatment photographs, then a score of 0 was given]</P>
<P>Time points: at baseline and after 3, 6, and 9 months of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 19:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Galderma Corporation, Texas, US.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 15:23:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>Histology on 36 participants showed no significant difference between treatment groups. There was no follow-up period. A sample size calculation was provided. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:33:35 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Kaufmann-2008">
<CHAR_METHODS MODIFIED="2012-11-06 11:29:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open, active-controlled, intraindividual study.</P>
<P>Start date: January 2005</P>
<P>End date: February 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:05:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: upper and lower extremities, trunk, neck</LI>
<LI>Non-hyperkeratotic lesions of mild or moderate thickness</LI>
<LI>At least 4 comparable symmetrical lesions of similar severity and total number on both sides of the body (at least 2 lesions on each side and no more than a 2-fold difference between the 2 sides)</LI>
<LI>Women of child-bearing age were required to have a negative pregnancy test at the beginning of the study and to use effective birth control for the duration of the study</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Participants receiving topical treatment within the past 3 months or those on ultraviolet therapy</LI>
<LI>Participants with thick lesions</LI>
<LI>Participants with pigmented lesions in the target area</LI>
<LI>Porphyria</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>121 participants</LI>
<LI>78 men, 43 women</LI>
<LI>Age: mean = 69; range = 39 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:33:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 121 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy: double freeze/thaw (1 to 2 mm frozen rim outside marked outline of lesion), 20 seconds (1 or 2 treatments with a 12-week interval) (N = 121 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 12 weeks</P>
<P>Preparation of lesions: gentle scraping</P>
<P>Cream concentration (%): 16 %</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: 3 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: Aktilite CL128</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:05:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates for baseline lesions at week 24</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Cosmetic outcome assessed by investigator and participants</P>
<P>2) Participant preference</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Mean percentage of reduction in lesion counts</P>
<P>2) Treatment-related adverse events (= minor adverse events)</P>
<P>3) Participants reporting at least one adverse event</P>
<P>4) Minor adverse events</P>
<P>5) Serious adverse events including squamous cell carcinoma</P>
<P>6) Observation of Bowen's disease and new actinic keratoses</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting [efficacy evaluations only included lesions present at baseline (i.e. lesions appearing after baseline, if any, were to be reported as an adverse event)]</P>
<P>Time points: at baseline and weeks 12 and 24</P>
<P>Definitions for lesion response: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: spontaneous reporting of adverse events by the participant or elicited following non-leading questioning (severity, duration and need for additional therapy)</P>
<P>Time points: at each follow-up visit</P>
<P>Definitions for adverse events: 1. phototoxic reaction (any observed erythema, oedema, itching, pain, etc), 2. cryotherapy reaction (any observed blisters, infection, etc)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. investigator assessment of cosmetic outcome for all lesions with complete response, 2. participant assessment of cosmetic outcome</P>
<P>Time points: at week 24</P>
<P>Definitions for investigator assessment: 1. excellent (only slight occurrence of redness or change in pigmentation), 2. good (moderate redness or change in pigmentation), 3. fair (slight to moderate scarring, atrophy or induration), 4. poor (extensive scarring, atrophy, or induration)</P>
<P>Definitions for participant assessment on a 5-point scale: &#8211;2 (cryotherapy a lot better than MALPDT) to 2 (MAL-PDT a lot better than cryotherapy)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-17 20:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Galderma.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:33:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>A participant questionnaire showed that participants preferred MAL-PDT over cryotherapy for all questions except for effectiveness of treatment.</P>
<P>A sample size calculation was provided. Intention-to-treat values were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:39:05 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Korman-2005">
<CHAR_METHODS MODIFIED="2012-11-13 10:39:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: August 2001 </P>
<P>End date: August 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:03:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Healthy men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or bald scalp</LI>
<LI>4 to 8 actinic keratoses within a 25 cm² area</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Any condition that could be exacerbated by treatment or impair the examination area</LI>
<LI>Previous treatment with 5% imiquimod cream in the treatment area</LI>
<LI>Any known allergies to any excipients in the study cream</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 6 months with psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, or chemical peel</LI>
<LI>within 4 weeks with prescribed topical retinoids, 5-fluorouracil, masoprocol, cryodestruction, chemodestruction, surgical excision, photodynamic therapy, curettage, interferon/interferon inducers, cytotoxic drugs, drugs with major organ toxicity, immunomodulators, immunosuppressive therapies, oral corticosteroids, or topical steroids anywhere on the head</LI>
</UL>
<LI>The use of moisturisers, over-the-counter retinol products, or products containing &#945; or &#946; hydroxy acids in the treatment area</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>492 participants</LI>
<LI>431 men, 61 women</LI>
<LI>Age: mean = 66.3; range = 41 to 93</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:38:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod applied 3 times per week for 16 weeks (N = 242 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle cream applied 3 times per week for 16 weeks (N = 250 participants). Applied to entire treatment area at same time of day (before sleeping). Cream to remain in place for approximately 8 hours. Rest periods allowed at discretion of investigator, but did not alter length of 16-week treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:02:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates for all lesions at 8 weeks post-treatment</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participant partial (&gt; 75%) clearance rates for all lesions at 8 weeks post-treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Median percentage reduction of baseline lesions at 8 weeks post-treatment</P>
<P>2) Participants experiencing at least 1 adverse event<BR/>3) Application site reactions</P>
<P>4) Local skin reactions</P>
<P>5) Frequency and severity of adverse events (= minor adverse events)</P>
<P>6) Serious adverse events</P>
<P>7) Rest periods</P>
<P>8) Skin quality (cosmetic outcome)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting (baseline and new lesions)</P>
<P>Time points: at weeks 4, 8, and 16, and post-treatment week 8</P>
<P>Definitions: 1. complete clearance rate (proportion of participants at the 8-week post-treatment visit with no clinically-visible lesions in the treatment area), 2. partial clearance rate (proportion of participants at the 8-week post-treatment visit with at least a 75% reduction in the number of baseline lesions in the treatment area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. reviewing concomitant medication use, 2. assessing the incidence and severity of adverse events spontaneously reported, 3. assessing of local skin reactions (erythema, edema, erosion/ulceration, scabbing/crusting, weeping/exudation, vesicles, and flaking/scaling/dryness) rated as 0 = none, 1= mild, 2 = moderate, and 3 = severe by investigator (reactions within the treatment area that were not assessed as local skin reactions were reported as adverse events)</P>
<P>Time points: at weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16, and post-treatment weeks 4 and 8</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: investigator-performed (visual, clinical, and tactile examinations) skin quality assessments including skin surface (roughness/dryness/scaliness), hyperpigmentation, hypopigmentation, mottled or irregular pigmentation (hyperpigmentation and hypopigmentation), degree of scarring, and degree of atrophy area rated as 0 = none; 1 = mild; 2 = moderate; and 3 = severe<BR/>Time points: at the treatment initiation and the 8-week post-treatment visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-23 17:16:57 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:40:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>2 phase III studies were included. Clearance rates increased with intensity of erythema. Increase in lesion counts (new or subclinical lesions) was higher in imiquimod group at any point during the treatment period. Long-term clinical outcomes were presented in <LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:51:18 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Kose-2008">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, open-label, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 11:46:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Age18 years and older</LI>
<LI>General good health</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>
<U>&gt;</U> 3 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnancy or lactation</LI>
<LI>Use of medication for actinic keratosis or other systemic treatments within 1 month</LI>
<LI>Sensitivity to any component of the study medications</LI>
<LI>Dermatologic conditions, such as psoriasis, eczema, chemical peeling</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>49 participants</LI>
<LI>28 men, 21 women</LI>
<LI>Age: mean = 56; range = 41 to 82</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:46:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 3% diclofenac sodium in 2.5% hyaluronic acid, once daily for 12 weeks (N = 24 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 5% imiquimod, 3 times/week for 12 weeks (N = 25 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:51:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Investigator (IGII) and participant (PGII) global improvement indices at the end of treatment</P>
<P>2) Lesion severity index</P>
<P>3) Local skin reactions</P>
<P>4) Participants experiencing at least 1 treatment-related adverse event</P>
<P>5) Clinical laboratory tests</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting, 2. severity of actinic keratoses at baseline, 3. qualitative assessment (GII) by the investigator and participant</P>
<P>Time points: at baseline and monthly up to 1 year follow-up</P>
<P>Definitions for global improvement indices on a 7-point scale: -2 (significantly worse), -1 (slightly worse), 0 (no change), 1 (slightly improved), 2 (moderately improved), 3 (significantly improved), and 4 (completely improved)</P>
<P>Definitions for baseline severity index: 0 (no lesions visible), 1 (clearly visible lesions), 2 (many visible, small, moderately-thick lesions, or a few large, thick, rough scaly lesions), 3 (many thick, hypertrophic lesions, which are clearly visible and palpable with well-defined borders)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of tolerability by investigator (erythema, itching, dry skin, and scaling), 2. clinical examination, 3. reporting of adverse events, 4. routine laboratory tests (complete blood cell counts, urine analysis, and fasting chemistry)</P>
<P>Time points: 1. monthly up to 1 year follow-up, 2. before and after treatment (laboratory tests)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 11:46:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:39:26 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Krawtchenko-2007">
<CHAR_METHODS MODIFIED="2012-11-13 10:39:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, active-controlled, parallel-group study.</P>
<P>Start date: August 2004 </P>
<P>End date: February 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 11:51:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>White participants</LI>
<LI>Typical, visible, and histologically-proven actinic keratoses</LI>
<LI>Anatomical locations: head, neck, and décolleté</LI>
<LI>5 to 10  lesions in 1 anatomical area up to 5 X 10 cm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Participants using interferon or interferon inducers, immunomodulators, cytotoxic or immunosupressor drugs, corticosteroids, retinoids, or investigational drugs within 4 weeks</LI>
<LI>Topical drug for actinic keratoses within 2 weeks</LI>
<LI>Invasive tumours within the treated area</LI>
<LI>Cardiovascular, haematological, hepatic, neurological, renal, endocrine, vascular, or gastrointestinal abnormalities or diseases</LI>
<LI>Dermatological disease within the treated or adjacent (3 cm distance) area</LI>
<LI>Known allergies to ingredients contained within the drugs studied</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>75 participants</LI>
<LI>61 men, 14 women</LI>
<LI>Age: mean = 73; range = 57 to 88</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 11:51:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 0.25 g of 5% imiquimod cream 3 times per week for 8 hours each over a span of 4 weeks, 1 or 2 treatments with a 4-week rest period (N = 26 participants)</P>
<P>
<B>
<U>Control interventions</U>
</B>
</P>
<P>B: 5% 5-fluorouracil cream twice daily for 4 weeks (N= 24 participants)</P>
<P>C: cryosurgery using bursts of 20 to 40 seconds, 1 or 2 treatments with a 2-week rest period (N = 25 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 18:55:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at test of cure and 12 months after the end of treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participant histological clearance rates at test of cure</P>
<P>2) Negative predictive value, i.e. ratio between histological and clinical clearance</P>
<P>3) Serious adverse events</P>
<P>4) Global cosmetic outcome assessments by participant and investigator (presented graphically)</P>
<P>5) Skin quality</P>
<P>6) Recurrence (individual lesion and field) at 12 months after the end of treatment</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using precise documentation of location of each lesion on body grid charts with raster and photographs, 2. a 4 mm punch biopsy specimen obtained from 1 of the selected lesions and evaluated independently by 2 expert dermatopathologists</P>
<P>Time points: at baseline, test of cure (6, 4, and 8 weeks after last treatment for cryotherapy, 5-fluorouracil and imiquimod, respectively), and 1 year after the end of treatment (recurrence)</P>
<P>Definitions: 1. complete clearance (absence of clinically detectable lesions in treated skin regions), 2. recurrence (for cryotherapy: recurrence of initially cleared lesions determined and expressed as percentage of participants with lesion recurrence in relation to all treated participants; for 5-fluorouracil and imiquimod: total recurrences within the cleared cancer field determined and expressed as percentage of participants with field recurrence in relation to all treated participants, new lesions considered; missing values counted as recurrence)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: global assessment by investigator and participant based on the amount of scarring, atrophy, or indurations and on pigment change within the treatment area by comparison to adjacent, untreated skin</P>
<P>Time points: at test of cure</P>
<P>Definitions: 1. excellent (treated skin was indistinguishable from normal skin), 2. good (moderate redness or change in pigmentation), 3. fair (moderate redness or change in pigmentation and slight to moderate scarring, atrophy, or induration), 4. poor (extensive scarring, atrophy, or indurations)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 11:53:36 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 15:05:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>1 week of rest period for imiquimod and 5-fluorouracil during treatment in case of acute inflammation was allowed. The data on non-recurrence at 1 year follow-up were as follows: 86% (19/22) for imiquimod, 57% (13/23) for 5-fluorouracil, and 41% (7/17) for cryotherapy.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 12:02:19 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 12:00:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Between 18 and 85 years of age</LI>
<LI>Good general health</LI>
<LI>Anatomical locations: head or neck</LI>
<LI>3 to 30 actinic keratoses, at least 3 lesions with a minimum diameter of 5 mm</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Treated with topical steroids or topical antimicrobials with 2 weeks</LI>
<LI>Tretinoin within 2 months</LI>
<LI>Systemic corticosteroids within 3 months</LI>
<LI>Systemic cancer chemotherapy within 6 months</LI>
<LI>Previous treatment with 5-fluorouracil, masoprocol, isotretinoin, or etretinate</LI>
<LI>Abnormal skin conditions that might confound interpretation</LI>
<LI>Known allergy to any of the ingredients in the study drug</LI>
<LI>Proclivity for facial skin irritation, cutaneous hyperreactivity, or both</LI>
</UL>
<P> <B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>57 randomised, 54 evaluable participants</LI>
<LI>49 men, 5 women</LI>
<LI>Age: range = 18 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-29 16:23:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 10% masoprocol applied topically twice daily for 4 weeks (N = 27 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 5% 5-fluorouracil applied topically twice daily for 4 weeks (N = 30 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 12:02:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Investigator global assessment (= global improvement indices) at week 8<BR/>2) Absolute and per cent of mean reduction in lesion counts<BR/>
</P>
<P>3) Number of events for adverse events and their severity</P>
<P>4) Percentage of participants experiencing adverse events represented graphically in function of the event severity (= minor adverse events)</P>
<P>5) Percentage of participants who discontinued treatment</P>
<P>6) Mean max pain score</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesions counting and rating, 2. qualitative assessment (global assessment)</P>
<P>Time points: at baseline; days 7, 14, 21, and 28 (the last day of treatment); at day 42 and day 56; and at 1 year and 2 years (recurrence)</P>
<P>Definitions for lesion rating: 1. mild (thin actinic keratoses, visible and palpable), 2. moderate (moderately thick actinic keratoses, easily seen and palpated), 3. severe (thick and florid actinic keratoses with distinct borders)</P>
<P>Definitions for Global assessment: 1. cured (clear of palpable lesions, slight residual erythema remaining), 2. marked improvement (majority of lesions absent and scales of remaining lesions barely palpable), 3. moderate improvement (many lesions absent and scales decreased in thickness), 4. slight improvement (some lesions cleared, some decreased in scale, but many lesions remain), 5. no change (slightly worse, more or rougher larger lesions remain), 6. much worse (significantly more lesions or majority of lesions rougher, larger, or both)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of all adverse experiences noted by participants and questioning of participants; 2. evaluation by investigator on key adverse reactions based on the appearance of the lesions, i.e. degree of erythema, necrosis, ulceration, and erosion in the lesions, and the degree of erythema and contact dermatitis in tissue surrounding and scored as 0 = none, 1 = mild, 2 = moderate, or 3 = severe; 3. intensity of the pain rated by participant on a 9-point scale ranging from 0 = no pain to 8 = severe pain</P>
<P>Time points: at each visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-23 17:34:46 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Reed &amp; Carnrick Pharmaceuticals, A Division of Block Drug Company, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 12:05:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>The numbers for per-protocol analysis were used for meta-analyses of mean reduction in lesion counts, and intention-to-treat numbers were used for meta-analysis of global improvement indices.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:02:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Lebwohl-2004">
<CHAR_METHODS MODIFIED="2012-11-06 12:06:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: September 2001</P>
<P>End date: August 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:03:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Healthy men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or bald scalp</LI>
<LI>4 to 8 actinic keratoses within a 25 cm² area</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Any condition that could be exacerbated by treatment or impair the examination area</LI>
<LI>Previous treatment with 5% imiquimod cream in the treatment area</LI>
<LI>Any known allergies to any excipients in the study cream</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 6 months with psoralen plus lN A therapy, UVB therapy, laser abrasion, dermabrasion, or chemical peel</LI>
<LI>within 4 weeks with prescribed topical retinoids, 5-fluorouracil, masoprocol, cryodestruction, chemodestruction, surgical excision, photodynamic therapy, curettage, interferon/interferon inducers, cytotoxic drugs, drugs with major organ toxicity, immunomodulators, immunosuppressive therapies, oral corticosteroids, or topical steroids anywhere on the head</LI>
</UL>
<LI>The use of moisturisers over-the-counter retinol products or products containing &#945; or &#946; hydroxy acids in the treatment area</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>436 participants</LI>
<LI>380 men, 56 women</LI>
<LI>Age: range = 37 to 88</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 17:43:24 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% imiquimod cream, once per day, twice weekly for 16 weeks or less (N = 215 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once per day, twice weekly for 16 weeks or less (N = 221 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:02:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates (all lesions) at 8 weeks post-treatment</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participant partial (<U>&gt;</U> 75% of baseline lesions) clearance rates at 8 weeks post-treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Median per cent reduction in baseline lesions at 8 weeks post-treatment</P>
<P>2) Clinical laboratory tests</P>
<P>3) Participants experiencing at least 1 adverse event</P>
<P>4) Application site reactions<BR/>5) Local skin reaction: severe erythema, flaking/scaling/dryness, scabbing/crusting</P>
<P>6) Serious adverse events</P>
<P>7) Skin quality (cosmetic)</P>
<P>8) Increase in the number of lesions during the study</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using clinical counting</P>
<P>Time points: at baseline; weeks 1, 2, 4, 6, 8, 10, 12, 16 (end of treatment), 20, and 24</P>
<P>Definitions: 1. complete clearance rate (proportion of participants at the 8-week post-treatment visit with a count of 0 clinically-visible lesions in the treatment area), 2. partial clearance rate (proportion of participants at the 8-week post-treatment visit with at least a 75% reduction in the number of lesions counted at baseline in the treatment area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. clinical laboratory tests [hematology (haemoglobin, hematocrit, reel blood cell, white blood cell, and platelet counts), serum chemistry (random glucose, blood urea nitrogen, creatinine, total bilirubin, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, lactate dehydrogenase, alkaline phosphatase, potassium, sodium, calcium, chloride, total protein, albumin, phosphorous, and cholesterol) and urine analysis for colour/appearance, specific gravity, pH, protein, glucose, and ketones and a microscopic examination]; 2. vital sign measurements and physical examinations; 3. photography; 4. recording of adverse events; 5. assessment of local skin reactions (erythema, oedema, erosion/ulceration, scabbing/crusting, weeping/exudate, vesicles, or flaking/scaling/dryness) rated by a study investigator on a scale of 0 to 3, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe; and 6. recording of concomitant medication use</P>
<P>Time points: 1. at each visit, 2. pre-study visit and end of treatment at week 16 (physical exam and laboratory tests)</P>
<P>Definitions for spontaneous participant-reported adverse events: 1. mild (participant was aware of the signs and symptoms, but the signs and symptoms were easily tolerated), 2. moderate (the signs and symptoms were sufficient to restrict, but not prevent, usual daily activity), and 3. severe (the participant was unable to perform usual daily activity)<BR/>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of skin quality by visual, clinical, and tactile examinations of the treatment area by investigator [skin surface, hyperpigmentation, hypopigmentation, mottled or irregular pigmentation (both hyperpigmentation and hypopigmentation), degree of scarring, and atrophy on a scale of 0 to 3, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe]</P>
<P>Time points: at treatment initiation and 8-week post-treatment visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 15:04:23 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals, St Paul, Minnesota.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 13:26:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>An increase in lesion counts was observed during treatment. A sample size calculation was provided. Pooled data from 2 phase III studies were presented in Aldara product insert. Long-term clinical outcomes were presented in <LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 16:03:35 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Loven-2002">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, assessor-blinded, active-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:03:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Men and postmenopausal women (or using appropriate contraception)</LI>
<LI>Anatomical locations: face, anterior bald scalp, or forehead</LI>
<LI>
<U>&gt;</U> 6 visible or palpable actinic keratoses, 2 sides within 0.5 of each other of severity scale (based on a 4-point scale with 0.5 increments)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal cell carcinoma, squamous cell carcinoma, or any confounding skin condition</LI>
<LI>Known dihydropyrimidine dehydrogenase deficiency</LI>
<LI>Activities involving excessive or prolonged exposure to sunlight</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within the last 6 months with 5-fluorouracil or systemic cancer chemotherapy</LI>
<LI>within 2 months with systemic steroids</LI>
<LI>within 1 month with topical corticosteroids, tretinoin, or other topical actinic keratosis treatment</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>21 participants</LI>
<LI>17 men, 4 women</LI>
<LI>Age: mean = 70</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 13:30:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 0.5% 5-fluorouracil on either side of face, once daily for 4 weeks. Sunscreen/moisturiser was provided when needed (N = 21 participants).</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 5% 5-fluorouracil on either side of face, twice daily for 4 weeks. Sunscreen/moisturiser was provided when needed (N = 21 participants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 13:31:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Absolute and per cent of mean reduction in lesion counts at week 8<BR/>
</P>
<P>2) Total clearance (= participant complete clearance) rates at week 8</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Facial irritation (= skin irritation)</P>
<P>2) Eye irritation (= minor adverse events)</P>
<P>3) Serious adverse events including basal cell carcinoma</P>
<P>4) Participant preference</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of palpable or visible (to the unaided eye) lesions by a designated blinded evaluator</P>
<P>Time points: during screening period and at 4 weeks post-treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. participant-reported adverse events, 2. photography and evaluation of facial irritation (erythema, edema, dryness, pain, erosion, burning, pruritus, and other signs) on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe) by the same blinded individual and recording of days of onset and resolution (adverse events that occurred on the head were included in the assessment of facial irritation.)</P>
<P>Time points: at baseline and weekly throughout the 4-week treatment (twice weekly for facial irritation) and the post-treatment periods</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 13:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 13:29:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:15:28 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-McEwan-1997">
<CHAR_METHODS MODIFIED="2012-11-06 13:34:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: September 1994</P>
<P>End date: January 1996</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:15:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Age 21 years and older</LI>
<LI>Mentally competent</LI>
<LI>Anatomical locations: face, scalp, ear, neck, lower arm/elbow, hand, lower leg/knee</LI>
<LI>
<U>&gt;</U> 1 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Systemic corticosteroids, retinoids, antineoplastic drugs or cyclosporine</LI>
<LI>Allergy to the sunscreen preparation (SunSense), diclofenac, or other NSAID</LI>
<LI>Abnormal blood counts, liver function, urea, or electrolytes</LI>
<LI>Currently or recently involved in another clinical trial</LI>
<LI>Women were required to be postmenopausal, sterilised, or taking adequate contraceptive precautions</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>130 participants</LI>
<LI>73 men, 57 women</LI>
<LI>Age: range = 48 to 87</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 13:36:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 3% diclofenac in 2.5% hyaluronic acid gel, applied to single keratosis twice daily for 8 to 24 weeks. Sunscreen was applied after morning application (N = 65 participants).</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: 2.5% hyaluronic acid gel alone, applied to single keratosis twice daily for 8 to 24 weeks. Sunscreen was applied after morning application (N = 65 participants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 13:35:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Response to treatment (including participant complete response) rates at end of treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Local adverse reactions</P>
<P>2) Serious adverse events</P>
<P>
<U>Safety</U>
</P>
<P>Methods: diary recording of any adverse effects and any change in use of concomitant medications</P>
<P>Time points: at 8, 16, and 24 weeks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 15:55:09 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Hyal Pharmaceutical Australia Ltd. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 15:23:37 +0000" MODIFIED_BY="[Empty name]">
<P>There was no follow-up period. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:48:46 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Misiewicz-1991">
<CHAR_METHODS MODIFIED="2012-11-06 13:38:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, active-controlled, intraindividual study.</P>
<P>Start date: January 1988</P>
<P>End date: June 1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 13:38:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical location: face</LI>
<LI>
<U>&gt;</U> 3 actinic keratoses on each face side</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>26 participants</LI>
<LI>17 men, 9 women</LI>
<LI>Age: range = 55 to 88</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-05 14:33:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 0.05% (0.5 g) Ro14-9706 cream (arotinoid methyl sulfone) applied to 1 side of the face twice daily (N = 26 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 0.05% tretinoin cream applied to 1 side of the face twice daily (N = 26 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Participant overall response (= global improvement indices) rates at 16 weeks</P>
<P>2) Mean per cent decrease in the number of lesions (= mean percentage of reduction in lesion counts) at 16 weeks</P>
<P>3) Clinical laboratory tests</P>
<P>4) Tolerability (erythema and scaling) scoring</P>
<P>5) Increase of lesions during treatment</P>
<P>6) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting by 2 independent investigators, 2. qualitative assessment using photography of the treated areas</P>
<P>Time points: 1. at the beginning of the study and weekly intervals (counting), 2. at baseline and after 4, 8, 12, and 16 weeks (photography)</P>
<P>Definitions: healed or completely cleared lesion (the site had been replaced by normal, smooth, hypopigmented or hyperpigmented skin, and lesion not palpable)</P>
<P>Definitions for overall response: 1. worsening (increase in the number of lesions), 2. no response (no change or less than 50% reduction in the total number of lesions), 3. partial response (reduction greater than 50%, but less than 100%, in the number of lesions), 4. complete response (total clearing of lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of local tolerability (erythema and scaling) on a scale (in case of severe reactions, therapy was interrupted until the inflammation had disappeared), 2. routine laboratory (hematologic and biochemical) tests</P>
<P>Time points: 1. weekly, 2. before and after treatment (laboratory tests)</P>
<P>Definitions for tolerability scale: 0 (none), 1 (mild, minimal), 2 (moderate, more intense), and 3 (severe, very intense erythema, and scaling with exudation)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 16:06:46 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by La Roche Ltd. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 13:40:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>Ro 14-9706 had better tolerability. An initial increase in the number of visible actinic keratoses with tretinoin was observed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:44 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Moloney-2007">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single centre, randomised, double-blind, active-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 13:44:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>White men</LI>
<LI>Anatomical location: scalp</LI>
<LI>Extensive actinic keratoses for field-directed treatment, grade 1 to 3 (pretreated with white paraffin)</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>16 men</LI>
<LI>Age: mean = 71; range = 59 to 87</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-photodynamic therapy (PDT) (N = 16 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: methyl aminolevulinate (MAL)-PDT (N = 16 participants)</P>
<P>There was a 2-week interval between the 2 treatments (right versus left scalp).</P>
<P>
<U>Characteristics of PDT intervention:</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: hyperkeratotic lesions were treated with white paraffin gel to remove any keratotic debris</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: visible layer</P>
<P>Incubation with cream: occlusive dressing over cream for 3 (MAL) or 5 (ALA) hours</P>
<P>Type of light: red light</P>
<P>Light source: Waldmann PDT lamp MSR 1200</P>
<P>Wavelength (nm): 580-740</P>
<P>Energy fluence (J/cm²): 50</P>
<P>Intensities (mW/cm²): 50</P>
<P>Exposure time: 16 minutes 40 seconds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:52:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Field complete clearance (= participant complete clearance) rates at 1 month post-treatment</P>
<P>2) Mean number of lesions at baseline and at 1 month post-treatment</P>
<P>3) Mean reduction in lesion counts at 1 month post-treatment</P>
<P>4) Minor adverse events (qualitative)</P>
<P>5) Visual analogue score (VAS) for pain</P>
<P>6) Duration of discomfort</P>
<P>7) Participant preference</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. grading of PpIX fluorescence on a scale of 1 to 3 using a Wood's light (1 = light &#8260; pale; 2 = moderate; and 3 = strong), 2. clinical response (clear, improved, or no response, and number of residual palpable lesions) assessed by an investigator not involved in safety assessment</P>
<P>Time points: 1. before treatment (fluorescence), 2. at baseline and 1 month post-treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of pain using a VAS (1 to 100 mm) (If treatment had to be discontinued because of pain, the timing of this was recorded), 2. documentation of adverse effects, and 3. assessment of erythema and erosions by 1 investigator</P>
<P>Time points: 1. at 3, 6, 12, and 16 minutes during treatment (pain), 2. 4 days after their first and second treatments (erythema and erosion)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 13:46:15 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-07-18 16:36:02 +0100" MODIFIED_BY="Maryse Paquet">
<P>ALA-PDT was more painful than MAL-PDT.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:05:49 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Moloney-2010">
<CHAR_METHODS MODIFIED="2012-11-06 18:57:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: March 2008</P>
<P>End date: Not available</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:05:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Immununocompetent adults</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face, scalp, upper limbs</LI>
<LI>
<U>&gt;</U> 4 non-hyperkeratotic actinic keratoses</LI>
<LI>Symmetrically distributed non-hyperkeratotic actinic keratoses</LI>
<LI>Grade I (palpable only) or II (visible and palpable)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Treatment for actinic keratoses within 1 month</LI>
<LI>Pregnant or lactating</LI>
<LI>Taking immunosuppressive or photosensitising medications</LI>
<LI>Taking nicotinamide or other vitamin supplements</LI>
<LI>Participants unable to attend for regular follow up</LI>
<LI>Participants with active dermatitis in the treatment areas</LI>
<LI>Grade III (thicker hyperkeratotic)</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>30 participants</LI>
<LI>26 men, 4 women</LI>
<LI>Age: mean = 74; range = 48 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-05 14:36:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 1% nicotinamide, twice daily for 6 months (information from the protocol) (N = 13 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo, twice daily for 6 months (information from the protocol) (N = 17 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 13:50:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Mean percentage of reduction in lesion counts from baseline at 3 and 6 months</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Total count for appearance of new/subclinical lesions at 3 months (protocol)</P>
<P>
<B>
<U>Other outcome of the trial</U>
</B>
</P>
<P>1) Serious adverse events including basal cell carcinoma and squamous cell carcinoma</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of lesions by a single observer and photography</P>
<P>
<U>Safety</U>
</P>
<P>Methods: reporting of all adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 17:53:26 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Cancer Council NSW, the Dermatology Research Foundation and Epiderm. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 18:10:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a pilot study. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 18:38:16 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Moriarty-1982">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, cross-over study (2-part study).</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 13:52:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Histologically-proven actinic keratoses</LI>
<LI>Anatomical locations: not specified</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>50 participants [28 had a history of skin carcinoma, 8 had previously been treated for skin keratoses, 2 had other tumours (breast, parotid), and 7 had concurrent hypertension]</LI>
<LI>36 men, 14 women</LI>
<LI>Age: mean = 71; range = 50 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 13:57:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: etretinate, 75 mg/day (25 mg tablet 3 times daily) for 2 months (N = 25 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo. 3 times daily for 2 months (N = 25 participants)</P>
<P>Then treatment changes for 2 more months (placebo group gets etretinate, and vice versa)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 13:53:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>
<U>Part 1</U>
</P>
<P>1) Complete remission (= participant complete clearance) rates</P>
<P>2) Partial remission (50% size reduction of 75% of lesions) rates</P>
<P>3) Clinical laboratory tests<BR/>
<U>Part 2 (alternate therapy given to each group)</U>
</P>
<P>1) Complete remission</P>
<P>2) Partial remission rates</P>
<P>3) Clinical laboratory tests</P>
<P>4) Minor adverse events (for the 2 phases)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using direct measurement and photography of the lesions</P>
<P>Time points: every month</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. haematological and biochemical screen, 2. measurement of plasma vitamin A</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 13:53:25 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 13:57:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>17 participants required dosage reduction due to toxicity. Response was maintained when dosage was reduced. Vitamin A type unwanted effects (dry mouth, skin rash, desquamation, etc) were observed. Only part 1 data has been included in this review. Data for intention-to-treat analysis was used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:44 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Morton-2006">
<CHAR_METHODS MODIFIED="2012-11-06 13:58:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open-label, active-controlled, intraindividual study.</P>
<P>Start date: March 2004</P>
<P>End date: April 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:05:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis of non-hyperkeratotic actinic keratosis</LI>
<LI>Men and women,</LI>
<LI>Age 18 years and older (16 years and older in Scotland)</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>
<U>&gt;</U> 3 actinic keratoses on each sides of the face and no more than 2 2-fold differences between the 2 sides</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Topical treatment within 3 months</LI>
<LI>Regular UV therapy</LI>
<LI>Thick or pigmented lesions in the target area</LI>
<LI>Porphyria</LI>
<LI>Pregnancy and no appropriate birth control</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>119 participants</LI>
<LI>108 men, 11 women</LI>
<LI>Age: mean = 75; range = 53 to 93</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic (PDT) (N = 119 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy: double freeze-thaw (16 seconds total) using liquid nitrogen spray, lesions with non-complete response were retreated at 12 weeks</P>
<P>1 (assessment at 12 weeks) or 2 treatments (assessment at 24 weeks) (N = 119 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 12 weeks</P>
<P>Preparation of lesions: gentle scraping</P>
<P>Cream concentration (%): 16%</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: AktiliteCL 128</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 8 to 10 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:06:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates of baseline lesions only at 24 weeks</P>
<P>2) Participant preference</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates of baseline lesions only at 12 weeks</P>
<P>2) Cosmetic outcomes by investigator at 12 and 24 weeks</P>
<P>3) Investigator preference</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Mean per cent reduction in lesion counts from baseline at 12 and 24 weeks</P>
<P>2) Skin-related adverse events</P>
<P>3) Skin discomfort and pain after first or second treatments on a visual analogue scale (VAS)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting [efficacy evaluations included only lesions present at baseline (i.e. lesions appearing after baseline, if any, were to be reported as adverse events)]</P>
<P>Time points: at baseline, and at weeks 12 and 24</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance)<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. immediate evaluation of skin discomfort by participant after each procedure using a VAS of 0 (no discomfort) to 10 (worst possible skin discomfort), 2. adverse events reported spontaneously by the participant or elicited following non-leading questioning (severity, duration, and need for additional therapy) (If pain was the only reaction and concomitant treatment was not needed, it was not reported as an adverse event, as it was already recorded as skin discomfort)</P>
<P>Time points: at each visit (adverse events)</P>
<P>Definitions: 1. phototoxic reaction (any observed erythema, oedema, itching, etc), 2. cryotherapy reaction (any observed blisters, infection, etc)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of the overall cosmetic outcome</P>
<P>Time points: at weeks 12 and 24</P>
<P>Definitions: 1. excellent (only slight occurrence of redness or change in pigmentation), 2. good (moderate redness or change in pigmentation), 3. fair (slight to moderate scarring, atrophy, or induration), 4. poor (extensive scarring, atrophy, or induration)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 18:15:04 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Galderma France. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:06:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>The treatments were comparable in terms of efficacy; however, participants significantly preferred MAL-PDT over cryotherapy. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:57:55 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00774787">
<CHAR_METHODS MODIFIED="2012-11-06 14:08:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, assessor-blinded, active-controlled, intraindividual study.</P>
<P>Start date: October 2008</P>
<P>End date: September 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:04:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>A clinical diagnosis of actinic keratoses</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Able to comply with all study requirements</LI>
<LI>Anatomical locations: face or balding scalp</LI>
<LI>Actinic keratoses in 2 reasonably bilaterally symmetric areas: each area with a minimum of 25 cm² and a maximum of 50 cm² each; area with at least 6 typical, non-hypertrophic target actinic keratoses with target lesion counts of +/- 1 lesion between the areas; each area that the participant can distinguish with respect to study drug application</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Uncontrolled intercurrent or chronic illness</LI>
<LI>Systemic immunocompromised due to disease or treatment</LI>
<LI>Clinically relevant systemic autoimmune disease</LI>
<LI>Pregnant or nursing</LI>
<LI>Dermatologic disease, or condition in the treatment area that may be exacerbated by imiquimod or cause difficulty with examination, or both</LI>
<LI>Participation in another clinical study</LI>
<LI>Allergies to imiquimod or any of the excipients in the cream</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the past 90 days with psoralens plus ultraviolet A therapy, ultraviolet B therapy, systemic immunomodulators (e.g. oral or parenteral corticosteroids at greater than physiologic doses, interferons, anti-TNF agents, cytokines), chemotherapeutic or cytotoxic agents, or investigational agent</LI>
<LI>within the past 30 days with surgical excision, photodynamic therapy, curettage, topical corticosteroids, laser, dermabrasion, chemical peel, imiquimod 5% cream, topical retinoids, 5-fluorouracil, masoprocol, pimecrolimus, or tacrolimus</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>27 participants</LI>
<LI>26 men, 1 women</LI>
<LI>Age: mean = 68</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-05 14:43:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: cryotherapy followed by 5% imiquimod 3 times per week for 4 weeks (N = 27 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy (N = 27 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:57:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Mean percentage of reduction in lesion counts at 4 to 8 weeks post-treatment</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Cosmetic appearance scores by participant and investigator at 4 to 8 weeks post-treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 4 to 8 weeks post-treatment (posthoc analysis)</P>
<P>2) Local skin reactions (severity scores)</P>
<P>3) Minor adverse events (pooled)</P>
<P>4) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting of all (baseline and new) actinic keratoses in each respective treatment area</P>
<P>Time points: at baseline and 4 to 8 weeks post-treatment  </P>
<P>Definitions: 1. per cent change = [(actinic keratoses count at 4 to 8 weeks post-treatment)-(actinic keratoses count at baseline)]/(actinic keratoses count at baseline)]*100%, 2. complete clearance (actinic keratosis count of 0)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. mean maximum postbaseline intensity of investigator-assessed local skin reactions (erythema, edema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, erosion/ulceration) scored as 0 = none, 1 = mild, 2 = moderate, 3 = severe per treatment area; 2. serious adverse events; 3. adverse events collected by non-systematic assessment</P>
<P>Time points: postbaseline to the end of study</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: Cosmetic appearance score based on comparison to appearance at baseline by investigator and participant</P>
<P>Time points: at 4 to 8 weeks post-treatment  </P>
<P>Definitions for 7-point scale: +3 (treatment area is much better appearing), +2 (treatment area is moderately better appearing), + 1 (treatment area is slightly better appearing), 0 (treatment area appears same), -1 (treatment area is slightly worse appearing), -2 (treatment area is moderately worse appearing), and -3 (treatment area is much worse appearing)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 14:25:33 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:25:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>Local skin reactions were reported as scores, but their values were similar between the imiquimod-treated and topical untreated sides.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:58:03 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00828568-Aldara">
<CHAR_METHODS MODIFIED="2012-11-06 14:28:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: June 2008 </P>
<P>End date: May 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:58:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Participants must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic actinic keratosis lesions within a 25 cm² contiguous treatment area</LI>
<LI>Anatomical locations: face or balding scalp</LI>
<LI>Women either must be 1-year postmenopausal, surgically sterile, or agree to use a medically-accepted form or birth control</LI>
<LI>Free of any systemic or dermatological disorder</LI>
<LI>Any skin type or race, providing the skin pigmentation will allow discernment of erythema</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)</LI>
<LI>History of cutaneous hyperreactivity or facial irritation to topical products</LI>
<LI>Engaging in activities involving excessive or prolonged exposure to sunlight</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within 6 months with systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels</LI>
<LI>within 2 months with systemic steroids; within 28 days with over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments on the treatment area</LI>
</UL>
<LI>Pregnant or nursing mothers</LI>
<LI>History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation</LI>
<LI>Taking immunosuppressant medication</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>422 participants</LI>
<LI>347 men, 75 women</LI>
<LI>Age: mean = 67</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 14:30:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod (Taro), once per day, twice weekly for 16 weeks (N = 183 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once per day, twice weekly for 16 weeks (N = 30 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 14:31:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Number of participants with 100% clearance of lesions (= participant complete clearance) at week 24</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions including irritation</P>
<P>2) Minor adverse events</P>
<P>3) Serious adverse events including squamous cell carcinoma</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting</P>
<P>Time points: at baseline and week 24</P>
<P>Definitions: the participant is 100% clear of lesions (all lesions that were identified at baseline are no longer present, and there are no new lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: reporting of adverse events and serious adverse events termed from Medical Dictionary for Regulatory Activities (MedDRA)</P>
<P>Time points: at each follow-up visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 19:11:21 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Taro Pharmaceuticals USA.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:30:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was an equivalence study and was divided into 2 studies for our review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:06:10 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00828568-Taro">
<CHAR_METHODS MODIFIED="2012-11-06 14:32:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: June 2008</P>
<P>End date: May 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:06:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Participants must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic actinic keratosis lesions within a 25 cm² contiguous treatment area</LI>
<LI>Anatomical locations: face or balding scalp</LI>
<LI>Women either must be 1 year postmenopausal, surgically sterile, or agree to use a medically accepted form or birth control</LI>
<LI>Free of any systemic or dermatological disorder</LI>
<LI>Any skin type or race, providing the skin pigmentation will allow discernment of erythema</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)</LI>
<LI>History of cutaneous hyperreactivity or facial irritation to topical products</LI>
<LI>Engaging in activities involving excessive or prolonged exposure to sunlight</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 6 months with systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels</LI>
<LI>within 2 months with systemic steroids</LI>
<LI>within 28 days with over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments on the treatment area</LI>
</UL>
<LI>Pregnant or nursing mothers</LI>
<LI>History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation</LI>
<LI>Taking immunosuppressant medication</LI>
<LI>History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation</LI>
<LI>Taking immunosuppressant medication</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>422 participants</LI>
<LI>347 men, 75 women</LI>
<LI>Age: mean = 67</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 14:40:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod (Aldara), once per day, twice weekly for 16 weeks (N = 179 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once per day, twice weekly for 16 weeks (N = 30 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 14:41:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Number of participants with 100% clearance of lesions (= participant complete clearance) at week 24</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Application site reactions including irritation</P>
<P>2) Minor adverse events</P>
<P>3) Serious adverse events including squamous cell carcinoma</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting</P>
<P>Time points: at baseline and week 24</P>
<P>Definitions: the participant is 100% clear of lesions (all lesions that were identified at baseline are no longer present, and there are no new lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: reporting of adverse events and serious adverse events termed from Medical Dictionary for Regulatory Activities (MedDRA)</P>
<P>Time points: at each follow-up visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 19:04:08 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Taro Pharmaceuticals USA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:41:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was an equivalence study and was divided into 2 studies for our review. 
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 16:05:31 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Olsen-1991">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:05:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>White men and women</LI>
<LI>General good health</LI>
<LI>Between 18 and 85 years old</LI>
<LI>Anatomical locations: head and neck</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses, at least 5 mm in diameter</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 2 weeks with topical steroids or topical antimicrobials</LI>
<LI>within 1 month with systemic steroids</LI>
<LI>within 2 months with tretinoin</LI>
<LI>within 6 months with topical 5-fluorouracil, systemic chemotherapy</LI>
</UL>
<LI>Ever used isotretinoin or etretinate</LI>
<LI>Skin cancer</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>176 participants</LI>
<LI>129 evaluable men, 25 evaluable women</LI>
<LI>Age: 18 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-07 14:07:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 10% masoprocol cream applied twice daily for 14 to 28 days (N = 131 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo applied twice daily for 14 to 28 days (N = 45 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 14:47:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>1) Investigator global assessment (global improvement indices-cured) at 1 month post-treatment</P>
<P>2) Mean reduction in lesion counts</P>
<P>3) Median percentage reduction in lesion counts between baseline and 1 month post-treatment<BR/>
</P>
<P>4) Skin irritation</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment by counting all actinic keratoses in the test area, 2. qualitative assessment (global assessment)</P>
<P>Time points: at baseline and 1 month post-treatment</P>
<P>Definitions: evaluable (participant who completed at least 14 days of therapy<BR/>and returned for the follow-up visit 1 month after the drug was stopped)</P>
<P>Definitions for global assessment: 1. cured (clear of palpable lesions, slight residual<BR/>erythema may remain), 2. marked improvement (majority of lesions absent and scales of remaining lesions are barely palpable), 3. moderate improvement (many lesions are now absent and scales have decreased in thickness), 4. slight improvement (some lesions cleared, some decreased in scale, but many lesions remain), 5. no change, 6. slightly worse (more or rougher, larger lesions, or both, remain), and 7. much worse (significantly more lesions or majority of lesions rougher, larger, or both)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: clinical assessment and participant history</P>
<P>Time points: at each visit (weekly during treatment)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 19:14:27 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Chemex Pharmaceuticals, Denver. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-18 19:26:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>Inflammatory response was not essential for therapeutic activity of masoprocol. The percentage of reduction in lesion counts did not correlate with baseline lesion severity.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:06:16 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ooi-2006">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 14:49:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Histologically-confirmed clinical diagnosis</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: scalp, extremities, or upper trunk</LI>
<LI>6 to 15 actinic keratoses suitable for biopsy</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>18 participants</LI>
<LI>15 men, 3 women</LI>
<LI>Age: mean = 68</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 14:48:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod, applied to 5 lesions, once per day 3 times per week for up to 16 weeks, biopsy of 1 lesion after 2 weeks of treatment (N = 12 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, applied to 5 lesions, once per day 3 times per week for up to 16 weeks, biopsy of 1 lesion after 2 weeks of treatment (N = 6 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:06:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Immunological outcome</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at the end of treatment</P>
<P>2) Clearance rates</P>
<P>3) Percentage lesion reduction (proportion of baseline lesions cleared at end of treatment = lesion complete response) rates</P>
<P>4) Clinical laboratory tests</P>
<P>5) Application site reactions</P>
<P>6) Local skin reactions</P>
<P>7) Minor adverse events</P>
<P>8) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at the end-of-treatment visit</P>
<P>Definitions: 1. clearance (clinical resolution of <U>&gt;</U> 50% of the 4 treated, non-biopsied lesions), 2. complete clearance rate (proportion of participants with 100% clinical clearance of treated lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. laboratory tests, 2. recording of local skin reactions and adverse events</P>
<P>Time points: pre-study and end of treatment (laboratory tests)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-23 19:01:18 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:54:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a phase I study, mainly on cutaneous immune response (biomarker changes).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 14:57:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ortonne-2010">
<CHAR_METHODS MODIFIED="2012-11-06 14:54:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: February 2006</P>
<P>End date: January 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 14:55:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: head (balding scalp or face, but not both)</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses, non-hyperkeratotic, non-hypertophic lesions within 20 cm² area</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>12 participants</LI>
<LI>Age: mean = 66</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 14:55:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% imiquimod, once per day, 3 times per week, 4 weeks on, 4 weeks off, 4 weeks on (N = 9 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: vehicle, once per day, 3 times per week, 4 weeks on, 4 weeks off, 4 weeks on (N = 3 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 14:56:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Comparison of evaluation techniques</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Histological clearance (confirmation)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Mean lesion counts at baseline and week 20 (transformed to mean reduction in lesion counts)</P>
<P>2) New/sub-clinical lesions during the study</P>
<P>3) Minor adverse events (pooled)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using clinical counting</P>
<P>Time points: at baseline and weeks 4, 8, 12, and 20</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. general physical examination, 2. recording of any adverse events</P>
<P>Time points: 1. at the start and end of the study (physical exam), 2. at each visit (adverse events)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 19:47:14 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 14:57:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a pilot study. Cross polarised light photography, fluorescence diagnostic, and clinical lesion counting were used for efficacy analysis, but only data obtained with clinical counting were used for analyses because it was the technique used in the other studies.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-06 18:38:18 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ostertag-2006">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, double-blind, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 14:58:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Histologically-confirmed clinical diagnosis</LI>
<LI>Anatomical locations: face, scalp, or both</LI>
<LI>Widespread actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Participants with age above 85 years</LI>
<LI>Life-expectation less than 3 years</LI>
<LI>Bad general health</LI>
<LI>Former total skin treatment with laser or dermabrasion</LI>
<LI>Untreated facial skin cancer</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>55 participants</LI>
<LI>50 men, 5 women</LI>
<LI>Age: mean = 72; range = 52 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-06 15:00:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: 5% 5-fluorouracil twice daily for 4 to 7 weeks followed by chlorhexidine cream (N = 27 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: Er:YAG laser resurfacing with oral prophylactic antibiotics and antivirals, Erbium mode: 7 to 28 J/cm², 10 to 12 pulses per second with 50% CO&#8322; from 2 to 4 W (N = 28 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 15:08:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Recurrence rates according to clinical evaluation at 12 months post-treatment</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Recurrence rates according to clinical evaluation at 3 and 6 months post-treatment</P>
<P>2) Recurrence rates according to histological evaluation at 3 months and at time of recurrence</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction in lesion counts at 3, 6, and 12 months post-treatment</P>
<P>2) Mean per cent lesions cleared (= mean percentage of reduction in lesion counts) at 6 and 12 months post-treatment</P>
<P>3) Skin irritation</P>
<P>4) Minor adverse events after treatment, at 3, 6, and 12 months post-treatment</P>
<P>5) Cosmetic outcome: proportion of participants with improvement of surface with actinic damage</P>
<P>6) Cosmetic outcome: proportion of participants with decrease in photoageing score</P>
<P>7) Cosmetic outcome: number of participants with changes in pigmentation or scarring</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using clinical evaluation including the number of lesions and the surface of actinic damage (0% to 25%, 25% to 50%, 50% to 75%, and 75% to 100%) performed by 2 investigators, 2. histopathological evaluation (3 months after treatment and evaluation of recurrence)</P>
<P>Time points: at baseline; at 3 days (laser only); at 1 (laser only), 2, and 4 weeks; and at 3, 6, and 12 months post-treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: evaluation of adverse effects</P>
<P>Time points: at day 3 (laser only), at weeks 1 (laser only), 2 and 4 , and at 3, 6, and 12 months post-treatment</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: photoageing score (simplified form of the Glogau score) performed by 2 investigators</P>
<P>Time points: at baseline; at day 3 (laser only); at weeks 1 (laser only), 2, and 4; and at 3, 6, and 12 months post-treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-06 15:01:09 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:02:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>There were significantly less recurrences in the laser group than 5-fluorouracil group. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:45 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Pariser-2003">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:06:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>4 to 10 previously-untreated mild (slightly palpable, better felt than seen) to moderate (moderately thick, easily felt and seen) non-pigmented actinic keratoses, at least 3 mm in diameter</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Immunosuppression for idiopathic disease-specific or therapeutic reasons</LI>
<LI>Porphyria</LI>
<LI>Pigmented actinic keratoses</LI>
<LI>Known allergy to methyl aminolevulinate (MAL) or similar photosensitising agents or excipients</LI>
<LI>Known hypersensitivity to nut products</LI>
<LI>Current or prior (within the last 30 days) participation in other clinical studies</LI>
<LI>Pregnancy; lactation; inadequate contraceptive measures during treatment and 1 month thereafter in women of child-bearing potential</LI>
<LI>Any conditions that might be associated with a risk of poor protocol compliance</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>80 participants</LI>
<LI>70 men, 10 women</LI>
<LI>Age: mean = 66</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: MAL-photodynamic therapy (PDT) (N = 42 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 38 participants)</P>
<P>
<U>Characteristics of PDT intervention:</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts and scales removed by curettage and gentle scraping</P>
<P>Cream concentration (%): 16%</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: --</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 50 to 200</P>
<P>Exposure time: 8 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:06:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at 3 months after last treatment</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 3 months after last treatment<BR/>
</P>
<P>2) Local adverse events</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events</P>
<P>5) Cosmetic outcome with MAL-PDT in completely cleared participants: physician assessment, participant assessment</P>
<P>6) Participants' satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using inspection, photography, and palpation of each lesion by the same investigator at each centre</P>
<P>Time points: at baseline and at 3 months after the second PDT</P>
<P>Definitions: complete response (complete disappearance of the lesion)<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. recording of local skin reactions, phototoxicity reactions, or both, by study-centre personnel who were not involved in evaluation of the participant, 2. adverse events reported spontaneously by the participant or elicited after non-leading questioning (severity, duration, and need for additional therapy) and rated (the clinician assessed the causal relationship of the event to the study treatment as related, uncertain, or not related)</P>
<P>Time points: at baseline, during, and immediately after PDT; at week 2; and at 3 months after the second PDT treatment<BR/>Definitions for adverse events (any unfavourable and unintended sign, symptom, or disease) rating: 1. mild (the event was transient and easily tolerated), 2. moderate (the event caused the participant discomfort and interrupted usual activities), and 3. severe (the event caused considerable interference with usual activities and may have been incapacitating or life-threatening)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of overall cosmetic outcome in participants with complete response in all lesions by both the investigator and participant using a 4-point rating scale</P>
<P>Definitions for the 4-point scale: 1. excellent (no scarring, atrophy, or induration, and no or slight occurrence of redness or change in pigmentation compared with adjacent skin), 2. good (no scarring, atrophy, or induration, but moderate redness or change in pigmentation compared with adjacent skin), 3. fair (slight to moderate occurrence of scarring, atrophy, or induration), 4. poor (extensive occurrence of scarring, atrophy, or induration)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 20:07:46 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by PhotoCure ASA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:17:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>The response rate was similar for mild and moderate lesions. Most pain and erythema was gone within 24 hours. Data for intention-to-treat analysis were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:46 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Pariser-2008">
<CHAR_METHODS MODIFIED="2012-11-06 15:17:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: January 2006</P>
<P>End date: December 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:06:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Age 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>4 to 10 lesions, untreated, unpigmented, non-hyperkeratotic, grade 1 or 2, at least 3 mm in diameter</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Immunosuppression</LI>
<LI>Porphyria</LI>
<LI>Known allergy to methyl aminolevulinate (MAL) or similar photosensitising agents or excipients</LI>
<LI>Known hypersensitivity to nut products or other known protein antigens</LI>
<LI>Current or prior (within 30 days) participation in other clinical trials</LI>
<LI>Pregnancy, lactation, inadequate contraceptive measures during treatment</LI>
<LI>Any condition associated with a risk of poor protocol compliance</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 30 days with regular UV radiation therapy, local therapy including cryotherapy and curettage</LI>
<LI>within 3 months with topical therapy including imiquimod, 5-fluorouracil, or diclofenac</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>100 participants treated and evaluated for safety, 96 randomised and evaluated for efficacy</LI>
<LI>79 men, 17 women</LI>
<LI>Age: mean = 66; range = 43 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: MAL-photodynamic therapy (PDT) (N = 49 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 47 participants)</P>
<P>
<U>Characteristics of PDT intervention:</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts and scales removed by curettage and gentle scraping</P>
<P>Cream concentration (%): 16.8%</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: Aktilite CL 128</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 8 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:06:36 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Complete participant response rates (= participant complete clearance) at 3 months post-treatment</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Complete lesion response rates (= lesion complete response) at 3 months post-treatment</P>
<P>2) Application site and local adverse reactions (in general and severe)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Serious adverse events</P>
<P>2) New lesions during the study</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: clinical assessment by inspection, palpation, and characterisation<BR/>of lesions (in accordance with <LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>) by the same blinded investigator</P>
<P>Time points: at baseline and 3 months post-treatment</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion) (non-completely responding lesions were treated at the discretion of the investigator)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: adverse events reported spontaneously or elicited by non-leading questioning (severity, localisation, duration, and need for additional treatment) (the clinician assessed the causal relationship of the event to the study treatment as related, uncertain, or not related.)</P>
<P>Time points: after lesion preparation before cream application, at the end of the 3-hour cream application and after illumination during each treatment session, and at 2 weeks and 3 months post-treatment</P>
<P>Definitions for the severity of the adverse events: 1. mild (transient and easily tolerated), 2. moderate (caused the participant's discomfort and interrupted usual activities), 3. severe (caused considerable interference with usual activities and may have been incapacitating or life-threatening)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-18 20:24:49 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by PhotoCure ASA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:31:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>Within the MAL-PDT group, complete lesion response rates were slightly higher in grade-1 than grade-2 lesions (89% vs 80%), and in lesions on the scalp than on the face (93% vs 87%). Larger lesions (diameter &gt; 20 mm) had lower complete response rates than smaller lesions (74% vs 86% to 90%). At 3 months post-treatment, 31% (15/49) of participants treated with MAL had new lesions compared to 26% (12/47) of participants treated with vehicle. A sample size calculation was provided. This study is study #1 in the Metvixia product insert 2008. The studies included in the Metvixia product insert were changed between 2004 (PhotoCure) and 2008 (Galderma), which correspond to the use of different types of light.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:47 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Perrett-2007">
<CHAR_METHODS MODIFIED="2012-11-06 15:34:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single centre, randomised, active-controlled, intraindividual study.</P>
<P>Start date: May 2004</P>
<P>End date: August 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:14:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Organ transplant recipients on chronic immunosuppressive therapy</LI>
<LI>Histologically-confirmed clinical diagnosis</LI>
<LI>Anatomical locations: forearm, hand</LI>
<LI>Several actinic keratoses with 2 equivalent areas (clinically and histologically)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>No wash-out period of 8 weeks for lesion treatments</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>3 kidney transplant recipients and 1 kidney and liver transplant recipient</LI>
<LI>Forearm (1), hand (3), Fitzpatrick skin phototype 1 or 2</LI>
<LI>3 men, 1 woman</LI>
<LI>Age; range = 49 to 71</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 4 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 5-fluorouracil twice daily for 3 weeks (N = 4 participants)</P>
<P>
<U>Characteristics of PDT intervention:</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: scales removed by curettage</P>
<P>Cream concentration (%): 16%</P>
<P>Application of cream: 1 mm thick onto area</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: Paterson PDT Omnilux</P>
<P>Wavelength (nm): 633 <U>+</U> 15</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 80</P>
<P>Exposure time: 8 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:06:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete resolution of lesional area (= participant complete clearance) rates at 1, 3, and 6 months</P>
<P>2) Overall reduction in lesional area</P>
<P>3) Local skin reactions (pooled for carcinomas in situ and actinic keratoses)</P>
<P>4) Minor adverse events (pooled for carcinomas in situ and actinic keratoses)</P>
<P>5) Cosmestic outcomes by participant and investigator (pooled for carcinomas in situ and actinic keratoses)</P>
<P>6) Treatment-associated pain score</P>
<P>7) Participant's preference</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using photographic mapping, tracing of the clinical margins of each lesional area onto transparencies and calculating the surface area by overlaying on 1 mm squared graph paper</P>
<P>Time points: before treatment, at 1, 3, and 6 months post-treatment</P>
<P>Definitions: 1. complete response (complete clinical resolution of the treated lesion), 2. partial response (at least a 30% reduction in the surface area of the lesion after treatment based upon the European Organisation for Research and Treatment of Cancer (EORTC) guidelines for the evaluation of tumour treatment response), 3. non-responders (lesions that failed to meet the criteria for partial response)<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. participants kept a record of pain and erythema using a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe); 2. documentation of other local skin reactions, such as pruritus, erosions, ulceration, crusting, skin infection, and scarring</P>
<P>Time points: daily</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: cosmetic scoring by clinician and participant</P>
<P>Time points: at the 6-month assessment</P>
<P>Definitions: 1. poor (extensive scarring, atrophy, or induration), 2. moderate (slight to moderate occurrence of scarring), 3. good (no scarring, atrophy or induration, but moderate redness or pigmentation change compared with adjacent skin), 4. excellent (no scarring, atrophy, or induration, and no or slight occurrence of redness or pigmentation change compared with adjacent skin)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 14:13:12 +0000" MODIFIED_BY="[Empty name]">
<P>The light source was provided by Omnilux.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:43:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study with immunocompromised participants included participants with actinic keratoses (N = 4) or carcinoma in situ (N = 5). Separated data were presented for efficacy but not for local skin reactions, adverse events, and cosmetic outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:48:48 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Persaud-2002">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, vehicle-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 15:44:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face, arms, legs</LI>
<LI>
<U>&gt;</U> 6 bilateral discrete, visible, palpable, or both, actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Previous treatment with 5-fluorouracil, laser resurfacing, chemical peel, or cryotherapy within 28 days</LI>
<LI>Pregnancy, lactation</LI>
<LI>Allergy to imiquimod</LI>
<LI>Any condition that may have interfered significantly with participation in the study</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>22 participants</LI>
<LI>14 evaluable men, 3 evaluable women</LI>
<LI>Age: mean = 72; range = 41 to 90</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-07 14:21:13 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% Imiquimod, 3 times per week for 8 weeks or less (clearance achieved) (N = 22 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle, 3 times per week for 8 weeks or less (clearance achieved) (N = 22 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean lesion counts (transformed to mean reduction of lesion counts) at baseline and week 16</P>
<P>2) Changes in lesion size</P>
<P>3) Participants experiencing at least 1 adverse event (pooled)</P>
<P>4) Local adverse reactions (pooled)</P>
<P>5) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting and photography (only participants who completed the 8-week course of treatment with imiquimod were assessed for changes in lesion size)</P>
<P>Time points: at baseline; at weeks 2, 4, 6, 8, and 16<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring of concomitant medications, and 2. recording of the type and severity (mild, moderate, or severe) of local adverse reactions (erythema, itching, scabbing)<BR/>
</P>
<P>Time points: at baseline; at weeks 2, 4, 6, and 8, or until total clearance of lesions</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 14:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:45:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>If needed, a rest period of 3 weeks was allowed and the dosing frequency reduced to 2 times per week.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:47 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-06 15:46:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Untreated facial and scalp actinic keratoses, slightly palpable (better felt than seen)</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>Non-hyperkeratotic actinic keratoses (maximum of 6 treatment fields)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Hyperkeratotic actinic keratoses</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>111 participants</LI>
<LI>63% (70/111) of participants had less than 4 lesions at baseline; 31% (34/111) of the enrolled participants had 4 to 10 lesions; and 6% (7/111) had more than 10 lesions at baseline</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 88 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 23 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: debridement</P>
<P>Cream concentration (%): 16.8%</P>
<P>Application of cream: onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 2.5 to 4 hours</P>
<P>Type of light: red light</P>
<P>Light source: CureLight BroadBand Model CureLight 01</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 15:54:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete responders (= participant complete clearance) rates at 3 months</P>
<P>2) Participant partial (<U>&gt;</U> 75%) clearance rates at 3 months</P>
<P>3) Lesion complete response rates at 3 months</P>
<P>4) Local adverse reactions</P>
<P>5) Cosmetic outcomes: hyperpigmentation</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at 3 months after the second treatment session</P>
<P>Definitions: 1. cleared lesion (not visible and not palpable), 2. complete responder (participant with all treated lesions cleared)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 14:43:03 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photocure ASA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:54:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>Participants with <U>&gt;</U> 4 lesions had lower success rates than those with &lt; 4 lesions<BR/>when treated with MAL-PDT. Lesions that were slightly palpable, i.e. grade 1, had a better success rate than lesions that were visible and palpable, i.e. grade 2. Local skin reactions and cosmetic outcomes from Photocure ASA Australian and US studies were combined. The studies included in the Metvixia product insert were changed between 2004 (PhotoCure) and 2008 (Galderma), which correspond to the use of different types of light.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:48 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Photocure_x002d_US-2004">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-07 14:24:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Untreated facial and scalp actinic keratoses, slightly palpable (better felt than seen)</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>Non-hyperkeratotic actinic keratoses (maximum of 6 treatment fields)</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Hyperkeratotic actinic keratoses</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>80 participants</LI>
<LI>4 to 10 non-hyperkeratotic actinic keratoses</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 42 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 38 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: debridement</P>
<P>Cream concentration (%): 16.8%</P>
<P>Application of cream: onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 2.5 to 4 hours</P>
<P>Type of light: red light</P>
<P>Light source: CureLight BroadBand Model CureLight 01</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 15:56:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Complete responders (= participant complete clearance) rates at 3 months</P>
<P>2) Participant partial (<U>&gt;</U> 75%) clearance rates at 3 months</P>
<P>3) Lesion complete response rates at 3 months</P>
<P>4) Local adverse reactions</P>
<P>5) Cosmetic outcomes: hyperpigmentation</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at 3 months after the second treatment session</P>
<P>Definitions: 1. cleared lesion (not visible and not palpable), 2. complete responder (participant with all treated lesions cleared)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 14:59:01 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photocure ASA.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 15:57:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>Lesions that were slightly palpable, i.e. grade 1, had a better success rate than lesions that were visible and palpable, i.e. grade 2. Local skin/adverse reactions and cosmetic outcomes from Photocure ASA Australian and US studies were combined. The studies included in the Metvixia product insert were changed between 2004 (PhotoCure) and 2008 (Galderma), which correspond to the use of different types of light.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:49 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Piacquadio-2004">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, assessor-blinded, vehicle-controlled, parallel group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:06:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and non-pregnant, non-lactating women (postmenopausal, surgically sterile, or using a medically-acceptable form of birth control and had a negative urine pregnancy test result)</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>4 to 15 actinic keratoses, grade 1 or 2 lesions</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>History of cutaneous photosensitisation</LI>
<LI>Porphyria</LI>
<LI>Hypersensiticity to porphyrins</LI>
<LI>Photodermatosis</LI>
<LI>Use of photosensitising drugs within a given time-frame</LI>
<LI>Very hyperkeratotic, grade 3</LI>
<LI>Treatment as follows:</LI>
<UL>
<LI>within the last 2 weeks with topical medications, such as corticosteroids, &#945; hydroxy acids, or retinoids</LI>
<LI>within 4 weeks with systemic steroid therapy</LI>
<LI>within 2 months with cryotherapy of target lesions, laser resurfacing, chemical peels, topical application of 5-fluorouracil or masoprocol; systemic treatment with chemotherapeutic agents, sporalens, immunotherapy, or retinoids</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>243 participants</LI>
<LI>203 men, 40 women</LI>
<LI>Age: range = 34 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-photodynamic therapy (PDT) (N = 181 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 62 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 8 weeks</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 14 to 18 hours</P>
<P>Type of light: blue light</P>
<P>Light source: Blu-U</P>
<P>Wavelength (nm): 417 <U>+</U> 5</P>
<P>Energy fluence (J/cm²): 10</P>
<P>Intensities (mW/cm²): 10</P>
<P>Exposure time: 1000 seconds (16 minutes)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-06 16:07:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>Assessments at 8 weeks (1 treatment) and 12 weeks (1 or 2 treatments):</P>
<P>1) Clearing of individual lesions (= lesion complete response) rates</P>
<P>2) Percentage of participants who experienced 100% clearance of all target lesions (= participant complete clearance)</P>
<P>3) Percentage of participants who experienced 75% or greater clearance of all target lesions (= participant partial clearance)</P>
<P>4) Clinical laboratory tests</P>
<P>5) Application site reactions</P>
<P>6) Local skin reactions by location, i.e. face or scalp</P>
<P>7) Treatment-related adverse events (= minor adverse events) given for ALA treatment only</P>
<P>8) Minor adverse events in general and by location, i.e. face or scalp</P>
<P>9) Serious adverse events</P>
<P>10) Changes in pigmentation reported per lesion</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: assessments performed by a blinded investigator</P>
<P>Time points: at weeks 4, 8, and 12</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. laboratory tests, 2. assessment of phototoxic effects such as erythema, edema, stinging or burning, by an unblinded investigator, 3. assessment of adverse events</P>
<P>Time points: 1. at baseline and 24 hours after initial light treatment and<BR/>at week 8 and 24 hours after retreatment (laboratory tests), 2. every visit (phototoxic effect), 3. before, during, and after treatment and at each visit during the study period (adverse events)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of changes in pigmentation by an unblinded investigator</P>
<P>Time points: at every visit<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 15:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by DUSA Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-06 16:07:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>Pooled results from 2 independent and identical phase III clinical trials also presented in the Levulan kerastick product insert. Recurrence was presented in a follow-up paper (<LINK REF="STD-Fowler-2002" TYPE="STUDY">Fowler 2002</LINK>). Data for intention-to-treat analysis were used for the meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:15:42 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Rivers-2002">
<CHAR_METHODS MODIFIED="2012-11-06 16:08:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: 1995</P>
<P>End date: 1996</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:14:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>General good health</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: forehead, central face, scalp, dorsum of hands</LI>
<LI>
<U>&gt;</U> 5 lesions in 3 treatment blocks</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women who were not sterile, not postmenopausal, or not using contraception</LI>
<LI>History or suspected hypersensitivity to any of the ingredients of the active or vehicle medication</LI>
<LI>Allergy to aspirin or other non-steroidal anti-inflammatory drugs</LI>
<LI>Dermatological condition that could affect the absorption, accumulation, metabolism, or both, of the study medication</LI>
<LI>Current treatment with a disallowed medication (masoprocol, 5-fluorouracil, etretinate, cyclosporine, retinoids, topical steroids, recent trichloroacetic acid, or glycolic acid peels)</LI>
<LI>Unwillingness to discontinue the use of cosmetics or sunscreen on the designated site</LI>
<LI>Treatment with any other investigational drug or participation in another study within the previous 60 days</LI>
<LI>Refusal to undergo a wash-out period before entry into the study</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>195 participants</LI>
<LI>142 men, 53 women</LI>
<LI>Age: range = 34 to 90</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-11 12:38:07 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: topical 3% diclofenac in 2.5% hyaluronic acid gel, twice daily for 30 days (0.5 g/treatment with 6 hours between applications) (N = 49 participants)</P>
<P>B: topical 3% diclofenac in 2.5% hyaluronic acid gel, twice daily for 60 days (0.5 g/treatment with 6 hours between applications) (N = 48 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>C: topical 2.5% hyaluronic acid gel, twice daily for 30 days (0.5 g/treatment with 6 hours between applications) (N = 49 participants)</P>
<P>D: topical 2.5% hyaluronic acid gel, twice daily for 60 days (0.5 g/treatment with 6 hours between applications) (N = 49 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:15:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Investigator global improvement indices (IGII)</P>
<P>2) Participant global improvement indices (PGII)</P>
<P>3) Number of participants with complete target lesion clearance at day 60 (target lesion number score = TLNS)<BR/>4) Number of participants with complete lesion clearance including new lesions (cumulative lesion number score = CLNS) (TLNS and CLNS transformed to participant complete clearance)</P>
<P>5) Mean numbers of target lesions at baseline and follow-up (transformed to mean reduction in lesion counts).</P>
<P>6) Total thickness score (TTS)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Clinical laboratory tests</P>
<P>2) Application site reactions</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events (including basal and squamous cell carcinoma)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using outlining and counting of lesions on a 5 cm² transparent grid, 2. TTS determined by palpation and visual assessments, 3. qualitatively assessments of overall improvements by investigator and participant (IGII and PGII), 4. severity of the lesions (mild, moderate, and severe)</P>
<P>Time points: at baseline (visit 2, day 1 of treatment) and subsequent visits</P>
<P>Definitions for TTS: R (lesion resolved completely), 0 (lesion visible, but not palpable), 1 (lesion visible and palpable), 2 (lesion raised with visible scaling), 3 (lesion hyperkeratotic and &gt; 1 mm in thickness)<BR/>Definitions for the 7-point scale for IGII and PGII: -2 (significantly worse), -1 (slightly worse), 0 (no change), 1 (slightly improved), 2 (moderately improved), 3 (significantly improved), 4 (completely improved)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. participant-recorded concomitant medications taken and side-effects experienced, 2. review of adverse events and photography, 3. clinical laboratory analyses (standard haematological, biochemical parameters, assessment of electrolytes and urinalysis), 4. serology (antidiclofenac antibodies)</P>
<P>Time points: 1. daily (participant record), 2. at each visit (adverse events review), 3. at screening and end of treatment or onset of reaction (serology)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 15:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Hyal Pharmaceutical Corporation. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:09:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>A sample size calculation was provided. Data were reported in the Solaraze gel product insert.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 16:14:09 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Seckin-2009">
<CHAR_METHODS MODIFIED="2012-11-07 16:11:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, assessor-blinded, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:13:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Between 35 and 85 years of age</LI>
<LI>Anatomical locations: face, scalp, or both</LI>
<LI>
<U>&gt;</U> 2 visible, palpable, or both, actinic keratoses with a minimum diameter of 2 mm on each half side</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnant or lactating women</LI>
<LI>Known  hypersensitivity to calcipotriol</LI>
<LI>Participants with hypercalcemia, skin disorder affecting face or scalp</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 month with topical retinoids, topical 5-fluorouracil, cryotherapy, electrocoterization, photodynamic therapy, oral and topical corticosteroids, topical imiquimod, or topical diclofenac</LI>
<LI>within 6 months with phototherapy, laser, dermabrasion, chemical peeling, or systemic retinoids</LI>
</UL>
</UL>
<UL>
<LI>Suspected basal or squamous cell carcinoma</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>9 participants</LI>
<LI>6 men, 3 women</LI>
<LI>Age: mean = 70; range = 56 to 79</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 16:13:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: calcipotriol (vitamin D), twice daily for 12 weeks on right/left side (N = 9 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: placebo twice daily for 12 weeks on right/left side (N = 9 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:14:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Mean numbers of lesions at baseline and week 12 (transformed to mean reduction in lesion counts)</P>
<P>2) Mean diameter of target lesion at baseline and week 12</P>
<P>3) Local skin reactions graded on scale</P>
<P>4) Minor adverse events at week 1 and 12</P>
<P>5) Total score for cosmetic appearance of a target lesion (1 target lesion per treatment side)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting and recording of diameters of the target lesions</P>
<P>Time points: at baseline and weeks 3, 6, 9, and 12 of therapy</P>
<P>
<U>Safety</U>
</P>
<P>Methods: side-effects, such as erythema, dryness, burning sensation, and pruritus, graded from 0 to 3 (0 = none, 1 = mild, 2 = moderate, and 3 = severe)</P>
<P>Time points: at baseline and weeks 3, 6, 9, and 12 of therapy</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: total scores of the target lesions = the sum of erythema, desquamation, and induration scored between 0 to 3</P>
<P>Time points: at baseline and weeks 3, 6, 9, and 12 of therapy</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 16:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-10-21 15:49:21 +0100" MODIFIED_BY="Maryse Paquet">
<P>Similar number of adverse events reports between to treatment and placebo were reported. Neutrogena sunscreen was used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:49 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Shaffelburg-2009">
<CHAR_METHODS MODIFIED="2012-11-07 16:14:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:02:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Healthy men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face</LI>
<LI>
<U>&gt;</U> 10 actinic keratoses</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnancy or lactation</LI>
<LI>History of photosensitive disorder (porphyries, lupus, dermatomyosis)</LI>
<LI>Known allergy to components of ALA or imiquimod</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 year with photodynamic therapy, imiquimod, 5-fluorouracil, diclofenac, or oral retinoids</LI>
<LI>within 6 months with PUVA, UVB therapy, ablative laser procedures, dermabrasion, or chemical peel</LI>
<LI>within 1 month with topical treatments of the face with retinoids, corticosteroids, or alpha hydroxyl and beta hydroxyl acids</LI>
</UL>
</UL>
<UL>
<LI>Systemic treatments with interferon inducers, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or corticosteroids</LI>
<LI>Cryotherapy, curettage, surgical excision, or chemodestruction</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>25 participants</LI>
<LI>20 men, 5 women</LI>
<LI>Age: mean = 70</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-photodynamic therapy (PDT) followed by imiquimod once per day, twice per week for 16 weeks (N = 25 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: ALA-PDT followed by vehicle once per day, twice per week for 16 weeks (N = 25 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 4 weeks</P>
<P>Preparation of lesions: microdermabrasion</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 1 hour</P>
<P>Type of light: blue light</P>
<P>Light source: Blu-U 4170</P>
<P>Wavelength (nm): (417)</P>
<P>Energy fluence (J/cm²): --</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 8 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:16:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Median and mean per cent reduction of the number of lesions at baseline and month 12 (= mean percentage of reduction in lesion counts)</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Severe local skin reactions (pooled)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Median and mean lesion counts at baseline and month 12 (converted to mean reduction of lesion counts)</P>
<P>2) Participant complete clearance rates</P>
<P>3) Treatment-related adverse events (= minor adverse events)</P>
<P>4) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting and mapping by marking their locations on clear acetate templates using permanent marker</P>
<P>Time points: at baseline and months 1, 2, 3, 4, 6, and 12 of the study</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. incidence of severe local skin reactions (erythema, edema, erosion/ulceration, scabbing/crusting, weeping/exudates, vesicles, and flaking/scaling/dryness) associated with imiquimod treatment and compare the incidence to those reported in imiquimod studies in which PDT pretreatment was not utilised, 2. assessment of local skin reactions types on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) by the investigator</P>
<P>Time points: at months 2, 3, 4, and 6</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-23 20:01:47 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals and Graceway Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 15:45:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>The data were changed for intention-to-treat (ITT) analysis for meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 16:22:12 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Siller-2009">
<CHAR_METHODS MODIFIED="2012-11-07 16:17:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: March 2005</P>
<P>End date: September 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:18:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinically diagnosis and confirmed histologically</LI>
<LI>Men and women of non-child-bearing potential</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: arms, shoulders, chest, face, scalp, or both</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses (3 to 15 mm)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Any factors with potential influence on treatment outcomes including recurrent lesions, prior or concomitant  therapy, immunosuppression, and use of topical corticosteroids</LI>
<LI>Lesions markedly hyperkeratotic or had atypical histology</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>63 randomised participants, 58 participants received treatment</LI>
<LI>White and 90% had a Fitzpatrick&#8211;Pathak skin type of I or II</LI>
<LI>52 men, 6 women</LI>
<LI>Age: mean = 66; range = 44 to 88</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 17:45:46 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 0.0025% ingenol mebutate, once per day at days 1 &amp; 2 or days 1 &amp; 8 (N = 15 participants)</P>
<P>B: 0.01% ingenol mebutate, once per day at days 1 &amp; 2 or days 1 &amp; 8 (N = 16 participants)</P>
<P>C: 0.05% ingenol mebutate, once per day at days 1 &amp; 2 or days 1 &amp; 8 (N = 15 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>D: vehicle, once per day at days 1 &amp; 2 or days 1 &amp; 8 (N = 12 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:21:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Application site reactions (pain)</P>
<P>2) Local skin responses (= local skin reactions)</P>
<P>3) Treatment-related adverse events (= minor adverse events)</P>
<P>4) Serious adverse events</P>
<P>5) Clinical laboratory tests</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 85 days (target lesions)</P>
<P>2) Lesion complete and marked clinical clearance rates at 85 days</P>
<P>3) Participant partial (&gt; 80%) clearance rates at 85 days [included in participant partial (<U>&gt;</U> 75%) clearance]</P>
<P>4) Participant histological clearance rates at 85 days</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Cosmetic outcomes: changes in pigmentation</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. clinical evaluation of each lesion by the investigator, 2. histological evaluation by a central blinded dermatopathologist based on a repeat biopsy of the lesion biopsied prior to treatment.</P>
<P>Time points: at day 85 (end of study)</P>
<P>Definitions: 1. complete clearance (no evidence of residual disease), 2. marked clearance (50% to 90% improvement), 3. slight clearance (10% to 50% improvement), 4. unchanged (10%), and 5. worsened (clinically-observable growth)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. vital signs, 2. physical examinations, 3. laboratory tests (haematology, serum chemistry, liver function tests, and urinalysis), 4. recording of local skin reactions (itching, erythema,oedema, erosion/ulceration, scabbing/crusting, weeping/exudates, vesicles, flaking/scaling/dryness) and abnormal skin proliferation (treatment was withheld if a severe local skin reaction occurred prior to the second scheduled dose)</P>
<P>Time points: 1. at each visit (vital signs), 2. at screening and final visit (day 85) (physical exam), 3. at screening, last day of treatment, and day 85 (or early exit) (laboratory tests)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: recording of hypopigmentation, hyperpigmentation and scarring</P>
<P>Time points: at day 85</P>
<P>Definitions for local skin reaction rating: 1. mild (easily tolerated), 2. moderate (associated with discomfort sufficient to interfere with usual activities), and 3. severe (incapacitating with inability to work or perform usual activities).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 16:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Peplin Ltd. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:22:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a phase IIa study. Application was done only on predetermined 5 lesions with 2 template diameters. There were 2 application regimens, i.e. days 1 &amp; 2 or days 1 &amp; 8, but no differences were detected and results were pooled together.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:50 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Smith-2003">
<CHAR_METHODS MODIFIED="2012-11-07 16:24:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:24:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>White participants</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>
<U>&gt;</U> 4 non-hyperkeratotic actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Hyperkeratotic lesions</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>36 participants</LI>
<LI>29 men, 7 women</LI>
<LI>Age: mean = 61</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-blue light photodynamic therapy (PDT) (N = 12 participants)</P>
<P>B: ALA-pulsed dye laser (PDL) PDT (N = 12 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>C: 0.5% 5-fluorouracil once or twice daily for 4 weeks (N = 12 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 4 weeks</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 1 hour</P>
<P>Type of light: blue light or pulsed dye laser</P>
<P>Light source: Blu-U Photodynamic Therapy Illuminator</P>
<P>Wavelength (nm): 595 (PDL)</P>
<P>Energy fluence (J/cm²): 7.5 (PDL)</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 1000 sec (16 min), 10 ms (PDL)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:32:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) 100% lesions cleared (= participant complete response) at 4 weeks post-treatment<BR/>2) <U>&gt;</U> 75% lesions cleared (= participant partial clearance) at 4 weeks post-treatment</P>
<P>3) Tolerability, i.e. grading of local skin reactions</P>
<P>4) Photoageing</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. grading of target lesions on a 4-point scale (from resolved to very thick, markedly keratotic, or both), 2. high magnification digital photography of lesions identified with 3 black ink dots and small adhesive label</P>
<P>Time points: at baseline and the end of treatment, 2 weeks and 4 weeks post-treatment</P>
<P>Definitions: therapeutic success (sustained clearance of 75% or more of target lesions)<BR/>
<U>Safety</U>
</P>
<P>Methods: grading of erythema, edema, crusting/erosions, and stinging/ burning</P>
<P>Time points: immediately after PDT treatments</P>
<P>Definitions for erythema score: 0 (none), 1 (minimal, scant rare erythema), 2 (mild, easily-seen erythema up to &#8531; of the treated area), 3 (moderate, easily-seen erythema involving between &#8531; to &#8532; of the treated area), 4 (severe, easily-seen erythema involving over &#8532; of the treated area)</P>
<P>Definitions for oedema score: 0 (none), 1 (minimal, scant rare oedema), 2 (mild, easily-seen oedema, minimally palpable, involving up to &#8531; of the treated area), 3 (moderate, easily-seen oedema and typically palpable involving between &#8531; to &#8532; of the treated area), 4 (severe, easily-seen oedema, indurated in some areas involving over &#8532; of the treated area)</P>
<P>Definitions for crusts and erosions score: 0 (none), 1 (rare, a few 3 mm or smaller areas), 2 (mild, up to 12 lesions 3 mm or less, areas readily seen), 3 (moderate), 4 (severe)</P>
<P>Definitions for stinging/burning score: 0 (none), 1 (minimal), 2 (moderate), 3 (severe)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. global response, 2. assessment of tactile roughness by lightly palpitating by stroking gently with the index finger and molted hyperpigmentation (including area involved, the colour intensity, and the evenness of pigment distribution)</P>
<P>Definitions for global response: 0 (complete response = complete resolution of<BR/>photodamage), 1 (almost complete response = very significant improvement in photodamage, approximately 90% improvement), 2 (marked response = significant improvement in photodamage, approximately 75% improvement), 3 (moderate response = intermediate improvement in photodamage, approximately 50% improvement), 4 (slight response = some improvement in photodamage), 5 (no response), 6 (condition worsened)<BR/>Definitions for tactile roughness grading: 0 (skin is very smooth), 1 (skin is smooth with very occasional rough area), 2 (mild roughness), 3 (moderate roughness), 4 (severe roughness)<BR/>Definitions for molted hyperpigmentation grading: 0 (evenly pigmented skin), 1 (light hyperpigmentation involving small areas), 2 (moderate hyperpigmentation involving small areas, light hyperpigmentation involving moderate areas), 3 (moderate hyperpigmentation involving moderate sized areas, light hyperpigmentation involving large areas, small areas of heavy hyperpigmentation), 4 (heavy hyperpigmentation)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 17:09:10 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by DUSA Laboratories.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-23 20:14:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>PDT treatments were better tolerated than 5-fluorouracil.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:14:10 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Solaraze-study-2">
<CHAR_METHODS MODIFIED="2012-11-07 16:33:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:14:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>No clinically-significant medical problems outside of the actinic keratosis lesions</LI>
<LI>Anatomical locations: face, scalp, forehead, arm/forearm, back of hand</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses within a 5 X 5 cm area in 1 anatomical region, up to 3 anatomical regions per participant</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>No 60-day wash-out period from disallowed medication (masoprocol, 5-fluorouracil, cyclosporine, retinoids, trichloroacetic acid/lactic acid/peel, 50% glycolic acid peel) and hyaluronic acid-containing cosmetics</LI>
<LI>Known or suspected hypersensitivity to any Solaraze® ingredient</LI>
<LI>Pregnancy</LI>
<LI>Allergies to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)</LI>
<LI>Other dermatological conditions that might affect the absorption of the study medication</LI>
<LI>Application of dermatologic products, such as sunscreens, cosmetics, and other drug products, was not permitted</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>108 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 16:34:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac in hyaluronic acid for 90 days (N = 53 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: hyaluronic acid for 90 days (N = 55 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:34:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Complete clearing of lesions (= participant complete clearance) rates at 30 days post-treatment</P>
<P>2) Application site reactions (for the 3 studies included in insert, i.e. <LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>; <LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>; <LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>) reported as incidences (i.e. number of events, not number of participants)</P>
<P>3) Minor adverse events (for the 3 studies included in insert, i.e. <LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK>; <LINK REF="STD-Solaraze-study-2" TYPE="STUDY">Solaraze study 2</LINK>; <LINK REF="STD-Wolf-2001" TYPE="STUDY">Wolf 2001</LINK>) reported as incidences (i.e. number of events, not number of participants)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 18:02:46 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Nycomed US Inc.<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-10-21 17:29:07 +0100" MODIFIED_BY="Maryse Paquet">
<P>This study was included in the product package insert as study 2. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:51 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Sotiriou-2009">
<CHAR_METHODS MODIFIED="2012-11-07 16:35:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, active-controlled, intraindividual study.</P>
<P>Start date: September 2007</P>
<P>End date: July 2008</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:35:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Anatomical locations: dorsa of hands and forearms</LI>
<LI>
<U>&gt;</U> 6 comparable non-hyperkeratotic lesions of similar severity (grade 1 or 2) on both sides (3 lesions/side)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Other dermatological diseases or conditions in the treatment or surrounding (3 cm distance) area</LI>
<LI>Topical treatments for actinic keratosis within 2 months in the area</LI>
<LI>Invasive tumours within the treated area</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>30 Participants</LI>
<LI>25 men, 5 women</LI>
<LI>Age: mean = 64; range = 49 to 79</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: aminolevulinic acid (ALA)-photodynamic therapy (PDT) (N = 30 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 5% imiquimod once per day, 3 times per week for 4 weeks on, 4 weeks off (N = 30 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 15 days</P>
<P>Preparation of lesions: crust removed by curettage</P>
<P>Cream concentration (%): 20%</P>
<P>Application of cream: onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 4 hours</P>
<P>Type of light: red light</P>
<P>Light source: Waldmann PDT 1200</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 75</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:37:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Lesion complete response rates at 1 and 6 months</P>
<P>2) Application site reactions</P>
<P>3) Local skin reactions</P>
<P>4) Investigator-assessed cosmetic outcome</P>
<P>5) Participant's preference</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting and recording of lesions by the same examiners</P>
<P>Time points: at baseline and 1 and 6 months post-treatment</P>
<P>Definitions: 1. clinical lesion response (complete response = complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion).</P>
<P>
<U>Safety</U>
</P>
<P>Methods: recording of adverse events (severity, duration, and need for additional therapy)</P>
<P>Time points: at each visit<BR/>
<U>Cosmetic</U>
</P>
<P>Methods: assessment by investigators based on the amount of scarring,<BR/>atrophy, induration, erythema, and pigment change within the treated area in comparison with adjacent, untreated skin</P>
<P>Time points: at month 6 post-treatment</P>
<P>Definitions: 1. excellent (no erythema, change in pigmentation, scarring, atrophy, or induration), 2. good (slight to moderate erythema or change in pigmentation, but no scarring, atrophy, or induration), 3. fair (slight scarring, atrophy, or induration), 4. poor (moderate to extensive scarring, atrophy, or induration)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 16:36:16 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:37:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>There was a difference in lesion complete response between treatments for grade II lesions, i.e. 57.8% for PDT and 37% for imiquimod, but not for grade I lesions (71% to 72%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:52:51 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Stockfleth-2002">
<CHAR_METHODS MODIFIED="2012-11-07 16:37:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:52:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical locations: face, scalp, forehead, dorsal forearm, neck, back of the hand</LI>
<LI>3 to 10 actinic keratoses within 20 cm²</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 4 weeks with interferon/interferon inducers, immunomodulators, immunosuppressants, cytotoxic drugs, or investigational drugs</LI>
<LI>within 2 weeks with any topical therapy for actinic keratoses lesions</LI>
</UL>
</UL>
<UL>
<LI>Having bacterial or viral infection within 2 weeks</LI>
<LI>Previously treated or currently living with a patient being treated with imiquimod</LI>
<LI>Allergic to components of the vehicle cream</LI>
<LI>Cardiovascular, hematologic, hepatic, neurologic, renal, endocrine, vascular, or gastrointestinal abnormalities or diseases</LI>
<LI>Taking immunosuppressant medication</LI>
<LI>Dependent on alcohol of drugs</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>52 participants screened, 36 enrolled</LI>
<LI>38 men, 14 women</LI>
<LI>Age: mean = 68; range = 45 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-07 14:37:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% imiquimod cream, 3 times (or less based on adverse events) per week for a maximum of 12 weeks (N = 25 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo, 3 times (or less based on adverse events) per week for a maximum of 12 weeks (N = 11 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:39:38 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates at 14 weeks.</P>
<P>2) Participant partial clearance rates</P>
<P>3) Local skin reactions (graphical representation)</P>
<P>4) Minor adverse events (graphical representation)</P>
<P>5) Recurrence</P>
<P>6) Compliance</P>
<P>7) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. clinical evaluation, 2. biopsy (histology) assessed by the same dermatopathologist</P>
<P>Time points: at baseline and week 14 after treatment initiation</P>
<P>Definitions: 1. complete clearance (complete clinical clearance confirmed histologically), 2. partial clearance (the clearance of 1 or more lesions treated with imiquimod)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. vital signs recording; 2. photography; 3. assessment and recording of local and systemic adverse or abnormal effects; 4. recording of the incidence and severity of erythema, edema, induration, vesicles, erosion, ulceration, excoriation<BR/>or flaking, and scabbing on a scale of 1 (mild) to 3 (severe)</P>
<P>Time points: at each visit (at weeks 2, 3, 6, 9, and 12)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 18:35:38 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:39:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>The recurrence rate at 1 year was 10% (2/25) for participants treated with imiquimod. A sample size calculation was based on rate of spontaneous healing of actinic keratoses lesions.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 16:44:24 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Swanson-2010a">
<CHAR_METHODS MODIFIED="2012-11-07 16:40:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: January 2008</P>
<P>End date: June 2008</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 16:42:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical assessment by the investigator</LI>
<LI>Adults in general good health with 5 to 20 visible or palpable actinic keratoses within 25 cm²</LI>
<LI>Anatomical locations: face or balding scalp</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women who were pregnant, lactating, or planning to become pregnant during the study</LI>
<LI>Participants who had had a medical event within 90 days of the first visit (such as stroke or heart attack)</LI>
<LI>Participants who had had any skin condition in the treatment area that may have been made worse by treatment with imiquimod (e.g. rosacea, psoriasis, atopic dermatitis, or eczema)</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 year with 5% imiquimod cream on the head</LI>
<LI>within 90 days, with interferon, interferon, inducers, cytotoxic drugs, immunomodulators, immunosuppressants, oral or parenteral corticosteroids, topical corticosteroids greater than 2 g/d, investigational drug or device use outside of the treatment area, dermatologic procedures or surgeries in the treatment area, and any actinic keratosis therapy in the target treatment area</LI>
<LI>within 30 days, with imiquimod outside of the head, and topical prescription drugs, and investigational drug or device use within treatment area</LI>
</UL>
</UL>
<UL>
<LI>Chemical or alcohol dependency</LI>
<LI>Allergy to imiquimod or study cream excipients.</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>479 participants</LI>
<LI>389 men, 90 women</LI>
<LI>Age: mean = 64</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-07 14:38:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 3.75% imiquimod, once daily for 2 weeks on, 2 weeks off, 2 weeks on (N = 160 participants)</P>
<P>B: 2.5% imiquimod, once daily for 2 weeks on, 2 weeks off, 2 weeks on (N = 160 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>C: placebo, once daily for 2 weeks on, 2 weeks off, 2 weeks on (N = 159 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 16:44:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates at week 14</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant partial (&gt; 75%) clearance rates at week 14</P>
<P>2) Median percentage of reduction in lesion counts</P>
<P>3) Local skin reactions</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>2) Application site reactions including irritation</P>
<P>3) Treatment-related adverse events (= minor adverse events)</P>
<P>4) Serious adverse events</P>
<P>5) Clinical laboratory tests</P>
<P>6) Investigator global integrated photodamage (IGIP-cosmetic outcome)</P>
<P>7) Number of participants with the different cosmetic outcomes</P>
<P>8) Rest periods</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by counting all of the visible or palpable lesions (baseline or new) in the treatment area by the investigator</P>
<P>Time points: at each visit</P>
<P>Definitions: 1. complete clearance rate (proportion of participants at the end-of-study visit with a count of 0 lesions in the treatment area), 2. partial clearance rates (proportion of participants with 75% or more reduction in lesion count in the treatment area at the end-of-study visit as compared with baseline), 3. per cent change (changes in lesion number at the end-of-study visit as compared with baseline)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. measurement of vital signs; 2. recording and coding (Medical Dictionary for Regulatory Activities) of adverse events; 3. investigator assessment of local skin reactions (erythema, edema, weeping/exudate, flaking/scaling/dryness, scabbing/crusting, and erosion/ulceration) graded as none, mild, moderate, or severe; 4. laboratory tests (hematology, serum chemistry, and urinalyses)</P>
<P>(treatment-emergent adverse events were summarised for each treatment group by<BR/>preferred term, intensity, and investigator assessment of relationship to study cream)</P>
<P>Time points: 1. at each visit, 2. pre-study visit and end-of-study visit (laboratory tests)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: an overall assessment (IGIP score) of the participant's photodamage change from baseline in the treatment area (including an integrated assessment of fine wrinkling, coarse wrinkling, mottled pigmentation, roughness, shallowness, skin laxity, and telangiectasias) rated on a 7-point symmetric scale, ranging from significantly improved = +3 to significantly worse = -3</P>
<P>Time points: at end-of-study visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 18:52:54 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Graceway Pharmaceuticals LLC. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:44:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>Data from 2 studies were pooled together. Temporary dosing interruptions could have been instructed by the investigator to manage local skin reactions and adverse events. A sample size calculation was provided. A follow-up study was published (<LINK REF="STD-Hanke-2011" TYPE="STUDY">Hanke 2011</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 14:54:29 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Swanson-2010b">
<CHAR_METHODS MODIFIED="2012-11-07 16:45:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>Start date: August 2008</P>
<P>End date: February 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men or women (must have been of non-child-bearing potential or provided negative serum and urine pregnancy test or been using effective contraception)</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: non-head</LI>
<LI>4 to 8 actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.</LI>
<LI>Treatment with immunomodulators or interferon/interferon inducers or systemic medications that suppress the immune system within 4 weeks</LI>
<LI>Treatment with 5-fluorouracil, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>255 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-07 14:40:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 0.05% ingenol mebutate for 2 days (N = 117 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle for 2 days (N = 118 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:48:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at day 57</P>
<P>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Participant partial (percentage criteria was not specified) clearance rates at day 57</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Median percentage reduction in lesion counts</P>
<P>2) Local skin reactions (qualitative)</P>
<P>3) Treatment-related adverse events (qualitative)</P>
<P>4) Serious adverse events</P>
<P>5) Pigmentation changes (cosmetic)</P>
<P>6) Compliance</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: on days 3, 8, 15, 29, and 57</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of the incidence rate of adverse events, serious adverse events, and local skin responses; 2. grading of local skin responses</P>
<P>Time points: on days 3, 8, 15, 29, and 57</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of pigmentation and scarring</P>
<P>Time points: on days 3, 8, 15, 29, and 57</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-23 20:31:28 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Peplin Ltd.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 16:46:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study report was a conference abstract and was included in the following study awaiting classification <LINK REF="STD-Lebwohl-2012" TYPE="STUDY">Lebwohl 2012</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:52 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2002">
<CHAR_METHODS MODIFIED="2012-11-07 22:07:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open, active-controlled, parallel-group study.</P>
<P>Start date: April 1999</P>
<P>End date: November 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:11:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men or women</LI>
<LI>Age 18 years and older</LI>
<LI>Anatomical locations: face, scalp, other</LI>
<LI>
<U>&lt;</U> 10 actinic keratoses, suitable to cryotherapy</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>No treatment for last 4 weeks</LI>
<LI>Participants receiving regular UV therapy</LI>
<LI>Participants with pigmented lesions</LI>
<LI>Porphyria</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>202 participants</LI>
<LI>124 men, 78 women</LI>
<LI>Face (61% to 65%), scalp (26% to 30%), other (8.9% to 8.0%)</LI>
<LI>Age: range = 42 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) (N = 102 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy: prior skin preparation, variable liquid nitrogen spray unit, 1 to 2 mm rim of frozen tissue beyond marked outline, 2 freeze-thaw cycles in the same session; mean freeze time of 24 <U>+</U> 18 seconds, (N = 100 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: once for face and scalp, twice for others (8% of lesions)</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts removed by curettage</P>
<P>Cream concentration (%): 16%</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: --</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 70 to 200</P>
<P>Exposure time: 10 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:07:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 3 months post-treatment</P>
<P>2) Skin irritation</P>
<P>3) Local adverse reactions</P>
<P>4) Investigator's and participant's cosmetic outcomes in participants with &gt; 75% reduction of total lesions: number of participants (excellent and good pooled together)</P>
<P>5) Participants' satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Time points: at 3 months after the initial treatment</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: recording of adverse events (including the local phototoxicity due to PDT)</P>
<P>Time points: before and after illumination, after 2 weeks by telephone contact, and after a final examination 3 months post-treatment</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment and grading of overall cosmetic outcome</P>
<P>Time points: at 3 months after the initial treatment</P>
<P>Definitions: 1. excellent (only slight occurrence of redness or change in pigmentation), 2. good (moderate redness or change in pigmentation), 3. fair (slight to moderate scarring, atrophy, or induration), and 4. poor (extensive scarring, atrophy, or induration)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 19:30:11 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photocure ASA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:12:49 +0000" MODIFIED_BY="[Empty name]">
<P>Higher response rates were obtained with thin lesions. High participant satisfaction was obtained with MAL-PDT. 43% of participants treated with MAL-PDT reported local adverse events compared to 26% treated with placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:45:08 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2004">
<CHAR_METHODS MODIFIED="2012-11-07 22:13:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, vehicle-controlled, parallel group study.</P>
<P>Start date: January 2002</P>
<P>End date: March 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-13 10:45:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Anatomical locations: face or (not and) bald scalp</LI>
<LI>5 to 9 actinic keratoses</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Any condition in the treatment area that could be exacerbated by treatment with imiquimod 5% cream or that would impair the examination of the treatment area</LI>
<LI>Any known allergies to any excipients in the study cream</LI>
<LI>No prior treatment with imiquimod 5% or topical steroids in the treatment area</LI>
<LI>No prior treatment with corticosteroids causing suppression of the hypothalamic adrenal pituitary axis, suppression of the nuclear factor kappa B, or induction of IL-12, and other cytokines that result in activation of a Th1-immune response with imiquimod</LI>
<LI>No prior treatment with the following:</LI>
<UL>
<LI>within 6 months with psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, or chemical peel</LI>
<LI>within 4 weeks with prescribed topical retinoids, 5-fluorouracil, masoprocol, cryodestruction, chemodestruction, surgical excision, photodynamic therapy, curettage, IFN/IFN inducers, cytotoxic drugs, drugs with major organ toxicity, immunomodulators, or immunosuppressive therapies</LI>
</UL>
<LI>Excluded treatments were also prohibited during study participation; exceptions to this criteria included surgical excision, cryodestruction, and curettage (all allowed on areas other than the head), and steroids (topical and inhaled steroids were allowed with restrictions). The use of moisturisers, over-the-counter retinol products, or products containing alpha- or beta-hydroxy acids in thetreatment area was prohibited</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>286 participants</LI>
<LI>248 men, 38 women</LI>
<LI>Age: range = 44 to 94</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 22:14:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: imiquimod 5% cream, once per day, 3 days per week for 16 weeks or less (N = 147 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle, once per day, 3 days per week for 16 weeks or less (N = 139 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-13 10:41:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates at 8 weeks post-treatment</P>
<P>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates at 8 weeks post-treatment</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Histological clearance at 8 weeks post-treatment</P>
<P>2) Clinical laboratory tests</P>
<P>3) Application site reactions (including irritation)<BR/>4) Local skin reactions</P>
<P>5) Minor adverse events</P>
<P>6) Serious adverse events</P>
<P>7) Skin quality (cosmetic)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using clinical counting and recording the number lesions present in the treatment area, 2. by the histologic result from the biopsy specimen of a predefined lesion biopsy site<BR/>
</P>
<P>Time points: 1. at weeks 1, 2, 4, 8, 12, 16 (end of treatment), and 24 (8 weeks post-treatment); 2. at the 8-week post-treatment visit (biopsy)</P>
<P>Definitions: 1. complete clearance rate (proportion of participants at the 8-week post-treatment visit with no evidence of lesion on the histology result of the post-treatment target lesion biopsy site and no clinically-visible lesions in the remainder of the treatment area), 2. partial clearance rate (proportion of participants at the 8-week post-treatment visit with at least 75% reduction in the number of lesions counted at baseline in the treatment area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. photography of the treatment area; 2. reviewing adverse events and local skin reactions (erythema, edema, erosion/ulceration, scabbing/crusting, weeping/exudate, vesicles, or flaking/scaling/dryness) rated on a scale of 0 (none) to 3 (severe) and concomitant medication use; 3. clinical laboratory tests (hematology, serum chemistry, urinalyses, and pregnancy test)</P>
<P>Time points: 1. at weeks 1, 2, 4, 8, 12, 16 (end of treatment), and 24 (8 weeks post-treatment), 2. pre-study and end-of-study visits (laboratory tests)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: visual, clinical, and tactile examinations of skin quality within the treatment area by investigator [skin surface (roughness/dryness/scaliness), hyperpigmentation, hypopigmentation, mottled or irregular pigmentation (both hyperpigmentation<BR/>and hypopigmentation), degree of scarring, and atrophy] on a scale of 0 (none) to 3 (severe)</P>
<P>Time points: at the treatment initiation and 8-week post-treatment visits</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 19:46:34 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:15:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a phase III study. A high rate of agreement was observed between clinical and histologic lesion clearances. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:07:25 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2008">
<CHAR_METHODS MODIFIED="2012-11-07 22:20:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:07:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or balding scalp</LI>
<LI>4 to 8 non-hypertrophic, non-hyperkeratotic actinic keratoses within 25 cm² area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Dermatological condition in the treatment area that might be exacerbated by treatment or impair</LI>
<LI>Allergy to resiquimod or gel excipients</LI>
<LI>Previous imiquimod usage in the treatment area</LI>
<LI>Unstable medical condition</LI>
<LI>Pregnancy, lactation</LI>
<LI>Enrolled in another clinical study</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 6 months with chemotherapy, radiation therapy, systemic retinoids, UVB, topical retinoids, or psoralens with UVA</LI>
<LI>within 2 months with diclofenac, photodynamic treatment, or 5-fluorouracil</LI>
<LI>within 6 weeks with dermabrasion or chemical peel</LI>
<LI>within 4 weeks with immunomodulatory treatment, cytotoxic, investigational, systemic corticosteroids, laser treatment, cryotherapy, surgery or topical corticosteroids</LI>
<LI>within 2 weeks with high-dose vitamin A (&gt; 15000 units/day)</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>132 participants</LI>
<LI>109 men, 23 women</LI>
<LI>Age: mean = 70</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 17:46:29 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 0.03% resiquimod, once per day, 3 days per week, 4 week on, 8 weeks off, 1or 2 courses (N = 31 participants)</P>
<P>B: 0.06% resiquimod, once per day, 3 days per week, 4 week on, 8 weeks off, 1or 2 courses (N = 32 participants)</P>
<P>C: 0.1% resiquimod, once per day, 3 days per week, 4 week on, 8 weeks off, 1or 2 courses (N = 34 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>D: 0.01 % resiquimod, once per day, 3 days per week, 4 week on, 8 weeks off, 1or 2 courses (N = 35 participants)</P>
<P>The gel application was done using a dosing paper template.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:27:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates after 1 to 2 treatment courses (week 24)</P>
<P>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Participant partial (&gt; 75%) clearance rates after 1 to 2 treatment courses</P>
<P>2) Participant complete clearance rates after 1 course only (week 12) .</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Application site reactions</P>
<P>2) Severe local skin reactions</P>
<P>3) Treatment-related adverse events (minor adverse events)</P>
<P>4) Serious adverse events</P>
<P>5) Clinical laboratory tests</P>
<P>6) Compliance</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting and mapping with a transparent plastic template by a qualified dermatologist</P>
<P>Time points: at baseline; weeks 2, 4, 8, and 12 for course 1, and if applicable, at weeks 14, 16, 20, and 24 for course 2</P>
<P>Definitions: 1. overall complete clearance rate (proportion of participants at the end of course 1 (week 12) or course 2 (week 24) with no lesions in the treatment area), 2. partial clearance rate (proportion of participants at their last study visit with at least 75% reduction in the number of lesions in the treatment area)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of adverse events, 2. assessment of local skin reactions (erythema, oedema, erosion &#8260;ulceration, weeping &#8260;exudate, flaking &#8260;scaling &#8260;dryness, and scabbing &#8260;crusting), 3. photographs of treatment area, 4. laboratory tests (haematology, biochemistry, urine analysis, and where applicable, pregnancy tests), 5. vital signs measurements and physical examination, and if appropriate, skin cultures (suspected infection) or skin biopsy (lesion suspicious for malignancy)</P>
<P>Time points: at weeks 2, 4, 8, and 12 for course 1, and if applicable, at weeks 14, 16, 20, and 24 for course 2<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 20:14:52 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:28:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a phase II study. Serious adverse events and local skin reactions were more frequent with higher doses, and there was lowest compliance in the 0.1% group. A sample size calculation was provided. Intention-to-treat data were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:52 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2009">
<CHAR_METHODS MODIFIED="2012-11-07 22:30:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: March 2006</P>
<P>End date: January 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:07:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>4 to 10 previously untreated actinic keratoses, non-pigmented, non-hyperkeratotic, grade 1 or 2, <U>&gt;</U> 3 mm in diameter</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Immunosuppression for idiopathic, disease-specific or therapeutic reasons</LI>
<LI>Porphyria</LI>
<LI>Pigmented actinic keratoses</LI>
<LI>Known allergy to methyl aminolevulinate (MAL) or similar photosensitising agents or excipients</LI>
<LI>Known hypersensitivity to nut products</LI>
<LI>Current or prior (within the last 30 days) participation in other clinical studies</LI>
<LI>Pregnancy, lactation</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 30 days with regular UV radiation therapy or treatment of the face or scalp with local therapy (including cryotherapy and curettage)</LI>
<LI>within 3 months with topical therapy (including imiquimod, 5-fluorouraccil, and diclofenac)</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>115 participants</LI>
<LI>91 men, 24 women</LI>
<LI>Age: range = 41 to 90</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: MAL-photodynamic therapy (PDT) (N = 57 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 58 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts and scales removed by curettage</P>
<P>Cream concentration (%): 16%</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light LED</P>
<P>Light source: Aktilite CL 128</P>
<P>Wavelength (nm): 630</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): 56 to 83</P>
<P>Exposure time: 9 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:07:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete response (= participant complete clearance) rates at 3 months after last treatment</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rates at 3 months post-treatment</P>
<P>2) Treatment site reactions (= application site reactions) reported by events (i.e. not per participants)</P>
<P>3) Local skin reactions (in general and severe)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least one adverse event</P>
<P>2) Treatment-related adverse events (= minor adverse events) reported by events (i.e. not per participants)</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events including squamous cell carcinoma</P>
<P>5) Percentage of participants with new lesions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using inspection, palpation, and characterisation of lesions (<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>) by the same investigator, who was not involved in the treatment procedure, 2. documentation of any lesions not present at baseline (lesions with a non-complete response were treated at the discretion of the investigator)</P>
<P>Time points: at baseline and 3 months post-treatment</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion), 3. participant complete response (all participants in whom 100% of lesions had responded completely 3 months post-treatment)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of tolerability, 2. recording of adverse events (severity, localisation, duration, and need for additional treatment) (the clinician assessed the causal relationship of the event to the study treatment as related, uncertain, or not related)</P>
<P>Time points: after lesion preparation before cream application, at the end of the 3-hour cream application, after illumination during each treatment session, and at 2 weeks and 3 months post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-21 20:29:45 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Photocure ASA. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:33:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>A sample size calculation was provided. This study was study #2 in the Metvixia product insert 2008. The studies included in the Metvixia product insert were changed between 2004 (PhotoCure) and 2008 (Galderma), which correspond to the use of different types of light.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:53 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2010b">
<CHAR_METHODS MODIFIED="2012-11-07 22:35:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:37:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>White men and women</LI>
<LI>Between 18 and 85 years of age</LI>
<LI>Anatomical locations: face, bald scalp, or both</LI>
<LI>4 to 8 actinic keratoses, mild to moderate lesions, 0.5 to 1.5 cm in diameter, with a minimum of 1.0 cm interlesional distance</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>All clinical conditions that could influence the study aims and intolerance to any ingredient of BF-200 aminolevulinic acid (ALA)</LI>
<LI>Known hypersensitivity to ALA</LI>
<LI>Immunosuppressive therapy</LI>
<LI>Porphyria</LI>
<LI>Hypersensitivity to porphyrins</LI>
<LI>Participants receiving hypericin or systemically acting drugs with phototoxic or photoallergic potential</LI>
<LI>Participants showing cornu cutaneum-like alterations (cutaneous horns) of the skin in the target area</LI>
<LI>Dermatoses</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 12 weeks with topical treatments within the treatment area</LI>
<LI>within 8 weeks with substances with phototoxic or photoallergic potential</LI>
<LI>within 1 to 6 months with systemic treatments considered to have a possible impact on the outcome, e.g. cytotoxic drugs</LI>
</UL>
</UL>
<UL>
<LI>Use of other treatment for actinic keratoses during the study</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>122 participants</LI>
<LI>105 men, 17 women</LI>
<LI>Age: mean = 71; range = 57 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: ALA-photodynamic therapy (PDT) (N = 81 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo-PDT (N = 41 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 12 weeks</P>
<P>Preparation of lesions: crusts removed by curettage, roughening, and alcohol wiping</P>
<P>Cream concentration (%): BF-200 gel</P>
<P>Application of cream: air dry for 10 min</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: Aktilite CL 128 or PhotoDyn 750</P>
<P>Wavelength (nm): 590-670 (Aktilite), 595-1400 (PhotoDyn)</P>
<P>Energy fluence (J/cm²): 37 (Aktilite), 170 (PhotoDyn)</P>
<P>Intensities (mW/cm²): 50-70 (Aktilite), 196 (PhotoDyn)</P>
<P>Exposure time: 15 minutes (PhotoDyn)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:39:52 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance at 12 and 24 weeks</P>
<P>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Lesion complete response at 12 and 24 weeks</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Local skin reactions for first and second treatment by light sources and in general</P>
<P>2) Cosmetic outcomes: general</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment of lesion clearance by visual inspection and by palpation by an investigator not involved in treatment and safety evaluation, 2. histological assessment using biopsy of a lesion defined and marked before the PDT treatment</P>
<P>Time points: 1. at baseline; 3, and 12 weeks post-treatment, 2. end-of-study visit (biopsy)</P>
<P>Definitions: participant complete clearance (all lesions were considered to be cleared both by the clinical and histological assessment)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of adverse effects, 2. documentation of local adverse reactions (pain, itching, burning, erythema, oedema, and induration) at the application site and rated as mild, moderate, and severe by the assessing physician or reporting participants, 3. serious adverse events</P>
<P>Time points: 1. at 1 week after PDT (by phone) and 3 weeks, 2. during and after PDT (local adverse reactions)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. general cosmetic outcome assessed by the investigator as very good, good, unsatisfactory, and impaired; 2. assessment of skin quality</P>
<P>Time points: at 12 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 13:40:08 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Biofrontera Bioscience GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:40:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>Pain, itching, and burning were reported separately for 1<SUP>st</SUP> and 2<SUP>nd</SUP> treatment, anatomical area, and light sources. In general, more symptoms were reported for Aktilite CL128 than PhotoDyn 750. A sample size calculation was provided. Data with intention-to-treat analyses were used for meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 22:44:07 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Tan-2007">
<CHAR_METHODS MODIFIED="2012-11-07 22:41:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, parallel-group study (part 1).</P>
<P>Start date: April 2005</P>
<P>End date: December 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:42:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>
<U>&gt;</U> 4 discreet actinic keratoses in an area <U>&lt;</U> 50 cm²</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Known hypersensitivity to imiquimod cream</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 5 months with imiquimod in the same area</LI>
<LI>within 4 weeks with cryosurgery in the same area</LI>
<LI>within 4 weeks with cytotoxic drugs or investigational drugs</LI>
<LI>within 2 weeks with bacterial or viral infection</LI>
</UL>
</UL>
<UL>
<LI>previous treatment with interferon or interferon inducers, immunomodulators, immunosuppressants</LI>
<LI>Pregnancy or lactating</LI>
<LI>Concomitant medical conditions that in the investigator's opinion may confounded clinical evaluations</LI>
<LI>Unwillingness to comply with photoprotection throughout the study duration</LI>
<LI>Presence of basal or squamous cell carcinomas in treatment area</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>65 participants</LI>
<LI>57 men, 8 women</LI>
<LI>Age: Imiquimod group: mean = 71.0, Vehicle group = mean 69.4</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 22:42:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>Part 1:</P>
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: cryotherapy: 3 to 5 second freeze cycle followed (2 weeks after) by 5% imiquimod cream applied twice weekly for 8 weeks (N = 33 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy: 3 to 5 second freeze cycle followed (2 weeks after) by vehicle cream for 8 weeks (N = 32 participants)</P>
<P>Part 2:</P>
<P>Participants with residual actinic keratosis lesions were offered cryotherapy and open-label imiquimod twice weekly for 8 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:43:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial (protocol)</B>
</U>
</P>
<P>1) Recurrence rate</P>
<P>2) Time to recurrence of lesions<BR/>
</P>
<P>
<U>
<B>Secondary outcomes of the trial (protocol)</B>
</U>
</P>
<P>1) Time to reach treatment success</P>
<P>2) Proportion of participants completely clear [= participant complete clearance rates for target, subclinical and total lesions at week 22 (i.e. part 1 only)]</P>
<P>3) Participant improvement assessment</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Clearance rates of target lesion (= lesion complete response)</P>
<P>2) Skin irritation</P>
<P>3) Treatment-related adverse events (= minor adverse events)</P>
<P>4) Serious adverse events</P>
<P>5) New actinic keratoses (subclinical) during the study</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion mapping on a transparent overlay map</P>
<P>Time points: at baseline, at week 22 after cryotherapy (end of part 1)</P>
<P>Definitions: 1. target lesions (those within a designated 50 cm² treatment field established at baseline), 2. subclinical lesions (those within the designated treatment field unapparent at baseline), 3. total lesions (the sum of target and subclinical lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: monitoring of the frequency and duration of adverse events (local and systemic)</P>
<P>Time points: at every study visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 14:15:04 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:44:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>An increase in subclinical actinic keratoses was observed within the first 3 weeks of imiquimod treatment with a subsequent progressive reduction there after, but this was not observed with vehicle. This was a 2-part study: part 1, included in the meta-analyses, is randomised, double-blind, and controlled, but part 2 is an optional open study not included in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 22:47:00 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Tanghetti-2007">
<CHAR_METHODS MODIFIED="2012-11-07 22:44:36 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, assessor-blinded, active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:45:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 21 years and older</LI>
<LI>Anatomical locations: face, forehead or scalp</LI>
<LI>
<U>&gt;</U> 4 actinic keratoses within 25 cm²area</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 month with investigational product, liquid nitrogen,</LI>
<LI>within 2 months with ALA, systemic or topical chemotherapy, systemic, or topical immunotherapy, systemic or topical steroids,  oral or topical retinoids diclofenac, topical 5-fluorouracil, or any other treatment that could affect actinic keratoses</LI>
<LI>within 6 month with facial resurfacing</LI>
</UL>
</UL>
<UL>
<LI>Pregnancy, lactation, of child-bearing potential</LI>
<LI>Immunosuppressed</LI>
<LI>Scheduled elective surgery within 30 days</LI>
<LI>Clinical laboratory value outside the normal range</LI>
<LI>Any organic or psychological disease that could interfere with interpretation</LI>
<LI>Active herpes infection in the 30 days preceding study entry</LI>
<LI>Unwillingness to stop using topical products on the affected area or make-up for the assessment visits</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>39 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 22:45:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% 5-fluorouracil twice daily for 2 to 4 weeks (N = 20 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 5% imiquimod twice weekly for 16 weeks (N = 19 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:47:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Physician global assessment as scores (presented in a graph)</P>
<P>2) Lesion counts at baseline, during and after treatment (= lesion complete response)</P>
<P>3) Participant complete and partial (&gt; 66%) clearance</P>
<P>4) Mean percentage of reduction in lesion counts</P>
<P>5) Physician's grading of erythema (scores represented in a graph)</P>
<P>6) Local skin reactions (qualitative)</P>
<P>7) Participant's perception of efficacy</P>
<P>8) New/subclinical lesions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting, 2. qualitative assessment using physician's global assessment and participant's perception of efficacy</P>
<P>Time points: at baseline and weeks 4, 8, 12, 16, and 24</P>
<P>Definitions for physician's global assessment and the participant's perception of efficacy scales: 1 (very effective), 2 (moderately effective), 3 (slightly effective), 4 (not effective at all)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. physician's assessment of erythema on a 0 = none to 3 = severe scale, 2. participant perception of discomfort associated with the treatment.</P>
<P>Time points: at baseline and weeks 4, 8, 12, 16, and 24</P>
<P>Definitions for participant's perception of discomfort scale: 1 (very painful), 2 (moderately painful), 3 (slightly painful), 4 (not painful at all)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 14:36:23 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Valeant Pharmaceuticals International.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-24 14:06:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>Treatment with 5-fluorouracil, but not imiquimod, uncovered and treated subclinical lesions. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Tarstedt-2005">
<CHAR_METHODS MODIFIED="2012-11-07 22:47:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, open, active-controlled, parallel-group study.</P>
<P>Start date: January 2002</P>
<P>End date: October 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:49:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>
<U>&lt;</U> 10 mild (grade 1: slightly palpable, better felt than seen, i.e. thin lesions) or moderate (grade 2: easily palpable lesions) actinic keratoses</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>211 participants (413 lesions): 105 - single treatment, 106 - 2 treatments</LI>
<LI>82 men, 129 women</LI>
<LI>Age: mean = 68</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-photodynamic therapy (PDT) once (N = 105 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: MAL-PDT twice with a 1 week interval (N = 106 participants)</P>
<P>There was possible retreatment for single treatment group (not included in meta-analysis).</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 1 week</P>
<P>Preparation of lesions: crusts removed by curettage and gentle scrapping</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: 1 mm thick onto lesion and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: Aktilite CL 16</P>
<P>Wavelength (nm): 590-670</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): 750 to 2050</P>
<P>Exposure time: 8 min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:50:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Lesion complete response at 3 months post-treatment</P>
<P>2) Participant complete response (= participant complete clearance)</P>
<P>3) Participants experiencing at least 1 adverse event</P>
<P>4) Local adverse events</P>
<P>5) Lesion cosmetic outcomes</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: assessment by investigator</P>
<P>Time points: at 3 months post-treatment</P>
<P>Definitions: 1. lesion complete response (complete disappearance of the lesion), 2. lesion non-complete response (incomplete disappearance of the lesion)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: recording of adverse events, including local phototoxicity reactions that normally occur after PDT, and rating as mild, moderate, or severe (the clinician assessed the causal relationship of any adverse events to the study treatment as related, uncertain, or not related)</P>
<P>Time points: before and after illumination, and at 3 months post- treatment</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of hypopigmentation, hyperpigmentation, scar formation, and tissue defect by their rating as none, slight, or obvious for each lesion that had responded completely</P>
<P>Time points: at 3 months post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 14:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by PhotoCure ASA.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 22:50:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>A sample size calculation was provided. Data for intention-to-treat analysis were used for the meta-analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 22:51:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Thompson-1993">
<CHAR_METHODS MODIFIED="2012-11-07 22:50:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single -centre, randomised, placebo-controlled, parallel-group study.</P>
<P>Start date: September 1991</P>
<P>End date: March 1992</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:51:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis during a by-invitation free skin-cancer screening and histological diagnosis on a randomised subsample of participants</LI>
<LI>Living in Maryborough and surrounding districts in the state of Victoria, Australia</LI>
<LI>Aged 40 years and older</LI>
<LI>Anatomical locations: head, neck, forearms, and hands</LI>
<LI>1 to 30 solar keratoses</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Any lesion treated by a doctor during the course of the study was excluded from analysis</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>588 white participants randomised, 431 evaluable participants</LI>
<LI>180 men, 251 women</LI>
<LI>Age: mean = 63; range = 40 to 93</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-08 10:07:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: sunscreen SPF 17 (8% 2-ethyl-hexyl p-methoxycinnamate/2% 4-tert-butyl-4-methoxy-4-dibenzoylmethane), as needed daily for 7 months (N = 221 evaluable participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo, as needed daily for 7 months (N = 210 evaluable participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:51:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Mean reduction/increase in lesion counts at 7 months (= mean reduction in lesion counts)</P>
<P>2) New lesions</P>
<P>3) Number and per cent of baseline lesion remitting (= lesion complete response)</P>
<P>4) Compliance</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using recording of lesions</P>
<P>Time points: at baseline and 7 months (end of the trial)</P>
<P>Definitions: incident lesions (the number of new lesions appearing during the study)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: recording of any untoward reactions to the creams</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 22:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by grants from the Victorian Health Promotion Foundation, Melbourne; the Skin and Cancer Foundation, Sydney; the Skin and Psoriasis Foundation, Melbourne; the Uoyd Williams Trust, Maryborough; the Sydney Melanoma<BR/>Foundation; and the Australasian College of Dermatologists.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-22 15:02:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>A sex-based difference in the change in the number of lesions was noted.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 22:54:29 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Tong-1996">
<CHAR_METHODS MODIFIED="2012-11-07 22:52:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 22:54:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Anatomical locations: arms</LI>
<LI>10 to 50 actinic keratoses on each arm</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Oral steroids</LI>
<LI>Immunosuppressive therapy</LI>
<LI>Previously treated with liquid nitrogen or 5-fluorouracil within 30 days</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>20 participants</LI>
<LI>wWhite participants with skin phototype 1</LI>
<LI>11 men, 9 women</LI>
<LI>Age: mean = 69; range = 52 to 93</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-08 10:08:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: &#946;-1,3-D-glucan, twice daily for 7 days (N = 20 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo, twice daily for 7 days (N = 20 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 22:54:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Mean lesion counts (converted to mean reduction of lesion counts)</P>
<P>2) Tolerability (= local skin/adverse reactions)</P>
<P>3) Minor adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion counting by the same investigator</P>
<P>Time points: at baseline, and weeks 1, 4, and 8</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. grading of erythema and burning/stinging as absent, mild, moderate, or severe, 2. participant-reported adverse events and concomitant medication use</P>
<P>Time points: at baseline and weeks 1, 4, and 8</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 22:52:51 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-22 15:22:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a pilot study. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:52:57 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ulrich-2007">
<CHAR_METHODS MODIFIED="2012-11-07 22:54:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: November 2002</P>
<P>End date: September 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:52:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>HIstological confirmation of actinic keratosis</LI>
<LI>participants with 1 of 3 organ transplant types (kidney, liver, heart) more than 3 years prior to inclusion into the study, with stable status of the transplanted graft in the 12 months prior to entering the study</LI>
<LI>Immunosuppressive therapy must have been stable within the previous 6 months before enrolment, with an expectation that the therapy would remain stable for 7 months of study participation</LI>
<LI>Anatomical locations: face, forehead, or balding scalp</LI>
<LI>4 to 10 clinically typical actinic keratoses within a continuous 100 cm² area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Unstable cardiovascular, immunological, haematological, hepatic, neurological, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or disease</LI>
<LI>Persistent hepatitis B, C infections, or both</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 3 days with steroids</LI>
<LI>within 6 months with any systemic cancer chemotherapy or radiation therapy</LI>
<LI>within 4 weeks with other systemic treatment including retinoids, interferons, or investigational drugs</LI>
</UL>
</UL>
<UL>
<LI>Used any porphylatic antibody in the first 6 months after transplantation</LI>
<LI>Invasive malignant tumours of the skin within the treatment area within 6 months</LI>
<LI>Vitamin A usage &gt; 15000 units per day</LI>
</UL>
<P> <B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>43 participants</LI>
<LI>29 men, 5 women</LI>
<LI>Age: range = 37 to 76</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-08 10:09:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% imiquimod, 3 times per week for 16 weeks (N = 29 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle, 3 times per week for 16 weeks (N = 14 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 23:26:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Safety of the graft (rejection)</P>
<P>2) Application site reactions (imiquimod only)</P>
<P>3) Skin irritation (qualitative)</P>
<P>4) Minor adverse events (imiquimod only)</P>
<P>5) Serious adverse events</P>
<P>6) Clinical laboratory tests</P>
<P>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete or partial (<U>&gt;</U> 75%) clearance</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Lesion complete response</P>
<P>2) Skin quality (cosmetic)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using clinical counting of visible lesions in the treatment area, 2. biopsy of a lesion mapped at baseline (week 24)</P>
<P>Time points: at weeks 7, 12, and 16 (treatment period) and weeks 19 and 24 (post-treatment)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring of safety of the graft by an independent and blinded safety committee; monitoring of transplant rejection status, laboratory results, adverse events, local skin reactions, vital signs measurements, and the dosage of immunosuppressive medications, changes in haematology and serum chemistry (specifically: levels of serum creatinine, C-reactive protein, and proteinuria for renal transplant recipients; levels of gamma glutamyl-transpeptidase, glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase, and bilirubin for liver transplant recipients; GOT and GPT, white cell blood count, serum creatinine, haemoglobin, and signs of heart failure for heart transplant recipients), 2. assessment of local skin reactions (erythema, oedema, erosion/ulceration, scabbing/crusting, weeping/exudate, vesicles, and flaking/scaling/dryness)</P>
<P>Time points: at weeks 1, 2, 3, 5, 7, 9, 12, and 16 during the treatment period, and weeks 19 and 24 post-treatment</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of skin quality of the treatment area (skin surface, hyperpigmentation, hypopigmentation, the degree of scarring, and any atrophy)</P>
<P>Time points: at the 8-week post-treatment visit (week 24)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 15:30:55 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 23:26:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>The participants were organ transplant recipients, i.e. immunocompromised participants. There was no graft rejection during the study. There was an increase in the number of lesions in the vehicle group only. Clinical clearance was confirmed histologically.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 23:30:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ulrich-2010">
<CHAR_METHODS MODIFIED="2012-11-07 23:27:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:28:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Participants with kidney (± pancreas), liver, or heart transplantation within 3 years and stable status of the transplanted graft in the 12 months prior to entering the study</LI>
<LI>Criteria for determining the stability of grafts were specific to each transplant type</LI>
<LI>Immunosuppressive therapy must have been stable within the previous 6 months before enrolment and during therapy with the study drug</LI>
<LI>Anatomical locations: face, forehead, hands, balding scalp</LI>
<LI>
<U>&gt;</U> 3 actinic keratoses within 50 cm²</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Severe renal or hepatic impairment or had any evidence of graft rejection</LI>
<LI>Ongoing treatments for actinic keratosis</LI>
<LI>Evidence of invasive skin cancers</LI>
<LI>Evidence of unstable and severe cardiovascular, immunological, hematologic, hepatic, neurological, renal, endocrine, collagen-vascular, gastrointestinal or non-study related skin abnormalities or disease</LI>
<LI>Malignant tumours of the skin within the treatment area within 6 months</LI>
<LI>Evidence of systemic cancer or any systemic cancer chemotherapy or radiation therapy within 6 months</LI>
<LI>Other systemic treatments, including retinoids, interferons, or investigational drugs, within 4 weeks of study initiation</LI>
<LI>Vitamin A usage &gt; 15,000 units per day</LI>
<LI>Women of child-bearing potential could not be pregnant or nursing, and they must have been willing to use medically-accepted methods of contraception</LI>
<LI>History of hypersensitivity or allergy to any of the ingredients of active drug or vehicle or other non-steroidal anti-inflammatory drugs</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>32 participants</LI>
<LI>31 men, 3 women</LI>
<LI>Age: range = 49 to 77</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 23:27:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac in 2.5% hyaluronic acid, twice daily for 16 weeks (N = 24 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle, 2.5% hyaluronic acid, twice daily for 16 weeks (N = 8 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 23:30:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Participant complete clearance at 20 weeks and 24 months (recurrence)</P>
<P>2) Participant partial (<U>&gt;</U> 75%) clearance at 20 weeks and 24 months (recurrence)</P>
<P>3) Average percentage reduction of lesions at 20 weeks (= mean percentage of lesion counts)</P>
<P>4) Safety of the graft (rejection)</P>
<P>5) Minor adverse events (qualitative)</P>
<P>6) Skin irritation (tolerability, presented graphically)</P>
<P>7) Clinical laboratory tests</P>
<P>8) Cosmetic outcomes</P>
<P>9) Skin quality (cosmetic) at 20 weeks</P>
<P>10) 24-month follow up for development of new lesions and invasive squamous cell carcinoma</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using clinical counting of visible lesions supported by a transparent grid, 2. 3 to 4 mm punch biopsy of a target lesion mapped at the initiation visit </P>
<P>Time points: at baseline, at each visit (weeks 4, 8, 12, 16) and at the post-treatment visit (week 20)</P>
<P>Definitions: 1. complete clearance rate (proportion of participants at the 4-week post-treatment visit who had no evidence of lesions on the histology results of a target biopsy lesion site and no clinically-visible lesions in the remainder of the treatment area), 2. partial clearance rate (proportion of participants at the 4-week post-treatment visit who obtained at least 75% reduction in the number of lesions counted at baseline in the treatment area), 3. clearance rate of individual lesions (percentage reduction of lesions from baseline to the 4-weeks post-treatment visit)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: monitoring of transplant rejection status, laboratory results, adverse events, local skin reactions, vital signs measurements, and the dosage of immunosuppressive medications; clinical laboratory analyses: serum levels of immunosuppressive medication; levels in serum creatinine, C-reactive protein, and proteinuria for renal transplant recipients; gamma glutamyltranspeptidase, glutamic-pyruvic transaminase, glutamicoxalacetic transaminase, and bilirubin for liver transplant recipients; GOT and GPT, white cell blood count, serum creatinine, hemoglobin, and signs of heart failure for heart transplant recipients)</P>
<P>Time points: at each visit (weeks 4, 8, 12, 16) and at the post-treatment visit (week 20)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of skin quality by investigator based on skin surface, hyperpigmentation, hypopigmentation, the degree of scarring, and any atrophy</P>
<P>Time points: at the post-treatment visit (week 20)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 15:53:15 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Shire Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 23:29:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>New actinic keratoses developed at an average of 9.3 months, but no invasive squamous cell carcinoma developed within a period of 24 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Van-der-Geer-2009">
<CHAR_METHODS MODIFIED="2012-11-07 23:31:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, vehicle-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:31:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>General good health</LI>
<LI>Anatomical locations: dorsum of the both hands</LI>
<LI>With extensive actinic keratosis (minimum affected area of 5 X 5 cm)</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Allergy to aspirin or other NAIDs</LI>
<LI>History of gastrointestinal ulcer or bleeding</LI>
<LI>History of skin cancer on the dorsum of the hands</LI>
<LI>Dermatologic disease that could affect the amount of absorption or accumulation of diclofenac</LI>
<LI>Pregnancy, breastfeeding</LI>
<LI>Participants with actinic keratosis due to immune suppressive disease or immune suppressive medication</LI>
<LI>Treatment within the last 60 days with topical or oral treatment for actinic keratoses</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>10 participants</LI>
<LI>6 men, 4 women</LI>
<LI>Age: mean = 67; range = 50 to 77</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac in 2.5% hyaluronic acid gel twice daily for 4 weeks, 2 weeks off followed by aminolevulinic acid (ALA)-photodynamic therapy (PDT) (N = 10 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 2.5% hyaluronic acid gel twice daily for 4 weeks, 2 weeks off followed by ALA-PDT (N = 10 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: no</P>
<P>Cream concentration (%): --</P>
<P>Application of cream: --</P>
<P>Incubation with cream: occlusive dressing over cream for 4 hours</P>
<P>Type of light: red light</P>
<P>Light source: Omnilux</P>
<P>Wavelength (nm): 633</P>
<P>Energy fluence (J/cm²): 80</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 16 minutes (fractions)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 23:33:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Mean reduction of lesion counts in a 5 X 5 cm area</P>
<P>2) Participant and investigator global improvement indices (GIIs) expressed as scores</P>
<P>3) Total thickness scores</P>
<P>4) Pain score</P>
<P>5) Severe local adverse reactions (qualitative)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesions counting in a 5 X 5 cm area, 2. assessment of lesion thickness visually and by palpation and scored on a 1 to 4 scale, 3. qualitative assessment of global improvement by the investigator and the participant (an independent dermatologist evaluated the efficacy by using photographs)</P>
<P>Time points: at baseline, at 6 weeks and 6 months after PDT, and 8 of 10 participants were examined 12 months post-treatment.</P>
<P>Definitions: 1. total lesion score (number of lesions counted in 5 × 5 cm area), 2. total thickness score (sum of the thickness scores for individual lesions)</P>
<P>Definitions for thickness score: 1 (lesion visible, but not palpable), 2 (lesion visible and palpable), 3 (elevated and keratotic lesion), 4 (hyperkeratotic lesion &gt; 1 mm in thickness)</P>
<P>Definitions for GIIs: &#8211;2 (significantly worse), &#8211;1 (slightly worse), 0 (no change), 1 (some improvement), 2 (moderate improvement), 3 (significant improvement), 4 (complete remission)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. scoring of pain, 2. participant-recorded side-effects in daily diary (number and severity)</P>
<P>Time points: 1. during PDT (pain), 2. at each visit (side-effects)</P>
<P>Definitions for pain score: 0 (painless), 1 (mild pain), 2 (moderate pain), 3 (severe pain), 4 (unbearable pain)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 23:32:26 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-22 16:11:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a pilot study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:55 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-von-Felbert-2010">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>Randomised, double-blind, active-controlled, parallel-group study</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:07:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>White participants</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>Untreated, non-pigmented grade I (hardly visible, slightly palpable) or II (easily visible and palpable) actinic keratoses</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Age under 45 years or over 85 years</LI>
<LI>Immunosuppression for idiopathic, disease-specific, or therapeutic reasons</LI>
<LI>Porphyria</LI>
<LI>Known hypersensitivity to porphyrins</LI>
<LI>Known photodermatoses or photosensitivity</LI>
<LI>Known allergy to MAL</LI>
<LI>Pregnancy, lactation</LI>
<LI>Diagnosis of basal cell carcinoma</LI>
<LI>Hyperkeratotic actinic keratoses</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 weeks with photosensitising pharmaceuticals; topical treatments with corticosteroids, retinoids, 5-fluorouracil ,or imiquimod</LI>
<LI>within 3 months with systemic retinoids, chemotherapy, or immunotherapy</LI>
<LI>within 2 months with laser resurfacing, chemical peels, cryotherapy, or photodynamic therapy (PDT)</LI>
</UL>
</UL>
<UL>
<LI>Participation in other studies within the last 3 months</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>80 participants</LI>
<LI>71 men, 9 women</LI>
<LI>Age: mean = 70; range = 56 to 85</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>2 subgroups: with and without cooling spray</P>
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)- visible + water-filtered infrared A (VIS + wIRA) PDT (N = 40 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: MAL-light-emitting diode (LED) red light PDT (N = 40 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 3 months</P>
<P>Preparation of lesions: gentle removal of scales</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: 1 mm thick to lesion area and 5 mm of surrounding normal tissue</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: visible + water-filtered infrared A (VIS + wIRA) or LED red light</P>
<P>Light source: Hydrosun type 505 Broadband with 7-mm water cuvette and orange filter OG590 (VIS + wIRA), Aktilite CL 128 (red light)</P>
<P>Wavelength (nm): 580-1400 (VIS + wIRA), 630 (red light)</P>
<P>Energy fluence (J/cm²): 240 including 60 VIS (VIS + wIRA), 37 (red light)</P>
<P>Intensities (mW/cm²): 200 including 50 VIS (VIS + wIRA), 75 (red light)</P>
<P>Exposure time: 20 minutes (VIS+ wIRA), 8 minutes (red light)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:07:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial </U>
</B>
</P>
<P>1) Participant complete and partial (<U>&gt;</U> 75%) clearance at 3 (1 treatment), 6 (1 or 2 treatments), and 12 (1 or 2 treatments) months</P>
<P>2) Efficacy on a visual assessment scale (VAS)</P>
<P>3) Pain on a VAS (first outcome presented)</P>
<P>4) Local skin reactions</P>
<P>5) Serious adverse events</P>
<P>6) Satisfaction and quality of life on a VAS</P>
<P>7) Number of spray cooling and illumination interruptions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. documentation of the global aspect of total actinic keratosis area by physicians, 2. rating of efficacy on a VAS [-50 mm (extreme worsening), 0 mm (unchanged), +50 mm (extreme improvement)], 3. rating of efficacy on a five-point scale-rated variable 'percentage of the cleared area in relation to the initial total actinic keratosis area' (100% clearance, <U>&gt;</U> 75% of the total area cleared, <U>&gt;</U> 50% of the total area cleared, <U>&gt;</U> 25% of the total area cleared, no relevant part of the area cleared)</P>
<P>Time points: before PDT; at 2 weeks; and at 3, 6, and 12 months after the first PDT</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. evaluation of the extent of erythema, scaling, crusts, indurations, erosions, ulcerations, and oedema on a VAS [0 (non-existent) to 100 mm (extremely high)] by physicians, 2. evaluation of the intensity of pain, side-effects on a VAS [0 (none) to 100 mm (extremely high)] by participants</P>
<P>Time points: 1. before PDT; 2 weeks; and 3, 6, and 12 months after the first PDT, 2. 2, 4, 6, 8, 10, 13, 15, 20, 22, and 25 minutes after the start of PDT (pain)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. evaluation of the extent of skin atrophy, scar formation, and pigmentation on a visual analogue scale (VAS) [0 (non-existent) to 100 mm (extremely high)] by physicians, 2. assessment of cosmetic appearance by physicians and participants [VAS: 0 (extremely bad) to 100 mm (extremely good)]</P>
<P>Time points: before treatment; at 2 weeks; and at 3, 6, and 12 months after the first PDT<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 16:32:22 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Erwin Braun Foundation. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-22 16:32:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>Efficacy was lower in participants receiving cooling spray. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-07 23:41:07 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Weiss-2002">
<CHAR_METHODS MODIFIED="2012-11-07 23:39:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind (treatment vs placebo),open (treatment duration), vehicle-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:39:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face or frontal scalp</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses (<U>&gt;</U> 4 mm in diameter)</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Basal or squamous cell carcinoma</LI>
<LI>Other confounding skin conditions</LI>
<LI>History of cutaneous hyperreactivity or facial skin irritation to topical products</LI>
<LI>Excessive sunlight exposure</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 6 months with fluorouracil or systemic cancer chemotherapy</LI>
<LI>within 1 month with other topical treatments for actinic keratoses</LI>
</UL>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>177 participants</LI>
<LI>152 men, 25 women</LI>
<LI>Age: range = 35 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-07 23:39:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 0.5% fluorouracil cream (microsphere) applied once daily to affected areas for 1 week with 4 week follow-up (N = 38 participants)</P>
<P>B: 0.5% fluorouracil cream (microsphere) applied once daily to affected areas for 2 weeks with 4 week follow-up (N = 41 participants)</P>
<P>C: 0.5% fluorouracil cream (microsphere) applied once daily to affected areas for 4 weeks with 4 week follow-up (N = 40 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>D: vehicle applied once daily to affected areas for 1, 2, or 4 weeks with 4-week follow-up (N = 58 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 23:41:07 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Physician global assessment of improvement (PGAI = global improvement indices)</P>
<P>2) Proportion of participants achieving total clearance (= participant complete clearance)<BR/>3) Per cent reduction of lesions (= mean percentage of reduction in lesion counts)</P>
<P>4) Mean number of lesions at baseline and end of study (transformed to absolute mean reduction in lesion counts)</P>
<P>5) Median number of lesions at baseline and end of study<BR/>
</P>
<P>6) Skin irritation (number of participants, severity, overtime)</P>
<P>7) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting, 2. qualitative assessment using PGAI (+5 = total clearance and -4 = much worse) reported as mean score</P>
<P>Time points: at baseline and 4 weeks post-treatment</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring of adverse events (onset, duration, severity, and frequency), 2. separate recording for adverse events affecting the facial skin and scalp, 3. monitoring of facial irritation including maximum severity (0 = none, 1 = mild, 2 = moderate,<BR/>or 3 = severe), symptoms (edema, erythema, dryness, erosion, pain, burning), onset, overall duration, and post-treatment duration</P>
<P>Time points: during treatment: days 1 and 8 (1-week groups); days 1, 8, and 15 (2-week groups); or days 1, 8, 15, and 29 (4-week groups); post-treatment: weekly visits and a final evaluation 4 weeks after completing or discontinuing treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 23:40:19 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 23:40:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:57 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wiegell-2008">
<CHAR_METHODS MODIFIED="2012-11-07 23:42:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, assessor-blind, active-controlled, intraindividual study.</P>
<P>Start date: May 2006</P>
<P>End date: February 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:42:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>General good health</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>Symmetrical distribution of actinic keratoses within 80 cm² area</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnancy and lactation</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>30 participants</LI>
<LI>23 men, 7 women</LI>
<LI>Age: mean = 78; range = 63 to 90</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: methyl aminolevulinate (MAL)-red light photodynamic therapy (PDT) (N = 30 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: MAL-daylight PDT (N = 30 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: crusts and hyperkeratoses removed</P>
<P>Cream concentration (%): 16.8</P>
<P>Application of cream: 1 g applied to lesion area</P>
<P>Incubation with cream: occlusive dressing over cream for 0.5 hour (daylight) and 3 hours (red light)</P>
<P>Type of light: LED red light or daylight</P>
<P>Light source: Aktilite CL 128 (red light), sun (daylight)</P>
<P>Wavelength (nm): 575-670 (red light), 290-670 (daylight)</P>
<P>Energy fluence (J/cm²): 37 (red light), 11.7-65.9 (mean = 43.2, measured with a dosimeter)</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 2.5 hours (daylight)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:07:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction in lesion counts at 3 months post-treatment</P>
<P>2) Local adverse events</P>
<P>3) Participant's pain scores</P>
<P>4) Participant's satisfaction</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting, grading (<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>), mapping, and photography of lesions</P>
<P>Time points: before treatment and at 3 months post-treatment</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. scoring (0 = no pain to 10 = worst imaginable pain) of the pain in the 2 treated areas by participants, 2. evaluation of adverse events (erythema, crusting or pain)</P>
<P>Time points: 1. during daylight exposure, during red LED light illumination, and after treatment (pain), 2. at 1 to 3 days after PDT (adverse events)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 18:09:20 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by The Eva and Henry Frænkels Memorial Foundation. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-24 14:46:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>PpIX fluorescence measured before, during, and after treatments showed less fluorescence associated with daylight. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:58 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wiegell-2009">
<CHAR_METHODS MODIFIED="2012-11-07 23:44:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a randomised, double-blind, active-controlled, intraindividual study.</P>
<P>Start date: June 2007 </P>
<P>End date: December 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:45:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>General good health</LI>
<LI>Capable of following the protocol instructions</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>2 symmetrical areas of 80 cm²</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnant or lactating women</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>30 participants</LI>
<LI>26 men, 4 women</LI>
<LI>Age: mean = 71; range = 51 to 94</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 16% methyl aminolevulinate (MAL)-daylight photodynamic therapy (PDT) (N = 30 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 8% MAL -daylight PDT (N = 30 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: sunscreen SPF20, crusts and hyperkeratoses removed</P>
<P>Cream concentration (%):8 or 16</P>
<P>Application of cream: 1 g applied to lesion area</P>
<P>Incubation with cream: all day</P>
<P>Type of light: daylight</P>
<P>Light source: sun (daylight)</P>
<P>Wavelength (nm): 290-670 (daylight)</P>
<P>Energy fluence (J/cm²): measured with dosimeter</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: all day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:47:36 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction in lesion counts</P>
<P>2) Total lesion count (lesion complete response)</P>
<P>3) Pain scores</P>
<P>4) Erythma scale and per cent by measurements before and after treatment with skin reflectance meter</P>
<P>5) Participant's preference</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using counting, grading (<LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>), mapping, and photography of lesions</P>
<P>Time points: before treatment and at 3 months post-treatment</P>
<P>Definitions: 1. complete response (complete disappearance of the lesion), 2. non-complete response (incomplete disappearance of the lesion)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. scoring (0 = no pain to 10 = worst imaginable pain) of the pain in the 2 treated areas by participants in a diary every hour, 2. evaluation of adverse events (erythema, crusting, or pain) visually on a 4-point scale by a dermatologist, 3. quantitative evaluation of erythema [erythema percentage measured with a skin reflectance meter (Optimize Scientific; Chromo Light Aps,Skodsborg, Denmark)]</P>
<P>Time points: 1. during daylight exposure, during red LED light illumination, and after PDT (pain), 2. 1 to 3 days after PDT(adverse events), 3. before curettage and on the day after PDT (erythema evaluation)</P>
<P>Definitions for visual evaluation of erythema: 1. 0 (no visible erythema), 2. (+) (just perceptible erythema), 3. + (uniform erythema), 4. ++ (bright red erythema and induration)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-11-07 23:45:18 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-07 23:45:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>PpIX fluorescence was measured using fluorescence camera, and there was no difference between the 2 cream concentrations. There was a correlation with light exposure/dose and response rate. Pain increased with light exposure. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-13 10:36:59 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wiegell-2011a">
<CHAR_METHODS MODIFIED="2012-11-09 12:09:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, active-controlled, parallel-group study.</P>
<P>Start date: June 2008</P>
<P>End date: January 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:49:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses within 25 cm²</LI>
<LI>All lesion grades were treated but only grade I (slightly palpable, more easily felt than seen) lesions were included in the data analysis</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Women of child-bearing potential</LI>
<LI>Porphyria</LI>
<LI>Known allergy to any of the constituents of the methyl aminolevulinate (MAL) cream</LI>
<LI>Treatment as follows</LI>
</UL>
<UL>
<UL>
<LI>within 4 weeks with any actinic keratosis treatment in the treatment area</LI>
<LI>within 3 months with oral immunosuppressives</LI>
</UL>
</UL>
<UL>
<LI>Any conditions associated with a risk of poor protocol compliance</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>120 participants</LI>
<LI>96 men, 24 women</LI>
<LI>Age: mean = 72; range = 47 to 95</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:36:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 2h MAL-1.5h daylight photodynamic therapy (PDT) (N = 58 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 3h MAL-2.5h daylight PDT (N = 62 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: sunscreen SPF20, crusts and hyperkeratoses removed</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: thick layer applied to lesion area</P>
<P>Incubation with cream: 2 or 3 hours (0.5 hour without light exposure)</P>
<P>Type of light: daylight</P>
<P>Light source: sun (daylight)</P>
<P>Wavelength (nm): 290-670 (daylight)</P>
<P>Energy fluence (J/cm²): 8.6 (1.5 hours), 10.2 (2.5 hours)</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 131 <U>+</U> 37 min (1.5 hours) or 187 <U>+</U> 52 min (2.5 hours)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:08:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Mean reduction in lesion counts at 3 months post-treatment</P>
<P>2) Mean percentage of reduction in lesion counts at 3 months post-treatment [which correspond to the primary and only outcome "response rate" in the protocol NCT00711178 based on the published report (see efficacy definitions below)]</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Pain scores</P>
<P>2) Local adverse reactions: erythema and pustular eruptions (pooled data)</P>
<P>3) Participants' satisfaction</P>
<P>4) New actinic keratosis lesions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion grading and counting using a template</P>
<P>Time points: at baseline and 3 months post-treatment</P>
<P>Definitions: 1. lesion response rate (number of completely responding lesions divided by the number of lesions treated within the individual participants), 2. complete response (complete disappearance of the lesion, visually and by palpation - mild erythema might<BR/>remain), 3. non-complete response (incomplete disappearance of the lesion, visually and by palpation)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. participant-recorded pain score (0 = no pain and 10 = worst imaginable pain) in diary, 2. erythema and pustular eruption rating by investigators (other adverse events were recorded if the investigators considered these to be related to treatment)</P>
<P>Time points: 1. every half hour during the day of treatment and 4 time-points the following day (pain), 2. at 2 days after PDT (erythema and pustules)</P>
<P>Definitions for erythema rating: 1. none (no redness), 2. mild (visibly pink colour), 3. moderate (red colour), 4. severe (dark red purple)</P>
<P>Definitions for pustular eruptions rating: 1. none (no pustules), 2. mild (few pustules), 3. moderate (several pustules), 4. severe (severe pustular eruption with yellow crusting)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 18:48:27 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Department of dermatology, Bisebjerg Hospital, Copenhagen.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-24 15:00:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>The effective daylight dose was measured with electronic wristband dosimeter. The weather conditions were monitored every half hour in diary. An increase in pain and  erythema was associated with higher effective light dose. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-08 15:15:47 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wolf-2001">
<CHAR_METHODS MODIFIED="2012-11-07 23:49:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:49:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Good general health</LI>
<LI>Outpatients</LI>
<LI>Men and women using reliable contraception</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: forehead, central face, scalp, arms, hands</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses in one to three 5 cm² treatment blocks</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Known allergy to aspirin or other NSAIDs</LI>
<LI>Dermatological condition that might interfere with absorption, accumulation  or metabolism of the study medication</LI>
<LI>Being treated with a disallowed concomitant medication (including masoprocol, 5-fluorouracil, etretinate, cyclosporine, retinoids, trichloroacetic acid peel or glycolic acid)</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>120 enrolled participants, 118 received treatment, 117 analysed for safety (1 participant missing)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-11 12:38:49 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac gel in 2.5% hyaluronic acid gel, 0.5 g twice daily for 90 days (N = 58 participants based on safety data)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 2.5% hyaluronic acid gel only, 0.5 g twice daily for 90 days (N = 59 participants based on safety data)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:15:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Participant Global Improvement Indices = 4</P>
<P>2) Investigator Global Improvement Indices = 4</P>
<P>3) Participants with target lesion number score = 0 at 30 days post-treatment (= participant complete clearance)<BR/>4) Participants with cumulative lesion number score = 0 at 30 days post-treatment (= participant complete clearance)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) Participants experiencing at least 1 adverse event</P>
<P>2) Application site reactions</P>
<P>3) Minor adverse events</P>
<P>4) Serious adverse events</P>
<P>5) Clinical laboratory tests</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting, 2. qualitative assessments (IGII and PGII)</P>
<P>Time points: at each visit</P>
<P>Definitions: 1. target lesion number score (number of lesions identified in the designated treatment blocks at baseline), 2. cumulative lesion number score (number of lesions identified -target or new-in the designated treatment blocks)</P>
<P>Definitions for IGII and PGII 7-point scale: + 2 (significantly worse), +1 (slightly worse), 0 (no change), 1 (slightly improved), 2 (moderately improved), 3 (significantly improved), and 4 (completely improved)<BR/>
</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. participant-recorded concomitant medications and adverse events in diary; 2. assessment of adverse events for duration, intensity, and causality by physician; 3. standard laboratory analyses [hematology, biochemistry, urinalysis, and serology (antidiclofenac)]</P>
<P>Time points: at screening and end of treatment (laboratory tests)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 19:16:40 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by Hyal Pharmaceutical Co.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-24 15:03:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-09 12:09:30 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Zeichner-2009">
<CHAR_METHODS MODIFIED="2012-11-09 12:09:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a single-centre, randomised, double-blind, placebo-controlled, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-07 23:51:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: head</LI>
<LI>
<U>&gt;</U> 6 actinic keratoses bilaterally symmetrically distributed within a 20 cm² area</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>20 participants</LI>
<LI>16 men, 4 women</LI>
<LI>Age: mean = 75</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-08 10:26:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% imiquimod, once weekly for 24 weeks (N = 20 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo, once weekly for 24 weeks (N = 20 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-07 23:51:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Investigator assessment scale (= global improvement indice)</P>
<P>2) Total lesion number score</P>
<P>3) Local skin reactions (qualitative)</P>
<P>4) Serious adverse events</P>
<P>5) Skin irritation score (graph)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. qualitative assessment with an investigator assessment scale (7-point), and 2. quantitative assessment with lesion counting</P>
<P>Time points: every 4 weeks during the treatment period and at 4 weeks post-treatment</P>
<P>Definitions for the investigator assessment scale: -2 (much worse), -1 (slightly worse), 0 (no change), 1 (mild improvement), 2 (moderate improvement), 3 (marked improvement), 4 (cured) </P>
<P>Definitions: total lesion number score (total number of lesions present in the target area<BR/>was determined for each side, 0 = 0 lesion, 1 = 1 to 3, 2 = 4 to 6, 3 = &gt; 6 lesions)<BR/>
<U>Safety</U>
</P>
<P>Methods: 1. monitoring the occurrence of local adverse events and systemic adverse events, 2. rating of skin irritation by participants on a 6-point scale (there was no objective measure of local side-effects)</P>
<P>Time points: at each visit</P>
<P>Definitions for skin irritation scale: 0 (no irritation), 1 (trace irritation), 2 (mild irritation) 3 (moderate irritation), 4 (marked irritation), 5 (severe irritation)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2011-11-22 19:39:51 +0000" MODIFIED_BY="[Empty name]">
<P>This study was supported by 3M Pharmaceuticals.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2011-11-24 15:05:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a pilot study. A sample size calculation was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-11-08 09:10:10 +0000" MODIFIED_BY="Maryse Paquet" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:56:53 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Alberts-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:56:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>We assessed actinic damage in general, and the study was not specific to actinic keratoses. Only 60% of participants had clinically-evaluable actinic keratoses on the forearms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:58:19 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Alexiades_x002d_Armenakas-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:58:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not randomise all the participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:21:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Apalla-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:21:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a conference abstract without numerical values for efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:25:16 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Apalla-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:25:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:58:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Apalla-2010c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:58:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>The efficacy of the intervention was on new actinic keratosis lesions (prevention), not on baseline lesions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:58:50 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Babilas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:58:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study was not randomised. Predefined sides were treated with 2 different light sources for PDT, i.e. always the same side for 1 treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:25:27 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Babilas-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:25:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:25:31 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Babilas-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:25:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:25:51 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Bartels-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:25:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 12:13:21 +0100" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Berlin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 12:13:21 +0100" MODIFIED_BY="Maryse Paquet">
<P>The study was not randomised; the participants were allocated based on participant and physician judgement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:26:09 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Biecha_x002d_Thalharnmer-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:26:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:26:14 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Braathen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:26:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:59:20 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Breza-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:59:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not present efficacy results numerically.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 08:59:52 +0000" MODIFIED_BY="Zbys Fedorowicz" STUDY_ID="STD-de-S_x00e9_vaux-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 08:59:52 +0000" MODIFIED_BY="Zbys Fedorowicz">
<P>The study did not present efficacy results numerically; they were given in graphical form.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:00:27 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Dermik-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:00:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not clearly present efficacy measures. The data were presented in graph form with no quantitative numbers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:03:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Dirschka-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:03:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study was randomised (90- versus 180-day treatments), but only partial data at 3 months were presented based on the conference abstract. And only data from the 90-day group were presented in the peer-reviewed paper, i.e. there was no comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-09 23:43:22 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-DUSA-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-09 23:43:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>This trial was terminated due to "Orphan Drug Designation for this indication not granted".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:04:41 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Edwards-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:04:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>The type of interventions were not covered in this review, i.e. injection in participant lesion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:24:11 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Elmets-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:24:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study was on the prevention of actinic keratosis lesions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:24:18 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Epstein-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:24:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:26:28 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Ericson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:26:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:05:05 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Fowler-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:05:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a follow-up study of an included study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:05:10 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Gold-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:05:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>It was not clear if the study was randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:05:18 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Goldman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:05:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>The randomisation was based on participant preference, and there was no efficacy comparison between the 2 treatments.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:05:32 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Green-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:05:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>Out of 80 participants, only 4 had actinic keratosis lesions, and mean lesions counts were reported for all subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 12:04:17 +0100" MODIFIED_BY="Zbys Fedorowicz" STUDY_ID="STD-Griffin-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 12:04:17 +0100" MODIFIED_BY="Zbys Fedorowicz">
<P>The randomisation was not mentioned. Little information was given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 12:04:18 +0100" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Grima_x00ee_tre-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 12:04:18 +0100" MODIFIED_BY="Maryse Paquet">
<P>The randomisation was not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:27:08 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Gupta-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:27:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:05:57 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Hanke-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:05:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a follow-up study for <LINK REF="STD-Hanke-2010" TYPE="STUDY">Hanke 2010</LINK>; <LINK REF="STD-Swanson-2010a" TYPE="STUDY">Swanson 2010a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 15:41:45 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Humphreys-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 15:41:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>Actinic keratosis lesions were not distinguished from lentigines for efficacy data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:06:15 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Jury-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:06:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>The criteria for outcomes was not met, i.e. median lesion counts were provided instead of mean lesion counts.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:06:54 +0000" MODIFIED_BY="Zbys Fedorowicz" STUDY_ID="STD-Kurwa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:06:54 +0000" MODIFIED_BY="Zbys Fedorowicz">
<P>This study did not meet the outcome requirements of the review; it presented results as the mean reduction in lesion area.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:07:10 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Marrero-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:07:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>There was an inadequate method of randomisation: Every other participant was given a combination treatment on the left side of the face and a monotherapy treatment on the right. All other participants were given the opposite treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:28:06 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Morales-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:28:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:07:24 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Naylor-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:07:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study was on the prevention of actinic keratosis lesions formation, not an intervention to cure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:07:31 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00005097">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:07:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>The trial was terminated because of the low conditional power for a positive study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:28:15 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Puizina_x002d_Ivic-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:28:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:28:19 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Radakovic_x002d_Fijan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:28:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:28:24 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Robins-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:28:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>50% of participants were lost to follow up. No statistics were reported. There was too much variability within and between groups as far as following instructions for application. There was no initial counting of lesions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 15:49:37 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Rosen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 15:49:37 +0000" MODIFIED_BY="Maryse Paquet">
<P>There was not enough information in this conference abstract of a phase II trial to be able to use the data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:08:12 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Shuttleworth-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:08:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>The type of interventions were not covered in this review, i.e. injection in participant lesion, and it was unclear if the study was randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 15:50:25 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Simmonds-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 15:50:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>There were no numerical results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:28:51 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Smith-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:28:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-08 12:30:18 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Sotiriou-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-08 12:30:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study did not meet the outcome requirements of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:08:23 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Spencer-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:08:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>No enough numerical information was provided, e.g. number of participants in each of the 8 treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:08:31 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Stockfleth-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:08:31 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a long-term follow-up to a previous study: <LINK REF="STD-Stockfleth-2002" TYPE="STUDY">Stockfleth 2002</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:08:39 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Szeimies-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:08:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a follow-up study of <LINK REF="STD-Hauschild-2009a" TYPE="STUDY">Hauschild 2009a</LINK>; <LINK REF="STD-Hauschild-2009b" TYPE="STUDY">Hauschild 2009b</LINK>; and <LINK REF="STD-Hauschild-2009c" TYPE="STUDY">Hauschild 2009c</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:09:11 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Touma-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:09:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not present efficacy results numerically; they were given in graph form.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 12:13:25 +0100" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Tsoukas-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 12:13:25 +0100" MODIFIED_BY="Maryse Paquet">
<P>It was unclear if the study was randomised based on this conference abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 12:04:20 +0100" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Valeant-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 12:04:20 +0100" MODIFIED_BY="Maryse Paquet">
<P>The randomisation was not mentioned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-09 23:37:19 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Vbeam-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-09 23:37:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This trial was terminated due low accrual.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:09:40 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Weinstock-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:09:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>The study did not present numerical data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:09:48 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wennberg-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:09:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study was on prevention of new lesions and mixed lesion types, i.e. not only actinic keratoses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:10:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Wulf-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:10:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study does not provide efficacy data on intervention. The primary outcome was mean time to occurrence of first new lesion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 09:10:10 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-Yamauchi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 09:10:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>There was not enough information. Results taken from 2 studies and combined, i.e. no direct comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-11-13 10:40:25 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-11-08 09:19:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akarsu-2011">
<CHAR_METHODS MODIFIED="2012-11-08 09:12:25 +0000" MODIFIED_BY="[Empty name]">
<P>This was a single-centre, randomised, open, assessor-blinded, placebo- and active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:12:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical and histopathological diagnosis</LI>
<LI>Aged 18 years and older</LI>
<LI>Men and women who were otherwise healthy</LI>
<LI>Anatomical locations: face</LI>
<LI>1 actinic keratose</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregancy or lactation</LI>
<LI>Sensitivity to any component of the study medications</LI>
<LI>Use of medication for actinic keratoses or other systemic treatments within 1 month before the study</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>68 participants randomised, 61 participants evaluated</LI>
<LI>37 men, 31 women</LI>
<LI>Age: mean = 66; range = 42 to 87</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 09:13:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3% diclofenac in 2.5% hyaluronic acid, twice daily for 12 weeks (N = 21 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: 5% imiquimod, twice per week for 16 weeks (N = 20 participants)</P>
<P>C: placebo (Ultrabase cream; Schering Alman, Istanbul, Turkey), twice daily for 12 weeks (N = 20 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:19:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Total thickness score (TTS)</P>
<P>2) Patient global improvement index (PGII)</P>
<P>3) Complete clearance (= lesion complete response)</P>
<P>4) Local skin reactions</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using a scale and photography of lesions</P>
<P>Time points: before treatment and at every 4 weeks up to 24 weeks</P>
<P>Definitions: 1. TTS scale, 0 = complete clearance, 1 = lesion visible but not palpable, 2 = lesion visible and palpable, 3 = lesion raised with visible scaling, 4 = lesion hyperkeratotic and &gt; 1 mm in thickness; 2. PGII is a self-report scale, and participants evaluated themselves according to a 7-point scale (0 = significantly worse, 1 = slightly worse, 2 = no change, 3 = slightly improved, 4 = moderately improved, 5 = significantly improved, 6 = completely improved)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: evaluation of local skin reactions (erythema, oedema, erosion &#8260; ulceration, scabbing &#8260; crusting, weeping&#8260; exudates, vesicles, and scaling &#8260; dryness) on a 0 to 3 scale</P>
<P>Time points: at every 4 weeks up to 24 weeks</P>
<P>Definitions: 0 = none, 1 = mild, 2 = moderate, 3 =severe</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:13:05 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apalla-2011">
<CHAR_METHODS MODIFIED="2012-11-08 09:19:52 +0000" MODIFIED_BY="[Empty name]">
<P>This was a single-centre, randomised, open, assessor-blinded, intraindividual study.</P>
<P>Start date: February 2009</P>
<P>End date: May 2010</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:20:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical and histological diagnosis</LI>
<LI>Men and women</LI>
<LI>Anatomical locations: face or scalp</LI>
<LI>
<U>&gt;</U> 3 actinic keratoses of similar severity, in terms of grade, size, and localisation</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Dermatological diseases in the treatment area, including pigmented lesions and invasive tumours</LI>
<LI>Treatment for face and scalp actinic keratoses within the past 3 months</LI>
<LI>Photosensitivity, hypersensitivity to ALA or ALA-cream excipients</LI>
<LI>Pregnancy or breastfeeding</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>50 white participants (3 lesions/participants were randomised)</LI>
<LI>29 men, 21 women</LI>
<LI>Age: mean = 58; range = 38 to 75</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 50 mW/cm² ALA-red light photodynamic therapy (PDT) (N = 50 participants)</P>
<P>B: 75 mW/cm² ALA-red light PDT (N = 50 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>C: 25 mW/cm² ALA-red light PDT (N = 50 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesion</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 4 hours with occlusion</P>
<P>Type of light: red</P>
<P>Light source: Waldmann PDT 1200 (non-coherent light)</P>
<P>Wavelength (nm): 570-670</P>
<P>Energy fluence (J/cm²): 75</P>
<P>Intensities (mW/cm²): 25-75</P>
<P>Exposure time:--</P>
<P>At the 3-month follow-up visit, lesions without a complete response were treated with surgical techniques (cryosurgery or excision).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:28:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Pain on a visual analogue scale (VAS) during illumination</P>
<P>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Lesion complete response at 3 and 12 months post-treatment</P>
<P>2) Adverse events (qualitative)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment using lesion counting,</P>
<P>Time points: at baseline; and at 3, 6, and 12 months post-treatment</P>
<P>Definitions: 1. complete response (CR): complete absence of any clinical sign indicative of actinic keratoses, 2. non-complete response (non-CR): remaining clinical signs indicative of actinic keratoses<BR/>
</P>
<P>
<U>Safety</U>
</P>
<P>Methods: recording of adverse events</P>
<P>Time points: from 5-ALA application time point until the end-of-study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:21:24 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-08 09:25:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azimi-2012">
<CHAR_METHODS MODIFIED="2012-11-08 09:22:14 +0000" MODIFIED_BY="[Empty name]">
<P>This was a randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>Start date: January 2010</P>
<P>End date: March 2011</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:23:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 0 to 150 years</LI>
<LI>Men and women</LI>
<LI>Clinical diagnosis of actinic keratoses</LI>
<LI>
<U>&gt;</U> 5 lesions</LI>
<LI>Willing to participate in the study</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnancy (first trimester)</LI>
<LI>Previous history of allergy to drugs of study</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 month with destructive methods, peeling methods, or drugs for treatment of lesions</LI>
<LI>within 2 months with isotretinoin</LI>
</UL>
</UL>
<UL>
<LI>Participation in the other clinical studies over the past month</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>112 participants randomised, 100 evaluated</LI>
<LI>88 men, 12 women</LI>
<LI>Age: mean = 67; range = 46 to 86</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 09:23:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention </B>
</U>
</P>
<P>A: cryotherapy followed by Acnalene 0.1% gel at day 10, twice daily for 3 months</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy followed by placebo at day 10, twice daily for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:25:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Changes in the average number of actinic keratosis lesions (= mean reduction in lesion counts)</P>
<P>2) Mean frequency of reduction (= mean percentage of reduction in lesion counts)</P>
<P>3) Clinical outcome based on change in lesion number [including 'recovery rate of over 75%' (= participant partial (<U>&gt;</U> 75%) clearance)]</P>
<P>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Adverse events</P>
<P>2) Cosmetic outcomes</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by lesion counting and photography</P>
<P>Time points: at baseline and monthly after the beginning of the topical treatment</P>
<P>Definitions: 1. full recovery (greater than or equal to 75% reduction in the number of lesions), 2. relative recovery (30 to 75 per cent reduction in the number of lesions), 3. no response (no reduction or [greater than or equal to] 30% reduction in the number of lesions), 4. worsening (an increase in the number of lesions)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: clinical examination and questioning of participants</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of changes in pigmentation and scar formation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:24:21 +0000" MODIFIED_BY="[Empty name]">
<P>This study corresponded to the protocol IRCT201010104901N1.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-08 14:59:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Damian-2011">
<CHAR_METHODS MODIFIED="2012-11-08 09:24:31 +0000" MODIFIED_BY="[Empty name]">
<P>This was a single-centre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:26:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Men and women</LI>
<LI>Symmetrically distributed non-hyperkeratotic actinic keratoses on face/scalp/upper limbs</LI>
<LI>
<U>&gt;</U> 4 actinic keratoses in one or more treatment areas</LI>
<LI>Participants have received no other treatments for actinic keratoses within the last month</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnant or lactating</LI>
<LI>Taking immunosuppressive or photosensitising medications</LI>
<LI>Taking nicotinamide or other vitamin supplements</LI>
<LI>Participants unable to attend for regular follow up</LI>
<LI>Participants with active dermatitis in the treatment areas</LI>
<LI>Liver disease</LI>
<LI>Currently taking Carbamazepine</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>35 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 09:26:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: administration of 500 mg nicotinamide tablet, twice daily for 4 months</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo tablet made of lactose. The dose, frequency, and duration of treatment are the same as for the nicotinamide group (i.e. 500 mg twice a day for 4 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:59:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Reduction in total actinic keratosis count at 4 months compared with baseline count</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Reduction in site-specific (i.e. face, arms, scalp) actinic keratosis count at 2 and 4 months compared with baseline count</P>
<P>2) Reduction in skin cancers (posthoc)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by blinded clinical examination by a medically-qualified observer</P>
<P>Time points: at baseline, and 2 and 4 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:26:52 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-09 12:09:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deonizio-2011">
<CHAR_METHODS MODIFIED="2012-11-06 18:38:29 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, open, active-controlled, intraindividual study</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:27:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 50 to 80 years</LI>
<LI>Men and women</LI>
<LI>Multiple actinic keratoses</LI>
<LI>Anatomical location: upper limbs</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Uncompensated chronic diseases</LI>
<LI>Coagulation disorders</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>16 participants (limbs were randomised)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-09 12:09:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: topical anaesthetic with occlusion (lidocaine 5% and prilocaine 5%) was applied for 2 hours before cryopeeling (on a field) followed by treatment of individual lesions with liquid nitrogen (LN) (N = 16 participants)</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: topical anaesthetic with occlusion (lidocaine 5% and prilocaine 5%) was applied for 2 hours before cryopeeling (on a field) followed by treatment of individual lesions with dimethyl ether, propane, and isobutane gases in a portable system (PS) (N = 16 participants)</P>
<P>Topical Vaseline was used in the postoperative period to moisturise the skin and reduce the discomfort of healing.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:39:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Percentage of lesions completely healed (= lesion complete response) at 2 months post-treatment</P>
<P>2) Pain on the visual analogue scale (VAS) from zero (no discomfort) to 10 (worst discomfort possible)</P>
<P>3) Global preference of physician and participant based on a 5-point scale, which ranged from -2 (right much better than left) to +2 (left much better than right)</P>
<P>4) Cosmetic outcomes</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using marking of the lesions with acetate sheets and permanent-ink pen, standardised photographic documentation, and counting</P>
<P>Time points: at baseline and days 7, 14, 21, 3, and 60</P>
<P>Definitions: lesions that had healed completely (showed no sign of a previous lesion)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 3 blinded dermatologists evaluated how much the appearance of the skin had improved following a standardised scale based on comparison with pictures taken at baseline</P>
<P>Time points: at 60 days</P>
<P>Definitions: 0 (no improvement), 1 (a little better), 2 (much better)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:37:57 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dirschka-2012">
<CHAR_METHODS MODIFIED="2012-11-08 09:39:28 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, assessor-blind, placebo- and active-controlled, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical and histological diagnosis</LI>
<LI>White men and women</LI>
<LI>Between 18 and 85 years of age</LI>
<LI>Anatomical locations: face, bald scalp, or both</LI>
<LI>4 to 8 actinic keratoses, mild to moderate lesions, 0.5 to 1.5 cm in diameter, with a minimum of 1.0 cm interlesional distance</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>All clinical conditions that could influence the study aims and intolerance to any ingredient of BF-200 aminolevulinic acid (ALA) or MAL cream</LI>
<LI>Porphyria</LI>
<LI>Photodermatoses</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 12 weeks with topical treatments within the treatment area</LI>
<LI>within 8 weeks with substances with phototoxic or photoallergic potential</LI>
<LI>within 1 to 6 months with systemic treatments considered to have a possible impact on the outcome, e.g. cytotoxic drugs</LI>
</UL>
</UL>
<UL>
<LI>Use of other treatment for actinic keratoses during the study</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>571 participants</LI>
<LI>479 men, 91 women</LI>
<LI>Age: mean = 71; range = 39 to 87</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: BF-200 (10%) ALA gel-photodynamic therapy (PDT) (N = 248 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: 16% MAL cream -PDT (N = 247 participants)</P>
<P>C: placebo gel-PDT (N = 76 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: individual lesions</P>
<P>Number of treatments: 1 or 2</P>
<P>Interval between treatments: 12 weeks</P>
<P>Preparation of lesions: mild curettage, roughening and alcohol wiping</P>
<P>Cream concentration (%): --</P>
<P>Application of cream: --</P>
<P>Incubation with cream: occlusive dressing over cream for 3 hours</P>
<P>Type of light: red light</P>
<P>Light source: Aktilite CL 128, PhotoDyn 750/505, Omnilux PDT, Waldmann PDT 1200L</P>
<P>Wavelength (nm): 630 (Aktilite, Omnilux), 580-1400 (PhotoDyn), 600-750 (Waldmann)</P>
<P>Energy fluence (J/cm²): 37 (Aktilite, Omnilux), 170 (PhotoDyn), 100 (Waldmann)</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:44:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance at 12 weeks after the first and last PDT</P>
<P>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Lesion complete response at 12 weeks after the last PDT</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Local skin reactions at application sites before and after PDT</P>
<P>2) Adverse events</P>
<P>3) Serious adverse events</P>
<P>3) Pain on a visual analogue scale (VAS: 0 represents no pain, 1 to 3 are interpreted as 'mild', 4 to 7 as 'moderate', and 8 to 10 as 'severe' pain) during PDT</P>
<P>4) Cosmetic outcomes: general</P>
<P>Outcomes were stratified for different light sources, mild and moderate lesions, and lesions on the face and scalp.</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment of lesion clearance by visual inspection and by palpation by an investigator not involved in treatment and safety evaluation</P>
<P>Time points: at baseline, and 3 and 12 weeks post-treatment</P>
<P>Definitions: participant complete clearance (all lesions were considered to be cleared both by the clinical assessment)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. recording of adverse effects, 2. documentation of local adverse reactions (pain, itching, burning, erythema, oedema, and induration) at the application site and rated as mild, moderate, and severe by the assessing physician or reporting participants, 3. serious adverse events</P>
<P>Time points: 1. at 1 week after PDT (by phone) and 3 weeks, 2. during and after PDT (local adverse reactions), 3. throughout the study (serious adverse events)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: 1. general cosmetic outcome assessed by the investigator as very good, good, unsatisfactory, and impaired; 2. assessment of skin quality</P>
<P>Time points: at 12 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:43:53 +0000" MODIFIED_BY="[Empty name]">
<P>This was a confirmatory phase III study.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galitzer-2011">
<CHAR_METHODS MODIFIED="2012-11-08 09:43:55 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, assessor-blind, intraindividual study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 09:45:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Men and women</LI>
<LI>Anatomical locations: dorsal forearm or hand</LI>
<LI>3 actinic keratoses within a continuous 25 cm² area (= target area)</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Participation in other trials</LI>
<LI>Porphyrin abnormalities</LI>
<LI>Sensitivity to trial components</LI>
<LI>Tanning</LI>
<LI>Use of photosensitising drugs or other medications that might interfere</LI>
<LI>Recent procedures or topical preparations directed at the target areas</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>10 participants (forearms or arms were randomised)</LI>
<LI>7 men, 3 women</LI>
<LI>Age: mean = 75</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: pretreatment with tazarotene gel (0.1 %) twice daily for 1 week +<BR/>ALA-blue light photodynamic therapy (PDT) on the entire treatment area, e.g. extensor surface of the hand or forearm between the elbow and<BR/>the base of the fingers, which includes target area (N = 10 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: no pretreatment + ALA-blue light PDT on the entire treatment area (N = 10 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20</P>
<P>Application of cream: first applied to individual lesions and then to entire treatment area</P>
<P>Incubation with cream: 1 hour, with occlusion on the control side</P>
<P>Type of light: blue light</P>
<P>Light source: BLU-U</P>
<P>Wavelength (nm): --</P>
<P>Energy fluence (J/cm²): 10</P>
<P>Intensities (mW/cm²): 10</P>
<P>Exposure time: 16 minutes 40 seconds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:49:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Lesion counts on the target and entire treatment areas after pretreatment and 8 weeks after PDT compared to baseline</P>
<P>2) Median per cent reduction in lesion counts in the target and entire treatment areas after pretreatment and 8 weeks after PDT</P>
<P>3) Participants with different percentage reduction in lesion counts in the target and entire treatment areas (100% = participant complete clearance) after pretreatment (target area only) and 8 weeks after PDT</P>
<P>4) Investigator global assessment (IGA) after pretreatment and 8 weeks after PDT</P>
<P>5) Tolerance (pigmentary changes, erythema, edema, stinging/burning, scaling/dryness, and oozing/vesiculation) at baseline, after pretreatment, after PD, and 8 weeks after PDT</P>
<P>6) Participant satisfaction on 5-point scale in which 0 = poor and 4 = excellent</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment by lesion counting, 2. qualitative assessment by investigator (IGA) on a 5-point scale</P>
<P>Time points: at baseline, after pretreatment, and 8 weeks after PDT</P>
<P>Definitions: IGA: 0 = clear and 5 = very severe</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. postinflammatory hyperpigmentation, erythema, scaling &amp; dryness, edema, and oozing/crusting/vesiculation were assessed using a 5-point ordinal scale (0 = none to 4 = severe), 2. participants rated stinging and burning on a 4-point scale (0 = none and 3 = severe), 3. adverse events were recorded</P>
<P>Time points: at each visit and phone call 24 to 48 hours after PDT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haddad-2011">
<CHAR_METHODS MODIFIED="2012-11-08 09:49:39 +0000" MODIFIED_BY="[Empty name]">
<P>This was a randomised, parallel-group study.</P>
<P>The start and end dates were not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 12:09:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical locations: face or scalp</LI>
<LI>
<U>&gt;</U> 5 actinic keratoses, not treated during the previous 6 months</LI>
<LI>Fitzpatrick skin types I to IV</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>History of porphyria or photosensitivity</LI>
<LI>Active infectious disease</LI>
<LI>Systemic retinoid treatment during the previous year</LI>
<LI>Hypertrophic or keloidal scars</LI>
<LI>Fitzpatrick skin type V and VI</LI>
<LI>Pregnancy or lactation</LI>
<LI>Use of photosensitising drugs (tetracycline, retinoid)</LI>
<LI>Presence of systemic uncontrolled diabetes, hypertension, or or cardiovascular disease</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>24 participants randomised, 21 participants evaluated</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: 20 J/cm² ALA-Intense Pulsed Light (IPL) PDT (N = 4 participants)</P>
<P>B: 25 J/cm² ALA-IPL PDT (N = 4 participants)</P>
<P>C: 40 J/cm² (2 passes of 20 J/cm²) ALA-IPL PDT (N = 5 participants)<BR/>D: 50 J/cm² (2 passes of 25 J/cm²) ALA-IPL PDT (N = 5 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>E: IPL PDT (N = 3 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: --</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20</P>
<P>Application of cream: twice</P>
<P>Incubation with cream: 2 hours</P>
<P>Type of light: IPL</P>
<P>Light source: --</P>
<P>Wavelength (nm): --</P>
<P>Energy fluence (J/cm²): --</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 09:53:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Global response to treatment (actinic keratoses and photodamage) was determined by a 7-point scale (= grade)</P>
<P>2) Mean clearance rates for actinic keratoses only (= difference between mean grades before PDT and 8 weeks after PDT)</P>
<P>3) Tolerability (adverse reactions) at 48 hours after PDT</P>
<P>4) Participant discomfort during PDT</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment of 5 previously identified lesions (non-hyperkeratotic, &lt; 1 cm in diameter, dry, rough, yellowish, with scales) marked in each participant, numbered from 1 to 5, and documented by the FotoFindermediscope system (photography); 2. qualitative assessment (global response) on a 7-point scale</P>
<P>Time points: at baseline, and 48 hours and 8 weeks after PDT</P>
<P>Definitions: 7-point scale: 0 = complete response, 1 = 90% improvement, 2 = 75% improvement, 3 = 50% improvement, 4 = 10% improvement, 5 = no improvement, and 6 = condition worsened</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. erythema, edema, crusts, and erosions were graded on a 5-point scale (0= none to 4= severe), 2. burning or stinging during treatment was graded on a 4-point scale (0 = none to 3 = severe).</P>
<P>Time points: at 48 hours after PDT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:55:15 +0000" MODIFIED_BY="[Empty name]">
<P>The study included participants with actinic keratoses, photodamage, or both.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-09 12:09:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lebwohl-2012">
<CHAR_METHODS MODIFIED="2012-11-08 09:53:30 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group studies (4 studies).</P>
<P>Start date: September 2008</P>
<P>End date: October 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 12:09:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men or women</LI>
<LI>Aged 18 years and older</LI>
<LI>Women must be of either non-child-bearing potential, postmenopausal, or of child-bearing potential but having had a negative serum and urine pregnancy test results prior to study treatment to rule out pregnancy</LI>
<LI>Anatomical location: face or scalp (2 studies), trunk or extremities (2 studies)</LI>
<LI>4 to 8 clinically typical, visible, and discrete actinic keratoses within a 25 cm² contiguous field</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Target treatment area within 5 cm of an incompletely-healed wound or within 10 cm of a suspected basal cell or squamous cell carcinoma</LI>
<LI>Previous treatment with ingenol mebutate gel (PEP-005)</LI>
<LI>Target treatment area contained hypertrophic and hyperkeratotic lesions, or cutaneous horns</LI>
<LI>Lesions that had not responded to repeated cryosurgery</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 weeks with cosmetic or therapeutic procedures within 2 cm of the selected treatment area</LI>
<LI>within 4 weeks with immunomodulators, interferon/interferon inducers, or systemic medications that suppress the immune system</LI>
<LI>within 8 weeks with 5-fluorouracil, imiquimod, diclofenac, or photodynamic therapy within 2 cm of the selected treatment area</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>1005 participants</LI>
<LI>751 men, 254 women</LI>
<LI>Age: mean = 65; range = 34 to 89</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 09:59:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: face or scalp: 0.015% PEP005 gel, once daily for 3 days (N = 277 participants)</P>
<P>trunk or extremities: 0.05% PEP005 gel, once daily for 2 days (N = 226 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle gel, once daily for 2 or 3 days (N = 502 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 14:59:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance rates at day 57</P>
<P>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates at day 57</P>
<P>2) Median percentage changes from baseline in total number of lesions at day 57 and 12 months follow-up (posthoc)</P>
<P>
<B>
<U>Other outcomes of the trial</U>
</B>
</P>
<P>1) New actinic keratosis lesions or recurrence at 12 months follow-up for participants complete cleared in 3 of the studies (posthoc)</P>
<P>2) Local skin reactions on a 5-point scale (individual scores and time course of the mean composite score)</P>
<P>3) Application-site adverse reactions</P>
<P>4) Adverse events</P>
<P>5) Serious adverse events</P>
<P>6) Pigmentation changes and scarring (cosmetic)</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by a study investigator who examined the selected treatment area in person</P>
<P>Time points: at baseline, and day 57 and 12 months follow-up</P>
<P>
<U>Safety</U>
</P>
<P>Methods: 1. assessment of the incidence rate of adverse events, serious adverse events, and local skin responses; 2. grading of local skin responses with photographic guides to ensure uniform reporting for the following: erythema, flaking or scaling, crusting, swelling, vesiculation or pustulation, and erosion or ulceration</P>
<P>Time points: on days 3 (trunk or extremities), 4 (face or scalp), 8, 15, 29, and 57</P>
<P>Definitions: composite local-skin response score (sum of the 6 individual scores that were reported at each study visit for each participant - maximum composite score = 24)</P>
<P>
<U>Cosmetic</U>
</P>
<P>Methods: assessment of pigmentation and scarring</P>
<P>Time points: on days 3, 8, 15, 29, and 57<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 16:01:09 +0000" MODIFIED_BY="[Empty name]">
<P>This included 4 studies: NCT00742391 (= <LINK REF="STD-Swanson-2010b" TYPE="STUDY">Swanson 2010b</LINK> included in analyses), NCT0091551, NTC00916006, and NCT00942604.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serra_x002d_Guillen-2012">
<CHAR_METHODS MODIFIED="2012-11-08 10:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>This was a randomised, active-controlled, parallel-group study.</P>
<P>Start date: January 2009</P>
<P>The end date was not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical locations: face or scalp</LI>
<LI>
<U>&gt;</U> 5 non-hyperkeratotic actinic keratoses or skin alterations indicating field cancerisation in a 25 cm² area of skin</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Previously received imiquimod or PDT on the face or scalp for any lesion</LI>
<LI>Received any other treatment within 3 months</LI>
<LI>Immunosuppressive treatment</LI>
<LI>Hereditary diseases that predispose to skin cancer (Gorlin syndrome, xeroderma pigmentosum)</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>136 participants randomised, 105 participants evaluated</LI>
<LI>92 men, 13 women</LI>
<LI>Age: mean = 73</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: MAL-red light PDT followed 1 month later by 5% imiquimod, 3 times per week for 4 weeks (N = 32 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: MAL-red light PDT (N = 40 participants)</P>
<P>C: 5% imiquimod, 3 times per week for 4 weeks (N = 33 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: curettage of the most hyperkeratotic lesions</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: whole treatment area</P>
<P>Incubation with cream: 3 hours with occlusion</P>
<P>Type of light: red light</P>
<P>Light source: Aktilite CL 1</P>
<P>Wavelength (nm): --</P>
<P>Energy fluence (J/cm²): 37</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 8 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 10:12:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates (clinical) at 1 month post-treatment</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rates (clinical) at 1 month post-treatment</P>
<P>2) Clinicopathologic response (= clinical complete clearance and histological clearance) at 1 month post-treatment</P>
<P>3) Local skin reactions for imiquimod treatment at week 4</P>
<P>4) Tolerance (comfort, discomfort, pain, local skin reaction, side-effects, waiting time, and duration of treatment) evaluated on an analogue scale of 0 (well tolerated) to 10 (very poorly tolerated) after PD, imiquimod treatment, or both</P>
<P>5) Participant satisfaction (benefit, improvement achieved, side-effects, and tolerance) on an analogue scale of 0 (very dissatisfied) to 10 (very satisfied) at 1 month post-treatment</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment by visual examination and palpation, 2. histological evaluation (biopsy) on 2 prespecified lesions identified by photography: lesion 1 before treatment and lesion 2 after treatment</P>
<P>Time points: at baseline, and at 1 month post-treatment</P>
<P>Definitions: 1. complete clinical clearance (total absence of actinic keratoses or lesions clinically suspected of being actinic keratoses), 2. clinicopathologic response (complete clinical response and absence of actinic keratoses in the biopsy specimen of lesion 2), 3. absence of actinic keratoses (normalisation of the stratum corneum with no parakeratosis and normal maturation of epidermal keratinocytes with no atypical keratinocytes)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: evaluation of the intensity of the local reaction (mild, moderate, or severe)</P>
<P>Time points: at week 4 of treatment</P>
<P>Definitions: 1. mild local reaction (occasional appearance of limited edema and mild erythema in the treatment area), 2. moderate local reaction (erythema, edema, ulceration, and flaking in at least 50% of the treatment area), 3. severe local reaction (erythema, edema, ulceration, and crusts occupying almost all of the treatment area and even extending beyond the treatment area)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 10:09:47 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:40:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stockfleth-2011">
<CHAR_METHODS MODIFIED="2012-11-08 10:12:44 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, double-blind, placebo- and active-controlled, parallel-group study.</P>
<P>Start date: 2008</P>
<P>End date: 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Participants with general good and stable health</LI>
<LI>Histological diagnosis</LI>
<LI>Men and women</LI>
<LI>Between 18 and 85 years of age</LI>
<LI>Anatomical locations: face, forehead, or bald scalp</LI>
<LI>Skin type I to IV</LI>
<LI>4 to 10 actinic keratoses within an area of 25 cm², grade I (mild) and II (moderate), with diameter between 0.5 cm and 1.5 cm</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Any treatment for actinic keratosis within the treatment area in the previous 3 months</LI>
<LI>Women of child-bearing potential without a highly effective method of contraception</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>470 participants</LI>
<LI>398 men, 72 women</LI>
<LI>Age: mean = 72</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:40:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 0.5% 5-FU in combination with 10% salicylic acid (SA) solution (LAS41005), once daily for up to 12 weeks (N = 98 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: 5-FU/SA vehicle, once daily for up to 12 weeks (N = 187 participants)</P>
<P>C: 3% diclofenac in hyaluronic acid (HA)(LAS106521), twice daily for up to 12 weeks (N = 185 participants)</P>
<P>If severe side-effects occurred, frequency of drug application could be<BR/>reduced to 3 times per week (5-FU &#8260;SA and vehicle) or to once daily (diclofenac/HA).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 10:17:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Histological clearance rate of 1 predefined lesion</P>
<P>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Lesion counts at baseline, and at week 12 (end of treatment) and 20 (8 weeks post-treatment)</P>
<P>2) Mean total lesion area at baseline and week 20 (8 weeks post-treatment)</P>
<P>3) Participant complete clearance (clinical) at week 20</P>
<P>4) Investigator's and participant's global assessment at weeks 6, 12, and 20</P>
<P>5) Treatment-emergent adverse events (including application site reactions)</P>
<P>6) Tolerance (inflammation and burning)</P>
<P>7) Serious adverse events</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: 1. quantitative assessment by visual inspection of the treatment area and determination of the number and size of lesions, 2. biopsy of 1 representative target lesion performed by 3 mm punch biopsy and a second predefined clinically identical lesion for the biopsy at the post-treatment visit evaluated by an independent and blinded dermatopathologist. Biopsy sites were selected on the basis of clinical appearance (clinical grade, area, and size). Photodocumentation and grid documentation were performed for the purposes of lesion identification. No skin tattoos were used, and no photodocumentation was performed during interim visits, 3. qualitative assessment by physician and participant ranging from 'very good' to 'none'</P>
<P>Time points: at weeks 2, 4, 6, 10, 12 (end of treatment), and 20 (8 weeks<BR/>post-treatment)</P>
<P>
<U>Safety</U>
</P>
<P>Methods: participant-reported adverse events</P>
<P>Time points: at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 10:19:37 +0000" MODIFIED_BY="[Empty name]">
<P>This corresponded to protocol NCT00987246 and EudraCT No. 2007-003889-18.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-11-13 10:37:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiegell-2011b">
<CHAR_METHODS MODIFIED="2012-11-08 10:17:27 +0000" MODIFIED_BY="[Empty name]">
<P>This was a randomised, assessor-blinded, active-controlled, intraindividual study.</P>
<P>Start date: December 2008</P>
<P>End date: May 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 10:19:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical locations: face and scalp</LI>
<LI>Multiple actinic keratoses, symmetrically distributed</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>20 participants (areas randomised)</LI>
<LI>19 men, 1 women</LI>
<LI>Age: mean = 74; range = 58 to 90</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: MAL-2.5h low-intensity artificial daylight photodynamic therapy (PDT) (N = 20 participants)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: MAL-red light-emitting diode (LED) PDT (N = 20 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: field-directed treatment (100 cm²)</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: scales and hyperkeratoses removed with a curette</P>
<P>Cream concentration (%): 16</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 3 hours (under occlusion for 0.5 hours for daylight and 3 hours for red LED)</P>
<P>Type of light: artificial daylight, red light</P>
<P>Light source: Xenon H4 light bulbs (daylight)</P>
<P>Wavelength (nm): --</P>
<P>Energy fluence (J/cm²): 37 (red LED)</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: 2.5 hours for artificial daylight</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 10:20:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Lesion complete response</P>
<P>
<U>
<B>Other outcomes of the trial</B>
</U>
</P>
<P>1) Mean reduction in lesion counts at 3 months post-treatment</P>
<P>2) Participant complete response (= participant complete clearance) at 3 months post-treatment</P>
<P>3) Pain scores (0 = no pain and 10 = worst imaginable pain) every half hour during 'daylight' exposure and every 1.5 minutes during red LED treatment</P>
<P>4) New actinic keratosis lesions</P>
<P>5) PpIX fluorescence</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment using lesion grading and counting using a template</P>
<P>Time points: at baseline and 3 months post-treatment</P>
<P>Definitions: complete response (complete disappearance of the lesion, visually and by palpation - mild erythema might remain)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-08 09:28:45 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-11-13 10:37:08 +0000" MODIFIED_BY="Maryse Paquet" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="NCT" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-11-08 15:17:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-ACTRN12610000689077">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 15:17:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>Randomised, double-blind, placebo-controlled study to assess efficacy of oral nicotinamide (500 mg daily) in the treatment and prevention of actinic keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 10:58:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a randomised, double-blind, placebo-controlled, parallel-group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 10:59:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Symmetrically distributed non-hyperkeratotic actinic keratoses on the face/scalp/upper limbs</LI>
<LI>
<U>&gt;</U> 4 actinic keratoses in 1 or more treatment areas</LI>
<LI>Participants have received no other treatments for actinic keratoses within the last month</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Under 18 years old</LI>
<LI>Pregnant or lactating</LI>
<LI>Taking immunosuppressive or photosensitising medications</LI>
<LI>Immune suppressive concurrent illness (e.g. human immunodeficiency virus - HIV - infection)</LI>
<LI>Malignancy (excluding non-melanoma skin cancer) in the previous 5 years</LI>
<LI>Taking nicotinamide supplements within the last month</LI>
<LI>Participants unable to attend for regular follow up</LI>
<LI>Participants with active dermatitis in assessment areas</LI>
<LI>Liver disease (although hepatic effects of nicotinamide are rare, in contrast to nicotinic acid)</LI>
<LI>Currently taking carbamazepine (case reports of interaction with nicotinamide)</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>40 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 10:59:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: oral nicotinamide 500 mg daily for 4 months</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo tablets (lactose tablets identical in appearance and size to nicotinamide tablets but without active ingredient) daily for 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-24 15:08:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Reduction in total actinic keratosis count at 2 and 4 months from baseline </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 20:37:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>August 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 11:00:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>A/Prof Diona Damian (diona.damian@sswahs.nsw.gov.au)</P>
<P>Dermatology<BR/>Gloucester House Level 3<BR/>Royal Prince Alfred Hospital<BR/>Missenden Rd<BR/>Camperdown 2050</P>
<P>Australia</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-11-08 11:00:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-04-13 19:41:12 +0100" MODIFIED_BY="Maryse Paquet">
<P>This study is ongoing and the last update was in August 2010. (April 2012)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:06:23 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00115154">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:01:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:01:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:05:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Have actinic keratoses on arm or hand</LI>
<LI>Discontinuation of sun tanning and the use of tanning beds</LI>
<LI>Discontinuation of the use of moisturisers, body oils, over-the-counter retinol products, and products containing alpha or beta hydroxy acid in the treatment and surrounding area</LI>
<LI>Withholding from the use of sunscreen in the treatment area for 24 hours prior to all study visits and for 8 hours before applying study cream</LI>
<LI>Postponement of the treatment of non-study actinic keratosis lesions anywhere on the arm being treated until study participation is complete</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Subjects must not have any evidence of systemic cancer, immunosuppression, or other unstable health conditions</LI>
<LI>Participation in another clinical study</LI>
<LI>Have previously received treatment with imiquimod within the treatment area</LI>
<LI>Have squamous cell carcinoma (SCC), basal cell carcinoma (BCC), or other malignancy in the treatment or surrounding area that requires treatment</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>270 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:06:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: imiquimod 5% cream, once per day, 2 days per week for 16 weeks</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle cream, once per day, 2 days per week for 16 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-10 20:07:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Efficacy of imiquimod 5% cream compared to vehicle cream<BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Safety of treatment with imiquimod 5% cream<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 14:21:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>May 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 14:24:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>Graceway Pharmaceuticals, LLC</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 14:25:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00115154<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:06:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed and the last update was in February 2007 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:12:02 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00204542">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:06:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:06:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, open, active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:11:48 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 to 80 years</LI>
<LI>Men and women</LI>
<LI>Visible and histologically-proven actinic keratosis</LI>
<LI>Prepared and able to give written informed consent</LI>
<LI>Prepared to comply with all study requirements, including the following: application of gel on the treatment area twice a day, and 5/7 clinic visits during the pre-study, treatment, post-treatment, and follow-up period</LI>
<LI>Pre- and post-treatment biopsy for histological confirmation (of clearance) of actinic keratosis diagnosis</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Data of clinically significant, unstable, cardiovascular or haematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or diseases</LI>
<LI>Known allergies to any excipient in the study drug</LI>
<LI>Any dermatological disease, condition, or both, in the treatment or surrounding area (3 cm distances from treatment area) that may be exacerbated by treatment with diclofenac or cause difficulty with examination</LI>
<LI>Active chemical dependency or alcoholism, as assessed by the investigator</LI>
<LI>Currently participating in another clinical study or have completed another clinical study with an investigational drug within the past 30 days</LI>
<LI>Received topical treatment at the treatment area with imiquimod or 5-fluorouracil within a time period of 1 month</LI>
<LI>Invasive tumours within the treatment area, e.g. merkel cell carcinoma, squamous cell carcinoma, or basal cell carcinoma; the latter is accepted if completely surgically removed</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>418 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-02 17:37:05 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: diclofenac, twice daily for 3 months</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>B: diclofenac, twice daily for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:08:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Histologically controlled complete clearance of the actinic keratosis at 6 weeks post-treatment <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 14:11:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>June 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 14:13:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>Claus Garbe, MD</P>
<P>Skin Cancer Program, </P>
<P>Department of Dermatology, </P>
<P>University Hospital Tübingen</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-11 14:16:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00204542<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:12:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in December 2010, and the last update was in August 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:18:30 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00472459">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:12:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:13:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:16:14 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Transplant recipients with at least 2 clinically-diagnosed actinic keratosis lesions and maximum 10 skin lesions [actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) in situ, warts, or both) in each of the 2 contralateral areas (diameter 5 x 10 cm) in the face, the scalp, the extremities, or on the trunk/neck</LI>
<LI>Transplant recipients who previously are treated more than once for their skin lesions</LI>
<LI>Transplant recipients who have received immunosuppressive therapy for more than 3 years</LI>
<LI>Men or women above 18 years of age</LI>
<LI>Written informed consent</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Participants with more than 10 skin lesions (AK, BCC, SCC in situ, warts) in 1 of the 2 areas</LI>
<LI>Participants with SCC (not SCC in situ) in 1 of the 2 areas</LI>
<LI>Participants not previously treated or treated only once for their skin lesions</LI>
<LI>Participants with rosacea in 1 of the 2 areas</LI>
<LI>Participants with morpheaform/highly infiltrating BCC</LI>
<LI>Known allergy to methyl-aminolevulinate, a similar compound or excipients of the cream</LI>
<LI>Participation in other clinical studies either concurrently or within the last 30 days</LI>
<LI>Pregnant or breastfeeding (all women of child-bearing potential must document a negative pregnancy test and use the pill or intrauterine device (IUD) during the treatments and for at least 1 month thereafter)</LI>
<LI>Conditions associated with a risk of poor protocol compliance</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>81 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:17:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: the treatment area on a randomised side (5 x 10 cm²) will be treated at baseline and at visits at 3, 9, and 15 months. At baseline the area will be treated with fractionated Metvix® PDT treatment consisting of 2 treatments 1 week apart and at visits at 3, 9, and 15 months with single Metvix® PDT treatment</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: in the contralateral control area (5 x 10 cm²), new and recurrent lesions and lesions in non-complete response will be treated with lesion-specific treatment at the discretion of the investigator at each study visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:18:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Occurrence of new lesions (actinic keratosis, basal cell carcinoma, squamous cell carcinoma and warts) at  3, 9, 15, 21, and 27 months after first treatment<BR/>2) Number of actinic keratosis lesions that show complete response at 3, 9, 15, 21, and 27 months after first treatment <BR/>
<U>
<B>Secondary outcomes of the trial </B>
</U>
</P>
<P>1) Number of BCC lesions that show complete response in the treated area with the contralateral control area at  3, 9, 15, 21, and 27 months after first treatment <BR/>2) Number of recurrent lesions at 9, 15, 21, and 27 months after first treatment<BR/>3) Assess the cosmetic outcome at 3, 9, 15, 21, and 17 months after first treatment <BR/>4) Investigate product safety in this participant population at 3, 9, 15, 21, and 27 months after first treatment <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 20:04:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>July 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 20:05:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>Ann-Marie Wennberg, MD, PhD (PI)</P>
<P>Sahlgrenska University Hospital</P>
<P>Gothenburg, </P>
<P>Sweden</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 20:05:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00472459<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:18:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in July 2006, and the last update was in September 2010 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:53:22 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00608634">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:19:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:18:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a single-centre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:53:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Women must not be of child-bearing potential, and therefore must be postmenopausal or surgically sterile by hysterectomy</LI>
<LI>Not pregnant or nursing</LI>
</UL>
<P>
<U>Disease characteristics</U>
</P>
<UL>
<LI>Resident of Pima or adjoining Southern Arizona county</LI>
<LI>Participants outside of Pima County are also eligible</LI>
<LI>Sun-damaged skin as judged by the study physician and quantifiable, clinically-diagnosed, and visible actinic keratoses on both dorsal forearms, with at least 2 AK on each arm</LI>
<LI>AK lesions must not be clustered, confluent, or too numerous to count accurately</LI>
<LI>Presence of actinic keratoses on sites other than the test area allowed</LI>
<LI>No significant inflammation or irritation of the skin of the upper extremities that is not clinically-diagnosed as sun damage, or AK participants must agree to limit sun exposure as much as possible and may continue their normal pattern of sunscreen use</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Concurrent skin malignancy or disorder of the upper extremities</LI>
<LI>Participants with squamous or basal cell carcinoma in an area other than the test area are eligible upon excision of the squamous or basal cell carcinoma</LI>
<LI>Participants who are immunosuppressed by virtue of medication or disease</LI>
<LI>Serious concurrent illness that could interfere with study regimen</LI>
<LI>Invasive cancer within the past 5 years</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 30 days with prior topical medications to the skin of the upper extremities, except for emollients or sunscreens; concurrent mega-doses of vitamins, defined as any of the following: more than 5 times the recommended daily allowance, more than 5 capsules of multivitamins, 400 IU of vitamin E, 200 &#956;g of selenium, or 1 g of vitamin C</LI>
<LI>within 6 months with concurrent therapy for squamous cell carcinoma or basal cell carcinoma anywhere in the test area (i.e. the forearms or hands), treatment for squamous cell carcinoma or basal cell carcinoma on sites other than the test area is allowed, within 4 weeks, with surgical biopsy, surgical excision, or cryotherapy for actinic keratosis in the test area and the sites must have healed</LI>
<LI>within 6 months with topical treatment (e.g. 5-fluorouracil or imiquimod) for actinic keratosis</LI>
</UL>
</UL>
<UL>
<LI>No concurrent therapy that may interfere with clinical evaluations</LI>
<LI>No concurrent topical drug treatment (e.g. retinoids, aminolevulinic acid, diclofenac sodium, imiquimod, or fluorouracil) to any area of skin, including test area</LI>
<LI>No concurrent enrolment in another clinical trial</LI>
<LI>No concurrent topical citrus peel or consumption of citrus peel</LI>
<LI>No chemotherapy for cancer within the past 5 years</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>94 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:24:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: perillyl alcohol (POH) cream (0.3%) applied topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity</P>
<P>B: perillyl alcohol (POH) cream (0.76%) applied topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>C: placebo cream applied topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:25:02 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) To determine if topical administration of perillyl alcohol (POH) cream can reverse actinic damage as evidenced by normalisation of quantitative skin histopathology scores in skin tissue biopsy samples from participants with moderate to severe sun damage</P>
<P>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) To determine if topically-administered POH results in significant alterations in surrogate end point biomarkers of epidermal cell proliferation, including optical coherence tomography, p53 expression, c-Fos expression, and apoptosis (as measured by activated caspase-3 expression)</P>
<P>2)To determine if topically-administered POH results in normalisation of nuclear chromatin patterns in skin biopsy tissue from these participants, as determined by karyometric analysis</P>
<P>3) To determine if topical POH can be administered safely to the forearms of these participants</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 19:48:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>May 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 19:49:08 +0000" MODIFIED_BY="Maryse Paquet">
<P>Steve Stratton, MD (study chair)</P>
<P>University of Arizona</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 19:49:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00608634<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:25:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>The status of this study is unknown, and the last update was in September 2010 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:27:05 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00695578">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:25:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:25:36 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a single-centre, randomised, assessor-blinded, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:26:25 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Subject must give written consent</LI>
<LI>Aged 50 years and older</LI>
<LI>Men and women</LI>
<LI>Subjects must have had cryotherapy treatment of at least 1 actinic keratosis on each forearm in the dermatology clinic (Wake Forest University Health Sciences Dermatology)</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Subjects age &lt; 50 years of age</LI>
<LI>Subjects with known allergy or sensitivity to topical Biafine or polysporin ointment</LI>
<LI>Inability to complete all study-related visits</LI>
<LI>Introduction of any other prescription medication, topical or systemic, for actinic keratoses while participating in the study</LI>
<LI>Subjects using other topical agent's glycolic acid products, alpha hydroxy acid products, retinoids, and chemical peel agents in the treatment areas while on study</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>20 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-12 09:31:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: cryotherapy followed by Biafine cream</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy followed by standard care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:27:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) The change of the target lesions from baseline to end of treatment in the IGA at  4 weeks <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 16:27:11 +0000" MODIFIED_BY="Maryse Paquet">
<P>October 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 16:27:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>Steve Feldman, MD, PhD (PI)</P>
<P>Wake Forest University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 16:27:46 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00695578<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:26:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in February 2008, and the last update was in February 2009 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 14:54:34 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00700063">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:27:36 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:27:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:34 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Men or women</LI>
<LI>Women must be of non-child-bearing potential; child-bearing potential provided negative pregnancy test and using effective contraception</LI>
<LI>4 to 8 actinic keratosis lesions on the face or scalp</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Treatment as follows:</LI>
<UL>
<LI>within 2 weeks with cosmetic or therapeutic procedures within 2 cm of the selected treatment area</LI>
<LI>within 4 weeks with immunomodulators, interferon/interferon inducers, or systemic medications that suppress the immune system</LI>
<LI>within 8 weeks with 5-fluorouracil, imiquimod, diclofenac, or photodynamic therapy within 2 cm of treatment area</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>265 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:29:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: PEP005 topical gel 0.005%, 2-day treatment</P>
<P>B: PEP005 topical gel 0.01%, 2-day treatment</P>
<P>C: PEP005 topical gel 0.015%, 2-day treatment</P>
<P>D: PEP005 topical gel 0.005%, 3-day treatment</P>
<P>E: PEP005 topical gel 0.01%, 3-day treatment</P>
<P>F: PEP005 topical gel 0.015%, 3-day treatment</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>G: vehicle gel, 2-day treatment</P>
<P>H: vehicle gel, 3-day treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:29:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Safety and toleration (incidence of adverse events, serious adverse events, and skin responses) at 57 days <BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Efficacy (clearance of actinic keratosis lesions) at 57 days <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 17:56:49 +0000" MODIFIED_BY="Maryse Paquet">
<P>June 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 17:57:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>Peplin</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 17:57:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00700063<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:29:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in October 2008, and the last update was in July 2010 (April 2012).</P>
<P>Incomplete data were published in abstract form in an excluded study (<LINK REF="STD-Spencer-2010" TYPE="STUDY">Spencer 2010</LINK>).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:34:05 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00756288">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:30:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Randomized Controlled Paired Comparison of Photo-therapy With a Topical Retinoid Cream Pretreatment Versus PDT Alone for Actinic Keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:30:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a single-centre, randomised, double-blind, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:32:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 to 80 years old</LI>
<LI>Participants with actinic keratosis lesions who will receive PDT</LI>
<LI>Participants with actinic keratosis lesions in 2 areas other than the face and scalp, each with a surface area of 10 cm² or greater and at least 3 clinically-diagnosed non-hypertrophic actinic keratosis lesions in each</LI>
<LI>Participants in good health</LI>
<LI>Participants with willingness and the ability to understand and provide informed consent</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Participants who are pregnant or lactating</LI>
<LI>Participants with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 1 week with photosensitising drugs</LI>
<LI>within 2 weeks with topical medications, such as corticosteroids, alpha hydroxy acids, or retinoids</LI>
<LI>within 4 weeks with previous treatment of target actinic keratoses</LI>
</UL>
</UL>
<UL>
<LI>Participants who are unable to understand the protocol or give informed consent</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>20 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:32:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: topical retinoid, for 4 weeks followed by blue-light photodynamic therapy with photosensitising agent (at week 4)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: blue-light photodynamic therapy with photosensitising agent at week 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:34:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Live blinded rater and blinded photo rater analysis of areas at week 0 and week 6 for erythema, edema, crusting, ulceration, palpability, and the need to cease/delay treatment</P>
<P>2) Overall response in reduction of number of AKs at 6 weeks <BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Participants will assess pain, burning, and itching on a scale of 0 to 3 at week 0, during retinoid treatment, during phototherapy, 1 day after, and at week 6</P>
<P>2) Principal investigator will evaluate adverse events at week 6<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 15:38:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>August 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 15:39:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>Murad Alam, MD (PI)</P>
<P>Department of Dermatology</P>
<P>Northwestern University</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 15:39:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00756288<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-04-13 19:53:31 +0100" MODIFIED_BY="Maryse Paquet">
<P>This study is ongoing and the last update was in April 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:39:00 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00786994">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:34:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>Randomized, Multicenter, Double Blind Study to Compare the Efficacy and Tolerability of Oleogel-S-10 for 3 Month Versus Placebo Only in Patients With Mild to Moderate Actinic Keratoses Located at the Face and Head Oleogel-S-10 in Actinic Keratoses Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:34:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:38:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Histologically-proven actinic keratoses within 3 months before study entry</LI>
<LI>Aged 18 years and older</LI>
<LI>
<U>&gt;</U> 2 mild to moderate actinic keratoses located at the facial skin or the head (except lips)</LI>
<LI>Actinic keratoses with a diameter of 0.5 to 2 cm that are definitely distinguished from other lesions and display a minimum distance of 0.5 cm to neighboured lesions that are evaluated as histopathological grade 1 to 3</LI>
<LI>Prepared and able to give written informed consent</LI>
<LI>In case of women: postmenopause defined as natural menopause with menses &gt; 1 year ago serum FSH (&gt; 20 IU/l) and E2 levels in the postmenopausal range or participants who had bilateral oophorectomy</LI>
<LI>Prepared and comply with all study requirements, including the following: application of Oleogel-S10 on the treatment area once or twice a day; 4 clinic visits during the pre-study, treatment, post-treatment, and follow-up period; pre- and post-treatment biopsy for histological confirmation (of clearance) of actinic keratosis-diagnosis</LI>
<LI>Representative histologic slide and tissue block were shipped</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Active immunosuppressive therapy</LI>
<LI>Data of clinically significant, unstable, cardiovascular or hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or diseases (note: participants with clinically-stable medical conditions including, but not limited to, controlled hypertension, diabetes mellitus type II, hypercholesterolemia, or osteoarthritis will be allowed to enter the study</LI>
<LI>Known allergies to any excipient in the study drug</LI>
<LI>Any dermatological disease, condition, or both, in the treatment or surrounding area (3 cm distances from treatment area) that may be exacerbated by treatment with Oleogel-S-10 or cause difficulty with examination</LI>
<LI>Active chemical dependency or alcoholism, as assessed by the investigator</LI>
<LI>Pregnant and lactating women</LI>
<LI>Currently participating in another clinical study or have completed another clinical study with an investigational drug within the past 30 days</LI>
<LI>Treatment as follows: within 1 month with topical treatment at the treatment area with diclofenac gel, imiquimod, or 5-fluorouracil</LI>
<LI>Concomitant existence of non-treated (non-excised) basal cell carcinoma, squamous cell carcinoma, or malignant melanoma</LI>
<LI>Invasive tumours within the treatment area, e.g. merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma; the latter is accepted if completely surgically removed. Note: a biopsy of any lesion within the treatment or surrounding area suggestive of malignancy should be performed at the pre-study screening visit. If invasive SCC or other malignant conditions are confirmed within the treatment area, the participant will not be included in the study</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>165 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:38:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: oleogel-S-10 for 3 months once a day (N = 54 participants)</P>
<P>B: oleogel-S-10 for 3 months twice a day (N = 54 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>C: placebo (petroleum jelly) for 3 months once a day (N = 27 participants)</P>
<P>D: placebo (petroleum jelly) for 3 months twice a day (N = 27 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:38:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification) assessed at 18 weeks. The marker actinic keratosis is defined as an initially-selected lesion within the target area that will be used for final biopsy<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Histologically-controlled complete clearance,</P>
<P>2) Histologically-controlled down staging 75% clearance rate</P>
<P>3) Dose response relationship</P>
<P>4)Time to clinically complete response</P>
<P>5) Tolerability<BR/>Assessment at 18 weeks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-07 20:05:59 +0000" MODIFIED_BY="Maryse Paquet">
<P>October 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-07 20:08:22 +0000" MODIFIED_BY="Maryse Paquet">
<P>Birken GmbH</P>
<P>Principal investigator Claus Garbe, Prof. Dr, Universitätshautklinik Tübingen</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-07 20:06:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00786994<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:39:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in November 2010 and the last update was in January 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:00:05 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00859105">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:39:23 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Multicenter, Double-Blind, Vehical-Controlled Study Comparing Imiquimod Cream, 5% (Apotex Inc.) to Aldara&#8482; Cream, 5%(3M Pharmaceutials, U.S.) and Aldara&#8482; Cream, 5%(3M Pharmaceuticals, Canada) in the Treatments of Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:39:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:00:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>4 to 8 clinically-diagnosed, non-hyperkeratotic, non-hypertrophic actinic keratosis lesions within a 25 cm² contiguous treatment area on either the face or balding scalp</LI>
<LI>Women either must be 1 year postmenopausal, surgically sterile, or agree to use a medically-accepted form of birth control</LI>
<LI>Free of any systemic or dermatological disorder</LI>
<LI>Any skin type or race, providing the skin pigmentation will allow discernment of erythema</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)</LI>
<LI>History of cutaneous hyperreactivity or facial irritation to topical products</LI>
<LI>Engaging in activities involving excessive or prolonged exposure to sunlight</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 6 months with systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels</LI>
<LI>within 2 months with systemic steroids</LI>
<LI>within 28 days with over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments in the treatment area</LI>
</UL>
</UL>
<UL>
<LI>Pregnant or nursing mothers</LI>
<LI>History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation</LI>
<LI>Taking immunosuppressant medication</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>497 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-12 09:41:30 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: Apotex, 5% imiquimod applied as a thin layer to target area once a day, 2 days each week, 16 weeks</P>
<P>B: Aldara US, 5% imiquimod applied as a thin layer to target area once a day, 2 days each week, 16 weeks</P>
<P>C: Aldara Canada, 5% imiquimod applied as a thin layer to target area once a day, 2 days each week, 16 weeks</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>D: vehicle applied as a thin layer to target area once a day, 2 days each week, 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:41:33 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Apotex Inc. and 2 Aldara (imiquimod) creams, manufactured by 3M (US &amp; Canada) at 24 weeks </P>
<P>2) Superiority over vehicle in the treatment of AK at 24 weeks <BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) The secondary objective is to compare the safety profiles of the 3 creams at 24 weeks <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 19:20:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>February 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 19:20:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>William Brooks (study director)</P>
<P>Apotex Inc</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 19:23:50 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00859105<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:41:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in November 2008, and the last update was in March 2009 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:08:29 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00948428">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:42:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara&#8482; Cream in Subjects With Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:42:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, placebo- and active-controlled, parallel-group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:08:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men or non-pregnant women</LI>
<LI>Aged 18 years and older</LI>
<LI>In general good health</LI>
<LI>Women who were postmenopausal, surgically sterile, or using a medically acceptable form of birth control with a negative urine pregnancy test at the baseline visit</LI>
<LI>Participants provided written and verbal informed consent.</LI>
<LI>4 to 12 visible, discrete non-hyperkeratotic, non-hypertrophic actinic keratosis lesions within a 25 cm² treatment area on the face, anterior scalp, or both</LI>
<LI>Participants were willing and able to comply with study instructions and return to the clinic for required visits.</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Participants who were lactating, or planning to become pregnant during the study</LI>
<LI>Participants had hyperkeratotic, hypertrophic or large mat-like actinic keratoses within the 25 cm² treatment area</LI>
<LI>Participants who had the need or were planning to be exposed to artificial tanning devices or excessive sunlight during the trial</LI>
<LI>Participants who were immunosuppressed (e.g. HIV, systemic malignancy, graft vs host disease, etc)</LI>
<LI>Participants who experienced an unsuccessful outcome from previous imiquimod therapy</LI>
<LI>Participants with known hypersensitivity or previous allergic reaction to any of the active or inactive components of the study drugs</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 months with laser resurfacing, photodynamic therapy, chemical peels, dermabrasion, topical application of 5-fluorouracil, imiquimod, diclofenac sodium, or other treatments for actinic keratoses or photodamage</LI>
<LI>within 2 days with topicals of any kind to the selected treatment area</LI>
<LI>within 2 weeks with facial topical medications: corticosteroids; alpha hydroxy acids (e.g. glycolic acid, lactic acid, etc, greater than 5%); beta hydroxy acid (salicylic acid greater than 2%); urea - greater than 5% or prescription retinoids (e.g. tazarotene, adapalene, tretinoin) to the face, anterior scalp, or both; or cryotherapy to lesions adjacent to or within the 25 cm² treatment area</LI>
<LI>within 4 weeks with systemic steroid therapy: chemotherapeutic agents, psoralens, immunotherapy, or retinoids</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>462 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-24 14:09:26 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: generic 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: Aldara 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</P>
<P>C: topical cream vehicle matching generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:46:09 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Proportion of participants in each treatment group with complete clearance of actinic keratosis lesions at 8 weeks post-treatment (week 24, test of cure/TOC) visit<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) The partial clearance rates, defined as the proportion of subjects with at least a 75% reduction in the number of lesions counted at baseline</P>
<P>2) Proportion of participants with complete clearance of lesions at week 16 (end of treatment) and week 24 (TOC)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 16:40:00 +0000" MODIFIED_BY="Maryse Paquet">
<P>May 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 16:40:40 +0000" MODIFIED_BY="Maryse Paquet">
<P>Christine M. Winslow, Ph.D. (study director)</P>
<P>Actavis Mid-Atlantic LLC</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 16:40:55 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00948428<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:45:26 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in April 2009, and last update was in August 2010 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 11:48:32 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT00991861">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:46:42 +0000" MODIFIED_BY="Maryse Paquet">
<P>Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:46:19 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:48:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Men and women</LI>
<LI>At least 4 to 10 clinically-assessed actinic keratoses grade I to II (according to <LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>) in the face/forehead, on the bald scalp, or both</LI>
<LI>The diameter of each actinic keratosis target lesion is not less than 0.5 cm and not greater than 1.5 cm</LI>
<LI>The target lesions must be located in overall 2 treatment areas with a size of 25 cm² per treatment area</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Have evidence of clinically-significant or unstable medical conditions, such as metastatic tumour or tumour with high probability of metastatic spread; heart failure (NYHA class III or higher); immunosuppressive disorder (e.g. HIV); hematologic, hepatic, renal, neurologic, or endocrine disorder; collagen-vascular disorder (e.g. cerebrovascular disorder or other bleedings); or gastrointestinal disorder (e.g. active ulcera or history of recurrent peptic ulcera or haemorrhage)</LI>
<LI>Suffer from paraesthesia in the treatment areas</LI>
<LI>Show Cornu cutaneum of the skin, hypertrophic actinic keratosis lesions in the treatment areas, or both</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>100 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-11 17:55:48 +0100" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Interventions</U>
</B>
</P>
<P>A: LAS41007 once daily</P>
<P>B: LAS41007 twice daily</P>
<P>
<B>
<U>Control intervention</U>
</B>
</P>
<P>C: LAS106521 (3% diclofenac in hyaluronic acid)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 11:48:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Histological clearance of 1 pre-selected target lesion at day 120 <BR/>2) Complete clinical clearance of all target lesions in the treatment areas at day 120 <BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Physician's Global Tolerability Assessment (PGT) at day 120 <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 13:59:56 +0000" MODIFIED_BY="Maryse Paquet">
<P>August 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-08 14:00:27 +0000" MODIFIED_BY="Maryse Paquet">
<P>Christoph Willers, MD, MBA</P>
<P>Almirall Hermal GmbH</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 17:58:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT00991861<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:48:32 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study has been completed in February 2010, and the last update was in July 2010 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:53:28 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT01203878">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:49:10 +0000" MODIFIED_BY="Maryse Paquet">
<P>An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:48:51 +0000" MODIFIED_BY="Maryse Paquet">
<P>This was a multicentre, randomised, open, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 11:50:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>10 to 30 clinically typical actinic keratoses on the face</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Hypertrophic actinic keratoses or other skin lesions on the head that might require excluded treatment during the study</LI>
<LI>Known contraindication to treatment with imiquimod or photodynamic therapy</LI>
<LI>Condition that would limit compliance, be a potential safety risk, or require therapy with an excluded treatment</LI>
<LI>Systemically immunocompromised</LI>
<LI>Pregnant or nursing</LI>
<LI>Dermatologic disease, condition, or both in the treatment area that might be exacerbated by treatment with imiquimod, cause difficulty with examination, or require therapy with an excluded treatment</LI>
<LI>Participation in another clinical study</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 60 days with ultraviolet therapy, systemic immunomodulators, chemotherapeutic or cytotoxic agentsInvestigational agents</LI>
<LI>on the head with imiquimod, photodynamic therapy, red or blue light source therapy, cryotherapy or chemotherapy, surgical excision or curettage, topical corticosteroids, laser dermabrasion, chemical peel, topical retinoids, topical 5-fluorouracil, topical pimecrolimus or tacrolimus, or topical diclofenac</LI>
</UL>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>60 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 11:50:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: imiquimod 3.75% cream, up to 2 packets, applied topically daily for 2 2-week cycles separated by a no-treatment interval of 2 weeks, followed 4 weeks later by photodynamic therapy with 20% aminolevulinic acid and blue light exposure of the entire face</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for 2 2-week cycles separated by a no-treatment interval of 2 weeks, followed by observation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:53:28 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Actinic keratosis count at  week 18</P>
<P>2) The per cent change in actinic keratosis count as compared to the baseline lesion count<BR/>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Complete clearance at week 18</P>
<P>2) The proportion of participants with complete clearance of actinic keratoses in the treatment area (entire face)<BR/>3) Cosmetic appearance at week 18</P>
<P>4) Change in investigator and participant scores of cosmetic appearance of the treatment area (entire face)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-07 20:51:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>September 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-07 20:52:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>Julie Biron <A HREF="mailto:jbiron%40goldskincare.com?subject=NCT01203878, 09US05N375-Gold, Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy">jbiron@goldskincare.com</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-07 20:52:17 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT01203878<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:50:57 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study is currently recruiting, and the last update was in July 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 14:54:35 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT01229319">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:56:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:56:15 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a single-centre, randomised, assessor-blinded, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Participants must be in good general health as confirmed by the medical history</LI>
<LI>Participants must be able to read, sign, and understand the informed consent</LI>
<LI>Prior to cryosurgery, participants have at least 3 hypertrophic actinic keratoses on each dorsal hand/forearm</LI>
<LI>Participant must be willing to forego any other treatments on the dorsum of the hands and or/forearms, including tanning bed use and excessive sun exposure while in the study</LI>
<LI>Participant is willing and able to participate in the study as an outpatient, making frequent visits to the study centre during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions</LI>
<LI>If the participant is a woman of child-bearing potential, she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Participants with a history of melanoma anywhere on the body</LI>
<LI>Participants with an unstable medical condition as deemed by the clinical investigator</LI>
<LI>Participants with non-melanoma skin cancer on the dorsum of the hands or forearms</LI>
<LI>Participants with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of AKs</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 6 months with imiquimod on the dorsum of the hands or forearms</LI>
<LI>within 30 days with imiquimod outside of the study area, any topical prescription medications on the study area</LI>
</UL>
</UL>
<UL>
<LI>Women who are pregnant, lactating, or planning to become pregnant during the study period</LI>
<LI>Participants who have experienced a clinically-important medical event within 90 days of the visit (e.g. stroke, myocardial infarction, etc)</LI>
<LI>Participants who have active chemical dependency or alcoholism as assessed by the investigator</LI>
<LI>Participants who have known allergies to any excipient in the study cream</LI>
<LI>Participants who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device on the study area within 30 days prior to study treatment initiation</LI>
</UL>
<P>
<B>
<U>Demographics:</U>
</B>
</P>
<UL>
<LI>20 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-12 10:17:35 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: cryotherapy + imiquimod 3.75% daily for 2 weeks on, 2 weeks off, 2 weeks on on one arm</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy alone on the other arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-11 15:28:44 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Clearance of actinic keratoses assessed at 14 weeks </P>
<P>2) Actinic keratosis lesion count</P>
<P>3) Photography<BR/>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Local skin reactions assessed at 14 weeks <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-07 20:38:03 +0000" MODIFIED_BY="Maryse Paquet">
<P>October 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 11:57:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>Gary S Goldenberg, MD (<A HREF="mailto:garygoldenbergmd%40gmail.com?subject=NCT01229319, 10-0933, Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses">garygoldenbergmd@gmail.com</A>)</P>
<P>Giselle Singer, BS (<A HREF="mailto:giselle.singer%40mssm.edu?subject=NCT01229319, 10-0933, Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses">giselle.singer@mssm.edu</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-07 20:39:21 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT01229319<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 11:58:01 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study is currently recruiting, and the last update was in June 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 14:53:54 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT01260987">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 11:58:41 +0000" MODIFIED_BY="Maryse Paquet">
<P>Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 11:58:47 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a single-centre, randomised, assessor-blinded, active-controlled, intraindividual.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:53:54 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Skin type I to III</LI>
<LI>Fertile women using secure birth control</LI>
<LI>Moderate to severe actinic keratoses in the face or on the hands</LI>
<LI>Difficult-to-treat nodular basal cell carcinomas in the face</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnancy or breastfeeding participants</LI>
<LI>Participants with porphyria</LI>
<LI>Participants with Gorlins syndrome</LI>
<LI>Participants with a tendency to produce hypertrophic scars or keloids</LI>
<LI>Participants with known allergy to Metvix</LI>
<LI>Participants who are not considered able to follow the treatment protocol (e.g. severely alcoholic, dementia, mentally ill, etc)</LI>
<LI>Participants with pigmented or morphea basal cell carcinomas</LI>
<LI>Known herpes simplex virus infection in treatment areas</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>47 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:00:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: fractional CO&#8322; laser assisted photodynamic therapy (PDT) pretreatment with fractional CO&#8322; laser before methyl-aminolevulinate (MAL)-red light PDT (37 J/cm²)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: conventional photodynamic therapy using methyl-aminolevulinate (MAL) and red light (37 J/cm²)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:00:39 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Treatment response at 3 months, clinical evaluation by a blinded physician<BR/>2) Reoccurrence at 12 months, clinical evaluation by a blinded physician<BR/>3) Treatment response at 12 months <BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Pain during treatment, participant score (VAS 0 to 10)<BR/>2) Adverse effects at 12 months </P>
<P>3) Scaring, hyper- and hypopigmentation<BR/>4) Fluorescence at 3 hours, MAL uptake<BR/>5) Cosmetic result at 12 months, 4-point scale<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 16:15:53 +0000" MODIFIED_BY="Maryse Paquet">
<P>October 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:00:12 +0000" MODIFIED_BY="Maryse Paquet">
<P>Christina S Haak, MD (<A HREF="mailto:christinahaak%40dadlnet.dk?subject=NCT01260987, H-1-2010-044, Fractional CO2 Laser Assisted Photodynamic Therapy">christinahaak@dadlnet.dk</A>)</P>
<P>Katrine Togsverd-Bo, MD (<A HREF="mailto:KTOG0001%40regionh.bbh.dk?subject=NCT01260987, H-1-2010-044, Fractional CO2 Laser Assisted Photodynamic Therapy">KTOG0001@regionh.bbh.dk</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 16:17:06 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT01260987<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:00:16 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study is currently recruiting, and the last update was June 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-09 12:10:43 +0000" MODIFIED_BY="Maryse Paquet" STUDY_ID="STD-NCT01265602">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:00:58 +0000" MODIFIED_BY="Maryse Paquet">
<P>Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:01:05 +0000" MODIFIED_BY="Maryse Paquet">
<P>This is a multicentre, randomised, double-blind, placebo- and active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 12:05:04 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Aged 18 years and older</LI>
<LI>Men and women</LI>
<LI>6 to 16 clinically-confirmed actinic keratosis target lesions of mild to moderate (grade I to II, according to <LINK REF="STD-Olsen-1991" TYPE="STUDY">Olsen 1991</LINK>) intensity in the whole treatment area (TA) (and additionally 1 representative lesion for histological diagnosis of actinic keratosis), which must be located in the face including the forehead (excluding eyelids, lips, and mucosa), bald scalp, or both</LI>
<LI>The actinic keratosis target lesions must be discrete and quantifiable; the distance from 1 lesion to its neighbour lesion must be greater than 1.0 cm</LI>
<LI>The diameter of each target lesion should be not less than 0.5 cm and not greater than 1.5 cm</LI>
<LI>The target lesions must be located in up to 3 TAs with a size of 25 cm² per TA (i.e. total area of TA is up to 75 cm²)</LI>
<LI>Diagnosis of actinic keratosis histologically confirmed</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Have known hypersensitivity, intolerance, or allergies against ingredients of the IMPs and other non-steroidal anti-inflammatory agents</LI>
<LI>Have a history of bronchospasm, asthma, urticaria, or rhinitis after the intake of non-steroidal anti-inflammatory drugs (NSAIDs)</LI>
<LI>Have a history of gastrointestinal bleeding or perforation associated with prior therapy with NSAIDs</LI>
<LI>Have evidence of clinically significant or unstable medical conditions</LI>
<LI>Have currently and within the past 3 months other malignant tumours of the skin in the TAs</LI>
<LI>Suffer from paraesthesia in the TAs</LI>
<LI>Show cornu cutaneum of the skin, hypertrophic, or both, actinic keratosis lesions in the TAs</LI>
<LI>Are known to be pregnant or lactating (currently or within the past 3 months)</LI>
<LI>Any clinically relevant abnormal finding during screening, baseline, or both</LI>
<LI>Specific topical treatments in the target area within defined time periods</LI>
<LI>Specific physical treatments in the TAs within defined time periods</LI>
<LI>Specific systemic treatments within defined time periods</LI>
<LI>Participants suffering from actinic keratoses in locations other than the target areas, receiving any topical therapy throughout the interventional phase of the study until termination of V6</LI>
<LI>Participants who need a permanent therapy with any other NSAID. The use of NSAIDs as "prn" (pro re nata), i.e. to be taken as needed (&#8804; 3 days at a stretch) and the use of ASA as anticoagulative therapy will be allowed</LI>
<LI>Participants taking methotrexate or sulfonylurea during the interventional phase of the study</LI>
<LI>Anticoagulative therapy, e.g. with cumarines or heparines throughout the interventional phase of the study. Treatment with ASA at a dose not exceeding 100 mg/d and clopidogrel at a dose not exceeding 75 mg/d will be allowed</LI>
<LI>Participants having any significant physical abnormalities in the potential TAs that may cause difficulty with examination or final evaluation</LI>
<LI>Have any dermatological disease in the TAs or surrounding area that may be exacerbated by treatment with topical diclofenac or cause difficulty with examination</LI>
<LI>Physical or mental inability, unwillingness, or both, to apply the study preparations correctly and to follow the study restrictions and visits</LI>
<LI>Any suspicion of current drug or alcohol abuse, or both, as assessed by the investigator</LI>
<LI>Anticipated non-availability for study visits/procedures</LI>
<LI>Exposure to an investigational product within the last 3 months</LI>
<LI>Any previous randomisation into this trial</LI>
<LI>Participant is institutionalised because of legal or regulatory order</LI>
<LI>Employee of the study site or of the Sponsor's company or the CRO</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>915 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 15:35:45 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Intervention</U>
</B>
</P>
<P>A: LAS41007, twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the immunologically mediated photodermatoses (IMP) should be applied, which is sufficient to cover a total area of 75 cm² (corresponding to 3 single TAs, each with a size of 25 cm² ) in maximum. The IMPs will be applied for 90 days in maximum</P>
<P>
<B>
<U>Control interventions</U>
</B>
</P>
<P>B: LASW1510, twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm² (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum</P>
<P>C: vehicle, twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm² (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 12:10:43 +0000" MODIFIED_BY="Maryse Paquet">
<P>
<B>
<U>Primary outcomes of the trial</U>
</B>
</P>
<P>1) Superiority of LAS41007 compared to vehicle at day 1</P>
<P>2) Superiority of LAS41007 compared to LASW1510 assessed by histology to evaluate the histological clearance of one pre-selected target lesion<BR/>3) Superiority of LAS41007 compared to vehicle at day 150 </P>
<P>4) Superiority of LAS41007 compared toLASW1510 each assessed by histology to evaluate the histological clearance of one pre-selected target lesion<BR/>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Superiority of LAS41007 compared to vehicle at day 1 </P>
<P>2) Improved clinical efficacy of LAS41007 compared to LASW1510 with respect to clinical efficacy at  day 1 <BR/>3) Superiority of LAS41007 compared to vehicle at day 21 </P>
<P>4) Improved clinical efficacy of LAS41007 compared to LASW1510 with respect to clinical efficacy at day 21<BR/>5) Superiority of LAS41007 compared to vehicle at  day 56 </P>
<P>6) Improved clinical efficacy of LAS41007 compared to LASW1510 with respect to clinical efficacy at day 56<BR/>7) Superiority of LAS41007 compared to vehicle at day 90 </P>
<P>8) Improved clinical efficacy of LAS41007 compared to LASW1510 with respect to clinical efficacy at day 90 <BR/>9) Superiority of LAS41007 compared to vehicle at day 150 </P>
<P>10) Improved clinical efficacy of LAS41007 compared to LASW1510 with respect to clinical efficacy at  day 150 <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-08 15:25:24 +0000" MODIFIED_BY="Maryse Paquet">
<P>November 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:10:20 +0000" MODIFIED_BY="Maryse Paquet">
<P>Sven Silberborth, PhD (<A HREF="mailto:sven.silberborth%40almirall.com?subject=NCT01265602, H 569 000 - 1004, Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis">sven.silberborth@almirall.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2011-11-08 15:26:18 +0000" MODIFIED_BY="Maryse Paquet">
<P>NCT01265602<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:10:29 +0000" MODIFIED_BY="Maryse Paquet">
<P>This study is currently recruiting, and the last update was in December 2010 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:00:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01354717">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:11:02 +0000" MODIFIED_BY="[Empty name]">
<P>Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:10:46 +0000" MODIFIED_BY="[Empty name]">
<P>This is a randomised, double-blind, placebo- and active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:00:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Between 48 and 85 year</LI>
<LI>Women who have had surgical sterilisation or are postmenopausal (absence of menses for at least 1 year) are eligible. Women of child-bearing potential who are non-pregnant and non-nursing and willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study are eligible. (Adequate contraception is defined as regular use of, diaphragm with condoms, IUD with condoms, or systemic contraceptives - if used for at least 3 months prior to enrolment in the study). A negative pregnancy test is required at entry into the study</LI>
<LI>Able to refrain from the use of all other topical medications to the facial area during the treatment period</LI>
<LI>Considered reliable and capable of understanding their responsibility and role in the study. Have provided written informed consent</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>History of allergy or hypersensitivity to 5-fluorouracil</LI>
<LI>Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency</LI>
<LI>&gt; 10 lesions total on the face [lesions that are hyperkeratotic, thicker than 1 mm (a piece of paper) or larger than 9 mm, or lesions suspicious for squamous cell carcinoma will not be included in lesion counts]</LI>
<LI>Clinical evidence of severe, uncontrolled autoimmune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease</LI>
<LI>Dermatologic conditions if present on the face, such as atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, or albinism</LI>
<LI>Positive urine pregnancy test in women of child-bearing potential</LI>
<LI>Inability to use adequate birth control measures for women of child-bearing potential, as defined above</LI>
<LI>Serious psychological illness</LI>
<LI>Significant history (within the past year) of alcohol or drug abuse</LI>
<LI>Participation in any clinical research study during the 30 day period preceding study initiation</LI>
<LI>Medical history which, based on the clinical judgment of the investigator, implies an unlikelihood of successful completion of the study</LI>
<LI>Treatment for actinic keratosis or skin cancer as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 weeks and until day 42 visit with sun lamps or sun tanning beds or booths</LI>
<LI>within 28 days with topical 5 fluorouracil, cryodestruction (liquid nitrogen spray), curettage (scraping of pre-cancer or skin cancers), surgical removal of skin cancer, photodynamic therapy, surgical excision, topical diclofenac (Solaraze), topical imiquimod (Aldara), or topical retinoids if used for actinic keratosis or other treatments for actinic keratoses</LI>
<LI>within 1 month with any immunomodulators like interferon or cytotoxic drugs, any oral (systemic steroids) or topical corticosteroids, except for subjects on chronic low dose corticosteroids less than 5 mg daily for greater than 1 year</LI>
<LI>within 6 months with chemical peel, dermabrasion, laser abrasion, PUVA (psoralen plus ultraviolet A) therapy, or UVB therapy to the face or bald scalp, systemic 5-fluorouracil, or systemic cancer therapy</LI>
</UL>
</UL>
<UL>
<LI>Subjects with lesions suspicious for squamous cell carcinoma</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>377 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: generic 0.5% 5-fluorouracil, once daily (duration of treatment was not specified)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: carac 0.5% 5-fluorouracil, once daily (duration of treatment was not specified)</P>
<P>C: placebo, once daily (duration of treatment was not specified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-13 14:29:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Participant complete clearance at 6 weeks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-13 14:29:18 +0100" MODIFIED_BY="[Empty name]">
<P>September 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-13 14:30:00 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01354717</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>This study has been completed in March 2011, and the last update was in JUne 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:37:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01358851">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:14:30 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:14:35 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, open, active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:37:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>General good and stable health confirmed by a physical examination and by medical history</LI>
<LI>Men or women</LI>
<LI>Between 18 and 85 years</LI>
<LI>Anatomical location: face/forehead or bald scalp</LI>
<LI>4 to 10 clinically-confirmed hyperkeratotic target lesions of moderate to severe intensity</LI>
<LI>Skin type I to IV according to Fitzpatrick's</LI>
<LI>Free of any significant physical abnormalities (e.g. tattoos, dermatoses) in the potential treatment area that may cause difficulty with examination or final evaluation</LI>
<LI>Physical ability to apply the study preparation correctly and to follow the study restrictions and visit</LI>
<LI>Women of child-bearing potential are allowed to participate in this study, but only if they use a highly effective method of contraception</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Immunosuppressive therapy</LI>
<LI>Known hypersensitivity to the ingredients</LI>
<LI>Coagulation defects that are inherited or acquired</LI>
<LI>Evidence of clinically significant, unstable medical conditions</LI>
<LI>Current other malignant or benign tumours of the skin within the treatment area</LI>
<LI>Current treatment of actinic keratosis within the treatment area (face/scalp) within 3 months with phenytoin, methotrexate or sulfonylurea, or inhibitors of DPD (e.g. Brivudin, Sorivudin)</LI>
<LI>Participants who have taken topical or systemic treatments that might interfere with the study end points, within a time window that is not allowed, or who are currently taking phenytoin, methotrexate, or sulfonylurea</LI>
<LI>Pregnancy or lactation (currently or within the past 3 months)</LI>
<LI>Any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment</LI>
<LI>Currently or within the past 8 weeks participating in another clinical study</LI>
<LI>Active chemical dependency or alcoholism as assessed by the investigator</LI>
<LI>Institutionalised because of legal or regulatory order</LI>
<LI>Any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment</LI>
<LI>Currently or within the past 8 weeks participating in another clinical study</LI>
<LI>Active chemical dependency or alcoholism as assessed by the investigator</LI>
<LI>Institutionalised because of legal or regulatory order</LI>
<LI>Pregnancy or lactation (currently or within the past 3 months)</LI>
<LI>Any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment</LI>
<LI>Currently or within the past 8 weeks participating in another clinical study</LI>
<LI>Active chemical dependency or alcoholism as assessed by the investigator</LI>
<LI>Institutionalised because of legal or regulatory order</LI>
<LI>Pregnancy or lactation (currently or within the past 3 months)</LI>
<LI>Any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment</LI>
<LI>Currently or within the past 8 weeks participating in another clinical study</LI>
<LI>Active chemical dependency or alcoholism as assessed by the investigator</LI>
<LI>Institutionalised because of legal or regulatory order</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>67 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:18:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: LAS41005 (0.5% 5-fluorouracil/ 10% salicylic acid) once daily (number of weeks was not specified)</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy 1 to 2 times during the treatment time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:18:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Histological clearance of 1 predefined target lesion at 8 weeks after the end of treatment with LAS41005 or 14 weeks after first cryotherapy<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rates at days 21, 42, and 98</P>
<P>2) Participant partial (% was not specified) clearance rates at days 21, 42, and 98<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 17:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>April 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-04-12 17:54:08 +0100" MODIFIED_BY="[Empty name]">
<P>Rosario Rodríguez  </P>
<P>Almirall, S.A.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 17:54:34 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01358851</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>This study is ongoing, and the last update was January 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-09 12:11:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01413763">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:18:51 +0000" MODIFIED_BY="[Empty name]">
<P>A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:19:04 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, double-blind, placebo-controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 14:54:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>General good health</LI>
<LI>Men and women</LI>
<LI>Aged18 years and older</LI>
<LI>Anatomical location: face or balding scalp</LI>
<LI>
<U>&gt;</U> 5 typical visible or palpable actinic keratoses</LI>
<LI>Women of child-bearing potential must be non-pregnant and non-lactating</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Previous clinical study participation within 30 days (drug or device)</LI>
<LI>Evidence of clinically significant diseases</LI>
<LI>History of drug or alcohol abuse</LI>
<LI>Uncontrolled systemic hypertension, NYHA heart failure classification Class &gt; II, or a history of atrial fibrillation or atrial flutter</LI>
<LI>Treatment within 30 days with imiquimod or interferon</LI>
<LI>Known allergies to any excipient in the study cream</LI>
<LI>Melanoma anywhere on the body</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>50 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-12 16:03:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3.75% imiquimod cream, daily for 2 weeks</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo cream, daily for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-09 12:11:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Change in 24-hour supraventricular beat count at day 14<BR/>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Change in 24-hour supraventricular premature couplet and run counts and atrial fibrillation (per cent time) at day 14</P>
<P>2) Change in 24-hour mean heart rate at day 14</P>
<P>3) Change in 24-hour ventricular premature beat count, ventricular premature couplet, and run counts at day 14<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 16:05:27 +0100" MODIFIED_BY="[Empty name]">
<P>July 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:20:05 +0000" MODIFIED_BY="[Empty name]">
<P>Irma Benavides (<A HREF="mailto:ibenavides%40cnsmail.com?subject=NCT01413763, GW01-1001, Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis">ibenavides@cnsmail.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 16:06:13 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01413763</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:20:10 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in August 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:01:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01453179">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:20:38 +0000" MODIFIED_BY="[Empty name]">
<P>Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:20:30 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, open, active-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 12:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Histological diagnosis</LI>
<LI>Immunocompetent</LI>
<LI>Men and women</LI>
<LI>Aged18 years and older</LI>
<LI>Anatomical location: face or scalp</LI>
<LI>5 to 10 typical visible actinic keratoses in 1 contiguous area of up to 50 cm² (the eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area), grade I or II</LI>
<LI>Willingness to comply with the obligations of the study</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>History of hypersensitivity to imiquimod, diclofenac, acetyl salicylic acid, other non-steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients</LI>
<LI>Pregnancy, breastfeeding, or planned pregnancy during the study. Women of child-bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. &lt; 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation, or vasectomised partner</LI>
<LI>Presence of actinic keratosis lesions in the treatment area with clinically-excessive hyperkeratosis as seen in cutaneous horns</LI>
<LI>Persisting actinic keratoses at screening visit following topical treatment with imiquimod or diclofenac in the treatment area</LI>
<LI>Presence of any histologically-confirmed skin tumour in the treatment area: in situ SCC including Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours</LI>
<LI>Any dermatological disease or condition that may exacerbate by treatment with imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis)</LI>
<LI>Any dermatological disease or condition in the treatment area that causes difficulty with examination (e.g. eczema)</LI>
<LI>History of any malignant tumour with high tumour burden or any systemic antitumour treatment (including radiotherapy)</LI>
<LI>History of any malignant skin tumour having metastasised or in which metastasis within the study period is likely</LI>
<LI>History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease within the last two years which might hinder regular treatment and supervision and might lead to premature withdrawal from the study</LI>
<LI>Mentally incapacitated participant. Present or history of drug or alcohol abuse within the last 3 years</LI>
<LI>Treatment as follows</LI>
</UL>
<UL>
<UL>
<LI>within 4 weeks with systemic immunomodulatory treatment, such as interferon, azathioprine, cyclosporine, retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids with dosages of &gt; 1200 µg/day beclomethasone or equivalent</LI>
<LI>within 2 months with any topical treatment including imiquimod or diclofenac; any systemic treatment, such as systemic retinoids; or any surgical treatment</LI>
</UL>
</UL>
<UL>
<LI>Exposure to an investigational product within the last 3 months</LI>
<LI>Lack of ability or willingness to give informed consent</LI>
<LI>Age below 18 years</LI>
<LI>Lack of willingness to have personal study related data collected, archived, or transmitted according to protocol</LI>
<LI>Anticipated non-availability for study visits/procedures</LI>
<LI>Vulnerable subjects (such as persons kept in detention)</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>220 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-12 18:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% imiquimod, 3 times per week for 4 weeks on, 4 weeks off, once or twice</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 3% diclofenac in hyaluronic acid, twice daily for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:01:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Long-term outcome (3 years) with respect to the risk of progression to SCC (in situ, invasive, or both)<BR/>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Recurrence rate at 3 years post-treatment</P>
<P>2) Time to recurrence at 3 years post-treatment</P>
<P>3) Need of rescue treatment at 3 years post-treatment</P>
<P>4) Cosmetic outcome at 3 years post-treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 18:30:20 +0100" MODIFIED_BY="[Empty name]">
<P>October 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:25:38 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Ursula Petzold</P>
<P>MEDA Pharma GmbH &amp; Co. KG</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 18:32:34 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01453179</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>This study is ongoing, and the last update was in March 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:17:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01458587">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>A Phase II Study of Photodynamic Therapy With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:26:25 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:17:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical location: upper extremities</LI>
<LI>
<U>&gt;</U> 4 grade I/II actinic keratoses on each upper extremity</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnancy</LI>
<LI>History of cutaneous photosensitisation, porphyria, hypersensitivity to porphyrins, or photodermatosis</LI>
<LI>Lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the treatment area</LI>
<LI>Skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy</LI>
<LI>Immunosuppressed</LI>
<LI>Unsuccessful outcome from previous ALA-PDT therapy</LI>
<LI>Currently enrolled in an investigational drug or device study or has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment</LI>
<LI>Known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)</LI>
<LI>Treatment on the extremities to be treated as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 days with keratolytics including urea (greater than 5%), alpha hydroxy acids [e.g. glycolic acid, lactic acid, etc, greater than 5%], or salicylic acid (greater than 2%)</LI>
<LI>within 2 weeks with cryotherapy</LI>
<LI>within 4 weeks with retinoids, including tazarotene, adapalene, tretinoin, or retinol</LI>
<LI>within 8 weeks with microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod, or other topical treatments for actinic keratosis</LI>
<LI>within 6 months with 2 or more ALA PDT treatments or systemic retinoid therapy</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>64 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:27:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3 hours 20% ALA-blue light PDT</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 3 hours vehicle-blue light PDT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:28:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Clearance rate for baseline grade I/II lesions at week 12<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Clearance rate for all baseline lesions at weeks 8 and 12</P>
<P>2) Clearance rate for baseline grade I/II lesions at week 8</P>
<P>3) Per cent change in total actinic keratoses at weeks 8 and 12</P>
<P>4) Participant complete clearance at weeks 8 and 12</P>
<P>5) Participant complete clearance excluding grade III lesions at weeks 8 and 12</P>
<P>6) Participant partial (<U>&gt;</U> 75%) clearance at weeks 8 and 12</P>
<P>7) Participant satisfaction score</P>
<P>8) Changes in pigmentation (hypo and hyper) at 2, 8, and 12 weeks after PDT</P>
<P>9) Local skin reactions during PDT (stinging/burning); 5 minutes after PDT (erythema, edema); and 2, 8, and 12 weeks after PDT (erythema, edema, stinging/burning, scaling/dryness, oozing/vesiculation/crusting)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 20:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>November 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:28:08 +0000" MODIFIED_BY="[Empty name]">
<P>Jim Berg (<A HREF="mailto:jberg%40therapeuticsinc.com?subject=NCT01458587, CP0106, Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)">jberg@therapeuticsinc.com</A>)</P>
<P>Dan Piacquadio, MD (<A HREF="mailto:danp%40therapeuticsinc.com?subject=NCT01458587, CP0106, Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)">danp@therapeuticsinc.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 20:03:43 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01458587</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:28:12 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in November 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 12:30:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01459393">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:29:14 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, open, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 12:30:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged18 years and older</LI>
<LI>Anatomical location: upper limbs</LI>
<LI>Symmetrical actinic keratoses, same grade, I, II, or III</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Concomitant skin diseases, congenital or acquired (albinism, vitiligo, xeroderma, Gorlin, etc)</LI>
<LI>Immunosuppression (HIV, transplanted patients, etc)</LI>
<LI>Pregnancy or lactation</LI>
<LI>Participants who do not agree with the informed consent initially or during the protocol</LI>
<LI>Presence of pigmented lesions near the keratoses</LI>
<LI>Porphyria</LI>
<LI>Treatment for keratosis within 2 months in the upper limbs</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>137 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 4 hours 20% ALA-red light PDT, once or twice with a 3-month interval</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy, once or twice with a 3-month interval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:30:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Changes in lesion area at 0, 3, and 6 months<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Pain on a visual analogue scale (VAS) and a graduated scale at the time 0 and 15 minutes after each intervention</P>
<P>2) Cosmetic outcome evaluated subjectively by the participant and investigator (awful, bad, regular, good, excellent) and objectively by the investigator (presence or absence of 1 or more of these criteria: hypochromia, hyperpigmentation, hyperemia, scar)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 14:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>November 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-04-12 14:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>Catarina Robert, MD</P>
<P>René AC Vieira, PHD</P>
<P>Fundação Pio XII - Hospital de Câncer de Barretos</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 14:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01459393</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>This study is ongoing, and the last update was in October 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 12:31:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01475071">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:30:49 +0000" MODIFIED_BY="[Empty name]">
<P>IIntra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:30:56 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, assessor-blind, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 12:31:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>Anatomical location: face or the scalp</LI>
<LI>Mild (with or without moderate in the treatment area) actinic keratoses</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis of at least 1 severe actinic keratose on the treatment area</LI>
<LI>Clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the treatment area</LI>
<LI>Pigmented actinic keratoses on the treatment area</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>100 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:31:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A:16% MAL-daylight photodynamic therapy (PDT), once or twice with a 12-week interval</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 16% MAL-conventional PDT, once or twice with a 12-week interval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:31:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Per cent change from baseline in total number of treated mild lesions per side at week 12</P>
<P>2) Participant assessment of maximal pain on a scale from 0 (no pain) to 10 (extreme pain) per side at baseline<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-13 14:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>March 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:31:32 +0000" MODIFIED_BY="[Empty name]">
<P>Catherine Bosc (<A HREF="mailto:catherine.bosc%40galderma.com?subject=NCT01475071, RD.03.SPR.29102, Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses">catherine.bosc@galderma.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-13 14:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01475071<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:31:36 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in March 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:17:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01475955">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:31:51 +0000" MODIFIED_BY="[Empty name]">
<P>A Phase II Study of Photodynamic Therapy With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:31:59 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:17:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>Anatomical location: face or scalp</LI>
<LI>6 to 20 actinic keratoses, grade I/II</LI>
<LI>History of actinic keratosis therapy within the treatment area at least twice in the 2 years prior to study entry</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnancy</LI>
<LI>Grade III or atypical actinic keratoses (e.g. &gt; 1 cm² in size) within the treatment area</LI>
<LI>Lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the treatment area</LI>
<LI>Plans to be exposed to artificial tanning devices or excessive sunlight during the trial</LI>
<LI>Immunosuppressed</LI>
<LI>Unsuccessful outcome from previous ALA-PDT therapy</LI>
<LI>History of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis</LI>
<LI>Skin pathology or condition that could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy</LI>
<LI>Skin pathology or condition that could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy</LI>
<LI>Any condition which would make it unsafe for the subject to participate in this research study</LI>
<LI>Currently enrolled in an investigational drug or device study or has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment</LI>
<LI>Known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)</LI>
<LI>An active herpes simplex infection or a history of 2 or more outbreaks within the past 12 months, in the treatment area</LI>
<LI>Treatment on the treatment area as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 days with keratolytics including urea (greater than 5%), alpha hydroxy acids [e.g. glycolic acid, lactic acid, etc, greater than 5%], or salicylic acid (greater than 2%)</LI>
<LI>within 2 weeks with cryotherapy</LI>
<LI>within 4 weeks with retinoids, including tazarotene, adapalene, tretinoin, or retinol within 8 weeks with microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod, or other topical treatments for actinic keratosis</LI>
<LI>within 6 months with 2 or more ALA PDT treatments</LI>
<LI>systemic retinoid therapy within 6 months of initiation of treatment</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>220 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:34:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: field application 1 hours 20% ALA-blue light photodynamic therapy (PDT)</P>
<P>B: field application 2 hours 20% ALA-blue light PDT</P>
<P>C: field application 3 hours 20% ALA-blue light PDT</P>
<P>D: Individual lesion application 2 hours 20% ALA-blue light PDT</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>E: field/individual application 1 to 3 hours 20% ALA-blue light PDT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 12:35:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rate at week 12<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rate at weeks 4, 8, and 24</P>
<P>2) Participant partial (<U>&gt;</U> 75%) clearance rate at weeks 4, 8, 12, and 24</P>
<P>3) Per cent change in lesion number at weeks 4, 8, 12, and 24</P>
<P>4) Participant satisfaction score on a 0 to 3 scale</P>
<P>5) Changes in pigmentation (hyper- and hypo-) at 24 to 48 hours after PDT, and at weeks 2, 4, 8, 12, and 24</P>
<P>6) Local skin reactions during PDT (stinging/burning); at 5 minutes after PDT (erythema, edema); at 24 to 48 hours after PDT; and weeks 2, 4, 8, 12, and 24 (erythema, edema, stinging/burning, scaling/dryness, oozing/vesiculation/crusting)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-13 13:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>December 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:34:43 +0000" MODIFIED_BY="[Empty name]">
<P>Jim Berg (<A HREF="mailto:jberg%40therapeuticsinc.com?subject=NCT01475955, CP0105, Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)">jberg@therapeuticsinc.com</A>)</P>
<P>Dan Piacquadio, MD (<A HREF="mailto:danp%40therapeuticsinc.com?subject=NCT01475955, CP0105, Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)">danp@therapeuticsinc.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-13 13:48:43 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01475955<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:34:53 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in March 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:53:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01481155">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:36:01 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, Single-center, Investigator-blinded, Randomized, Half-side, Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, assessor-blind, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:53:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical and histological (on a lesion <U>&gt;</U> 4 mm diameter in treatment area) diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>
<U>&gt;</U> 2 symmetrical clinically-visible actinic keratoses (at least 1 per treatment area)</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Aged 17 years or younger</LI>
<LI>Lack of participant's informed consent for any of the 2 treatments</LI>
<LI>Contraindication for CO&#8322; therapy or for photodynamic therapy</LI>
<LI>Skin infection in the treatment area</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>21 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 12:36:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: CO&#8322; laser therapy</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 4h ALA- red light photodynamic therapy (PDT)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-12 15:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Number of actinic keratoses at 3 months post-treatment<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Histologic features at 1 month post-treatment </P>
<P>2) Epidermal thickness in optical coherence tomography at 1 month post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 15:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>March 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-04-12 15:50:36 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Nina Scola, </P>
<P>Consultant in Ruhr University of Bochum, Ruhr University of Bochum</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 15:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01481155<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:36:49 +0000" MODIFIED_BY="[Empty name]">
<P>This study is ongoing, and the last update was in December 2011 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-09 12:11:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01493921">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 12:37:10 +0000" MODIFIED_BY="[Empty name]">
<P>A Randomized, Double-Blind, Parallel, Vehicle-Controlled Phase III Trial to Assess the Efficacy and Safety of Topical SR-T100 Gel in the Treatment of Patients With Actinic Keratosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 12:37:04 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 12:11:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Clinical and histological (on a lesion <U>&gt;</U> 4 mm diameter in treatment area) diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 20 years or older</LI>
<LI>Anatomical location: arms, shoulder, chest, face, and scalp</LI>
<LI>
<U>&gt;</U> 2 clinically-visible, discrete, non-hyperkeratotic, hypertrophic AK lesions located within a 25 cm² contiguous or non-contiguous treatment area</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Dermatological disease and condition, such as atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, melanoma, or other possible confounding skin conditions in the treatment or surrounding area within 5 cm distances from treatment area</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 4 weeks with immunomodulators or immunosuppressive therapy, interferon and cytotoxic drugs</LI>
<LI>on the treatment area with topical 5-FU, diclofenac gel, imiquimod, corticosteroids, retinoids, masoprocol, cryodestruction, chemodestruction, curettage, photodynamic therapy, or surgical excision</LI>
<LI>within 6 months on the treatment area with psoralen plus UVA therapy, UVB therapy, laser abrasion, or dermabrasion chemical peel</LI>
</UL>
</UL>
<UL>
<LI>Participant is known to be hypersensitive to the study medication</LI>
<LI>Women who are pregnant, breastfeeding, or considering becoming pregnant while on the study</LI>
<LI>Participant who had used of any investigational drug within the past 30 days before enrolment</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>113 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-12 15:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: SR-T100 gel, once daily with an occlusive dressing for 16 weeks</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: vehicle gel, once daily with an occlusive dressing for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-12 15:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance at 8 weeks post-treatment (week 24)<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Lesion size reduction at 8 weeks post-treatment (week 24)</P>
<P>2) Participant partial (<U>&gt;</U> 75%) clearance at 8 weeks post-treatment (week 24)</P>
<P>3)Tolerance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 15:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>October 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>Kou-Wha Kuo, Ph.D (<A HREF="mailto:kwkuo%40geherbs.com.tw?subject=NCT01493921, GESRTAKA, Efficacy Study &amp; Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment">kwkuo@geherbs.com.tw</A>)</P>
<P>Tony Chiu, B.S (<A HREF="mailto:tonychiu%40geherbs.com.tw?subject=NCT01493921, GESRTAKA, Efficacy Study &amp; Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment">tonychiu@geherbs.com.tw</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 15:35:54 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01493921<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:39:29 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update in March 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-09 12:11:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01502020">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 13:27:36 +0000" MODIFIED_BY="[Empty name]">
<P>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 3.75% and Zyclara&#8482; (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:27:14 +0000" MODIFIED_BY="[Empty name]">
<P>This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-09 12:11:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Good general health and free of any disease state or physical condition that might have impaired evaluation of lesions or which, in the investigator's opinion, exposed the subject to an unacceptable risk by study participation</LI>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>Anatomical location: face (excluding ears) or balding scalp, but not both</LI>
<LI>5 to 20 clinically typical, visible, or palpable actinic keratoses, each at least 4 mm in diameter, in an area greater than 25cm²</LI>
<LI>Women of child-bearing potential (WOCBP) must have had a negative urine pregnancy test (UPT) and agreed to use an effective form of birth control for the duration of the study (e.g. abstinence, stabilised on hormonal contraceptives for at least 3 months [oral, implant, injection, IUD, patch, or NuvaRing], condom and spermicidal, or diaphragm and spermicidal). Abstinence was an acceptable form of birth control for subjects who were not sexually active. Subjects who became sexually active during the trial had to agree to use an effective, non-prohibited form of birth control for the duration of the study</LI>
<LI>Participant was willing and able to apply the test article as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Pregnancy, lactation, or planning to become pregnant during the study</LI>
<LI>Hyperkeratotic, hypertrophic, or atypical actinic keratose (e.g. &gt; 1 cm² in size) in the treatment area</LI>
<LI>Enrollement in an investigational drug or device study during the study period</LI>
<LI>Panning to be exposed to artificial tanning devices or excessive sunlight during the trial</LI>
<LI>Immunosuppressed (e.g. HIV, systemic malignancy, graft versus host disease, etc)</LI>
<LI>Unsuccessful outcome from previous imiquimod therapy (i.e. after a reasonable therapeutic trial with no compliance issues, topical application did not work)</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 30 days with investigational drug or investigational device</LI>
<LI>within 6 months with laser resurfacing, PUVA (Psoralen + ultraviolet A) therapy, UVB therapy, chemical peels, or dermabrasion on the face or balding scalp</LI>
<LI>within 1 month with cryodestruction or chemodestruction, curettage, photodynamic therapy, surgical excision or other treatments for actinic keratosis on the face or scalp, corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies or retinoids, corticosteroids, alpha hydroxy acids (e.g. glycolic acid, lactic acid etc &gt; 5%), beta hydroxy acid (salicylic acid &gt; 2%), urea &gt; 5%, 5-fluorouracil, diclofenac, imiquimod, or prescription retinoids (e.g. tazarotene, adapalene, or tretinoin)</LI>
<LI>within 1 day with topical creams, lotions, or gels of any kind to the selected treatment area</LI>
</UL>
</UL>
<UL>
<LI>Basal cell or squamous cell carcinoma within the treatment area within 1 year of study enrolment</LI>
<LI>History of sensitivity to any of the ingredients in the test articles</LI>
<LI>Any skin pathology or condition (e.g. facial/scalp psoriasis, atopic dermatitis, acne, rosacea, etc) that, in the investigator's opinion, could have interfered with the evaluation of the test article, worsened due to the treatment or required the use of interfering topical, systemic, or surgical therapy</LI>
<LI>Any condition which, in the investigator's opinion, would have made it unsafe or precluded the participant's ability to fully participate in the research study</LI>
<LI>Known to be non-compliant or was unlikely to comply with the requirements of the study protocol (e.g. due to alcoholism, drug dependency, or mental incapacity) in the opinion of the investigator</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>410 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-12 16:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: generic 3.75% imiquimod, once daily for 2 weeks on, 2 weeks off, 2 weeks on</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: placebo, once daily for 2 weeks on, 2 weeks off, 2 weeks on</P>
<P>C: Zyclara 3.75% imiquimod, once daily for 2 weeks on, 2 weeks off, 2 weeks on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 13:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcomes of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rate at 8 weeks post-treatment (week 14)</P>
<P>2) Compliance</P>
<P>3) Severity and frequency of adverse events</P>
<P>4) Severity and frequency of local skin reactions<BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rate at 8 weeks post-treatment (week 14)</P>
<P>2) Per cent change in the lesion number at 8 weeks post-treatment (week 14)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 16:53:55 +0100" MODIFIED_BY="[Empty name]">
<P>February 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 12:39:41 +0000" MODIFIED_BY="[Empty name]">
<P>Daniel Piacquadio, M.D</P>
<P>Therapeutics, Inc</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 16:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01502020<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 12:39:48 +0000" MODIFIED_BY="[Empty name]">
<P>This study has been completed in November 2011, and the last update was in December 2011 (Apil 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 13:35:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01516515">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 13:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK) on the Head (Face and/or Scalp)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:33:16 +0000" MODIFIED_BY="[Empty name]">
<P>This is a randomised, double-blind, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 13:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Good general health condition (performance status &#8804; 2 Eastern Cooperative Oncology Group (ECOG)</LI>
<LI>Men and women</LI>
<LI>Aged 20 years or older</LI>
<LI>Anatomical location: face, balding scalp, or both</LI>
<LI>4 to 8 clinically diagnosed, discrete, non-hyperkeratotic, non-hypertrophic actinic keratoses, located with or without a contiguous 25 cm² areas</LI>
<LI>Biopsy allowed to be performed on selected lesion.</LI>
<LI>Photographs allowed on selected lesion and used as part of the study data package</LI>
<LI>Women with child-bearing potential must take reliable contraception method(s) during the participation of the study</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Recurrent invasive squamous cell carcinoma (SCC).</LI>
<LI>Grossly suspicious or inflamed lymph nodes on physical examination.</LI>
<LI>Clinically significant or unstable medical conditions</LI>
<LI>Skin condition in the treatment area that may be made worse by treatment.</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 28 days on the treatment area(s), OTC retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil (5-FU), imiquimod, topical diclofenac, retinoids, or other topical AK treatments (such as laser abrasion, dermabrasion, glycolic acids, or chemical peels)</LI>
<LI>within 6 months with systemic cancer chemotherapy or immunosuppressant; on the target evaluation area, psoralen plus UVA therapy, UVB therapy</LI>
<LI>within 12 months with prednisone, prednisolone, or both (&#8805; 10 mg or the equivalent) for more than 2 weeks continuously</LI>
</UL>
</UL>
<UL>
<LI>Engaging in activities involving excessive or prolonged exposure to sunlight</LI>
<LI>History of allergy or sensitivity to related compounds or other components of the investigational product formulation</LI>
<LI>Woman who is pregnant, lactating, or planning to become pregnant during the study</LI>
<LI>Participant used any investigational drug within 8 weeks prior to the screening visit</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>87 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 13:34:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Interventions</B>
</U>
</P>
<P>A: SR-T100 with 1.0% of SM in Solanum undatum plant extract for 16 weeks</P>
<P>B: SR-T100 with 2.3% of SM in Solanum undatum plant extract for 16 weeks</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: placebo for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 13:34:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance rate at 8 weeks post-treatment (week 24)<BR/>
<U>
<B>Secondary outcome of the trial</B>
</U>
</P>
<P>1) Participant partial (<U>&gt;</U> 75%) clearance rate at 8 weeks post-treatment (week 24)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-11-08 13:34:59 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:35:10 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Kou-Wha Kuo (<A HREF="mailto:kwkuo%40geherbs.com.tw?subject=NCT01516515, GESRTAKB, Efficacy and Safety Phase II Dose-ranging Study of SR-T100 to Treat Actinic Keratosis">kwkuo@geherbs.com.tw</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 16:25:23 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01516515<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 13:35:17 +0000" MODIFIED_BY="[Empty name]">
<P>This study is not yet recruiting, and the last update was January 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 13:36:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01525329">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 13:35:50 +0000" MODIFIED_BY="[Empty name]">
<P>Combination Therapy With 5-Fluorouracil and Photodynamic Therapy for the Treatment of Post-transplant Premalignant Skin Disease</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:35:41 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, open, parallel-group (1 arm with immunocompetent controls and 1 arm with immunosuppressed organ transplant recipients), intraindividual (1 side with topical and PDT and 1 side with only PDT) study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>Anatomical location: face, scalp, or ears</LI>
<LI>
<U>&gt;</U> 4 actinic keratoses</LI>
<LI>Participants in the solid organ transplant arm of the study must have had either a kidney or liver transplant, and the transplantation surgery must have occurred at least 2 years prior to enrolment</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Pregnant or nursing</LI>
<LI>Currently participating in another clinical trial</LI>
<LI>Using any topical treatment for their actinic keratoses</LI>
<LI>Currently being treated for other cancers with medical or radiation therapy</LI>
<LI>Known hypersensitivity to 5-aminolevulinic acid, 5-fluorouracil, or any component of the study material</LI>
<LI>History of a photosensitivity disease, including porphyria cutanea tarda</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>40 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 13:36:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 5% 5-fluorouracil once daily for 6 days followed by 3 hours MAL-red light phototherapy (PDT) in immunocompetent and immunosuppressed participants</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 3 hours MAL-red light PDT in immunocompetent and immunosuppressed participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 13:36:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Accumulation of PpIX at 3 hours after MAL application<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Rate of lesion clearance at day 14 and at 3 months<BR/>
</P>
<P>2) Rate of development of new AK at months 3, 6 9, and 12<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 20:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>September 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:36:47 +0000" MODIFIED_BY="[Empty name]">
<P>Margo Riha, BSN, RN (<A HREF="mailto:riham%40ccf.org?subject=NCT01525329, 09-1050, Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease">riham@ccf.org</A>)</P>
<P>Sara Lohser, MD (<A HREF="mailto:lohsers%40ccf.org?subject=NCT01525329, 09-1050, Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease">lohsers@ccf.org</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 20:29:30 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01525329<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 13:36:58 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in February 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:00:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01538901">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 13:37:23 +0000" MODIFIED_BY="[Empty name]">
<P>Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:37:15 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, open, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 13:39:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinical diagnosis</LI>
<LI>Men and women</LI>
<LI>Aged 18 years or older</LI>
<LI>Participants who had received a kidney, liver, lung, or heart transplant more than 3 years prior to inclusion into the study</LI>
<LI>Participants who had been treated at least 6 months prior to study entry with a stable 2-fold or 3-fold immunosuppressive treatment</LI>
<LI>Anatomical location: face, scalp, or both</LI>
<LI>Actinic keratoses in at least 2 anatomically separated contralateral areas with comparable size and extension and minimum distance of 5 cm</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Invasive squamous cell carcinoma or basal cell carcinoma in the treatment area</LI>
<LI>Known allergy to imiquimod, methyl-aminolaevulinate, or both, or 1 of the other components of the investigational products, peanut oil, or both</LI>
<LI>Treatment within 4 weeks with retinoids, interferons, or investigational drugs</LI>
<LI>Participants who are participating in other dermatological study</LI>
<LI>Persistent Hepatitis B or C infections</LI>
<LI>Any evidence of systemic cancer</LI>
<LI>Participants who have received any systemic cancer chemotherapy or radiation therapy</LI>
<LI>Pregnant or lactating women</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>34 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 13:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 3 hours 16% MAL-red light photodynamic therapy (PDT) (70 J/cm²), twice with a 2 week interval</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 5% imiquimod, 3 times per week for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:00:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Lesion complete response rate at 4 weeks post-treatment<BR/>
<B>
<U>Secondary outcomes of the trial</U>
</B>
</P>
<P>1) Lesion complete response rate at 6 and 12 months post-treatment</P>
<P>2) Global reduction in the area of specific PpIX fluorescence at 1, 6, and 12 months post-treatment</P>
<P>3) Global participant's satisfaction on a 10 cm visual analogue scale (VAS, 0 means extremely unsatisfied, 1 to 3 means unsatisfied, 5 to 7 means moderately satisfied, 8 to 10 means highly satisfied) at 3, 6, and 12 months post-treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 15:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>April 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:39:49 +0000" MODIFIED_BY="[Empty name]">
<P>Stanislava Tzaneva, Doz. Dr (<A HREF="mailto:stanislava.tzaneva%40meduniwien.ac.at?subject=NCT01538901, IPDTAKOTR/V06/28.12.11, Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients">stanislava.tzaneva@meduniwien.ac.at</A>)</P>
<P>Alexandra Geusau, Prof. Dr (<A HREF="mailto:alexandra.geusau%40meduniwien.ac.at?subject=NCT01538901, IPDTAKOTR/V06/28.12.11, Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients">alexandra.geusau@meduniwien.ac.at</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 15:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01538901<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 13:39:55 +0000" MODIFIED_BY="[Empty name]">
<P>This study is not yet recruiting, and the last update was in February 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:53:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01541228">
<CHAR_STUDY_NAME MODIFIED="2012-04-12 13:50:18 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical Effect of Photodynamic Treatment When Treating Actinic Keratoses With Different Light Doses</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:40:20 +0000" MODIFIED_BY="[Empty name]">
<P>This is a single-centre, randomised, participant-blinded, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 13:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Inclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>Clinically and histologically diagnosed</LI>
<LI>Men and women</LI>
<LI>Age older than 50 years</LI>
<LI>Anatomical location: face or scalp</LI>
<LI>2 to 5 actinic keratoses with symmetrical distribution, largest diameter &#8804; 3 cm (measuring the longest axis), grade I or II</LI>
<LI>Participant must be willing and capable of co-operating to the extent and degree required by the protocol</LI>
<LI>Participant is not the subject of the administrative or legal judicial proceeding</LI>
<LI>Participant has social health security required by laws of healthcare institutions.</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the trial</B>
</U>
</P>
<UL>
<LI>&gt; 5 actinic keratoses in the planned treatment area</LI>
<LI>Recurrent actinic keratoses, i.e. previously treated in the study area</LI>
<LI>Very hyperkeratotic, grade 3 (on a 0 to 3 scale) lesions among the target lesions</LI>
<LI>Actinic keratoses located on the nose</LI>
<LI>Other skin lesions (diseases) in the tumour study area</LI>
<LI>Subject with known hereditary basal cell carcinoma syndromes (Gorlin-Goltz, Basex-Dupre-Christol, et al)</LI>
<LI>Subject with a history of cutaneous photosensitization or porphyria or Xeroderma pigmentosum, hypersensitivity to porphyrins, or photodermatosis</LI>
<LI>Treatment</LI>
</UL>
<UL>
<UL>
<LI>within 30 days with photosensitising drugs</LI>
<LI>within 6 months with immunomodulatory or immunosuppressive therapies, including systemic and topical steroids, imiquimod or solaraze, interferon, and acitretin</LI>
<LI>within 2 months in the study area with laser resurfacing, chemical peels, topical application fluorouracil, or other drugs for the treatment of actinic keratoses</LI>
</UL>
</UL>
<UL>
<LI>Participant who had participated in another investigational drug or device research study within 30 days of enrolment</LI>
<LI>Participant with known hypersensitivity to 5-aminolevulinc acid, a similar compound or excipients of the cream</LI>
<LI>Participant with known status after organ transplantation</LI>
</UL>
<P>
<U>
<B>Demographics</B>
</U>
</P>
<UL>
<LI>38 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 13:42:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: 20% ALA-red light photodynamic therapy (PDT) (70 J/cm²), twice with a 2-week interval</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: 20% ALA-red light PDT (100 J/cm²), twice with a 2-week interval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 15:53:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Primary outcome of the trial</U>
</B>
</P>
<P>1) Relapse of clinically cleared actinic keratosis, evaluation by two investigators for clinical/histological relapse at 1, 3, 6, 12, and 24 months post-treatment<BR/>
<B>
<U>Secondary outcome of the trial</U>
</B>
</P>
<P>1) Pain during treatment, participant scoring on a visual analogue scale (VAS)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 14:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>April 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:42:48 +0000" MODIFIED_BY="[Empty name]">
<P>Evelina Buinauskaite, MD</P>
<P>Skaidra Valiukeviciene, Prof.</P>
<P>Lithuanian University of Health Sciences, </P>
<P>Medical Academy, </P>
<P>Department of Skin and Venereal Diseases</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 14:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01541228<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 13:42:52 +0000" MODIFIED_BY="[Empty name]">
<P>This study is ongoing, and the last update was in February 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-08 15:53:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01541553">
<CHAR_STUDY_NAME MODIFIED="2012-11-08 13:43:28 +0000" MODIFIED_BY="[Empty name]">
<P>A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:43:14 +0000" MODIFIED_BY="[Empty name]">
<P>This is a multicentre, randomised, double-blinded, placebo-controlled, parallel-group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 15:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Men and women</LI>
<LI>Aged 18 years and older</LI>
<LI>Anatomical location: face or scalp</LI>
<LI>4 to 8 clinically typical, visible and discrete actinic keratoses within a contiguous 25 cm² treatment area</LI>
<LI>Women must be of either: non-child-bearing potential, i.e. postmenopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus), or child-bearing potential provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy</LI>
<LI>Women of child-bearing potential must be willing to use effective contraception</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Location of the selected treatment area: on any location other than the face or scalp, within 5 cm of an incompletely healed wound, within 10 cm of a suspected basal cell carcinoma (BCC) or SCC</LI>
<LI>Prior treatment with PEP005 Gel on face or scalp</LI>
<LI>Selected treatment area lesions that have atypical clinical appearance, recalcitrant disease, or both</LI>
<LI>History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication</LI>
<LI>Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant adverse event or interfere with assessments of safety and efficacy</LI>
<LI>Any abnormal vital signs measurements that are medically significant or would impact the safety of the subject or the interpretation of the trial results</LI>
<LI>Anticipated need for hospitalisation or outpatient surgery during the first 15 days after the first trial medication application</LI>
<LI>Known sensitivity or allergy to any of the ingredients in PEP005 gel</LI>
<LI>Recent excessive exposure to ultraviolet light</LI>
<LI>Current enrolment or participation in a clinical trial within 30 days of entry into this study</LI>
<LI>Participants previously randomised in the trial</LI>
<LI>Women who are breastfeeding</LI>
<LI>Treatment as follows:</LI>
</UL>
<UL>
<UL>
<LI>within 2 weeks prior to visit 1 with cosmetic or therapeutic procedures, use of acid-containing therapeutic products, or use of topical medicated creams, ointments, lotions, gels, foams, or sprays within 2 cm of the selected treatment area</LI>
<LI>within 4 weeks prior to visit 1 with immunomodulators, cytotoxic drugs or interferon /interferon inducers, systemic medications that suppress the immune system, treatment/therapy with ultraviolet light A (UVA), or ultraviolet light B (UVB).</LI>
<LI>within 8 weeks prior to visit 1 with 5-FU, imiquimod, diclofenac sodium, or photodynamic therapy within 2 cm of the selected treatment area</LI>
<LI>within 6 months prior to visit 1 with systemic retinoids or biologic/monoclonal antibody therapies</LI>
</UL>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>326 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-08 13:45:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: cryotherapy followed by 0.015% PEP005 (ingenol mebutate) gel (field) daily for 3 consecutive days</P>
<P>
<U>
<B>Control intervention</B>
</U>
</P>
<P>B: cryotherapy followed by vehicle gel (field) daily for 3 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 13:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Primary outcome of the trial</B>
</U>
</P>
<P>1) Participant complete clearance at week 11<BR/>
<U>
<B>Secondary outcomes of the trial</B>
</U>
</P>
<P>1) Per cent reduction from baseline in number of lesions at week 11</P>
<P>2) Participant complete clearance for 12 months (recurrence)<BR/>3) Per cent reduction from baseline in number of lesions at week 11 through to month 12<BR/>4) Participant partial (<U>&gt;</U> 75%) clearance at week 11</P>
<P>4) Participant partial (<U>&gt;</U> 75%) clearance at week 11 through to month 12<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-12 19:22:08 +0100" MODIFIED_BY="[Empty name]">
<P>March 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:45:58 +0000" MODIFIED_BY="[Empty name]">
<P>Birgitte Vestbjerg (<A HREF="mailto:birgitte.vestbjerg%40leo-pharma.com?subject=NCT01541553, LP0041-21, A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp">birgitte.vestbjerg@leo-pharma.com</A>)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-04-12 19:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>NCT01541553<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-11-08 13:46:04 +0000" MODIFIED_BY="[Empty name]">
<P>This study is recruiting, and the last update was in March 2012 (April 2012).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-11-13 10:37:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Willey-2011">
<CHAR_STUDY_NAME MODIFIED="2012-04-11 23:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>Temperature modulated photodynamic therapy for the treatment of actinic keratoses on the extremities</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-11-08 13:46:59 +0000" MODIFIED_BY="[Empty name]">
<P>This is a randomised, blinded, active-controlled, intraindividual study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-13 20:36:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<U>Inclusion criteria of the trial</U>
</B>
</P>
<UL>
<LI>Anatomical location: upper and lower extremities</LI>
</UL>
<P>
<B>
<U>Demographics</U>
</B>
</P>
<UL>
<LI>20 participants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-13 10:37:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Intervention</B>
</U>
</P>
<P>A: ALA + heat followed by blue light photodynamic therapy (PDT) (N= 20 participants)</P>
<P>
<U>
<B>Control interventions</B>
</U>
</P>
<P>B: ALA + no heat followed by blue light PDT (N = 20 participants)</P>
<P>
<U>Characteristics of PDT intervention</U>
</P>
<P>Type of treatment: --</P>
<P>Number of treatments: 1</P>
<P>Interval between treatments: --</P>
<P>Preparation of lesions: --</P>
<P>Cream concentration (%): 20</P>
<P>Application of cream: --</P>
<P>Incubation with cream: 1 hour under occlusion</P>
<P>Type of light: blue light</P>
<P>Light source: --</P>
<P>Wavelength (nm): 417 nm</P>
<P>Energy fluence (J/cm²): 10</P>
<P>Intensities (mW/cm²): --</P>
<P>Exposure time: --</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-08 13:46:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>Outcomes of the trial</B>
</U>
</P>
<P>1) Clearance rates</P>
<P>2) Tolerability during and following treatment on a 4-point scale</P>
<P>
<U>Efficacy</U>
</P>
<P>Methods: quantitative assessment by lesion counting performed by an unblinded investigator and photographs evaluation by a blinded investigator </P>
<P>Time points: at baseline, and 2 and 6 months post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-11-08 13:46:11 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-11-08 13:46:11 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2012-11-08 13:46:10 +0000" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2012-04-11 23:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract from 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-09 12:16:24 +0000" MODIFIED_BY="Maryse Paquet">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-09 12:00:31 +0000" MODIFIED_BY="Maryse Paquet" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 12:29:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>Quote (page 200): "Patients were randomly assigned to treatment with 0.5% colchicine cream or 1% colchicine cream."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:43:56 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>Quote (page1282): "Before randomisation, participants were stratified on the basis of gender and numbers of actinic keratoses on the forearms. Participants were then randomly assigned, in a double-blind fashion, to treatment with hydrophilic DFMO ointment on the right versus the left forearm and placebo hydrophilic ointment on the contralateral forearm twice daily for 6 months."</P>
<P>Comment: Stratification was used for randomisation sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 13:19:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>Quote (page 448): "Patients were randomly assigned to treatment with 0.1% isotretinoin or a color-matched vehicle."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 13:29:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>Quote (page 134): "Eligible patients were randomised to either imiquimod 5% cream or vehicle cream in a 1:1 ratio."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:02:43 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>Each centre was allocated an initial block of 4 randomisation numbers and enrolled participants were assigned a participant number in ascending order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:28:09 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>Quote (page 550): "Tretinoin 0.05% cream (RETIN-A Cream, Ortho Pharmaceutical Corp., Raritan, NJ, U.S.A.) and a placebo cream, Eucerin (Beiersdorf Inc., Norwalk, CT, U.S.A.) were supplied to each patient in unmarked jars labelled only with the randomly assigned side to which the medication was to be applied."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 18:41:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Quote (page 252): "Randomisation codes were prepared using permuted blocks of four and stratifying by study centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:35:43 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>Quote (page 197): "Two lesional areas within a patient, measuring a maximum of 4 X 4 cm, were randomised to receive 2 consecutive treatments of topical PDT 1 week apart using either MAL or placebo cream."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 18:41:34 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>Quote (page 347): "Sixty-four lesions of actinic keratosis in 20 patients were evaluated, 32 for active treatment and another 32 lesions with relatively similar characteristics but on the opposite side, as controls. Lesions were randomised to receive either 3% diclofenac in 2.5% hyaluronic acid gel or placebo (the inactive gel vehicle, hyaluronic acid only) 0.5 g twice daily in each 5 cm² treatment area for 90 days."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:22:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>A progressive randomisation program was used to make sure that allocation did not vary by gender, age, or actinic keratosis lesions (stratification).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:52:03 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>Randomisation was performed per participant for each treatment option (first: PDT or cryo, second: MAL or placebo) and stratified by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:52:20 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>Quote (page 40):"They were randomly allocated to either active treatment (N = 73) or placebo (N = 77)."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:55:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>A computer-generated randomisation schedule was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:04:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>Quote (page 575): "Eligible subjects were randomised to placebo, imiquimod 2.5%, or imiquimod 3.75% cream in a 1:1:1 treatment allocation."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:55:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>Quote (page 977): "Patients were prospectively randomised to 1 of 3 treatment arms..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:23:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>Stratification was performed by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:29:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>Stratification was performed by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:36:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>Quote (page 118): "Patients were randomly allocated to treatment."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:42:23 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>A computer-generated randomisation plan was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:48:33 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>Quote (page 97): "Each patient had a minimum of 4 target lesions with 2 lesions being randomised to ALA solution and 2 to vehicle."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:52:54 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>Quote (page 336): "Of the 207 randomised participants,..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:58:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>A computer-generated randomisation schedule was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:04:25 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>A computer-generated randomisation schedule was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:07:26 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>Quote (page 266): "Randomised patients applied imiquimod or vehicle cream (randomised 1:1)..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 12:00:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>A computer-generated allocation sequence was generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:03:17 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>Adequate randomisation sequence in blocks of 9 using a unique 4-digit number was generated by a computer program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:33:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>Quote (page 995) : "At the baseline visit, eligible patients received treatment with PDT using MAL... and conventional cryotherapy, randomly allocated to alternate sides of the body."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:41:35 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>Adequate randomisation was achieved by a computer-generated randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:47:04 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>Quote (page 159): "Patients were randomly assigned to treatment with DFS or IMI."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:58:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>Quote (page 35): "Each patient was randomly assigned to one of [the] equally sized treatment groups (cryosurgery, 5-FU, or IMIQ) by '<U>on-call</U> randomisation' provided by a specialised external company."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 12:04:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>Quote (page 162): "Patients were randomised in a double-blind fashion to twice-daily treatment with either 10% masoprocol in an emollient cream base or 5% 5-fluorouracil in a vanishing cream base."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:27:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>A computer-generated randomisation schedule was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:31:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>A computer-generated randomisation list was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:36:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>A permuted block randomisation design of size 10 was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:40:41 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>Quote (page 448): "The study was randomised, double-blind, with each agent applied to opposite sides of the patient's face at a 0.05% concentration, for a period of 16 weeks."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:48:03 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>Quote (page 88): "Patients were randomised so that half would receive ALA and half MAL as their first split scalp treatment."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:11:35 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>Quote (page 1138): "Participants were randomised (unstratified, size six randomised block)."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:55:52 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>Quote (pages 364 to 365): "Each treatment was given for 2 months and the order of administration was randomised."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:07:01 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>Quote (page 1030): "At baseline visit, eligible subjects received treatment with PDT using MAL... and conventional<BR/>cryotherapy, randomly allocated to alternate sides of the<BR/>face/scalp."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:25:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>Quote (page 1 of study data document): "Study design: Allocation: Randomised..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:31:56 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>Quote (page 1 of study data document): "Study design: Allocation: Randomised..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:41:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>Quote (page 1 of study data document): "Study design: Allocation: Randomised..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:47:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>Quote (page 739): "Patients were randomly assigned to treatment with topical masoprocol or vehicle in a 3:1 ratio, respectively."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:54:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>A computer-generated randomisation schedule was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:56:47 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>Quote (page 641): "Eligible patients were randomised in a 3:1 ratio (active:vehicle) to either imiquimod or vehicle cream."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:08:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>A computer program, Sampsize 2.0, was used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:11:59 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>Prerandomised numbers assigned to participants at screening visit and stratified per centre were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:12:03 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>Prerandomised numbers assigned to participants at screening visit and stratified per centre were used for allocation generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:43:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>Quote (page 321): "Each patient was randomly assigned to apply topical 5-FU cream to 1 lesional area twice daily for 3 weeks and to<BR/>receive topical PDT twice at a 1-week interval to the other lesional area."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:46:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>Quote (page 554): "Application sites were randomised at the<BR/>time of treatment."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:54:47 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>Quote (page 2): "These trials were not identical; however, both were randomised, multicenter, and double-blinded with patients randomised to Metvixia-PDT and Vehicle-PDT study arms that required 2 treatment sessions (7 days apart)."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:57:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>Quote (page 2): "These trials were not identical; however, both were randomised, multicenter, and double-blinded with patients randomised to Metvixia-PDT and Vehicle-PDT study arms that required 2 treatment sessions (7 days apart)."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 16:07:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>The method used for allocation generation is unclear, but it was performed separately for each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:11:01 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>Quote (page 95): "This randomised, double-blind, placebo-controlled, parallel-group trial was conducted between 1995 and 1996 at 6 Canadian centres."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 15:49:49 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>Adequate allocation generation was achieved with a random digits table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:17:01 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>A previous generated list using a random number generator was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:23:16 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>Quote (page 17): "Randomisation was performed by an independent clinical research organisation and identical packaging was used to maintain blinding of both investigator and patients regarding allocation to active or vehicle gel."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:32:49 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Quote (page 630): "Caucasian patients with a minimum of 4 nonhyperkeratotic AK of either the face or scalp were recruited and<BR/>randomised to 3 treatment groups."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:34:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>Randomisation was not stated in the product insert, but the other 2 studies included were randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:37:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>Quote (page 1062): "Eligible patients received PDT treatment and treatment with imiquimod 5% cream randomly allocated to alternate upper extremities."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:40:09 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>Quote (page 1500): "Each patient was randomly assigned a number that was paired with a box containing 12 sachets."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:45:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>Quote (page 584): "Eligible patients were centrally randomised to placebo, imiquimod 2.5%, or imiquimod 3.75% cream in a 1:1:1 treatment allocation."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:46:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>Quote (page AB2): "A total of 255 patients were randomised to treatment with 0.05'X, ingenol mebutate gel or vehicle."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:12:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>Adequate allocation sequence was generated by stratification with respect to the number of lesions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:20:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>An adequate method of randomisation was achieved by the use of a computer-generated randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:04:05 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>Pre-assigned numbering with 1:1:1:1 randomisation with a block size 4 was used for allocation generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:35:20 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>A computer-generated randomisation scheme was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:40:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>A validated SAS programme based on the random number function RANUNI and random blocks for 6 participants was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:43:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>Quote (page 2): "The initial randomised double-blind phase in which subjects were allocated to either vehicle or imiquimod 5% cream twice weekly for 8 weeks was followed by an optional open-label phase..."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:47:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>Quote (page 145): "Patients were randomly assigned to receive one of the following treatments to be applied in a thin layer to completely cover each affected cosmetic unit:.."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:50:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>Quote (page 425): "The randomisation was performed after the patient was included in the study."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:04:10 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>Adequate randomisation was achieved by stratification according to sex and self-rated skin.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:54:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>Quote (page 137): "...the respective arms to which each preparation was applied were determined by randomisation.</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:26:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>Quote (page 3): "Baseline data were collected, and the patients were randomised to study drug."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:30:56 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>Quote (page): "Patients with one of three organ transplant types (kidney, liver, heart) were randomised 3:1 (active:vehicle) in this vehicle-controlled, double-blind, parallel group design."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:33:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>Quote (page 260): "The pharmacist of the hospital randomly assigned the vehicle to 1 hand and the active drug to the other hand on each patient."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:40:35 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>Quote (page 23): "Patients were randomised to receive 0.5% fluorouracil cream or vehicle control for 1, 2, or 4 weeks (Figure 1)."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:04:12 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>Adequate randomisation sequence generation was achieved by drawing lots.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:04:13 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>Adequate randomisation sequence was achieved by drawing lots.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:49:32 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>Quote (page 2): "The randomisation procedure was performed by a computer-generated sequence blocked by centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:50:51 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Quote (page 710): "One week after the Screening Visit, patients were randomised to receive either the active treatment, 3% diclofenac in 2.5% hyaluronan gel (SolarazeTM Bioglan) or placebo, which consisted of the inactive gel vehicle, hyaluronan only."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:51:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>Quote (page): "Enrolled patients were randomised, 1:1, to apply imiquimod to a 20-cm²area on the right or left side."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:39:06 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>Quote (page 608): "The patient number was randomly assigned to either group 1 (VIS + wIRA PDT, n = 40 patients) or group 2 (red light PDT, n = 40 patients, Table 1)."</P>
<P>Comment: Insufficient detail was reported about the method used to generate this allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-11-07 23:49:29 +0000" MODIFIED_BY="Maryse Paquet" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-17 15:44:29 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:45:31 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:46:02 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-17 16:57:16 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-26 17:44:58 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-26 17:46:22 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:31:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Quote (page 252): "Randomisation codes were concealed within opaque, sealed envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:50:18 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-17 19:17:04 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:51:16 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:51:41 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>Sealed envelopes were used to conceal the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-17 20:13:41 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:53:03 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:53:39 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 16:12:00 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:54:27 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:54:55 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 18:09:07 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>This was no stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:56:06 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:57:20 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:58:14 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:58:41 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:59:06 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 20:21:09 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:59:41 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:00:31 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-19 16:01:57 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-15 13:39:07 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>Participants were assigned the next sequential participant study number and the corresponding study cream.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-19 17:57:28 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:58:52 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>Randomisation involving "on call" randomisation by an external company was used to conceal the allocation. (See previous quote.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 13:44:50 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:04:11 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 14:45:45 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:05:22 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:05:54 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 16:08:10 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-09 14:15:22 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>Allocation was concealed within sealed opaque envelopes (protocol).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:07:25 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 17:48:00 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>This was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 18:07:38 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 18:34:21 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 18:22:37 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 18:48:40 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:04:47 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:32:25 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:45:05 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:09:37 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-04 12:03:40 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>Randomisation sequence was prepared by sponsor.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 14:13:33 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 14:24:17 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 14:42:30 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 14:55:30 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-26 17:54:14 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 15:36:48 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 15:50:01 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:20:11 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>Sequential assignment upon participation enrolment was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:22:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>Randomisation sequence was generated by an independent company (see previous quote in random sequence generation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 16:42:25 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 17:32:08 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 17:49:49 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:40:20 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>The key to codes were held by the pharmaceutical company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:45:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>Centralised randomisation was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 18:47:12 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 19:04:37 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:26:22 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>Adequate allocation concealment was achieved by sealed, tamper-proof envelopes containing a number allocated to each participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 14:11:34 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:28:06 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:28:48 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:07:55 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 16:30:16 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:43:50 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>Sealed envelopes were used to conceal the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-26 15:16:28 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 17:51:04 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 18:16:21 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 18:58:30 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-08 12:12:54 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>A third party (the pharmacist) randomly assigned the vehicle to 1 hand.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 20:10:17 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 20:21:17 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>Opaque sealed envelopes were used to conceal allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 20:38:02 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>Opaque sealed envelopes were used to conceal allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:49:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>Quote (page 2): "Allocations were contained in opaque, sequentially numbered, sealed envelopes and were concealed from assessors throughout the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-25 14:17:04 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-25 14:26:41 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 19:44:57 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-22 20:01:31 +0000" MODIFIED_BY="Maryse Paquet" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-11-09 12:00:36 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 20:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>Both the investigators and the participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 16:59:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 17:40:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 17:50:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>This study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 20:42:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>The centre personnel and the participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 21:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-05 23:31:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>The study was double-blind, and randomisation codes were not revealed until all final assessments were completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 21:36:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>The study was double-blind, but because discomfort was higher with MAL than placebo cream, the blinding could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 09:14:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 22:51:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-24 15:50:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>The study was double-blind for the comparison between MAL-PDT and placebo-PDT and open for the comparison between MAL-PDT and cryotherapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 15:21:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 09:56:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>The study was double-blind for intervention versus control but not for the frequency of application. 4 groups of vehicle were used to match the number of application and conceal treatment allocation, but there was not use of the vehicle to have all groups applying cream for 7 days/week, e.g. tubes labelled for each day of the week (with intervention or control) to conceal frequency allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 10:07:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>The study was double-blind, but authors mentioned that local effects of imiquimod may have led to investigator and subject bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 16:14:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>The study was open because physically different treatments were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 16:39:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 22:11:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>The study was open because the treatments were physically distinct. Similar patches were used for ALA-PDTand placebo-PDT, but no concealment was possible for the physically distinct treatments, i.e. PDT versus cryotherapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 17:37:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>This was not stated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 17:56:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>This study was open. This study did not use placebo cream to conceal the allocation to cryotherapy only versus cryotherapy with betulin-based oleogel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 10:49:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>A non-blinded investigator performed treatments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 18:05:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>This study was double-blind (treatment vs placebo) and open (treatment duration). No placebo cream was used to conceal the treatment duration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 18:50:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>This study was double-blinded. All study personnel, and participants were blinded to actual treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 11:05:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>This study was double-blinded. All study personnel and participants were blinded to the actual treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 19:23:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-09 12:00:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>The study was double-blind for imiquimod versus placebo (subject, caregiver, investigator).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 20:08:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 20:30:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>There was no blinding. This study was open because physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 20:48:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 11:08:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>The study was open. The difference in dosing regimen frequency of the 2 topical treatments was not concealed by the use of double-dummy technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 11:58:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>This was not stated, but the study compared physically distinct interventions and topical treatments with different application regimens.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 12:06:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>This study was double-blinded, and treatments were given with the same application regiment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 15:34:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 13:31:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>Participants and clinic staff were not blinded to the difference in dosing regimens (once versus twice daily).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 13:37:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>The participants, the investigator, and the data managers were kept "blind" as to the treatment until all assessments and data entry had been completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-23 17:59:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 11:27:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>Quote (page 88): "Both patients and investigators remained blinded until study completion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 11:28:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>Quote (page 1138): "Patients and observers (F.M., M.V.) remained blinded until all patients had completed the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 18:12:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 14:07:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>This study was open because 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 18:55:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>This study was single-blinded (assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 14:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>This study was double-blinded (subject, caregiver, investigator).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 14:41:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>This study was double-blinded (subject, caregiver, investigator).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 19:27:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 19:44:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 19:52:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 20:05:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-18 20:23:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 14:11:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>This study was double-blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 14:28:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>This study was open-label. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 14:39:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 14:57:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 14:59:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 16:07:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>Quote (page 42): "Drug application and activation, light treatment, and all safety evaluations were performed by an unblinded investigator..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 15:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 16:02:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 16:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 17:06:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 22:11:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>The blinding was not stated, but 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 16:34:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>The blinding was not stated in the product insert, but the other 2 studies were double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 22:11:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>The blinding was not stated, but 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 18:50:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 16:45:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>This study was double-blinded (subject, caregiver, </P>
<P>investigator), but the authors mentioned that adverse events could be an issue for the concealment of the assigned treatment in some participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 19:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 22:10:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>This study was open because 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 20:13:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 20:27:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-21 20:42:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 14:12:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 14:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>This study was double-blinded for part I.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 12:07:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>The 2 distinct dosing schedules were not concealed with a double-dummy technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 14:59:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>This study was open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 22:51:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>This was not stated. Base cream (vehicle) and sunscreen cream had the same consistency by adding 10% mineral oil to the vehicle. Participant blinding concealment was tested by a question at the end of study, and answers were not significant for both treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 15:29:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 15:46:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 16:08:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 16:30:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>This study was double-blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 23:41:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>This study was double-blinded (treatment vs placebo) and open (treatment duration). Indeed, placebo cream was not used to conceal allocation to 1, 2 , or 4 weeks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 12:16:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>The 2 treatments were physically distinct.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 18:46:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>Quote (page 1309): "The evaluating dermatologist and participants were blinded to the concentrations of creams."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-04-03 16:29:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>This was not stated, but the participants were exposed to light for different periods of time.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 19:36:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-22 19:57:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 12:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>This study was a double-blinded.</P>
<P>Quote (page 609): "Both patients and investigators remained blinded until study completion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-11-09 12:00:39 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 20:04:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>The investigators were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-16 17:00:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-05 13:19:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>2 independent investigators counted lesions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-05 13:29:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>This study was double-blind and used 2 independent blinded dermatologists for histological evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 20:42:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>The investigator was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-16 21:04:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-05 23:31:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>The study was double-blind, and randomisation codes were not revealed until all final assessments were completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-16 21:36:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>The study was double-blind, but because discomfort was higher with MAL than placebo cream, the blinding could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 09:14:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-16 22:51:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-24 15:50:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>The study was double-blind for the comparison between MAL-PDT and placebo-PDT and open for the comparison between MAL-PDT and cryotherapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 15:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 15:37:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>The study was double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 10:07:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>The study was double-blind, but authors mentioned that local effects of imiquimod may have led to investigator and subject bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 16:17:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>Blinding of assessor was not stated and physically different treatments were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 10:23:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>The study was double-blind, and treatment was performed by a second investigator to guarantee an observer-blinded status.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 16:42:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>The study was open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 10:37:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>To keep the assessor blinded, 1 investigator performed the evaluation, and another investigator administered the treatments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 17:56:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>This study was open. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 10:49:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>Different investigators were involved for the treatment and the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 18:05:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>This study was double-blind (treatment vs placebo) and open (treatment duration). No placebo cream was used to conceal the treatment duration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 18:50:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>This study was double-blinded. Investigators were blinded to actual treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 11:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>This study was double-blinded. Investigators were blinded to the actual treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 19:22:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>Authors reported that blinded investigators may have been biased toward participants treated with imiquimod identified by treatment site reactions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-09 12:00:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>The study was double-blind for imiquimod versus placebo (outcomes assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 20:08:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>Investigators were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 20:30:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>There was no blinding. This study was open because physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-17 20:48:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 14:13:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>The study was open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 14:39:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>There was no statement about assessor-blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 14:58:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 15:34:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 15:52:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>This study was evaluator blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 13:37:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>The participants, the investigator, and the data managers were kept "blind" as to the treatment until all assessments and data entry had been completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-08 11:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>The assessment was performed by 2 independent investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 17:07:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>Assessment was performed by a second investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 13:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>Quote (page 1138): "Patients and observers (F.M., M.V.) remained blinded until all patients had completed the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 18:12:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 14:07:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>This study was open because 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 18:55:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>This study was single-blinded (assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 14:31:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>This study was double-blinded (outcomes assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 14:41:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>This study was double-blinded (outcomes assessor).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 19:27:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 19:44:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 19:52:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 20:05:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-18 20:23:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 14:10:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>This study was evaluator-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 14:22:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>Quote (page 322): "Assessments were not blinded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 14:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 14:57:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 14:59:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 16:08:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>This study was assessor-blinded for efficacy, but not for safety. Safety and efficacy assessments were performed by different investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 15:49:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 16:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>This study was assessor-blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 16:14:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 17:06:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 22:11:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>The blinding was not stated, but 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 16:34:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>The blinding was not stated in the product insert, but the other 2 studies were double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 22:11:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>The blinding was not stated, but 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 18:50:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 16:44:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>This study was double-blinded (outcomes assessor), but authors mentioned that adverse events could be an issue for the concealment of the assigned treatment in some participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 19:27:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-08 12:01:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>This study was open because 2 physically distinct treatments were compared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 20:13:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 20:27:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-21 20:41:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>A clinician not involved in treatment procedure assessed response.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 22:40:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>Treatment and safety assessment were performed by 1 investigator and efficacy assessment by another.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 14:20:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>This study was double-blinded for part I.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 14:38:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>The assessor was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 14:59:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>This study was open.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 15:03:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>This was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 15:29:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 15:46:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 16:08:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 16:30:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>An independent dermatologist evaluated the efficacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-07 23:41:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>Different assessment time points were used for 1-, 2-, or 4-week groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 18:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>The evaluator was blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 18:46:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>Quote (page 1309): "The evaluating dermatologist and participants were blinded to the concentrations of creams."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-08 12:18:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>This study was assessor-blinded (based on the protocol NCT00711178, clinicaltrials.gov).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 19:36:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 19:57:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>This study was double-blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-22 16:59:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>The assessor was not involved in treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-11-09 11:48:17 +0000" MODIFIED_BY="Maryse Paquet" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:16:35 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>An intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-05 13:14:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 6 dropouts (the reasons were reported)</P>
<P>Control - B: 6 dropouts (the reasons were reported)</P>
<P>Comment: The associated risk with PP analysis is unclear because the same number of participants were lost in both treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-09 11:45:34 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>Modified intention-to-treat (ITT) analysis was used (i.e. participants with at least 1 postbaseline assessment were included in the analysis, N = 93), but the number of participants lost to follow up was higher than 20%. The numbers used for analysis were unclear. 1 participant in the isotretinoin group was missing in the data for skin irritation.</P>
<P>Intervention - A: 11 dropouts (the reasons were reported)</P>
<P>Control - B: 10 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-05 13:30:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used, and all subjects were accounted for.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 3 dropouts (the reasons were not all reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-08 14:57:07 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>Modified ITT analysis was used (i.e. at least 1 dose and 1 postbaseline assessment).</P>
<P>Intervention - A: 0 dropouts, B: 1 dropout, C: 0 dropouts</P>
<P>Control - D: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-09 11:48:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>It was unclear if the only lost participant was included or not in the analysis.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reasons were reported)</P>
<P>Control - B: 1 dropout (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-05 23:31:59 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Per-protocol analysis was used.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 1 dropout (the reasons were reported)</P>
<P>5 participants with protocol violation (4 imiquimod, 1 placebo) were excluded, and 1 with protocol violation was included (imiquimod not cured).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:16:55 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:16:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:22:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 6 dropouts (the reasons were reported)</P>
<P>Control - B: 6 dropouts (the reasons were reported)</P>
<P>Comment: The associated risk with PP analysis is unclear because the same number of participants were lost in both treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:30:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>Both intention-to-treat (ITT) and per-protocol (PP) analyses were used, but only values for PP were presented and the authors only mentioned that results were similar for ITT analysis.</P>
<P>Intervention - A: 11 dropouts</P>
<P>Control - B: 4 dropouts, C: 3 dropouts</P>
<P>Thus, there was less lost in cryotherapy (3.4%) than placebo-PDT (17%) and MAL-PDT (12.5%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 18:42:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used and 1 withdrawn participant was accounted for in the wrong treatment group (see below).</P>
<P>Intervention - A: 23 dropouts stated but 22 based on the details of the reasons</P>
<P>Control - B: 12 dropouts stated but 13 based on the details of the reasons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 09:57:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 4 dropouts, B: 2 dropouts, C: 9 dropouts, D: 12 dropouts</P>
<P>Control - E: 1 dropout</P>
<P>The imiquimod 5X/week and 7X/week groups lost 30% and 40% of participants, respectively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:07:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 10 dropouts, B: 7 dropouts</P>
<P>Control - C: 10 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:17:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>The type of analysis was unclear.</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Controls - B: 0 dropouts, C: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:24:25 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>Modified ITT analysis was used (4 participants were not included, and the criteria were not specified but the numbers correspond to the following: ALA-PDT: 1 missed control visit, 1 curettage before the study, 1 stop of illumination, and placebo-PDT: 1 consent withdrawn).</P>
<P>Intervention - A: 17 dropouts (the reasons were reported)</P>
<P>Control - B: 8 dropouts (the reasons were reported)</P>
<P>24% of participants were lost before the end of study, but similar percentages were lost for both treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:31:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 19 dropouts (the reasons were reported)</P>
<P>Controls - B: 6 dropouts (the reasons were reported), C: 23 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:35:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Lost participants were mentioned (9) but not by treatment group and the reasons were not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:42:40 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 1 dropout (the reason was reported), B: 1 dropout (the reason was reported)</P>
<P>Control - C: 1 dropout (the reason was reported)</P>
<P>Comment: The effect of PP analysis is difficult to assess because the same number of participants was lost in each treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:49:22 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 4 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:53:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>It was unclear which type of analysis was used.</P>
<P>Intervention - A: 2 dropouts, B: 1 dropout, C: 1 dropout</P>
<P>Control - D: 0 dropouts (the reasons were not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 10:58:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>Modified Intention-to-treat (ITT) analysis was used (i.e. participants at 4 week evaluation based on information, efficacy: 142, safety: 143-received one treatment).</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 7 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:03:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was stated.</P>
<P>Intervention - A: 5 dropouts (the reasons were reported)</P>
<P>Control - B: 12 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:07:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 4 dropouts (the reasons were not reported)</P>
<P>Control - B: 3 dropouts (the reasons were not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:13:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A &amp; B: 14 dropouts (the reasons were reported)</P>
<P>Controls - C &amp; D: 10 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:29:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 2 dropouts (the reasons were not reported), B: 3 dropouts (the reasons were reported)</P>
<P>Control - C: 2 dropouts (the reasons were not completely reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:34:10 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>Both per-protocol (PP) and intention-to-treat (ITT) analyses were used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 4 dropouts (the reasons were reported)</P>
<P>Comment: ITT and PP populations were respectively 121 and 106. Thus, 11 participants were not accounted for, and it was not always clear which analysis type was used for the different outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:41:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 15 dropouts (the reasons were reported)</P>
<P>Control - B: 15 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:49:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropout</P>
<P>Control - B: 0 dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 11:56:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts at test of cure</P>
<P>Control - B: 0 dropouts at test of cure, C: 0 dropouts at test of cure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 12:06:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>Per-protocol analysis was used.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 4 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:27:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 9 dropouts (the reasons were not all reported)</P>
<P>Control - B: 11 dropouts (the reasons were not all reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:31:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:38:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 31 participants did not complete the 24-week treatment (the reasons were reported)</P>
<P>Control - B: 16 participants did not complete the 24-week treatment (the reasons were reported), and 29 completed. There was no information given for 20 participants. There were also inconsistency between data presented in a table and the description in the text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:43:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was not reported)</P>
<P>Control - B: 1 dropout (the reason was not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:47:55 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>Per-protocol (PP) analysis.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:51:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>It was unclear if intention-to-treat (ITT) or per-protocol (PP) analysis was used, but ITT was stated in the protocol.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 2 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 13:55:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 3 dropouts (the reasons were not reported)</P>
<P>Control - B: 2 dropouts (the reasons were not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 14:07:20 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>Per-protocl (PP) and intention-to-treat (ITT) analyses were used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 6 dropouts (the reasons were reported)</P>
<P>Control - B: 6 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 14:26:40 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis for participant complete clearance and per-protocol (PP) analysis for other analyses were used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-08 14:58:06 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>Per-protocol (PP) and modified (no postbaseline assessment but received treatment) intention-to-treat ( ITT) analyses were used.</P>
<P>Intervention - A: 31 dropouts (the reasons were reported)</P>
<P>Control - B: 7 dropouts of the entire group, i.e. 60 participants (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-08 14:58:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>Per-protocol (PP) and modified (no postbaseline assessment but received treatment) Intention-to-treat (ITT) analyses were used.</P>
<P>Intervention - A: 29 dropouts (the reasons were reported)</P>
<P>Control - B: 7 dropouts of the entire group, i.e. 60 participants (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 14:47:55 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used, and there was a difference in the percentages of participant lost between treatment (14%) and placebo (9%).</P>
<P>Intervention - A: 18 dropouts (the reasons were reported)</P>
<P>Control - B: 4 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 14:54:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 14:57:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:08:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:17:26 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 3 dropouts (the reasons were reported)</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:31:13 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropout</P>
<P>Control - B: 0 dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:43:37 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used for the review based on the individual data presented in a table.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:46:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>Per-protocol (PP) analysis with 23% of lost participants was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 5 dropouts (the reasons were reported)</P>
<P>Control - B: 5 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 15:55:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>This was not stated, and the information provided did not allow to make any conclusion. There was no information provided on study dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-21 14:55:30 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>This was not stated and the information provided did not allow to make any conclusion. There was no information provided on study dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-06 16:08:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 7 dropouts (the reasons were reported)</P>
<P>Control - B: 3 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:11:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 3 dropouts, B: 5 dropouts (the reasons were reported)</P>
<P>Control - C: 2 dropouts, D: 1 dropout (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:14:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used, and there was missing information about participants lost after the baseline evaluation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:17:25 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported, and the lost was before treatment)</P>
<P>Control - B: 1 dropout (the reason was reported, and the lost was before treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:23:34 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>Modified intention-to-treat (ITT) analysis was used (participants with no treatment were excluded).</P>
<P>Intervention - A: 0 dropouts, B: 1 dropout (the reason was reported), C: 0 dropouts</P>
<P>Control - D: 0 dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:33:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A &amp; B: 0 dropouts</P>
<P>Control - C: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:34:56 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>The type of analysis was not stated, but the 2 other studies had intention-to-treat (ITT) analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:37:23 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 2 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:40:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:44:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 11 dropouts (the reasons were reported), B: 6 dropouts (the reasons were reported)</P>
<P>Control - C: 9 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 16:47:16 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>The type of analysis was not stated. Only 1 dropout due to adverse events was reported, but the treatment group was not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:13:07 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>There was discrepancy in the text (415) and table (384) for number of lesions in the PDT group. Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 5 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-08 15:50:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used, but some lost to follow up participants were missing for the description.</P>
<P>Intervention - A: 10 dropouts (the reasons were not all reported)</P>
<P>Control - B: 18 dropouts (the reasons were not all reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:28:32 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>Intention-to-treat (ITT) and per-protocol (P) analyses were used.</P>
<P>Intervention - A: 5 dropouts (the reasons were reported), B: 10 dropouts (the reasons were reported), C: 14 dropouts (the reasons were reported)</P>
<P>Control - D: 2 dropouts (the reasons were reported)</P>
<P>Dropping rates were higher for higher doses, i.e.  6%, 16%, 31%, and 41% for 0.01, 0.03, 0.06, and 0.1% resiquimod groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:35:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:40:49 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>Intention-to-treat (ITT) and per-protocol (PP) analyses were used.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 4 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:44:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:47:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>Intention-to-treat was used.</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 2 dropouts (the reasons were provided)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:50:27 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 6 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:52:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>The type of analysis was unclear. The initial number of participants randomised and the number of dropouts (157) were given for the 2 groups together. The reasons for withdrawal were provided in a table, but because 1 participant could have more than 1 reason, it was impossible to determine how many participants withdrew in each treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 22:54:41 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>An unclear type of analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 0 dropouts</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:26:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 4 dropouts (the reasons were reported)</P>
<P>Control - B: 6 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:31:01 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 2 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:33:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>Modified intention-to-treat (ITT, exclusion of only 1 participant who withdrew before PDT) was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 2 dropouts (the reasons were reported)</P>
<P>Control - B: 2 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:41:23 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used.</P>
<P>Intervention - A: 1 dropout (the reason was not reported), B: 1 dropout (the reason was reported), C: 4 dropouts (the reasons were reported)</P>
<P>Control - D: 1 dropout (the reason was not reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:44:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:46:40 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>The type of data analysis was unclear, but only 1 participant was lost to follow up.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 1 dropout (the reason was reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:49:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used for primary outcomes, and per-protocol (PP) analysis was used for secondary outcomes.</P>
<P>Intervention - A: 1 dropout (the reason was reported)</P>
<P>Control - B: 0 dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:50:55 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>Intention-to-treat (ITT) analysis was used, but the initial randomised numbers for each group were not given explicitly.</P>
<P>Intervention - A: 14 dropouts (the reasons were reported)</P>
<P>Control - B: 8 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:52:09 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used with 25% of subjects lost.</P>
<P>Intraindividual study:</P>
<P>Intervention - A: 5 dropouts (the reasons were reported)</P>
<P>Control - B: 5 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-07 23:39:10 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>Per-protocol (PP) analysis was used.</P>
<P>Intervention - A: 1 dropout (the reasons were reported)</P>
<P>Control - B: 3 dropouts (the reasons were reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-11-09 11:49:53 +0000" MODIFIED_BY="Maryse Paquet" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-19 17:09:53 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>All outcomes were reported even if there was no difference between treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 13:15:03 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>The percentage reduction in lesion counts was given only for the DFMO-treated group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-22 20:22:27 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>A poor efficiency was reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 13:30:32 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>The participant complete clearance for the face and scalp was reported for the imiquimod group but not the vehicle group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-08 15:45:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>Data were pooled for safety and cosmetic outcomes. Based on the protocol NCT00375739, safety was supposed to be the primary outcome. However, efficacy data were presented first.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:28:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>Based on the text, the data should have been presented as percentage of reduction in lesion count, but only the absolute counts at baseline and 3 months were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:31:04 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:49:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>The same data were reported in the abstract and published paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:14:49 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 18:41:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>No statistically different results were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:31:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>Types of adverse events were not reported separately for PDT and cryotherapy treatments, but more adverse events were reported for PDT than cryotherapy, and more for MAL-PDT than placebo-PDT. Risk of bias for more than 2 groups: cosmetic outcomes were not presented for the placebo-PDT treatment group, and satisfaction was reported only for PDT participants. Similar data were presented in abstract form and published paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:37:29 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 14:35:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>All outcomes were reported even if efficacy was low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:08:04 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>All outcomes from the protocol NCT00603798 were reported, but additional outcomes were also presented in the published paper (e.g. cosmetic).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:16:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 17:30:58 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>Details on investigator cosmetic outcomes and adverse events for placebo group were not given. Outcomes in protocol (NCT00308854) were all presented in published paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 17:53:42 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>Details on investigator cosmetic outcomes and adverse events for placebo group were not given. Outcomes in protocol (NCT00308867) were all presented in published paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:36:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>Adverse events were not always clearly reported by group, and the number of participants included in the safety analysis was not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:42:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:49:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-18 19:29:04 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>Values for absolute reductions in lesion numbers, standard deviations on mean percentages, and PGAI were not given. Details on local skin reactions and adverse events, other than facial irritation, was not reported in the published version of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:58:13 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 16:21:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>Standard deviations on percentage of mean reduction in lesion counts were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 18:54:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>Statistically significantly more application site reactions, local skin reactions, and adverse events for imiquimod were reported but not all the numbers supporting it were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:13:47 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>All outcomes from the protocol were reported, and the data were consistent in conference abstract, published paper, and the study results section of the protocol (NCT00894647) in clinicaltrials.gov. Additonal outcomes were reported in the published report. The data for "no cryotherapy" was not given for all outcomes. Cosmetic outcomes were reported separately for each criteria but were not reported as a global assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:29:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>Authors pooled together selected PGAI data, i.e. for clear, marked, moderate (but not slight) improvement to reach statistically significant difference.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-19 16:31:27 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>The standard deviation associated with the mean percentage of reduction in lesion counts were not provided. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-19 17:02:18 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>Skin quality rating was not reported for placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:50:07 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>Participant partial (&gt; 75%) clearance was mentioned, but no data were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:56:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 12:06:21 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:27:38 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>As a similar study (<LINK REF="STD-Szeimies-2004" TYPE="STUDY">Szeimies 2004</LINK>) was also supported by Graceway/3M Pharmaceuticals, not all skin quality outcomes were reported. All outcomes presented in the product insert were reported in the published paper. Another Graceway clinical trial on the arms and hands (<LINK REF="STD-NCT00115154" TYPE="STUDY">NCT00115154</LINK>) was not published or included in the product insert.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:34:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>Only estimates on clearance rates were provided, i.e. exact values were not given and standard deviations for absolute and per cent mean values were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:37:16 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:43:40 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>Negative (tolerability) data for the sponsored product were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:49:07 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>Wood's light was used to look at PpIX fluorescence after cream incubation, but the results were not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:51:21 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>Appearance of new/subclinical lesions was not reported, but this outcome was included in the protocol ACTRN12607000428460 at anzctr.org.au.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:55:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 17:51:15 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>Standard deviations for the mean percentages of reduction in lesion counts were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-08 14:58:00 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>A "favourable" efficacy outcome was analysed posthoc, whereas the prespecified outcome was not favourable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:31:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:41:21 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:47:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:54:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-06 18:43:05 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>All outcomes in the protocol (NCT00294320) were reported in the published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 19:10:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>The standard deviations associated with mean values were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 19:15:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>The cosmetic outcomes were reported for MAL-PDT participants only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 13:50:28 +0100" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>All outcomes from the protocol (NCT00306800) and protocol mistakes were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:43:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 19:40:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>The adverse events were not reported separately for the 2 treatments. The standard deviations associated with mean values were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:55:13 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>The adverse events were reported for the whole study, i.e. not separated for MAL and vehicle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:57:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>The adverse events were reported for the whole study, i.e. not separated for MAL and vehicle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 16:11:03 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>The Levulan kerastick product insert mentioned 7 clinical trials. Efficacy data from only 2 randomised phase III (<LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK>) and open studies were presented. Only safety data from the 2 phase III studies were presented. Levulan kerastick reported efficacy outcomes separately for the face and scalp, but <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK> did not. <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK> reported adverse events for ALA-PDT, whereas Levulan kerastick reported them for both ALA-PDT and placebo-PDT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:11:22 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>Statistically significant and non-significant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 15:51:55 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>The severity of local skin reactions was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:17:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>The number of participants with severe local skin reactions was not given separately for the 2 treatments. The standard deviations associated with mean values were not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:23:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>All outcomes were reported based on protocol NCT00107965, as well as the mistakes made in the dose application schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 20:14:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>The percentages of participants reporting adverse events were not given except for stinging.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:35:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>This was the only study of 3 presented in the Solaraze product insert that was not published and with no significant difference for participant complete clearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:37:44 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>All outcomes were reported, i.e. significantly different or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:39:56 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:44:37 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>All outcomes from the protocol (NCT00605176) were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-10 18:41:54 +0100" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>All outcomes in the protocol (NCT00742391) were reported in the published study. Another similar study (NCT00942604) has not been published yet. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-21 19:06:31 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>Overall cosmetic outcomes were pooled together. Satisfaction was reported for PDT participants only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:20:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>As a similar study (<LINK REF="STD-Lebwohl-2004" TYPE="STUDY">Lebwohl 2004</LINK>) was also supported by 3M Pharmaceuticals not all skin quality outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:25:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:35:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>All outcomes were presented based on the protocol (NCT00304239), and protocol mistakes were acknowledged.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:40:54 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>All outcomes were reported, but little information was given on adverse events and cosmetic outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:44:27 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>Some outcomes (recurrence rate, time to recurrence, time to reach success, participant improvement assessment) in the protocol (NCT00110682) were not presented in the published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 15:25:45 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>Values for participant&#8217;s perception of efficacy were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 14:09:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="YES" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>The results were similar to previously reported data in an abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:51:46 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-22 15:29:41 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>All outcomes were presented even if efficacy was higher for placebo. The standard deviations associated with mean values were not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:27:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>Little was reported on skin quality outcomes. A lot of outcomes were reported for the imiquimod-treated group only. All outcomes from the protocol (NCT00189267) were reported in the published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:31:09 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>There was discrepancy in the number of participants completely cleared between the abstract and published report. The lowest number in the published report was used for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-24 19:21:53 +0100" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>Only mean values were reported i.e. the associated standard deviations were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:41:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>The standard deviations associated with the mean number of lesions and percentages were not reported. Adverse events were not reported in this study, but they were reported in a similar study included (<LINK REF="STD-Jorizzo-2002" TYPE="STUDY">Jorizzo 2002</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 19:34:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>No outcomes were specified in the protocol (NCT00432224). <BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:46:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>The number of participants and average time spent outside were different between the abstract and published report. There was a little confusion regarding the type of efficacy outcome reported in the abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:49:11 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>All primary outcomes were reported based on the protocol NCT00711178. Additional secondary outcomes, which were not included in our review, were also reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:50:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:52:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:38:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-11-09 12:16:24 +0000" MODIFIED_BY="Maryse Paquet" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 12:28:51 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Akar-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 12:33:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alberts-2000">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 11:10:04 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Alirezai-1994">
<DESCRIPTION>
<P>The partial response criteria was very large (30% to 100%). Baseline mean withinparticipant differences in lesion number on the face was significantly different between treatment and control groups (P = 0.04).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 13:27:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Alomar-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:21:43 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-08 15:10:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Bercovitch-1987">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:31:05 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 23:36:22 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Dragieva-2004a">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:18:12 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Fariba-2006">
<DESCRIPTION>
<P>The presentation of the data was confusing. The wording in the manuscript for the efficacy analysis created confusion between 'lesion complete response' and 'participant complete clearance', but based on the numbers and the percentages given, the outcome was lesion complete response.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:22:58 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Foote-2009">
<DESCRIPTION>
<P>Unprecise evaluation: 8 participants at baseline and 6 at the end of treatment had lesions too numerous to count and a number of 78 was used for analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:31:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Freeman-2003">
<DESCRIPTION>
<P>There was a difference in baseline; the placebo PDT group included a greater proportion of men, and slightly more participants with skin type I and fewer with skin type 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:37:30 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:55:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Gebauer-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:08:27 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hanke-2010">
<DESCRIPTION>
<P>Data for safety were reported differently in the published and the study results section of the protocol NCT00603798 in clinicaltrials.gov.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:17:01 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hantash-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:23:33 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009a">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:30:59 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009b">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:35:51 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Hauschild-2009c">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:42:16 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Huyke-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:49:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jeffes-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:54:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 10:58:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:05:25 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2006">
<DESCRIPTION>
<P>There was some inconsistency in the numbers in the manuscript as well as with the previous paper, <LINK REF="STD-Jorizzo-2004" TYPE="STUDY">Jorizzo 2004</LINK>, for efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 16:25:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Jorizzo-2007">
<DESCRIPTION>
<P>There was no demographic description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:13:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Jorizzo-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:29:17 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 15:40:48 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kaufmann-2008">
<DESCRIPTION>
<P>Participant's assessment of cosmetic outcomes has negative value if cryotherapy is better and positive value if MAL-PDT is better. This could influence the participant perception.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:41:15 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Korman-2005">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:49:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Kose-2008">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 11:56:47 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Krawtchenko-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-18 14:57:43 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Kulp_x002d_Shorten-1993">
<DESCRIPTION>
<P>A significantly higher percentage (65.5%) of participants treated with 5-fluorouracil failed to complete 28 days of treatment than participants treated with masoprocol (16%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:27:06 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Lebwohl-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:31:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Loven-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:37:20 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-McEwan-1997">
<DESCRIPTION>
<P>End of treatment varied as participants ceased treatment at varying times. 34% (diclofenac) and 20% (hyaluronic acid) of participants ceased the treatment before 8 weeks. Between 8 and 16 weeks, 11% (diclofenac) and 5% (hyaluronic acid) of participants ceased the treatment. Between 16 and 24 weeks, 55% (diclofenac) and 75% (hyaluronic acid) of participants ceased the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:43:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Misiewicz-1991">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:48:33 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:50:40 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moloney-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 13:55:37 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Moriarty-1982">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:06:43 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Morton-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:26:28 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00774787">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:32:18 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Aldara">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:41:22 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-NCT00828568-Taro">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:48:14 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Olsen-1991">
<DESCRIPTION>
<P>25 participants stopped treatment between 14 &amp; 28 days due to adverse reactions, but it was stated that their results were comparable to those who completed the full 28 days of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:54:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ooi-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 14:57:06 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ortonne-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:08:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ostertag-2006">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:17:21 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Pariser-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:31:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Pariser-2008">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:43:31 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Perrett-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:46:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Persaud-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:54:51 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_Australian-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 15:57:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Photocure_x002d_US-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 18:59:16 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Piacquadio-2004">
<DESCRIPTION>
<P>Data between <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK> (PP) and the Levulan kerastick (ITT?) product insert was not always the same. Data from <LINK REF="STD-Piacquadio-2004" TYPE="STUDY">Piacquadio 2004</LINK> was used for analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:11:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Rivers-2002">
<DESCRIPTION>
<P>There were different safety data between <LINK REF="STD-Rivers-2002" TYPE="STUDY">Rivers 2002</LINK> and the Solaraze product insert.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:14:10 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Seckin-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:17:02 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Shaffelburg-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:23:53 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Siller-2009">
<DESCRIPTION>
<P>There were higher percentages of women and scalp lesions in the vehicle group at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:32:42 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:34:41 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Solaraze-study-2">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:37:19 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Sotiriou-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:39:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Stockfleth-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:44:43 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010a">
<DESCRIPTION>
<P>Data for safety were reported differently in the published study, and the data results linked to the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 16:46:50 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Swanson-2010b">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:12:45 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2002">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:19:57 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2004">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-09 12:16:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Szeimies-2008">
<DESCRIPTION>
<P>The values for overall partial (&gt; 75%) clearance were lower than overall complete clearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:35:08 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:40:33 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Szeimies-2010b">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-22 14:19:21 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Tan-2007">
<DESCRIPTION>
<P>There were differences between the protocol and the published report. The primary and secondary outcomes in the published report were different than the protocol. The protocol did not mention the second part of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:47:07 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tanghetti-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:50:23 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tarstedt-2005">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:51:47 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1993">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 22:54:36 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Tong-1996">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:26:49 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2007">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:30:39 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Ulrich-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:33:35 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Geer-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:42:26 +0000" MODIFIED_BY="Maryse Paquet" RESULT="NO" STUDY_ID="STD-Weiss-2002">
<DESCRIPTION>
<P>There was slight difference (P = 0.048) in the women ratio [more in 4-week group (C) and less in placebo group (D)] at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:44:06 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wiegell-2008">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:46:24 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wiegell-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:49:00 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wiegell-2011a">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:50:37 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-2001">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:52:13 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-Zeichner-2009">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-07 23:38:54 +0000" MODIFIED_BY="Maryse Paquet" RESULT="UNKNOWN" STUDY_ID="STD-von-Felbert-2010">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-09-16 19:38:48 +0100" MODIFIED_BY="Maryse Paquet"/>
<ADDITIONAL_TABLES MODIFIED="2012-11-08 16:15:29 +0000" MODIFIED_BY="Maryse Paquet">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-11-08 13:50:21 +0000" MODIFIED_BY="Maryse Paquet" NO="1">
<TITLE MODIFIED="2011-10-07 14:04:58 +0100" MODIFIED_BY="Maryse Paquet">Overview for 3% diclofenac in 2.5% hyaluronic acid</TITLE>
<TABLE COLS="7" ROWS="27">
<TR>
<TH COLSPAN="7">
<P>
<B>Diclofenac in 2.5% hyaluronic acid compared to interventions for actinic keratoses in immunocompetent participants</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Intervention/Comparison intervention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
<P>
<B>With comparator</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
<P>
<B>With intervention</B>
</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Participant complete clearance</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/2.5% hyaluronic acid</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.46 </B>
<BR/>(1.66 to 3.66)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>420<BR/>(3 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>For all lesions, data from 30, 60, and 90 day treatments pooled together, assessment at 30 days after the end of treatment (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>127 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>313 per 1000</B>
<BR/>(211 to 466)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>132 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>325 per 1000</B>
<BR/>(219 to 483)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/5% imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid + ALA-red light PDT/2.5% hyaluronic acid + ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean reduction in lesion counts </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>2.5 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction of lesion counts in the intervention groups was<BR/>
<B>2.55 higher</B>
<BR/>(1.56 to 3.53 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>345<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from 30, 60, and 90 day treatments pooled together, assessment 30 days after the end of treatment (<LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/ 5% imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid + ALA-red light PDT/2.5% hyaluronic acid + ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: at 6 weeks; diclofenac/hyaluronic acid (HA) +  ALA-PDT = 10.13, HA + ALA-PDT= 9.9, at 6 months; diclofenac/HA + ALA-PDT = 11.56, HA + ALA-PDT = 10.56, at 12 months; diclofenac/HA + ALA-PDT = 12.5, HA + ALA-PDT = 8.8</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean percentage of reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All comparisons</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/2.5% hyaluronic acid</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.59 </B>
<BR/>(1.92 to 6.7)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>592<BR/>(4 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>(<LINK REF="CMP-006.13" TYPE="ANALYSIS">Analysis 6.13</LINK>)</P>
<P>Additional data from intraindividual study: no participant withdrew because of adverse events (N = 20). GRADE = low.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>40 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>144 per 1000</B>
<BR/>(77 to 269)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>43 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>154 per 1000</B>
<BR/>(83 to 288)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/5% imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid + ALA-red light PDT/2.5% hyaluronic acid + ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Skin irritation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study reported irritation only on the diclofenac treated side of 8 out of  20 participants</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid/5% imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid + ALA-red light PDT/2.5% hyaluronic acid + ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> -</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-11-08 15:46:03 +0000" MODIFIED_BY="Maryse Paquet" NO="2">
<TITLE MODIFIED="2011-10-07 14:08:52 +0100" MODIFIED_BY="Maryse Paquet">Overview for 5-fluorouracil</TITLE>
<TABLE COLS="7" ROWS="69">
<TR>
<TH COLSPAN="7">
<P>
<B>5-fluorouracil (5-FU) compared to interventions for actinic keratoses in immunocompetent participants</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Intervention/Comparison intervention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
<P>
<B>With comparator</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
<P>
<B>With intervention</B>
</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Participant complete clearance</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>0.5% 5-FU/Vehicle</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 8.86 </B>
<BR/>(3.67 to 21.40)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>522<BR/>(3 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Data from 1, 2, and 4 week treatments were pooled together (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>136 per 1000</B>
<BR/>(56 to 328)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU with cryotherapy/Vehicle with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>71 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>291 per 1000</B>
<BR/>(116 to 731)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 4.08 </B>
<BR/>(1.63 to 10.23)</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 cycle (<LINK REF="CMP-062.01" TYPE="ANALYSIS">Analysis 62.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/ALA-PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>292 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>499 per 1000</B>
<BR/>(239 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.71 </B>
<BR/>(0.74 to 3.98)</P>
</TD>
<TD VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from blue light and pulsed dye laser were pooled</P>
<P>(<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/5.0% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>21<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: 0.5% and 5.0% 5-FU = 9/21</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU with 0.05% tretinoin /5% 5-FU with placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU /10% masoprocol</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>5% 5-FU/5% Imiquimod</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.85 </B>
<BR/>(0.41 to 8.33)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>89<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>(<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(246 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>555 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(230 to 1000)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Carbon dioxide laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Er:YAG laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>680 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>959 per 1000</B>
<BR/>(721 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.41 </B>
<BR/>(1.06 to 1.87)</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Only data after the treatment</P>
<P>(<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Trichloroacetic acid peel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/Vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>4 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was<BR/>
<B>5.40 higher</B>
<BR/>(2.94 to 7.86 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from 1, 2, and 4 week treatment were pooled. (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>) Results from another study (N = 177) with no SD: placebo: 2.7 lesions, 5-FU = 8.8 lesions, GRADE = moderate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU with cryotherapy/Vehicle with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>6.6 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was<BR/>
<B>2 higher</B>
<BR/>(0.49 lower to 4.49 higher)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 cycle (<LINK REF="CMP-062.02" TYPE="ANALYSIS">Analysis 62.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/ALA-PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/5.0% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>21<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: results with no SD: 0.5% 5-FU = 8.8 lesions, 5.0% 5-FU = 6.1 lesions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU with 0.05% tretinoin /5% 5-FU with placebo</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>11.1 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was<BR/>
<B>1.2 higher</B>
<BR/>(3.24 lower to 5.64 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU /10% masoprocol</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>11.3 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was<BR/>
<B>1.5 higher</B>
<BR/>(2.36 lower to 5.36 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/5% Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Carbon dioxide laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Er:YAG laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Results with no SD: number of lesions at 3 months:5-FU = 13.2, resurfacing = 13.8, at 6 months:5-FU = 12.5, resurfacing = 13.9, at 12 months: 5-FU = 12.4, resurfacing = 14.2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Trichloroacetic acid peel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean percentage of reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/Vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts ranged across control groups from<BR/>
<B>28.8 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>33.60 higher</B>
<BR/>(22.88 to 44.32 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from 1 week treatment.(<LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>) Results from two other studies with no SD</P>
<P>1) (N = 207) placebo = 21.6%, 5-FU = 69.5%, GRADE = low,</P>
<P>2)(N = 177) placebo = 34.4%, 5-FU = 78.5%, GRADE = moderate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU with cryotherapy/Vehicle with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>45.6 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>21.4 higher</B>
<BR/>(5.1 to 37.7 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/ALA-PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/5.0% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>21<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: results with no SD: 0.5% 5-FU = 67% and 5.0% 5-FU = 47%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU with 0.05% tretinoin /5% 5-FU with placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU /10% masoprocol</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>77.6 percent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>20 higher</B>
<BR/>(11.82 to 28.18 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/5% Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Results with no SD: 5% 5-FU = 94%, 5% imiquimod = 66%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Carbon dioxide laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>92 percent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>8.80 lower</B>
<BR/>(20.76 lower to 3.16 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>14<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK> )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Er:YAG laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Results with no SD: at 6 months: 5-FU = 79.2%, resurfacing 94.5%, at 12 months: 5-FU = 76.6%, resurfacing = 91.1%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Trichloroacetic acid peel</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>89 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>5.8 lower</B>
<BR/>(15.38 lower to 3.78 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>18<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/Vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A</B> (5/119 = 42/1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 5.41 </B>
<BR/>(0.3 to 96.18)</P>
</TD>
<TD VALIGN="TOP">
<P>177<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from 1, 2, and 4 week treatments were pooled.(<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>) Another study reported 24/207 participants withdrew because of adverse events and 12 of them were in 4 week 5-FU group. GRADE = low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU with cryotherapy/Vehicle with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals in the first part of this three part study (incomplete data were given for the whole study).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/ALA-PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A</B> (1/12 = 83/1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 5.77 </B>
<BR/>(0.25 to 131.92)</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from blue light and pulsed dye laser were pooled</P>
<P>(<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/5.0% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>21<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: 16/21 discontinued treatment but did not withdraw: 4 because of 0.5%, 8 because of 5.0% , 4 because of both creams.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU with 0.05% tretinoin /5% 5-FU with placebo</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: 1 participant withdrew because of irritation but associated treatment was not specified.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU /10% masoprocol</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A</B> (1/30 = 33/1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.71 </B>
<BR/>(0.12 to 63.84)</P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/5% Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>89<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Carbon dioxide laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>45 per 1000</B>
<BR/>(2 to 817)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.18 </B>
<BR/>(0.01 to 3.27)</P>
</TD>
<TD VALIGN="TOP">
<P>17<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Er:YAG laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A</B> (1/27 = 37/1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.11 </B>
<BR/>(0.13 to 73.11)</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Trichloroacetic acid peel</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>18<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Skin irritation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/Vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>654 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>948 per 1000</B>
<BR/>(830 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.45 </B>
<BR/>(1.27 to 1.65)</P>
</TD>
<TD VALIGN="TOP">
<P>384<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from 1, 2, and 4 week treatments were pooled</P>
<P>(<LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU with cryotherapy/Vehicle with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/ALA-PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5% 5-FU/5.0% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>21<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: All participants reported facial irritation in association with both creams</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU with 0.05% tretinoin /5% 5-FU with placebo</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: 12 had more irritation with tretinoin, 4 had more with placebo, and 3 had equal irritation.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU /10% masoprocol</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/5% Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Carbon dioxide laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Er:YAG laser resurfacing</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>429 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>703 per 1000</B>
<BR/>(429 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.64 </B>
<BR/>(1 to 2.69)</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>At the end of treatment</P>
<P>(<LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% 5-FU/Trichloroacetic acid peel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-11-08 16:15:22 +0000" MODIFIED_BY="Maryse Paquet" NO="3">
<TITLE MODIFIED="2011-10-07 14:22:40 +0100" MODIFIED_BY="Maryse Paquet">Overview for photodynamic therapy</TITLE>
<TABLE COLS="7" ROWS="132">
<TR>
<TH COLSPAN="7">
<P>
<B>Photodynamic therapy compared to interventions for actinic keratoses in immunocompetent participants</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Intervention/Comparison intervention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
<P>
<B>With comparator</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
<P>
<B>With intervention</B>
</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Participant complete clearance</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /1h ALA-pulsed dye laser PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
<BR/>(71 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 6 </B>
<BR/>(0.85 to 42.59)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-048.01" TYPE="ANALYSIS">Analysis 48.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B> (225 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1 </B>
<BR/>(0.45 to 2.23)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-050.01" TYPE="ANALYSIS">Analysis 50.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14-18h ALA-blue light PDT /14-18h placebo-blue light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>97  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>602 per 1000</B>
<BR/>(279 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 6.22 </B>
<BR/>(2.88 to 13.43)</P>
</TD>
<TD VALIGN="TOP">
<P>243<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 treatment.</P>
<P>(<LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>) Additional intraindividual study: ALA-PDT: 16/35, placebo-PDT = 2/35. GRADE = moderate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-pulsed dye laser PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>85 per 1000</B>
<BR/>(10 to 590)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.17 </B>
<BR/>(0.02 to 1.18)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-050.01" TYPE="ANALYSIS">Analysis 50.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/1h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>474 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>237 per 1000</B>
<BR/>(118 to 469)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.5 </B>
<BR/>(0.25 to 0.99)</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment (<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/2h ALA-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>471 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>235 per 1000</B>
<BR/>(118 to 475)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.5 </B>
<BR/>(0.25 to 1.01)</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment</P>
<P>(<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>735 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>235 per 1000</B>
<BR/>(125 to 449)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.32 </B>
<BR/>(0.17 to 0.61)</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment</P>
<P>(<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /2h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>471 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>475 per 1000</B>
<BR/>(292 to 772)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.62 to 1.64)</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment</P>
<P>(<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>735 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>471 per 1000</B>
<BR/>(324 to 699)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.44 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment</P>
<P>(<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h ALA-red light PDT/4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>735 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>471 per 1000</B>
<BR/>(309 to 706)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.42 to 0.96)</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 8 weeks after the end of treatment (<LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3-4h ALA-red light PDT/3 to 4h placebo-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>89 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>527 per 1000</B>
<BR/>(297 to 935)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 5.94 </B>
<BR/>(3.35 to 10.54)</P>
</TD>
<TD VALIGN="TOP">
<P>422<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 treatment (<LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronan gel + 4h ALA-red light PDT /2.5% hyaluronan gel + 4h ALA-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4h ALA-red light PDT/Cryotherapy</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>443 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>580 per 1000</B>
<BR/>(465 to 726)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.31 </B>
<BR/>(1.05 to 1.64)</P>
</TD>
<TD VALIGN="TOP">
<P>297<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-051.01" TYPE="ANALYSIS">Analysis 51.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-red light PDT <U>(individual lesions)</U>/5% imiquimod <U>(</U>field-directed<U> treatment)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-blue light PDT + 5% imiquimod / ALA-blue light PDT + placebo</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Intraindividual study: ALA-PDT + 5% imiquimod = 2/25; ALA-PDT + placebo = 2/25</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT versus MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5h ALA-red light PDT /3h MAL-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>16<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: ALA-PDT = 6/16, MAL-PDT = 7/16</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All day 16% MAL-daylight PDT /All day 8% MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h MAL-daylight PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5-4h MAL-red light PDT /2.5-4h placebo-red light PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>147 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>656 per 1000</B>
<BR/>(466 to 924)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 4.46 </B>
<BR/>(3.17 to 6.28)</P>
</TD>
<TD VALIGN="TOP">
<P>482<BR/>(5 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-052.01" TYPE="ANALYSIS">Analysis 52.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-broad visible + water-filtered infrared A PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>575 per 1000</B>
<BR/>(380 to 865)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.15 </B>
<BR/>(0.76 to 1.73)</P>
</TD>
<TD VALIGN="TOP">
<P>80<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data from assessment at 12 weeks after the end of treatment.(<LINK REF="CMP-053.01" TYPE="ANALYSIS">Analysis 53.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Single 3h MAL-red light PDT /Multiple 3h MAL-red light PDT [2 treatments 1 week apart]</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>755 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>883 per 1000</B>
<BR/>(777 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.17 </B>
<BR/>(1.03 to 1.33)</P>
</TD>
<TD VALIGN="TOP">
<P>211<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-057.01" TYPE="ANALYSIS">Analysis 57.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light PDT /Cryotherapy</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /1h ALA-pulsed dye laser PDT</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14-18h ALA-blue light PDT /14-18h placebo-blue light PDT</P>
<P>
<U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-pulsed dye laser PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/1h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/2h ALA-red light PDT</P>
<P>
<U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /2h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3-4h ALA-red light PDT /3-4h placebo-red light PDT</P>
<P>
<U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid gel + 4h ALA-red light PDT /2.5% hyaluronic acid gel + 4h ALA-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual study: at 6 weeks; diclofenac/hyaluronic acid (HA) +  ALA-PDT = 10.13, HA + ALA-PDT= 9.9, at 6 months:;  diclofenac/HA + ALA-PDT = 11.56, HA + ALA-PDT = 10.56, at 12 months;  diclofenac/HA + ALA-PDT = 12.5, HA + ALA-PDT = 8.8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4h ALA-red light PDT /Cryotherapy</P>
<P>
<U>(individual lesions</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-red light PDT <U>(individual lesions)</U>/5% imiquimod <U>(</U>field-directed<U> treatment)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-blue light PDT + 5% imiquimod / ALA-blue light PDT + placebo</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Results from intraindividual study without SD: ALA-PDT + 5% imiquimod = 19.9 lesions; ALA-PDT + placebo = 16.0 lesions</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT versus MAL-PDT         </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5h ALA-red light PDT /3h MAL-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>5.6 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was <B>0.6 higher</B>
<BR/>(1.28 lower to 2.48 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-059.01" TYPE="ANALYSIS">Analysis 59.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All day 16% MAL-daylight PDT /All day 8% MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>14.5 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was <B>0.3 higher</B>
<BR/>(3.77 lower to 4.37 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-056.01" TYPE="ANALYSIS">Analysis 56.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h MAL-daylight PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>9.7 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was <B>0.1 higher</B>
<BR/>(3.17 lower to 3.37 higher)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>120<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-055.01" TYPE="ANALYSIS">Analysis 55.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5-4h MAL-red light PDT /2.5-4h placebo-red light PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-broad visible + water-filtered infrared A PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>8.4 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was <B>0.4 lower</B>
<BR/>(3.23 lower to 2.43 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-054.01" TYPE="ANALYSIS">Analysis 54.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Single 3h MAL-red light PDT /Multiple 3h MAL-red light PDT [2 treatments 1 week apart]</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light PDT /Cryotherapy</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean percentage of reduction in lesion count</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /1h ALA-pulsed dye laser PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>1h ALA-blue light PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>14-18h ALA-blue light PDT /14-18h placebo-blue light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>1h ALA-pulsed dye laser PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>0.5h ALA-red light PDT/1h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>0.5h ALA-red light PDT/2h ALA-red light PDT</P>
<P>
<U>(individual lesions</U>)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>0.5h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>1h ALA-red light PDT /2h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>1h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>2h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions</U>)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>3-4h ALA-red light PDT /3-4h placebo-red light PDT</P>
<P>
<U>(individual lesions<I>)</I>
</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>3% diclofenac in 2.5% hyaluronic acid gel + 4h ALA-red light PDT /2.5% hyaluronic acid gel + 4h ALA-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>4h ALA-red light PDT /Cryotherapy</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-red light PDT <U>(individual lesions)</U>/5% imiquimod <U>(</U>field-directed<U> treatment)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-blue light PDT + 5% imiquimod / ALA-blue light PDT + placebo</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Results from intraindividual study without SD: ALA-PDT + 5% imiquimod = 86.7%; ALA-PDT + placebo = 73.1%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT versus MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5h ALA-red light PDT /3h MAL-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All day 16% MAL-daylight PDT /All day 8% MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data with no SD:</P>
<P>16% MAL-daylight PDT = 76.9%, 8% MAL-daylight PDT = 79.5%.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h MAL-daylight PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>74.6 percent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was <B>2.6 higher</B>
<BR/>(6.46 lower to 11.66 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>120<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-055.02" TYPE="ANALYSIS">Analysis 55.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5-4h MAL-red light PDT /2.5-4h placebo-red light PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-broad visible + water-filtered infrared A PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data with no SD: MAL-red light LED PDT = 71%, MAL-daylight PDT = 79%.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Single 3h MAL-red light PDT /Multiple 3h MAL-red light PDT [2 treatments 1 week apart]</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light PDT /Cryotherapy</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>240<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual studies with no SD: at 12 weeks: MAL-PDT = 84.4%, cryotherapy = 74.5%, at 24 weeks: MAL-PDT = 75-86.7%, cryotherapy = 83.9-87%</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /1h ALA-pulsed dye laser PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>28 per 1000</B>
<BR/>(1 to 621)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.33 </B>
<BR/>(0.01 to 7.45)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-050.03" TYPE="ANALYSIS">Analysis 50.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14-18h ALA-blue light PDT /14-18h placebo-blue light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>271<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-pulsed dye laser PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>28 per 1000</B>
<BR/>(1 to 621)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.33 </B>
<BR/>(0.01 to 7.45)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-050.03" TYPE="ANALYSIS">Analysis 50.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/1h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/2h ALA-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /2h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h ALA-red light PDT /4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>No details were given for the reasons for withdrawal.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3-4h ALA-red light PDT /3-4h placebo-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>391<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid gel + 4h ALA-red light PDT /2.5% hyaluronic acid gel + 4h ALA-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4h ALA-red light PDT /Cryotherapy</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>255<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-red light PDT <U>(individual lesions)</U>/5% imiquimod <U>(</U>field-directed<U> treatment)</U>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>30<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-blue light PDT + 5% imiquimod / ALA-blue light PDT + placebo</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT versus MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5h ALA-red light PDT /3h MAL-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>15<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All day 16% MAL-daylight PDT /All day 8% MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>One of 30 participants withdrew because of adverse events unrelated to treatments.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h MAL-daylight PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>120<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5-4h MAL-red light PDT /2.5-4h placebo-red light PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A</B> (3/130 = 23/1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2 </B>
<BR/>(0.23 to 17.74)</P>
</TD>
<TD VALIGN="TOP">
<P>191<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-052.03" TYPE="ANALYSIS">Analysis 52.3</LINK>)</P>
<P>Two additional studies with no participant withdrawals because of adverse events (N = 211). GRADE = low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-broad visible + water-filtered infrared A PDT</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>78<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light LED PDT /3h MAL-daylight PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0  per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>29<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Single 3h MAL-red light PDT /Multiple 3h MAL-red light PDT [2 treatments 1 week apart]</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>9 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3 per 1000</B>
<BR/>(0 to 77)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.34 </B>
<BR/>(0.01 to 8.17)</P>
</TD>
<TD VALIGN="TOP">
<P>211<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-057.02" TYPE="ANALYSIS">Analysis 57.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3h MAL-red light PDT /Cryotherapy</P>
<P>(individual lesions)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(1 to 67)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.94 </B>
<BR/>(0.14 to 6.36)</P>
</TD>
<TD VALIGN="TOP">
<P>379<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-058.01" TYPE="ANALYSIS">Analysis 58.1</LINK>)</P>
<P>Two additional intraindividual studies: 4 of 119 and 2 of 121 participants withdrew because of adverse events and one of them was related to MAL-PDT. GRADE = low</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Skin irritation</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /1h ALA-pulsed dye laser PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-blue light PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14-18h ALA-blue light PDT /14-18h placebo-blue light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-pulsed dye laser PDT /0.5% 5-FU</P>
<P>
<U>(</U>field-directed<U> treatments</U>)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/1h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/2h ALA-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0.5h ALA-red light PDT/4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT/2h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1h ALA-red light PDT/4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2h ALA-red light PDT/4h ALA-red light PDT <U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3 to 4h ALA-red light PDT /3 to 4h placebo-red light PDT</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N/A (77/217 = 355/1000)</B>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 59.72</B>
<BR/>(3.75  to 952.48)</P>
</TD>
<TD VALIGN="TOP">
<P>300<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Data for ALA-PDT was given separately for two studies but not for placebo. Data from assessment after treatment (<LINK REF="CMP-047.07" TYPE="ANALYSIS">Analysis 47.7</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3% diclofenac in 2.5% hyaluronic acid gel + 4h ALA-red light PDT /2.5% hyaluronic acid gel + 4h ALA-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4h ALA-red light PDT /Cryotherapy</P>
<P>
<U>(individual lesions)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>101 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>371 per 1000</B>
<BR/>(220 to 627)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.69 </B>
<BR/>(2.19 to 6.23)</P>
</TD>
<TD VALIGN="TOP">
<P>297<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Assessment one day after the treatment (<LINK REF="CMP-051.02" TYPE="ANALYSIS">Analysis 51.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-red light PDT <U>(individual lesions)</U>/5% imiquimod <U>(</U>field-directed<U> treatment)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-blue light PDT + 5% imiquimod / ALA-blue light PDT + placebo</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>ALA-PDT versus MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5h ALA-red light PDT /3h MAL-red light PDT</P>
<P>
<U>(</U>field-directed<U> treatments)</U>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>MAL-PDT</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>All comparisons</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-11-08 16:15:29 +0000" MODIFIED_BY="Maryse Paquet" NO="4">
<TITLE MODIFIED="2011-10-19 14:49:14 +0100" MODIFIED_BY="Maryse Paquet">Overview for cryotherapy</TITLE>
<TABLE COLS="7" ROWS="58">
<TR>
<TH COLSPAN="7">
<P>
<B>Cryotherapy compared to interventions for actinic keratoses in immunocompetent participants</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Intervention/ Comparison intervention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>With comparator</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>With intervention</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Participant complete clearance</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>643 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>784 per 1000</B>
<BR/>(489 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.22 </B>
<BR/>(0.76 to 1.97)</P>
</TD>
<TD VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-042.01" TYPE="ANALYSIS">Analysis 42.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/cryotherapy with betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>714 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>786 per 1000</B>
<BR/>(514 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.1 </B>
<BR/>(0.72 to 1.69)</P>
</TD>
<TD VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-061.01" TYPE="ANALYSIS">Analysis 61.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>958 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>680 per 1000</B>
<BR/>(518 to 901)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.71 </B>
<BR/>(0.54 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Assessment after treatment (<LINK REF="CMP-043.01" TYPE="ANALYSIS">Analysis 43.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vehicle with cryotherapy/0.5% 5-FU with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>292 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>70 per 1000</B>
<BR/>(29 to 178)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.24 </B>
<BR/>(0.1 to 0.61)</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 cycle (<LINK REF="CMP-063.01" TYPE="ANALYSIS">Analysis 63.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>846 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>677 per 1000</B>
<BR/>(499 to 931)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.8 </B>
<BR/>(0.59 to 1.10)</P>
</TD>
<TD VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>5% imiquimod (<LINK REF="CMP-044.01" TYPE="ANALYSIS">Analysis 44.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Cryotherapy with vehicle /Cryotherapy with imiquimod</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.2 </B>
<BR/>(0.05 to 0.73)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>311<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Pooled data (5% and 3.75% imiquimod)(<LINK REF="CMP-064.01" TYPE="ANALYSIS">Analysis 64.1</LINK>)</P>
<P>Results from an additional intraindividual study: cryotherapy + vehicle = 5/27, cryotherapy+imiquimod = 8/27 GRADE = moderate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>287 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>57 per 1000</B>
<BR/>(14 to 209)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>264 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(13 to 193)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>581 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>442 per 1000</B>
<BR/>(354 to 558)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.61 to 0.96)</P>
</TD>
<TD VALIGN="TOP">
<P>297<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-046.01" TYPE="ANALYSIS">Analysis 46.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/MAL-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/cryotherapy with betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vehicle + cryotherapy/0.5% 5-FU + cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>8.6 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was<BR/>
<B>2 lower</B>
<BR/>(4.49 lower to 0.49 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 cycle (<LINK REF="CMP-063.02" TYPE="ANALYSIS">Analysis 63.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy with vehicle /Cryotherapy with imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/MAL-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean percentage of reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/cryotherapy with betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vehicle with cryotherapy/0.5% 5-FU with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>67 percent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was<BR/>
<B>21.4 lower</B>
<BR/>(37.7 to 5.1 lower)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-063.03" TYPE="ANALYSIS">Analysis 63.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy with vehicle /Cryotherapy with imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>301<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>High heterogeneity (I<SUP>2</SUP>=86%) between 3.75% (parallel group, MD -34.10, 95% CI -41.38 to -26.82)) and 5.0% (intraindividual, MD -11.20, 95% CI -26.53 to 4.13) imiquimod studies. (<LINK REF="CMP-064.04" TYPE="ANALYSIS">Analysis 64.4</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/MAL-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>240<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intraindividual studies with no SD: at 12 weeks: cryotherapy = 74.5%, MAL-PDT= 84.4%, at 24 weeks: cryotherapy = 83.9-87%, MAL-PDT = 75-86.7%</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/cryotherapy with betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vehicle with cryotherapy/0.5% 5-FU with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>142<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events in the first part of this three part study (incomplete data were given for the whole study).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Cryotherapy with vehicle /Cryotherapy with imiquimod</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.28 to 3.07)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>312<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Pooled data (5% and 3.75% imiquimod) (<LINK REF="CMP-064.06" TYPE="ANALYSIS">Analysis 64.6</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
<BR/>(9 to 100)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(6 to 64)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /ALA- red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>297<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/MAL- red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(2 to 75)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.16 to 7.16)</P>
</TD>
<TD VALIGN="TOP">
<P>379<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-045.02" TYPE="ANALYSIS">Analysis 45.2</LINK>)</P>
<P>Two additional intraindividual studies: 4 of 119 and 2 of 121 participants withdrew because of adverse events and one of them was related to MAL-PDT. GRADE = low</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Skin irritation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/cryotherapy with betulin-based oleogel</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vehicle with cryotherapy/0.5% 5-FU with cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /Imiquimod</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Cryotherapy with vehicle /Cryotherapy with imiquimod</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.39 </B>
<BR/>(0.1 to 1.54)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>311<BR/>(2 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Pooled data (5% and 3.75% imiquimod)</P>
<P>(<LINK REF="CMP-064.07" TYPE="ANALYSIS">Analysis 64.7</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(8 to 128)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>125 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>49 per 1000</B>
<BR/>(13 to 192)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy /ALA-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>372 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>100 per 1000</B>
<BR/>(59 to 171)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.27 </B>
<BR/>(0.16 to 0.46)</P>
</TD>
<TD VALIGN="TOP">
<P>297<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Assessment one day after the treatment (<LINK REF="CMP-046.02" TYPE="ANALYSIS">Analysis 46.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy/MAL-red light PDT</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2012-11-08 16:15:29 +0000" MODIFIED_BY="Maryse Paquet" NO="5">
<TITLE MODIFIED="2011-10-18 15:43:01 +0100" MODIFIED_BY="Maryse Paquet">Overview for imiquimod</TITLE>
<TABLE COLS="7" ROWS="70">
<TR>
<TH COLSPAN="7">
<P>
<B>Imiquimod compared to interventions for actinic keratoses in immunocompetent participants</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Intervention/Comparison intervention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks*  (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>With comparator</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>With intervention</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Participant complete clearance </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>277 per 1000</B>
<BR/>(148 to 518)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 4.49 </B>
<BR/>(2.4 to 8.39)</P>
</TD>
<TD VALIGN="TOP">
<P>486<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3.75% imiquimod/placebo</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 6.45 </B>
<BR/>(3.87 to 10.73)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>730<BR/>(3 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>(<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>53 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>343 per 1000</B>
<BR/>(206 to 571)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>322 per 1000</B>
<BR/>(193 to 536)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 3.75% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>301 per 1000</B>
<BR/>(111 to 820)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 9.12 </B>
<BR/>(3.36 to 24.79)</P>
</TD>
<TD VALIGN="TOP">
<P>247<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>For all lesions</P>
<P>(<LINK REF="CMP-065.01" TYPE="ANALYSIS">Analysis 65.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>5% imiquimod/placebo</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 7.70 </B>
<BR/>(4.63 to 12.79)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>1871<BR/>(9 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>(<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>371 per 1000</B>
<BR/>(223 to 617)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>246 per 1000</B>
<BR/>(148 to 409)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/3% diclofenac in 2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod /5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<BR/>-</P>
</TD>
<TD VALIGN="TOP">
<P>89<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The two studies was associated with high heterogeneity (I²= 93%) and the results could not be pooled together. One study favoured 5-FU (RR 0.31, 95% CI 0.14 to 0.67] whereas the other did not (RR 0.88, 95% CI 0.73 to 1.06] (<LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>680 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>843 per 1000</B>
<BR/>(619 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.24 </B>
<BR/>(0.91 to 1.7)</P>
</TD>
<TD VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 5% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>225 per 1000</B>
<BR/>(64 to 796)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.48</B>
<BR/>(0.70 to 8.76)</P>
</TD>
<TD VALIGN="TOP">
<P>64<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>For all lesions.(<LINK REF="CMP-065.01" TYPE="ANALYSIS">Analysis 65.1</LINK>) Results from an additional intraindividual study:  cryotherapy + imiquimod side (8/27 = 30%), cryotherapy alone side (5/27 = 19%), GRADE = low</P>
</TD>
</TR>
<TR>
<TD>
<P>5% imiquimod/ALA-PDT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-PDT + 5% imiquimod/ALA-PDT + placebo</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Intraindividual study: ALA-PDT + 5% imiquimod = 2/25; ALA-PDT + placebo = 2/25</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3.75% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 3.75% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the control groups was<BR/>
<B>0.6 lesions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean reduction in lesion counts in the intervention groups was <B>2.20 higher</B>
<BR/>(1.05 lower to 5.45 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-019.05" TYPE="ANALYSIS">Analysis 19.5</LINK>)</P>
<P>Results from an additional intraindividual study with no SD (N = 21): 5% imiquimod: 3.9 lesions, placebo = 0.5 lesions, GRADE = very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/3% diclofenac in 2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod /5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 5% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>5% imiquimod/ALA-PDT</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-PDT + 5% imiquimod/ALA-PDT + placebo</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Results from intraindividual study without SD: ALA-PDT + 5% imiquimod= 19.9 lesions; ALA-PDT + placebo= 16.0 lesions</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Mean percentage of reduction in lesion counts</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3.75% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>21.1 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was <B>46.90 higher</B>
<BR/>(36.68 to 57.12 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>247<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 3.75% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>43.3 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was <B>34.1 higher</B>
<BR/>(26.82 to 41.38 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>247<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>For all lesions (<LINK REF="CMP-065.02" TYPE="ANALYSIS">Analysis 65.2</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/3% diclofenac in 2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod /5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Results with no SD: 5% imiquimod = 66%, 5% 5-FU = 94%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 5% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the control groups was<BR/>
<B>62 per cent</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean percentage of reduction in lesion counts in the intervention groups was <B>11.2 higher</B>
<BR/>(4.13 lower to 26.53 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>For all lesions.(<LINK REF="CMP-065.02" TYPE="ANALYSIS">Analysis 65.2</LINK>) Results from an additional intraindividual study: cryotherapy-5% imiquimod = 73.2<U>+</U>27.1%, cryotherapy + vehicle = 62.0<U>+</U>30.3%. GRADE = moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>5% imiquimod/ALA-PDT</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-PDT + 5% imiquimod/ALA-PDT + placebo</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>Results from intraindividual study without SD: ALA-PDT + 5% imiquimod = 86.7% ; ALA-PDT + placebo = 73.1 %</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(2 to 50)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.5 </B>
<BR/>(0.09 to 2.7)</P>
</TD>
<TD VALIGN="TOP">
<P>486<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3.75% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(4 to 73)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.22 to 3.93)</P>
</TD>
<TD VALIGN="TOP">
<P>483<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 3.75% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(11 to 150)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.3 </B>
<BR/>(0.36 to 4.73)</P>
</TD>
<TD VALIGN="TOP">
<P>247<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-065.03" TYPE="ANALYSIS">Analysis 65.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="6" VALIGN="TOP">
<P>5% imiquimod/placebo</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.59 </B>
<BR/>(1.59 to 4.23)</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>2290<BR/>(8 studies)</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>(<LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>) Four small sample size studies with no participant withdrawal are not included in meta-analysis: pooled data, imiquimod 0/79 and placebo 0/31. Additional two intraindividual studies: no participant withdrew because of adverse events (0/42) GRADE  = very low (both studies had more  than 20% participant lost).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 per 1000</B>
<BR/>(34 to 91)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(8 to 22)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/3% diclofenac in 2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod /5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 5% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(0 to 246)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.34 </B>
<BR/>(0.01 to 8.13)</P>
</TD>
<TD VALIGN="TOP">
<P>65<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-065.03" TYPE="ANALYSIS">Analysis 65.3</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>5% imiquimod/ALA-PDT</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>30<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-PDT + 5% imiquimod/ALA-PDT + placebo</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>0 per 1000</B>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>25<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD>
<P>There were no participant withdrawals due to adverse events.</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Skin irritation</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2.5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>21 per 1000</B>
<BR/>(4 to 117)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.45 </B>
<BR/>(0.63 to 18.97)</P>
</TD>
<TD VALIGN="TOP">
<P>486<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.06" TYPE="ANALYSIS">Analysis 20.6</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3.75% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
<BR/>(6 to 159)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 4.86 </B>
<BR/>(0.92 to 25.83)</P>
</TD>
<TD VALIGN="TOP">
<P>484<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.06" TYPE="ANALYSIS">Analysis 20.6</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 3.75% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>8 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>56 per 1000</B>
<BR/>(7 to 445)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 6.72 </B>
<BR/>(0.84 to 53.83)</P>
</TD>
<TD VALIGN="TOP">
<P>247<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-065.04" TYPE="ANALYSIS">Analysis 65.4</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(4 to 79)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.68 </B>
<BR/>(0.86 to 15.74)</P>
</TD>
<TD VALIGN="TOP">
<P>708<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-020.06" TYPE="ANALYSIS">Analysis 20.6</LINK>)</P>
<P>Additional intraindividual study: similar mild irritation between the two treatment sides (N = 20) GRADE = very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/3% diclofenac in 2.5% hyaluronic acid</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/5% 5-FU</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5% imiquimod/Cryotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy + 5% imiquimod/Cryotherapy + vehicle</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>121 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>194 per 1000</B>
<BR/>(61 to 622)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.6 </B>
<BR/>(0.5 to 5.13)</P>
</TD>
<TD VALIGN="TOP">
<P>64<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>(<LINK REF="CMP-065.04" TYPE="ANALYSIS">Analysis 65.4</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>5% imiquimod/ALA-PDT</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>ALA-PDT + 5% imiquimod/ALA-PDT + placebo</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-08 16:34:14 +0100" MODIFIED_BY="Maryse Paquet">
<COMPARISON ID="CMP-001" MODIFIED="2012-04-04 15:12:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1">
<NAME>Adapalene gel versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-25 15:33:46 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Global Improvement Indices (investigator)-cleared</NAME>
<GROUP_LABEL_1>Adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adapalene</GRAPH_LABEL_2>
<DICH_DATA CI_END="51.31489565413961" CI_START="0.1258230696270056" EFFECT_SIZE="2.540983606557377" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7102434501290327" LOG_CI_START="-0.9002397238099838" LOG_EFFECT_SIZE="0.40500186315952447" MODIFIED="2011-07-25 15:33:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="626" O_E="0.0" SE="1.5334107384718942" STUDY_ID="STD-Kang-2003" TOTAL_1="60" TOTAL_2="30" VAR="2.3513484928609203" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-07-25 15:38:59 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.21" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean changes in lesion counts</NAME>
<GROUP_LABEL_1>Adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adapalene</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2011-07-21 20:19:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>0.1% adapalene gel</NAME>
<CONT_DATA CI_END="-1.2675221855758272" CI_START="-2.732477814424173" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="1.5" MODIFIED="2011-07-21 20:19:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9183" SD_1="0.9" SD_2="1.3" SE="0.37372003781797236" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2011-07-21 20:19:51 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>0.3% adapalene gel</NAME>
<CONT_DATA CI_END="-3.267522185575827" CI_START="-4.732477814424173" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="1.5" MODIFIED="2011-07-21 20:19:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9184" SD_1="0.9" SD_2="1.3" SE="0.37372003781797236" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-04 15:12:00 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>0.1-0.3% Adapelene</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.1-0.3%adapalene</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.7200240635438" CI_START="0.18967216585507302" EFFECT_SIZE="3.557377049180328" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8242561942643107" LOG_CI_START="-0.7219963965887854" LOG_EFFECT_SIZE="0.5511298988377625" MODIFIED="2011-09-21 17:30:06 +0100" MODIFIED_BY="Maryse Paquet" ORDER="601" O_E="0.0" SE="1.4956813760207104" STUDY_ID="STD-Kang-2003" TOTAL_1="60" TOTAL_2="30" VAR="2.237062778575206" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 14:44:08 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatitis</NAME>
<GROUP_LABEL_1>adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adapalene</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.335230940928875" CI_START="1.075071391690886" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.0143201853900594" LOG_CI_START="0.03143730517061573" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2011-07-25 16:20:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="620" O_E="0.0" SE="0.5773502691896257" STUDY_ID="STD-Kang-2003" TOTAL_1="60" TOTAL_2="30" VAR="0.3333333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-04-04 15:07:55 +0100" MODIFIED_BY="Maryse Paquet" NO="2">
<NAME>0.1% adapalene vs 0.3% adapalene</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-25 15:34:10 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.1672526666150587" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Global Improvement Indices (investigator)-cleared</NAME>
<GROUP_LABEL_1>0.1% adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>0.3% adapalene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.3%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.1%</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1304682433017708" CI_START="0.7583926619625728" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.05325836681183485" LOG_CI_START="-0.12010587778573421" LOG_EFFECT_SIZE="-0.0334237554869497" MODIFIED="2011-07-22 15:41:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="612" O_E="0.0" SE="0.10183501544346314" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.010370370370370377" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2012-04-04 15:07:55 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean changes in lesion counts</NAME>
<GROUP_LABEL_1>0.3% adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>0.1% adapalene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.3%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.1%</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5445455277226023" CI_START="-2.4554544722773977" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-0.5" MODIFIED="2011-07-22 15:57:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="459" SD_1="0.9" SD_2="0.9" SE="0.23237900077244503" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 17:44:53 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="474.3443653387362" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>0.1% adapelene</GROUP_LABEL_1>
<GROUP_LABEL_2>0.3% adapelene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.1% adapalene</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.3% adapalene</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-09-21 17:31:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1535" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 14:45:27 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatitis</NAME>
<GROUP_LABEL_1>0.1% adapalene</GROUP_LABEL_1>
<GROUP_LABEL_2>0.3% adapalene</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.1%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.3%</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9981665126016623" CI_START="0.010004585820506876" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6018608773254143" LOG_CI_START="-1.9998008859974516" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-07-25 16:25:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="622" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Kang-2003" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-09-22 15:15:27 +0100" MODIFIED_BY="Maryse Paquet" NO="3">
<NAME>Arotinoid Methyl Sulfone (Ro 14-9706) versus Tretinoin</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-07-22 20:08:20 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="12.310921745547224" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<GROUP_LABEL_1>Arotinoid Methyl Sulfone</GROUP_LABEL_1>
<GROUP_LABEL_2>Tretinoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tretinoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours arotinoid methyl</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.428485230202876" CI_START="6.571514769797117" EFFECT_SIZE="7.4999999999999964" ESTIMABLE="YES" MEAN_1="37.8" MEAN_2="30.3" MODIFIED="2011-07-22 20:08:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="438" SD_1="1.3" SD_2="1.98" SE="0.4737256590052939" STUDY_ID="STD-Misiewicz-1991" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-09-02 14:48:48 +0100" MODIFIED_BY="Maryse Paquet" NO="4">
<NAME>Calcipotriol (vitamin D) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2011-07-11 23:34:37 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="14.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean changes in lesion counts</NAME>
<GROUP_LABEL_1>Calciprotriol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcipotriol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9250718386513013" CI_START="-8.1850718386513" EFFECT_SIZE="-3.63" ESTIMABLE="YES" MEAN_1="-2.88" MEAN_2="0.75" MODIFIED="2011-03-24 16:02:44 +0000" MODIFIED_BY="Maryse Paquet" ORDER="127" SD_1="2.64" SD_2="6.02" SE="2.32405894933842" STUDY_ID="STD-Seckin-2009" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2011-09-02 14:48:48 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.915739566190807" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Reduction in total cosmetic appearance score</NAME>
<GROUP_LABEL_1>Calciprotriol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcipotriol</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.9655082101659374" CI_START="-1.1655082101659375" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.1" MODIFIED="2011-07-22 22:13:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="603" SD_1="1.92" SD_2="2.28" SE="1.0538500842150176" STUDY_ID="STD-Seckin-2009" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-07-25 16:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="5">
<NAME>1% colchicine cream versus 0.5% colchicine cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-25 14:16:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.8931077665744143" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>1% cochicine</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1%</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3826909566635566" CI_START="0.5313507505132181" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.1407251223987073" LOG_CI_START="-0.27461870165993374" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-07-25 13:58:58 +0100" MODIFIED_BY="Maryse Paquet" ORDER="595" O_E="0.0" SE="0.24397501823713333" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" VAR="0.059523809523809534" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2011-07-25 16:26:44 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts-total</NAME>
<GROUP_LABEL_1>1% cochicine</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1.0%</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.403273796702489" CI_START="-2.603273796702489" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2011-07-25 16:26:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="627" SD_1="2.4" SD_2="2.7" SE="1.27720397744448" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2011-07-25 16:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts-per anatomical locations</NAME>
<GROUP_LABEL_1>1% cochicine</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1.0%</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" MODIFIED="2011-07-25 16:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<CONT_DATA CI_END="2.641578826687043" CI_START="-3.2415788266870433" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.6" MODIFIED="2011-07-25 16:25:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="624" SD_1="2.9" SD_2="3.1" SE="1.5008331019803636" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.02" MODIFIED="2011-07-25 16:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<CONT_DATA CI_END="1.5380327156048117" CI_START="-2.5380327156048117" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.5" MODIFIED="2011-07-25 16:25:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="625" SD_1="1.7" SD_2="2.4" SE="1.039831717154271" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.03" MODIFIED="2011-07-25 16:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Upper extremities</NAME>
<CONT_DATA CI_END="2.2166102883186136" CI_START="-1.6166102883186133" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.3" MODIFIED="2011-07-25 16:25:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="626" SD_1="1.8" SD_2="2.1" SE="0.9778803607803973" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-25 16:26:18 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.883508422871529" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Number of participants with decreased infiltration and disappearance of crust</NAME>
<GROUP_LABEL_1>1% cochicine</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1.0%</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3826909566635566" CI_START="0.5313507505132181" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.1407251223987073" LOG_CI_START="-0.27461870165993374" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-07-25 14:10:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="596" O_E="0.0" SE="0.24397501823713333" STUDY_ID="STD-Akar-2001" TOTAL_1="8" TOTAL_2="8" VAR="0.059523809523809534" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-09-04 13:52:38 +0100" MODIFIED_BY="Maryse Paquet" NO="6">
<NAME>3% diclofenac in 2.5% hyaluronic acid versus 2.5% hyaluronic acid (vehicle)</NAME>
<DICH_OUTCOME CHI2="0.39781335553444597" CI_END="4.4587673894957325" CI_START="1.7141250045166656" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7645767617590464" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.6492148161276973" LOG_CI_START="0.23404249016140194" LOG_EFFECT_SIZE="0.44162865314454963" METHOD="MH" MODIFIED="2011-12-05 13:55:21 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8196264516803184" P_Q="0.8225449364017379" P_Z="3.0497358380328543E-5" Q="0.39070448662586055" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" WEIGHT="300.0" Z="4.16972038148091">
<NAME>Investigator Global Improvement Indices-completely improved</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.891616531635773" CI_START="0.8942735818034646" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.252649581431133" LOG_CI_START="-0.04852959877520817" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-07-25 14:41:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.06971408553837498" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="1.8137638804644518">
<NAME>30 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="17.891616531635773" CI_START="0.8942735818034646" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.252649581431133" LOG_CI_START="-0.04852959877520817" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-07-20 14:06:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="596" O_E="0.0" SE="0.7643190913940249" STUDY_ID="STD-Rivers-2002" TOTAL_1="49" TOTAL_2="49" VAR="0.5841836734693877" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.7663640224372825" CI_START="1.2076315535692157" DF="0" EFFECT_SIZE="3.0625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.8902177427939463" LOG_CI_START="0.08193445195123143" LOG_EFFECT_SIZE="0.4860760973725889" MODIFIED="2011-07-20 14:07:29 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.018407320347587616" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.3573211407173438">
<NAME>60 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="7.7663640224372825" CI_START="1.2076315535692157" EFFECT_SIZE="3.0625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8902177427939463" LOG_CI_START="0.08193445195123143" LOG_EFFECT_SIZE="0.4860760973725889" MODIFIED="2011-07-20 14:07:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="597" O_E="0.0" SE="0.4747896061078288" STUDY_ID="STD-Rivers-2002" TOTAL_1="48" TOTAL_2="49" VAR="0.2254251700680272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5501850239593535" CI_START="1.3701279866486422" DF="0" EFFECT_SIZE="2.4968652037617556" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.6580290567122358" LOG_CI_START="0.13676113744770255" LOG_EFFECT_SIZE="0.3973950970799692" MODIFIED="2011-07-25 15:09:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.0028043678839303468" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="59" WEIGHT="100.0" Z="2.9884059583351097">
<NAME>90 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="4.5501850239593535" CI_START="1.3701279866486422" EFFECT_SIZE="2.4968652037617556" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.6580290567122358" LOG_CI_START="0.13676113744770255" LOG_EFFECT_SIZE="0.3973950970799692" MODIFIED="2011-07-25 15:09:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="598" O_E="0.0" SE="0.30619535609380205" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.09375559609341023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3783541209802721" CI_END="4.447164387722476" CI_START="1.635734896060881" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6971062228834954" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.6480831832742655" LOG_CI_START="0.21371291882967047" LOG_EFFECT_SIZE="0.43089805105196793" METHOD="MH" MODIFIED="2011-12-05 13:56:29 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.8276400055323988" P_Q="0.8299159490696977" P_Z="1.0082688933173595E-4" Q="0.37286181880935576" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" WEIGHT="300.0" Z="3.8885933508834034">
<NAME>Participant Global Improvement Indices-completely improved</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.891616531635773" CI_START="0.8942735818034646" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="1.252649581431133" LOG_CI_START="-0.04852959877520817" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-07-25 15:24:48 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.06971408553837498" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="1.8137638804644518">
<NAME>30 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="17.891616531635773" CI_START="0.8942735818034646" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.252649581431133" LOG_CI_START="-0.04852959877520817" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-07-20 14:25:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="598" O_E="0.0" SE="0.7643190913940249" STUDY_ID="STD-Rivers-2002" TOTAL_1="49" TOTAL_2="49" VAR="0.5841836734693877" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.319826329742975" CI_START="1.1161561868273622" DF="0" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.8645007771063365" LOG_CI_START="0.04772497088395484" LOG_EFFECT_SIZE="0.45611287399514566" MODIFIED="2011-07-20 14:25:50 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.028596184009735185" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.1890090257451718">
<NAME>60 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="7.319826329742975" CI_START="1.1161561868273622" EFFECT_SIZE="2.8583333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8645007771063365" LOG_CI_START="0.04772497088395484" LOG_EFFECT_SIZE="0.45611287399514566" MODIFIED="2011-07-20 14:25:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="599" O_E="0.0" SE="0.4797781516804741" STUDY_ID="STD-Rivers-2002" TOTAL_1="48" TOTAL_2="49" VAR="0.23018707482993203" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.641831474150726" CI_START="1.284047680354508" DF="0" EFFECT_SIZE="2.4413793103448276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="0.6666893689559624" LOG_CI_START="0.10858115062566345" LOG_EFFECT_SIZE="0.3876352597908129" MODIFIED="2011-07-25 15:25:16 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.00647715300580368" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="59" WEIGHT="100.0" Z="2.722594376412446">
<NAME>90 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="4.641831474150726" CI_START="1.284047680354508" EFFECT_SIZE="2.4413793103448276" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.6666893689559624" LOG_CI_START="0.10858115062566345" LOG_EFFECT_SIZE="0.3876352597908129" MODIFIED="2011-07-25 15:25:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="599" O_E="0.0" SE="0.32783553012745426" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.10747613481394895" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26508396643428783" CI_END="3.126874564500143" CI_START="1.2130113952837855" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9475457577067856" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.4951104597405132" LOG_CI_START="0.08386488073930354" LOG_EFFECT_SIZE="0.28948767023990835" METHOD="MH" MODIFIED="2011-07-26 15:17:05 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.6066487648338844" P_Q="1.0" P_Z="0.00579163277654071" Q="0.0" RANDOM="YES" SCALE="6.76" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="142" WEIGHT="100.0" Z="2.7593507948055493">
<NAME>Participant complete clearance at end of treatment (&gt;56 days)</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.379218215965488" CI_START="1.1204119519463362" EFFECT_SIZE="2.2150684931506848" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.641396586577932" LOG_CI_START="0.04937773299395843" LOG_EFFECT_SIZE="0.3453871597859452" MODIFIED="2011-03-28 14:43:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9172" O_E="0.0" SE="0.3477548051358145" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="0.12093340449504833" WEIGHT="48.25378770873734"/>
<DICH_DATA CI_END="3.3358522999579066" CI_START="0.8943654592914119" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.5232068133286196" LOG_CI_START="-0.04848498173941172" LOG_EFFECT_SIZE="0.23736091579460392" ORDER="9173" O_E="0.0" SE="0.33581459034298755" STUDY_ID="STD-McEwan-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.11277143908722856" WEIGHT="51.74621229126265"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8799517813516099" CI_END="4.386279091419599" CI_START="2.021286300945255" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9775704592182253" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.6420962616340878" LOG_CI_START="0.30562783262188814" LOG_EFFECT_SIZE="0.47386204712798796" METHOD="MH" MODIFIED="2011-12-05 13:58:40 +0000" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.8302631132600966" P_Q="0.9481243020584909" P_Z="3.378584440691632E-8" Q="0.10653933722855115" RANDOM="YES" SCALE="18.79" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="234" WEIGHT="300.0" Z="5.520592518816104">
<NAME>Participant complete clearance (target lesions)</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.014976127139295" CI_START="0.7649090390613139" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="1.204526295615551" LOG_CI_START="-0.11639020691499961" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-03-31 20:02:40 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.10640460335627595" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="100.0" Z="1.61456650745571">
<NAME>30 day treatment/ 30 day follow-up</NAME>
<DICH_DATA CI_END="16.014976127139295" CI_START="0.7649090390613139" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.204526295615551" LOG_CI_START="-0.11639020691499961" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-03-31 20:02:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="195" O_E="0.0" SE="0.7759128922285867" STUDY_ID="STD-Rivers-2002" TOTAL_1="49" TOTAL_2="49" VAR="0.6020408163265305" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.21285303739692" CI_START="1.2993184052509652" DF="0" EFFECT_SIZE="3.266666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.9144940515356289" LOG_CI_START="0.11371559041003595" LOG_EFFECT_SIZE="0.5141048209728325" MODIFIED="2011-03-31 20:03:18 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.011848705784573681" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.516618471402989">
<NAME>60 day treatment/ 30 day follow-up</NAME>
<DICH_DATA CI_END="8.21285303739692" CI_START="1.2993184052509652" EFFECT_SIZE="3.2666666666666666" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9144940515356289" LOG_CI_START="0.11371559041003595" LOG_EFFECT_SIZE="0.5141048209728324" MODIFIED="2011-03-31 20:03:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="196" O_E="0.0" SE="0.4703812319824852" STUDY_ID="STD-Rivers-2002" TOTAL_1="48" TOTAL_2="49" VAR="0.22125850340136055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7716302205546284" CI_END="4.483848286990754" CI_START="1.8421750839992144" DF="1" EFFECT_SIZE="2.874027417184277" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="20" I2="0.0" ID="CMP-006.04.03" LOG_CI_END="0.6516509096237801" LOG_CI_START="0.2653309040373836" LOG_EFFECT_SIZE="0.45849090683058186" MODIFIED="2011-03-31 20:43:44 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.3797132426734956" P_Z="3.283570712604097E-6" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="136" WEIGHT="100.0" Z="4.652234684367551">
<NAME>90 day treatment/ 30 day follow-up</NAME>
<DICH_DATA CI_END="7.565891949798441" CI_START="1.8014063282311636" EFFECT_SIZE="3.691780821917808" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" LOG_CI_END="0.8788601347440129" LOG_CI_START="0.25561168406059037" LOG_EFFECT_SIZE="0.5672359094023016" MODIFIED="2011-03-31 19:59:32 +0100" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;sent email to Dr. Gebauer for clarification about data analysis (ITT or PP).&lt;/p&gt;" NOTES_MODIFIED="2011-03-31 19:59:32 +0100" NOTES_MODIFIED_BY="Maryse Paquet" ORDER="197" O_E="0.0" SE="0.3660992250610296" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="0.1340286425902864" WEIGHT="38.42129353219967"/>
<DICH_DATA CI_END="4.333032534816284" CI_START="1.3947282253753057" EFFECT_SIZE="2.4583333333333335" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6367919499709396" LOG_CI_START="0.14448958989013685" LOG_EFFECT_SIZE="0.3906407699305382" MODIFIED="2011-03-31 20:43:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="199" O_E="0.0" SE="0.2891808432474483" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.08362556010130527" WEIGHT="61.57870646780032"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5808235881537316" CI_END="3.6621945313201194" CI_START="1.6560488812180796" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4626760153125407" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.5637414097731613" LOG_CI_START="0.21907315160947374" LOG_EFFECT_SIZE="0.3914072806913175" METHOD="MH" MODIFIED="2011-12-05 17:48:18 +0000" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.6637457628985415" P_Q="0.5594031673301911" P_Z="8.52753036067675E-6" Q="1.161770359512594" RANDOM="YES" SCALE="54.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="212" WEIGHT="100.0" Z="4.451493024213533">
<NAME>Participant complete clearance (all lesions)</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.014976127139295" CI_START="0.7649090390613139" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="1.204526295615551" LOG_CI_START="-0.11639020691499961" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-03-22 15:27:00 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.10640460335627595" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="6.808506350126995" Z="1.61456650745571">
<NAME>30 day treatment/ 30 day follow-up</NAME>
<DICH_DATA CI_END="16.014976127139295" CI_START="0.7649090390613139" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.204526295615551" LOG_CI_START="-0.11639020691499961" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2011-03-22 15:27:00 +0000" MODIFIED_BY="Maryse Paquet" ORDER="122" O_E="0.0" SE="0.7759128922285867" STUDY_ID="STD-Rivers-2002" TOTAL_1="49" TOTAL_2="49" VAR="0.6020408163265305" WEIGHT="6.808506350126995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.707914515793382" CI_START="1.3685709756097353" DF="0" EFFECT_SIZE="3.8281249999999996" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="1.0297048954372507" LOG_CI_START="0.13626732532403965" LOG_EFFECT_SIZE="0.5829861103806453" MODIFIED="2011-03-31 19:46:28 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.010532684352769182" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="14.882440555387193" Z="2.557832394911196">
<NAME>60 day treatment/ 30 day follow-up</NAME>
<DICH_DATA CI_END="10.707914515793382" CI_START="1.3685709756097353" EFFECT_SIZE="3.828125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0297048954372507" LOG_CI_START="0.13626732532403965" LOG_EFFECT_SIZE="0.5829861103806453" MODIFIED="2011-03-22 15:27:46 +0000" MODIFIED_BY="Maryse Paquet" ORDER="123" O_E="0.0" SE="0.5248096512717989" STUDY_ID="STD-Rivers-2002" TOTAL_1="48" TOTAL_2="49" VAR="0.2754251700680272" WEIGHT="14.882440555387193"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39680279667228396" CI_END="3.439297971090726" CI_START="1.4027513913545393" DF="1" EFFECT_SIZE="2.1964698983210216" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="21" I2="0.0" ID="CMP-006.05.03" LOG_CI_END="0.5364698035029002" LOG_CI_START="0.14698070814170341" LOG_EFFECT_SIZE="0.34172525582230173" MODIFIED="2011-04-04 19:33:51 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.5287454644920243" P_Z="5.833945797485187E-4" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="114" WEIGHT="78.30905309448582" Z="3.439219233587685">
<NAME>90 day treatment/30 day follow-up</NAME>
<DICH_DATA CI_END="3.667606003531175" CI_START="0.9513404766140302" EFFECT_SIZE="1.8679245283018868" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5643826749579524" LOG_CI_START="-0.02166402496443059" LOG_EFFECT_SIZE="0.27135932499676085" MODIFIED="2011-04-04 19:33:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="202" O_E="0.0" SE="0.34424673251235877" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="53" TOTAL_2="55" VAR="0.11850581284543549" WEIGHT="34.58900979263402"/>
<DICH_DATA CI_END="4.5501850239593535" CI_START="1.3701279866486422" EFFECT_SIZE="2.4968652037617556" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="11" LOG_CI_END="0.6580290567122358" LOG_CI_START="0.13676113744770255" LOG_EFFECT_SIZE="0.3973950970799692" MODIFIED="2011-03-31 20:42:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="198" O_E="0.0" SE="0.30619535609380205" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.09375559609341023" WEIGHT="43.7200433018518"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 18:35:21 +0000" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="188.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance for 30 day treatment by locations</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:26:32 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="83.6853278467926" CI_START="0.2987381497240339" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.922649321867425" LOG_CI_START="-0.5247093131953876" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-09-06 16:26:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1559" O_E="0.0" SE="1.4375905768565218" STUDY_ID="STD-Rivers-2002" TOTAL_1="5" TOTAL_2="5" VAR="2.066666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:27:17 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Forehead</NAME>
<DICH_DATA CI_END="10.080509445693664" CI_START="0.3968053421852381" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0034824809054168" LOG_CI_START="-0.4014224895774544" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-09-06 16:27:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1560" O_E="0.0" SE="0.8252481340534014" STUDY_ID="STD-Rivers-2002" TOTAL_1="29" TOTAL_2="29" VAR="0.6810344827586208" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:27:27 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<DICH_DATA CI_END="10.01439050967295" CI_START="0.37140430578470707" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0006245226420156" LOG_CI_START="-0.430153065680517" LOG_EFFECT_SIZE="0.2852357284807493" MODIFIED="2011-09-06 16:27:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1561" O_E="0.0" SE="0.8404458378439423" STUDY_ID="STD-Rivers-2002" TOTAL_1="14" TOTAL_2="18" VAR="0.7063492063492063" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 18:35:21 +0000" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Back of hand</NAME>
<DICH_DATA CI_END="7.2400905220167475" CI_START="0.01534664667150609" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8597439961649092" LOG_CI_START="-1.8139865056042341" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-09-06 16:27:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1563" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Rivers-2002" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-06 16:44:01 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="188.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="66" TOTAL_2="66" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance for 60 day treatment by locations</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:25:20 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="99.14000551208579" CI_START="0.37841055995731826" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9962489387154745" LOG_CI_START="-0.42203675264233426" LOG_EFFECT_SIZE="0.7871060930365701" MODIFIED="2011-09-06 16:25:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1554" O_E="0.0" SE="1.42051298581081" STUDY_ID="STD-Rivers-2002" TOTAL_1="7" TOTAL_2="6" VAR="2.017857142857143" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:25:29 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Forehead</NAME>
<DICH_DATA CI_END="7.521916930593233" CI_START="1.211992066139522" EFFECT_SIZE="3.0193548387096776" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8763285329172522" LOG_CI_START="0.083499776890413" LOG_EFFECT_SIZE="0.47991415490383255" MODIFIED="2011-09-06 16:25:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1555" O_E="0.0" SE="0.4657115358558022" STUDY_ID="STD-Rivers-2002" TOTAL_1="31" TOTAL_2="36" VAR="0.21688723462917014" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-006.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:25:48 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<DICH_DATA CI_END="13.121713120209053" CI_START="0.8919263057205733" EFFECT_SIZE="3.4210526315789473" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1179905385521962" LOG_CI_START="-0.04967102717214317" LOG_EFFECT_SIZE="0.5341597556900266" MODIFIED="2011-09-06 16:25:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1556" O_E="0.0" SE="0.6858901837244462" STUDY_ID="STD-Rivers-2002" TOTAL_1="19" TOTAL_2="13" VAR="0.4704453441295546" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:26:00 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Arm/forearm</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-06 16:26:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1557" O_E="0.0" SE="0.0" STUDY_ID="STD-Rivers-2002" TOTAL_1="1" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.07.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-06 16:26:08 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Back of hand</NAME>
<DICH_DATA CI_END="20.376389679930686" CI_START="0.24844931214611624" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.309127237522174" LOG_CI_START="-0.604762201299449" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-09-06 16:26:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1558" O_E="0.0" SE="1.1242281302693367" STUDY_ID="STD-Rivers-2002" TOTAL_1="8" TOTAL_2="9" VAR="1.2638888888888888" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.153445618165762" CI_END="2.6758947770094865" CI_START="1.222446627264669" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8086289130361681" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.427469031867604" LOG_CI_START="0.0872299066582788" LOG_EFFECT_SIZE="0.25734946926294144" METHOD="MH" MODIFIED="2012-09-04 13:52:38 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.5187598852726707" P_Q="0.9737457534245321" P_Z="0.0030273389781611706" Q="0.4974809584744057" RANDOM="YES" SCALE="188.34" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="134" TOTAL_2="131" WEIGHT="500.0" Z="2.9649482015658473">
<NAME>Participant complete clearance for 90 day treatment by locations</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8348488316562785" CI_END="6.084286876068318" CI_START="0.2517426422292874" DF="1" EFFECT_SIZE="1.2376083606142998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.7842096829871764" LOG_CI_START="-0.5990432138663653" LOG_EFFECT_SIZE="0.09258323456040554" MODIFIED="2011-09-06 16:14:31 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.3608742460686828" P_Z="0.7930386806124724" STUDIES="2" TAU2="0.0" TOTAL_1="10" TOTAL_2="13" WEIGHT="100.0" Z="0.2623667815529351">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="59.38797168142719" CI_START="0.21477584904293534" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.773698492769759" LOG_CI_START="-0.6680145554541975" LOG_EFFECT_SIZE="0.5528419686577808" MODIFIED="2011-09-06 16:14:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1522" O_E="0.0" SE="1.4342743312012722" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="6" TOTAL_2="4" VAR="2.057142857142857" WEIGHT="32.093266963583964"/>
<DICH_DATA CI_END="5.1803285365522935" CI_START="0.1085838467639671" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7143573035844673" LOG_CI_START="-0.9642347768010671" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-09-06 16:14:26 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1523" O_E="0.0" SE="0.9860132971832692" STUDY_ID="STD-Wolf-2001" TOTAL_1="4" TOTAL_2="9" VAR="0.9722222222222221" WEIGHT="67.90673303641603"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0015939942049070116" CI_END="2.854716049750211" CI_START="1.028866852507849" DF="1" EFFECT_SIZE="1.7138035817765525" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" I2="0.0" ID="CMP-006.08.02" LOG_CI_END="0.4555629167291675" LOG_CI_START="0.012359175576241032" LOG_EFFECT_SIZE="0.2339610461527043" MODIFIED="2011-09-06 16:15:01 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.968153039287157" P_Z="0.03852028252535917" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="46" WEIGHT="100.0" Z="2.069275060953921">
<NAME>Forehead</NAME>
<DICH_DATA CI_END="3.9864389567566754" CI_START="0.7567206048651626" EFFECT_SIZE="1.736842105263158" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6005851182483379" LOG_CI_START="-0.12106444039822083" LOG_EFFECT_SIZE="0.23976033892505855" MODIFIED="2011-09-06 16:14:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1526" O_E="0.0" SE="0.423900522971916" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="19" TOTAL_2="22" VAR="0.1796916533758639" WEIGHT="37.718475804397436"/>
<DICH_DATA CI_END="3.24523976770378" CI_START="0.8905351243260724" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.5112467892546901" LOG_CI_START="-0.050348946498142304" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2011-09-06 16:15:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1527" O_E="0.0" SE="0.3298841151249401" STUDY_ID="STD-Wolf-2001" TOTAL_1="30" TOTAL_2="24" VAR="0.10882352941176474" WEIGHT="62.281524195602564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5363370487724283" CI_END="4.403525281679925" CI_START="1.0545683407908624" DF="1" EFFECT_SIZE="2.1549520528150534" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-006.08.03" LOG_CI_END="0.643800494073709" LOG_CI_START="0.023074729231161644" LOG_EFFECT_SIZE="0.3334376116524353" MODIFIED="2011-09-06 16:15:22 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.46395483087588274" P_Z="0.03523193541826829" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="2.105682563686072">
<NAME>Face</NAME>
<DICH_DATA CI_END="11.483267800738332" CI_START="0.8917322296830529" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0600654931037556" LOG_CI_START="-0.0497655364639436" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2011-09-06 16:15:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1528" O_E="0.0" SE="0.6519202405202649" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="5" TOTAL_2="8" VAR="0.42500000000000004" WEIGHT="31.281373844121525"/>
<DICH_DATA CI_END="4.262551726809085" CI_START="0.7601080778966735" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6296696622718609" LOG_CI_START="-0.1191246520652488" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-09-06 16:15:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1529" O_E="0.0" SE="0.43984548683325336" STUDY_ID="STD-Wolf-2001" TOTAL_1="17" TOTAL_2="17" VAR="0.19346405228758168" WEIGHT="68.71862615587847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1029545162411374" CI_END="14.402528976320692" CI_START="0.26181718457865655" DF="1" EFFECT_SIZE="1.9418624017660993" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="52.44785408923538" ID="CMP-006.08.04" LOG_CI_END="1.1584387576526711" LOG_CI_START="-0.5820018515868155" LOG_EFFECT_SIZE="0.28821845303292776" MODIFIED="2011-09-06 16:15:46 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.14701487541883973" P_Z="0.516245680728643" STUDIES="2" TAU2="1.233860734077838" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0" Z="0.6491434233670619">
<NAME>Arm/forearm</NAME>
<DICH_DATA CI_END="109.60961412063656" CI_START="0.4906301167942242" EFFECT_SIZE="7.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.039848648823716" LOG_CI_START="-0.3092457966186286" LOG_EFFECT_SIZE="0.8653014261025438" MODIFIED="2011-09-06 16:15:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1530" O_E="0.0" SE="1.3798697054578755" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="8" TOTAL_2="5" VAR="1.9040404040404038" WEIGHT="33.30844539701152"/>
<DICH_DATA CI_END="3.1005692822786637" CI_START="0.3225214175072657" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.491441440109722" LOG_CI_START="-0.49144144010972196" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-06 16:15:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1531" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Wolf-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.33333333333333337" WEIGHT="66.69155460298848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.3022553432201525" CI_END="65.86632389179731" CI_START="0.04425315702887478" DF="1" EFFECT_SIZE="1.707276419944478" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="76.75637728997461" ID="CMP-006.08.05" LOG_CI_END="1.818663425426355" LOG_CI_START="-1.354055741207697" LOG_EFFECT_SIZE="0.23230384210932906" MODIFIED="2011-09-06 16:16:30 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.03806204871989438" P_Z="0.7741017194010567" STUDIES="2" TAU2="5.3502575752630515" TOTAL_1="33" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.2870138452799786">
<NAME>Back of hand</NAME>
<DICH_DATA CI_END="2.7142434238371087" CI_START="0.03626192195379026" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.43364879427747494" LOG_CI_START="-1.440549181161498" LOG_EFFECT_SIZE="-0.5034501934420116" MODIFIED="2011-09-06 16:16:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1532" O_E="0.0" SE="1.1009131682024558" STUDY_ID="STD-Solaraze-study-2" TOTAL_1="17" TOTAL_2="16" VAR="1.2120098039215685" WEIGHT="52.92788583084031"/>
<DICH_DATA CI_END="187.01223094968958" CI_START="0.7035603703324849" EFFECT_SIZE="11.470588235294118" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.271870011136782" LOG_CI_START="-0.15269863116829377" LOG_EFFECT_SIZE="1.0595856899842442" MODIFIED="2011-09-06 16:16:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1533" O_E="0.0" SE="1.4242036222983434" STUDY_ID="STD-Wolf-2001" TOTAL_1="16" TOTAL_2="14" VAR="2.0283559577677224" WEIGHT="47.072114169159676"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-06 16:43:45 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="277.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance in immunosuppressed participants</NAME>
<GROUP_LABEL_1>Diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="87.3481827271442" CI_START="0.3828192216830266" EFFECT_SIZE="5.782608695652174" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.9412538739465024" LOG_CI_START="-0.4170062640475165" LOG_EFFECT_SIZE="0.762123804949493" MODIFIED="2011-07-25 21:57:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="654" O_E="0.0" SE="1.3852536786336387" STUDY_ID="STD-Ulrich-2010" TOTAL_1="22" TOTAL_2="6" VAR="1.9189277541680285" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-06 16:43:34 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="277.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance in immunosuppressed participants</NAME>
<GROUP_LABEL_1>Diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.94039518221203" CI_START="0.5729271432665675" EFFECT_SIZE="3.5454545454545454" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.341244445659312" LOG_CI_START="-0.2419006019227636" LOG_EFFECT_SIZE="0.5496719218682742" MODIFIED="2011-07-25 22:05:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="655" O_E="0.0" SE="0.9299472376440853" STUDY_ID="STD-Ulrich-2010" TOTAL_1="22" TOTAL_2="6" VAR="0.8648018648018648" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.141767256733094E-33" CI_END="3.075847936069087" CI_START="-1.4758479360690875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999997" ESTIMABLE="YES" I2="99.99999999999999" I2_Q="0.0" ID="CMP-006.11" MODIFIED="2011-10-03 16:23:04 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="0.4908476167224646" Q="0.0" RANDOM="YES" SCALE="7.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="73" TOTAL_2="77" UNITS="" WEIGHT="100.00000000000001" Z="0.6889613153769358">
<NAME>Mean reduction of lesion counts (30-90 days ): At the end of study</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.141767256733094E-33" CI_END="3.075847936069087" CI_START="-1.4758479360690875" DF="0" EFFECT_SIZE="0.7999999999999997" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-006.11.01" MODIFIED="2011-10-03 16:18:17 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.4908476167224646" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="77" WEIGHT="100.00000000000001" Z="0.6889613153769358">
<NAME>90 days</NAME>
<CONT_DATA CI_END="3.075847936069087" CI_START="-1.4758479360690875" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="4.7" MODIFIED="2011-07-25 16:30:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="631" SD_1="7.3" SD_2="6.9" SE="1.1611682428966477" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1961449591517717" CI_END="3.528134984369379" CI_START="1.5621361895751176" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5451355869722483" ESTIMABLE="YES" I2="8.931330253697357" I2_Q="8.931330253697357" ID="CMP-006.12" MODIFIED="2012-06-12 13:31:20 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.3335135782299463" P_Q="0.3335135782299463" P_Z="3.882177948716635E-7" Q="2.1961449591517717" RANDOM="YES" SCALE="7.65" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0697349239579775" TOTALS="YES" TOTAL_1="170" TOTAL_2="175" UNITS="" WEIGHT="99.99999999999997" Z="5.0746461284162105">
<NAME>Mean reduction of lesion counts (30-90 days): 30 day follow-up</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.367395803391898" CI_START="0.6326041966081026" DF="0" EFFECT_SIZE="2.0000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.12.01" MODIFIED="2011-10-03 16:19:34 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.004147621688066892" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="45.203167030617" Z="2.8667105452251063">
<NAME>30 days</NAME>
<CONT_DATA CI_END="3.367395803391898" CI_START="0.6326041966081026" EFFECT_SIZE="2.0000000000000004" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="2.4" MODIFIED="2011-10-03 16:15:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="633" SD_1="3.3" SD_2="3.6" SE="0.6976637398328446" STUDY_ID="STD-Rivers-2002" TOTAL_1="49" TOTAL_2="49" WEIGHT="45.203167030617"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.072798401880166" CI_START="0.7272015981198343" DF="0" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.12.02" MODIFIED="2011-10-03 16:14:16 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.0049234095507010465" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="31.51481474833185" Z="2.812002664283454">
<NAME>60 days</NAME>
<CONT_DATA CI_END="4.072798401880166" CI_START="0.7272015981198345" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="2.5" MODIFIED="2011-10-03 16:14:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="686" SD_1="4.0" SD_2="4.4" SE="0.8534842553613159" STUDY_ID="STD-Rivers-2002" TOTAL_1="48" TOTAL_2="49" WEIGHT="31.51481474833185"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.770400266088048" CI_START="1.829599733911953" DF="0" EFFECT_SIZE="3.8000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-006.12.03" MODIFIED="2011-10-03 16:14:09 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="1.5690825158596095E-4" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="77" WEIGHT="23.282018221051132" Z="3.7798731909628147">
<NAME>90 days</NAME>
<CONT_DATA CI_END="5.770400266088048" CI_START="1.829599733911953" EFFECT_SIZE="3.8000000000000003" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="2.4" MODIFIED="2011-10-03 16:14:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="685" SD_1="7.5" SD_2="4.3" SE="1.0053247312860405" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" WEIGHT="23.282018221051132"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.7024011465680786" CI_END="6.6990865833422495" CI_START="1.9235487741325403" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.589710264797945" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="0.8260155909310858" LOG_CI_START="0.28410320289553326" LOG_EFFECT_SIZE="0.5550593969133095" METHOD="MH" MODIFIED="2011-10-03 16:49:36 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.6364001864389439" P_Q="1.0" P_Z="5.943899699623423E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="293" TOTAL_2="299" WEIGHT="100.0" Z="4.0150269720692835">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>3% diclofenac/2.5% HA</GROUP_LABEL_1>
<GROUP_LABEL_2>2.5% hyaluronic acid (HA)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.466962381414955" CI_START="1.5924226781437678" EFFECT_SIZE="5.273972602739726" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2422173849088882" LOG_CI_START="0.20205835386720145" LOG_EFFECT_SIZE="0.7221378693880448" MODIFIED="2011-09-22 17:28:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4394" O_E="0.0" SE="0.6109945637041304" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="0.3733143568760007" WEIGHT="27.14305144383976"/>
<DICH_DATA CI_END="16.451185205129548" CI_START="1.5196473499188916" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2161971916176508" LOG_CI_START="0.18174281705438664" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-09-22 17:28:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4395" O_E="0.0" SE="0.6076436202501999" STUDY_ID="STD-McEwan-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.3692307692307692" WEIGHT="27.443245898816695"/>
<DICH_DATA CI_END="14.648817382068945" CI_START="0.627117077214378" EFFECT_SIZE="3.0309278350515463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.165802564951352" LOG_CI_START="-0.202651372659527" LOG_EFFECT_SIZE="0.48157559614591244" MODIFIED="2011-09-22 17:28:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4396" O_E="0.0" SE="0.8038366169088704" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.6461533066834981" WEIGHT="15.681867892030429"/>
<DICH_DATA CI_END="6.388163424004703" CI_START="0.6479358495387489" EFFECT_SIZE="2.0344827586206895" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8053760178665086" LOG_CI_START="-0.18846799038013243" LOG_EFFECT_SIZE="0.3084540137431881" MODIFIED="2011-09-22 17:29:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4398" O_E="0.0" SE="0.5837888900512601" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.3408094681472823" WEIGHT="29.731834765313113"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: body as a whole : in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2100987366434186" CI_START="0.5494909857782474" EFFECT_SIZE="1.1020114942528736" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.34441167631928715" LOG_CI_START="-0.2600394276424494" LOG_EFFECT_SIZE="0.04218612433841886" MODIFIED="2011-07-25 16:44:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="643" O_E="0.0" SE="0.35505757054834436" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.12606587840369252" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: body as a whole : "flu"</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.562482854600243" CI_START="0.3495646142853332" EFFECT_SIZE="1.2628865979381443" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6592012454280389" LOG_CI_START="-0.4564725365594262" LOG_EFFECT_SIZE="0.1013643544343064" MODIFIED="2011-07-25 22:43:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="665" O_E="0.0" SE="0.6553523022137264" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.42948664001683146" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event:: body as a whole : infection</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.694235158150085" CI_START="0.09471378498953938" EFFECT_SIZE="0.5051546391752577" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4304354991189138" LOG_CI_START="-1.0235868075943764" LOG_EFFECT_SIZE="-0.2965756542377312" MODIFIED="2011-07-25 22:44:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="666" O_E="0.0" SE="0.854099900489885" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.7294866400168315" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: cardiovascular: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.493403568452745" CI_START="0.32684828934729604" EFFECT_SIZE="3.0517241379310347" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4547443292925097" LOG_CI_START="-0.4856537836947709" LOG_EFFECT_SIZE="0.4845452727988694" MODIFIED="2011-07-25 16:53:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="650" O_E="0.0" SE="1.1397994566942975" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="1.2991428014806157" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: cardiovascular: sinus bradycardia</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.40294022267243" CI_START="0.1308754546705627" EFFECT_SIZE="3.1621621621621623" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8831100718991443" LOG_CI_START="-0.8831417965408112" LOG_EFFECT_SIZE="0.49998413767916666" MODIFIED="2011-07-26 14:13:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="625" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="143.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: dermatological: bursitis</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.48921558029694" CI_START="0.01454171718561808" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9288675624598196" LOG_CI_START="-1.837384305980136" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-07-26 14:21:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="632" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.603102685538371" CI_END="4.7768181744916705" CI_START="1.2025684673533834" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3967584173053895" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="28" I2="56.55104531377441" I2_Q="0.0" ID="CMP-006.20" LOG_CI_END="0.6791387105490434" LOG_CI_START="0.0801098119874734" LOG_EFFECT_SIZE="0.37962426126825843" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="20" P_CHI2="0.1001035868958684" P_Q="1.0" P_Z="0.012984762750153233" Q="0.0" RANDOM="YES" SCALE="107.6" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20157086517076941" TOTALS="YES" TOTAL_1="228" TOTAL_2="234" WEIGHT="100.0" Z="2.484186928310387">
<NAME>Minor adverse event: dermatological: dry skin</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.42678771379771" CI_START="2.0099438688102516" EFFECT_SIZE="8.438356164383562" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5493317749293203" LOG_CI_START="0.3031839291586188" LOG_EFFECT_SIZE="0.9262578520439696" MODIFIED="2011-07-26 14:23:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="633" O_E="0.0" SE="0.7319934131370314" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="0.5358143568760007" WEIGHT="16.79099077175603"/>
<DICH_DATA CI_END="2.8624460100894216" CI_START="0.9416252797904497" EFFECT_SIZE="1.6417525773195876" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" LOG_CI_END="0.456737303997248" LOG_CI_START="-0.026121890514961683" LOG_EFFECT_SIZE="0.21530770674114316" MODIFIED="2011-07-25 22:34:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="659" O_E="0.0" SE="0.28363388104803333" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.08044817847836994" WEIGHT="43.90280988974758"/>
<DICH_DATA CI_END="4.133526811798131" CI_START="1.103991848280773" EFFECT_SIZE="2.136206896551724" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.616320758990091" LOG_CI_START="0.042965866636161386" LOG_EFFECT_SIZE="0.32964331281312614" MODIFIED="2011-07-25 16:36:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="636" O_E="0.0" SE="0.3367915019211885" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.11342851576632991" WEIGHT="39.30619933849639"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="414.13" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: dermatological: herpes zoster</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.48921558029694" CI_START="0.01454171718561808" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9288675624598196" LOG_CI_START="-1.837384305980136" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-07-26 14:29:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="638" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="223.14980997208497" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: dermatological: rash vesiculobullous</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="134.83258497866794" CI_START="0.3758371418303168" EFFECT_SIZE="7.11864406779661" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1297948607920136" LOG_CI_START="-0.4250003032805009" LOG_EFFECT_SIZE="0.8523972787557562" MODIFIED="2011-07-25 16:40:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="639" O_E="0.0" SE="1.5006993258162162" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="2.252098466505246" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="895.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event::dermatological: seborrhoea</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.40294022267243" CI_START="0.1308754546705627" EFFECT_SIZE="3.1621621621621623" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8831100718991443" LOG_CI_START="-0.8831417965408112" LOG_EFFECT_SIZE="0.49998413767916666" MODIFIED="2011-07-26 14:36:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="643" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="245.81350228381214" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: dermatological: skin exfoliation</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="134.83258497866794" CI_START="0.3758371418303168" EFFECT_SIZE="7.11864406779661" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1297948607920136" LOG_CI_START="-0.4250003032805009" LOG_EFFECT_SIZE="0.8523972787557562" MODIFIED="2011-07-25 16:40:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="640" O_E="0.0" SE="1.5006993258162162" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="2.252098466505246" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="291.059502072487" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: dermatological: ulcerated skin</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="134.83258497866794" CI_START="0.3758371418303168" EFFECT_SIZE="7.11864406779661" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1297948607920136" LOG_CI_START="-0.4250003032805009" LOG_EFFECT_SIZE="0.8523972787557562" MODIFIED="2011-07-25 16:40:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="641" O_E="0.0" SE="1.5006993258162162" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="2.252098466505246" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: digestive : in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.624532234021337" CI_START="0.27380011928293635" EFFECT_SIZE="0.8477011494252874" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41905191106172424" LOG_CI_START="-0.56256636699856" LOG_EFFECT_SIZE="-0.0717572279684179" MODIFIED="2011-07-25 16:47:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="645" O_E="0.0" SE="0.5766074356214538" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.332476134813949" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.27" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: hemic and lymphatic: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.880747965636855" CI_START="0.06515940093125934" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2008709533617878" LOG_CI_START="-1.1860229172033738" LOG_EFFECT_SIZE="0.007424018079206875" MODIFIED="2011-07-25 16:54:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="651" O_E="0.0" SE="1.4020732748851903" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="1.9658094681472824" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.28" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="81.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: metabolic and nutritional disorders : in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.216234037801783" CI_START="1.1644413067719923" EFFECT_SIZE="5.086206896551724" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3466704418588062" LOG_CI_START="0.06611760297164528" LOG_EFFECT_SIZE="0.7063940224152258" MODIFIED="2011-07-25 16:46:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="644" O_E="0.0" SE="0.7522030764011022" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.5658094681472823" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.29" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="29" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.910772646999802" CI_START="0.11759881596401921" EFFECT_SIZE="0.6781609195402298" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5922625689504818" LOG_CI_START="-0.9295970509034307" LOG_EFFECT_SIZE="-0.16866724097647437" MODIFIED="2011-07-25 16:51:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="648" O_E="0.0" SE="0.8939478740288024" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.7991428014806156" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.30" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="279.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: musculoskeletal and connective tissue: hypokinesia</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.48921558029694" CI_START="0.01454171718561808" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9288675624598196" LOG_CI_START="-1.837384305980136" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-07-26 14:16:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="627" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-006.31" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.6320537893262976" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: nervous system: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5454625650658214" CI_START="0.542343656979543" EFFECT_SIZE="0.9155172413793103" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.1890584898378585" LOG_CI_START="-0.26572543480079486" LOG_EFFECT_SIZE="-0.03833347248146822" MODIFIED="2011-07-25 16:43:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="642" O_E="0.0" SE="0.2671423285494791" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.07136502370283786" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.32" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: nervous system: headache</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6385518708303433" CI_START="0.005147219315650778" EFFECT_SIZE="0.09183673469387756" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.21446019418273368" LOG_CI_START="-2.288427326689073" LOG_EFFECT_SIZE="-1.03698356625317" MODIFIED="2011-07-25 22:40:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="663" O_E="0.0" SE="1.4702085192531429" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="2.1615130900845188" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.228492088024153" CI_END="2.5954911993947904" CI_START="0.30132990864601955" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8843636842414889" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.33" LOG_CI_END="0.41421956064281656" LOG_CI_START="-0.5209577600781082" LOG_EFFECT_SIZE="-0.05336909971764584" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="33" P_CHI2="0.6326442042792104" P_Q="1.0" P_Z="0.822987534159441" Q="0.0" RANDOM="YES" SCALE="151.36" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="175" WEIGHT="100.0" Z="0.22370412758358116">
<NAME>Minor adverse event: nervous system: hyperaesthesia</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.69282293317662" CI_START="0.04885939250341037" EFFECT_SIZE="0.5273972602739726" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7553276759351684" LOG_CI_START="-1.311051937159079" LOG_EFFECT_SIZE="-0.27786213061195525" MODIFIED="2011-07-26 14:32:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="639" O_E="0.0" SE="1.2138016134756127" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="1.4733143568760008" WEIGHT="20.481780863310995"/>
<DICH_DATA CI_END="3.379213730243863" CI_START="0.3020598634486129" EFFECT_SIZE="1.0103092783505154" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5288156611238283" LOG_CI_START="-0.5199069782713284" LOG_EFFECT_SIZE="0.004454341426249989" MODIFIED="2011-07-25 22:38:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="662" O_E="0.0" SE="0.6160248696415036" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.37948664001683147" WEIGHT="79.518219136689"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0185495832134315" CI_END="11.200814019458399" CI_START="0.5714878168975581" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5300452073937025" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="50.45947801747583" I2_Q="0.0" ID="CMP-006.34" LOG_CI_END="1.0492495861802213" LOG_CI_START="-0.24299302355489455" LOG_EFFECT_SIZE="0.4031282813126634" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="34" P_CHI2="0.1553878924803095" P_Q="1.0" P_Z="0.22138200906119343" Q="0.0" RANDOM="YES" SCALE="135.1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.664089985711436" TOTALS="YES" TOTAL_1="170" TOTAL_2="175" WEIGHT="100.0" Z="1.2228615688261664">
<NAME>Minor adverse event: nervous system: paraesthesia</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="58.55338088496111" CI_START="0.9310646409202081" EFFECT_SIZE="7.383561643835616" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.767551976390308" LOG_CI_START="-0.031020166257742544" LOG_EFFECT_SIZE="0.8682659050662828" MODIFIED="2011-07-26 14:33:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="640" O_E="0.0" SE="1.056490179667158" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="1.1161714997331436" WEIGHT="32.36529143417658"/>
<DICH_DATA CI_END="3.5435702166981944" CI_START="0.6481121425223242" EFFECT_SIZE="1.5154639175257731" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5494410428326648" LOG_CI_START="-0.18834984186880233" LOG_EFFECT_SIZE="0.18054560048193122" MODIFIED="2011-07-25 22:37:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="661" O_E="0.0" SE="0.43338201779742175" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.1878199733501648" WEIGHT="67.63470856582342"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.35" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="35" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: respiratory: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.880028358825002" CI_START="0.22994885213219413" EFFECT_SIZE="0.8137931034482758" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4593967641552638" LOG_CI_START="-0.6383687540129629" LOG_EFFECT_SIZE="-0.08948599492884952" MODIFIED="2011-07-25 16:48:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="646" O_E="0.0" SE="0.6448328993989701" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.4158094681472823" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.36" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="36" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: respiratory: bronchitis</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1545570565158485" CI_START="0.009825473788564196" EFFECT_SIZE="0.20204081632653062" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6185247277193177" LOG_CI_START="-2.007646498581245" LOG_EFFECT_SIZE="-0.6945608854309637" MODIFIED="2011-07-25 22:51:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="669" O_E="0.0" SE="1.542625978086178" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="2.379694908266337" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.37" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="37" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="97" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: respiratory: pharyngitis</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0331438320921684" CI_START="0.0803268177536289" EFFECT_SIZE="0.4041237113402062" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30816810331800804" LOG_CI_START="-1.0951394378095833" LOG_EFFECT_SIZE="-0.3934856672457876" MODIFIED="2011-07-25 22:50:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="668" O_E="0.0" SE="0.8243097961427072" STUDY_ID="STD-Rivers-2002" TOTAL_1="97" TOTAL_2="98" VAR="0.6794866400168315" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.38" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="38" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="135.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="73" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: respiratory: upper respiratory tract infection</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.48921558029694" CI_START="0.01454171718561808" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9288675624598196" LOG_CI_START="-1.837384305980136" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-07-26 14:19:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="629" O_E="0.0" SE="1.6249100406892192" STUDY_ID="STD-Gebauer-2003" TOTAL_1="73" TOTAL_2="77" VAR="2.64033264033264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.39" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="39" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: special senses: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.322444835468836" CI_START="0.4687240777816804" EFFECT_SIZE="4.068965517241379" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5480507555455945" LOG_CI_START="-0.3290827367312557" LOG_EFFECT_SIZE="0.6094840094071693" MODIFIED="2011-07-25 16:52:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="649" O_E="0.0" SE="1.1026375053240673" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="1.2158094681472824" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.40" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 13:50:04 +0100" MODIFIED_BY="Maryse Paquet" NO="40" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: urogenital: in general</NAME>
<GROUP_LABEL_1>diclofenac/hyaluronic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>hyaluronic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diclofenac/hyaluronic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hyaluronic acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.611571063203978" CI_START="0.07134377181563974" EFFECT_SIZE="0.3390804597701149" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.20724946074931314" LOG_CI_START="-1.1466439340302244" LOG_EFFECT_SIZE="-0.46969723664045554" MODIFIED="2011-07-25 16:50:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="647" O_E="0.0" SE="0.795283681973891" STUDY_ID="STD-Wolf-2001" TOTAL_1="58" TOTAL_2="59" VAR="0.6324761348139489" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-10-05 18:10:00 +0100" MODIFIED_BY="Maryse Paquet" NO="7">
<NAME>3% diclofenac in 2.5% hyaluronic acid versus 5% imiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-11 23:52:56 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Investigator Global Improvement Indices-Complete improvement</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8503113148144228" CI_START="0.14660633534434064" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.26724480458220784" LOG_CI_START="-0.833847261989307" LOG_EFFECT_SIZE="-0.28330122870354957" MODIFIED="2011-04-07 17:53:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="223" O_E="0.0" SE="0.6467869303977418" STUDY_ID="STD-Kose-2008" TOTAL_1="24" TOTAL_2="25" VAR="0.41833333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-11 23:53:06 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Participant Global Improvement Indices-Complete improvement</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diclofenac</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0973577570157262" CI_START="0.47682579573354567" EFFECT_SIZE="1.2152777777777777" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4909913709765522" LOG_CI_START="-0.32164025779446265" LOG_EFFECT_SIZE="0.08467555659104475" MODIFIED="2011-04-07 17:53:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="222" O_E="0.0" SE="0.47734384133153207" STUDY_ID="STD-Kose-2008" TOTAL_1="24" TOTAL_2="25" VAR="0.22785714285714284" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-09-06 18:02:30 +0100" MODIFIED_BY="Maryse Paquet" NO="8">
<NAME>2-(Difluoromethyl)-dl-ornithine (DFMO) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2011-07-11 23:53:31 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="33.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesions counts</NAME>
<GROUP_LABEL_1>DFMO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DFMO</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.639247165328456" CI_START="-3.839247165328456" EFFECT_SIZE="5.8999999999999995" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="0.7" MODIFIED="2011-04-01 21:09:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="200" SD_1="20.9" SD_2="24.5" SE="4.969094964065867" STUDY_ID="STD-Alberts-2000" TOTAL_1="42" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2012-09-28 16:58:16 +0100" MODIFIED_BY="Maryse Paquet" NO="9">
<NAME>0.5% 5-FU versus vehicle</NAME>
<DICH_OUTCOME CHI2="2.6916591536441103" CI_END="21.397435249632313" CI_START="3.6663668354142076" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="8.857248272583018" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="1.3303617208405776" LOG_CI_START="0.5642359157887302" LOG_EFFECT_SIZE="0.9472988183146539" METHOD="MH" MODIFIED="2011-08-23 14:22:10 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8464315200979893" P_Q="0.822560757057686" P_Z="1.2539902665609463E-6" Q="0.3906660193230794" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="196" WEIGHT="100.00000000000001" Z="4.8469104010102475">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>0.5% fluorouracil</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.5% 5-fu</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8616518281615388" CI_END="33.76324159985975" CI_START="2.0382406626189318" DF="2" EFFECT_SIZE="8.295638126790562" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="1" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="1.5284441364532555" LOG_CI_START="0.30925546145486277" LOG_EFFECT_SIZE="0.9188497989540592" MODIFIED="2011-08-23 14:21:37 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.6499720719986655" P_Z="0.0031339925984240034" STUDIES="3" TAU2="0.0" TOTAL_1="155" TOTAL_2="112" WEIGHT="39.487382053806655" Z="2.9542802522410234">
<NAME>1 week treatment with 4 week follow-up</NAME>
<DICH_DATA CI_END="131.27710513123904" CI_START="0.46655231306182293" EFFECT_SIZE="7.826086956521739" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1181889912672296" LOG_CI_START="-0.33109965309580336" LOG_EFFECT_SIZE="0.8935446690857132" MODIFIED="2011-08-23 14:20:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9104" O_E="0.0" SE="1.4387242738731714" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="23" VAR="2.069927536231884" WEIGHT="9.784085596232782"/>
<DICH_DATA CI_END="402.96694758929027" CI_START="1.4671738199957567" EFFECT_SIZE="24.315068493150687" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.605269425624323" LOG_CI_START="0.16648156891699062" LOG_EFFECT_SIZE="1.385875497270657" ORDER="9106" O_E="0.0" SE="1.432556059224476" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" VAR="2.05221686282076" WEIGHT="9.868522454617809"/>
<DICH_DATA CI_END="36.23138165100244" CI_START="0.6900095679709831" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.5590848957779835" LOG_CI_START="-0.16114488710594593" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-08-23 14:21:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9105" O_E="0.0" SE="1.010471489740778" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="19" VAR="1.0210526315789474" WEIGHT="19.834774002956067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9438990858376353" CI_END="32.59228038249003" CI_START="1.265201466497973" DF="1" EFFECT_SIZE="6.421510798592455" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="1.5131147477890194" LOG_CI_START="0.10215968663572464" LOG_EFFECT_SIZE="0.807637217212372" MODIFIED="2011-08-23 14:21:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.33127727829729503" P_Z="0.024846241870549703" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="42" WEIGHT="29.483145656566897" Z="2.243784939566437">
<NAME>2 week treatment with 4 week follow-up</NAME>
<DICH_DATA CI_END="290.6805287966887" CI_START="1.1471678500733529" EFFECT_SIZE="18.26086956521739" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.463415941576524" LOG_CI_START="0.05962696718409103" LOG_EFFECT_SIZE="1.2615214543803075" MODIFIED="2011-08-23 14:20:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9107" O_E="0.0" SE="1.411997542505442" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="23" VAR="1.9937370600414075" WEIGHT="10.15798351667866"/>
<DICH_DATA CI_END="27.570307216146094" CI_START="0.4985145712476553" EFFECT_SIZE="3.707317073170732" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.4404416054795" LOG_CI_START="-0.3023221430294257" LOG_EFFECT_SIZE="0.5690597312250371" MODIFIED="2011-08-23 14:21:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9108" O_E="0.0" SE="1.0237080526938296" STUDY_ID="STD-Weiss-2002" TOTAL_1="41" TOTAL_2="19" VAR="1.0479781771501926" WEIGHT="19.325162139888235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4572673131315071" CI_END="63.661743959381496" CI_START="2.6824373984806007" DF="1" EFFECT_SIZE="13.067847674699202" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="1" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="1.803878531576249" LOG_CI_START="0.42852959538666485" LOG_EFFECT_SIZE="1.1162040634814567" MODIFIED="2011-08-23 14:21:40 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.4989039047906839" P_Z="0.0014660027773425028" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="42" WEIGHT="31.029472289626465" Z="3.181330506397907">
<NAME>4 week treatment with 4 week follow-up</NAME>
<DICH_DATA CI_END="434.27002151087675" CI_START="1.7607541028434786" EFFECT_SIZE="27.652173913043477" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="0" LOG_CI_END="2.637759850219305" LOG_CI_START="0.2456987090423367" LOG_EFFECT_SIZE="1.441729279630821" MODIFIED="2011-08-23 14:21:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9109" O_E="0.0" SE="1.4051085552209674" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="23" VAR="1.9743300519551543" WEIGHT="10.257833117839816"/>
<DICH_DATA CI_END="62.50883284635823" CI_START="1.3030258491659765" EFFECT_SIZE="9.025" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.7959413899103478" LOG_CI_START="0.11495303124504333" LOG_EFFECT_SIZE="0.9554472105776955" MODIFIED="2011-08-23 14:21:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9110" O_E="0.0" SE="0.987420882906575" STUDY_ID="STD-Weiss-2002" TOTAL_1="40" TOTAL_2="19" VAR="0.9750000000000001" WEIGHT="20.77163917178665"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2011-07-27 20:55:10 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="18.23406931874937" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.861172648325645" CI_START="2.938827351674355" EFFECT_SIZE="5.4" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="4.0" MODIFIED="2011-07-27 20:52:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="690" SD_1="9.2" SD_2="5.3" SE="1.2557234049906332" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="44.324933179869966" CI_START="22.875066820130023" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="33.599999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2012-09-28 16:58:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="8.234244439068222E-10" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="99.99999999999999" Z="6.140345005053376">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<GROUP_LABEL_1>0.5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="44.324933179869966" CI_START="22.875066820130023" EFFECT_SIZE="33.599999999999994" ESTIMABLE="YES" MEAN_1="62.4" MEAN_2="28.8" MODIFIED="2012-09-14 18:09:13 +0100" MODIFIED_BY="[Empty name]" ORDER="698" SD_1="32.6" SD_2="32.6" SE="5.47200523298738" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:16:14 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="621.8097374448857" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>0.5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="96.17573376504401" CI_START="0.3041314924188877" EFFECT_SIZE="5.408333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9830655084063966" LOG_CI_START="-0.5169386069009078" LOG_EFFECT_SIZE="0.7330634507527444" MODIFIED="2011-09-22 18:44:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4399" O_E="0.0" SE="1.468514792551466" STUDY_ID="STD-Weiss-2002" TOTAL_1="119" TOTAL_2="58" VAR="2.1565356959424755" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.518777815754664E-4" CI_END="1.6475347655930648" CI_START="1.2703693457921388" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.446712708984153" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.2168345876641815" LOG_CI_START="0.10393000561675707" LOG_EFFECT_SIZE="0.16038229664046927" METHOD="MH" MODIFIED="2012-09-14 18:16:08 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.9796307069569568" P_Q="1.0" P_Z="2.5723056719991716E-8" Q="0.0" RANDOM="YES" SCALE="3.85" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="127" WEIGHT="100.0" Z="5.568304128544619">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>0.5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7245060100000085" CI_START="1.2098651677568868" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="45" LOG_CI_END="0.23666471224663466" LOG_CI_START="0.08273697348838914" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2011-07-27 16:59:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="633" O_E="0.0" SE="0.09041791570118891" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="138" TOTAL_2="69" VAR="0.008175399479747306" WEIGHT="53.800877087208754"/>
<DICH_DATA CI_END="1.7548123137304255" CI_START="1.1970742388179605" EFFECT_SIZE="1.4493586908447589" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="38" LOG_CI_END="0.24423067324055076" LOG_CI_START="0.07812108483348133" LOG_EFFECT_SIZE="0.16117587903701608" MODIFIED="2011-07-27 16:22:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="623" O_E="0.0" SE="0.09757359448603635" STUDY_ID="STD-Weiss-2002" TOTAL_1="119" TOTAL_2="58" VAR="0.009520606340925462" WEIGHT="46.19912291279125"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:16:02 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: body as a whole : in general</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5064037021116214" CI_START="0.4502952027035516" EFFECT_SIZE="0.8236057068741893" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" LOG_CI_END="0.17794137432450916" LOG_CI_START="-0.34650267984247174" LOG_EFFECT_SIZE="-0.08428065275898132" MODIFIED="2011-07-27 20:15:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="676" O_E="0.0" SE="0.30806103345762115" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.09490160033497758" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:56 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: body as a whole : allergy</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.380204292520717" CI_START="0.1254380652652961" EFFECT_SIZE="0.7412451361867705" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6414943664505353" LOG_CI_START="-0.9015706530898481" LOG_EFFECT_SIZE="-0.1300381433196564" MODIFIED="2011-07-27 20:19:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="678" O_E="0.0" SE="0.9064040307730566" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.8215682670016442" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:41 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: body as a whole : "flu" or common cold</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.887474408805803" CI_START="0.2512659521969475" EFFECT_SIZE="0.9883268482490273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5896675430892973" LOG_CI_START="-0.5998663565120103" LOG_EFFECT_SIZE="-0.00509940671135646" MODIFIED="2011-07-27 20:16:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="677" O_E="0.0" SE="0.6987381009135761" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.48823493366831094" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:33 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2211159602205945" CI_START="0.0719924226454348" EFFECT_SIZE="0.2964980544747082" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.08675690759160742" LOG_CI_START="-1.1427132115749956" LOG_EFFECT_SIZE="-0.5279781519916941" MODIFIED="2011-07-27 20:22:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="680" O_E="0.0" SE="0.7221968339737057" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.5215682670016443" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:27 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="279.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: musculoskeletal and connective tissue: soreness</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0515447578358543" CI_START="0.004799096938114662" EFFECT_SIZE="0.09922480620155039" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3120809962574014" LOG_CI_START="-2.3188404775601623" LOG_EFFECT_SIZE="-1.0033797406513807" MODIFIED="2011-07-27 20:24:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="681" O_E="0.0" SE="1.545416296991769" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="2.388311531007752" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:21 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation:nervous system: headache</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.8827137028652015" CI_START="0.3556455668482223" EFFECT_SIZE="1.317769130998703" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6886612602433689" LOG_CI_START="-0.44898260044948196" LOG_EFFECT_SIZE="0.11983932989694347" MODIFIED="2011-07-27 20:25:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="682" O_E="0.0" SE="0.6682576351989136" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.44656826700164426" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-009.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:15 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: respiratory: in general</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.501624578750762" CI_START="0.16262219811666762" EFFECT_SIZE="0.49416342412451364" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.17656136824972277" LOG_CI_START="-0.788820173000398" LOG_EFFECT_SIZE="-0.30612940237533764" MODIFIED="2011-07-27 20:26:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="683" O_E="0.0" SE="0.5670698960460203" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.32156826700164426" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:08 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: respiratory: sinusitis</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.324245323680791" CI_START="0.18346073473086605" EFFECT_SIZE="0.9883268482490273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7262580581223673" LOG_CI_START="-0.7364568715450802" LOG_EFFECT_SIZE="-0.00509940671135646" MODIFIED="2011-07-27 20:27:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="684" O_E="0.0" SE="0.8592059902423347" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.7382349336683109" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:15:03 +0100" MODIFIED_BY="Maryse Paquet" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="517.8220189316155" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: respiratory: upper respiratory tract infection</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0515447578358543" CI_START="0.004799096938114662" EFFECT_SIZE="0.09922480620155039" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3120809962574014" LOG_CI_START="-2.3188404775601623" LOG_EFFECT_SIZE="-1.0033797406513807" MODIFIED="2011-07-27 20:28:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="685" O_E="0.0" SE="1.545416296991769" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="2.388311531007752" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-009.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:14:57 +0100" MODIFIED_BY="Maryse Paquet" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation: special senses: in general</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.286423247199993" CI_START="0.5283907007694686" EFFECT_SIZE="1.317769130998703" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.5167234940006092" LOG_CI_START="-0.27704483420672227" LOG_EFFECT_SIZE="0.11983932989694347" MODIFIED="2011-07-27 20:30:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="686" O_E="0.0" SE="0.4662634452055807" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.21740160033497757" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 18:14:51 +0100" MODIFIED_BY="Maryse Paquet" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event excluding skin irritation:special senses: eye irritation</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.879361549312637" CI_START="0.6749377639570903" EFFECT_SIZE="2.30609597924773" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.8964910288037988" LOG_CI_START="-0.1707362716373232" LOG_EFFECT_SIZE="0.3628773785832379" MODIFIED="2011-07-27 20:30:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="687" O_E="0.0" SE="0.6268945991394532" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="257" TOTAL_2="127" VAR="0.3929968384302157" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-12-05 18:18:51 +0000" MODIFIED_BY="Maryse Paquet" NO="10">
<NAME>0.5% 5-FU at varying application durations</NAME>
<DICH_OUTCOME CHI2="10.436897881295433" CI_END="0.75492066485332" CI_START="0.37021563592518747" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5286619279007494" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="115" I2="52.09304472585874" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.12209868628710475" LOG_CI_START="-0.4315452429233979" LOG_EFFECT_SIZE="-0.2768219646052513" METHOD="MH" MODIFIED="2011-07-27 22:54:17 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0637612057983824" P_Q="0.5944248684581936" P_Z="4.5377791348940813E-4" Q="1.0403221791103385" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12207733578818658" TOTALS="SUB" TOTAL_1="252" TOTAL_2="255" WEIGHT="300.0" Z="3.5066545037927916">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Shorter duration</GROUP_LABEL_1>
<GROUP_LABEL_2>Longer duration</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours longer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours shorter</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.374161578992484" CI_END="0.814844966451234" CI_START="0.18745050551018796" DF="1" EFFECT_SIZE="0.3908236186231789" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="45" I2="57.87986761944118" ID="CMP-010.01.01" LOG_CI_END="-0.08892501287904596" LOG_CI_START="-0.7271133840501705" LOG_EFFECT_SIZE="-0.4080191984646082" MODIFIED="2011-07-27 22:53:41 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.12335798419548127" P_Z="0.01220483752256225" STUDIES="2" TAU2="0.16330878085351475" TOTAL_1="83" TOTAL_2="84" WEIGHT="100.0" Z="2.5061657971736984">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="0.5428730126214637" CI_START="0.12765312677807958" EFFECT_SIZE="0.26324786324786326" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" LOG_CI_END="-0.2653017475152528" LOG_CI_START="-0.893968542976182" LOG_EFFECT_SIZE="-0.5796351452457174" MODIFIED="2011-04-28 14:34:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="474" O_E="0.0" SE="0.3692819876045762" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="44" VAR="0.13636918636918635" WEIGHT="46.89409540424028"/>
<DICH_DATA CI_END="1.0338593211539207" CI_START="0.2968821864914154" EFFECT_SIZE="0.554016620498615" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.014461447652409868" LOG_CI_START="-0.5274158601357632" LOG_EFFECT_SIZE="-0.2564772062416767" MODIFIED="2011-04-28 14:34:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="475" O_E="0.0" SE="0.31830141293070663" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="40" VAR="0.10131578947368422" WEIGHT="53.10590459575972"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.254481586362963" CI_END="2.369123167513743" CI_START="0.2310683405359471" DF="1" EFFECT_SIZE="0.7398846929371273" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="76.49537365009795" ID="CMP-010.01.02" LOG_CI_END="0.3745876396932516" LOG_CI_START="-0.6362595546179495" LOG_EFFECT_SIZE="-0.13083595746234894" MODIFIED="2011-07-27 22:54:03 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0391470555206852" P_Z="0.611899405413666" STUDIES="2" TAU2="0.5394794565777274" TOTAL_1="83" TOTAL_2="86" WEIGHT="99.99999999999997" Z="0.507364052553471">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="0.8957282411977242" CI_START="0.18928751513256561" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.04782373280464885" LOG_CI_START="-0.7228780299233853" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2011-04-28 14:34:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="476" O_E="0.0" SE="0.3965302357002088" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="45" VAR="0.15723622782446312" WEIGHT="50.604674602145344"/>
<DICH_DATA CI_END="3.0568518800644418" CI_START="0.5950399859363307" EFFECT_SIZE="1.3486842105263157" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4852743954715425" LOG_CI_START="-0.22545384924957906" LOG_EFFECT_SIZE="0.12991027311098172" MODIFIED="2011-04-28 14:34:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="477" O_E="0.0" SE="0.41748528911073834" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="41" VAR="0.17429396662387678" WEIGHT="49.395325397854634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2285417851060376" CI_END="0.8661871764665933" CI_START="0.36298931285196856" DF="1" EFFECT_SIZE="0.5607287115769938" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="45" I2="18.602687175700076" ID="CMP-010.01.03" LOG_CI_END="-0.06238825010400792" LOG_CI_START="-0.4401061612937563" LOG_EFFECT_SIZE="-0.25124720569888215" MODIFIED="2011-07-27 22:54:17 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.2676908906793717" P_Z="0.009122617692319961" STUDIES="2" TAU2="0.02069239702004845" TOTAL_1="86" TOTAL_2="85" WEIGHT="100.0" Z="2.6074245345424374">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.0259873941522892" CI_START="0.4166862042711915" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.011142024826740307" LOG_CI_START="-0.3801908780118284" LOG_EFFECT_SIZE="-0.18452442659254403" MODIFIED="2011-04-28 14:34:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="478" O_E="0.0" SE="0.22987088425648586" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="45" TOTAL_2="45" VAR="0.052840623428858716" WEIGHT="66.94651240332297"/>
<DICH_DATA CI_END="0.8287710980394227" CI_START="0.20360593997279552" EFFECT_SIZE="0.41078305519897307" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.08156540260470169" LOG_CI_START="-0.6912095561006153" LOG_EFFECT_SIZE="-0.38638747935265844" MODIFIED="2011-04-28 14:34:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="479" O_E="0.0" SE="0.35810799355072964" STUDY_ID="STD-Weiss-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.1282413350449294" WEIGHT="33.05348759667703"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 19:04:20 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="291.059502072487" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="117" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-22 18:53:45 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="2.0989773648695254" CI_START="0.006500484473101524" EFFECT_SIZE="0.1168091168091168" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.32200775522591324" LOG_CI_START="-2.1870542747180903" LOG_EFFECT_SIZE="-0.9325232597460886" MODIFIED="2011-09-22 18:53:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4402" O_E="0.0" SE="1.4738354564464642" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="40" VAR="2.1721909526787577" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-22 18:53:48 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="8.553055903014988" CI_START="0.015066263083306556" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9321213105994005" LOG_CI_START="-1.821994453295923" LOG_EFFECT_SIZE="-0.4449365713482612" MODIFIED="2011-09-22 18:53:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4403" O_E="0.0" SE="1.617781232805016" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="41" VAR="2.6172161172161172" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-22 18:53:57 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="2.0888035031087515" CI_START="0.028479653386979793" EFFECT_SIZE="0.24390243902439024" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31989758716586686" LOG_CI_START="-1.5454653006053378" LOG_EFFECT_SIZE="-0.6127838567197355" MODIFIED="2011-09-22 18:53:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4405" O_E="0.0" SE="1.0957233939720192" STUDY_ID="STD-Weiss-2002" TOTAL_1="41" TOTAL_2="40" VAR="1.200609756097561" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4347596316359614" CI_END="0.9972126853628619" CI_START="0.9145604779053577" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9549928324855345" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="247" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-0.001212205551285591" LOG_CI_START="-0.03878757028365656" LOG_EFFECT_SIZE="-0.019999887917471062" METHOD="MH" MODIFIED="2011-09-22 19:04:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.7862867564377258" P_Q="0.9394013217030609" P_Z="0.03694028769580405" Q="0.12502501292790671" RANDOM="YES" SCALE="2.024229800371862" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="258" TOTAL_2="257" WEIGHT="100.0" Z="2.086423394278395">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2867961451666683" CI_END="1.0287501724850538" CI_START="0.8920511422649036" DF="1" EFFECT_SIZE="0.9579654307283268" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="82" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.01230992103617152" LOG_CI_START="-0.04961024633380665" LOG_EFFECT_SIZE="-0.01865016264881758" MODIFIED="2011-08-31 15:53:45 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.5922810596438766" P_Z="0.23773379919899773" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="36.824950058946804" Z="1.1806701645066782">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="1.0513069654104292" CI_START="0.8318814487482822" EFFECT_SIZE="0.9351806036615536" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="43" LOG_CI_END="0.02172954183153871" LOG_CI_START="-0.07993856051565837" LOG_EFFECT_SIZE="-0.029104509342059867" MODIFIED="2011-07-27 23:13:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="720" O_E="0.0" SE="0.05972034658396673" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="47" TOTAL_2="45" VAR="0.0035665197961091064" WEIGHT="13.659568323779874"/>
<DICH_DATA CI_END="1.0630390665279559" CI_START="0.8881357496388225" EFFECT_SIZE="0.97165991902834" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.026549225074339662" LOG_CI_START="-0.05152064817045919" LOG_EFFECT_SIZE="-0.012485711548059728" MODIFIED="2011-07-27 23:14:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="804" O_E="0.0" SE="0.045858629996100034" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="40" VAR="0.002103013945119206" WEIGHT="23.16538173516693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.974593634051323" CI_END="1.0770298778947474" CI_START="0.8640794557430482" DF="1" EFFECT_SIZE="0.9646965277797444" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="83" I2="49.356668493442115" ID="CMP-010.03.02" LOG_CI_END="0.03222775123190642" LOG_CI_START="-0.06344632047924095" LOG_EFFECT_SIZE="-0.015609284623667249" MODIFIED="2011-08-31 15:53:45 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.1599614377466706" P_Z="0.5224725503896899" STUDIES="2" TAU2="0.0031204313491226825" TOTAL_1="85" TOTAL_2="87" WEIGHT="30.534079269990535" Z="0.6395386992452653">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="1.017286528730104" CI_START="0.8202574948023524" EFFECT_SIZE="0.9134751773049645" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.007443293453890434" LOG_CI_START="-0.0860497927170636" LOG_EFFECT_SIZE="-0.039303249631586615" MODIFIED="2011-07-27 23:13:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="722" O_E="0.0" SE="0.054918301615058854" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="47" TOTAL_2="46" VAR="0.003016019852282576" WEIGHT="16.152785200069502"/>
<DICH_DATA CI_END="1.145674490023018" CI_START="0.9119627204793219" EFFECT_SIZE="1.0221606648199446" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.05906124305232524" LOG_CI_START="-0.04002291454552029" LOG_EFFECT_SIZE="0.00951916425340245" MODIFIED="2011-07-27 23:15:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="805" O_E="0.0" SE="0.05820252464746483" STUDY_ID="STD-Weiss-2002" TOTAL_1="38" TOTAL_2="41" VAR="0.003387533875338751" WEIGHT="14.381294069921035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.045592172842373505" CI_END="1.0183770600545472" CI_START="0.8752649594507798" DF="1" EFFECT_SIZE="0.9441132115240458" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="82" I2="0.0" ID="CMP-010.03.03" LOG_CI_END="0.007908607845192277" LOG_CI_START="-0.05786045782496226" LOG_EFFECT_SIZE="-0.024975924989884966" MODIFIED="2011-08-31 15:53:45 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.8309190173759741" P_Z="0.13659274858764817" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="85" WEIGHT="32.640970671062654" Z="1.488599935606579">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.0513069654104292" CI_START="0.8318814487482822" EFFECT_SIZE="0.9351806036615536" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="43" LOG_CI_END="0.02172954183153871" LOG_CI_START="-0.07993856051565837" LOG_EFFECT_SIZE="-0.029104509342059867" MODIFIED="2011-07-27 23:14:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="725" O_E="0.0" SE="0.05972034658396673" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="47" TOTAL_2="45" VAR="0.0035665197961091064" WEIGHT="13.659568323779874"/>
<DICH_DATA CI_END="1.04982795645831" CI_START="0.8607402555250094" EFFECT_SIZE="0.9505941213258287" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.021118133657799933" LOG_CI_START="-0.06512788526072426" LOG_EFFECT_SIZE="-0.022004875801462147" MODIFIED="2011-07-27 23:15:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="806" O_E="0.0" SE="0.050661338437420135" STUDY_ID="STD-Weiss-2002" TOTAL_1="41" TOTAL_2="40" VAR="0.0025665712122708226" WEIGHT="18.981402347282778"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole : in general</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:25 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="1.4096451114093114" CI_START="0.24139251434538772" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.14910978956587712" LOG_CI_START="-0.617276201632613" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2011-07-28 14:09:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="756" O_E="0.0" SE="0.4501789249018331" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="0.20266106442577025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:25 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="3.407780731357424" CI_START="0.4184297839049387" EFFECT_SIZE="1.1941176470588235" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.532471642953499" LOG_CI_START="-0.37837740988362106" LOG_EFFECT_SIZE="0.07704711653493898" MODIFIED="2011-07-28 14:09:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="758" O_E="0.0" SE="0.5350372424120524" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="0.2862648507678934" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-010.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:25 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.2421932119833827" CI_START="0.1921101022557758" EFFECT_SIZE="0.4885057471264368" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.09418915169570592" LOG_CI_START="-0.7164497968323198" LOG_EFFECT_SIZE="-0.31113032256830697" MODIFIED="2011-07-28 14:10:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="761" O_E="0.0" SE="0.476173331092874" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="0.22674104124408384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole : allergy</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:21 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="8.068832465692276" CI_START="0.013770407501152425" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9068106982425123" LOG_CI_START="-1.861053207681837" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-07-28 14:11:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="762" O_E="0.0" SE="1.6258569594872663" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="2.643410852713178" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-010.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:21 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="4.201055754933861" CI_START="0.009969422182125744" EFFECT_SIZE="0.20465116279069767" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6233584453797997" LOG_CI_START="-2.0013300122386353" LOG_EFFECT_SIZE="-0.6889857834294179" MODIFIED="2011-07-28 14:11:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="764" O_E="0.0" SE="1.541754992422473" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="2.3770084566596195" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-010.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="21.150483090566528" CI_START="0.18052570351510858" EFFECT_SIZE="1.9540229885057472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3253202913881894" LOG_CI_START="-0.7434609538688786" LOG_EFFECT_SIZE="0.2909296687596554" MODIFIED="2011-07-28 14:12:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="767" O_E="0.0" SE="1.2152123440963245" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="1.4767410412440838" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole : "flu" or common cold</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-010.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:16 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="10.630083694720586" CI_START="0.3762905462340427" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0265366839035623" LOG_CI_START="-0.42447669257559995" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-07-28 14:13:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="768" O_E="0.0" SE="0.8523324399759135" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="0.7264705882352942" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-010.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:16 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="168.477489124977" CI_START="0.5033981083433984" EFFECT_SIZE="9.209302325581396" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.226541881457194" LOG_CI_START="-0.2980884207653425" LOG_EFFECT_SIZE="0.9642267303459258" MODIFIED="2011-07-28 14:13:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="770" O_E="0.0" SE="1.4829803366470649" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="2.199230678881842" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-010.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:16 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="4.012268641979706" CI_START="0.009521416123321533" EFFECT_SIZE="0.19545454545454546" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6033900035665979" LOG_CI_START="-2.0212984540518373" LOG_EFFECT_SIZE="-0.7089542252426196" MODIFIED="2011-07-28 14:13:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="773" O_E="0.0" SE="1.541754992422473" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="2.3770084566596195" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-010.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:10 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="15.728190232720898" CI_START="0.06358010586110548" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1966787533187657" LOG_CI_START="-1.196678753318766" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-28 14:16:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="780" O_E="0.0" SE="1.4058700467096148" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="1.9764705882352942" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-010.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:10 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="16.101300375290457" CI_START="0.06506384157363478" EFFECT_SIZE="1.0235294117647058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2068609519950422" LOG_CI_START="-1.1866602981863907" LOG_EFFECT_SIZE="0.010100326904325756" MODIFIED="2011-07-28 14:16:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="781" O_E="0.0" SE="1.405966230477846" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="1.9767410412440838" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-010.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:10 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="15.36951977955788" CI_START="0.06210678496096069" EFFECT_SIZE="0.9770114942528736" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1866602981863907" LOG_CI_START="-1.2068609519950422" LOG_EFFECT_SIZE="-0.010100326904325779" MODIFIED="2011-07-28 14:16:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="782" O_E="0.0" SE="1.405966230477846" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="1.9767410412440838" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-010.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:08 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="4.815353967925283" CI_START="0.20766905333666563" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6826282168326222" LOG_CI_START="-0.6826282168326221" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-28 14:18:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="786" O_E="0.0" SE="0.8019583872633048" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="0.6431372549019608" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-010.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:08 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="8.96000279261346" CI_START="0.263072242524841" EFFECT_SIZE="1.535294117647059" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9523081450211014" LOG_CI_START="-0.5799249731010874" LOG_EFFECT_SIZE="0.18619158596000707" MODIFIED="2011-07-28 14:19:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="787" O_E="0.0" SE="0.9000413182612325" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="0.8100743745774172" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-010.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:08 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="3.801237220629894" CI_START="0.11160710807192945" EFFECT_SIZE="0.6513409961685823" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5799249731010874" LOG_CI_START="-0.9523081450211014" LOG_EFFECT_SIZE="-0.18619158596000707" MODIFIED="2011-07-28 14:19:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="788" O_E="0.0" SE="0.9000413182612325" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="0.8100743745774172" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: in general</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-010.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:04 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="41.90132020087665" CI_START="0.5966399120636051" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6222277066637456" LOG_CI_START="-0.22428769799170786" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-07-28 14:20:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="789" O_E="0.0" SE="1.0846522890932808" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="1.1764705882352942" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-010.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:04 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="200.46693109845756" CI_START="0.631991256918675" EFFECT_SIZE="11.255813953488373" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.302042741914101" LOG_CI_START="-0.19928892978444862" LOG_EFFECT_SIZE="1.051376906064826" MODIFIED="2011-07-28 14:20:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="790" O_E="0.0" SE="1.4692946057471936" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="2.158826638477801" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:53:04 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="7.88670604039798" CI_START="0.01345530030153093" EFFECT_SIZE="0.32575757575757575" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8968956537571464" LOG_CI_START="-1.871106605009673" LOG_EFFECT_SIZE="-0.4871054756262634" MODIFIED="2011-07-28 14:20:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="791" O_E="0.0" SE="1.625938228631791" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="2.643675123326286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 18:18:51 +0000" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: sinusitis</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-010.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 18:18:51 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="164.61970352611314" CI_START="0.49204316533805004" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.216481815205157" LOG_CI_START="-0.3079967963265068" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2011-07-28 14:21:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="792" O_E="0.0" SE="1.482891232784365" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="2.198966408268734" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-010.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 18:18:51 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="168.477489124977" CI_START="0.5033981083433984" EFFECT_SIZE="9.209302325581396" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.226541881457194" LOG_CI_START="-0.2980884207653425" LOG_EFFECT_SIZE="0.9642267303459258" MODIFIED="2011-07-28 14:21:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="793" O_E="0.0" SE="1.4829803366470649" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="2.199230678881842" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 18:18:51 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-28 14:21:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="794" O_E="0.0" SE="0.0" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-010.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: special senses: in general</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-010.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:16 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="2.9770015133872194" CI_START="0.335908462089495" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47377905542453846" LOG_CI_START="-0.47377905542453846" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-28 14:23:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="798" O_E="0.0" SE="0.5566003248010437" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="0.3098039215686274" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-010.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:16 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="7.9223615227186714" CI_START="0.5289394854012679" EFFECT_SIZE="2.0470588235294116" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8988546567680183" LOG_CI_START="-0.27659401163140435" LOG_EFFECT_SIZE="0.31113032256830697" MODIFIED="2011-07-28 14:23:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="799" O_E="0.0" SE="0.69046436638257" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="0.47674104124408384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-010.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:16 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.8905754393460958" CI_START="0.126224989497429" EFFECT_SIZE="0.4885057471264368" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27659401163140435" LOG_CI_START="-0.8988546567680183" LOG_EFFECT_SIZE="-0.31113032256830697" MODIFIED="2011-07-28 14:23:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="800" O_E="0.0" SE="0.69046436638257" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="0.47674104124408384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-010.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:01:27 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="101.64" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="257" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: special senses: eye irritation</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-010.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:21 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 4 weeks</NAME>
<DICH_DATA CI_END="2.6268477440406057" CI_START="0.26436417794670236" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41943490116852755" LOG_CI_START="-0.5777973932637773" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-07-28 14:24:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="801" O_E="0.0" SE="0.5857791861290061" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="85" VAR="0.3431372549019608" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-010.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:21 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 1 week versus 2 weeks</NAME>
<DICH_DATA CI_END="6.916285129453174" CI_START="0.4207511037512998" EFFECT_SIZE="1.7058823529411764" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.839872889112528" LOG_CI_START="-0.3759747360711637" LOG_EFFECT_SIZE="0.23194907652068214" MODIFIED="2011-07-28 14:24:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="802" O_E="0.0" SE="0.714194913575711" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="85" TOTAL_2="87" VAR="0.5100743745774172" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-010.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 15:54:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Daily for 2 weeks versus 4 weeks</NAME>
<DICH_DATA CI_END="1.8905754393460958" CI_START="0.126224989497429" EFFECT_SIZE="0.4885057471264368" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27659401163140435" LOG_CI_START="-0.8988546567680183" LOG_EFFECT_SIZE="-0.31113032256830697" MODIFIED="2011-07-28 14:24:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="803" O_E="0.0" SE="0.69046436638257" STUDY_ID="STD-Jorizzo-2002" TOTAL_1="87" TOTAL_2="85" VAR="0.47674104124408384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2012-09-18 14:06:29 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>0.5% 5-FU versus ALA-PDT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 16:34:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="134.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>0.5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>ALA-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.5% 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 16:32:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="2.225879116358687" CI_START="0.4492606955385334" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3475015748576669" LOG_CI_START="-0.3475015748576669" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-14 16:32:30 +0100" MODIFIED_BY="[Empty name]" ORDER="9121" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.16666666666666669" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 16:33:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2012-09-14 16:33:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1492" O_E="0.0" SE="1.0" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 16:34:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="3.9785730663656658" CI_START="0.7386506320690961" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.5997273382744486" LOG_CI_START="-0.13156092620771276" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2012-09-14 16:34:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1124" O_E="0.0" SE="0.42956234649211233" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="24" VAR="0.18452380952380956" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-18 14:06:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="683.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>ALA-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 14:06:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-09-18 14:06:29 +0100" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 16:35:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-09-14 16:35:16 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-011.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 16:35:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="131.91963228680433" CI_START="0.2523053096166672" EFFECT_SIZE="5.769230769230769" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.120309432084352" LOG_CI_START="-0.5980736099146257" LOG_EFFECT_SIZE="0.7611179110848633" MODIFIED="2012-09-14 16:35:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1123" O_E="0.0" SE="1.5967916550832766" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="24" VAR="2.5497435897435894" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2012-09-14 16:31:42 +0100" MODIFIED_BY="Maryse Paquet" NO="12">
<NAME>5% 5-FU with 0.05% tretinoin versus 5% 5-FU with placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.01" MODIFIED="2011-07-11 23:58:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>Tretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tretinoin</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.638437640417514" CI_START="-3.238437640417512" EFFECT_SIZE="1.200000000000001" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="11.1" MODIFIED="2011-04-02 00:05:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="205" SD_1="6.6" SD_2="7.34" SE="2.264550611861923" STUDY_ID="STD-Bercovitch-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2012-09-14 16:54:06 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>5% 5-FU versus 5% imiquimod</NAME>
<DICH_OUTCOME CHI2="14.329708374114443" CI_END="8.329120050474284" CI_START="0.4114326554201776" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.851181239014721" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" I2="93.02149092017514" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.9205991217657779" LOG_CI_START="-0.3857012413093626" LOG_EFFECT_SIZE="0.2674489402282076" METHOD="MH" MODIFIED="2012-09-14 16:54:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.5342590516853605E-4" P_Q="1.0" P_Z="0.42223080200415464" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.0996779581831662" TOTALS="YES" TOTAL_1="44" TOTAL_2="45" WEIGHT="100.0" Z="0.8025570617108377">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% 5-FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.361250074848267" CI_START="0.9423160889752616" EFFECT_SIZE="1.1325757575757576" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.1339379166434923" LOG_CI_START="-0.025803393734295153" LOG_EFFECT_SIZE="0.05406726145459858" MODIFIED="2012-09-14 16:53:57 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.09383283644815148" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.008804601195905544" WEIGHT="53.11686500345494"/>
<DICH_DATA CI_END="7.008207757739771" CI_START="1.4886687667725094" EFFECT_SIZE="3.23" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.8456069679748845" LOG_CI_START="0.17279807668732114" LOG_EFFECT_SIZE="0.5092025223311029" MODIFIED="2012-09-14 16:54:06 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.39521127320003957" STUDY_ID="STD-Tanghetti-2007" TOTAL_1="20" TOTAL_2="19" VAR="0.15619195046439632" WEIGHT="46.88313499654505"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2012-09-17 17:24:56 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>5% 5-FU versus cryotherapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 17:49:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="84.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="17" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 17:49:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>After treatment</NAME>
<DICH_DATA CI_END="1.8675928132207344" CI_START="1.063489408823457" EFFECT_SIZE="1.4093137254901962" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.27128219403121245" LOG_CI_START="0.02673316916828862" LOG_EFFECT_SIZE="0.14900768159975056" MODIFIED="2012-09-14 17:49:18 +0100" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.1436493077416778" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="24" TOTAL_2="25" VAR="0.020635123614663256" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-014.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 17:49:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="61.69747866367665" CI_START="1.125563733698063" EFFECT_SIZE="8.333333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7902674164671768" LOG_CI_START="0.05137009143757362" LOG_EFFECT_SIZE="0.9208187539523752" MODIFIED="2012-09-14 17:49:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1412" O_E="0.0" SE="1.0214368964029708" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="24" TOTAL_2="25" VAR="1.0433333333333332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2012-09-17 17:24:56 +0100" MODIFIED_BY="Maryse Paquet" NO="15">
<NAME>5% 5-FU versus 10% masoprocol</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-28 17:12:53 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Investigator Global Improvement Indices -cleared</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Masoprocol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Masoprocol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.261615944784074" CI_START="1.5687003712853806" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.9170650021949377" LOG_CI_START="0.19553999933963676" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2011-07-28 17:12:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="498" O_E="0.0" SE="0.42382735828357004" STUDY_ID="STD-Kulp_x002d_Shorten-1993" TOTAL_1="30" TOTAL_2="27" VAR="0.17962962962962964" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.02" MODIFIED="2011-07-28 17:15:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="17.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction of lesion counts</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Masoprocol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours masoprocol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.363949525023267" CI_START="-2.363949525023268" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="11.3" MODIFIED="2011-07-28 17:15:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="436" SD_1="7.3" SD_2="6.5" SE="1.971439044544496" STUDY_ID="STD-Kulp_x002d_Shorten-1993" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-015.03" MODIFIED="2011-08-31 15:59:56 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="48.088986119357756" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction of lesion counts</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Masoprocol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours masoprocol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.17598012670694" CI_START="11.824019873293059" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="97.6" MEAN_2="77.6" MODIFIED="2011-05-03 16:33:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="437" SD_1="5.6" SD_2="19.3" SE="4.171495084194418" STUDY_ID="STD-Kulp_x002d_Shorten-1993" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-015.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 20:01:31 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Masoprocol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours masoprocol</GRAPH_LABEL_2>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" MODIFIED="2011-09-22 20:01:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4407" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kulp_x002d_Shorten-1993" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2012-09-17 16:54:26 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>5% 5-FU versus carbon dioxide laser resurfacing</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2012-09-14 19:15:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction of lesion counts</NAME>
<GROUP_LABEL_1>5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Resurfacing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.156248867137311" CI_START="-20.756248867137305" EFFECT_SIZE="-8.799999999999997" ESTIMABLE="YES" MEAN_1="83.2" MEAN_2="92.0" MODIFIED="2012-09-14 19:15:31 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="12.5" SD_2="10.3" SE="6.100239066353603" STUDY_ID="STD-Hantash-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-17 16:54:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="485.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Resurfacing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours laser resurfacing</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2705151613018266" CI_START="0.009906696163152227" EFFECT_SIZE="0.18" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5146161667547782" LOG_CI_START="-2.004071156548166" LOG_EFFECT_SIZE="-0.744727494896694" MODIFIED="2012-09-17 16:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1135" O_E="0.0" SE="1.4794894014114763" STUDY_ID="STD-Hantash-2006" TOTAL_1="9" TOTAL_2="8" VAR="2.1888888888888887" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2012-09-17 17:19:33 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>5% 5-FU versus Er:YAG laser resurfacing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-17 17:19:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Er:YAG laser resurfacing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Er:YAG</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.10554543848733" CI_START="0.13206025174680158" EFFECT_SIZE="3.107142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8639503217183169" LOG_CI_START="-0.8792278791655183" LOG_EFFECT_SIZE="0.4923612212763993" MODIFIED="2012-09-17 17:14:53 +0100" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="27" TOTAL_2="28" VAR="2.5964696223316914" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-17 17:19:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="185.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="81" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Er:YAG laser resurfacing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Er:YAG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="12" I2="0.0" ID="CMP-017.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 17:15:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="2.6876850589569643" CI_START="1.003124568187392" EFFECT_SIZE="1.6419753086419753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.4293783770415615" LOG_CI_START="0.001354867135310511" LOG_EFFECT_SIZE="0.21536662208843604" MODIFIED="2012-09-17 17:15:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1411" O_E="0.0" SE="0.2514231284694767" STUDY_ID="STD-Ostertag-2006" TOTAL_1="27" TOTAL_2="28" VAR="0.06321358952937899" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-017.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 17:16:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="5.391052854685162" CI_START="0.049871789665905775" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7316735897372958" LOG_CI_START="-1.3021450466987943" LOG_EFFECT_SIZE="-0.2852357284807493" MODIFIED="2012-09-17 17:16:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1412" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Ostertag-2006" TOTAL_1="27" TOTAL_2="28" VAR="1.4272486772486772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-017.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 17:16:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="4.125891344433966" CI_START="0.010399731762978051" EFFECT_SIZE="0.20714285714285716" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6155177866196565" LOG_CI_START="-1.9829778621782204" LOG_EFFECT_SIZE="-0.6837300377792819" MODIFIED="2012-09-17 17:16:14 +0100" MODIFIED_BY="[Empty name]" ORDER="1413" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="27" TOTAL_2="28" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2012-09-17 20:41:59 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>5% 5-FU versus Trichloroacetic acid peel</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-018.01" MODIFIED="2012-09-17 20:41:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="32.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesions</NAME>
<GROUP_LABEL_1>5% 5-FU</GROUP_LABEL_1>
<GROUP_LABEL_2>Peel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours peel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.779242517789484" CI_START="-15.379242517789478" EFFECT_SIZE="-5.799999999999997" ESTIMABLE="YES" MEAN_1="83.2" MEAN_2="89.0" MODIFIED="2012-09-17 20:41:59 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="12.5" SD_2="6.6" SE="4.887458439720997" STUDY_ID="STD-Hantash-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="19">
<NAME>5% Imiquimod versus placebo</NAME>
<DICH_OUTCOME CHI2="38.50338125679595" CI_END="11.256860591721338" CI_START="4.246654869928088" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="6.914043813278523" ESTIMABLE="YES" EVENTS_1="694" EVENTS_2="62" I2="61.04238248594736" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="1.0514172876914996" LOG_CI_START="0.6280469668592018" LOG_EFFECT_SIZE="0.8397321272753507" METHOD="MH" MODIFIED="2011-08-03 22:33:34 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="7.598975883232884E-4" P_Q="0.5629976747338584" P_Z="7.546823280921092E-15" Q="5.802441803352352" RANDOM="YES" SCALE="397.9" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.44127613833489054" TOTALS="YES" TOTAL_1="1649" TOTAL_2="1231" WEIGHT="100.00000000000003" Z="7.774965060778701">
<NAME>Participant complete clearance-number of doses</NAME>
<GROUP_LABEL_1>5% imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.402069212193854" CI_START="0.39222559337180585" DF="0" EFFECT_SIZE="2.7586206896551726" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-019.01.01" LOG_CI_END="1.2878480494929079" LOG_CI_START="-0.40646407130693285" LOG_EFFECT_SIZE="0.4406919890929875" MODIFIED="2011-04-01 18:54:06 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.3079293601187304" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="4.31952183388158" Z="1.0195765187465278">
<NAME>9 or 18 doses (3 times/week for 3 weeks on, 4 weeks off)</NAME>
<DICH_DATA CI_END="19.402069212193854" CI_START="0.39222559337180585" EFFECT_SIZE="2.7586206896551726" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.2878480494929079" LOG_CI_START="-0.40646407130693285" LOG_EFFECT_SIZE="0.4406919890929875" MODIFIED="2011-03-31 18:58:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="186" O_E="0.0" SE="0.9952473267380879" STUDY_ID="STD-Chen-2003" TOTAL_1="29" TOTAL_2="10" VAR="0.9905172413793103" WEIGHT="4.31952183388158"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.679100908731258" CI_END="56.67457715807944" CI_START="1.0947901414505221" DF="2" EFFECT_SIZE="7.87697710695812" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="6" I2="70.05584992157405" ID="CMP-019.01.02" LOG_CI_END="1.753388288593917" LOG_CI_START="0.039330877948064835" LOG_EFFECT_SIZE="0.8963595832709909" MODIFIED="2011-08-03 22:20:52 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.035452989393332524" P_Z="0.04037312455041098" STUDIES="3" TAU2="2.055173797496193" TOTAL_1="283" TOTAL_2="260" WEIGHT="15.808047070938278" Z="2.0499109183822544">
<NAME>12-16 doses (2 times/week for 8 weeks or 3 times/week for 4 weeks)</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-03 22:20:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="129" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="2.0952935057479083"/>
<DICH_DATA CI_END="345.2128399784491" CI_START="6.778019564963419" EFFECT_SIZE="48.372093023255815" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="1" LOG_CI_END="2.538086940658707" LOG_CI_START="0.8311028181076427" LOG_EFFECT_SIZE="1.684594879383175" MODIFIED="2011-07-29 20:11:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="190" O_E="0.0" SE="1.0026909232941772" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="1.0053890876565295" WEIGHT="4.275116767975226"/>
<DICH_DATA CI_END="16.343698695804644" CI_START="2.6652473721374745" EFFECT_SIZE="6.6" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="5" LOG_CI_END="1.2133503472639167" LOG_CI_START="0.4257375238198207" LOG_EFFECT_SIZE="0.8195439355418687" MODIFIED="2011-07-29 20:11:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="681" O_E="0.0" SE="0.4626476712374162" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.21404286770140432" WEIGHT="9.437636797215143"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.19355871170358" CI_END="67.31592842727234" CI_START="1.1520377964103297" DF="1" EFFECT_SIZE="8.806275821746118" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="21" I2="91.0662906609456" ID="CMP-019.01.03" LOG_CI_END="1.8281178399977338" LOG_CI_START="0.061466727787860366" LOG_EFFECT_SIZE="0.944792283892797" MODIFIED="2011-07-29 15:37:12 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="8.208209353802731E-4" P_Z="0.03605122261374286" STUDIES="2" TAU2="1.9695000413704566" TOTAL_1="252" TOTAL_2="253" WEIGHT="20.474317848302395" Z="2.096349229910926">
<NAME>12 or 24 doses (3 times/week for 4 weeks on , 4 weeks off, 4 weeks on)</NAME>
<DICH_DATA CI_END="5.792814446292731" CI_START="2.3208829782297933" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="18" LOG_CI_END="0.7628896175303386" LOG_CI_START="0.36565324334678656" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2011-03-25 19:43:23 +0000" MODIFIED_BY="Maryse Paquet" ORDER="128" O_E="0.0" SE="0.23333861254718363" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.05444690810544468" WEIGHT="12.476044456058935"/>
<DICH_DATA CI_END="73.77832717564539" CI_START="7.709969642618348" EFFECT_SIZE="23.850129198966407" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="3" LOG_CI_END="1.8679288039590616" LOG_CI_START="0.8870526680549399" LOG_EFFECT_SIZE="1.3774907360070006" MODIFIED="2011-04-01 19:30:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="191" O_E="0.0" SE="0.576171497645261" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="0.33197359469878296" WEIGHT="7.998273392243459"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.082707248176337" CI_START="0.07087663066780928" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.01.04" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-08-03 22:20:55 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="1.0" P_Z="0.8476292526438887" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="2.3051787588438732" Z="0.19214420097248297">
<NAME>24 doses (3 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="25.082707248176337" CI_START="0.07087663066780928" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-08-03 22:20:55 +0100" MODIFIED_BY="Maryse Paquet" ORDER="214" O_E="0.0" SE="1.4972196454317137" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.2416666666666667" WEIGHT="2.3051787588438732"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.2626467237324235" CI_END="16.577714343342855" CI_START="3.056294290845061" DF="3" EFFECT_SIZE="7.118031589057402" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="13" I2="52.096930701336845" ID="CMP-019.01.05" LOG_CI_END="1.2195246518776213" LOG_CI_START="0.485195170170839" LOG_EFFECT_SIZE="0.8523599110242301" MODIFIED="2011-08-02 16:17:27 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0995082072407878" P_Z="5.3649278790352595E-6" STUDIES="4" TAU2="0.36434218172389454" TOTAL_1="596" TOTAL_2="292" WEIGHT="29.6687200358136" Z="4.549986808619853">
<NAME>32-36 doses (2 times/ week for 16 weeks or 3 times/ week for 12 weeks)</NAME>
<DICH_DATA CI_END="12.199011964195824" CI_START="1.3854592992864063" EFFECT_SIZE="4.111111111111111" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="3" LOG_CI_END="1.0863246572424354" LOG_CI_START="0.1415937720129048" LOG_EFFECT_SIZE="0.6139592146276701" MODIFIED="2011-08-02 16:17:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="320" O_E="0.0" SE="0.5549395984771297" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="180" TOTAL_2="30" VAR="0.307957957957958" WEIGHT="8.254646706394992"/>
<DICH_DATA CI_END="10.82811436459627" CI_START="1.2211858917100382" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" LOG_CI_END="1.0345528340628938" LOG_CI_START="0.08678177827658107" LOG_EFFECT_SIZE="0.5606673061697374" MODIFIED="2011-08-02 16:17:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="321" O_E="0.0" SE="0.5567254097112704" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="176" TOTAL_2="30" VAR="0.3099431818181818" WEIGHT="8.23283240907911"/>
<DICH_DATA CI_END="29.965738405936484" CI_START="6.7706448249034485" EFFECT_SIZE="14.243853820598007" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="7" LOG_CI_END="1.4766249839071064" LOG_CI_START="0.8306300321358802" LOG_EFFECT_SIZE="1.1536275080214935" MODIFIED="2011-07-29 20:13:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="680" O_E="0.0" SE="0.37946063239700184" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.14399037153913255" WEIGHT="10.567258951163668"/>
<DICH_DATA CI_END="301.01190838007875" CI_START="1.30848584896475" EFFECT_SIZE="19.846153846153847" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" LOG_CI_END="2.478583677126917" LOG_CI_START="0.11676903018586952" LOG_EFFECT_SIZE="1.2976763536563933" MODIFIED="2011-07-29 20:13:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9134" O_E="0.0" SE="1.3873416147842266" STUDY_ID="STD-Stockfleth-2002" TOTAL_1="25" TOTAL_2="11" VAR="1.9247167561121052" WEIGHT="2.613981969175834"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.268218240049002" CI_START="0.03470975650366249" DF="0" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.01.06" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-03 22:21:04 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="1.0" P_Z="0.8716501947710975" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="2.096009336553226" Z="0.1615627478811938">
<NAME>40 doses (5 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="17.268218240049002" CI_START="0.03470975650366249" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-03 22:21:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="215" O_E="0.0" SE="1.5841112972738176" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.5094086021505375" WEIGHT="2.096009336553226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.436995696781914" CI_END="33.148289593162694" CI_START="3.586097424350336" DF="2" EFFECT_SIZE="10.902889338687237" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="21" I2="63.214979162411815" ID="CMP-019.01.07" LOG_CI_END="1.520461124311978" LOG_CI_START="0.5546220839665472" LOG_EFFECT_SIZE="1.0375416041392627" MODIFIED="2011-07-29 15:37:12 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.06597398110786634" P_Z="2.543124985250135E-5" STUDIES="3" TAU2="0.5690438497523724" TOTAL_1="400" TOTAL_2="395" WEIGHT="23.023949855387393" Z="4.21093803755867">
<NAME>48 doses (3 times/ week for 16 weeks)</NAME>
<DICH_DATA CI_END="99.46303741231105" CI_START="0.41395891561637377" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9976617176275944" LOG_CI_START="-0.38304275937788035" LOG_EFFECT_SIZE="0.8073094791248571" MODIFIED="2011-03-25 20:53:45 +0000" MODIFIED_BY="Maryse Paquet" ORDER="132" O_E="0.0" SE="1.3984375944702379" STUDY_ID="STD-Ooi-2006" TOTAL_1="11" TOTAL_2="6" VAR="1.9556277056277054" WEIGHT="2.5802715369082208"/>
<DICH_DATA CI_END="10.676175038069365" CI_START="4.22338149932474" EFFECT_SIZE="6.714876033057851" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="18" LOG_CI_END="1.0284156855205355" LOG_CI_START="0.6256603131483883" LOG_EFFECT_SIZE="0.8270379993344619" MODIFIED="2011-04-19 15:56:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9132" O_E="0.0" SE="0.23658049940264606" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.055970332697605416" WEIGHT="12.43782133323257"/>
<DICH_DATA CI_END="81.79979509337818" CI_START="8.569565013351305" EFFECT_SIZE="26.476190476190474" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="3" LOG_CI_END="1.9127522157749095" LOG_CI_START="0.9329587779213669" LOG_EFFECT_SIZE="1.4228554968481382" ORDER="9133" O_E="0.0" SE="0.5755355154509089" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3312411295453433" WEIGHT="8.0058569852466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.290675388552945" CI_START="0.06854203662477795" DF="0" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.01.08" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-03 22:33:34 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="1.0" P_Z="0.8648505641286888" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="2.3042552602796706" Z="0.17020290898569543">
<NAME>56 doses (7 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-03 22:33:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="212" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="2.3042552602796706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-05 10:49:24 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance in immunosuppressed participants</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="286.4474398742248" CI_START="1.1948090726531793" EFFECT_SIZE="18.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.4570449450933443" LOG_CI_START="0.0772985117126834" LOG_EFFECT_SIZE="1.2671717284030137" MODIFIED="2011-03-29 19:48:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="166" O_E="0.0" SE="1.3978748349026295" STUDY_ID="STD-Ulrich-2007" TOTAL_1="29" TOTAL_2="14" VAR="1.954054054054054" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.59824187267914" CI_END="5.7059511566889665" CI_START="3.1895218491397728" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="4.266058588953487" ESTIMABLE="YES" EVENTS_1="631" EVENTS_2="116" I2="75.36839149005228" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="0.7563280497481082" LOG_CI_START="0.5037255815384738" LOG_EFFECT_SIZE="0.630026815643291" METHOD="MH" MODIFIED="2011-12-05 18:31:08 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.3289873421751253E-5" P_Q="0.6760711846682166" P_Z="1.4152912325322942E-22" Q="4.8679746586901045" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3165691068351413" TOTALS="SUB" TOTAL_1="1128" TOTAL_2="1024" WEIGHT="800.0" Z="9.776863042609095">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>5% imiquimod cream</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.386825729963638" CI_START="0.9122524071574488" DF="0" EFFECT_SIZE="2.413793103448276" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" I2="0.0" ID="CMP-019.03.01" LOG_CI_END="0.805285066220972" LOG_CI_START="-0.03988498199037048" LOG_EFFECT_SIZE="0.38270004211530073" MODIFIED="2011-04-01 18:55:11 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.07590184081577885" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="100.0" Z="1.7749760560383407">
<NAME>9 or 18 doses (3 times/ week for 3 weeks on, 4 weeks off. 3 weeks on)</NAME>
<DICH_DATA CI_END="6.386825729963638" CI_START="0.9122524071574488" EFFECT_SIZE="2.413793103448276" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="0.805285066220972" LOG_CI_START="-0.03988498199037048" LOG_EFFECT_SIZE="0.38270004211530073" ORDER="9128" O_E="0.0" SE="0.4964570699785544" STUDY_ID="STD-Chen-2003" TOTAL_1="29" TOTAL_2="10" VAR="0.24646962233169126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.039714299344271446" CI_END="5.338447010529787" CI_START="1.531974954030382" DF="1" EFFECT_SIZE="2.859784452288319" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="11" I2="0.0" ID="CMP-019.03.02" LOG_CI_END="0.7274149362702182" LOG_CI_START="0.1852516651560406" LOG_EFFECT_SIZE="0.45633330071312944" MODIFIED="2011-08-03 22:47:27 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.8420403213317753" P_Z="9.690436682532903E-4" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="130" WEIGHT="100.00000000000001" Z="3.2993634279429567">
<NAME>12-16 doses (3 times/week for 4 weeks or 2 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="59.00590880838229" CI_START="0.23832358968772135" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7708955037503464" LOG_CI_START="-0.6228329682949085" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2011-08-03 22:47:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="682" O_E="0.0" SE="1.40608795362642" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="1.9770833333333333" WEIGHT="5.129917902293742"/>
<DICH_DATA CI_END="5.3491314301358965" CI_START="1.4847548361938094" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="11" LOG_CI_END="0.7282832688020163" LOG_CI_START="0.1716547485500791" LOG_EFFECT_SIZE="0.44996900867604767" MODIFIED="2011-03-25 20:14:36 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;email sent to DR. Jorizzo to confirm ITT numbers&lt;/p&gt;" NOTES_MODIFIED="2011-03-25 20:14:36 +0000" NOTES_MODIFIED_BY="Maryse Paquet" ORDER="130" O_E="0.0" SE="0.32696634815160097" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.10690699282359392" WEIGHT="94.87008209770627"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.95480256638502" CI_END="55.10401410889777" CI_START="0.7041488279956447" DF="1" EFFECT_SIZE="6.229079141625657" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="36" I2="95.44518791742131" ID="CMP-019.03.03" LOG_CI_END="1.7411832366348354" LOG_CI_START="-0.15233553922979726" LOG_EFFECT_SIZE="0.794423848702519" MODIFIED="2011-12-05 18:31:08 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="2.7915577807124947E-6" P_Z="0.1000519688599183" STUDIES="2" TAU2="2.364243363497866" TOTAL_1="252" TOTAL_2="253" WEIGHT="100.0" Z="1.6446017348897386">
<NAME>12 or 24 doses (3 times/week for 4 weeks on, 4 weeks off)</NAME>
<DICH_DATA CI_END="40.82756644944829" CI_START="7.188721063334205" EFFECT_SIZE="17.131782945736433" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="5" LOG_CI_END="1.610953494322377" LOG_CI_START="0.8566516324493464" LOG_EFFECT_SIZE="1.2338025633858618" MODIFIED="2011-04-01 19:32:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="193" O_E="0.0" SE="0.44308064751865334" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="0.19632046020554914" WEIGHT="48.31464918096535"/>
<DICH_DATA CI_END="3.384382543903408" CI_START="1.7294965210513698" EFFECT_SIZE="2.4193548387096775" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="31" LOG_CI_END="0.5294794463636144" LOG_CI_START="0.2379196927512403" LOG_EFFECT_SIZE="0.3836995695574274" MODIFIED="2011-12-05 18:31:08 +0000" MODIFIED_BY="Maryse Paquet" NOTES="&lt;p&gt;email sent to Dr. Jorizzo to confirm ITT numbers&lt;/p&gt;" NOTES_MODIFIED="2011-12-05 18:31:08 +0000" NOTES_MODIFIED_BY="Maryse Paquet" ORDER="131" O_E="0.0" SE="0.17126364251596526" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.029331235247836346" WEIGHT="51.685350819034646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.84829044595074" CI_START="0.25458130820216873" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-019.03.04" LOG_CI_END="1.7982934688161243" LOG_CI_START="-0.5941734861601995" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-08-05 15:46:26 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="1.0" P_Z="0.3239158846698811" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="100.0" Z="0.9864427987863107">
<NAME>24 doses (3 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="62.84829044595074" CI_START="0.25458130820216873" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7982934688161243" LOG_CI_START="-0.5941734861601995" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-08-03 22:47:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="217" O_E="0.0" SE="1.4053469322555197" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="1.975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.3260286348634756" CI_START="3.441119555586631" DF="0" EFFECT_SIZE="5.02093023255814" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="26" I2="0.0" ID="CMP-019.03.05" LOG_CI_END="0.8648686118358826" LOG_CI_START="0.5366997616734059" LOG_EFFECT_SIZE="0.7007841867546443" MODIFIED="2011-08-05 15:46:26 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="1.0" P_Z="5.724654203444887E-17" STUDIES="1" TAU2="0.0" TOTAL_1="215" TOTAL_2="221" WEIGHT="100.0" Z="8.370762589406441">
<NAME>32 doses (2 times/week for 16 weeks)</NAME>
<DICH_DATA CI_END="7.3260286348634756" CI_START="3.441119555586631" EFFECT_SIZE="5.02093023255814" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="26" LOG_CI_END="0.8648686118358826" LOG_CI_START="0.5366997616734059" LOG_EFFECT_SIZE="0.7007841867546443" ORDER="9131" O_E="0.0" SE="0.19276800704744612" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.03715950454104423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.508795600047165" CI_START="0.21033818163420098" DF="0" EFFECT_SIZE="3.3548387096774195" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-019.03.06" LOG_CI_END="1.7284251757894264" LOG_CI_START="-0.6770818848604111" LOG_EFFECT_SIZE="0.5256716454645077" MODIFIED="2011-08-05 15:46:26 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="1.0" P_Z="0.3916573444680892" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="0.8566156463710506">
<NAME>40 doses (5 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="53.508795600047165" CI_START="0.21033818163420098" EFFECT_SIZE="3.3548387096774195" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.7284251757894264" LOG_CI_START="-0.6770818848604111" LOG_EFFECT_SIZE="0.5256716454645077" MODIFIED="2011-08-03 22:47:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="218" O_E="0.0" SE="1.4130067548777057" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9965880893300247" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.382997776080964" CI_END="31.158177851476456" CI_START="2.294963265396359" DF="1" EFFECT_SIZE="8.456173696526399" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="40" I2="89.34242526893495" ID="CMP-019.03.07" LOG_CI_END="1.4935720519470028" LOG_CI_START="0.3607757383424141" LOG_EFFECT_SIZE="0.9271738951447085" MODIFIED="2011-08-05 15:46:26 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.002190084353976607" P_Z="0.0013347932665712674" STUDIES="2" TAU2="0.7956923926884223" TOTAL_1="389" TOTAL_2="389" WEIGHT="100.0" Z="3.208392223853339">
<NAME>48 doses (3 times/ week for 16 weeks)</NAME>
<DICH_DATA CI_END="6.527174434197776" CI_START="3.3980489330908292" EFFECT_SIZE="4.709528439474964" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="34" LOG_CI_END="0.8147252190690852" LOG_CI_START="0.5312296285702002" LOG_EFFECT_SIZE="0.6729774238196428" ORDER="9129" O_E="0.0" SE="0.16652671318485057" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.027731146204149484" WEIGHT="53.77192451241718"/>
<DICH_DATA CI_END="36.775932205961645" CI_START="7.588229732670108" EFFECT_SIZE="16.705215419501133" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="6" LOG_CI_END="1.5655636901493692" LOG_CI_START="0.8801404706247218" LOG_EFFECT_SIZE="1.2228520803870455" MODIFIED="2011-03-21 17:25:16 +0000" MODIFIED_BY="Maryse Paquet" ORDER="9130" O_E="0.0" SE="0.4026209920484346" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.16210366323806566" WEIGHT="46.22807548758282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.555000569740081E-32" CI_END="90.3422126359578" CI_START="0.3899613232241787" DF="0" EFFECT_SIZE="5.935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="100.0" ID="CMP-019.03.08" LOG_CI_END="1.955890722973431" LOG_CI_START="-0.40897846462290344" LOG_EFFECT_SIZE="0.7734561291752637" MODIFIED="2011-08-05 15:46:26 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Z="0.19982336099246842" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="1.2820549777183172">
<NAME>56 doses (7 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="90.3422126359578" CI_START="0.38996132322417854" EFFECT_SIZE="5.935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.955890722973431" LOG_CI_START="-0.4089784646229036" LOG_EFFECT_SIZE="0.7734561291752637" MODIFIED="2011-08-03 22:47:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="219" O_E="0.0" SE="1.3891358670853624" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9296984572230014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-04-04 15:37:22 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance in immunosuppressed participants</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="360.93942953936016" CI_START="1.5300351106134222" EFFECT_SIZE="23.5" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="0" LOG_CI_END="2.5574343276012286" LOG_CI_START="0.18470139694224444" LOG_EFFECT_SIZE="1.3710678622717363" MODIFIED="2011-03-29 19:50:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="167" O_E="0.0" SE="1.3937550686865183" STUDY_ID="STD-Ulrich-2007" TOTAL_1="29" TOTAL_2="14" VAR="1.9425531914893617" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-019.05" MODIFIED="2011-07-29 20:46:15 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="13.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="3" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.446290503241746" CI_START="-1.0462905032417464" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="0.6" MODIFIED="2011-04-21 20:15:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="449" SD_1="2.1" SD_2="2.6" SE="1.6563010998406458" STUDY_ID="STD-Ortonne-2010" TOTAL_1="9" TOTAL_2="3" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.4799653140155042" CI_END="3.954918021713037" CI_START="1.5474566125754534" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="2.473876319643662" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-019.06" LOG_CI_END="0.59713748578903" LOG_CI_START="0.1896184811601879" LOG_EFFECT_SIZE="0.393377983474609" METHOD="MH" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.9677742738914412" P_Q="0.9480761036506717" P_Z="1.543865281875584E-4" Q="1.6612150456973873" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1338" TOTAL_2="951" WEIGHT="700.0" Z="3.7839053941714416">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>5% imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5% imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.909922646603808E-33" CI_END="16.739020923288855" CI_START="0.033604115950258404" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-019.06.01" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.8559215720794137" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="100.0" Z="0.18156824422312373">
<NAME>12-16 doses (2 times/week for 8 weeks or 3 times/week for 4 weeks)</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-09-23 14:54:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2792" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7964657591389658" CI_END="8.231105082248567" CI_START="0.3124293395090291" DF="1" EFFECT_SIZE="1.6036329767987227" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-019.06.02" LOG_CI_END="0.9154581461362236" LOG_CI_START="-0.5052481892999573" LOG_EFFECT_SIZE="0.20510497841813316" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.37215220487672673" P_Z="0.5714526599168834" STUDIES="2" TAU2="0.0" TOTAL_1="252" TOTAL_2="253" WEIGHT="100.0" Z="0.5659133921240462">
<NAME>12 or 24 doses (3 times/week for 4 weeks on , 4 weeks off, 4 weeks on)</NAME>
<DICH_DATA CI_END="103.93374392479872" CI_START="0.24425267209583362" EFFECT_SIZE="5.038461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0167565718219564" LOG_CI_START="-0.6121606764520638" LOG_EFFECT_SIZE="0.7022979476849462" MODIFIED="2011-09-23 14:56:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2796" O_E="0.0" SE="1.544239004986415" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="2.384674104521433" WEIGHT="29.20483807396004"/>
<DICH_DATA CI_END="6.986390280347705" CI_START="0.14313543330279438" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8442528429487831" LOG_CI_START="-0.8442528429487831" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 14:57:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2795" O_E="0.0" SE="0.9918365981341755" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.9837398373983739" WEIGHT="70.79516192603997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.082707248176337" CI_START="0.07087663066780928" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.06.03" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.8476292526438887" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="100.0" Z="0.19214420097248297">
<NAME>24 doses (3 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="25.082707248176337" CI_START="0.07087663066780928" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-09-23 14:54:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2797" O_E="0.0" SE="1.4972196454317137" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.2416666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6405720465131903" CI_END="6.565368875238017" CI_START="0.7954670668943542" DF="2" EFFECT_SIZE="2.285286573334966" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="4" I2="0.0" ID="CMP-019.06.04" LOG_CI_END="0.8172591319456604" LOG_CI_START="-0.09937779585664784" LOG_EFFECT_SIZE="0.3589406680445063" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.7259414231293548" P_Z="0.12478814792763844" STUDIES="3" TAU2="0.0" TOTAL_1="577" TOTAL_2="281" WEIGHT="100.0" Z="1.534982413681911">
<NAME>32-36 doses (2 times/ week for 16 weeks or 3 times/ week for 12 weeks)</NAME>
<DICH_DATA CI_END="17.124310317454515" CI_START="0.7558413146186375" EFFECT_SIZE="3.597674418604651" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2336130892823967" LOG_CI_START="-0.12156937304283465" LOG_EFFECT_SIZE="0.556021858119781" MODIFIED="2011-10-20 14:03:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2800" O_E="0.0" SE="0.7960408866312189" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.6336810931886171" WEIGHT="45.75084852500084"/>
<DICH_DATA CI_END="13.463604515608354" CI_START="0.24152625879029196" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.1291613460447456" LOG_CI_START="-0.6170356457498295" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-09-23 15:00:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2798" O_E="0.0" SE="1.0257247567946484" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="183" TOTAL_2="30" VAR="1.0521112767014404" WEIGHT="27.555495649208137"/>
<DICH_DATA CI_END="10.338066197295657" CI_START="0.17389100309417385" EFFECT_SIZE="1.3407821229050279" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.0144393087397952" LOG_CI_START="-0.7597228872763696" LOG_EFFECT_SIZE="0.12735821073171283" MODIFIED="2011-09-23 15:00:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2799" O_E="0.0" SE="1.0421516561844038" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="179" TOTAL_2="30" VAR="1.0860800744878956" WEIGHT="26.693655825791023"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.5982949163927" CI_START="0.31801806291585943" DF="0" EFFECT_SIZE="4.903225806451613" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-019.06.05" LOG_CI_END="1.8785120003060654" LOG_CI_START="-0.49754821208506556" LOG_EFFECT_SIZE="0.6904818941104999" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="1.0" P_Z="0.25464933823293834" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="1.1391290821470184">
<NAME>40 doses (5 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="75.5982949163927" CI_START="0.31801806291585943" EFFECT_SIZE="4.903225806451613" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.8785120003060654" LOG_CI_START="-0.49754821208506556" LOG_EFFECT_SIZE="0.6904818941104999" MODIFIED="2011-09-23 15:01:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2802" O_E="0.0" SE="1.3957095304462916" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9480050933786077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3674424557611996" CI_END="4.896573377809891" CI_START="1.4766159516966018" DF="1" EFFECT_SIZE="2.6889325685719596" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" I2="0.0" ID="CMP-019.06.06" LOG_CI_END="0.689892267029411" LOG_CI_START="0.16926755574051042" LOG_EFFECT_SIZE="0.4295799113849607" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.5444019268073486" P_Z="0.001218873322295291" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="389" WEIGHT="100.0" Z="3.2344263979018746">
<NAME>48 doses (3 times/ week for 16 weeks)</NAME>
<DICH_DATA CI_END="4.886573763002999" CI_START="1.15531523022227" EFFECT_SIZE="2.37603305785124" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.6890044588462881" LOG_CI_START="0.06270049857211038" LOG_EFFECT_SIZE="0.37585247870919924" MODIFIED="2011-09-23 15:01:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2804" O_E="0.0" SE="0.3678940465196556" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.13534602946460655" WEIGHT="69.100189774211"/>
<DICH_DATA CI_END="10.42367546776029" CI_START="1.2062479407362081" EFFECT_SIZE="3.545918367346939" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0180208815269625" LOG_CI_START="0.08143658494031325" LOG_EFFECT_SIZE="0.5497287332336379" MODIFIED="2011-09-23 15:02:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2805" O_E="0.0" SE="0.550154251982037" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3026697009739147" WEIGHT="30.899810225789"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.96917233319923" CI_START="0.3539797498509474" DF="0" EFFECT_SIZE="5.419354838709678" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-019.06.07" LOG_CI_END="1.9189167577673958" LOG_CI_START="-0.4510215819842153" LOG_EFFECT_SIZE="0.7339475878915902" MODIFIED="2012-10-01 15:39:38 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="1.0" P_Z="0.22476119582301257" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="1.2139647810063534">
<NAME>56 doses (7 times/week for 8 weeks)</NAME>
<DICH_DATA CI_END="82.96917233319923" CI_START="0.3539797498509474" EFFECT_SIZE="5.419354838709677" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.9189167577673958" LOG_CI_START="-0.4510215819842153" LOG_EFFECT_SIZE="0.7339475878915901" MODIFIED="2011-09-23 15:03:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2806" O_E="0.0" SE="1.3921135121540795" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9379800307219663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-019.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 15:06:57 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events in immunosuppressed participants</NAME>
<GROUP_LABEL_1>5% imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5% imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-019.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-23 15:06:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>48 doses (3 times/ week for 16 weeks)</NAME>
<DICH_DATA CI_END="9.767574604281585" CI_START="0.09544063712521597" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9897867370305904" LOG_CI_START="-1.0202666701440641" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2011-09-23 15:06:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2822" O_E="0.0" SE="1.1807153212992278" STUDY_ID="STD-Ulrich-2010" TOTAL_1="29" TOTAL_2="14" VAR="1.3940886699507389" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:06 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:11 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>12-16 doses</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-05 13:55:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="906" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:11 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>24-28 doses</NAME>
<DICH_DATA CI_END="32.55296360847741" CI_START="0.10703923877262678" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.5125905326958826" LOG_CI_START="-0.9704569881228068" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2011-08-05 13:55:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="907" O_E="0.0" SE="1.4585544050123576" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.1273809523809524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:11 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>40 doses</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 13:55:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="908" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:11 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>56 doses</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:55:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="909" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:07 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: "flu" or "cold"</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:08 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>12-16 doses</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-05 14:06:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="910" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:08 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>24-28 doses</NAME>
<DICH_DATA CI_END="32.55296360847741" CI_START="0.10703923877262678" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.5125905326958826" LOG_CI_START="-0.9704569881228068" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2011-08-05 14:06:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="911" O_E="0.0" SE="1.4585544050123576" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.1273809523809524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:08 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>40 doses</NAME>
<DICH_DATA CI_END="17.268218240049002" CI_START="0.03470975650366249" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-05 14:06:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="912" O_E="0.0" SE="1.5841112972738176" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.5094086021505375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:08 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>56 doses</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 14:06:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="913" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:07 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:04 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>12-16 doses</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-05 13:58:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="914" O_E="0.0" SE="0.0" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:04 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>24-28 doses</NAME>
<DICH_DATA CI_END="17.831958554094268" CI_START="0.03589061729021652" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2511990460649878" LOG_CI_START="-1.4450190720811007" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-08-05 13:58:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="915" O_E="0.0" SE="1.5837718690939466" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.5083333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:04 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>40 doses</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:58:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="916" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:04 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>56 doses</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:58:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="917" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:07 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: nausea</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:01 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>12-16 doses</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-05 14:08:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="918" O_E="0.0" SE="0.0" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-019.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:01 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>24-28 doses</NAME>
<DICH_DATA CI_END="17.831958554094268" CI_START="0.03589061729021652" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2511990460649878" LOG_CI_START="-1.4450190720811007" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-08-05 14:08:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="919" O_E="0.0" SE="1.5837718690939466" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.5083333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-019.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:01 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>40 doses</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 14:08:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="920" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-019.11.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:57:01 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>56 doses</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 14:08:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="921" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:07 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:58 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>12-16 doses</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-05 14:00:26 +0100" MODIFIED_BY="Maryse Paquet" ORDER="930" O_E="0.0" SE="0.0" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-019.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:58 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>24-28 doses</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-05 14:00:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="931" O_E="0.0" SE="0.0" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-019.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:58 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>40 doses</NAME>
<DICH_DATA CI_END="38.82808628343901" CI_START="0.1389298667438743" EFFECT_SIZE="2.3225806451612905" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.589145986038615" LOG_CI_START="-0.8572043808446234" LOG_EFFECT_SIZE="0.3659708025969958" MODIFIED="2011-08-05 14:00:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="932" O_E="0.0" SE="1.4369983151368317" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.0649641577060933" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-019.12.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:58 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>56 doses</NAME>
<DICH_DATA CI_END="38.82808628343901" CI_START="0.1389298667438743" EFFECT_SIZE="2.3225806451612905" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.589145986038615" LOG_CI_START="-0.8572043808446234" LOG_EFFECT_SIZE="0.3659708025969958" MODIFIED="2011-08-05 14:00:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="933" O_E="0.0" SE="1.4369983151368317" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.0649641577060933" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7238697724373813" CI_END="5.584081594861633" CI_START="1.8649468437005507" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2270753547606446" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="61" I2="73.14621452657644" I2_Q="72.32627320135184" ID="CMP-019.13" LOG_CI_END="0.7469517555927658" LOG_CI_START="0.27066645769080444" LOG_EFFECT_SIZE="0.5088091066417851" METHOD="MH" MODIFIED="2011-10-13 13:52:34 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.05364016773829239" P_Q="0.05731133286354717" P_Z="2.8191268667719086E-5" Q="3.6135357094327065" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11672144403125696" TOTALS="YES" TOTAL_1="348" TOTAL_2="335" WEIGHT="99.99999999999999" Z="4.187605741419178">
<NAME>Cosmetic outcome: decrease in roughness/dryness/scaliness of the skin</NAME>
<GROUP_LABEL_1>5% Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.369644953573297" CI_START="1.9126731588164816" DF="0" EFFECT_SIZE="2.538706256627784" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="46" I2="0.0" ID="CMP-019.13.01" LOG_CI_END="0.5275841433558786" LOG_CI_START="0.2816407633102484" LOG_EFFECT_SIZE="0.4046124533330635" MODIFIED="2011-08-05 15:49:08 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="1.1270292601194414E-10" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="210" WEIGHT="56.88720989610032" Z="6.448848804810821">
<NAME>32-36 doses</NAME>
<DICH_DATA CI_END="3.369644953573297" CI_START="1.9126731588164816" EFFECT_SIZE="2.538706256627784" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="46" LOG_CI_END="0.5275841433558786" LOG_CI_START="0.2816407633102484" LOG_EFFECT_SIZE="0.4046124533330635" MODIFIED="2011-08-02 15:46:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="973" O_E="0.0" SE="0.14446835887816903" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="205" TOTAL_2="210" VAR="0.020871106716951443" WEIGHT="56.88720989610032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.295072237516239" CI_START="2.688827992613226" DF="0" EFFECT_SIZE="4.428904428904429" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="15" I2="0.0" ID="CMP-019.13.02" LOG_CI_END="0.8630295967365794" LOG_CI_START="0.42956302079963" LOG_EFFECT_SIZE="0.6462963087681047" MODIFIED="2011-08-05 15:49:08 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="5.078134788678994E-9" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="125" WEIGHT="43.11279010389966" Z="5.844591296519787">
<NAME>48 doses</NAME>
<DICH_DATA CI_END="7.295072237516239" CI_START="2.688827992613226" EFFECT_SIZE="4.428904428904429" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="15" LOG_CI_END="0.8630295967365794" LOG_CI_START="0.42956302079963" LOG_EFFECT_SIZE="0.6462963087681047" MODIFIED="2011-08-02 15:46:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="974" O_E="0.0" SE="0.25462041239952027" STUDY_ID="STD-Szeimies-2004" TOTAL_1="143" TOTAL_2="125" VAR="0.06483155441050178" WEIGHT="43.11279010389966"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2012-09-17 20:38:33 +0100" MODIFIED_BY="Maryse Paquet" NO="20">
<NAME>Imiquimod versus placebo: different concentrations</NAME>
<DICH_OUTCOME CHI2="15.573080064098649" CI_END="9.00318524654624" CI_START="5.026291645658294" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="6.727007863012304" ESTIMABLE="YES" EVENTS_1="721" EVENTS_2="60" I2="16.522615009412885" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.9543961861353121" LOG_CI_START="0.7012476845003559" LOG_EFFECT_SIZE="0.827821935317834" METHOD="MH" MODIFIED="2011-11-07 13:43:52 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.2729536899443218" P_Q="0.41944655131904185" P_Z="1.2905504851174359E-37" Q="1.7376400444979945" RANDOM="YES" SCALE="397.9" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04861723323297041" TOTALS="YES" TOTAL_1="1917" TOTAL_2="1170" WEIGHT="99.99999999999997" Z="12.818572247959583">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.13862690120339" CI_END="12.788776710779345" CI_START="4.634136205528478" DF="8" EFFECT_SIZE="7.698372112326213" ESTIMABLE="YES" EVENTS_1="476" EVENTS_2="35" I2="39.11083661819131" ID="CMP-020.01.01" LOG_CI_END="1.1068290047471245" LOG_CI_START="0.6659687943309752" LOG_EFFECT_SIZE="0.8863988995390499" MODIFIED="2011-10-28 19:53:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.1071682007808481" P_Z="3.2359107443069873E-15" STUDIES="9" TAU2="0.19784509441001555" TOTAL_1="1145" TOTAL_2="726" WEIGHT="56.18639014795996" Z="7.88145483754383">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="19.402069212193854" CI_START="0.39222559337180585" EFFECT_SIZE="2.7586206896551726" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.2878480494929079" LOG_CI_START="-0.40646407130693285" LOG_EFFECT_SIZE="0.4406919890929875" MODIFIED="2011-10-28 19:53:05 +0100" MODIFIED_BY="Maryse Paquet" ORDER="695" O_E="0.0" SE="0.9952473267380879" STUDY_ID="STD-Chen-2003" TOTAL_1="29" TOTAL_2="10" VAR="0.9905172413793103" WEIGHT="2.1279144956388745"/>
<DICH_DATA CI_END="55.63902124257416" CI_START="0.18671490662660137" EFFECT_SIZE="3.2231404958677685" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.745379481623965" LOG_CI_START="-0.7288210082038667" LOG_EFFECT_SIZE="0.5082792367100492" MODIFIED="2011-07-29 20:16:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="685" O_E="0.0" SE="1.453357615214818" STUDY_ID="STD-Gebauer-2009" TOTAL_1="120" TOTAL_2="29" VAR="2.112248357702903" WEIGHT="1.023288686126882"/>
<DICH_DATA CI_END="10.676175038069365" CI_START="4.22338149932474" EFFECT_SIZE="6.714876033057851" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="18" LOG_CI_END="1.0284156855205355" LOG_CI_START="0.6256603131483883" LOG_EFFECT_SIZE="0.8270379993344619" MODIFIED="2011-07-29 20:16:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="564" O_E="0.0" SE="0.23658049940264606" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.055970332697605416" WEIGHT="21.14199036731884"/>
<DICH_DATA CI_END="29.965738405936484" CI_START="6.7706448249034485" EFFECT_SIZE="14.243853820598007" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="7" LOG_CI_END="1.4766249839071064" LOG_CI_START="0.8306300321358802" LOG_EFFECT_SIZE="1.1536275080214935" MODIFIED="2011-07-29 20:16:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="555" O_E="0.0" SE="0.37946063239700184" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.14399037153913255" WEIGHT="11.48028040773302"/>
<DICH_DATA CI_END="12.199011964195824" CI_START="1.3854592992864063" EFFECT_SIZE="4.111111111111111" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="3" LOG_CI_END="1.0863246572424354" LOG_CI_START="0.1415937720129048" LOG_EFFECT_SIZE="0.6139592146276701" MODIFIED="2011-08-02 16:19:26 +0100" MODIFIED_BY="Maryse Paquet" ORDER="563" O_E="0.0" SE="0.5549395984771297" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="180" TOTAL_2="30" VAR="0.307957957957958" WEIGHT="6.201186639093956"/>
<DICH_DATA CI_END="10.82811436459627" CI_START="1.2211858917100382" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" LOG_CI_END="1.0345528340628938" LOG_CI_START="0.08678177827658107" LOG_EFFECT_SIZE="0.5606673061697374" MODIFIED="2011-08-02 16:19:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="562" O_E="0.0" SE="0.5567254097112704" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="176" TOTAL_2="30" VAR="0.3099431818181818" WEIGHT="6.166852833239024"/>
<DICH_DATA CI_END="99.46303741231105" CI_START="0.41395891561637377" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9976617176275944" LOG_CI_START="-0.38304275937788035" LOG_EFFECT_SIZE="0.8073094791248571" MODIFIED="2011-07-29 20:16:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="683" O_E="0.0" SE="1.3984375944702379" STUDY_ID="STD-Ooi-2006" TOTAL_1="11" TOTAL_2="6" VAR="1.9556277056277054" WEIGHT="1.103253034882314"/>
<DICH_DATA CI_END="301.01190838007875" CI_START="1.30848584896475" EFFECT_SIZE="19.846153846153847" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" LOG_CI_END="2.478583677126917" LOG_CI_START="0.11676903018586952" LOG_EFFECT_SIZE="1.2976763536563933" MODIFIED="2011-10-28 19:53:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="696" O_E="0.0" SE="1.3873416147842266" STUDY_ID="STD-Stockfleth-2002" TOTAL_1="25" TOTAL_2="11" VAR="1.9247167561121052" WEIGHT="1.1205347515345965"/>
<DICH_DATA CI_END="81.79979509337818" CI_START="8.569565013351305" EFFECT_SIZE="26.476190476190474" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="3" LOG_CI_END="1.9127522157749095" LOG_CI_START="0.9329587779213669" LOG_EFFECT_SIZE="1.4228554968481382" MODIFIED="2011-07-29 20:16:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="684" O_E="0.0" SE="0.5755355154509089" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3312411295453433" WEIGHT="5.821088932392451"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1407764026369527" CI_END="10.73101915888606" CI_START="3.8728225613965606" DF="2" EFFECT_SIZE="6.446652860617879" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="15" I2="0.0" ID="CMP-020.01.02" LOG_CI_END="1.0306409702475405" LOG_CI_START="0.588027599652842" LOG_EFFECT_SIZE="0.8093342849501913" MODIFIED="2011-11-07 13:43:52 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.932031947221547" P_Z="7.625279794397603E-13" STUDIES="3" TAU2="0.0" TOTAL_1="448" TOTAL_2="282" WEIGHT="26.297545167986716" Z="7.167727661839651">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="18.53718706920603" CI_START="2.6131193107066055" EFFECT_SIZE="6.959876543209877" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="4" LOG_CI_END="1.2680438326668284" LOG_CI_START="0.4171592393479061" LOG_EFFECT_SIZE="0.8426015360073672" MODIFIED="2011-11-07 13:43:52 +0000" MODIFIED_BY="Maryse Paquet" ORDER="686" O_E="0.0" SE="0.49981382206220126" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="0.2498138567244258" WEIGHT="7.409379873126577"/>
<DICH_DATA CI_END="15.578013937508999" CI_START="3.040548762270957" EFFECT_SIZE="6.882275132275132" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" LOG_CI_END="1.192512088063043" LOG_CI_START="0.4829519727266173" LOG_EFFECT_SIZE="0.83773203039483" MODIFIED="2011-07-14 16:36:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1164" O_E="0.0" SE="0.4167991241278342" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" VAR="0.17372150987372975" WEIGHT="9.945137228667388"/>
<DICH_DATA CI_END="13.482803628197756" CI_START="2.3498693177017698" EFFECT_SIZE="5.62875" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="5" LOG_CI_END="1.129780209235821" LOG_CI_START="0.37104371070615777" LOG_EFFECT_SIZE="0.7504119599709893" MODIFIED="2011-08-03 22:41:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="557" O_E="0.0" SE="0.4456855750425647" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="79" VAR="0.19863563180102153" WEIGHT="8.94302806619275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07800832189226134" CI_END="8.38814344333491" CI_START="2.3996997463808833" DF="1" EFFECT_SIZE="4.486538275059877" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="10" I2="0.0" ID="CMP-020.01.03" LOG_CI_END="0.9236658486073448" LOG_CI_START="0.3801569056085103" LOG_EFFECT_SIZE="0.6519113771079276" MODIFIED="2011-08-03 22:41:50 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.780014845680161" P_Z="2.5793545972796617E-6" STUDIES="2" TAU2="0.0" TOTAL_1="324" TOTAL_2="162" WEIGHT="17.516064684053305" Z="4.701754540389183">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="9.981873720372073" CI_START="1.6840525607624504" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="5" LOG_CI_END="0.999212071351333" LOG_CI_START="0.22635564208813788" LOG_EFFECT_SIZE="0.6127838567197355" MODIFIED="2011-08-03 22:41:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="687" O_E="0.0" SE="0.45397969225022583" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="0.20609756097560974" WEIGHT="8.681039977736297"/>
<DICH_DATA CI_END="11.81516397617947" CI_START="2.0321343020212432" EFFECT_SIZE="4.9" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="5" LOG_CI_END="1.07243975334509" LOG_CI_START="0.30795240671193747" LOG_EFFECT_SIZE="0.6901960800285137" MODIFIED="2011-08-03 22:41:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="558" O_E="0.0" SE="0.4490636516857116" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="80" VAR="0.2016581632653061" WEIGHT="8.835024706317009"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.65194457405652" CI_END="4.295116474603333" CI_START="2.6013256442191537" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3426032714478415" ESTIMABLE="YES" EVENTS_1="748" EVENTS_2="124" I2="76.3927792913638" I2_Q="76.74493149486705" ID="CMP-020.02" LOG_CI_END="0.632974945487781" LOG_CI_START="0.4151947222977459" LOG_EFFECT_SIZE="0.5240848338927634" METHOD="MH" MODIFIED="2011-12-05 14:01:37 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0998114134075365E-4" P_Q="0.013566721558626371" P_Z="3.975837701785049E-21" Q="8.600275675638416" RANDOM="YES" SCALE="592.85" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20484236612761708" TOTALS="SUB" TOTAL_1="1370" TOTAL_2="962" WEIGHT="300.0" Z="9.433247741482466">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>5% imiquimod cream</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.094424797126571" CI_END="11.566433458441441" CI_START="3.8915853125718827" DF="3" EFFECT_SIZE="6.709080605098638" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="66" I2="70.28062459929401" ID="CMP-020.02.01" LOG_CI_END="1.063199463696596" LOG_CI_START="0.5901265556310145" LOG_EFFECT_SIZE="0.8266630096638052" MODIFIED="2011-07-29 19:28:04 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.01778035472885542" P_Z="7.394822890205091E-12" STUDIES="4" TAU2="0.17726220241588247" TOTAL_1="724" TOTAL_2="639" WEIGHT="100.0" Z="6.849809822835742">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="248.02113998501156" CI_START="0.9837033907904027" EFFECT_SIZE="15.619834710743802" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="0" LOG_CI_END="2.394488699324435" LOG_CI_START="-0.007135831610847115" LOG_EFFECT_SIZE="1.193676433856794" MODIFIED="2011-07-29 19:28:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="565" O_E="0.0" SE="1.4107261377045441" STUDY_ID="STD-Gebauer-2009" TOTAL_1="120" TOTAL_2="29" VAR="1.9901482356027806" WEIGHT="3.5627897865661526"/>
<DICH_DATA CI_END="6.527174434197776" CI_START="3.3980489330908292" EFFECT_SIZE="4.709528439474964" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="34" LOG_CI_END="0.8147252190690852" LOG_CI_START="0.5312296285702002" LOG_EFFECT_SIZE="0.6729774238196428" MODIFIED="2011-07-29 16:48:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="688" O_E="0.0" SE="0.16652671318485057" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.027731146204149484" WEIGHT="37.66965037574476"/>
<DICH_DATA CI_END="7.3260286348634756" CI_START="3.441119555586631" EFFECT_SIZE="5.02093023255814" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="26" LOG_CI_END="0.8648686118358826" LOG_CI_START="0.5366997616734059" LOG_EFFECT_SIZE="0.7007841867546443" MODIFIED="2011-04-19 20:50:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="566" O_E="0.0" SE="0.19276800704744612" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.03715950454104423" WEIGHT="36.013274408924346"/>
<DICH_DATA CI_END="36.775932205961645" CI_START="7.588229732670108" EFFECT_SIZE="16.705215419501133" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="6" LOG_CI_END="1.5655636901493692" LOG_CI_START="0.8801404706247218" LOG_EFFECT_SIZE="1.2228520803870455" MODIFIED="2011-07-29 16:48:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="689" O_E="0.0" SE="0.4026209920484346" STUDY_ID="STD-Szeimies-2009" TOTAL_1="147" TOTAL_2="139" VAR="0.16210366323806566" WEIGHT="22.75428542876474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3491137799395547" CI_END="4.660884261696222" CI_START="2.0791839169789355" DF="1" EFFECT_SIZE="3.113010696386864" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="29" I2="25.87726736844955" ID="CMP-020.02.02" LOG_CI_END="0.6684683187380458" LOG_CI_START="0.3178929071267023" LOG_EFFECT_SIZE="0.4931806129323741" MODIFIED="2011-08-31 21:02:54 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.2454332684929691" P_Z="3.498615730516716E-8" STUDIES="2" TAU2="0.02293105924455682" TOTAL_1="322" TOTAL_2="162" WEIGHT="100.0" Z="5.514455419323343">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="7.066087359926571" CI_START="2.2681501865573104" EFFECT_SIZE="4.0033670033670035" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="11" LOG_CI_END="0.8491790024307708" LOG_CI_START="0.35567180817218774" LOG_EFFECT_SIZE="0.6024254053014793" MODIFIED="2011-08-31 21:02:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="690" O_E="0.0" SE="0.2898885688075019" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="0.08403538232526178" WEIGHT="39.64519522553506"/>
<DICH_DATA CI_END="4.042104795682282" CI_START="1.7227991157824" EFFECT_SIZE="2.638888888888889" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="18" LOG_CI_END="0.6066075688518637" LOG_CI_START="0.23623464019125728" LOG_EFFECT_SIZE="0.4214211045215605" MODIFIED="2011-08-31 21:02:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="567" O_E="0.0" SE="0.2175588916708054" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="80" VAR="0.04733187134502924" WEIGHT="60.35480477446494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2516090824983586" CI_END="3.6812943700583767" CI_START="1.6695243877147934" DF="1" EFFECT_SIZE="2.479114908423897" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="29" I2="20.102848886020972" ID="CMP-020.02.03" LOG_CI_END="0.5660005466453737" LOG_CI_START="0.22259276742908551" LOG_EFFECT_SIZE="0.3942966570372296" MODIFIED="2011-08-31 21:03:03 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.2632454629271552" P_Z="6.769376622734804E-6" STUDIES="2" TAU2="0.01717690708677573" TOTAL_1="324" TOTAL_2="161" WEIGHT="100.00000000000001" Z="4.500813864969408">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="5.6702534870252155" CI_START="1.785452266872128" EFFECT_SIZE="3.1818181818181817" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="11" LOG_CI_END="0.7536024743347977" LOG_CI_START="0.2517482440493035" LOG_EFFECT_SIZE="0.5026753591920505" MODIFIED="2011-08-31 21:02:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="691" O_E="0.0" SE="0.2947916590882041" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="0.08690212226797593" WEIGHT="39.09599124125391"/>
<DICH_DATA CI_END="3.268605651407916" CI_START="1.364860075657268" EFFECT_SIZE="2.1121527777777778" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="18" LOG_CI_END="0.5143625272648868" LOG_CI_START="0.135088130142498" LOG_EFFECT_SIZE="0.3247253287036925" MODIFIED="2011-08-31 21:03:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="568" O_E="0.0" SE="0.2227876583082359" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="79" VAR="0.04963434069446728" WEIGHT="60.9040087587461"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-020.03" MODIFIED="2011-12-05 14:02:41 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="126" TOTAL_2="121" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-020.03.01" MODIFIED="2011-10-04 13:55:17 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<CONT_DATA CI_END="57.11794357041886" CI_START="36.68205642958114" EFFECT_SIZE="46.9" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="21.1" MODIFIED="2011-07-29 17:07:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="692" SD_1="40.6" SD_2="41.3" SE="5.213332311724446" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-04 13:55:30 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="338" TOTAL_2="170" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: 'flu" or "cold"</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-020.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-02 20:22:35 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="63.05436240286164" CI_START="0.22531510985624054" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.799715138521337" LOG_CI_START="-0.6472096830779832" LOG_EFFECT_SIZE="0.5762527277216769" MODIFIED="2011-08-02 20:22:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1162" O_E="0.0" SE="1.4373357526806552" STUDY_ID="STD-Ooi-2006" TOTAL_1="12" TOTAL_2="6" VAR="2.0659340659340657" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-020.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:01 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="228.42267995058128" CI_START="0.827502437495039" EFFECT_SIZE="13.748466257668712" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.3587392225527153" LOG_CI_START="-0.08223071829050826" LOG_EFFECT_SIZE="1.1382542521311034" MODIFIED="2011-08-03 21:21:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1164" O_E="0.0" SE="1.4338378262473885" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="2.055890911977836" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-020.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:56:01 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="114.68252289650016" CI_START="0.37288744626917536" EFFECT_SIZE="6.539393939393939" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.0594972384074817" LOG_CI_START="-0.428422237469473" LOG_EFFECT_SIZE="0.8155375004690044" MODIFIED="2011-08-03 21:21:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1165" O_E="0.0" SE="1.461416215530149" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="2.1357373550144634" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.664705886509369" CI_END="3.271946001859848" CI_START="1.3392871099935633" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="2.093340656674367" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="26" I2="0.0" I2_Q="57.708066254025006" ID="CMP-020.05" LOG_CI_END="0.5148061277352844" LOG_CI_START="0.12687368897593262" LOG_EFFECT_SIZE="0.3208399083556085" METHOD="MH" MODIFIED="2012-04-04 15:58:47 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.5607753377135271" P_Q="0.09399489874228473" P_Z="0.001187022208248903" Q="4.729034174726863" RANDOM="YES" SCALE="551.89" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1984" TOTAL_2="1275" WEIGHT="300.0" Z="3.2419803159086302">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.361704441324577" CI_END="4.225311193064637" CI_START="1.5895582942521773" DF="7" EFFECT_SIZE="2.5915976641316174" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="20" I2="0.0" ID="CMP-020.05.01" LOG_CI_END="0.6258587001386806" LOG_CI_START="0.2012764595284361" LOG_EFFECT_SIZE="0.41356757983355835" MODIFIED="2012-04-04 15:57:15 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8496492608326023" P_Z="1.3440940918753812E-4" STUDIES="8" TAU2="0.0" TOTAL_1="1338" TOTAL_2="952" WEIGHT="100.0" Z="3.818235828621279">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="103.93374392479872" CI_START="0.24425267209583362" EFFECT_SIZE="5.038461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0167565718219564" LOG_CI_START="-0.6121606764520638" LOG_EFFECT_SIZE="0.7022979476849462" MODIFIED="2011-09-23 15:17:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2839" O_E="0.0" SE="1.544239004986415" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="2.384674104521433" WEIGHT="2.6083737294915688"/>
<DICH_DATA CI_END="178.72509863048566" CI_START="0.6964841714685248" EFFECT_SIZE="11.15702479338843" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" LOG_CI_END="2.2521855454061592" LOG_CI_START="-0.157088749049047" LOG_EFFECT_SIZE="1.047548398178556" MODIFIED="2011-09-23 15:13:06 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2826" O_E="0.0" SE="1.4152196466630873" STUDY_ID="STD-Gebauer-2009" TOTAL_1="120" TOTAL_2="29" VAR="2.0028466483011935" WEIGHT="3.1056403109586137"/>
<DICH_DATA CI_END="6.986390280347705" CI_START="0.14313543330279438" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8442528429487831" LOG_CI_START="-0.8442528429487831" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 15:17:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2838" O_E="0.0" SE="0.9918365981341755" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.9837398373983739" WEIGHT="6.322933209742166"/>
<DICH_DATA CI_END="4.886573763002999" CI_START="1.15531523022227" EFFECT_SIZE="2.37603305785124" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.6890044588462881" LOG_CI_START="0.06270049857211038" LOG_EFFECT_SIZE="0.37585247870919924" MODIFIED="2011-09-23 15:13:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2827" O_E="0.0" SE="0.3678940465196556" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.13534602946460655" WEIGHT="45.95717593074364"/>
<DICH_DATA CI_END="17.124310317454515" CI_START="0.7558413146186375" EFFECT_SIZE="3.597674418604651" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2336130892823967" LOG_CI_START="-0.12156937304283465" LOG_EFFECT_SIZE="0.556021858119781" MODIFIED="2011-10-20 14:07:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2828" O_E="0.0" SE="0.7960408866312189" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.6336810931886171" WEIGHT="9.815854306672676"/>
<DICH_DATA CI_END="13.463604515608354" CI_START="0.24152625879029196" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.1291613460447456" LOG_CI_START="-0.6170356457498295" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-09-23 15:14:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2825" O_E="0.0" SE="1.0257247567946484" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="183" TOTAL_2="30" VAR="1.0521112767014404" WEIGHT="5.912037467304546"/>
<DICH_DATA CI_END="10.338066197295657" CI_START="0.17389100309417385" EFFECT_SIZE="1.3407821229050279" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.0144393087397952" LOG_CI_START="-0.7597228872763696" LOG_EFFECT_SIZE="0.12735821073171283" MODIFIED="2011-09-23 15:14:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2829" O_E="0.0" SE="1.0421516561844038" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="179" TOTAL_2="30" VAR="1.0860800744878956" WEIGHT="5.727129549416902"/>
<DICH_DATA CI_END="10.42367546776029" CI_START="1.2062479407362081" EFFECT_SIZE="3.545918367346939" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0180208815269625" LOG_CI_START="0.08143658494031325" LOG_EFFECT_SIZE="0.5497287332336379" MODIFIED="2011-10-05 16:08:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2823" O_E="0.0" SE="0.550154251982037" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3026697009739147" WEIGHT="20.550855495669886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9120446903393195" CI_END="3.9287713469970447" CI_START="0.21687913395490596" DF="1" EFFECT_SIZE="0.9230755804610847" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-020.05.02" LOG_CI_END="0.5942567537730968" LOG_CI_START="-0.6637822296555144" LOG_EFFECT_SIZE="-0.03476273794120873" MODIFIED="2011-09-23 15:19:40 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.3395726157896818" P_Z="0.9137439729921856" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="161" WEIGHT="100.0" Z="0.10831733398767057">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="17.824325209706235" CI_START="0.22998767398092324" EFFECT_SIZE="2.0246913580246915" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2510130973879583" LOG_CI_START="-0.638295439049862" LOG_EFFECT_SIZE="0.30635882916904816" MODIFIED="2011-09-23 15:19:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2832" O_E="0.0" SE="1.1097891865316618" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.2316320385426076" WEIGHT="44.33864576365562"/>
<DICH_DATA CI_END="3.440510528797553" CI_START="0.07085839745568327" EFFECT_SIZE="0.49375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5366228912310035" LOG_CI_START="-1.1496086739619702" LOG_EFFECT_SIZE="-0.30649289136548336" MODIFIED="2011-09-23 15:19:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2830" O_E="0.0" SE="0.9905007683752188" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="79" VAR="0.9810917721518988" WEIGHT="55.66135423634439"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.648612820164823" CI_END="2.7009744744756046" CI_START="0.09253938393372346" DF="1" EFFECT_SIZE="0.4999465110276147" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-020.05.03" LOG_CI_END="0.43152047991245107" LOG_CI_START="-1.0336733960731541" LOG_EFFECT_SIZE="-0.3010764580803516" MODIFIED="2011-09-23 15:21:06 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.4206093370145626" P_Z="0.4205373703504731" STUDIES="2" TAU2="0.0" TOTAL_1="324" TOTAL_2="162" WEIGHT="100.00000000000001" Z="0.8054893268420539">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="10.867470978231006" CI_START="0.09201772905611005" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0361284890735065" LOG_CI_START="-1.0361284890735065" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 15:20:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2834" O_E="0.0" SE="1.2172540068010336" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="1.4817073170731707" WEIGHT="49.992282759685146"/>
<DICH_DATA CI_END="2.7158675687214466" CI_START="0.02301290413413759" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4339085890341861" LOG_CI_START="-1.638028571690111" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-09-23 15:21:06 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2833" O_E="0.0" SE="1.2170661444638085" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="80" VAR="1.48125" WEIGHT="50.00771724031487"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5450107923463404" CI_END="9.884686374770384" CI_START="1.563814258718014" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="3.931642595127589" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-020.06" LOG_CI_END="0.9949628944016001" LOG_CI_START="0.19418516866999566" LOG_EFFECT_SIZE="0.5945740315357979" METHOD="MH" MODIFIED="2011-10-21 19:41:22 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.9972468673165582" P_Q="0.9547799161332403" P_Z="0.003608166406745828" Q="0.09254884230544275" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1155" TOTAL_2="523" WEIGHT="100.0" Z="2.9105297275552164">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.38907239983025627" CI_END="15.737268640042723" CI_START="0.8594125037795618" DF="2" EFFECT_SIZE="3.677608658434268" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" ID="CMP-020.06.01" LOG_CI_END="1.1969293584238547" LOG_CI_START="-0.06579833196121154" LOG_EFFECT_SIZE="0.5655655132313216" MODIFIED="2011-10-21 19:25:28 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8232164410895205" P_Z="0.07913896120243806" STUDIES="3" TAU2="0.0" TOTAL_1="509" TOTAL_2="199" WEIGHT="40.21652672721086" Z="1.7557040132592177">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="32.68411188938231" CI_START="0.10508395829404114" EFFECT_SIZE="1.8532608695652173" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.514336688574362" LOG_CI_START="-0.9784635766084396" LOG_EFFECT_SIZE="0.26793655598296123" MODIFIED="2011-10-18 14:58:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="691" O_E="0.0" SE="1.4642832153287002" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="183" TOTAL_2="30" VAR="2.144125334693357" WEIGHT="10.319270680517414"/>
<DICH_DATA CI_END="54.796630665188815" CI_START="0.1954032235490558" EFFECT_SIZE="3.272222222222222" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.738753855409507" LOG_CI_START="-0.709068276041916" LOG_EFFECT_SIZE="0.5148427896837956" MODIFIED="2011-10-18 14:58:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="690" O_E="0.0" SE="1.4378628369295356" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="179" TOTAL_2="30" VAR="2.067449537823052" WEIGHT="10.70198294897848"/>
<DICH_DATA CI_END="46.52855875239035" CI_START="0.6917956574818818" EFFECT_SIZE="5.673469387755102" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.667719600231999" LOG_CI_START="-0.16002216845287368" LOG_EFFECT_SIZE="0.7538487158895626" MODIFIED="2011-10-21 19:25:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="694" O_E="0.0" SE="1.0736245623931648" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="1.1526697009739149" WEIGHT="19.195273097714967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.011651074337330968" CI_END="25.83330811872949" CI_START="0.91543510219515" DF="1" EFFECT_SIZE="4.862994659436501" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-020.06.02" LOG_CI_END="1.4121800238936677" LOG_CI_START="-0.038372438645255046" LOG_EFFECT_SIZE="0.6869037926242063" MODIFIED="2011-10-18 14:58:24 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.9140431754024989" P_Z="0.06341543953162726" STUDIES="2" TAU2="0.0" TOTAL_1="322" TOTAL_2="162" WEIGHT="30.47593842547205" Z="1.8562674969107353">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="35.345928546032965" CI_START="0.5871422048716357" EFFECT_SIZE="4.555555555555555" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.548339395167536" LOG_CI_START="-0.2312567006067148" LOG_EFFECT_SIZE="0.6585413472804106" MODIFIED="2011-10-18 14:38:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="687" O_E="0.0" SE="1.045343555800541" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.0927431496537188" WEIGHT="20.24795095596548"/>
<DICH_DATA CI_END="98.85566688943254" CI_START="0.3098147467784186" EFFECT_SIZE="5.53416149068323" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.995001570243193" LOG_CI_START="-0.5088979142331427" LOG_EFFECT_SIZE="0.7430518280050251" MODIFIED="2011-10-18 14:47:55 +0100" MODIFIED_BY="Maryse Paquet" ORDER="688" O_E="0.0" SE="1.4708029516837435" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="80" VAR="2.1632613226816124" WEIGHT="10.227987469506571"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05087626860718372" CI_END="18.965391179354953" CI_START="0.6291835100826239" DF="1" EFFECT_SIZE="3.454375687778702" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-020.06.03" LOG_CI_END="1.2779618048707755" LOG_CI_START="-0.20122266807985104" LOG_EFFECT_SIZE="0.5383695683954622" MODIFIED="2011-10-18 14:58:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.8215454575350672" P_Z="0.1536629855259402" STUDIES="2" TAU2="0.0" TOTAL_1="324" TOTAL_2="162" WEIGHT="29.307534847317086" Z="1.4267117911569644">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="24.506859629294194" CI_START="0.3672441159797514" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.389287663228894" LOG_CI_START="-0.43504515378956893" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-10-18 14:38:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="686" O_E="0.0" SE="1.0716221273097328" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="1.1483739837398375" WEIGHT="19.267076766751547"/>
<DICH_DATA CI_END="83.07854333693447" CI_START="0.2467825408510338" EFFECT_SIZE="4.527950310559007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9194888731991548" LOG_CI_START="-0.6076855686269047" LOG_EFFECT_SIZE="0.655901652286125" MODIFIED="2011-10-18 14:48:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="689" O_E="0.0" SE="1.4844747768438684" STUDY_ID="STD-Swanson-2010a" TOTAL_1="160" TOTAL_2="80" VAR="2.203665363085653" WEIGHT="10.040458080565541"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:36 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: pyrexia</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-020.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:51:54 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="116.08388160862877" CI_START="0.37748157546626326" EFFECT_SIZE="6.619631901840491" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.0647719215956326" LOG_CI_START="-0.4231042410377268" LOG_EFFECT_SIZE="0.8208338402789529" MODIFIED="2011-08-05 15:18:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1224" O_E="0.0" SE="1.461390773116457" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="2.135662991749916" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-020.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:51:54 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="36.64325420255676" CI_START="0.062149375688961755" EFFECT_SIZE="1.509090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.563994035395823" LOG_CI_START="-1.206563229632163" LOG_EFFECT_SIZE="0.17871540288183005" MODIFIED="2011-08-03 21:37:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1226" O_E="0.0" SE="1.6274390519570852" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="2.648557867834976" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:33 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: hemic and lymphatic: lymphadenopathy</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-020.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:05 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="132.10871443767397" CI_START="0.44160301276436054" EFFECT_SIZE="7.638036809815951" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1209314664212413" LOG_CI_START="-0.354967972365647" LOG_EFFECT_SIZE="0.8829817470277973" MODIFIED="2011-08-03 21:34:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1200" O_E="0.0" SE="1.4543555862433009" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="2.1151501712370955" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-020.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:05 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="83.0906834932883" CI_START="0.2466726410881316" EFFECT_SIZE="4.527272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9195523314341585" LOG_CI_START="-0.6078790162311734" LOG_EFFECT_SIZE="0.6558366576014925" MODIFIED="2011-08-03 21:34:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1202" O_E="0.0" SE="1.4846256846055614" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="2.204113423390532" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 14:04:35 +0000" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="795.1398506603231" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-020.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:10 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="100.07855958994486" CI_START="0.3134911609974298" EFFECT_SIZE="5.601226993865031" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.0003410460194924" LOG_CI_START="-0.5037746997588102" LOG_EFFECT_SIZE="0.7482831731303411" MODIFIED="2011-08-03 21:40:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1260" O_E="0.0" SE="1.4709299846430297" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="2.163635019721944" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:26 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="268.5735261759132" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: fatigue</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-020.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:16 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="31.82905427972957" CI_START="0.5151739739713936" EFFECT_SIZE="4.049382716049383" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.5028237348447988" LOG_CI_START="-0.2880460851787401" LOG_EFFECT_SIZE="0.6073888248330294" MODIFIED="2011-08-03 21:33:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1188" O_E="0.0" SE="1.051965797230408" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.1066320385426076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-020.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:16 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="21.049909878518505" CI_START="0.29691338519117094" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3232502408203382" LOG_CI_START="-0.5273702234762628" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-08-03 21:33:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1190" O_E="0.0" SE="1.0870636214468639" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="1.1817073170731707" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:22 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="338" TOTAL_2="170" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-020.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-02 20:23:22 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>5.0% imiquimod</NAME>
<DICH_DATA CI_END="63.05436240286164" CI_START="0.22531510985624054" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.799715138521337" LOG_CI_START="-0.6472096830779832" LOG_EFFECT_SIZE="0.5762527277216769" MODIFIED="2011-08-02 20:23:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1163" O_E="0.0" SE="1.4373357526806552" STUDY_ID="STD-Ooi-2006" TOTAL_1="12" TOTAL_2="6" VAR="2.0659340659340657" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-020.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:20 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="31.82905427972957" CI_START="0.5151739739713936" EFFECT_SIZE="4.049382716049383" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.5028237348447988" LOG_CI_START="-0.2880460851787401" LOG_EFFECT_SIZE="0.6073888248330294" MODIFIED="2011-08-03 21:22:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1166" O_E="0.0" SE="1.051965797230408" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.1066320385426076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-020.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:20 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="24.506859629294194" CI_START="0.3672441159797514" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.389287663228894" LOG_CI_START="-0.43504515378956893" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-08-03 21:22:26 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1167" O_E="0.0" SE="1.0716221273097328" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="1.1483739837398375" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:19 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="452.166373244016" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: cough</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-020.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:25 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="17.824325209706235" CI_START="0.22998767398092324" EFFECT_SIZE="2.0246913580246915" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2510130973879583" LOG_CI_START="-0.638295439049862" LOG_EFFECT_SIZE="0.30635882916904816" MODIFIED="2011-08-03 21:39:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1248" O_E="0.0" SE="1.1097891865316618" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.2316320385426076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-020.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:25 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="4.071472689172973" CI_START="0.006905486187662419" EFFECT_SIZE="0.16767676767676767" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6097515259564982" LOG_CI_START="-2.160805739071488" LOG_EFFECT_SIZE="-0.7755271065574948" MODIFIED="2011-08-03 21:39:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1250" O_E="0.0" SE="1.6274390519570852" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="2.648557867834976" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-020.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:16 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="7.98" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: sinusitis</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-020.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:30 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="4.448571491722856" CI_START="0.31356723170303896" EFFECT_SIZE="1.1810699588477367" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6482205743830409" LOG_CI_START="-0.5036693281116806" LOG_EFFECT_SIZE="0.07227562313568016" MODIFIED="2011-08-03 21:32:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1176" O_E="0.0" SE="0.6766258306723767" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="0.4578225147330838" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-020.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:30 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="4.400708754538317" CI_START="0.12782031972007032" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6435226272581686" LOG_CI_START="-0.8934001004747684" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-03 21:32:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1178" O_E="0.0" SE="0.9027960181605278" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="0.815040650406504" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-020.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:12 +0100" MODIFIED_BY="Maryse Paquet" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="551.8855077988062" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-020.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:38 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="2.750242636196845" CI_START="0.023289849055649278" EFFECT_SIZE="0.25308641975308643" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4393710105258843" LOG_CI_START="-1.632833326171675" LOG_EFFECT_SIZE="-0.5967311578228954" MODIFIED="2011-08-03 21:35:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1212" O_E="0.0" SE="1.217223084953045" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.4816320385426076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-020.14.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="5.3470824785048485" CI_START="0.18701787451754814" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7281168831247037" LOG_CI_START="-0.7281168831247037" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-03 21:35:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1214" O_E="0.0" SE="0.8553989227683015" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="0.7317073170731707" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-18 14:40:09 +0100" MODIFIED_BY="Maryse Paquet" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="752.2527140913325" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="326" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: urogenital: urinary tract infection</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-020.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:42 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="11.000970544787377" CI_START="0.09315939622259709" EFFECT_SIZE="1.0123456790123457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0414310018538466" LOG_CI_START="-1.0307733348437127" LOG_EFFECT_SIZE="0.005328833505066964" MODIFIED="2011-08-03 21:36:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1236" O_E="0.0" SE="1.217223084953045" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="1.4816320385426076" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-020.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 15:52:42 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="17.608125807562683" CI_START="0.22716784532979667" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2457131325288824" LOG_CI_START="-0.6436531412009199" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-08-03 21:36:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1238" O_E="0.0" SE="1.1098231017027762" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="1.2317073170731707" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.858411325943408" CI_END="3.107616574172751" CI_START="2.0315329253817533" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.512613259117684" ESTIMABLE="YES" EVENTS_1="401" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-020.16" LOG_CI_END="0.4924274290499225" LOG_CI_START="0.3078238654001778" LOG_EFFECT_SIZE="0.4001256472250501" METHOD="MH" MODIFIED="2011-10-18 14:39:15 +0100" MODIFIED_BY="Maryse Paquet" NO="16" P_CHI2="0.4139745369718102" P_Q="0.40381681905417954" P_Z="1.9557952491288304E-17" Q="0.696932325632073" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="630" TOTAL_2="315" WEIGHT="200.0" Z="8.496389152484944">
<NAME>Cosmetic outcome: Participant's significantly or much improved cosmetic outcome assessed by investigator</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6575221093556214" CI_END="3.575574377376518" CI_START="2.054357736285534" DF="1" EFFECT_SIZE="2.7102599292001095" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="40" I2="0.0" ID="CMP-020.16.01" LOG_CI_END="0.5533458164555448" LOG_CI_START="0.3126760718644304" LOG_EFFECT_SIZE="0.43301094415998764" MODIFIED="2011-08-03 22:07:05 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.41743638837173336" P_Z="1.7547785608860782E-12" STUDIES="2" TAU2="0.0" TOTAL_1="313" TOTAL_2="157" WEIGHT="100.00000000000001" Z="7.052700844529787">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="4.599052530377673" CI_START="2.040881478503103" EFFECT_SIZE="3.0636777128005197" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="19" LOG_CI_END="0.6626683701139086" LOG_CI_START="0.3098177843698283" LOG_EFFECT_SIZE="0.48624307724186844" MODIFIED="2011-08-03 22:07:05 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1285" O_E="0.0" SE="0.2072661807046415" STUDY_ID="STD-Hanke-2010" TOTAL_1="162" TOTAL_2="82" VAR="0.042959269663889105" WEIGHT="46.52231405436646"/>
<DICH_DATA CI_END="3.558402054956009" CI_START="1.6678211455967973" EFFECT_SIZE="2.436140018921476" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="21" LOG_CI_END="0.5512550163684957" LOG_CI_START="0.22214947577107141" LOG_EFFECT_SIZE="0.38670224606978354" MODIFIED="2011-08-03 17:15:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="594" O_E="0.0" SE="0.19331822364562673" STUDY_ID="STD-Swanson-2010a" TOTAL_1="151" TOTAL_2="75" VAR="0.037371935593500556" WEIGHT="53.47768594563355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.355108825107487" CI_END="3.140409900529571" CI_START="1.6190554250575573" DF="1" EFFECT_SIZE="2.2548830759835123" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="40" I2="26.205188729349455" ID="CMP-020.16.02" LOG_CI_END="0.4969863378565871" LOG_CI_START="0.20926171619293168" LOG_EFFECT_SIZE="0.3531240270247594" MODIFIED="2011-08-03 22:07:14 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.24438713443476856" P_Z="1.5023554398692413E-6" STUDIES="2" TAU2="0.014988025229489978" TOTAL_1="317" TOTAL_2="158" WEIGHT="100.0" Z="4.810922131324173">
<NAME>2.5% imiquimod</NAME>
<DICH_DATA CI_END="4.051871420704201" CI_START="1.778187262500123" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="19" LOG_CI_END="0.6076556553050598" LOG_CI_START="0.24997749498515495" LOG_EFFECT_SIZE="0.4288165751451074" MODIFIED="2011-08-03 22:07:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1286" O_E="0.0" SE="0.2101019219073605" STUDY_ID="STD-Hanke-2010" TOTAL_1="164" TOTAL_2="82" VAR="0.044142817589166605" WEIGHT="48.307569807809756"/>
<DICH_DATA CI_END="2.8392501944130224" CI_START="1.2929213500207546" EFFECT_SIZE="1.915966386554622" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="21" LOG_CI_END="0.4532036641938284" LOG_CI_START="0.11157210702201768" LOG_EFFECT_SIZE="0.28238788560792305" MODIFIED="2011-08-03 17:15:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="595" O_E="0.0" SE="0.20067606778620337" STUDY_ID="STD-Swanson-2010a" TOTAL_1="153" TOTAL_2="76" VAR="0.04027088418213289" WEIGHT="51.69243019219024"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2012-10-01 15:39:23 +0100" MODIFIED_BY="Maryse Paquet" NO="21">
<NAME>Imiquimod versus placebo: frequency of application</NAME>
<DICH_OUTCOME CHI2="31.43748007624488" CI_END="7.899606669429534" CI_START="4.09658219422277" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="5.688707060778263" ESTIMABLE="YES" EVENTS_1="824" EVENTS_2="80" I2="55.467168596064326" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.8976054678032336" LOG_CI_START="0.6124216730094709" LOG_EFFECT_SIZE="0.7550135704063523" METHOD="MH" MODIFIED="2011-08-05 15:52:59 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.004812125812375556" P_Q="0.4595293324776021" P_Z="3.1269094193833256E-25" Q="2.588385891331046" RANDOM="YES" SCALE="397.9" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.24595086143880054" TOTALS="SUB" TOTAL_1="2115" TOTAL_2="1401" WEIGHT="400.0" Z="10.377864611175387">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.8882136163390495" CI_END="14.163361385268484" CI_START="2.0286220052286836" DF="3" EFFECT_SIZE="5.360233817116737" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="13" I2="61.968575574753366" ID="CMP-021.01.01" LOG_CI_END="1.15116633653379" LOG_CI_START="0.30720113213115235" LOG_EFFECT_SIZE="0.7291837343324713" MODIFIED="2011-08-05 15:52:59 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.04837947290606248" P_Z="7.071097471356328E-4" STUDIES="4" TAU2="0.5556041285904928" TOTAL_1="602" TOTAL_2="288" WEIGHT="99.99999999999999" Z="3.3868075364923182">
<NAME>2 times/week</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-03 22:55:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="694" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="8.015842790837999"/>
<DICH_DATA CI_END="29.965738405936484" CI_START="6.7706448249034485" EFFECT_SIZE="14.243853820598007" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="7" LOG_CI_END="1.4766249839071064" LOG_CI_START="0.8306300321358802" LOG_EFFECT_SIZE="1.1536275080214935" MODIFIED="2011-08-01 15:19:23 +0100" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="0.37946063239700184" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.14399037153913255" WEIGHT="35.12997984356331"/>
<DICH_DATA CI_END="10.82811436459627" CI_START="1.2211858917100382" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" LOG_CI_END="1.0345528340628938" LOG_CI_START="0.08678177827658107" LOG_EFFECT_SIZE="0.5606673061697374" MODIFIED="2011-08-02 16:20:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="701" O_E="0.0" SE="0.5567254097112704" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="176" TOTAL_2="30" VAR="0.3099431818181818" WEIGHT="28.39445099380806"/>
<DICH_DATA CI_END="12.199011964195824" CI_START="1.3854592992864063" EFFECT_SIZE="4.111111111111111" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="3" LOG_CI_END="1.0863246572424354" LOG_CI_START="0.1415937720129048" LOG_EFFECT_SIZE="0.6139592146276701" MODIFIED="2011-08-02 16:20:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="702" O_E="0.0" SE="0.5549395984771297" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="180" TOTAL_2="30" VAR="0.307957957957958" WEIGHT="28.459726371790627"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.926667347837647" CI_END="18.51608339531808" CI_START="3.7936076812082398" DF="5" EFFECT_SIZE="8.381095166764963" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="42" I2="76.10704123646974" ID="CMP-021.01.02" LOG_CI_END="1.267549128151219" LOG_CI_START="0.579052415984328" LOG_EFFECT_SIZE="0.9233007720677735" MODIFIED="2011-08-05 15:52:59 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="8.363152217163439E-4" P_Z="1.4660324164104246E-7" STUDIES="6" TAU2="0.5770486015970205" TOTAL_1="681" TOTAL_2="655" WEIGHT="100.0" Z="5.25677531401837">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="25.082707248176337" CI_START="0.07087663066780928" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-08-03 22:55:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="695" O_E="0.0" SE="1.4972196454317137" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.2416666666666667" WEIGHT="5.8026681916369895"/>
<DICH_DATA CI_END="81.79979509337818" CI_START="8.569565013351305" EFFECT_SIZE="26.476190476190474" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="3" LOG_CI_END="1.9127522157749095" LOG_CI_START="0.9329587779213669" LOG_EFFECT_SIZE="1.4228554968481382" MODIFIED="2011-08-01 15:19:01 +0100" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.5755355154509089" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3312411295453433" WEIGHT="18.007546345221865"/>
<DICH_DATA CI_END="99.46303741231105" CI_START="0.41395891561637377" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9976617176275944" LOG_CI_START="-0.38304275937788035" LOG_EFFECT_SIZE="0.8073094791248571" MODIFIED="2011-08-01 15:19:14 +0100" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="1.3984375944702379" STUDY_ID="STD-Ooi-2006" TOTAL_1="11" TOTAL_2="6" VAR="1.9556277056277054" WEIGHT="6.458018098000843"/>
<DICH_DATA CI_END="10.676175038069365" CI_START="4.22338149932474" EFFECT_SIZE="6.714876033057851" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="18" LOG_CI_END="1.0284156855205355" LOG_CI_START="0.6256603131483883" LOG_EFFECT_SIZE="0.8270379993344619" MODIFIED="2011-08-01 15:19:42 +0100" MODIFIED_BY="[Empty name]" ORDER="703" O_E="0.0" SE="0.23658049940264606" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.055970332697605416" WEIGHT="25.838199368650507"/>
<DICH_DATA CI_END="5.792814446292731" CI_START="2.3208829782297933" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="18" LOG_CI_END="0.7628896175303386" LOG_CI_START="0.36565324334678656" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2011-08-01 21:29:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="755" O_E="0.0" SE="0.23333861254718363" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.05444690810544468" WEIGHT="25.90053163820837"/>
<DICH_DATA CI_END="73.77832717564539" CI_START="7.709969642618348" EFFECT_SIZE="23.850129198966407" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="3" LOG_CI_END="1.8679288039590616" LOG_CI_START="0.8870526680549399" LOG_EFFECT_SIZE="1.3774907360070006" MODIFIED="2011-08-01 21:29:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="756" O_E="0.0" SE="0.576171497645261" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="0.33197359469878296" WEIGHT="17.993036358281422"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.268218240049002" CI_START="0.03470975650366249" DF="0" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.01.03" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-05 15:52:59 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.8716501947710975" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="0.1615627478811938">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="17.268218240049002" CI_START="0.03470975650366249" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-03 22:55:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="696" O_E="0.0" SE="1.5841112972738176" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.5094086021505375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3063219181324834" CI_END="7.979506895001015" CI_START="3.6463589994904426" DF="3" EFFECT_SIZE="5.394084424448971" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="25" I2="0.0" ID="CMP-021.01.04" LOG_CI_END="0.9019760543335791" LOG_CI_START="0.5618594245554851" LOG_EFFECT_SIZE="0.7319177394445321" MODIFIED="2011-08-05 15:52:59 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.7276325497473546" P_Z="3.29698738073931E-17" STUDIES="4" TAU2="0.0" TOTAL_1="802" TOTAL_2="451" WEIGHT="100.0" Z="8.435532304863788">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-03 22:55:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="697" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="1.7797198089010493"/>
<DICH_DATA CI_END="15.578013937508999" CI_START="3.040548762270957" EFFECT_SIZE="6.882275132275132" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" LOG_CI_END="1.192512088063043" LOG_CI_START="0.4829519727266173" LOG_EFFECT_SIZE="0.83773203039483" MODIFIED="2011-08-01 15:20:10 +0100" MODIFIED_BY="[Empty name]" ORDER="704" O_E="0.0" SE="0.4167991241278342" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" VAR="0.17372150987372975" WEIGHT="22.976154488496725"/>
<DICH_DATA CI_END="10.351002576983444" CI_START="2.7818104001289328" EFFECT_SIZE="5.366053169734151" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="9" LOG_CI_END="1.0149824167073591" LOG_CI_START="0.44432752645264567" LOG_EFFECT_SIZE="0.7296549715800024" MODIFIED="2011-08-01 15:25:01 +0100" MODIFIED_BY="[Empty name]" ORDER="705" O_E="0.0" SE="0.33520550732288296" STUDY_ID="STD-Hanke-2010" TOTAL_1="326" TOTAL_2="164" VAR="0.11236273213959133" WEIGHT="35.52291914613675"/>
<DICH_DATA CI_END="9.341062905097061" CI_START="2.696129465915909" EFFECT_SIZE="5.0184375" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="10" LOG_CI_END="0.9703962967391172" LOG_CI_START="0.4307407428272589" LOG_EFFECT_SIZE="0.7005685197831881" MODIFIED="2011-08-01 15:23:46 +0100" MODIFIED_BY="[Empty name]" ORDER="706" O_E="0.0" SE="0.3169963437059003" STUDY_ID="STD-Swanson-2010a" TOTAL_1="320" TOTAL_2="159" VAR="0.10048668192290927" WEIGHT="39.72120655646547"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.432896976312477" CI_END="5.2360541483349055" CI_START="3.0993800505586893" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="4.028463946840566" ESTIMABLE="YES" EVENTS_1="748" EVENTS_2="123" I2="70.83793225736322" I2_Q="39.817397086674035" ID="CMP-021.02" LOG_CI_END="0.7190041291318612" LOG_CI_START="0.4912748333352802" LOG_EFFECT_SIZE="0.6051394812335708" METHOD="MH" MODIFIED="2011-08-05 15:53:02 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="5.950106354508655E-4" P_Q="0.1729115624269345" P_Z="2.0886068146941465E-25" Q="4.984829260908759" RANDOM="YES" SCALE="592.85" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18837610470492006" TOTALS="SUB" TOTAL_1="1370" TOTAL_2="961" WEIGHT="400.0" Z="10.416328603593367">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>5% imiquimod cream</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5% imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04243525019308488" CI_END="7.261220673599064" CI_START="3.4346458853661894" DF="1" EFFECT_SIZE="4.993968533071963" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="26" I2="0.0" ID="CMP-021.02.01" LOG_CI_END="0.8610096354722597" LOG_CI_START="0.5358819676083529" LOG_EFFECT_SIZE="0.6984458015403063" MODIFIED="2011-08-05 15:53:02 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8367924505722575" P_Z="3.7370456268337536E-17" STUDIES="2" TAU2="0.0" TOTAL_1="246" TOTAL_2="228" WEIGHT="99.99999999999999" Z="8.420868178744005">
<NAME>2 times/week</NAME>
<DICH_DATA CI_END="59.00590880838229" CI_START="0.23832358968772135" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7708955037503464" LOG_CI_START="-0.6228329682949085" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2011-08-03 22:59:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="707" O_E="0.0" SE="1.40608795362642" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="1.9770833333333333" WEIGHT="1.844837367288768"/>
<DICH_DATA CI_END="7.3260286348634756" CI_START="3.441119555586631" EFFECT_SIZE="5.02093023255814" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="26" LOG_CI_END="0.8648686118358826" LOG_CI_START="0.5366997616734059" LOG_EFFECT_SIZE="0.7007841867546443" MODIFIED="2011-08-01 15:27:45 +0100" MODIFIED_BY="[Empty name]" ORDER="712" O_E="0.0" SE="0.19276800704744612" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.03715950454104423" WEIGHT="98.15516263271122"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.410117102948798" CI_END="23.319621332882008" CI_START="2.5078438279896833" DF="2" EFFECT_SIZE="7.647350418983342" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="40" I2="78.74627937017627" ID="CMP-021.02.02" LOG_CI_END="1.367721494012576" LOG_CI_START="0.3993004879983516" LOG_EFFECT_SIZE="0.8835109910054638" MODIFIED="2011-08-05 15:53:02 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.009049414223091357" P_Z="3.4858059813086187E-4" STUDIES="3" TAU2="0.6493658824150917" TOTAL_1="418" TOTAL_2="396" WEIGHT="100.0" Z="3.576233294325229">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="62.84829044595074" CI_START="0.25458130820216873" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.7982934688161243" LOG_CI_START="-0.5941734861601995" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-08-03 22:59:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="708" O_E="0.0" SE="1.4053469322555197" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="1.975" WEIGHT="12.330458424045624"/>
<DICH_DATA CI_END="6.527174434197776" CI_START="3.3980489330908292" EFFECT_SIZE="4.709528439474964" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="34" LOG_CI_END="0.8147252190690852" LOG_CI_START="0.5312296285702002" LOG_EFFECT_SIZE="0.6729774238196428" MODIFIED="2011-08-01 15:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="711" O_E="0.0" SE="0.16652671318485057" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.027731146204149484" WEIGHT="47.79172413234767"/>
<DICH_DATA CI_END="36.775932205961645" CI_START="7.588229732670108" EFFECT_SIZE="16.705215419501133" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="6" LOG_CI_END="1.5655636901493692" LOG_CI_START="0.8801404706247218" LOG_EFFECT_SIZE="1.2228520803870455" MODIFIED="2011-08-01 15:28:07 +0100" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.4026209920484346" STUDY_ID="STD-Szeimies-2009" TOTAL_1="147" TOTAL_2="139" VAR="0.16210366323806566" WEIGHT="39.87781744360671"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.508795600047165" CI_START="0.21033818163420098" DF="0" EFFECT_SIZE="3.3548387096774195" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-021.02.03" LOG_CI_END="1.7284251757894264" LOG_CI_START="-0.6770818848604111" LOG_EFFECT_SIZE="0.5256716454645077" MODIFIED="2011-08-05 15:53:02 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.3916573444680892" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="0.8566156463710506">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="53.508795600047165" CI_START="0.21033818163420098" EFFECT_SIZE="3.3548387096774195" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.7284251757894264" LOG_CI_START="-0.6770818848604111" LOG_EFFECT_SIZE="0.5256716454645077" MODIFIED="2011-08-03 22:59:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="709" O_E="0.0" SE="1.4130067548777057" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9965880893300247" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.454545720658488" CI_END="4.3650154921835735" CI_START="1.9891046565939465" DF="2" EFFECT_SIZE="2.946603577274531" ESTIMABLE="YES" EVENTS_1="340" EVENTS_2="57" I2="42.10526761768346" ID="CMP-021.02.04" LOG_CI_END="0.6399857894294233" LOG_CI_START="0.29865763409753954" LOG_EFFECT_SIZE="0.4693217117634814" MODIFIED="2011-08-05 15:53:02 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.17776885052115066" P_Z="7.051680856715254E-8" STUDIES="3" TAU2="0.0488443391016941" TOTAL_1="676" TOTAL_2="330" WEIGHT="100.0" Z="5.3898492570863965">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="90.3422126359578" CI_START="0.38996132322417854" EFFECT_SIZE="5.935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="1.955890722973431" LOG_CI_START="-0.4089784646229036" LOG_EFFECT_SIZE="0.7734561291752637" MODIFIED="2011-08-03 22:59:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="710" O_E="0.0" SE="1.3891358670853624" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9296984572230014" WEIGHT="2.031767376716586"/>
<DICH_DATA CI_END="5.6953329400002595" CI_START="2.483671157791529" EFFECT_SIZE="3.7610283377154543" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="21" LOG_CI_END="0.7555191173138845" LOG_CI_START="0.3950940939962623" LOG_EFFECT_SIZE="0.5753066056550733" MODIFIED="2011-08-01 15:31:03 +0100" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="0.21171544282941082" STUDY_ID="STD-Hanke-2010" TOTAL_1="326" TOTAL_2="164" VAR="0.04482342873245353" WEIGHT="42.916990550346085"/>
<DICH_DATA CI_END="3.2197873863450344" CI_START="1.7503261837422623" EFFECT_SIZE="2.3739583333333334" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="36" LOG_CI_END="0.5078271946816306" LOG_CI_START="0.24311898959998363" LOG_EFFECT_SIZE="0.37547309214080715" MODIFIED="2011-08-01 15:32:11 +0100" MODIFIED_BY="[Empty name]" ORDER="715" O_E="0.0" SE="0.15549090999170734" STUDY_ID="STD-Swanson-2010a" TOTAL_1="320" TOTAL_2="159" VAR="0.024177423090049235" WEIGHT="55.05124207293733"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.19920252578442" CI_END="3.6607304192377876" CI_START="1.4740533084851493" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3229532466129594" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.5635677480707649" LOG_CI_START="0.16851318987466127" LOG_EFFECT_SIZE="0.36604046897271314" METHOD="MH" MODIFIED="2012-10-01 15:39:23 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.844173481829943" P_Q="0.8802851308536732" P_Z="2.811941717100007E-4" Q="0.669791964643443" RANDOM="YES" SCALE="407.5591098087596" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1984" TOTAL_2="1274" WEIGHT="400.0" Z="3.632035733730434">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.088314233525995" CI_END="5.530840887821136" CI_START="0.7497205535282504" DF="3" EFFECT_SIZE="2.036316550022108" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="4" I2="0.0" ID="CMP-021.03.01" LOG_CI_END="0.7427911647907643" LOG_CI_START="-0.12510058284263637" LOG_EFFECT_SIZE="0.30884529097406394" MODIFIED="2011-10-20 14:18:46 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.7798958261816209" P_Z="0.16303588656647613" STUDIES="4" TAU2="0.0" TOTAL_1="608" TOTAL_2="288" WEIGHT="100.00000000000003" Z="1.3949335242663228">
<NAME>2 times/week</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-09-23 15:23:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2843" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="10.352864079095662"/>
<DICH_DATA CI_END="17.124310317454515" CI_START="0.7558413146186375" EFFECT_SIZE="3.597674418604651" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2336130892823967" LOG_CI_START="-0.12156937304283465" LOG_EFFECT_SIZE="0.556021858119781" MODIFIED="2011-10-20 14:18:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2844" O_E="0.0" SE="0.7960408866312189" STUDY_ID="STD-Lebwohl-2004" TOTAL_1="215" TOTAL_2="221" VAR="0.6336810931886171" WEIGHT="41.01432536217457"/>
<DICH_DATA CI_END="13.463604515608354" CI_START="0.24152625879029196" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.1291613460447456" LOG_CI_START="-0.6170356457498295" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-09-23 15:24:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2842" O_E="0.0" SE="1.0257247567946484" STUDY_ID="STD-NCT00828568-Aldara" TOTAL_1="183" TOTAL_2="30" VAR="1.0521112767014404" WEIGHT="24.702712638324503"/>
<DICH_DATA CI_END="10.338066197295657" CI_START="0.17389100309417385" EFFECT_SIZE="1.3407821229050279" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.0144393087397952" LOG_CI_START="-0.7597228872763696" LOG_EFFECT_SIZE="0.12735821073171283" MODIFIED="2011-09-23 15:24:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2841" O_E="0.0" SE="1.0421516561844038" STUDY_ID="STD-NCT00828568-Taro" TOTAL_1="179" TOTAL_2="30" VAR="1.0860800744878956" WEIGHT="23.93009792040528"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6623307257239643" CI_END="4.297169477126388" CI_START="1.422644011807748" DF="4" EFFECT_SIZE="2.4725174265021646" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="16" I2="0.0" ID="CMP-021.03.02" LOG_CI_END="0.6331824822688129" LOG_CI_START="0.15309624017624046" LOG_EFFECT_SIZE="0.3931393612225267" MODIFIED="2012-10-01 15:39:23 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.797548395001009" P_Z="0.0013273387511023263" STUDIES="5" TAU2="0.0" TOTAL_1="670" TOTAL_2="649" WEIGHT="100.0" Z="3.210002376000837">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="103.93374392479872" CI_START="0.24425267209583362" EFFECT_SIZE="5.038461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0167565718219564" LOG_CI_START="-0.6121606764520638" LOG_EFFECT_SIZE="0.7022979476849462" MODIFIED="2011-09-23 15:25:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2845" O_E="0.0" SE="1.544239004986415" STUDY_ID="STD-Alomar-2007" TOTAL_1="129" TOTAL_2="130" VAR="2.384674104521433" WEIGHT="3.334914387432355"/>
<DICH_DATA CI_END="25.082707248176337" CI_START="0.07087663066780928" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.399374409331374" LOG_CI_START="-1.1494969361147744" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-09-23 15:23:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2850" O_E="0.0" SE="1.4972196454317137" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.2416666666666667" WEIGHT="3.5476657162108074"/>
<DICH_DATA CI_END="6.986390280347705" CI_START="0.14313543330279438" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8442528429487831" LOG_CI_START="-0.8442528429487831" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-09-23 15:25:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2846" O_E="0.0" SE="0.9918365981341755" STUDY_ID="STD-Jorizzo-2007" TOTAL_1="123" TOTAL_2="123" VAR="0.9837398373983739" WEIGHT="8.084133302497728"/>
<DICH_DATA CI_END="4.886573763002999" CI_START="1.15531523022227" EFFECT_SIZE="2.37603305785124" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.6890044588462881" LOG_CI_START="0.06270049857211038" LOG_EFFECT_SIZE="0.37585247870919924" MODIFIED="2011-09-23 15:25:58 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2847" O_E="0.0" SE="0.3678940465196556" STUDY_ID="STD-Korman-2005" TOTAL_1="242" TOTAL_2="250" VAR="0.13534602946460655" WEIGHT="58.75816240760537"/>
<DICH_DATA CI_END="10.42367546776029" CI_START="1.2062479407362081" EFFECT_SIZE="3.545918367346939" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0180208815269625" LOG_CI_START="0.08143658494031325" LOG_EFFECT_SIZE="0.5497287332336379" MODIFIED="2011-09-23 15:26:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2849" O_E="0.0" SE="0.550154251982037" STUDY_ID="STD-Szeimies-2004" TOTAL_1="147" TOTAL_2="139" VAR="0.3026697009739147" WEIGHT="26.27512418625374"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.5982949163927" CI_START="0.31801806291585943" DF="0" EFFECT_SIZE="4.903225806451613" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-021.03.03" LOG_CI_END="1.8785120003060654" LOG_CI_START="-0.49754821208506556" LOG_EFFECT_SIZE="0.6904818941104999" MODIFIED="2011-09-23 15:27:10 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.25464933823293834" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="1.1391290821470184">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="75.5982949163927" CI_START="0.31801806291585943" EFFECT_SIZE="4.903225806451613" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="1.8785120003060654" LOG_CI_START="-0.49754821208506556" LOG_EFFECT_SIZE="0.6904818941104999" MODIFIED="2011-09-23 15:27:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2851" O_E="0.0" SE="1.3957095304462916" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9480050933786077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2638914016822262" CI_END="7.179464593027128" CI_START="0.33461308411325885" DF="2" EFFECT_SIZE="1.5499492861880193" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="38.723451430731124" ID="CMP-021.03.04" LOG_CI_END="0.8560920580356292" LOG_CI_START="-0.47545708116474483" LOG_EFFECT_SIZE="0.19031748843544222" MODIFIED="2011-09-23 15:29:35 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.19554889077220905" P_Z="0.575293338251782" STUDIES="3" TAU2="0.7203525712753985" TOTAL_1="676" TOTAL_2="330" WEIGHT="100.0" Z="0.5602728611061089">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="82.96917233319923" CI_START="0.3539797498509474" EFFECT_SIZE="5.419354838709677" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="1.9189167577673958" LOG_CI_START="-0.4510215819842153" LOG_EFFECT_SIZE="0.7339475878915901" MODIFIED="2011-09-23 15:27:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2855" O_E="0.0" SE="1.3921135121540795" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="1.9379800307219663" WEIGHT="23.013373334190998"/>
<DICH_DATA CI_END="24.863474867592494" CI_START="0.3664318136144954" EFFECT_SIZE="3.01840490797546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3955618246419255" LOG_CI_START="-0.4360068279151206" LOG_EFFECT_SIZE="0.4797774983634025" MODIFIED="2011-09-23 15:27:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2853" O_E="0.0" SE="1.0758724929230603" STUDY_ID="STD-Hanke-2010" TOTAL_1="326" TOTAL_2="164" VAR="1.1575016210284803" WEIGHT="32.578248549297854"/>
<DICH_DATA CI_END="2.4340282676299476" CI_START="0.10143052523600957" EFFECT_SIZE="0.496875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.3863256176099114" LOG_CI_START="-0.9938313256088203" LOG_EFFECT_SIZE="-0.3037528539994545" MODIFIED="2011-09-23 15:29:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2852" O_E="0.0" SE="0.8107110203337352" STUDY_ID="STD-Swanson-2010a" TOTAL_1="320" TOTAL_2="159" VAR="0.657252358490566" WEIGHT="44.408378116511145"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:13:57 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:body as a whole: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 13:56:41 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>2 times/week</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-05 13:56:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="875" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 13:56:43 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="32.55296360847741" CI_START="0.10703923877262678" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.5125905326958826" LOG_CI_START="-0.9704569881228068" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2011-08-05 13:56:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="876" O_E="0.0" SE="1.4585544050123576" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.1273809523809524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-021.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 13:56:47 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 13:56:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="877" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 13:56:48 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:56:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="878" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.487354575341218" CI_END="7.282521899645775" CI_START="0.5198971886496838" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9458064297112376" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.05" LOG_CI_END="0.8622817992909189" LOG_CI_START="-0.28408253101271824" LOG_EFFECT_SIZE="0.2890996341391003" METHOD="MH" MODIFIED="2011-09-28 16:13:57 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.4815771788240779" P_Q="0.744887097088696" P_Z="0.3228785550474713" Q="1.2338944771957903" RANDOM="YES" SCALE="770.35" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="458" TOTAL_2="198" WEIGHT="400.0" Z="0.9885598424128589">
<NAME>Minor adverse events excluding skin irritation: body as a whole:"flu" or "cold"</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.909922646603808E-33" CI_END="16.739020923288855" CI_START="0.033604115950258404" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-021.05.01" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-05 14:07:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.8559215720794137" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="7" WEIGHT="100.0" Z="0.18156824422312373">
<NAME>2 times/week</NAME>
<DICH_DATA CI_END="16.739020923288855" CI_START="0.033604115950258404" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2237300522206755" LOG_CI_START="-1.4736075254372754" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-05 14:07:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="879" O_E="0.0" SE="1.5844294451526286" STUDY_ID="STD-Gebauer-2009" TOTAL_1="31" TOTAL_2="7" VAR="2.5104166666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11822707113628853" CI_END="19.830324191523612" CI_START="0.35847736508140904" DF="1" EFFECT_SIZE="2.6662187391299135" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-021.05.02" LOG_CI_END="1.297329814227436" LOG_CI_START="-0.44553826128093676" LOG_EFFECT_SIZE="0.42589577647324955" MODIFIED="2011-09-22 20:35:22 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.7309654396705767" P_Z="0.3381168336474828" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="13" WEIGHT="100.0" Z="0.9578927915261827">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="32.55296360847741" CI_START="0.10703923877262678" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.5125905326958826" LOG_CI_START="-0.9704569881228068" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2011-08-05 14:07:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="880" O_E="0.0" SE="1.4585544050123576" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.1273809523809524" WEIGHT="49.26732327313227"/>
<DICH_DATA CI_END="63.05436240286164" CI_START="0.22531510985624054" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.799715138521337" LOG_CI_START="-0.6472096830779832" LOG_EFFECT_SIZE="0.5762527277216769" MODIFIED="2011-09-22 20:35:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4410" O_E="0.0" SE="1.4373357526806552" STUDY_ID="STD-Ooi-2006" TOTAL_1="12" TOTAL_2="6" VAR="2.0659340659340657" WEIGHT="50.73267672686772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.268218240049002" CI_START="0.03470975650366249" DF="0" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.05.03" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-05 14:07:53 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.8716501947710975" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="0.1615627478811938">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="17.268218240049002" CI_START="0.03470975650366249" EFFECT_SIZE="0.7741935483870968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2372475287408944" LOG_CI_START="-1.4595484329862276" LOG_EFFECT_SIZE="-0.11115045212266667" MODIFIED="2011-08-05 14:07:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="881" O_E="0.0" SE="1.5841112972738176" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.5094086021505375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.055375594862244" CI_END="95.17897138960697" CI_START="0.28386210391077404" DF="1" EFFECT_SIZE="5.197855621957694" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" I2="51.34709186488019" ID="CMP-021.05.04" LOG_CI_END="1.9785410070163048" LOG_CI_START="-0.546892582680123" LOG_EFFECT_SIZE="0.7158242121680909" MODIFIED="2011-09-22 20:35:30 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.1516703032543688" P_Z="0.2665304232775747" STUDIES="2" TAU2="2.2610922276785312" TOTAL_1="356" TOTAL_2="171" WEIGHT="100.0" Z="1.1110881559786845">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 14:07:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="882" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="48.8612663187296"/>
<DICH_DATA CI_END="323.89499739974906" CI_START="1.195631523212366" EFFECT_SIZE="19.678899082568808" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.510404240327367" LOG_CI_START="0.07759735683287163" LOG_EFFECT_SIZE="1.2940007985801194" MODIFIED="2011-09-22 20:35:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4411" O_E="0.0" SE="1.4290428059529603" STUDY_ID="STD-Hanke-2010" TOTAL_1="326" TOTAL_2="164" VAR="2.04216334124591" WEIGHT="51.13873368127041"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 14:05:18 +0000" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="89" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:18 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="17.831958554094268" CI_START="0.03589061729021652" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2511990460649878" LOG_CI_START="-1.4450190720811007" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-08-05 13:59:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="884" O_E="0.0" SE="1.5837718690939466" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.5083333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:18 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:59:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="885" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:18 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 13:59:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="886" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 14:05:44 +0000" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="89" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: nausea</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-021.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:44 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="17.831958554094268" CI_START="0.03589061729021652" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2511990460649878" LOG_CI_START="-1.4450190720811007" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-08-05 14:09:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="888" O_E="0.0" SE="1.5837718690939466" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="2.5083333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:44 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 14:09:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="889" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-021.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:44 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="24.290675388552945" CI_START="0.06854203662477795" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3854395902865584" LOG_CI_START="-1.164042995299179" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2011-08-05 14:09:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="890" O_E="0.0" SE="1.4975786909153959" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.242741935483871" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 14:06:09 +0000" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="59" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-021.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:05:59 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-05 14:01:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="892" O_E="0.0" SE="0.0" STUDY_ID="STD-Gebauer-2009" TOTAL_1="29" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-021.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 14:06:09 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="38.82808628343901" CI_START="0.1389298667438743" EFFECT_SIZE="2.3225806451612905" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.589145986038615" LOG_CI_START="-0.8572043808446234" LOG_EFFECT_SIZE="0.3659708025969958" MODIFIED="2011-08-05 14:01:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="894" O_E="0.0" SE="1.4369983151368317" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.0649641577060933" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9125136021675435" CI_END="12.9092683392905" CI_START="1.0090707322681494" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6092055713375353" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-021.09" LOG_CI_END="1.1109016283846735" LOG_CI_START="0.003921609801916613" LOG_EFFECT_SIZE="0.5574116190932951" METHOD="MH" MODIFIED="2011-12-05 14:07:10 +0000" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.8224071194187281" P_Q="0.8643581214189753" P_Z="0.048398710472837905" Q="0.29153623456019856" RANDOM="YES" SCALE="202.55" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="184" WEIGHT="300.0" Z="1.9738508006417872">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.05436240286164" CI_START="0.22531510985624054" DF="0" EFFECT_SIZE="3.7692307692307696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-021.09.01" LOG_CI_END="1.799715138521337" LOG_CI_START="-0.6472096830779832" LOG_EFFECT_SIZE="0.5762527277216769" MODIFIED="2011-12-05 14:07:10 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.35593106730109136" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="6" WEIGHT="100.0" Z="0.9231461321228902">
<NAME>3 times/week</NAME>
<DICH_DATA CI_END="63.05436240286164" CI_START="0.22531510985624054" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.799715138521337" LOG_CI_START="-0.6472096830779832" LOG_EFFECT_SIZE="0.5762527277216769" MODIFIED="2011-09-22 20:34:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4408" O_E="0.0" SE="1.4373357526806552" STUDY_ID="STD-Ooi-2006" TOTAL_1="12" TOTAL_2="6" VAR="2.0659340659340657" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.791028972698226E-33" CI_END="31.525632848566687" CI_START="0.10351155979757057" DF="0" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-021.09.02" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-12-05 14:07:10 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.6852252658462363" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="7" WEIGHT="100.0" Z="0.40534318806788106">
<NAME>5 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 14:11:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="897" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6030764078545722" CI_END="23.310654973634264" CI_START="0.859977821175174" DF="1" EFFECT_SIZE="4.477348129684828" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-021.09.03" LOG_CI_END="1.3675544763279088" LOG_CI_START="-0.06551274906508626" LOG_EFFECT_SIZE="0.6510208636314113" MODIFIED="2011-12-05 14:07:10 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.43740680864846204" P_Z="0.07495097096504308" STUDIES="2" TAU2="0.0" TOTAL_1="356" TOTAL_2="171" WEIGHT="100.0" Z="1.7807642562641293">
<NAME>7 times/week</NAME>
<DICH_DATA CI_END="31.525632848566687" CI_START="0.10351155979757057" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.498663813401559" LOG_CI_START="-0.9850111470577037" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2011-08-05 14:11:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="898" O_E="0.0" SE="1.4589229661631065" STUDY_ID="STD-Gebauer-2009" TOTAL_1="30" TOTAL_2="7" VAR="2.1284562211981566" WEIGHT="33.29228544101901"/>
<DICH_DATA CI_END="53.095181218665154" CI_START="0.9342292484917616" EFFECT_SIZE="7.042944785276074" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.7250551074259597" LOG_CI_START="-0.029546540109965772" LOG_EFFECT_SIZE="0.8477542836579969" MODIFIED="2011-09-22 20:34:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4409" O_E="0.0" SE="1.0306616931808346" STUDY_ID="STD-Hanke-2010" TOTAL_1="326" TOTAL_2="164" VAR="1.062263525790385" WEIGHT="66.70771455898098"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2012-10-08 16:34:14 +0100" MODIFIED_BY="Maryse Paquet" NO="22">
<NAME>5% imiquimod versus 5% 5-FU</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.998518365585316" CI_START="0.6981283263821709" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8349215265088913" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="-6.439428122992264E-4" LOG_CI_START="-0.15606474024616365" LOG_EFFECT_SIZE="-0.07835434152923149" METHOD="MH" MODIFIED="2012-10-08 16:34:14 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.048131550827455453" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="45" TOTAL_2="44" WEIGHT="0.0" Z="1.976205114955654">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.061215033574846" CI_START="0.734618876044114" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.025803393734295105" LOG_CI_START="-0.1339379166434923" LOG_EFFECT_SIZE="-0.0540672614545986" MODIFIED="2011-03-31 15:59:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="179" O_E="0.0" SE="0.09383283644815148" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="26" TOTAL_2="24" VAR="0.008804601195905544" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.671741103407468" CI_START="0.14268983377320876" EFFECT_SIZE="0.30959752321981426" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.17279807668732114" LOG_CI_START="-0.8456069679748845" LOG_EFFECT_SIZE="-0.5092025223311029" MODIFIED="2011-05-04 15:07:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="436" O_E="0.0" SE="0.39521127320003957" STUDY_ID="STD-Tanghetti-2007" TOTAL_1="19" TOTAL_2="20" VAR="0.15619195046439632" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-022.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-05 18:50:01 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="339.01116089670603" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: Investigator cosmetic outcome "excellent"</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="133.2626652247307" CI_START="2.819719333811837" EFFECT_SIZE="19.384615384615383" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="2.1247084948154935" LOG_CI_START="0.45020588213392104" LOG_EFFECT_SIZE="1.2874571884747072" MODIFIED="2011-08-05 18:47:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1128" O_E="0.0" SE="0.9836111236107705" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="26" TOTAL_2="24" VAR="0.9674908424908425" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-05 18:54:02 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.28" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: normal skin surface</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1121329089121947" CI_START="0.9961937999313584" EFFECT_SIZE="1.4505494505494505" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" LOG_CI_END="0.3247212433082791" LOG_CI_START="-0.0016561655387666" LOG_EFFECT_SIZE="0.16153253888475624" MODIFIED="2011-08-05 18:53:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1129" O_E="0.0" SE="0.1917157055509844" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="26" TOTAL_2="24" VAR="0.03675491175491175" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2012-09-17 20:37:56 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>5% imiquimod versus cryotherapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-17 18:45:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.22" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="17" I2="0.0" ID="CMP-023.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 18:45:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="1.7049334914933914" CI_START="0.9081830627392854" EFFECT_SIZE="1.244343891402715" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.2317074420729199" LOG_CI_START="-0.041826601782616026" LOG_EFFECT_SIZE="0.09494042014515196" MODIFIED="2012-09-17 18:45:18 +0100" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.16067525137609617" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="26" TOTAL_2="25" VAR="0.025816536404771696" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2012-09-17 20:37:45 +0100" MODIFIED_BY="Maryse Paquet" NO="24">
<NAME>Ingenol mebutate (PEP005) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="78" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-05 20:52:48 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="162" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.018971851966196" CI_START="1.8578395428580112" EFFECT_SIZE="3.611111111111111" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="8" LOG_CI_END="0.8462735007737647" LOG_CI_START="0.26900820230533434" LOG_EFFECT_SIZE="0.5576408515395496" MODIFIED="2011-08-05 20:52:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1276" O_E="0.0" SE="0.33908849382966877" STUDY_ID="STD-Anderson-2009" TOTAL_1="162" TOTAL_2="60" VAR="0.11498100664767333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2786395001780827" CI_END="7.743081974194938" CI_START="2.6138651709739076" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.498818988172789" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="0.8889138570618098" LOG_CI_START="0.4172831819391627" LOG_EFFECT_SIZE="0.6530985195004863" METHOD="MH" MODIFIED="2011-08-08 15:57:04 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.5975943865216786" P_Q="1.0" P_Z="5.6929610043803636E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="279" TOTAL_2="177" WEIGHT="100.0" Z="5.428186265638925">
<NAME>Participant complete clearance of all lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.117735050290934" CI_START="1.9398316721360596" EFFECT_SIZE="3.9682539682539684" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="7" LOG_CI_END="0.9094348725449035" LOG_CI_START="0.2877640458920082" LOG_EFFECT_SIZE="0.5985994592184559" MODIFIED="2011-08-05 20:53:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1277" O_E="0.0" SE="0.365172520896133" STUDY_ID="STD-Anderson-2009" TOTAL_1="162" TOTAL_2="60" VAR="0.13335097001763668" WEIGHT="57.555007262691355"/>
<DICH_DATA CI_END="12.273184379460886" CI_START="2.317609152197378" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="6" LOG_CI_END="1.0889572586522376" LOG_CI_START="0.365040197220287" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2011-08-08 15:36:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1299" O_E="0.0" SE="0.4252324653323751" STUDY_ID="STD-Swanson-2010b" TOTAL_1="117" TOTAL_2="117" VAR="0.18082264957264957" WEIGHT="42.44499273730864"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17331414661325864" CI_END="4.580807009937818" CI_START="1.8148740794460667" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8833293091981336" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="0.660941995272132" LOG_CI_START="0.25884649796781456" LOG_EFFECT_SIZE="0.4598942466199733" METHOD="MH" MODIFIED="2011-08-08 20:43:12 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.6771833568046126" P_Q="1.0" P_Z="7.346529205009498E-6" Q="0.0" RANDOM="YES" SCALE="33.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="72" WEIGHT="100.0" Z="4.483393453123609">
<NAME>Participant partial (&gt;75%) clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.90410204683943" CI_START="1.8247562784384397" EFFECT_SIZE="2.9914529914529915" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="13" LOG_CI_END="0.690559498606231" LOG_CI_START="0.26120486660199704" LOG_EFFECT_SIZE="0.475882182604114" MODIFIED="2011-08-05 20:54:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1278" O_E="0.0" SE="0.25220503617899254" STUDY_ID="STD-Anderson-2009" TOTAL_1="162" TOTAL_2="60" VAR="0.06360738027404694" WEIGHT="87.70535577877355"/>
<DICH_DATA CI_END="8.302724202448088" CI_START="0.5921940891578227" EFFECT_SIZE="2.217391304347826" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="0.9192206118911828" LOG_CI_START="-0.22753593173049563" LOG_EFFECT_SIZE="0.3458423400803435" MODIFIED="2011-08-08 14:34:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1249" O_E="0.0" SE="0.6736104702598148" STUDY_ID="STD-Siller-2009" TOTAL_1="46" TOTAL_2="12" VAR="0.4537510656436488" WEIGHT="12.294644221226449"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5569139626831" CI_END="17.79933032242665" CI_START="0.6333428493912425" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.357540555773175" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="21.7807079475878" I2_Q="0.0" ID="CMP-024.04" LOG_CI_END="1.250403662828788" LOG_CI_START="-0.19836112838726785" LOG_EFFECT_SIZE="0.5260212672207601" METHOD="MH" MODIFIED="2012-04-16 19:37:28 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.27846676466977405" P_Q="1.0" P_Z="0.1546614978314357" Q="0.0" RANDOM="YES" SCALE="636.81" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4840412678155934" TOTALS="YES" TOTAL_1="325" TOTAL_2="189" WEIGHT="100.0" Z="1.4232575848139286">
<NAME>Cosmetic outcomes: changes in pigmentation</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ingenol mebutate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="85.06630187992955" CI_START="0.27823618688169316" EFFECT_SIZE="4.865030674846626" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.92975755296418" LOG_CI_START="-0.5555863871368881" LOG_EFFECT_SIZE="0.687085582913646" MODIFIED="2012-04-16 19:07:38 +0100" MODIFIED_BY="[Empty name]" ORDER="727" O_E="0.0" SE="1.4599033330662856" STUDY_ID="STD-Anderson-2009" TOTAL_1="162" TOTAL_2="60" VAR="2.13131774189805" WEIGHT="27.69106487597194"/>
<DICH_DATA CI_END="8.497281572646777" CI_START="0.12814061433628746" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.9292800096171534" LOG_CI_START="-0.8923131982291269" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2011-08-08 15:26:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1294" O_E="0.0" SE="1.0700128673207085" STUDY_ID="STD-Siller-2009" TOTAL_1="46" TOTAL_2="12" VAR="1.144927536231884" WEIGHT="44.45884772746539"/>
<DICH_DATA CI_END="259.65820156950383" CI_START="0.8665237556140639" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4144020447825087" LOG_CI_START="-0.06221952667114631" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2011-08-08 15:44:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1301" O_E="0.0" SE="1.4547797705463739" STUDY_ID="STD-Swanson-2010b" TOTAL_1="117" TOTAL_2="117" VAR="2.1163841807909605" WEIGHT="27.850087396562667"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2012-09-17 20:37:37 +0100" MODIFIED_BY="Maryse Paquet" NO="25">
<NAME>Ingenol mebutate (PEP005) versus placebo: different concentrations</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="78" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-08 20:20:34 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="162" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="3" I2="0.0" ID="CMP-025.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-05 20:07:52 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>0.025% 3 days</NAME>
<DICH_DATA CI_END="8.352460612555412" CI_START="0.9386455517329729" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="0.9218144363257124" LOG_CI_START="-0.027498373641273943" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2011-08-05 20:07:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="205" O_E="0.0" SE="0.5576310437488043" STUDY_ID="STD-Anderson-2009" TOTAL_1="50" TOTAL_2="20" VAR="0.3109523809523809" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="6" I2="0.0" ID="CMP-025.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-08 20:20:34 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>0.05% 2-3 days</NAME>
<DICH_DATA CI_END="7.253443087841523" CI_START="1.5870365910959836" EFFECT_SIZE="3.392857142857143" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="6" LOG_CI_END="0.8605442078253188" LOG_CI_START="0.20058694006793837" LOG_EFFECT_SIZE="0.5305655739466285" MODIFIED="2011-08-08 20:20:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="204" O_E="0.0" SE="0.38766216592184755" STUDY_ID="STD-Anderson-2009" TOTAL_1="112" TOTAL_2="40" VAR="0.15028195488721804" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12541495344305822" CI_END="8.69251147683191" CI_START="2.7879178104710904" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.9228048472374" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.9391452727601253" LOG_CI_START="0.44527996634669714" LOG_EFFECT_SIZE="0.6922126195534112" METHOD="MH" MODIFIED="2011-08-08 20:21:25 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.9392181843578911" P_Q="0.7414465769831258" P_Z="3.92355653263545E-8" Q="0.1088593199099925" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="279" TOTAL_2="177" WEIGHT="200.0" Z="5.49425839940687">
<NAME>Participant complete clearance of all lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.552124327745016" CI_START="1.028798359813519" DF="0" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" I2="0.0" ID="CMP-025.02.01" LOG_CI_END="1.1917897194596287" LOG_CI_START="0.012330263196295984" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-08-08 16:03:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.04539847294255327" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="20" WEIGHT="100.0" Z="2.0009435564215723">
<NAME>0.025% 3 days</NAME>
<DICH_DATA CI_END="15.552124327745016" CI_START="1.0287983598135193" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.1917897194596287" LOG_CI_START="0.012330263196296078" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2011-08-05 20:08:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="206" O_E="0.0" SE="0.6928203230275509" STUDY_ID="STD-Anderson-2009" TOTAL_1="50" TOTAL_2="20" VAR="0.48000000000000004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.016584750108106828" CI_END="9.622707769914806" CI_START="2.750815150886649" DF="1" EFFECT_SIZE="5.144928602617953" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="10" I2="0.0" ID="CMP-025.02.02" LOG_CI_END="0.9832972969922307" LOG_CI_START="0.43946140767534597" LOG_EFFECT_SIZE="0.7113793523337882" MODIFIED="2011-08-08 20:21:25 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.8975303173749982" P_Z="2.935080749239425E-7" STUDIES="2" TAU2="0.0" TOTAL_1="229" TOTAL_2="157" WEIGHT="99.99999999999999" Z="5.127568582025785">
<NAME>0.05% 2-3 days</NAME>
<DICH_DATA CI_END="12.680132529135713" CI_START="1.9018030561201136" EFFECT_SIZE="4.910714285714286" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="4" LOG_CI_END="1.103123792691735" LOG_CI_START="0.2791655409563894" LOG_EFFECT_SIZE="0.6911446668240622" MODIFIED="2011-08-08 20:21:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="207" O_E="0.0" SE="0.48399715572846785" STUDY_ID="STD-Anderson-2009" TOTAL_1="112" TOTAL_2="40" VAR="0.23425324675324674" WEIGHT="43.563755730753606"/>
<DICH_DATA CI_END="12.273184379460886" CI_START="2.317609152197378" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="6" LOG_CI_END="1.0889572586522376" LOG_CI_START="0.365040197220287" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2011-04-21 21:31:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="450" O_E="0.0" SE="0.4252324653323751" STUDY_ID="STD-Swanson-2010b" TOTAL_1="117" TOTAL_2="117" VAR="0.18082264957264957" WEIGHT="56.43624426924638"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5533056623998163" CI_END="4.377029342392871" CI_START="1.7146948493464889" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.739574724083923" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="15" I2="0.0" I2_Q="13.015464671271573" ID="CMP-025.03" LOG_CI_END="0.6411794580128389" LOG_CI_START="0.23418684330794184" LOG_EFFECT_SIZE="0.4376831506603904" METHOD="MH" MODIFIED="2011-08-31 21:28:35 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.4698195800470575" P_Q="0.32745191661907047" P_Z="2.4920081700169727E-5" Q="3.4488889187744944" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="208" TOTAL_2="72" WEIGHT="400.0" Z="4.21552225244377">
<NAME>Participant partial (&gt;75%) clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.412933195124873" CI_START="0.21131485732086452" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-025.03.01" LOG_CI_END="0.9249474403118042" LOG_CI_START="-0.6750699670952044" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-08-08 14:37:46 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.7595353988371508" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="4" WEIGHT="99.99999999999999" Z="0.3060909498766635">
<NAME>0.0025% 2 days</NAME>
<DICH_DATA CI_END="8.412933195124873" CI_START="0.21131485732086452" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="0.9249474403118042" LOG_CI_START="-0.6750699670952044" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-08-08 14:37:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1250" O_E="0.0" SE="0.939858145324779" STUDY_ID="STD-Siller-2009" TOTAL_1="15" TOTAL_2="4" VAR="0.8833333333333333" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.231997292711791" CI_START="0.05907376179813297" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-025.03.02" LOG_CI_END="0.6265453812008754" LOG_CI_START="-1.228605372528838" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-08-08 14:37:51 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.5247272324909378" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="4" WEIGHT="100.0" Z="0.6360754764338825">
<NAME>0.01% 2 days</NAME>
<DICH_DATA CI_END="4.231997292711791" CI_START="0.05907376179813297" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.6265453812008754" LOG_CI_START="-1.228605372528838" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-08-08 14:37:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1251" O_E="0.0" SE="1.0897247358851685" STUDY_ID="STD-Siller-2009" TOTAL_1="16" TOTAL_2="4" VAR="1.1875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.958234019877828" CI_START="1.1267226680797453" DF="0" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-025.03.03" LOG_CI_END="0.8424990308836172" LOG_CI_START="0.05181703180082111" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2011-08-08 14:36:31 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="1.0" P_Z="0.026633007674120097" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="20" WEIGHT="100.0" Z="2.216854912202975">
<NAME>0.025% 3 days</NAME>
<DICH_DATA CI_END="6.958234019877828" CI_START="1.1267226680797453" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="0.8424990308836172" LOG_CI_START="0.05181703180082111" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2011-08-05 20:09:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="209" O_E="0.0" SE="0.46445052020025307" STUDY_ID="STD-Anderson-2009" TOTAL_1="50" TOTAL_2="20" VAR="0.2157142857142857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07274804145102418" CI_END="6.043548264793483" CI_START="1.842176551780723" DF="1" EFFECT_SIZE="3.3366574446529014" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="9" I2="0.0" ID="CMP-025.03.04" LOG_CI_END="0.7812919948067264" LOG_CI_START="0.26533125006809555" LOG_EFFECT_SIZE="0.5233116224374109" MODIFIED="2011-08-08 20:22:19 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.7873768727387971" P_Z="7.015040702106975E-5" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="44" WEIGHT="100.00000000000001" Z="3.975775068656128">
<NAME>0.05% 2-3 days</NAME>
<DICH_DATA CI_END="6.468805193807988" CI_START="1.8266752353758917" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="8" LOG_CI_END="0.8108240726850671" LOG_CI_START="0.2616613409915709" LOG_EFFECT_SIZE="0.5362427068383191" MODIFIED="2011-08-08 20:22:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="210" O_E="0.0" SE="0.32258090699612335" STUDY_ID="STD-Anderson-2009" TOTAL_1="112" TOTAL_2="40" VAR="0.10405844155844157" WEIGHT="88.27367522409904"/>
<DICH_DATA CI_END="15.112426241686308" CI_START="0.4705472832347549" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.1793341942389324" LOG_CI_START="-0.3273967296943702" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-08-08 14:38:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1252" O_E="0.0" SE="0.8850612031567836" STUDY_ID="STD-Siller-2009" TOTAL_1="15" TOTAL_2="4" VAR="0.7833333333333334" WEIGHT="11.726324775900972"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8630346327821279" CI_END="18.39021057124571" CI_START="0.4995235474931385" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0308980886355243" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-025.04" LOG_CI_END="1.2645867020171149" LOG_CI_START="-0.3014440343543358" LOG_EFFECT_SIZE="0.48157133383138956" METHOD="MH" MODIFIED="2011-12-05 14:07:34 +0000" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.3939555598175962" P_Q="0.5250921570823484" P_Z="0.22804118454201505" Q="0.40388017975032886" RANDOM="YES" SCALE="867.45" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="125" WEIGHT="200.0" Z="1.2054201087820307">
<NAME>Cosmetic outcomes: changes in pigmentation</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.884144988240426" CI_START="0.08355036485725083" DF="0" EFFECT_SIZE="1.4705882352941178" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-025.04.01" LOG_CI_END="1.4130338238273605" LOG_CI_START="-1.078051649239833" LOG_EFFECT_SIZE="0.16749108729376372" MODIFIED="2011-12-05 14:07:34 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.7921182079538578" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="4" WEIGHT="100.0" Z="0.2635610077425684">
<NAME>0.01% 2 days</NAME>
<DICH_DATA CI_END="25.884144988240426" CI_START="0.08355036485725083" EFFECT_SIZE="1.4705882352941178" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.4130338238273605" LOG_CI_START="-1.078051649239833" LOG_EFFECT_SIZE="0.16749108729376372" MODIFIED="2011-08-08 15:29:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1297" O_E="0.0" SE="1.4632759379516342" STUDY_ID="STD-Siller-2009" TOTAL_1="16" TOTAL_2="4" VAR="2.1411764705882352" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3156751103836735" CI_END="49.39267931893323" CI_START="0.47858016671987136" DF="1" EFFECT_SIZE="4.861929319025135" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="23.99339380157592" ID="CMP-025.04.02" LOG_CI_END="1.6936625852193967" LOG_CI_START="-0.32004530334605635" LOG_EFFECT_SIZE="0.6868086409366702" MODIFIED="2011-12-05 14:07:34 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.2513698432488094" P_Z="0.18123674724147879" STUDIES="2" TAU2="0.6714226791652743" TOTAL_1="132" TOTAL_2="121" WEIGHT="100.00000000000001" Z="1.3369567732743393">
<NAME>0.05% 2 days</NAME>
<DICH_DATA CI_END="27.434243193991385" CI_START="0.08899120098690069" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.438292984170996" LOG_CI_START="-1.0506529321387703" LOG_EFFECT_SIZE="0.19382002601611284" MODIFIED="2011-08-08 15:29:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1298" O_E="0.0" SE="1.4620191517213446" STUDY_ID="STD-Siller-2009" TOTAL_1="15" TOTAL_2="4" VAR="2.1374999999999997" WEIGHT="49.81135572961461"/>
<DICH_DATA CI_END="259.65820156950383" CI_START="0.8665237556140639" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4144020447825087" LOG_CI_START="-0.06221952667114631" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2011-08-08 15:44:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1302" O_E="0.0" SE="1.4547797705463739" STUDY_ID="STD-Swanson-2010b" TOTAL_1="117" TOTAL_2="117" VAR="2.1163841807909605" WEIGHT="50.1886442703854"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2012-09-17 20:37:26 +0100" MODIFIED_BY="Maryse Paquet" NO="26">
<NAME>0.05% Ingenol mebutate (PEP005) versus placebo: number of doses</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-08 16:45:27 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="112" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="4" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-08 16:45:25 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>0.05% 2 days</NAME>
<DICH_DATA CI_END="8.551519966140809" CI_START="1.2524959123128274" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="0.9320433140543938" LOG_CI_START="0.09777631716373068" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2011-08-08 16:45:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1304" O_E="0.0" SE="0.4900525636618129" STUDY_ID="STD-Anderson-2009" TOTAL_1="55" TOTAL_2="30" VAR="0.24015151515151517" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="4" I2="0.0" ID="CMP-026.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-08 16:45:27 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>0.05% 3 days</NAME>
<DICH_DATA CI_END="11.102286088821238" CI_START="1.6981978275021432" EFFECT_SIZE="4.342105263157895" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="4" LOG_CI_END="1.0454124142402625" LOG_CI_START="0.22998828095392967" LOG_EFFECT_SIZE="0.6377003475970962" MODIFIED="2011-08-08 16:45:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1305" O_E="0.0" SE="0.4789841723069502" STUDY_ID="STD-Anderson-2009" TOTAL_1="57" TOTAL_2="30" VAR="0.22942583732057414" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5777094213429903" CI_END="7.168759811741762" CI_START="2.5160578993809875" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.247000677313087" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.8554440296561382" LOG_CI_START="0.4007206308480899" LOG_EFFECT_SIZE="0.6280823302521141" METHOD="MH" MODIFIED="2011-08-08 16:44:14 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.7491210626580052" P_Q="0.91961067614193" P_Z="6.150731451203459E-8" Q="0.010185683219971792" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="229" TOTAL_2="177" WEIGHT="200.0" Z="5.414362884544606">
<NAME>Participant complete clearance of all lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5680536735628481" CI_END="8.114911402115434" CI_START="2.3041722574127754" DF="1" EFFECT_SIZE="4.324136182420367" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="10" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="0.9092837825994137" LOG_CI_START="0.3625149433481327" LOG_EFFECT_SIZE="0.6358993629737731" MODIFIED="2011-08-08 16:44:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.45103348979334856" P_Z="5.141542555223848E-6" STUDIES="2" TAU2="0.0" TOTAL_1="172" TOTAL_2="147" WEIGHT="100.0" Z="4.558927867678914">
<NAME>0.05% 2 days</NAME>
<DICH_DATA CI_END="8.551519966140809" CI_START="1.2524959123128274" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="0.9320433140543938" LOG_CI_START="0.09777631716373068" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2011-08-08 16:44:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1308" O_E="0.0" SE="0.4900525636618129" STUDY_ID="STD-Anderson-2009" TOTAL_1="55" TOTAL_2="30" VAR="0.24015151515151517" WEIGHT="42.953384013750615"/>
<DICH_DATA CI_END="12.273184379460886" CI_START="2.317609152197378" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="6" LOG_CI_END="1.0889572586522376" LOG_CI_START="0.365040197220287" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2011-08-08 16:33:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1307" O_E="0.0" SE="0.4252324653323751" STUDY_ID="STD-Swanson-2010b" TOTAL_1="117" TOTAL_2="117" VAR="0.18082264957264957" WEIGHT="57.04661598624938"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.471131804947035" CI_START="1.5889219947063002" DF="0" EFFECT_SIZE="4.078947368421052" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" I2="0.0" ID="CMP-026.02.02" LOG_CI_END="1.0199936262898734" LOG_CI_START="0.20110257681708912" LOG_EFFECT_SIZE="0.6105481015534813" MODIFIED="2011-08-08 16:44:14 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.003471036247353736" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="30" WEIGHT="100.0" Z="2.9226166060663417">
<NAME>0.05% 3 days</NAME>
<DICH_DATA CI_END="10.471131804947035" CI_START="1.5889219947063002" EFFECT_SIZE="4.078947368421052" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="1.0199936262898734" LOG_CI_START="0.20110257681708912" LOG_EFFECT_SIZE="0.6105481015534813" MODIFIED="2011-08-08 16:44:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1309" O_E="0.0" SE="0.4810206560363836" STUDY_ID="STD-Anderson-2009" TOTAL_1="57" TOTAL_2="30" VAR="0.23138087153367287" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17891776725556413" CI_END="4.611247498971858" CI_START="1.841452812610219" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.913999772927851" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="0.6638184326841923" LOG_CI_START="0.26516059449934043" LOG_EFFECT_SIZE="0.46448951359176643" METHOD="MH" MODIFIED="2011-08-31 21:32:28 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.9144259065449549" P_Q="0.6724362118103234" P_Z="4.941915585077315E-6" Q="0.1787656128893479" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="64" WEIGHT="200.0" Z="4.567238522044354">
<NAME>Participant partial (&gt;75%) clearance of target lesions</NAME>
<GROUP_LABEL_1>Ingenol mebutate</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ingenol mebutate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.703822865195865E-5" CI_END="4.998568659085458" CI_START="1.4066595755475688" DF="1" EFFECT_SIZE="2.6516569288530767" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="8" I2="0.0" ID="CMP-026.03.01" LOG_CI_END="0.6988456618453385" LOG_CI_START="0.14818900692329787" LOG_EFFECT_SIZE="0.4235173343843182" MODIFIED="2011-08-08 16:44:56 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.9945277978028886" P_Z="0.002570906305962357" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="34" WEIGHT="99.99999999999999" Z="3.0148685748261386">
<NAME>0.05% 2 days</NAME>
<DICH_DATA CI_END="5.235147519587336" CI_START="1.3407566524062322" EFFECT_SIZE="2.6493506493506493" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="7" LOG_CI_END="0.7189289240358895" LOG_CI_START="0.12734996047094432" LOG_EFFECT_SIZE="0.4231394422534169" MODIFIED="2011-08-08 16:44:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1314" O_E="0.0" SE="0.34749641156114647" STUDY_ID="STD-Anderson-2009" TOTAL_1="55" TOTAL_2="30" VAR="0.1207537560478737" WEIGHT="86.64357035221879"/>
<DICH_DATA CI_END="15.112426241686308" CI_START="0.4705472832347549" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.1793341942389324" LOG_CI_START="-0.3273967296943702" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-08-08 16:33:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1313" O_E="0.0" SE="0.8850612031567836" STUDY_ID="STD-Siller-2009" TOTAL_1="15" TOTAL_2="4" VAR="0.7833333333333334" WEIGHT="13.356429647781203"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.288818209442995" CI_START="1.6621284700358845" DF="0" EFFECT_SIZE="3.2330827067669174" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="7" I2="0.0" ID="CMP-026.03.02" LOG_CI_END="0.7985690407808821" LOG_CI_START="0.22066458844411943" LOG_EFFECT_SIZE="0.5096168146125007" MODIFIED="2011-08-08 16:44:57 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="5.467669519176236E-4" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="30" WEIGHT="100.0" Z="3.4567326779288354">
<NAME>0.05% 3 days</NAME>
<DICH_DATA CI_END="6.288818209442995" CI_START="1.6621284700358845" EFFECT_SIZE="3.2330827067669174" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="7" LOG_CI_END="0.7985690407808821" LOG_CI_START="0.22066458844411943" LOG_EFFECT_SIZE="0.5096168146125007" MODIFIED="2011-08-08 16:44:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1315" O_E="0.0" SE="0.3394639359757897" STUDY_ID="STD-Anderson-2009" TOTAL_1="57" TOTAL_2="30" VAR="0.11523576382817508" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2012-09-17 20:37:13 +0100" MODIFIED_BY="Maryse Paquet" NO="27">
<NAME>Isotretinoin versus vehicle</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-08 22:16:42 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Investigator global improvement indices-completely cleared</NAME>
<GROUP_LABEL_1>Isotretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours isotretinoin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-027.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-29 19:47:54 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<DICH_DATA CI_END="17.753017956043333" CI_START="0.07402114693948528" EFFECT_SIZE="1.146341463414634" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2492721923344423" LOG_CI_START="-1.1306441899024786" LOG_EFFECT_SIZE="0.05931400121598193" MODIFIED="2011-04-20 21:16:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="428" O_E="0.0" SE="1.3979746637020574" STUDY_ID="STD-Alirezai-1994" TOTAL_1="41" TOTAL_2="47" VAR="1.9543331603528802" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-027.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-29 19:50:03 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="85.28520620939848" CI_START="0.16103102313103607" EFFECT_SIZE="3.7058823529411766" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.930873703865894" LOG_CI_START="-0.7930904477152787" LOG_EFFECT_SIZE="0.5688916280753078" MODIFIED="2011-04-29 19:50:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="485" O_E="0.0" SE="1.600070026478796" STUDY_ID="STD-Alirezai-1994" TOTAL_1="16" TOTAL_2="20" VAR="2.5602240896358546" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-027.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-29 19:50:31 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Upper extremities</NAME>
<DICH_DATA CI_END="3.880477204887019" CI_START="0.2244855632740339" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5888851366007625" LOG_CI_START="-0.6488115833556488" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2011-04-29 19:50:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="484" O_E="0.0" SE="0.7270291799999699" STUDY_ID="STD-Alirezai-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.5285714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-027.02" MODIFIED="2011-10-12 17:23:41 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="81" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction of lesion counts</NAME>
<GROUP_LABEL_1>Isotretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-027.02.01" MODIFIED="2011-10-12 17:23:18 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<CONT_DATA CI_END="2.4327298303344094" CI_START="1.9672701696655912" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="1.7" MODIFIED="2011-03-17 17:18:26 +0000" MODIFIED_BY="Maryse Paquet" ORDER="105" SD_1="0.6" SD_2="0.5" SE="0.11874189126440701" STUDY_ID="STD-Alirezai-1994" TOTAL_1="41" TOTAL_2="47" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-027.02.02" MODIFIED="2011-04-29 19:52:58 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<CONT_DATA CI_END="1.3341368166543321" CI_START="-0.33413681665433304" EFFECT_SIZE="0.49999999999999956" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.6" MODIFIED="2011-04-29 19:52:58 +0100" MODIFIED_BY="Maryse Paquet" ORDER="487" SD_1="1.5" SD_2="0.9" SE="0.42558782877333323" STUDY_ID="STD-Alirezai-1994" TOTAL_1="16" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-027.02.03" MODIFIED="2011-10-12 17:23:10 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Upper extremities</NAME>
<CONT_DATA CI_END="2.518908977480822" CI_START="1.2810910225191774" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="1.0" MODIFIED="2011-04-29 19:53:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="486" SD_1="0.9" SD_2="0.8" SE="0.3157756889221932" STUDY_ID="STD-Alirezai-1994" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-17 16:38:19 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="938.789929546717" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Isotretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isotretinoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-10-17 16:38:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2859" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-Alirezai-1994" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 19:10:46 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.802910025159775" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Isotretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isotretinoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0111643672355846" CI_START="1.2283769824241522" EFFECT_SIZE="1.5717722534081797" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.30344756580625715" LOG_CI_START="0.08933166994960973" LOG_EFFECT_SIZE="0.19638961787793346" MODIFIED="2011-08-08 22:32:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1275" O_E="0.0" SE="0.12577273711697287" STUDY_ID="STD-Alirezai-1994" TOTAL_1="43" TOTAL_2="49" VAR="0.015818781401895163" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 19:10:35 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="43" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Severe-Skin irritation</NAME>
<GROUP_LABEL_1>Isotretinoin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours isotretinoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle</GRAPH_LABEL_2>
<DICH_DATA CI_END="124.09512721100974" CI_START="2.354415121610634" EFFECT_SIZE="17.093023255813954" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="1" LOG_CI_END="2.093754728582389" LOG_CI_START="0.3718830384268273" LOG_EFFECT_SIZE="1.2328188835046083" MODIFIED="2011-08-08 22:32:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1276" O_E="0.0" SE="1.011435954199707" STUDY_ID="STD-Alirezai-1994" TOTAL_1="43" TOTAL_2="49" VAR="1.023002689447872" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2012-09-17 20:37:04 +0100" MODIFIED_BY="Maryse Paquet" NO="28">
<NAME>Masoprocol versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-08 23:00:31 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="15.19" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="113" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Global improvement indices-cured</NAME>
<GROUP_LABEL_1>Masoprocol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours masoprocol</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.314902149830852" CI_START="0.5087858565632838" EFFECT_SIZE="2.1769911504424777" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.9691782971268705" LOG_CI_START="-0.2934649698869517" LOG_EFFECT_SIZE="0.33785666361995936" MODIFIED="2011-04-21 16:37:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="440" O_E="0.0" SE="0.7416829052288926" STUDY_ID="STD-Olsen-1991" TOTAL_1="113" TOTAL_2="41" VAR="0.5500935319087704" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-028.02" MODIFIED="2011-08-08 23:23:45 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.747714613056853" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="113" TOTAL_2="41" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>masprocol</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours masoprocol</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.832567218888343" CI_START="5.767432781111656" EFFECT_SIZE="7.3" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="2.3" MODIFIED="2011-04-21 16:35:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9182" SD_1="5.6" SD_2="3.7" SE="0.7819364187184247" STUDY_ID="STD-Olsen-1991" TOTAL_1="113" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 19:47:45 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="131" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Masoprocol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours masoprocol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.62471631989632" CI_START="0.08522291695813652" EFFECT_SIZE="1.7424242424242424" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5517514147374318" LOG_CI_START="-1.0694436051139458" LOG_EFFECT_SIZE="0.241153904811743" MODIFIED="2011-09-23 19:43:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2860" O_E="0.0" SE="1.5397029297853075" STUDY_ID="STD-Olsen-1991" TOTAL_1="131" TOTAL_2="45" VAR="2.3706851119894594" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2012-09-17 20:36:54 +0100" MODIFIED_BY="Maryse Paquet" NO="29">
<NAME>1% nicotinamide versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-029.01" MODIFIED="2011-07-22 19:19:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<GROUP_LABEL_1>nicotinamide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nicotinamide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-029.01.01" MODIFIED="2011-04-21 18:22:27 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="19.679663643141573" CI_START="3.920336356858427" EFFECT_SIZE="11.8" ESTIMABLE="YES" MEAN_1="21.8" MEAN_2="10.0" MODIFIED="2011-04-21 18:22:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="446" SD_1="10.0" SD_2="12.0" SE="4.0203104267707745" STUDY_ID="STD-Moloney-2010" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-029.01.02" MODIFIED="2011-04-21 18:22:59 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="11.734424730115395" CI_START="-7.334424730115389" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="24.6" MEAN_2="22.4" MODIFIED="2011-04-21 18:22:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="447" SD_1="15.4" SD_2="9.6" SE="4.864591801340084" STUDY_ID="STD-Moloney-2010" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 19:55:17 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>nicotinamide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nicotinamide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.937311710986485" CI_START="0.013392399113156346" EFFECT_SIZE="0.2571428571428571" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6934905467228619" LOG_CI_START="-1.8731416165447634" LOG_EFFECT_SIZE="-0.5898255349109508" MODIFIED="2011-09-23 19:55:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="2861" O_E="0.0" SE="1.5076524377375156" STUDY_ID="STD-Moloney-2010" TOTAL_1="13" TOTAL_2="17" VAR="2.273015873015873" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2012-09-17 20:36:46 +0100" MODIFIED_BY="Maryse Paquet" NO="30">
<NAME>0.1% resiquimod versus 0.01% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:08:56 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="68" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="14" I2="0.0" ID="CMP-030.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 00:39:22 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="3.650068999251881" CI_START="1.6408543180383885" EFFECT_SIZE="2.4472906403940886" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" LOG_CI_END="0.5623010742403415" LOG_CI_START="0.2150700242702802" LOG_EFFECT_SIZE="0.38868554925531085" MODIFIED="2011-08-09 00:39:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1333" O_E="0.0" SE="0.20396523757383214" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="0.04160181813854978" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="27" I2="0.0" ID="CMP-030.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 00:39:50 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.3888585809521714" CI_START="0.8802148590425443" EFFECT_SIZE="1.1056644880174291" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.14265802641516181" LOG_CI_START="-0.05541130431918332" LOG_EFFECT_SIZE="0.04362336104798926" MODIFIED="2011-08-09 00:39:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1331" O_E="0.0" SE="0.1163469053323541" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="0.013536602380415767" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:33:45 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="22" I2="0.0" ID="CMP-030.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 00:40:44 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.6680715375232915" CI_START="0.8872886310920678" EFFECT_SIZE="1.2165775401069518" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.22221467201239178" LOG_CI_START="-0.05193508309912729" LOG_EFFECT_SIZE="0.08513979445663224" MODIFIED="2011-08-09 00:40:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1332" O_E="0.0" SE="0.16103692321568056" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="0.025932890638772996" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:24:03 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="449.47074996239814" CI_START="1.7159119808407568" EFFECT_SIZE="27.771428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.65270143457146" LOG_CI_START="0.2344950065805375" LOG_EFFECT_SIZE="1.443598220575999" MODIFIED="2011-09-23 20:23:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4394" O_E="0.0" SE="1.4204664261167415" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="2.017724867724868" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="48.64126556205662" CI_START="0.7842885765105218" EFFECT_SIZE="6.176470588235294" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6870048660070194" LOG_CI_START="-0.10552411062369109" LOG_EFFECT_SIZE="0.7907403776916642" MODIFIED="2011-08-09 13:43:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1261" O_E="0.0" SE="1.0529403940344182" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="1.108683473389356" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="165.64648173076458" CI_START="0.517334826445852" EFFECT_SIZE="9.257142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.21918221606379" LOG_CI_START="-0.2862282843511166" LOG_EFFECT_SIZE="0.9664769658563366" MODIFIED="2011-08-09 13:44:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1262" O_E="0.0" SE="1.4716905299257097" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="2.165873015873016" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="55.497773898848365" CI_START="0.9356184372199935" EFFECT_SIZE="7.205882352941177" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7442755632517637" LOG_CI_START="-0.02890122860720922" LOG_EFFECT_SIZE="0.8576871673222773" MODIFIED="2011-08-09 13:44:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1265" O_E="0.0" SE="1.04157282490464" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="1.084873949579832" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.665864363229602" CI_START="0.19564205951798305" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3357760199659527" LOG_CI_START="-0.7085377740219496" LOG_EFFECT_SIZE="0.3136191229720017" MODIFIED="2011-08-09 13:44:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1263" O_E="0.0" SE="1.2008400421049796" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="1.4420168067226893" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="197.05745464805176" CI_START="0.6496230322934169" EFFECT_SIZE="11.314285714285715" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2945928687944934" LOG_CI_START="-0.18733858564402006" LOG_EFFECT_SIZE="1.0536271415752367" MODIFIED="2011-08-09 13:44:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1264" O_E="0.0" SE="1.4578988220960245" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="2.1254689754689755" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.11829665417517" CI_START="1.392160134808736" EFFECT_SIZE="10.294117647058824" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.8814890612496467" LOG_CI_START="0.14368919336639432" LOG_EFFECT_SIZE="1.0125891273080205" MODIFIED="2011-08-09 13:44:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1266" O_E="0.0" SE="1.0207922446427036" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="1.0420168067226894" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="260.04932408105344" CI_START="0.9153679486293798" EFFECT_SIZE="15.428571428571429" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.415055729296199" LOG_CI_START="-0.03840429835081332" LOG_EFFECT_SIZE="1.188325715472693" MODIFIED="2011-08-09 13:45:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1267" O_E="0.0" SE="1.4411745650628611" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="2.076984126984127" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="165.64648173076458" CI_START="0.517334826445852" EFFECT_SIZE="9.257142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.21918221606379" LOG_CI_START="-0.2862282843511166" LOG_EFFECT_SIZE="0.9664769658563366" MODIFIED="2011-08-09 13:45:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1268" O_E="0.0" SE="1.4716905299257097" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="2.165873015873016" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.247772878987405" CI_START="0.33762651918404224" EFFECT_SIZE="3.088235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4509842127043244" LOG_CI_START="-0.47156344864895866" LOG_EFFECT_SIZE="0.48971038202768297" MODIFIED="2011-08-09 13:45:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1269" O_E="0.0" SE="1.1293140130433266" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="1.2753501400560225" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-030.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:27 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.67355479828279" CI_START="0.27489297795530465" EFFECT_SIZE="1.5441176470588236" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9381971266424417" LOG_CI_START="-0.5608363539150382" LOG_EFFECT_SIZE="0.18868038636370177" MODIFIED="2011-08-09 13:46:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1270" O_E="0.0" SE="0.880539686814866" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="35" VAR="0.7753501400560223" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2012-09-17 20:36:27 +0100" MODIFIED_BY="Maryse Paquet" NO="31">
<NAME>0.1% resiquimod versus 0.03% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-031.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 13:54:32 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="68" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="23" I2="0.0" ID="CMP-031.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 13:54:28 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="1.659482277046704" CI_START="1.08565969490993" EFFECT_SIZE="1.3422492401215806" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.21997261858739436" LOG_CI_START="0.03569371495494204" LOG_EFFECT_SIZE="0.1278331667711682" MODIFIED="2011-08-09 13:54:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1271" O_E="0.0" SE="0.10824634018898718" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.011717270164309943" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="28" I2="0.0" ID="CMP-031.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 13:54:32 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.1316840121936593" CI_START="0.7879892744809658" EFFECT_SIZE="0.944327731092437" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.0537251804585028" LOG_CI_START="-0.10347969376099392" LOG_EFFECT_SIZE="-0.02487725665124559" MODIFIED="2011-08-09 13:54:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1272" O_E="0.0" SE="0.09234292129321003" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.008527215112963983" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-031.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:33:30 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="25" I2="0.0" ID="CMP-031.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 13:54:48 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.2224109147792404" CI_START="0.7355547648826102" EFFECT_SIZE="0.9482352941176471" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.08721721901894514" LOG_CI_START="-0.13338498683734934" LOG_EFFECT_SIZE="-0.023083883909202088" MODIFIED="2011-08-09 13:54:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1273" O_E="0.0" SE="0.1295828277185179" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.016791709239527088" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-031.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:25:21 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="14.276442666482795" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.131268014463704" CI_START="1.0798762742398222" EFFECT_SIZE="2.963235294117647" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.910158276066893" LOG_CI_START="0.033373999474890934" LOG_EFFECT_SIZE="0.47176613777089194" MODIFIED="2011-09-23 20:25:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4395" O_E="0.0" SE="0.5150274242223083" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.2652532477010655" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-031.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:47 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2296317268903234" CI_START="0.3706594208987932" EFFECT_SIZE="1.0941176470588236" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5091530027961506" LOG_CI_START="-0.4310249571168657" LOG_EFFECT_SIZE="0.03906402283964243" MODIFIED="2011-08-09 13:58:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1286" O_E="0.0" SE="0.5522651876088654" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.30499683744465533" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:47 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.891736249574635" CI_START="0.4305694556895256" EFFECT_SIZE="3.6470588235294117" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4898423182211273" LOG_CI_START="-0.36595678198116743" LOG_EFFECT_SIZE="0.5619427681199799" MODIFIED="2011-08-09 13:58:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1287" O_E="0.0" SE="1.0901055778125295" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="1.1883301707779887" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-031.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:47 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.514343033076888" CI_START="0.6023211415886446" EFFECT_SIZE="2.127450980392157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8758910169147374" LOG_CI_START="-0.22017189274151347" LOG_EFFECT_SIZE="0.32785956208661193" MODIFIED="2011-08-09 13:59:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1288" O_E="0.0" SE="0.6438327787309875" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.4145206469684648" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.13208134358818" CI_START="0.17380542429511167" EFFECT_SIZE="1.8235294117647058" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2817622186872977" LOG_CI_START="-0.7599366737753003" LOG_EFFECT_SIZE="0.26091277245599875" MODIFIED="2011-08-09 13:59:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1289" O_E="0.0" SE="1.1993040360050444" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="1.4383301707779887" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-031.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.911767130433464" CI_START="0.47615733830943535" EFFECT_SIZE="2.2794117647058822" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0378950890713021" LOG_CI_START="-0.322249518143192" LOG_EFFECT_SIZE="0.35782278546405516" MODIFIED="2011-08-09 13:59:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1290" O_E="0.0" SE="0.7989556751021852" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.6383301707779886" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-031.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.516508881038292" CI_START="0.5161632879809142" EFFECT_SIZE="1.1397058823529411" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.40079846740914393" LOG_CI_START="-0.28721288780899606" LOG_EFFECT_SIZE="0.05679278980007395" MODIFIED="2011-08-09 14:03:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1291" O_E="0.0" SE="0.4041412757662704" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.16333017077798861" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-031.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="53.35558218936963" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.822277449670308" CI_START="0.4009215743920103" EFFECT_SIZE="1.0637254901960784" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.45059970571098723" LOG_CI_START="-0.3969405728657257" LOG_EFFECT_SIZE="0.026829566422630752" MODIFIED="2011-08-09 14:04:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1292" O_E="0.0" SE="0.49784935502800254" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.24785398030179814" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.891736249574635" CI_START="0.4305694556895256" EFFECT_SIZE="3.6470588235294117" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4898423182211273" LOG_CI_START="-0.36595678198116743" LOG_EFFECT_SIZE="0.5619427681199799" MODIFIED="2011-08-09 14:04:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1293" O_E="0.0" SE="1.0901055778125295" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="1.1883301707779887" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-031.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.18755445859905" CI_START="0.19852037438836098" EFFECT_SIZE="0.9117647058823529" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6219604680246674" LOG_CI_START="-0.7021949144406323" LOG_EFFECT_SIZE="-0.04011722320798245" MODIFIED="2011-08-09 14:04:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1294" O_E="0.0" SE="0.7778154263349727" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="0.6049968374446553" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:49:48 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.939485317809403" CI_START="0.2999995314535136" EFFECT_SIZE="2.735294117647059" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3968874865947392" LOG_CI_START="-0.5228794235713791" LOG_EFFECT_SIZE="0.43700403151168" MODIFIED="2011-08-09 14:04:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1295" O_E="0.0" SE="1.1276805860310455" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="31" VAR="1.271663504111322" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2012-09-17 20:36:17 +0100" MODIFIED_BY="Maryse Paquet" NO="32">
<NAME>0.1% resiquimod versus 0.06% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 14:23:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="68" TOTAL_2="64" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="18" I2="0.0" ID="CMP-032.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:22:28 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="2.3845895533875625" CI_START="1.296501093402517" EFFECT_SIZE="1.7583011583011583" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.37741363702853103" LOG_CI_START="0.11277288736721323" LOG_EFFECT_SIZE="0.24509326219787217" MODIFIED="2011-08-09 14:22:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1296" O_E="0.0" SE="0.15545128634389618" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.024165102425972" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="25" I2="0.0" ID="CMP-032.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:23:00 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.3746705287295689" CI_START="0.8670806190279986" EFFECT_SIZE="1.091764705882353" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.13819862202051514" LOG_CI_START="-0.06194052101137646" LOG_EFFECT_SIZE="0.03812905050456934" MODIFIED="2011-08-09 14:23:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1297" O_E="0.0" SE="0.117562723321669" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.013820993914807296" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-032.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:33:19 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="20" I2="0.0" ID="CMP-032.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:23:27 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.69643605991459" CI_START="0.8824524877929426" EFFECT_SIZE="1.223529411764706" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.22953749536953943" LOG_CI_START="-0.05430866820056413" LOG_EFFECT_SIZE="0.08761441358448765" MODIFIED="2011-08-09 14:23:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1298" O_E="0.0" SE="0.16673264154224904" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.027799773755656114" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-032.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:25:55 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="14.958610545640713" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.386984322097801" CI_START="0.627161312956437" EFFECT_SIZE="1.223529411764706" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.37784956653554663" LOG_CI_START="-0.20262073936657132" LOG_EFFECT_SIZE="0.08761441358448765" MODIFIED="2011-09-23 20:25:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4396" O_E="0.0" SE="0.3409711310612595" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.11626131221719457" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-032.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:13 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.900801344985144" CI_START="0.5134552377356311" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8388995254470726" LOG_CI_START="-0.2894974115638084" LOG_EFFECT_SIZE="0.27470105694163205" MODIFIED="2011-08-09 14:32:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1311" O_E="0.0" SE="0.662825946455114" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.43933823529411764" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-032.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5579087827392915" CI_START="0.22163433624000947" EFFECT_SIZE="0.7529411764705882" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4078850530983321" LOG_CI_START="-0.6543629565591432" LOG_EFFECT_SIZE="-0.12323895173040557" MODIFIED="2011-08-09 14:32:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1312" O_E="0.0" SE="0.6239697390852521" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.38933823529411765" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-032.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9190994327682525" CI_START="0.4130349605945229" EFFECT_SIZE="1.0980392156862746" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4652488885361798" LOG_CI_START="-0.3840131867196515" LOG_EFFECT_SIZE="0.040617850908264086" MODIFIED="2011-08-09 14:33:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1313" O_E="0.0" SE="0.49886074692034765" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.24886204481792717" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-032.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.804430405945491" CI_START="0.07854561934848589" EFFECT_SIZE="0.3764705882352941" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2563401366605904" LOG_CI_START="-1.1048780314493638" LOG_EFFECT_SIZE="-0.42426894739438675" MODIFIED="2011-08-09 14:33:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1314" O_E="0.0" SE="0.7995862900863906" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.6393382352941176" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-032.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.27769003715932" CI_START="0.49091012092803676" EFFECT_SIZE="2.3529411764705883" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0522201540046656" LOG_CI_START="-0.30899801410528865" LOG_EFFECT_SIZE="0.37161106994968846" MODIFIED="2011-08-09 14:33:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1315" O_E="0.0" SE="0.7995862900863906" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.6393382352941176" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-032.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9561758320721874" CI_START="0.4528290014965479" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.29140788903370257" LOG_CI_START="-0.3440657664784008" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2011-08-09 14:34:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1316" O_E="0.0" SE="0.37328037089313665" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.13933823529411765" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-032.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="26.518462373166376" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0097181425229516" CI_START="0.33746060091298463" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.30313515307703703" LOG_CI_START="-0.4717769244771088" LOG_EFFECT_SIZE="-0.08432088570003593" MODIFIED="2011-08-09 14:34:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1317" O_E="0.0" SE="0.45518719023195336" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.2071953781512605" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-032.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.450400672492572" CI_START="0.25672761886781553" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5378695297830913" LOG_CI_START="-0.5905274072277896" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2011-08-09 14:34:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1318" O_E="0.0" SE="0.662825946455114" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.43933823529411764" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-032.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1728655561805112" CI_START="0.14676137354975946" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3370328556278196" LOG_CI_START="-0.8333882323052306" LOG_EFFECT_SIZE="-0.24817768833870552" MODIFIED="2011-08-09 14:35:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1319" O_E="0.0" SE="0.6875111407296982" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.47267156862745097" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-032.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:14 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9115029331365267" CI_START="0.17113838029247372" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4641172319657224" LOG_CI_START="-0.7666525826270206" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2011-08-09 14:35:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1320" O_E="0.0" SE="0.7229602815006166" STUDY_ID="STD-Szeimies-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.5226715686274509" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2012-09-17 20:35:57 +0100" MODIFIED_BY="Maryse Paquet" NO="33">
<NAME>0.06% resiquimod versus 0.01% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 14:56:57 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="14" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:56:53 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="2.336995870045404" CI_START="0.8461885140009167" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.36865794490481724" LOG_CI_START="-0.07253287399394187" LOG_EFFECT_SIZE="0.1480625354554377" MODIFIED="2011-08-09 14:56:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1321" O_E="0.0" SE="0.25915767095090664" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="0.06716269841269841" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="27" I2="0.0" ID="CMP-033.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:56:57 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.3097215912957276" CI_START="0.7830863142211847" EFFECT_SIZE="1.0127314814814814" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.1171789870953155" LOG_CI_START="-0.10619036600847562" LOG_EFFECT_SIZE="0.0054943105434199216" MODIFIED="2011-08-09 14:56:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1322" O_E="0.0" SE="0.1312082637092972" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="0.017215608465608472" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-033.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:32:27 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-033.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 14:57:59 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.4394760734218481" CI_START="0.6868253421843982" EFFECT_SIZE="0.9943181818181818" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.15820445054982754" LOG_CI_START="-0.16315368880553838" LOG_EFFECT_SIZE="-0.0024746191278554033" MODIFIED="2011-08-09 14:57:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1323" O_E="0.0" SE="0.188767361805787" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="0.03563311688311689" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:26:20 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="375.7677186982205" CI_START="1.3966778415643533" EFFECT_SIZE="22.90909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5749194681716143" LOG_CI_START="0.1450962430750236" LOG_EFFECT_SIZE="1.360007855623319" MODIFIED="2011-09-23 20:26:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4397" O_E="0.0" SE="1.4272901902406838" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="2.0371572871572874" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:22 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.965403637219076" CI_START="0.359301069087791" EFFECT_SIZE="3.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4766201320654186" LOG_CI_START="-0.4445414905653545" LOG_EFFECT_SIZE="0.5160393207500321" MODIFIED="2011-08-09 15:02:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1336" O_E="0.0" SE="1.128499847036722" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="1.2735119047619048" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="208.75715430237403" CI_START="0.6897967184943679" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.319641368087621" LOG_CI_START="-0.1612788759923715" LOG_EFFECT_SIZE="1.0791812460476249" MODIFIED="2011-08-09 15:02:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1337" O_E="0.0" SE="1.4573048321258575" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="2.1237373737373737" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="51.59296389926084" CI_START="0.8347340992870734" EFFECT_SIZE="6.5625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.712590477827169" LOG_CI_START="-0.0784518449991426" LOG_EFFECT_SIZE="0.8170693164140133" MODIFIED="2011-08-09 15:02:30 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1338" O_E="0.0" SE="1.0520671262306593" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="1.1068452380952383" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.33980683022929" CI_START="0.6745006056749513" EFFECT_SIZE="5.46875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6467937967453563" LOG_CI_START="-0.17101765601257943" LOG_EFFECT_SIZE="0.7378880703663885" MODIFIED="2011-08-09 15:02:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1339" O_E="0.0" SE="1.0677914456618256" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="1.1401785714285715" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="109.49149975922646" CI_START="0.2717294601053756" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0393804045555357" LOG_CI_START="-0.5658632741046988" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2011-08-09 15:02:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1340" O_E="0.0" SE="1.530333033009218" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="2.341919191919192" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="80.73302823895074" CI_START="1.4817839595453628" EFFECT_SIZE="10.9375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.907051242868661" LOG_CI_START="0.17078488919207832" LOG_EFFECT_SIZE="1.0389180660303696" MODIFIED="2011-08-09 15:03:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1341" O_E="0.0" SE="1.0198914508066883" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="1.0401785714285716" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="308.89643972793357" CI_START="1.1134278031836398" EFFECT_SIZE="18.545454545454547" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.489812902748122" LOG_CI_START="0.04666206178722508" LOG_EFFECT_SIZE="1.2682374822676739" MODIFIED="2011-08-09 15:03:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1342" O_E="0.0" SE="1.4351188977721399" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="2.0595662507427215" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="175.48316368853733" CI_START="0.5493216111943892" EFFECT_SIZE="9.818181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.244235455457599" LOG_CI_START="-0.26017331480014955" LOG_EFFECT_SIZE="0.9920310703287246" MODIFIED="2011-08-09 15:03:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1343" O_E="0.0" SE="1.471102108672751" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="2.1641414141414144" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.33980683022929" CI_START="0.6745006056749513" EFFECT_SIZE="5.46875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6467937967453563" LOG_CI_START="-0.17101765601257943" LOG_EFFECT_SIZE="0.7378880703663885" MODIFIED="2011-08-09 15:04:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1344" O_E="0.0" SE="1.0677914456618256" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="1.1401785714285715" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-033.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:23 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.145528180740083" CI_START="0.42933418429365616" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0471006542918544" LOG_CI_START="-0.3672045309031527" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2011-08-09 15:04:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1345" O_E="0.0" SE="0.8307698667071233" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="35" VAR="0.6901785714285714" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" MODIFIED="2012-09-17 20:35:41 +0100" MODIFIED_BY="Maryse Paquet" NO="34">
<NAME>0.06% resiquimod versus 0.03% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-034.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 15:57:43 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-034.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 15:57:39 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="1.096966091532825" CI_START="0.5239858581279346" EFFECT_SIZE="0.7581521739130435" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.040193203246740056" LOG_CI_START="-0.2806804340465802" LOG_EFFECT_SIZE="-0.12024361539992012" MODIFIED="2011-08-09 15:57:39 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1346" O_E="0.0" SE="0.1884827628962175" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.03552575190899174" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="28" I2="0.0" ID="CMP-034.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 15:57:43 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.0740783057693297" CI_START="0.6965486276293905" EFFECT_SIZE="0.8649553571428571" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.031035944793538224" LOG_CI_START="-0.15704855910516807" LOG_EFFECT_SIZE="-0.06300630715581493" MODIFIED="2011-08-09 15:57:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1347" O_E="0.0" SE="0.11048176862340987" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.012206221198156675" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-034.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:32:36 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="25" I2="0.0" ID="CMP-034.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 15:58:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.0662184388344815" CI_START="0.5633226533359927" EFFECT_SIZE="0.775" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.027846188801236273" LOG_CI_START="-0.24924278378861567" LOG_EFFECT_SIZE="-0.1106982974936897" MODIFIED="2011-08-09 15:58:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1348" O_E="0.0" SE="0.16276343411181446" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.026491935483870965" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-034.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:26:54 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.914437440418246" CI_START="0.848294393602931" EFFECT_SIZE="2.421875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.839756851623834" LOG_CI_START="-0.07145340325102544" LOG_EFFECT_SIZE="0.3841517241864043" MODIFIED="2011-09-23 20:26:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4398" O_E="0.0" SE="0.5352494142769995" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.286491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-034.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2274545938969066" CI_START="0.15167607161362273" EFFECT_SIZE="0.58125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3478088598150823" LOG_CI_START="-0.8190829280190615" LOG_EFFECT_SIZE="-0.23563703410198963" MODIFIED="2011-08-09 16:02:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1361" O_E="0.0" SE="0.6854380123812833" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.4698252688172043" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-034.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="39.13964079309497" CI_START="0.5994412208974373" EFFECT_SIZE="4.84375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5926168355710224" LOG_CI_START="-0.22225339587025156" LOG_EFFECT_SIZE="0.6851817198503856" MODIFIED="2011-08-09 16:02:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1362" O_E="0.0" SE="1.066063757701138" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="1.136491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-034.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.073096769586034" CI_START="0.5307302264181669" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8496095998624188" LOG_CI_START="-0.2751261775057229" LOG_EFFECT_SIZE="0.2872417111783479" MODIFIED="2011-08-09 16:02:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1363" O_E="0.0" SE="0.6606753631579363" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.436491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-034.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="39.13964079309497" CI_START="0.5994412208974373" EFFECT_SIZE="4.84375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5926168355710224" LOG_CI_START="-0.22225339587025156" LOG_EFFECT_SIZE="0.6851817198503856" MODIFIED="2011-08-09 16:03:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1364" O_E="0.0" SE="1.066063757701138" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="1.136491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-034.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.455662881691861" CI_START="0.1453726100167811" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8099408432066292" LOG_CI_START="-0.8375174121778957" LOG_EFFECT_SIZE="-0.013788284485633297" MODIFIED="2011-08-09 16:03:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1365" O_E="0.0" SE="0.967725134262757" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.936491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-034.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.661865360379047" CI_START="0.550880465530924" EFFECT_SIZE="1.2109375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.42518608467614094" LOG_CI_START="-0.25894262763129466" LOG_EFFECT_SIZE="0.08312172852242312" MODIFIED="2011-08-09 16:03:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1366" O_E="0.0" SE="0.40186059210113023" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.16149193548387097" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-034.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.294086198167768" CI_START="0.5064842500799689" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5177349594053237" LOG_CI_START="-0.2954340551599904" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2011-08-09 16:04:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1367" O_E="0.0" SE="0.47765950440720595" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.2281586021505376" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-034.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:48 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="32.76825332374285" CI_START="0.4582369664824384" EFFECT_SIZE="3.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5154532924022959" LOG_CI_START="-0.33890987871763767" LOG_EFFECT_SIZE="0.5882717068423291" MODIFIED="2011-08-09 16:04:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1368" O_E="0.0" SE="1.0892621059615868" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="1.186491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-034.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:49 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.18737387193585" CI_START="0.4213224211489519" EFFECT_SIZE="1.6145833333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7915063590477949" LOG_CI_START="-0.37538542878634884" LOG_EFFECT_SIZE="0.20806046513072304" MODIFIED="2011-08-09 16:04:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1369" O_E="0.0" SE="0.6854380123812833" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="0.4698252688172043" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-034.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:50:49 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="32.76825332374285" CI_START="0.4582369664824384" EFFECT_SIZE="3.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5154532924022959" LOG_CI_START="-0.33890987871763767" LOG_EFFECT_SIZE="0.5882717068423291" MODIFIED="2011-08-09 16:04:58 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1370" O_E="0.0" SE="1.0892621059615868" STUDY_ID="STD-Szeimies-2008" TOTAL_1="32" TOTAL_2="31" VAR="1.186491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" MODIFIED="2012-09-17 20:35:27 +0100" MODIFIED_BY="Maryse Paquet" NO="35">
<NAME>0.03% resiquimod versus 0.01% resiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-035.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 16:24:24 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.7583277579081162" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="62" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="14" I2="0.0" ID="CMP-035.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 16:24:20 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 cycle</NAME>
<DICH_DATA CI_END="2.9258301476475346" CI_START="1.175880507514769" EFFECT_SIZE="1.8548387096774193" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.46624911055192747" LOG_CI_START="0.07036319115878818" LOG_EFFECT_SIZE="0.2683061508553578" MODIFIED="2011-08-09 16:24:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1371" O_E="0.0" SE="0.23254534871843607" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="0.05407733921057904" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="27" I2="0.0" ID="CMP-035.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 16:24:24 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.4502433157174037" CI_START="0.9452797685306836" EFFECT_SIZE="1.1708482676224612" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.16144087244769395" LOG_CI_START="-0.0244396370492242" LOG_EFFECT_SIZE="0.06850061769923488" MODIFIED="2011-08-09 16:24:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1372" O_E="0.0" SE="0.10918713140185131" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="0.011921829663765145" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-035.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-09 19:33:08 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lower dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours higher dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="22" I2="0.0" ID="CMP-035.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-09 16:24:43 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>After 1 or 2 cycles</NAME>
<DICH_DATA CI_END="1.7450078574293708" CI_START="0.9433002942016635" EFFECT_SIZE="1.282991202346041" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.24179738684278318" LOG_CI_START="-0.02535003011111454" LOG_EFFECT_SIZE="0.10822367836583432" MODIFIED="2011-08-09 16:24:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1373" O_E="0.0" SE="0.1569237151197608" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="0.024625052366987848" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-23 20:27:38 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="180.8528769075049" CI_START="0.5668454201722787" EFFECT_SIZE="10.125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2573254216689222" LOG_CI_START="-0.24653535789551004" LOG_EFFECT_SIZE="1.0053950318867062" MODIFIED="2011-09-23 20:27:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="4399" O_E="0.0" SE="1.4707802162268993" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="2.1631944444444446" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="45.72778841338733" CI_START="0.6969032857147066" EFFECT_SIZE="5.645161290322581" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6601801975956794" LOG_CI_START="-0.15682748789163561" LOG_EFFECT_SIZE="0.7516763548520218" MODIFIED="2011-08-09 16:27:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1386" O_E="0.0" SE="1.0673193087883506" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.1391705069124425" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: rigors</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.94840484350587" CI_START="0.14247470005557272" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9028098029843887" LOG_CI_START="-0.8462622486503014" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2011-08-09 16:27:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1387" O_E="0.0" SE="1.6148185312563417" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="2.607638888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.904958256129593" CI_START="0.37121630978022563" EFFECT_SIZE="3.3870967741935485" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4900281613190491" LOG_CI_START="-0.43037295084771815" LOG_EFFECT_SIZE="0.5298276052356654" MODIFIED="2011-08-09 16:28:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1388" O_E="0.0" SE="1.1280531194255774" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.2725038402457758" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation:musculoskeletal and connective tissue: arthralgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.29973378827045" CI_START="0.0736840147571832" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.23803942017072" LOG_CI_START="-1.1326267191387138" LOG_EFFECT_SIZE="0.052706350516002996" MODIFIED="2011-08-09 16:28:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1389" O_E="0.0" SE="1.3925410252170105" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.9391705069124425" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="112.84465103133972" CI_START="0.28039100401145856" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.052480977834434" LOG_CI_START="-0.5522359242676337" LOG_EFFECT_SIZE="0.7501225267834001" MODIFIED="2011-08-09 16:28:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1390" O_E="0.0" SE="1.5300236018513644" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="2.3409722222222222" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.21568989899852" CI_START="1.195937266995439" EFFECT_SIZE="9.03225806451613" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.833884275724923" LOG_CI_START="0.07770839929097013" LOG_EFFECT_SIZE="0.9557963375079466" MODIFIED="2011-08-09 16:28:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1391" O_E="0.0" SE="1.0315864030280946" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.0641705069124425" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="249.5062081356268" CI_START="0.8572557236080203" EFFECT_SIZE="14.625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.397081356073649" LOG_CI_START="-0.06688960656521237" LOG_EFFECT_SIZE="1.1650958747542182" MODIFIED="2011-08-09 16:28:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1392" O_E="0.0" SE="1.4473487403070402" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="2.094818376068376" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: lethargy</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.94840484350587" CI_START="0.14247470005557272" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9028098029843887" LOG_CI_START="-0.8462622486503014" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2011-08-09 16:29:05 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1393" O_E="0.0" SE="1.6148185312563417" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="2.607638888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: psychiatric disorders</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.904958256129593" CI_START="0.37121630978022563" EFFECT_SIZE="3.3870967741935485" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4900281613190491" LOG_CI_START="-0.43037295084771815" LOG_EFFECT_SIZE="0.5298276052356654" MODIFIED="2011-08-09 16:29:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1394" O_E="0.0" SE="1.1280531194255774" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.2725038402457758" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-035.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 14:51:16 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: skin and subcutaneous disorders: in general</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours higher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lower</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.926850467224469" CI_START="0.053768601333855075" EFFECT_SIZE="0.5645161290322581" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7728239702492266" LOG_CI_START="-1.2694712605451828" LOG_EFFECT_SIZE="-0.2483236451479782" MODIFIED="2011-08-09 16:29:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1395" O_E="0.0" SE="1.199654328093073" STUDY_ID="STD-Szeimies-2008" TOTAL_1="31" TOTAL_2="35" VAR="1.4391705069124425" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" MODIFIED="2012-09-17 20:35:15 +0100" MODIFIED_BY="Maryse Paquet" NO="36">
<NAME>Sunscreen SPF 17 (8% 2-ethyl-hexyl p-methoxycinnamate/2% 4-tert-butyl-4-methoxy-4-dibenzoylmethane) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-036.01" MODIFIED="2011-07-12 00:25:24 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="210" TOTAL_2="221" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean change in lesion counts</NAME>
<GROUP_LABEL_1>Sunscreen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sunscreen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7691496212795964" CI_START="-2.430850378720404" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="1.0" MODIFIED="2011-04-12 20:48:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="261" SD_1="4.34" SD_2="4.46" SE="0.42391104391409506" STUDY_ID="STD-Thompson-1993" TOTAL_1="210" TOTAL_2="221" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" MODIFIED="2012-09-17 20:34:40 +0100" MODIFIED_BY="Maryse Paquet" NO="37">
<NAME>12.5% DL-&#945;-tocopherol (vitamin E) versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-037.01" MODIFIED="2011-08-10 00:30:50 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="15.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction of lesion counts</NAME>
<GROUP_LABEL_1>DL-&#945;-tocophero</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DL-&#945;-tocophero</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.116098640721496" CI_START="-8.116098640721496" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="8.0" MODIFIED="2011-05-04 18:47:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="126" SD_1="14.3" SD_2="14.3" SE="3.1205158303746914" STUDY_ID="STD-Foote-2009" TOTAL_1="42" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" MODIFIED="2012-09-17 20:34:20 +0100" MODIFIED_BY="Maryse Paquet" NO="38">
<NAME>Etretinate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-038.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-01 13:59:02 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="275.13" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>etretinate</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etretinate</GRAPH_LABEL_2>
<DICH_DATA CI_END="188.94601143053802" CI_START="0.6403945713587241" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.276337728579093" LOG_CI_START="-0.19355235826264286" LOG_EFFECT_SIZE="1.0413926851582251" MODIFIED="2011-12-01 13:59:02 +0000" MODIFIED_BY="Maryse Paquet" ORDER="499" O_E="0.0" SE="1.4508256631639465" STUDY_ID="STD-Moriarty-1982" TOTAL_1="25" TOTAL_2="25" VAR="2.104895104895105" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" MODIFIED="2012-09-17 20:33:51 +0100" MODIFIED_BY="Maryse Paquet" NO="39">
<NAME>Carbon dioxide laser resurfacing versus 5% 5-FU</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-039.01" MODIFIED="2011-09-15 20:15:36 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="6" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction of lesion counts</NAME>
<GROUP_LABEL_1>Resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours resurfacing</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.756248867137305" CI_START="-3.156248867137311" EFFECT_SIZE="8.799999999999997" ESTIMABLE="YES" MEAN_1="92.0" MEAN_2="83.2" MODIFIED="2011-05-04 19:08:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="134" SD_1="10.3" SD_2="12.5" SE="6.100239066353603" STUDY_ID="STD-Hantash-2006" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-039.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 17:59:20 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="485.8318171582511" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.94182596610577" CI_START="0.30576222725778485" EFFECT_SIZE="5.555555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.004071156548166" LOG_CI_START="-0.5146161667547782" LOG_EFFECT_SIZE="0.7447274948966939" MODIFIED="2011-09-27 17:59:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1135" O_E="0.0" SE="1.4794894014114763" STUDY_ID="STD-Hantash-2006" TOTAL_1="8" TOTAL_2="9" VAR="2.1888888888888887" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-040" MODIFIED="2012-09-17 20:33:43 +0100" MODIFIED_BY="Maryse Paquet" NO="40">
<NAME>Carbon dioxide laser resurfacing versus Trichloroacetic acid peel</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-040.01" MODIFIED="2011-08-10 14:36:30 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="28.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="6" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction of lesion counts</NAME>
<GROUP_LABEL_1>Resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>Peel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours peel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours resurfacing</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.200912400636339" CI_START="-6.200912400636339" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="92.0" MEAN_2="89.0" MODIFIED="2011-03-25 22:54:12 +0000" MODIFIED_BY="Maryse Paquet" ORDER="136" SD_1="10.3" SD_2="6.6" SE="4.694429322789583" STUDY_ID="STD-Hantash-2006" TOTAL_1="6" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 18:00:09 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="485.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="8" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>Peel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours peel</GRAPH_LABEL_2>
<DICH_DATA CI_END="111.70594568624207" CI_START="0.3343213181977048" EFFECT_SIZE="6.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.048076289588349" LOG_CI_START="-0.475835929478511" LOG_EFFECT_SIZE="0.7861201800549189" MODIFIED="2011-09-27 18:00:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1136" O_E="0.0" SE="1.4825585310468514" STUDY_ID="STD-Hantash-2006" TOTAL_1="8" TOTAL_2="10" VAR="2.197979797979798" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-041" MODIFIED="2012-09-17 20:32:52 +0100" MODIFIED_BY="Maryse Paquet" NO="41">
<NAME>Er:YAG laser resurfacing versus 5% 5-FU</NAME>
<OTHER_OUTCOME COLS="4" ID="CMP-041.01" MODIFIED="2011-12-05 18:19:58 +0000" MODIFIED_BY="Maryse Paquet" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean reduction in lesion counts</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>At 3 months</P>
</TH>
<TH>
<P>At 6 months</P>
</TH>
<TH>
<P>At 12 months</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-12-05 18:19:58 +0000" MODIFIED_BY="Maryse Paquet" ORDER="530" STUDY_ID="STD-Ostertag-2006">
<TR>
<TD>
<P>5-fluorouracil</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>12.4</P>
</TD>
</TR>
<TR>
<TD>
<P>Er:YAG laser resurfacing</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>13.9</P>
</TD>
<TD>
<P>14.2</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-041.02" MODIFIED="2011-08-10 14:55:50 +0100" MODIFIED_BY="Maryse Paquet" NO="2" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<TR>
<TH>
<P>Assessment</P>
</TH>
<TH>
<P>Resurfacing</P>
</TH>
<TH>
<P>5-FU</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-07-19 19:20:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="531" STUDY_ID="STD-Ostertag-2006">
<TR>
<TD>
<P>At 6 months</P>
</TD>
<TD>
<P>94.4%</P>
</TD>
<TD>
<P>79.2%</P>
</TD>
</TR>
<TR>
<TD>
<P>At 12 months</P>
</TD>
<TD>
<P>91.1%</P>
</TD>
<TD>
<P>76.6%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-041.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:03:43 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Er:YAG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.572301178989834" CI_START="0.013678852869532623" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8792278791655181" LOG_CI_START="-1.8639503217183169" LOG_EFFECT_SIZE="-0.4923612212763993" MODIFIED="2011-09-29 13:53:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="686" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-041.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:03:43 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="185.31902742930964" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="84" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="19" I2="0.0" ID="CMP-041.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:24:20 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="0.9968851643290545" CI_START="0.3720674030118989" EFFECT_SIZE="0.6090225563909775" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="-0.0013548671353104953" LOG_CI_START="-0.4293783770415615" LOG_EFFECT_SIZE="-0.21536662208843602" MODIFIED="2011-08-10 15:24:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1411" O_E="0.0" SE="0.2514231284694767" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.06321358952937899" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-041.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:24:28 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="20.05141597482389" CI_START="0.1854925238083944" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3021450466987943" LOG_CI_START="-0.7316735897372958" LOG_EFFECT_SIZE="0.2852357284807493" MODIFIED="2011-08-10 15:24:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1412" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.4272486772486772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-041.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:24:36 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="96.15632621986413" CI_START="0.2423718698625086" EFFECT_SIZE="4.827586206896552" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829778621782204" LOG_CI_START="-0.6155177866196565" LOG_EFFECT_SIZE="0.6837300377792819" MODIFIED="2011-08-10 15:24:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1413" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-041.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:01:52 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="84" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: acne</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-041.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:31:52 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="38.628973403578" CI_START="0.6017807728546722" EFFECT_SIZE="4.821428571428571" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5869131665687004" LOG_CI_START="-0.22056169226312675" LOG_EFFECT_SIZE="0.6831757371527869" MODIFIED="2011-08-10 15:21:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="284" O_E="0.0" SE="1.0617196792226642" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.1272486772486772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-041.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:31:52 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="44.939904987002734" CI_START="0.7448722867927662" EFFECT_SIZE="5.785714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6526321498885386" LOG_CI_START="-0.12791818348771525" LOG_EFFECT_SIZE="0.7623569832004117" MODIFIED="2011-08-10 15:22:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="285" O_E="0.0" SE="1.0459040796915098" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.093915343915344" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-041.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:31:52 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="14.651750998933705" CI_START="0.06346319554865361" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1658895293818077" LOG_CI_START="-1.1974780637482711" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2011-08-10 15:22:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="286" O_E="0.0" SE="1.388253823062871" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.9272486772486772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-041.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:01:38 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="112" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology:crustea</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="21" I2="0.0" ID="CMP-041.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:22:37 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="0.7850402517077443" CI_START="0.2685845031795092" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.10510807491539076" LOG_CI_START="-0.5709190489189115" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2011-08-10 15:22:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1399" O_E="0.0" SE="0.2736196719311769" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.07486772486772487" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-041.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:22:47 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="26.122756185987033" CI_START="0.3203575606416582" EFFECT_SIZE="2.892857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4170189969987521" LOG_CI_START="-0.4943650219258911" LOG_EFFECT_SIZE="0.46132698753643053" MODIFIED="2011-08-10 15:22:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1400" O_E="0.0" SE="1.1227564342198224" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.2605820105820105" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-041.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:23:00 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="96.15632621986413" CI_START="0.2423718698625086" EFFECT_SIZE="4.827586206896552" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829778621782204" LOG_CI_START="-0.6155177866196565" LOG_EFFECT_SIZE="0.6837300377792819" MODIFIED="2011-08-10 15:23:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1401" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-041.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:23:01 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="96.15632621986413" CI_START="0.2423718698625086" EFFECT_SIZE="4.827586206896552" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829778621782204" LOG_CI_START="-0.6155177866196565" LOG_EFFECT_SIZE="0.6837300377792819" MODIFIED="2011-08-10 15:23:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1402" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-041.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:01:30 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: infection</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-041.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:23:36 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="154.062411258483" CI_START="0.490126737590575" EFFECT_SIZE="8.689655172413794" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.187696690799354" LOG_CI_START="-0.3096916050341783" LOG_EFFECT_SIZE="0.939002542882588" MODIFIED="2011-08-10 15:23:36 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1407" O_E="0.0" SE="1.4669782472440576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.1520251778872472" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-041.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 14:01:12 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="84" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: milia</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-041.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:32:47 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="96.15632621986413" CI_START="0.2423718698625086" EFFECT_SIZE="4.827586206896552" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829778621782204" LOG_CI_START="-0.6155177866196565" LOG_EFFECT_SIZE="0.6837300377792819" MODIFIED="2011-08-10 15:27:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1416" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-041.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:32:47 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="154.062411258483" CI_START="0.490126737590575" EFFECT_SIZE="8.689655172413794" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.187696690799354" LOG_CI_START="-0.3096916050341783" LOG_EFFECT_SIZE="0.939002542882588" MODIFIED="2011-08-10 15:27:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1417" O_E="0.0" SE="1.4669782472440576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.1520251778872472" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-041.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:32:47 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="96.15632621986413" CI_START="0.2423718698625086" EFFECT_SIZE="4.827586206896552" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9829778621782204" LOG_CI_START="-0.6155177866196565" LOG_EFFECT_SIZE="0.6837300377792819" MODIFIED="2011-08-10 15:27:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1418" O_E="0.0" SE="1.5263692068647823" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.329802955665025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-041.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 13:57:09 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="328.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="56" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology:pain</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-041.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:29:28 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At the end of treatment</NAME>
<DICH_DATA CI_END="1.809382951532933" CI_START="0.28907031682712553" EFFECT_SIZE="0.7232142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2575304939667219" LOG_CI_START="-0.5389965015497857" LOG_EFFECT_SIZE="-0.14073300379153186" MODIFIED="2011-08-10 15:29:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1423" O_E="0.0" SE="0.4678839000386142" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.2189153439153439" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-041.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:29:34 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="20.05141597482389" CI_START="0.1854925238083944" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3021450466987943" LOG_CI_START="-0.7316735897372958" LOG_EFFECT_SIZE="0.2852357284807493" MODIFIED="2011-08-10 15:29:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1424" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.4272486772486772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-041.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 13:56:34 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="505.58958194360713" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="84" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: changes in pigmentation (hypo)</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-041.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:35:53 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2011-08-10 15:35:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1433" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-041.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:35:53 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="183.26067206880356" CI_START="0.6155114868788483" EFFECT_SIZE="10.620689655172415" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.263069274912818" LOG_CI_START="-0.21076383770984192" LOG_EFFECT_SIZE="1.0261527186014883" MODIFIED="2011-08-10 15:35:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1434" O_E="0.0" SE="1.4531418160259537" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.1116211374832066" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="1" I2="0.0" ID="CMP-041.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:35:53 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="83.00043758023251" CI_START="1.6132199189220024" EFFECT_SIZE="11.571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9190803819926936" LOG_CI_START="0.20769357573609218" LOG_EFFECT_SIZE="1.0633869788643928" MODIFIED="2011-08-10 15:35:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1435" O_E="0.0" SE="1.0052770814964451" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="1.0105820105820105" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-041.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 13:56:24 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="56" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: scarring</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser resurfacing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-041.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:42:43 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2011-08-10 15:42:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1436" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-041.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:43:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="68.15071061090849" CI_START="0.12310967582579363" EFFECT_SIZE="2.896551724137931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.833470388604843" LOG_CI_START="-0.9097078122789919" LOG_EFFECT_SIZE="0.46188128816292556" MODIFIED="2011-08-10 15:43:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1438" O_E="0.0" SE="1.6113564541502576" STUDY_ID="STD-Ostertag-2006" TOTAL_1="28" TOTAL_2="27" VAR="2.5964696223316914" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-041.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 13:56:14 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="69" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: improvement in photoageing score</NAME>
<GROUP_LABEL_1>Er:YAG laser resurfacing</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours laser resurfacing</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-041.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:47:01 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="2.1219820832059946" CI_START="0.8017613649439146" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.3267417126484417" LOG_CI_START="-0.09595487524430255" LOG_EFFECT_SIZE="0.11539341870206957" MODIFIED="2011-08-10 15:47:01 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1439" O_E="0.0" SE="0.24829406811005353" STUDY_ID="STD-Ostertag-2006" TOTAL_1="23" TOTAL_2="26" VAR="0.0616499442586399" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-041.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:47:08 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="2.431822950757448" CI_START="1.0074357926750004" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.3859319528753492" LOG_CI_START="0.003217376624039583" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2011-08-10 15:47:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1440" O_E="0.0" SE="0.2248084365577253" STUDY_ID="STD-Ostertag-2006" TOTAL_1="23" TOTAL_2="26" VAR="0.0505388331475288" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="10" I2="0.0" ID="CMP-041.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 15:47:15 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="2.8750090996979383" CI_START="1.005214209688462" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.4586392236142919" LOG_CI_START="0.0022586191422559283" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2011-08-10 15:47:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1441" O_E="0.0" SE="0.26808022618730065" STUDY_ID="STD-Ostertag-2006" TOTAL_1="23" TOTAL_2="23" VAR="0.07186700767263426" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-042" MODIFIED="2012-09-17 20:32:42 +0100" MODIFIED_BY="Maryse Paquet" NO="42">
<NAME>Cryotherapy versus betulin-based oleogel</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-042.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 19:30:54 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.854681504646981" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Betulin-based oleogel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oleogel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9687556728346651" CI_START="0.7587671650200132" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2941918225252909" LOG_CI_START="-0.11989147108749047" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2011-03-28 20:21:22 +0100" MODIFIED_BY="Maryse Paquet" ORDER="148" O_E="0.0" SE="0.24323457641350904" STUDY_ID="STD-Huyke-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.05916305916305917" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-042.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 19:31:02 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.299381906001905" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Betulin-based oleogel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oleogel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4029459432514122" CI_START="0.8365333794623592" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.1470409376000623" LOG_CI_START="-0.07751672508163843" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2011-03-28 20:23:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="149" O_E="0.0" SE="0.13190628263758855" STUDY_ID="STD-Huyke-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.017399267399267393" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-043" MODIFIED="2012-09-17 20:32:25 +0100" MODIFIED_BY="Maryse Paquet" NO="43">
<NAME>Cryotherapy versus 5% 5-FU</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-043.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 19:54:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="84.95905110483542" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="23" I2="0.0" ID="CMP-043.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 19:53:26 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>After treatment</NAME>
<DICH_DATA CI_END="0.9403008546237468" CI_START="0.5354486229123265" EFFECT_SIZE="0.7095652173913043" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="-0.026733169168288683" LOG_CI_START="-0.2712821940312124" LOG_EFFECT_SIZE="-0.14900768159975056" MODIFIED="2011-03-31 16:15:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="183" O_E="0.0" SE="0.1436493077416778" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="24" VAR="0.020635123614663256" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-043.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 19:54:33 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="0.8884436927569435" CI_START="0.016208117765252102" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.05137009143757359" LOG_CI_START="-1.7902674164671768" LOG_EFFECT_SIZE="-0.9208187539523752" MODIFIED="2011-08-10 19:54:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1412" O_E="0.0" SE="1.0214368964029708" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="24" VAR="1.0433333333333332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-043.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 20:04:18 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: excellent global cosmetic outcome</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2011-08-10 20:04:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1413" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-043.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 20:06:19 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: better skin appearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7161404107495071" CI_START="0.10505293645206612" EFFECT_SIZE="0.2742857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.1450018189836149" LOG_CI_START="-0.9785918036377995" LOG_EFFECT_SIZE="-0.5617968113107072" MODIFIED="2011-08-10 20:06:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1414" O_E="0.0" SE="0.48965488332284074" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="24" VAR="0.23976190476190476" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-044" MODIFIED="2012-09-17 20:32:02 +0100" MODIFIED_BY="Maryse Paquet" NO="44">
<NAME>Cryotherapy versus imiquimod</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-044.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 16:16:19 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.22" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="22" I2="0.0" ID="CMP-044.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-10 23:04:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="1.1010995921722806" CI_START="0.5865331433685876" EFFECT_SIZE="0.8036363636363636" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.04182660178261597" LOG_CI_START="-0.2317074420729199" LOG_EFFECT_SIZE="-0.09494042014515197" MODIFIED="2011-03-31 16:09:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="181" O_E="0.0" SE="0.16067525137609615" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="26" VAR="0.02581653640477169" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-044.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 18:18:26 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="827.2401682888195" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: excellent global cosmetic outcome</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.34102498155786765" CI_START="0.00719187110148524" EFFECT_SIZE="0.049523809523809526" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="21" LOG_CI_END="-0.4672138058892017" LOG_CI_START="-2.1431581049810764" LOG_EFFECT_SIZE="-1.3051859554351388" MODIFIED="2011-08-10 23:51:06 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1430" O_E="0.0" SE="0.9844579773446448" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="26" VAR="0.9691575091575092" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-044.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-12-05 18:18:26 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: better skin appearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4711743915967518" CI_START="0.07588564348681158" EFFECT_SIZE="0.1890909090909091" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.326818321553819" LOG_CI_START="-1.1198403788371079" LOG_EFFECT_SIZE="-0.7233293501954635" MODIFIED="2011-08-10 23:51:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1431" O_E="0.0" SE="0.4658250819706975" STUDY_ID="STD-Krawtchenko-2007" TOTAL_1="25" TOTAL_2="26" VAR="0.21699300699300703" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-045" MODIFIED="2012-09-18 14:46:54 +0100" MODIFIED_BY="Maryse Paquet" NO="45">
<NAME>Cryotherapy versus MAL-red light PDT</NAME>
<OTHER_OUTCOME COLS="3" ID="CMP-045.01" MODIFIED="2011-10-19 16:17:38 +0100" MODIFIED_BY="Maryse Paquet" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<TR>
<TH>
<P>Assessment at</P>
</TH>
<TH>
<P>Cryotherapy</P>
</TH>
<TH>
<P>MAL-PDT</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-10-19 16:17:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="566" STUDY_ID="STD-Kaufmann-2008">
<TR>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>87%</P>
</TD>
<TD>
<P>75%</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2011-10-19 16:17:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="567" STUDY_ID="STD-Morton-2006">
<TR>
<TD>
<P>12 weeks </P>
</TD>
<TD>
<P>74.5%</P>
</TD>
<TD>
<P>84.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>24 weeks</P>
</TD>
<TD>
<P>83.9%</P>
</TD>
<TD>
<P>86.7%</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.8083025878443255" CI_END="7.157270822037939" CI_START="0.15715750707498374" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0605747686287856" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-045.02" LOG_CI_END="0.854747450676482" LOG_CI_START="-0.803664868840667" LOG_EFFECT_SIZE="0.025541290917907515" METHOD="MH" MODIFIED="2011-09-26 19:45:48 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.36862262332144247" P_Q="1.0" P_Z="0.9518601501222925" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="0.06037100632770722">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAL-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.983550155430215" CI_START="0.013609946779862324" EFFECT_SIZE="0.3296296296296296" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9021960580240129" LOG_CI_START="-1.866143573052162" LOG_EFFECT_SIZE="-0.48197375751407456" MODIFIED="2011-09-26 19:45:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1190" O_E="0.0" SE="1.6261364027963263" STUDY_ID="STD-Freeman-2003" TOTAL_1="89" TOTAL_2="88" VAR="2.644319600499376" WEIGHT="35.887754918538775"/>
<DICH_DATA CI_END="22.142677365855803" CI_START="0.18794475172262698" EFFECT_SIZE="2.04" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3452301321216074" LOG_CI_START="-0.7259697972698097" LOG_EFFECT_SIZE="0.3096301674258988" MODIFIED="2011-09-26 19:45:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1191" O_E="0.0" SE="1.2166330911295207" STUDY_ID="STD-Szeimies-2002" TOTAL_1="100" TOTAL_2="102" VAR="1.4801960784313726" WEIGHT="64.11224508146123"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.95352201006358" CI_START="0.7398738256817196" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8399321266968326" ESTIMABLE="NO" EVENTS_1="55" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-045.03" LOG_CI_END="-0.020669277721451995" LOG_CI_START="-0.13084233632619427" LOG_EFFECT_SIZE="-0.07575580702382312" METHOD="MH" MODIFIED="2011-09-28 16:16:19 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.007031022100625705" Q="0.0" RANDOM="YES" SCALE="2.86317904124059" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="68" TOTAL_2="54" WEIGHT="0.0" Z="2.6953713596922624">
<NAME>Cosmetic outcomes: excellent or good cosmetic outcomes by investigator</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.95352201006358" CI_START="0.7398738256817196" EFFECT_SIZE="0.8399321266968326" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="52" LOG_CI_END="-0.020669277721451995" LOG_CI_START="-0.13084233632619427" LOG_EFFECT_SIZE="-0.07575580702382312" MODIFIED="2011-08-24 14:32:09 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1470" O_E="0.0" SE="0.06471619998986126" STUDY_ID="STD-Szeimies-2002" TOTAL_1="68" TOTAL_2="54" VAR="0.004188186541127719" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0088758519242587" CI_START="0.8553888934384218" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9289678135405105" ESTIMABLE="NO" EVENTS_1="62" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-045.04" LOG_CI_END="0.00383772704812199" LOG_CI_START="-0.06783639301972796" LOG_EFFECT_SIZE="-0.031999332985803" METHOD="MH" MODIFIED="2011-09-28 16:16:19 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.08010538577280564" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="68" TOTAL_2="54" WEIGHT="0.0" Z="1.7500749258479138">
<NAME>Cosmetic outcomes: excellent or good cosmetic outcomes by participant</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0088758519242587" CI_START="0.8553888934384218" EFFECT_SIZE="0.9289678135405105" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="53" LOG_CI_END="0.00383772704812199" LOG_CI_START="-0.06783639301972796" LOG_EFFECT_SIZE="-0.031999332985803" MODIFIED="2011-08-24 14:32:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1471" O_E="0.0" SE="0.04210173292047139" STUDY_ID="STD-Szeimies-2002" TOTAL_1="68" TOTAL_2="54" VAR="0.0017725559149067045" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-046" MODIFIED="2012-09-18 14:46:54 +0100" MODIFIED_BY="Maryse Paquet" NO="46">
<NAME>Cryotherapy versus ALA-red light PDT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="66" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-046.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-29 19:55:24 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="149" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ALA-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9557137022729082" CI_START="0.6080146588081929" EFFECT_SIZE="0.7622912439519276" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="86" LOG_CI_END="-0.019672187373210522" LOG_CI_START="-0.21608595006482087" LOG_EFFECT_SIZE="-0.11787906871901568" MODIFIED="2011-11-29 19:55:24 +0000" MODIFIED_BY="Maryse Paquet" ORDER="168" O_E="0.0" SE="0.11537441646885771" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="149" TOTAL_2="148" VAR="0.013311255975529426" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="95" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-046.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-26 18:54:34 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="298" TOTAL_2="296" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ALA-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="80" EVENTS_2="126" I2="0.0" ID="CMP-046.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-26 18:54:18 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="0.7427630564846656" CI_START="0.5354753495734823" EFFECT_SIZE="0.6306594226057314" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="126" LOG_CI_END="-0.1291497053143953" LOG_CI_START="-0.2712605169714766" LOG_EFFECT_SIZE="-0.20020511114293593" MODIFIED="2011-09-26 18:54:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1189" O_E="0.0" SE="0.08347659422723248" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="149" TOTAL_2="148" VAR="0.0069683417837780245" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="55" I2="0.0" ID="CMP-046.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-26 18:54:34 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>One day after treatment</NAME>
<DICH_DATA CI_END="0.4573201580857009" CI_START="0.16046772226929137" EFFECT_SIZE="0.2708968883465528" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="55" LOG_CI_END="-0.33977965505396" LOG_CI_START="-0.7946123118577985" LOG_EFFECT_SIZE="-0.5671959834558792" MODIFIED="2011-09-26 18:54:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1188" O_E="0.0" SE="0.26717095406453695" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="149" TOTAL_2="148" VAR="0.07138031869575492" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-047" MODIFIED="2012-09-17 20:31:10 +0100" MODIFIED_BY="Maryse Paquet" NO="47">
<NAME>ALA-PDT versus placebo-PDT</NAME>
<DICH_OUTCOME CHI2="0.8016067329998716" CI_END="9.563133807688391" CI_START="3.8118273393522113" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="6.0376332198991705" ESTIMABLE="YES" EVENTS_1="274" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-047.01" LOG_CI_END="0.9806002324816631" LOG_CI_START="0.5811332205956631" LOG_EFFECT_SIZE="0.7808667265386631" METHOD="MH" MODIFIED="2011-11-30 14:29:12 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.8490827382230788" P_Q="0.9235492724430525" P_Z="1.8225804856544792E-14" Q="0.0092090633244289" RANDOM="YES" SCALE="68.16141279402048" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="479" TOTAL_2="186" WEIGHT="199.99999999999997" Z="7.662563441800461">
<NAME>Participant complete clearance [1 treatment]</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.434663897953222" CI_START="2.8823712575828795" DF="0" EFFECT_SIZE="6.222836095764273" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="6" I2="0.0" ID="CMP-047.01.01" LOG_CI_END="1.1282268059318128" LOG_CI_START="0.459749918440286" LOG_EFFECT_SIZE="0.7939883621860494" MODIFIED="2011-11-30 14:29:03 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="3.2253183014492862E-6" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="100.0" Z="4.6559234078181255">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="13.434663897953222" CI_START="2.8823712575828795" EFFECT_SIZE="6.222836095764273" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="6" LOG_CI_END="1.1282268059318128" LOG_CI_START="0.459749918440286" LOG_EFFECT_SIZE="0.7939883621860494" MODIFIED="2011-11-30 14:29:03 +0000" MODIFIED_BY="[Empty name]" ORDER="9144" O_E="0.0" SE="0.3926666327264829" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="0.1541870844567546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.797608317130022" CI_END="10.536135057293814" CI_START="3.3456098343074236" DF="2" EFFECT_SIZE="5.937153953138944" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="11" I2="0.0" ID="CMP-047.01.02" LOG_CI_END="1.0226813289869003" LOG_CI_START="0.5244752920694749" LOG_EFFECT_SIZE="0.7735783105281876" MODIFIED="2011-11-30 14:29:12 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.6711223467883674" P_Z="1.1534752034963983E-9" STUDIES="3" TAU2="0.0" TOTAL_1="298" TOTAL_2="124" WEIGHT="99.99999999999997" Z="6.086580713625065">
<NAME>Red light</NAME>
<DICH_DATA CI_END="39.30173492177474" CI_START="2.596304658453743" EFFECT_SIZE="10.101449275362318" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="2" LOG_CI_END="1.5944117221393623" LOG_CI_START="0.41435565258214585" LOG_EFFECT_SIZE="1.0043836873607541" MODIFIED="2011-11-29 20:05:08 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1472" O_E="0.0" SE="0.6931707766296616" STUDY_ID="STD-Hauschild-2009a" TOTAL_1="69" TOTAL_2="34" VAR="0.4804857255733683" WEIGHT="17.824308301871366"/>
<DICH_DATA CI_END="13.214376522470527" CI_START="2.454024791986421" EFFECT_SIZE="5.694594594594594" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="5" LOG_CI_END="1.1210466771734946" LOG_CI_START="0.38987894590871586" LOG_EFFECT_SIZE="0.7554628115411052" MODIFIED="2011-11-29 20:04:58 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1473" O_E="0.0" SE="0.42949154468357265" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="148" TOTAL_2="49" VAR="0.1844629869546813" WEIGHT="46.42842365646043"/>
<DICH_DATA CI_END="12.550446608854061" CI_START="1.842407554675178" EFFECT_SIZE="4.808641975308642" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" LOG_CI_END="1.0986591805030974" LOG_CI_START="0.2653857057567694" LOG_EFFECT_SIZE="0.6820224431299334" MODIFIED="2011-11-30 14:29:12 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1474" O_E="0.0" SE="0.4894689638362166" STUDY_ID="STD-Szeimies-2010b" TOTAL_1="81" TOTAL_2="41" VAR="0.23957986655889948" WEIGHT="35.747268041668185"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-047.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 14:31:10 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="25.88" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="262" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance [1 or 2 treatments]</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="109" EVENTS_2="4" I2="0.0" ID="CMP-047.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 14:30:25 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="24.261730339630983" CI_START="3.591182458897338" EFFECT_SIZE="9.334254143646408" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="4" LOG_CI_END="1.3849217713926876" LOG_CI_START="0.5552374710907735" LOG_EFFECT_SIZE="0.9700796212417305" MODIFIED="2011-11-30 14:30:25 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1476" O_E="0.0" SE="0.48736066500086767" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="0.23752041779008798" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="4" I2="0.0" ID="CMP-047.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 14:31:10 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Red light</NAME>
<DICH_DATA CI_END="15.992001792762553" CI_START="2.4041802396137326" EFFECT_SIZE="6.200617283950617" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="4" LOG_CI_END="1.203902829796081" LOG_CI_START="0.3809670232871928" LOG_EFFECT_SIZE="0.792434926541637" MODIFIED="2011-11-30 14:31:10 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1475" O_E="0.0" SE="0.4833965663412613" STUDY_ID="STD-Szeimies-2010b" TOTAL_1="81" TOTAL_2="41" VAR="0.23367224035052145" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="129" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-047.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 14:33:01 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="180" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance [1 or 2 treatments] by anatomical location</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="108" EVENTS_2="5" I2="0.0" ID="CMP-047.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 14:33:01 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<DICH_DATA CI_END="14.281039522435194" CI_START="2.7447923276933355" EFFECT_SIZE="6.260869565217392" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="5" LOG_CI_END="1.1547598210554277" LOG_CI_START="0.43850949109988585" LOG_EFFECT_SIZE="0.7966346560776568" MODIFIED="2011-11-30 14:33:01 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1478" O_E="0.0" SE="0.4207289893121997" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="138" TOTAL_2="40" VAR="0.17701288244766505" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="2" I2="0.0" ID="CMP-047.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 22:26:04 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="20.302250051605963" CI_START="1.3576081434293894" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.3075441724375916" LOG_CI_START="0.13277443437432218" LOG_EFFECT_SIZE="0.7201593034059569" MODIFIED="2011-08-24 22:26:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1479" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="42" TOTAL_2="21" VAR="0.4761904761904762" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="128" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-047.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 14:33:45 +0000" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt; 75%) clearance [1 treatment]</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="128" EVENTS_2="10" I2="0.0" ID="CMP-047.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 14:33:20 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="7.794252187355665" CI_START="2.4664465878376243" EFFECT_SIZE="4.384530386740331" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="10" LOG_CI_END="0.891774453523018" LOG_CI_START="0.3920717150308575" LOG_EFFECT_SIZE="0.6419230842769377" MODIFIED="2011-11-30 14:33:20 +0000" MODIFIED_BY="[Empty name]" ORDER="9148" O_E="0.0" SE="0.2935278621587437" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="0.08615860586348245" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="133" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-047.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 14:34:35 +0000" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="13.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance[1 or 2 treatments]</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="133" EVENTS_2="7" I2="0.0" ID="CMP-047.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 14:34:35 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="13.147996154030846" CI_START="3.221616662312929" EFFECT_SIZE="6.50828729281768" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="7" LOG_CI_END="1.1188595683725147" LOG_CI_START="0.5080738627912821" LOG_EFFECT_SIZE="0.8134667155818983" MODIFIED="2011-11-30 14:34:35 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1477" O_E="0.0" SE="0.35877854689641986" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="0.12872204571310653" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-047.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-21 14:03:50 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="180" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance [1 or 2 treatment] by anatomical location</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="127" EVENTS_2="8" I2="0.0" ID="CMP-047.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 22:27:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Face</NAME>
<DICH_DATA CI_END="8.568634123632775" CI_START="2.471028069145251" EFFECT_SIZE="4.601449275362318" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="8" LOG_CI_END="0.9329115990707556" LOG_CI_START="0.39287767871072266" LOG_EFFECT_SIZE="0.6628946388907391" MODIFIED="2011-08-24 22:26:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1480" O_E="0.0" SE="0.3172185980305021" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="138" TOTAL_2="40" VAR="0.10062763893643728" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="4" I2="0.0" ID="CMP-047.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-24 22:27:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Scalp</NAME>
<DICH_DATA CI_END="9.530394516218706" CI_START="1.5755512507322336" EFFECT_SIZE="3.875" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="0.9791108788828674" LOG_CI_START="0.1974325348017909" LOG_EFFECT_SIZE="0.5882717068423291" MODIFIED="2011-08-24 22:27:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1481" O_E="0.0" SE="0.4591617286834319" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="42" TOTAL_2="21" VAR="0.21082949308755755" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="264" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-047.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:33 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="434" TOTAL_2="166" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="187" EVENTS_2="8" I2="0.0" ID="CMP-047.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 13:53:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Red light-during illumination</NAME>
<DICH_DATA CI_END="17.313268548510948" CI_START="4.617010802319457" EFFECT_SIZE="8.940668202764977" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="8" LOG_CI_END="1.2383790654825444" LOG_CI_START="0.6643608906616553" LOG_EFFECT_SIZE="0.9513699780720998" MODIFIED="2011-08-25 13:53:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1546" O_E="0.0" SE="0.3371811173255818" STUDY_ID="STD-Hauschild-2009a" TOTAL_1="217" TOTAL_2="83" VAR="0.11369110588092778" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="77" EVENTS_2="0" I2="0.0" ID="CMP-047.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 13:53:10 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Red light-after treatment</NAME>
<DICH_DATA CI_END="952.4776042287233" CI_START="3.7450205783600152" EFFECT_SIZE="59.72477064220183" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="0" LOG_CI_END="2.9788547728261543" LOG_CI_START="0.5734542084289825" LOG_EFFECT_SIZE="1.7761544906275684" MODIFIED="2011-08-25 13:53:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1547" O_E="0.0" SE="1.4129441984517248" STUDY_ID="STD-Hauschild-2009a" TOTAL_1="217" TOTAL_2="83" VAR="1.996411307938387" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-047.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:34 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: injury</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-047.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 00:01:04 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="23.84596111058593" CI_START="0.3985624839028281" EFFECT_SIZE="3.0828729281767955" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.3774148313457764" LOG_CI_START="-0.3995035832089879" LOG_EFFECT_SIZE="0.4889556240683942" MODIFIED="2011-08-25 00:01:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1530" O_E="0.0" SE="1.043770672597479" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="1.0894572169745935" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-047.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:35 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: cardiovascular: hypertension</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-047.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 00:02:41 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="46.26299133902506" CI_START="0.12691141677635534" EFFECT_SIZE="2.423076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6652337105796704" LOG_CI_START="-0.8964993076141431" LOG_EFFECT_SIZE="0.3843672014827637" MODIFIED="2011-08-25 00:02:41 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1536" O_E="0.0" SE="1.504774655669999" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="2.2643467643467643" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-047.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-10 15:55:51 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="52.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="217" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: skin discolouration</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-047.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-12-05 18:19:06 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Red light</NAME>
<DICH_DATA CI_END="28.096062145716154" CI_START="0.04756008690398381" EFFECT_SIZE="1.1559633027522935" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4486454548435965" LOG_CI_START="-1.322757360489718" LOG_EFFECT_SIZE="0.06294404717693924" MODIFIED="2011-08-25 14:46:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1538" O_E="0.0" SE="1.6279357323919768" STUDY_ID="STD-Hauschild-2009a" TOTAL_1="217" TOTAL_2="83" VAR="2.650174748798602" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-047.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:35 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: skin hypertrophy</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-047.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 00:03:31 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="46.26299133902506" CI_START="0.12691141677635534" EFFECT_SIZE="2.423076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6652337105796704" LOG_CI_START="-0.8964993076141431" LOG_EFFECT_SIZE="0.3843672014827637" MODIFIED="2011-08-25 00:03:31 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1538" O_E="0.0" SE="1.504774655669999" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="2.2643467643467643" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-047.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:35 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-047.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-25 00:04:02 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="181" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="8.92893601347102" CI_START="0.4730739338531412" EFFECT_SIZE="2.0552486187845305" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.950799710735291" LOG_CI_START="-0.325070980709865" LOG_EFFECT_SIZE="0.31286436501271303" MODIFIED="2011-08-25 00:04:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1537" O_E="0.0" SE="0.749452759816665" STUDY_ID="STD-Piacquadio-2004" TOTAL_1="181" TOTAL_2="62" VAR="0.5616794391968158" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-047.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:16:35 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="77" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: very good or good general cosmetic outcome</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2475319293898335" CI_START="1.026681558804024" EFFECT_SIZE="1.825974025974026" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.5115534297033862" LOG_CI_START="0.01143576131926037" LOG_EFFECT_SIZE="0.2614945955113233" MODIFIED="2011-08-25 22:01:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1577" O_E="0.0" SE="0.29377159403122044" STUDY_ID="STD-Szeimies-2010b" TOTAL_1="77" TOTAL_2="37" VAR="0.0863017494596442" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-048" MODIFIED="2012-09-17 20:26:58 +0100" MODIFIED_BY="Maryse Paquet" NO="48">
<NAME>ALA- blue light PDT versus ALA-pulsed laser PDT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-048.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-05 18:14:06 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="52.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Blue light</GROUP_LABEL_1>
<GROUP_LABEL_2>Pulsed dye laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pulsed dye laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blue light</GRAPH_LABEL_2>
<DICH_DATA CI_END="42.59442830538803" CI_START="0.8451809645593047" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6293527935984997" LOG_CI_START="-0.07305029283121235" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2011-08-25 21:40:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1572" O_E="0.0" SE="1.0" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-048.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-05 18:14:19 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="52.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Blue light</GROUP_LABEL_1>
<GROUP_LABEL_2>Pulsed dye laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pulsed dye laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blue light</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7912189420762292" CI_START="0.8546064074647298" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5787788655633196" LOG_CI_START="-0.0682338553567075" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-08-25 21:40:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1573" O_E="0.0" SE="0.3800584750330461" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.1444444444444445" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-048.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-05 18:14:34 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in global response</NAME>
<GROUP_LABEL_1>Blue light</GROUP_LABEL_1>
<GROUP_LABEL_2>Pulsed dye laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pulsed dye laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blue light</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7979481080542332" CI_START="0.4086290779249003" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.25477715307523086" LOG_CI_START="-0.3886707323364573" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-08-25 22:19:42 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1580" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-048.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-05 18:15:03 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in tactile roughness</NAME>
<GROUP_LABEL_1>Blue light</GROUP_LABEL_1>
<GROUP_LABEL_2>Pulsed dye laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pulsed dye laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blue light</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7762721743685985" CI_START="0.2502119049421176" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2495095125517467" LOG_CI_START="-0.6016920306631093" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-08-25 22:20:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1581" O_E="0.0" SE="0.5" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.25" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-048.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-05 18:15:19 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in mottled hyperpigmentation</NAME>
<GROUP_LABEL_1>Blue light</GROUP_LABEL_1>
<GROUP_LABEL_2>Pulsed dye laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pulsed dye laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours blue light</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7979481080542332" CI_START="0.4086290779249003" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.25477715307523086" LOG_CI_START="-0.3886707323364573" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-08-25 22:19:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1582" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-049" MODIFIED="2012-09-18 21:12:52 +0100" MODIFIED_BY="Maryse Paquet" NO="49">
<NAME>ALA-red light PDT at different application times</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="99" I2="0.0" I2_Q="0.0" ID="CMP-049.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-12 00:46:34 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.45" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="212" TOTAL_2="208" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance at 4 weeks</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours longer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours shorter</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-049.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:33:17 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 1.0h</NAME>
<DICH_DATA CI_END="1.3299307817076842" CI_START="0.3381293128184165" EFFECT_SIZE="0.6705882352941176" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.12382903803124022" LOG_CI_START="-0.470917178114843" LOG_EFFECT_SIZE="-0.17354407004180136" MODIFIED="2011-04-13 21:33:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="273" O_E="0.0" SE="0.3493568714054601" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="38" VAR="0.12205022359821119" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-049.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:33:33 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 2 h</NAME>
<DICH_DATA CI_END="1.1795829562050597" CI_START="0.30519260905412515" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.07172848880382883" LOG_CI_START="-0.5154259880365415" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-04-13 21:33:33 +0100" MODIFIED_BY="Maryse Paquet" ORDER="274" O_E="0.0" SE="0.34489744615756873" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.11895424836601304" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="18" I2="0.0" ID="CMP-049.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:33:46 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 4h</NAME>
<DICH_DATA CI_END="0.9517001883748879" CI_START="0.2626877697974371" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.021499844726403348" LOG_CI_START="-0.580560146601559" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-04-13 21:33:46 +0100" MODIFIED_BY="Maryse Paquet" ORDER="275" O_E="0.0" SE="0.32839478871459266" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.10784313725490194" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-049.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:34:05 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 2h</NAME>
<DICH_DATA CI_END="1.5446193164836837" CI_START="0.5182856436386896" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.18882146167535424" LOG_CI_START="-0.28543082082446425" LOG_EFFECT_SIZE="-0.04830467957455503" MODIFIED="2011-04-13 21:34:05 +0100" MODIFIED_BY="Maryse Paquet" ORDER="276" O_E="0.0" SE="0.27857813832705314" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="0.07760577915376676" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-049.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:34:20 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 4h</NAME>
<DICH_DATA CI_END="1.2359749580947252" CI_START="0.44979899121644124" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.09200967166586298" LOG_CI_START="-0.3469815229102228" LOG_EFFECT_SIZE="-0.12748592562217986" MODIFIED="2011-04-13 21:34:20 +0100" MODIFIED_BY="Maryse Paquet" ORDER="277" O_E="0.0" SE="0.2578656007354522" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="0.06649466804265566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-049.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:36:49 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>2h versus 4h</NAME>
<DICH_DATA CI_END="1.3650344643968209" CI_START="0.5087376638151803" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.13514361658439944" LOG_CI_START="-0.29350610867964905" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-04-13 21:36:49 +0100" MODIFIED_BY="Maryse Paquet" ORDER="278" O_E="0.0" SE="0.2517909704704629" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.06339869281045751" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="76" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-049.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-30 18:39:52 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.962696086206751" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="212" TOTAL_2="208" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance at 8 weeks</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours longer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours shorter</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-049.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:35:03 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 1.0h</NAME>
<DICH_DATA CI_END="0.9927964904048461" CI_START="0.2485330157606602" EFFECT_SIZE="0.49673202614379086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.003139766763660917" LOG_CI_START="-0.604615910309954" LOG_EFFECT_SIZE="-0.30387783853680744" MODIFIED="2011-04-13 21:35:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="279" O_E="0.0" SE="0.3533100640740212" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="38" VAR="0.12482800137598898" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="16" I2="0.0" ID="CMP-049.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:35:11 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 2 h</NAME>
<DICH_DATA CI_END="1.009970732846102" CI_START="0.24753192530193313" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.004308788884026871" LOG_CI_START="-0.6063687802119893" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-04-13 21:35:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="280" O_E="0.0" SE="0.35871502698971963" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.12867647058823528" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="25" I2="0.0" ID="CMP-049.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:35:18 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 4h</NAME>
<DICH_DATA CI_END="0.6060545456387993" CI_START="0.1689616895655281" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="25" LOG_CI_END="-0.21748828704840512" LOG_CI_START="-0.772211756311783" LOG_EFFECT_SIZE="-0.494850021680094" MODIFIED="2011-04-13 21:35:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="281" O_E="0.0" SE="0.32584731177076676" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.10617647058823529" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-049.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:35:40 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 2h</NAME>
<DICH_DATA CI_END="1.641932185049215" CI_START="0.6170785776118695" EFFECT_SIZE="1.006578947368421" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.21535521595813992" LOG_CI_START="-0.20965953021248745" LOG_EFFECT_SIZE="0.0028478428728262407" MODIFIED="2011-04-13 21:35:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="282" O_E="0.0" SE="0.24965576575755064" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="0.06232800137598899" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="25" I2="0.0" ID="CMP-049.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:35:50 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 4h</NAME>
<DICH_DATA CI_END="0.9525805669086888" CI_START="0.4356662487487504" EFFECT_SIZE="0.6442105263157895" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="-0.02109828254562187" LOG_CI_START="-0.36084608374095134" LOG_EFFECT_SIZE="-0.1909721831432866" MODIFIED="2011-04-13 21:35:50 +0100" MODIFIED_BY="Maryse Paquet" ORDER="283" O_E="0.0" SE="0.19956954020087583" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="0.039828001375989" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-049.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-13 21:36:08 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>2h versus 4h</NAME>
<DICH_DATA CI_END="0.9639885438550789" CI_START="0.4249013150736957" EFFECT_SIZE="0.64" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="-0.01592812726945837" LOG_CI_START="-0.37171192476276727" LOG_EFFECT_SIZE="-0.1938200260161128" MODIFIED="2011-04-13 21:36:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="284" O_E="0.0" SE="0.2089891638057708" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="0.043676470588235296" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-049.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-18 21:10:02 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="325.6858429809225" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="102" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: metabolic and nutritional disorders: elevated alanine transaminase (ALT)</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-049.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 14:29:04 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 1.0h</NAME>
<DICH_DATA CI_END="79.41862837084409" CI_START="0.14070620592149943" EFFECT_SIZE="3.342857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8999223821471836" LOG_CI_START="-0.8516867473554114" LOG_EFFECT_SIZE="0.524117817395886" MODIFIED="2011-08-26 14:29:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1539" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="38" VAR="2.6124542124542125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-049.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 14:30:35 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 2 h</NAME>
<DICH_DATA CI_END="71.14657198220529" CI_START="0.1264994187246438" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8521539795421889" LOG_CI_START="-0.8979114701028642" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-08-26 14:30:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1540" O_E="0.0" SE="1.6154020581650284" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="2.6095238095238096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-049.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 14:30:38 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 4h</NAME>
<DICH_DATA CI_END="71.14657198220529" CI_START="0.1264994187246438" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8521539795421889" LOG_CI_START="-0.8979114701028642" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-08-26 14:30:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1541" O_E="0.0" SE="1.6154020581650284" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="2.6095238095238096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-049.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-18 21:12:52 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="325.6858429809225" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="212" TOTAL_2="208" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: nervous system: headache</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-049.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:12:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 1h</NAME>
<DICH_DATA CI_END="79.41862837084409" CI_START="0.14070620592149943" EFFECT_SIZE="3.342857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8999223821471836" LOG_CI_START="-0.8516867473554114" LOG_EFFECT_SIZE="0.524117817395886" MODIFIED="2012-09-18 21:12:42 +0100" MODIFIED_BY="[Empty name]" ORDER="725" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="38" VAR="2.6124542124542125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-049.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:12:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 2h</NAME>
<DICH_DATA CI_END="15.344261514858012" CI_START="0.06517094348474765" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1859459916443629" LOG_CI_START="-1.1859459916443629" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-18 21:12:52 +0100" MODIFIED_BY="[Empty name]" ORDER="726" O_E="0.0" SE="1.393261092038472" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="1.9411764705882355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-049.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:11:59 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 4h</NAME>
<DICH_DATA CI_END="15.344261514858012" CI_START="0.06517094348474765" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1859459916443629" LOG_CI_START="-1.1859459916443629" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 14:28:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1535" O_E="0.0" SE="1.393261092038472" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="1.9411764705882355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-049.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:11:56 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 2h</NAME>
<DICH_DATA CI_END="7.107007068031556" CI_START="0.01259150429204739" EFFECT_SIZE="0.29914529914529914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8516867473554114" LOG_CI_START="-1.8999223821471836" LOG_EFFECT_SIZE="-0.524117817395886" MODIFIED="2011-08-26 14:28:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1536" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-049.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:11:54 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 4h</NAME>
<DICH_DATA CI_END="7.107007068031556" CI_START="0.01259150429204739" EFFECT_SIZE="0.29914529914529914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8516867473554114" LOG_CI_START="-1.8999223821471836" LOG_EFFECT_SIZE="-0.524117817395886" MODIFIED="2011-08-26 14:28:29 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1537" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-049.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-18 21:11:51 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>2h versus 4h</NAME>
<DICH_DATA CI_END="15.344261514858012" CI_START="0.06517094348474765" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1859459916443629" LOG_CI_START="-1.1859459916443629" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 14:28:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1538" O_E="0.0" SE="1.393261092038472" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="1.9411764705882355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-049.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-22 18:23:21 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="325.6858429809225" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="106" TOTAL_2="102" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: other: epistaxis (nose bleeding)</NAME>
<GROUP_LABEL_1>shorter</GROUP_LABEL_1>
<GROUP_LABEL_2>longer</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shorter</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours longer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-049.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 22:08:01 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>0.5h versus 4h</NAME>
<DICH_DATA CI_END="7.905174664689478" CI_START="0.014055490969404871" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8979114701028642" LOG_CI_START="-1.8521539795421889" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-26 14:32:05 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1547" O_E="0.0" SE="1.6154020581650284" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="2.6095238095238096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-049.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 22:08:01 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>1h versus 4h</NAME>
<DICH_DATA CI_END="7.107007068031556" CI_START="0.01259150429204739" EFFECT_SIZE="0.29914529914529914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8516867473554114" LOG_CI_START="-1.8999223821471836" LOG_EFFECT_SIZE="-0.524117817395886" MODIFIED="2011-08-26 14:31:13 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1549" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-049.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 22:08:01 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>2h versus 4h</NAME>
<DICH_DATA CI_END="7.905174664689478" CI_START="0.014055490969404871" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8979114701028642" LOG_CI_START="-1.8521539795421889" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-26 14:32:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1550" O_E="0.0" SE="1.6154020581650284" STUDY_ID="STD-Hauschild-2009c" TOTAL_1="34" TOTAL_2="34" VAR="2.6095238095238096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-050" MODIFIED="2012-09-17 20:26:19 +0100" MODIFIED_BY="Maryse Paquet" NO="50">
<NAME>ALA-PDT versus 0.5% 5-FU</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-050.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 14:26:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="134.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-050.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-09 19:31:57 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="2.225879116358687" CI_START="0.4492606955385334" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3475015748576669" LOG_CI_START="-0.3475015748576669" LOG_EFFECT_SIZE="0.0" ORDER="9121" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.16666666666666669" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-050.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:25:58 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2011-05-09 19:32:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1492" O_E="0.0" SE="1.0" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-050.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:26:12 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.3538200017494282" CI_START="0.2513463956346231" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.1315609262077127" LOG_CI_START="-0.5997273382744486" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2011-09-27 14:26:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1124" O_E="0.0" SE="0.4295623464921123" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="12" VAR="0.18452380952380953" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-050.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 14:26:38 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="57.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5% 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-050.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-09 19:34:10 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="1.5871944192581473" CI_START="0.6300425378684225" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.20063012778789294" LOG_CI_START="-0.2006301277878929" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-09 19:34:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1493" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.055555555555555566" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-050.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-05-09 19:33:41 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="1.1701293031099476" CI_START="0.2637674097113364" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.06823385535670759" LOG_CI_START="-0.5787788655633196" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2011-05-09 19:16:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9124" O_E="0.0" SE="0.3800584750330461" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="0.1444444444444445" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-050.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:26:38 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.2446203849395923" CI_START="0.48604239407046107" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.09503690977257091" LOG_CI_START="-0.313325848622707" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2011-09-27 14:26:38 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1125" O_E="0.0" SE="0.2398743057096415" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="12" VAR="0.05753968253968254" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-050.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-30 20:09:24 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="683.9734849597555" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-050.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-30 20:09:24 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-09-30 20:09:24 +0100" MODIFIED_BY="Maryse Paquet" ORDER="693" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-050.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-30 20:09:21 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-09-30 20:09:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="694" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-050.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-30 20:09:03 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="3.9634520633724324" CI_START="0.007580372857816312" EFFECT_SIZE="0.17333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5980736099146257" LOG_CI_START="-2.120309432084352" LOG_EFFECT_SIZE="-0.7611179110848633" MODIFIED="2011-09-27 14:23:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1123" O_E="0.0" SE="1.5967916550832766" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="12" VAR="2.5497435897435894" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-050.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 14:27:16 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in global response</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-050.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 15:39:43 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="1.3457234339567536" CI_START="0.35122837135285356" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.12895581512724366" LOG_CI_START="-0.45441041012264316" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2011-08-26 15:39:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1551" O_E="0.0" SE="0.3426722084211709" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.1174242424242424" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-050.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-12 19:38:57 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="1.4610247176926514" CI_START="0.44033318931599824" EFFECT_SIZE="0.8020833333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.1646575634132275" LOG_CI_START="-0.3562185791474005" LOG_EFFECT_SIZE="-0.09578050786708653" MODIFIED="2011-08-26 15:39:51 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1554" O_E="0.0" SE="0.30596522451860214" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.09361471861471862" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-050.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:27:16 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.2479270393668775" CI_START="0.44450886088463926" EFFECT_SIZE="0.7447916666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.09618919486032887" LOG_CI_START="-0.3521195773373045" LOG_EFFECT_SIZE="-0.12796519123848782" MODIFIED="2011-09-27 14:27:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1126" O_E="0.0" SE="0.2633387919531024" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="11" VAR="0.06934731934731936" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-050.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 14:27:44 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in tactile roughness</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-050.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 15:40:08 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="1.9082771822924427" CI_START="0.5751290635964059" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.280641457368601" LOG_CI_START="-0.24023468519202698" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2011-08-26 15:40:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1555" O_E="0.0" SE="0.30596522451860214" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.09361471861471862" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-050.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-12 19:39:14 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="1.6156297314002213" CI_START="0.38210917190814064" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.20834183661496433" LOG_CI_START="-0.41781253765499027" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2011-08-26 15:40:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1556" O_E="0.0" SE="0.3678061789603123" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.1352813852813853" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="7" I2="0.0" ID="CMP-050.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:27:44 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.6051920661091406" CI_START="0.5234749133881188" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.20552700450465214" LOG_CI_START="-0.28110412628345166" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2011-09-27 14:27:44 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1127" O_E="0.0" SE="0.28584953508787925" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="11" VAR="0.0817099567099567" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-050.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-27 14:28:11 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: improvement in mottled hyperpigmentation</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-050.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 15:40:52 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Blue light</NAME>
<DICH_DATA CI_END="1.3096743946598723" CI_START="0.20949971867230155" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.11716333674032643" LOG_CI_START="-0.6788165558917149" LOG_EFFECT_SIZE="-0.2808266095756942" MODIFIED="2011-08-26 15:40:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1557" O_E="0.0" SE="0.4675625290960757" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.21861471861471862" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-050.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-12 19:39:27 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Pulsed dye laser</NAME>
<DICH_DATA CI_END="1.6156297314002213" CI_START="0.38210917190814064" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.20834183661496433" LOG_CI_START="-0.41781253765499027" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2011-08-26 15:40:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1558" O_E="0.0" SE="0.3678061789603123" STUDY_ID="STD-Smith-2003" TOTAL_1="12" TOTAL_2="11" VAR="0.1352813852813853" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-050.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-27 14:28:11 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.2553241102127988" CI_START="0.34151590687982836" EFFECT_SIZE="0.6547619047619048" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.09875587012316983" LOG_CI_START="-0.4665890632584455" LOG_EFFECT_SIZE="-0.1839165965676378" MODIFIED="2011-09-27 14:28:11 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1128" O_E="0.0" SE="0.3320864123709148" STUDY_ID="STD-Smith-2003" TOTAL_1="24" TOTAL_2="11" VAR="0.11028138528138529" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-051" MODIFIED="2012-10-01 16:39:03 +0100" MODIFIED_BY="[Empty name]" NO="51">
<NAME>ALA-red light PDT vs cryotherapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="86" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-051.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 13:55:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="148" TOTAL_2="149" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.64469718865029" CI_START="1.0463384564035954" EFFECT_SIZE="1.311834561834562" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="66" LOG_CI_END="0.21608595006482095" LOG_CI_START="0.019672187373210547" LOG_EFFECT_SIZE="0.11787906871901573" MODIFIED="2012-09-14 13:55:46 +0100" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.11537441646885771" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="148" TOTAL_2="149" VAR="0.013311255975529426" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="181" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-051.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-14 14:03:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="296" TOTAL_2="298" WEIGHT="0.0" Z="0.0">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ALA-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="126" EVENTS_2="80" I2="0.0" ID="CMP-051.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 14:03:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="149" WEIGHT="0.0" Z="0.0">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="1.8674995978741538" CI_START="1.3463243645056615" EFFECT_SIZE="1.585641891891892" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="80" LOG_CI_END="0.27126051697147663" LOG_CI_START="0.12914970531439535" LOG_EFFECT_SIZE="0.200205111142936" MODIFIED="2012-09-14 14:03:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1189" O_E="0.0" SE="0.0834765942272325" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="148" TOTAL_2="149" VAR="0.006968341783778025" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="55" EVENTS_2="15" I2="0.0" ID="CMP-051.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-14 14:03:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="149" WEIGHT="0.0" Z="0.0">
<NAME>One day after treatment</NAME>
<DICH_DATA CI_END="6.231782852390929" CI_START="2.1866519162109666" EFFECT_SIZE="3.6914414414414414" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="15" LOG_CI_END="0.7946123118577985" LOG_CI_START="0.3397796550539601" LOG_EFFECT_SIZE="0.5671959834558793" MODIFIED="2012-09-14 14:03:39 +0100" MODIFIED_BY="[Empty name]" ORDER="1188" O_E="0.0" SE="0.26717095406453695" STUDY_ID="STD-Hauschild-2009b" TOTAL_1="148" TOTAL_2="149" VAR="0.07138031869575492" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-052" MODIFIED="2012-09-17 20:26:00 +0100" MODIFIED_BY="Maryse Paquet" NO="52">
<NAME>MAL-red light PDT versus placebo-red light PDT</NAME>
<DICH_OUTCOME CHI2="4.09935894831136" CI_END="6.278157834376372" CI_START="3.169955383101074" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="4.461107510813829" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="30" I2="2.4237679491884565" I2_Q="0.0" ID="CMP-052.01" LOG_CI_END="0.7978322297675067" LOG_CI_START="0.5010531495965002" LOG_EFFECT_SIZE="0.6494426896820034" METHOD="MH" MODIFIED="2011-11-30 16:57:06 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.3927263242822536" P_Q="1.0" P_Z="9.65436952328057E-18" Q="0.0" RANDOM="YES" SCALE="30.4258591762675" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003803392694029481" TOTALS="YES" TOTAL_1="278" TOTAL_2="204" WEIGHT="99.99999999999999" Z="8.577991959986555">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.853120799619131" CI_START="1.9111739092155133" EFFECT_SIZE="3.619047619047619" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="8" LOG_CI_END="0.8358883871720749" LOG_CI_START="0.2813002079216692" LOG_EFFECT_SIZE="0.5585942975468721" MODIFIED="2011-11-30 16:57:06 +0000" MODIFIED_BY="Maryse Paquet" ORDER="1514" O_E="0.0" SE="0.32576784174745055" STUDY_ID="STD-Pariser-2003" TOTAL_1="42" TOTAL_2="38" VAR="0.10612468671679198" WEIGHT="27.646052766958853"/>
<DICH_DATA CI_END="8.179205342876452" CI_START="1.9306002588563826" EFFECT_SIZE="3.9737609329446064" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="7" LOG_CI_END="0.9127111114991728" LOG_CI_START="0.2856923600846332" LOG_EFFECT_SIZE="0.5992017357919031" MODIFIED="2011-08-26 21:47:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1515" O_E="0.0" SE="0.36831391837377736" STUDY_ID="STD-Pariser-2008" TOTAL_1="49" TOTAL_2="47" VAR="0.13565514246784555" WEIGHT="21.791979102852583"/>
<DICH_DATA CI_END="17.85663567340929" CI_START="2.1427173089487854" EFFECT_SIZE="6.1856060606060606" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="3" LOG_CI_END="1.251799637861205" LOG_CI_START="0.3309648778724693" LOG_EFFECT_SIZE="0.7913822578668371" MODIFIED="2011-08-26 21:47:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1516" O_E="0.0" SE="0.5409028962229591" STUDY_ID="STD-Photocure_x002d_Australian-2004" TOTAL_1="88" TOTAL_2="23" VAR="0.2925759431423852" WEIGHT="10.25401273467803"/>
<DICH_DATA CI_END="7.047131960380105" CI_START="1.976533203072184" EFFECT_SIZE="3.732142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="8" LOG_CI_END="0.8480124039122439" LOG_CI_START="0.2959041142974633" LOG_EFFECT_SIZE="0.5719582591048535" MODIFIED="2011-08-26 21:47:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1517" O_E="0.0" SE="0.3243111422998326" STUDY_ID="STD-Photocure_x002d_US-2004" TOTAL_1="42" TOTAL_2="38" VAR="0.10517771701982229" WEIGHT="27.88627764886614"/>
<DICH_DATA CI_END="25.959866209145673" CI_START="3.791517434087682" EFFECT_SIZE="9.921052631578947" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="4" LOG_CI_END="1.4143024498856702" LOG_CI_START="0.5788130572922952" LOG_EFFECT_SIZE="0.9965577535889827" MODIFIED="2011-08-26 21:47:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1518" O_E="0.0" SE="0.49077060494854213" STUDY_ID="STD-Szeimies-2009" TOTAL_1="57" TOTAL_2="58" VAR="0.24085578668155802" WEIGHT="12.42167774664439"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7531353145988948" CI_END="6.233226183288018" CI_START="1.7287590660846446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.282643184282347" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="16" I2="42.95933738413152" I2_Q="0.0" ID="CMP-052.02" LOG_CI_END="0.7947128862970425" LOG_CI_START="0.23773447068220246" LOG_EFFECT_SIZE="0.5162236784896225" METHOD="MH" MODIFIED="2011-09-21 14:03:50 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.1854831792117837" P_Q="1.0" P_Z="2.800337861170002E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10170920939461359" TOTALS="YES" TOTAL_1="130" TOTAL_2="61" WEIGHT="100.0" Z="3.6331024306913435">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAL-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.147898976682315" CI_START="2.0300014962676665" EFFECT_SIZE="4.965909090909091" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="4" LOG_CI_END="1.0845011716186475" LOG_CI_START="0.307496358021859" LOG_EFFECT_SIZE="0.6959987648202532" MODIFIED="2011-04-27 14:53:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="472" O_E="0.0" SE="0.4564164737426121" STUDY_ID="STD-Photocure_x002d_Australian-2004" TOTAL_1="88" TOTAL_2="23" VAR="0.20831599750364052" WEIGHT="34.52668868433554"/>
<DICH_DATA CI_END="4.295277879412323" CI_START="1.6212535634257983" EFFECT_SIZE="2.638888888888889" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="12" LOG_CI_END="0.6329912653946483" LOG_CI_START="0.20985094364847273" LOG_EFFECT_SIZE="0.4214211045215605" MODIFIED="2011-04-27 14:53:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="473" O_E="0.0" SE="0.2485547195720771" STUDY_ID="STD-Photocure_x002d_US-2004" TOTAL_1="42" TOTAL_2="38" VAR="0.06177944862155388" WEIGHT="65.47331131566446"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6135586222999655" CI_END="17.744008216888776" CI_START="0.22649678103326681" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0047345818719102" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-052.03" LOG_CI_END="1.24905172991806" LOG_CI_START="-0.644937965789885" LOG_EFFECT_SIZE="0.3020568820640873" METHOD="MH" MODIFIED="2011-12-05 14:07:59 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.43345125281462427" P_Q="1.0" P_Z="0.5318679188176931" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="61" WEIGHT="100.0" Z="0.6251571605375451">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.234987650657764" CI_START="0.03402460309500564" EFFECT_SIZE="0.8089887640449438" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.2840919118150251" LOG_CI_START="-1.468206932242314" LOG_EFFECT_SIZE="-0.09205751021364433" MODIFIED="2011-09-27 15:27:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1129" O_E="0.0" SE="1.6167139650982856" STUDY_ID="STD-Freeman-2003" TOTAL_1="88" TOTAL_2="23" VAR="2.6137640449438204" WEIGHT="47.354804532784534"/>
<DICH_DATA CI_END="91.5671397577199" CI_START="0.22459116247129693" EFFECT_SIZE="4.534883720930233" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9617396485338419" LOG_CI_START="-0.6486073369679791" LOG_EFFECT_SIZE="0.6565661557829315" MODIFIED="2011-09-27 15:28:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1130" O_E="0.0" SE="1.533330740709742" STUDY_ID="STD-Pariser-2003" TOTAL_1="42" TOTAL_2="38" VAR="2.351103160405486" WEIGHT="52.64519546721547"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-052.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:04:07 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse event: nervous system: headache</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.38577365844857" CI_START="0.1269049810304582" EFFECT_SIZE="3.0517241379310347" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86561187707602" LOG_CI_START="-0.8965213314782813" LOG_EFFECT_SIZE="0.4845452727988694" MODIFIED="2011-09-27 15:38:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1134" O_E="0.0" SE="1.6224907194846905" STUDY_ID="STD-Szeimies-2009" TOTAL_1="57" TOTAL_2="58" VAR="2.632476134813949" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-052.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 16:04:07 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="130" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcome: hyperpigmentation</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAL-PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.359032677084144" CI_START="0.05867355040140462" EFFECT_SIZE="1.4198473282442747" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5360409284735768" LOG_CI_START="-1.2315576313492727" LOG_EFFECT_SIZE="0.15224164856215203" MODIFIED="2011-08-29 20:15:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1745" O_E="0.0" SE="1.6257010938737608" STUDY_ID="STD-Photocure_x002d_Australian-2004" TOTAL_1="130" TOTAL_2="61" VAR="2.6429040466223426" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-053" MODIFIED="2012-09-17 20:25:42 +0100" MODIFIED_BY="Maryse Paquet" NO="53">
<NAME>MAL-red light LED PDT versus MAL-broad visible + water-filtered infrared A PDT (1 or 2 treatments)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-053.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 17:47:09 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Red light LED</GROUP_LABEL_1>
<GROUP_LABEL_2>visible + wIRA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours visible + wIFR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours red light LED</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="20" I2="0.0" ID="CMP-053.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:46:52 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="1.730555896210605" CI_START="0.7642053070321946" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.23818563138153515" LOG_CI_START="-0.11678995067431179" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2011-11-30 17:46:52 +0000" MODIFIED_BY="Maryse Paquet" ORDER="445" O_E="0.0" SE="0.20851441405707474" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.04347826086956521" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="24" I2="0.0" ID="CMP-053.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:47:03 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="1.6136031506569086" CI_START="0.8435228392786627" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.20779673319155453" LOG_CI_START="-0.0739031539303281" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2011-11-30 17:47:03 +0000" MODIFIED_BY="Maryse Paquet" ORDER="447" O_E="0.0" SE="0.16547190813232432" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.02738095238095238" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-053.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:47:09 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="2.510503050812248" CI_START="0.896234720476454" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.39976075347380713" LOG_CI_START="-0.04757823536244458" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-11-30 17:47:09 +0000" MODIFIED_BY="Maryse Paquet" ORDER="446" O_E="0.0" SE="0.2627691364061218" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.06904761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="110" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-053.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 17:48:49 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="120" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Red light LED</GROUP_LABEL_1>
<GROUP_LABEL_2>visible + wIRA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours visible +wIFR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours red ligth LED</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="36" I2="0.0" ID="CMP-053.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:48:37 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="1.1965802060026918" CI_START="0.9311515644958707" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.07794181440531979" LOG_CI_START="-0.030979622706273965" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2011-11-30 17:48:37 +0000" MODIFIED_BY="Maryse Paquet" ORDER="448" O_E="0.0" SE="0.06398099132915949" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.0040935672514619825" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="36" I2="0.0" ID="CMP-053.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:48:43 +0000" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="1.1965802060026918" CI_START="0.9311515644958707" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.07794181440531979" LOG_CI_START="-0.030979622706273965" LOG_EFFECT_SIZE="0.0234810958495229" MODIFIED="2011-11-30 17:48:43 +0000" MODIFIED_BY="Maryse Paquet" ORDER="449" O_E="0.0" SE="0.06398099132915949" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.0040935672514619825" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="33" I2="0.0" ID="CMP-053.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-30 17:48:49 +0000" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.249863301208602" CI_START="0.8493123473784103" EFFECT_SIZE="1.0303030303030303" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="33" LOG_CI_END="0.09686251638628716" LOG_CI_START="-0.07093256205755191" LOG_EFFECT_SIZE="0.012964977164367635" MODIFIED="2011-11-30 17:48:49 +0000" MODIFIED_BY="Maryse Paquet" ORDER="450" O_E="0.0" SE="0.0985636596769451" STUDY_ID="STD-von-Felbert-2010" TOTAL_1="40" TOTAL_2="40" VAR="0.009714795008912654" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-054" MODIFIED="2012-09-17 20:23:19 +0100" MODIFIED_BY="Maryse Paquet" NO="54">
<NAME>MAL-red light LED PDT versus MAL-daylight PDT</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-054.01" MODIFIED="2011-10-05 18:20:49 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>Red light LED</GROUP_LABEL_1>
<GROUP_LABEL_2>Daylight</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daylight</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours red light LED</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4313825538942706" CI_START="-3.2313825538942713" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="8.4" MODIFIED="2011-04-13 16:20:59 +0100" MODIFIED_BY="Maryse Paquet" ORDER="258" SD_1="5.6" SD_2="5.4" SE="1.4446094806985512" STUDY_ID="STD-Wiegell-2008" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-055" MODIFIED="2012-09-17 20:23:10 +0100" MODIFIED_BY="Maryse Paquet" NO="55">
<NAME>2h MAL-day light PDT versus 3h MAL-daylight PDT</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-055.01" MODIFIED="2011-10-05 18:22:42 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="62" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>2h MAL</GROUP_LABEL_1>
<GROUP_LABEL_2>3h MAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3h MAL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2h MAL</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.374264923727527" CI_START="-3.1742649237275242" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.7" MODIFIED="2011-04-25 19:57:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="456" SD_1="8.8" SD_2="9.5" SE="1.670574025622159" STUDY_ID="STD-Wiegell-2011a" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-055.02" MODIFIED="2011-07-22 19:19:00 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="13.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="62" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts</NAME>
<GROUP_LABEL_1>2h</GROUP_LABEL_1>
<GROUP_LABEL_2>3h</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3h</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2h</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.662789297870095" CI_START="-6.462789297870078" EFFECT_SIZE="2.6000000000000085" ESTIMABLE="YES" MEAN_1="77.2" MEAN_2="74.6" MODIFIED="2011-04-25 19:59:17 +0100" MODIFIED_BY="Maryse Paquet" ORDER="457" SD_1="23.3" SD_2="27.3" SE="4.623957057046054" STUDY_ID="STD-Wiegell-2011a" TOTAL_1="58" TOTAL_2="62" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-056" MODIFIED="2012-09-17 20:23:01 +0100" MODIFIED_BY="Maryse Paquet" NO="56">
<NAME>16% MAL-daylight PDT versus 8% MAL-daylight PDT</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-056.01" MODIFIED="2011-11-30 18:32:54 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.29" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>16% MAL</GROUP_LABEL_1>
<GROUP_LABEL_2>8% MAL</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 8% MAL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 16% MAL</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.369153739804426" CI_START="-3.769153739804424" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="14.5" MODIFIED="2011-11-30 18:32:54 +0000" MODIFIED_BY="Maryse Paquet" ORDER="442" SD_1="8.2" SD_2="7.6" SE="2.0761369963434992" STUDY_ID="STD-Wiegell-2009" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-057" MODIFIED="2012-09-17 20:22:37 +0100" MODIFIED_BY="Maryse Paquet" NO="57">
<NAME>Single MAL-red light PDT versus multiple MAL-red light PDT (2 treatments 1 week apart)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="93" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-057.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-30 18:41:52 +0000" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.904509216752964" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="105" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Single MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours multiple</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3344230695694892" CI_START="1.0321088786358568" EFFECT_SIZE="1.1735714285714285" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="80" LOG_CI_END="0.1252935414622218" LOG_CI_START="0.01372551405142552" LOG_EFFECT_SIZE="0.06950952775682367" MODIFIED="2011-11-30 18:41:52 +0000" MODIFIED_BY="Maryse Paquet" ORDER="2736" O_E="0.0" SE="0.0655356115717443" STUDY_ID="STD-Tarstedt-2005" TOTAL_1="105" TOTAL_2="106" VAR="0.004294916384082545" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-057.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-14 23:13:20 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="105" TOTAL_2="106" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Single MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.166948427705302" CI_START="0.013862881224408072" EFFECT_SIZE="0.33647798742138363" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9120598131330445" LOG_CI_START="-1.8581464977314905" LOG_EFFECT_SIZE="-0.47304334229922307" MODIFIED="2011-09-27 17:32:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1134" O_E="0.0" SE="1.627232899744223" STUDY_ID="STD-Tarstedt-2005" TOTAL_1="105" TOTAL_2="106" VAR="2.647886910009992" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-058" MODIFIED="2012-09-17 20:22:26 +0100" MODIFIED_BY="[Empty name]" NO="58">
<NAME>MAL- red light PDT vs cryotherapy</NAME>
<DICH_OUTCOME CHI2="0.8083025878443255" CI_END="6.363043157224906" CI_START="0.13971806081738614" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9428849616070891" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-058.01" LOG_CI_END="0.803664868840667" LOG_CI_START="-0.854747450676482" LOG_EFFECT_SIZE="-0.025541290917907526" METHOD="MH" MODIFIED="2012-09-14 16:22:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36862262332144247" P_Q="1.0" P_Z="0.9518601501222925" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="189" WEIGHT="100.0" Z="0.06037100632770722">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>MAL-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.47567306285352" CI_START="0.12525755842090183" EFFECT_SIZE="3.033707865168539" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.866143573052162" LOG_CI_START="-0.9021960580240129" LOG_EFFECT_SIZE="0.4819737575140745" MODIFIED="2012-09-14 14:34:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1190" O_E="0.0" SE="1.6261364027963263" STUDY_ID="STD-Freeman-2003" TOTAL_1="88" TOTAL_2="89" VAR="2.644319600499376" WEIGHT="35.887754918538775"/>
<DICH_DATA CI_END="5.320712554271386" CI_START="0.045161656988328275" EFFECT_SIZE="0.49019607843137253" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7259697972698097" LOG_CI_START="-1.3452301321216074" LOG_EFFECT_SIZE="-0.3096301674258988" MODIFIED="2012-09-14 14:34:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1191" O_E="0.0" SE="1.2166330911295207" STUDY_ID="STD-Szeimies-2002" TOTAL_1="102" TOTAL_2="100" VAR="1.4801960784313726" WEIGHT="64.11224508146123"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-059" MODIFIED="2012-09-17 20:21:50 +0100" MODIFIED_BY="Maryse Paquet" NO="59">
<NAME>ALA-red light PDT versus MAL-red light PDT</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-059.01" MODIFIED="2012-06-12 20:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="8.71" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts</NAME>
<GROUP_LABEL_1>ALA-PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>MAL-PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAL-PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ALA-PDT</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.483334005898647" CI_START="-1.283334005898646" EFFECT_SIZE="0.6000000000000005" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="5.6" MODIFIED="2012-06-12 20:11:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="236" SD_1="1.9" SD_2="3.2" SE="0.960902353693305" STUDY_ID="STD-Moloney-2007" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-060" MODIFIED="2012-09-17 20:21:42 +0100" MODIFIED_BY="Maryse Paquet" NO="60">
<NAME>Trichloroacetic acid peel versus 5% 5-FU</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-060.01" MODIFIED="2011-07-22 19:19:00 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="32.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesions</NAME>
<GROUP_LABEL_1>Peel</GROUP_LABEL_1>
<GROUP_LABEL_2>5% 5-FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours peel</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.379242517789478" CI_START="-3.779242517789484" EFFECT_SIZE="5.799999999999997" ESTIMABLE="YES" MEAN_1="89.0" MEAN_2="83.2" MODIFIED="2011-05-10 15:22:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="135" SD_1="6.6" SD_2="12.5" SE="4.887458439720997" STUDY_ID="STD-Hantash-2006" TOTAL_1="10" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-061" MODIFIED="2012-09-17 20:21:33 +0100" MODIFIED_BY="Maryse Paquet" NO="61">
<NAME>Cryotherapy versus cryotherapy with betulin-based oleogel</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-061.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-31 21:49:07 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.523427827592673" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.690372762834315" CI_START="0.7158184434841136" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.22798248626499776" LOG_CI_START="-0.14519711594854762" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2011-03-28 20:27:18 +0100" MODIFIED_BY="Maryse Paquet" ORDER="150" O_E="0.0" SE="0.2192075456090599" STUDY_ID="STD-Huyke-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.04805194805194807" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-061.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-10 19:30:45 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.768830796984472" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Participant partial (&gt;75%) clearance</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.866591454881531" CI_START="0.9053936230021267" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.2710492733286843" LOG_CI_START="-0.043162568715010764" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2011-03-28 20:28:37 +0100" MODIFIED_BY="Maryse Paquet" ORDER="151" O_E="0.0" SE="0.18456959139016937" STUDY_ID="STD-Huyke-2009" TOTAL_1="14" TOTAL_2="14" VAR="0.034065934065934084" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-062" MODIFIED="2012-09-17 20:21:22 +0100" MODIFIED_BY="Maryse Paquet" NO="62">
<NAME>(0.5% 5-FU + cryotherapy) versus (vehicle + cryotherapy)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="84" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-062.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-31 21:50:31 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.69" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="216" TOTAL_2="210" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance at 6 months</NAME>
<GROUP_LABEL_1>0.5% 5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.5%FU + cryo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="5" I2="0.0" ID="CMP-062.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-21 15:31:57 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="10.227260698078332" CI_START="1.630310559526856" EFFECT_SIZE="4.083333333333333" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="1.0097593264769427" LOG_CI_START="0.2122703414848349" LOG_EFFECT_SIZE="0.6110148339808888" MODIFIED="2011-04-21 15:02:34 +0100" MODIFIED_BY="Maryse Paquet" ORDER="9102" O_E="0.0" SE="0.46844897741850655" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" VAR="0.21944444444444444" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="11" I2="0.0" ID="CMP-062.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-21 15:30:29 +0100" MODIFIED_BY="Maryse Paquet" NO="2" NOTES="&lt;p&gt;wait on reply from Dr. Jorizzo&lt;/p&gt;" NOTES_MODIFIED="2011-04-21 15:30:29 +0100" NOTES_MODIFIED_BY="Maryse Paquet" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>2 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="5.882968044394332" CI_START="1.8178275272332163" EFFECT_SIZE="3.2702020202020203" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="11" LOG_CI_END="0.769596489356187" LOG_CI_START="0.25955267562732987" LOG_EFFECT_SIZE="0.5145745824917584" MODIFIED="2011-04-14 16:53:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="127" O_E="0.0" SE="0.2996022609419274" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="70" VAR="0.08976151476151475" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="19" I2="0.0" ID="CMP-062.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-04-21 15:30:29 +0100" MODIFIED_BY="Maryse Paquet" NO="3" NOTES="&lt;p&gt;wait for a reply from Dr. Jorizzo&lt;/p&gt;" NOTES_MODIFIED="2011-04-21 15:30:29 +0100" NOTES_MODIFIED_BY="Maryse Paquet" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>3 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="2.175188845885242" CI_START="0.8137174203564292" EFFECT_SIZE="1.3304093567251463" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.3374969675736925" LOG_CI_START="-0.08952638637173765" LOG_EFFECT_SIZE="0.12398529060097739" MODIFIED="2011-04-14 16:54:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="274" O_E="0.0" SE="0.2508356319072386" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="70" VAR="0.0629185142343037" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-062.02" MODIFIED="2011-09-14 18:15:23 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.52" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="216" TOTAL_2="210" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts at 6 months</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU + cryo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-062.02.01" MODIFIED="2011-04-21 15:32:43 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="4.4929642228709845" CI_START="-0.4929642228709845" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="6.6" MODIFIED="2011-04-21 15:03:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="429" SD_1="7.0" SD_2="8.1" SE="1.2719438941404884" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-062.02.02" MODIFIED="2011-04-21 15:35:23 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>2 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="12.273926064084705" CI_START="0.12607393591529625" EFFECT_SIZE="6.200000000000001" ESTIMABLE="YES" MEAN_1="18.1" MEAN_2="11.9" MODIFIED="2011-04-21 15:35:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="433" SD_1="20.2" SD_2="16.6" SE="3.098998814261414" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-062.02.03" MODIFIED="2011-04-21 15:36:07 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>3 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="12.323874199911884" CI_START="-8.123874199911885" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="14.7" MEAN_2="12.6" MODIFIED="2011-04-21 15:36:07 +0100" MODIFIED_BY="Maryse Paquet" ORDER="432" SD_1="41.1" SD_2="16.2" SE="5.216358198699822" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-062.03" MODIFIED="2011-09-14 18:16:18 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts at 6 months</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vehicle + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-FU + cryo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-062.03.01" MODIFIED="2011-04-21 15:04:19 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at 4 weeks, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="37.69794201895022" CI_START="5.102057981049775" EFFECT_SIZE="21.4" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="45.6" MODIFIED="2011-04-21 15:04:19 +0100" MODIFIED_BY="Maryse Paquet" ORDER="428" SD_1="43.6" SD_2="54.7" SE="8.315429338246167" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-062.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="370.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: allergic reaction</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.4378652342329" CI_START="0.12255564329975914" EFFECT_SIZE="2.958904109589041" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8539284681250994" LOG_CI_START="-0.9116666860641496" LOG_EFFECT_SIZE="0.47113089103047495" MODIFIED="2011-08-10 20:37:08 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1417" O_E="0.0" SE="1.6245242834875664" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="2.6390791476407913" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-062.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: hyperesthesia</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.4378652342329" CI_START="0.12255564329975914" EFFECT_SIZE="2.958904109589041" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8539284681250994" LOG_CI_START="-0.9116666860641496" LOG_EFFECT_SIZE="0.47113089103047495" MODIFIED="2011-08-10 20:37:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1420" O_E="0.0" SE="1.6245242834875664" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="2.6390791476407913" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-062.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: skin discoloration</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.4378652342329" CI_START="0.12255564329975914" EFFECT_SIZE="2.958904109589041" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8539284681250994" LOG_CI_START="-0.9116666860641496" LOG_EFFECT_SIZE="0.47113089103047495" MODIFIED="2011-08-10 20:37:52 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1422" O_E="0.0" SE="1.6245242834875664" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="2.6390791476407913" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-062.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: dermatology: vesiculobullous rash</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.4378652342329" CI_START="0.12255564329975914" EFFECT_SIZE="2.958904109589041" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8539284681250994" LOG_CI_START="-0.9116666860641496" LOG_EFFECT_SIZE="0.47113089103047495" MODIFIED="2011-08-10 20:37:54 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1423" O_E="0.0" SE="1.6245242834875664" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="2.6390791476407913" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-062.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: cheilitis</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.937540581581437" CI_START="0.013617293699973235" EFFECT_SIZE="0.3287671232876712" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8996859586857746" LOG_CI_START="-1.8659091955034746" LOG_EFFECT_SIZE="-0.4831116184088499" MODIFIED="2011-08-10 20:43:27 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1424" O_E="0.0" SE="1.6245242834875664" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="2.6390791476407913" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-062.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: special senses: conjunctivitis</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.046098146033201" CI_START="0.4752534111533335" EFFECT_SIZE="0.9861111111111112" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.31092646185822115" LOG_CI_START="-0.3230747572826074" LOG_EFFECT_SIZE="-0.006074147712193153" MODIFIED="2011-08-10 20:43:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1425" O_E="0.0" SE="0.3724154544799722" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="72" TOTAL_2="71" VAR="0.13869327073552423" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-062.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:11:22 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: special senses: eye irritation</NAME>
<GROUP_LABEL_1>5-FU + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>vehicle + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.190807078056516" CI_START="0.431446501542813" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3406041353770332" LOG_CI_START="-0.3650730482110564" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2011-09-14 18:55:43 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1416" O_E="0.0" SE="0.41451827079803955" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="72" TOTAL_2="70" VAR="0.17182539682539683" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-063" MODIFIED="2012-09-17 21:00:37 +0100" MODIFIED_BY="[Empty name]" NO="63">
<NAME>(vehicle + cryotherapy) versus (0.5% 5-FU + cryotherapy)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-063.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-17 20:56:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.69" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="210" TOTAL_2="216" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance at 6 months</NAME>
<GROUP_LABEL_1>vehicle + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>0.5% 5-FU + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.5%FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="21" I2="0.0" ID="CMP-063.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 20:55:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="0.613380066856843" CI_START="0.09777789278295179" EFFECT_SIZE="0.24489795918367346" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="21" LOG_CI_END="-0.21227034148483487" LOG_CI_START="-1.0097593264769429" LOG_EFFECT_SIZE="-0.6110148339808888" MODIFIED="2012-09-17 20:55:55 +0100" MODIFIED_BY="[Empty name]" ORDER="9102" O_E="0.0" SE="0.46844897741850655" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="70" TOTAL_2="72" VAR="0.21944444444444444" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="37" I2="0.0" ID="CMP-063.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 20:56:04 +0100" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;wait on reply from Dr. Jorizzo&lt;/p&gt;" NOTES_MODIFIED="2012-09-17 20:56:04 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>2 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="0.5501071938997577" CI_START="0.1699822253756527" EFFECT_SIZE="0.30579150579150577" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="37" LOG_CI_END="-0.25955267562732987" LOG_CI_START="-0.769596489356187" LOG_EFFECT_SIZE="-0.5145745824917584" MODIFIED="2012-09-17 20:56:04 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.2996022609419274" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="70" TOTAL_2="72" VAR="0.08976151476151475" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="26" I2="0.0" ID="CMP-063.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-17 20:56:14 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;wait for a reply from Dr. Jorizzo&lt;/p&gt;" NOTES_MODIFIED="2012-09-17 20:56:14 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>3 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<DICH_DATA CI_END="1.228927850115307" CI_START="0.45973019854881964" EFFECT_SIZE="0.7516483516483516" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.08952638637173768" LOG_CI_START="-0.3374969675736924" LOG_EFFECT_SIZE="-0.12398529060097738" MODIFIED="2012-09-17 20:56:14 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.2508356319072386" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="70" TOTAL_2="72" VAR="0.0629185142343037" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-063.02" MODIFIED="2012-09-17 20:59:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.52" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="210" TOTAL_2="216" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in lesion counts at 6 months</NAME>
<GROUP_LABEL_1>Vehicle + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-063.02.01" MODIFIED="2012-09-17 20:58:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="0.4929642228709845" CI_START="-4.4929642228709845" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="8.6" MODIFIED="2012-09-17 20:58:34 +0100" MODIFIED_BY="[Empty name]" ORDER="429" SD_1="8.1" SD_2="7.0" SE="1.2719438941404884" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-063.02.02" MODIFIED="2012-09-17 20:58:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>2 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="-0.12607393591529625" CI_START="-12.273926064084705" EFFECT_SIZE="-6.200000000000001" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="18.1" MODIFIED="2012-09-17 20:58:51 +0100" MODIFIED_BY="[Empty name]" ORDER="433" SD_1="16.6" SD_2="20.2" SE="3.098998814261414" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-063.02.03" MODIFIED="2012-09-17 20:59:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>3 cycles ( 1 week topical, cryosurgery at week 4, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="8.123874199911885" CI_START="-12.323874199911884" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="14.7" MODIFIED="2012-09-17 20:59:07 +0100" MODIFIED_BY="[Empty name]" ORDER="432" SD_1="16.2" SD_2="41.1" SE="5.216358198699822" STUDY_ID="STD-Jorizzo-2006" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-063.03" MODIFIED="2012-09-17 21:00:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in lesion counts at 6 months</NAME>
<GROUP_LABEL_1>Vehicle + cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>5-FU + cryo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-FU + cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vehicle + cryo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-063.03.01" MODIFIED="2012-09-17 21:00:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>1 cycle (1 week topical, cryosurgery at 4 weeks, follow-up at 6 months)</NAME>
<CONT_DATA CI_END="-5.102057981049775" CI_START="-37.69794201895022" EFFECT_SIZE="-21.4" ESTIMABLE="YES" MEAN_1="45.6" MEAN_2="67.0" MODIFIED="2012-09-17 21:00:37 +0100" MODIFIED_BY="[Empty name]" ORDER="428" SD_1="54.7" SD_2="43.6" SE="8.315429338246167" STUDY_ID="STD-Jorizzo-2004" TOTAL_1="70" TOTAL_2="72" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-064" MODIFIED="2012-09-17 20:53:47 +0100" MODIFIED_BY="Maryse Paquet" NO="64">
<NAME>Cryotherapy with vehicle versus cryotherapy with imiquimod</NAME>
<DICH_OUTCOME CHI2="2.637978662878822" CI_END="0.729860389261158" CI_START="0.05403692112682113" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1985935756465857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="45" I2="62.09218770144631" I2_Q="60.193653676997386" ID="CMP-064.01" LOG_CI_END="-0.13676020559476504" LOG_CI_START="-1.2673094038343986" LOG_EFFECT_SIZE="-0.7020348047145819" METHOD="MH" MODIFIED="2011-09-19 18:39:09 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.1043362690667603" P_Q="0.11297112687311694" P_Z="0.014926824832106167" Q="2.5121622363571134" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5517893119999133" TOTALS="YES" TOTAL_1="154" TOTAL_2="157" WEIGHT="100.0" Z="2.4341495890257376">
<NAME>Participant complete clearance of all lesions</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4200804287105693" CI_START="0.11413766805120167" DF="0" EFFECT_SIZE="0.4025974025974026" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-064.01.01" LOG_CI_END="0.15231294209855992" LOG_CI_START="-0.9425710047749782" LOG_EFFECT_SIZE="-0.39512903133820915" MODIFIED="2011-08-11 15:58:02 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.15717120380847024" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="45.68129772029646" Z="1.4146497861814717">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="1.4200804287105693" CI_START="0.11413766805120167" EFFECT_SIZE="0.4025974025974026" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15231294209855992" LOG_CI_START="-0.9425710047749782" LOG_EFFECT_SIZE="-0.39512903133820915" MODIFIED="2011-08-11 13:52:48 +0100" MODIFIED_BY="Maryse Paquet" ORDER="139" O_E="0.0" SE="0.6431402501564623" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="31" VAR="0.4136293813713169" WEIGHT="45.68129772029646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.2978425371769133" CI_START="0.04034004852163817" DF="0" EFFECT_SIZE="0.1096128751631144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="38" I2="0.0" ID="CMP-064.01.02" LOG_CI_END="-0.5260132772286924" LOG_CI_START="-1.3942635837467776" LOG_EFFECT_SIZE="-0.960138430487735" MODIFIED="2011-08-11 15:58:02 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="1.4590640674344601E-5" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="54.31870227970353" Z="4.334779336791578">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="0.2978425371769133" CI_START="0.04034004852163817" EFFECT_SIZE="0.1096128751631144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="38" LOG_CI_END="-0.5260132772286924" LOG_CI_START="-1.3942635837467776" LOG_EFFECT_SIZE="-0.960138430487735" MODIFIED="2011-08-11 15:58:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1465" O_E="0.0" SE="0.5100145279570563" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="0.26011481872725895" WEIGHT="54.31870227970353"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4765114155018426" CI_END="1.0410226009891126" CI_START="0.3648364256160627" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6162815628674969" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="88" I2="59.62061819136178" I2_Q="59.60375501591801" ID="CMP-064.02" LOG_CI_END="0.017460158308141786" LOG_CI_START="-0.4379018078043794" LOG_EFFECT_SIZE="-0.21022082474811876" METHOD="MH" MODIFIED="2011-09-19 18:39:45 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.11555856894927141" P_Q="0.11563456881273859" P_Z="0.07034847633731103" Q="2.475477610342364" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09051417754718309" TOTALS="YES" TOTAL_1="154" TOTAL_2="157" WEIGHT="100.00000000000001" Z="1.8096603404281986">
<NAME>Participant complete clearance of target (cryotherapy treated) lesions</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6000712751540223" CI_START="0.4699286968886352" DF="0" EFFECT_SIZE="0.8671328671328671" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-064.02.01" LOG_CI_END="0.20413932872882892" LOG_CI_START="-0.32796803333448243" LOG_EFFECT_SIZE="-0.06191435230282677" MODIFIED="2011-08-11 15:59:16 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.6483104588645563" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="38.014316512099064" Z="0.45611058704061513">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="1.6000712751540223" CI_START="0.4699286968886352" EFFECT_SIZE="0.8671328671328671" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.20413932872882892" LOG_CI_START="-0.32796803333448243" LOG_EFFECT_SIZE="-0.06191435230282677" MODIFIED="2011-08-11 13:56:04 +0100" MODIFIED_BY="Maryse Paquet" ORDER="137" O_E="0.0" SE="0.31256249844991146" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="31" VAR="0.09769531543725091" WEIGHT="38.014316512099064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6810376115333794" CI_START="0.36684425916188157" DF="0" EFFECT_SIZE="0.49983471074380165" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="75" I2="0.0" ID="CMP-064.02.02" LOG_CI_END="-0.16682890272694517" LOG_CI_START="-0.4355182729196548" LOG_EFFECT_SIZE="-0.30117358782329995" MODIFIED="2011-08-11 15:59:16 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="1.1136451919511786E-5" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="61.98568348790095" Z="4.393842486623205">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="0.6810376115333794" CI_START="0.36684425916188157" EFFECT_SIZE="0.49983471074380165" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="75" LOG_CI_END="-0.16682890272694517" LOG_CI_START="-0.4355182729196548" LOG_EFFECT_SIZE="-0.30117358782329995" MODIFIED="2011-08-11 15:59:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1466" O_E="0.0" SE="0.1578294660850306" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="0.02491014036468582" WEIGHT="61.98568348790095"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-064.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-08-11 16:00:03 +0100" MODIFIED_BY="Maryse Paquet" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.44953409748431" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Participant complete clearance of subclinical lesions</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-064.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-11 16:00:03 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="1.012809829422992" CI_START="0.32539281605487547" EFFECT_SIZE="0.5740740740740741" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005527907566102486" LOG_CI_START="-0.4875920395434942" LOG_EFFECT_SIZE="-0.24103206598869584" MODIFIED="2011-08-11 14:54:57 +0100" MODIFIED_BY="Maryse Paquet" ORDER="138" O_E="0.0" SE="0.28966109791528294" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="31" VAR="0.08390355164548713" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.992612431297022" CI_END="-1.3355298902133619" CI_START="-46.03488696668623" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-23.685208428449798" ESTIMABLE="YES" I2="85.69919311523297" I2_Q="85.69919311523297" ID="CMP-064.04" MODIFIED="2011-09-19 18:45:18 +0100" MODIFIED_BY="Maryse Paquet" NO="4" P_CHI2="0.008184695978730505" P_Q="0.008184695978730505" P_Z="0.03779382443086986" Q="6.992612431297022" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="224.70756930779675" TOTALS="YES" TOTAL_1="148" TOTAL_2="153" UNITS="" WEIGHT="100.0" Z="2.0770838115933463">
<NAME>Mean percentage of reduction in all lesion counts</NAME>
<GROUP_LABEL_1>Cryotherapy + vehicle</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + vehicle</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.133346257478902" CI_START="-26.533346257478907" DF="0" EFFECT_SIZE="-11.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-064.04.01" MODIFIED="2011-08-11 16:01:28 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.1522512682327698" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="45.479439177075136" Z="1.4316246602819414">
<NAME>5% imquimod</NAME>
<CONT_DATA CI_END="4.1333462574789035" CI_START="-26.53334625747891" EFFECT_SIZE="-11.200000000000003" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="73.2" MODIFIED="2011-08-11 16:01:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1467" SD_1="30.3" SD_2="27.1" SE="7.823279600251017" STUDY_ID="STD-NCT00774787" TOTAL_1="27" TOTAL_2="27" WEIGHT="45.479439177075136"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-26.82138994586738" CI_START="-41.378610054132636" DF="0" EFFECT_SIZE="-34.10000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-064.04.02" MODIFIED="2011-08-11 16:01:28 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="4.217699264410168E-20" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="54.520560822924864" Z="9.18235368782651">
<NAME>3.75% imiquimod</NAME>
<CONT_DATA CI_END="-26.82138994586738" CI_START="-41.378610054132636" EFFECT_SIZE="-34.10000000000001" ESTIMABLE="YES" MEAN_1="43.3" MEAN_2="77.4" MODIFIED="2011-08-11 14:37:32 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1457" SD_1="30.7" SD_2="27.5" SE="3.7136447973255513" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" WEIGHT="54.520560822924864"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-064.05" MODIFIED="2011-09-20 14:54:16 +0100" MODIFIED_BY="Maryse Paquet" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean percentage of reduction in target (cryotherapy treated) lesion counts</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-064.05.01" MODIFIED="2011-09-20 14:54:16 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>3.75% imiquimod</NAME>
<CONT_DATA CI_END="-4.227806889476323" CI_START="-17.3721931105237" EFFECT_SIZE="-10.800000000000011" ESTIMABLE="YES" MEAN_1="73.1" MEAN_2="83.9" MODIFIED="2011-08-11 13:59:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="434" SD_1="25.8" SD_2="26.9" SE="3.353221366496685" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5871242099928821" CI_END="3.0701413078719053" CI_START="0.2811604248914269" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9290867745253863" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-064.06" LOG_CI_END="0.4871583649940239" LOG_CI_START="-0.5510458090463262" LOG_EFFECT_SIZE="-0.03194372202615114" METHOD="MH" MODIFIED="2011-10-06 16:40:32 +0100" MODIFIED_BY="Maryse Paquet" NO="6" P_CHI2="0.44353347220327344" P_Q="0.44481604799694896" P_Z="0.9040004941289504" Q="0.5838276346223746" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="153" WEIGHT="99.99999999999999" Z="0.12060931032431352">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Crypotherapy + vehicle</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.94634076504033" CI_START="0.12297061175900956" DF="0" EFFECT_SIZE="2.9117647058823524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-064.06.01" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.4641562775552947" MODIFIED="2011-09-29 16:27:12 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.5080147738519398" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="14.266181064800895" Z="0.6619320512498937">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="68.94634076504033" CI_START="0.12297061175900956" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8385112215238748" LOG_CI_START="-0.910198666413285" LOG_EFFECT_SIZE="0.46415627755529476" MODIFIED="2011-09-28 15:16:47 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1186" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="14.266181064800895"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7934137881269985" CI_START="0.2112877663332906" DF="0" EFFECT_SIZE="0.7682539682539683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-064.06.02" LOG_CI_END="0.44613527246780277" LOG_CI_START="-0.6751256480861412" LOG_EFFECT_SIZE="-0.1144951878091692" MODIFIED="2011-09-29 16:27:12 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="1.0" P_Z="0.6889538660032697" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="85.7338189351991" Z="0.40027515522124174">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="2.7934137881269985" CI_START="0.2112877663332906" EFFECT_SIZE="0.7682539682539683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.44613527246780277" LOG_CI_START="-0.6751256480861412" LOG_EFFECT_SIZE="-0.1144951878091692" MODIFIED="2011-09-29 16:27:12 +0100" MODIFIED_BY="Maryse Paquet" ORDER="694" O_E="0.0" SE="0.658634215064458" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" VAR="0.4337990292535747" WEIGHT="85.7338189351991"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5007192549331494" CI_END="1.5417273045290518" CI_START="0.09960091743451001" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3918640758795423" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="33.36528489837057" I2_Q="28.33456046587591" ID="CMP-064.07" LOG_CI_END="0.18800756397990903" LOG_CI_START="-1.0017366612257974" LOG_EFFECT_SIZE="-0.4068645486229443" METHOD="MH" MODIFIED="2011-10-18 20:38:39 +0100" MODIFIED_BY="Maryse Paquet" NO="7" P_CHI2="0.2205610998512979" P_Q="0.23750007652486171" P_Z="0.180075310272463" Q="1.3953727298691048" RANDOM="YES" SCALE="463.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3707229585841368" TOTALS="YES" TOTAL_1="154" TOTAL_2="157" WEIGHT="100.0" Z="1.3405231897624708">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0103841079489824" CI_START="0.19508952319240824" DF="0" EFFECT_SIZE="0.6262626262626263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-064.07.01" LOG_CI_END="0.30327904250784704" LOG_CI_START="-0.7097660527064391" LOG_EFFECT_SIZE="-0.203243505099296" MODIFIED="2011-10-18 20:37:19 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="1.0" P_Z="0.43160935040606074" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="67.38250240464887" Z="0.7864407062788087">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="2.0103841079489824" CI_START="0.19508952319240824" EFFECT_SIZE="0.6262626262626263" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.30327904250784704" LOG_CI_START="-0.7097660527064391" LOG_EFFECT_SIZE="-0.203243505099296" MODIFIED="2011-09-26 15:38:35 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1184" O_E="0.0" SE="0.5950677035829682" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="31" VAR="0.35410557184750735" WEIGHT="67.38250240464887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.376118268978702E-32" CI_END="1.1912064092936445" CI_START="0.018577499064121553" DF="0" EFFECT_SIZE="0.14876033057851237" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="100.0" ID="CMP-064.07.02" LOG_CI_END="0.07598702147462202" LOG_CI_START="-1.7310127519009104" LOG_EFFECT_SIZE="-0.827512865213144" MODIFIED="2011-10-18 20:38:23 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.07263375497638037" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="32.61749759535113" Z="1.79512519753288">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="1.1912064092936447" CI_START="0.018577499064121563" EFFECT_SIZE="0.1487603305785124" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.0759870214746221" LOG_CI_START="-1.73101275190091" LOG_EFFECT_SIZE="-0.827512865213144" MODIFIED="2011-10-18 20:38:23 +0100" MODIFIED_BY="Maryse Paquet" ORDER="693" O_E="0.0" SE="1.0614406116739257" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="1.1266561721107176" WEIGHT="32.61749759535113"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-064.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: body as a whole: fatigue</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6932463210250737" CI_START="0.005289105984009369" EFFECT_SIZE="0.09463487332339791" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.22872014067276158" LOG_CI_START="-2.2766177304267945" LOG_EFFECT_SIZE="-1.0239487948770165" MODIFIED="2011-08-11 00:40:56 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1514" O_E="0.0" SE="1.471647867106352" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="2.165747444758675" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-064.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: digestive: nausea</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6932463210250737" CI_START="0.005289105984009369" EFFECT_SIZE="0.09463487332339791" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.22872014067276158" LOG_CI_START="-2.2766177304267945" LOG_EFFECT_SIZE="-1.0239487948770165" MODIFIED="2011-08-11 00:41:14 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1515" O_E="0.0" SE="1.471647867106352" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="2.165747444758675" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-064.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: musculoskeletal and connective tissue: myalgia</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.756887591086199" CI_START="0.02468802596681063" EFFECT_SIZE="0.20826446280991737" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.24474397542090773" LOG_CI_START="-1.6075136344907197" LOG_EFFECT_SIZE="-0.681384829534906" MODIFIED="2011-08-11 00:42:25 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1516" O_E="0.0" SE="1.0880252888851318" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="1.1837990292535747" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-064.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.481667714088381" CI_START="0.514839628436348" EFFECT_SIZE="1.3388429752066116" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5417873202494373" LOG_CI_START="-0.2883280317970756" LOG_EFFECT_SIZE="0.12672964422618085" MODIFIED="2011-08-11 13:44:00 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1444" O_E="0.0" SE="0.4876138669293857" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="0.23776728322182866" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-064.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="344.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: bronchitis</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.92218977715498" CI_START="0.6172006491702657" EFFECT_SIZE="5.206611570247934" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6426839840929455" LOG_CI_START="-0.20957362581868202" LOG_EFFECT_SIZE="0.7165551791371316" MODIFIED="2011-08-11 13:45:03 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1445" O_E="0.0" SE="1.0880252888851318" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="1.1837990292535747" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-064.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="485.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="121" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: respiratory: sinusitis</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="204.88280484403387" CI_START="0.6399818240651338" EFFECT_SIZE="11.450819672131148" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3115055109892118" LOG_CI_START="-0.19383236011034438" LOG_EFFECT_SIZE="1.0588365754394338" MODIFIED="2011-08-11 13:45:55 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1446" O_E="0.0" SE="1.471647867106352" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="2.165747444758675" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-064.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="662.600470427028" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="33" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events excluding skin irritation: special senses: conjunctivitis</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.424293155719757" CI_START="0.013256976945063514" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.870655112105983" LOG_CI_START="-1.8775554989900065" LOG_EFFECT_SIZE="-0.5034501934420116" MODIFIED="2011-08-11 15:04:16 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1461" O_E="0.0" SE="1.6143125168197092" STUDY_ID="STD-Tan-2007" TOTAL_1="33" TOTAL_2="31" VAR="2.6060049019607843" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-064.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Improved global photoageing score</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.56130339277905" CI_START="0.24957589912761496" EFFECT_SIZE="0.3742830465519541" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="63" LOG_CI_END="-0.250802332694337" LOG_CI_START="-0.6027973556132058" LOG_EFFECT_SIZE="-0.42679984415377137" MODIFIED="2011-08-11 14:07:06 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1450" O_E="0.0" SE="0.2067636188660081" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="119" TOTAL_2="122" VAR="0.04275119408656786" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-064.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:18 +0100" MODIFIED_BY="Maryse Paquet" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Improved fine lines</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7573372363155295" CI_START="0.2810356765333763" EFFECT_SIZE="0.4613445378151261" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="40" LOG_CI_END="-0.12071068951264023" LOG_CI_START="-0.5512385443722374" LOG_EFFECT_SIZE="-0.33597461694243885" MODIFIED="2011-08-11 14:11:10 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1451" O_E="0.0" SE="0.25289419309177963" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="119" TOTAL_2="122" VAR="0.06395547289954233" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-064.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:19 +0100" MODIFIED_BY="Maryse Paquet" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Improved tactile roughness</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5291003779489653" CI_START="0.2574498649462774" EFFECT_SIZE="0.36907563025210083" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="75" LOG_CI_END="-0.27646192824097016" LOG_CI_START="-0.5893073316600204" LOG_EFFECT_SIZE="-0.43288462995049526" MODIFIED="2011-08-11 14:11:40 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1453" O_E="0.0" SE="0.1837669385780727" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="119" TOTAL_2="122" VAR="0.033770287714357146" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-064.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:19 +0100" MODIFIED_BY="Maryse Paquet" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Improved mottled pigmentation</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6035479840734432" CI_START="0.2594236618212297" EFFECT_SIZE="0.3956951201533245" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="57" LOG_CI_END="-0.21928819633730293" LOG_CI_START="-0.5859904147988325" LOG_EFFECT_SIZE="-0.4026393055680677" MODIFIED="2011-08-11 14:11:21 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1452" O_E="0.0" SE="0.21540269832955908" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="119" TOTAL_2="122" VAR="0.04639832244765504" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-064.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 15:51:19 +0100" MODIFIED_BY="Maryse Paquet" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="122" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: Improved sallowness</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8705054579757546" CI_START="0.28269190376371406" EFFECT_SIZE="0.4960693955001355" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" LOG_CI_END="-0.060228501558342584" LOG_CI_START="-0.5486866294344054" LOG_EFFECT_SIZE="-0.304457565496374" MODIFIED="2011-08-11 14:11:53 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1454" O_E="0.0" SE="0.2869227222211278" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="119" TOTAL_2="122" VAR="0.08232464852678248" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-064.20" MODIFIED="2011-09-28 15:51:19 +0100" MODIFIED_BY="Maryse Paquet" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.29637443085379" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="52" TOTAL_2="52" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cosmetic outcomes: cosmetic appearance score</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryotherapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-064.20.01" MODIFIED="2011-08-11 15:31:15 +0100" MODIFIED_BY="Maryse Paquet" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Investigator</NAME>
<CONT_DATA CI_END="0.09795582375031264" CI_START="-1.0979558237503126" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.1" MODIFIED="2011-08-11 15:31:15 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1464" SD_1="1.1" SD_2="1.1" SE="0.30508510792387605" STUDY_ID="STD-NCT00774787" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-064.20.02" MODIFIED="2011-08-11 15:31:28 +0100" MODIFIED_BY="Maryse Paquet" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Participant</NAME>
<CONT_DATA CI_END="-0.7695690049452982" CI_START="-2.030430995054702" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.6" MODIFIED="2011-08-11 15:31:28 +0100" MODIFIED_BY="Maryse Paquet" ORDER="1463" SD_1="1.3" SD_2="1.0" SE="0.32165437733930885" STUDY_ID="STD-NCT00774787" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-065" MODIFIED="2012-09-17 20:53:38 +0100" MODIFIED_BY="[Empty name]" NO="65">
<NAME>Cryotherapy with imiquimod versus cryotherapy with vehicle</NAME>
<DICH_OUTCOME CHI2="2.637978662878821" CI_END="18.505865603502198" CI_START="1.370125046808344" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0354096135495645" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="7" I2="62.092187701446306" I2_Q="60.19365367699738" ID="CMP-065.01" LOG_CI_END="1.2673094038343988" LOG_CI_START="0.13676020559476515" LOG_EFFECT_SIZE="0.702034804714582" METHOD="MH" MODIFIED="2012-09-17 17:36:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10433626906676041" P_Q="0.11297112687311717" P_Z="0.014926824832106144" Q="2.5121622363571126" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.551789311999913" TOTALS="YES" TOTAL_1="157" TOTAL_2="154" WEIGHT="100.0" Z="2.434149589025738">
<NAME>Participant complete clearance of all lesions</NAME>
<GROUP_LABEL_1>Cryotherapy + imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + vehicle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + imiquimod</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.761349492013494" CI_START="0.7041854670921692" DF="0" EFFECT_SIZE="2.483870967741936" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-065.01.01" LOG_CI_END="0.9425710047749785" LOG_CI_START="-0.15231294209855986" LOG_EFFECT_SIZE="0.39512903133820926" MODIFIED="2012-09-17 17:31:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.15717120380847016" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="33" WEIGHT="45.68129772029646" Z="1.414649786181472">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="8.76134949201349" CI_START="0.7041854670921691" EFFECT_SIZE="2.4838709677419355" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9425710047749782" LOG_CI_START="-0.15231294209855994" LOG_EFFECT_SIZE="0.3951290313382092" MODIFIED="2012-09-17 17:31:33 +0100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.6431402501564623" STUDY_ID="STD-Tan-2007" TOTAL_1="31" TOTAL_2="33" VAR="0.4136293813713169" WEIGHT="45.68129772029646"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.789261209331613" CI_START="3.3574787855302795" DF="0" EFFECT_SIZE="9.123015873015873" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" I2="0.0" ID="CMP-065.01.02" LOG_CI_END="1.3942635837467776" LOG_CI_START="0.5260132772286923" LOG_EFFECT_SIZE="0.960138430487735" MODIFIED="2012-09-17 17:31:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.4590640674344601E-5" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="54.31870227970354" Z="4.334779336791578">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="24.789261209331613" CI_START="3.3574787855302795" EFFECT_SIZE="9.123015873015873" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" LOG_CI_END="1.3942635837467776" LOG_CI_START="0.5260132772286923" LOG_EFFECT_SIZE="0.960138430487735" MODIFIED="2012-09-17 17:31:42 +0100" MODIFIED_BY="[Empty name]" ORDER="1465" O_E="0.0" SE="0.5100145279570563" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" VAR="0.26011481872725895" WEIGHT="54.31870227970354"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.992612431297022" CI_END="46.03488696668623" CI_START="1.3355298902133619" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="23.685208428449798" ESTIMABLE="YES" I2="85.69919311523297" I2_Q="85.69919311523297" ID="CMP-065.02" MODIFIED="2012-09-17 17:36:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.008184695978730505" P_Q="0.008184695978730505" P_Z="0.03779382443086986" Q="6.992612431297022" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="224.70756930779675" TOTALS="YES" TOTAL_1="153" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="2.0770838115933463">
<NAME>Mean percentage of reduction in all lesion counts</NAME>
<GROUP_LABEL_1>Cryotherapy + vehicle</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + imiquimod</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + vehicle</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="26.533346257478907" CI_START="-4.133346257478902" DF="0" EFFECT_SIZE="11.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-065.02.01" MODIFIED="2012-09-17 17:32:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1522512682327698" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="45.479439177075136" Z="1.4316246602819414">
<NAME>5% imquimod</NAME>
<CONT_DATA CI_END="26.53334625747891" CI_START="-4.1333462574789035" EFFECT_SIZE="11.200000000000003" ESTIMABLE="YES" MEAN_1="73.2" MEAN_2="62.0" MODIFIED="2012-09-17 17:32:31 +0100" MODIFIED_BY="[Empty name]" ORDER="1467" SD_1="27.1" SD_2="30.3" SE="7.823279600251017" STUDY_ID="STD-NCT00774787" TOTAL_1="27" TOTAL_2="27" WEIGHT="45.479439177075136"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="41.378610054132636" CI_START="26.82138994586738" DF="0" EFFECT_SIZE="34.10000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-065.02.02" MODIFIED="2012-09-17 17:33:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.217699264410168E-20" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="54.520560822924864" Z="9.18235368782651">
<NAME>3.75% imiquimod</NAME>
<CONT_DATA CI_END="41.378610054132636" CI_START="26.82138994586738" EFFECT_SIZE="34.10000000000001" ESTIMABLE="YES" MEAN_1="77.4" MEAN_2="43.3" MODIFIED="2012-09-17 17:33:07 +0100" MODIFIED_BY="[Empty name]" ORDER="1457" SD_1="27.5" SD_2="30.7" SE="3.7136447973255513" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" WEIGHT="54.520560822924864"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5871242099928824" CI_END="3.556688322640573" CI_START="0.32571790667614536" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0763257291126966" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-065.03" LOG_CI_END="0.5510458090463262" LOG_CI_START="-0.4871583649940238" LOG_EFFECT_SIZE="0.03194372202615116" METHOD="MH" MODIFIED="2012-09-17 17:34:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4435334722032732" P_Q="0.44481604799694885" P_Z="0.9040004941289504" Q="0.5838276346223749" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="159" WEIGHT="99.99999999999999" Z="0.12060931032431352">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Cryotherapy + imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Crypotherapy + vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + vehicle</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.132024275521538" CI_START="0.014504032975555047" DF="0" EFFECT_SIZE="0.34343434343434337" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-065.03.01" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.46415627755529487" MODIFIED="2012-09-17 17:34:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5080147738519398" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="14.266181064800895" Z="0.6619320512498938">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="8.132024275521538" CI_START="0.014504032975555047" EFFECT_SIZE="0.3434343434343434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.4641562775552948" MODIFIED="2012-09-17 17:34:16 +0100" MODIFIED_BY="[Empty name]" ORDER="1186" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Tan-2007" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="14.266181064800895"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.732881687161078" CI_START="0.35798491589407766" DF="0" EFFECT_SIZE="1.3016528925619835" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-065.03.02" LOG_CI_END="0.6751256480861412" LOG_CI_START="-0.4461352724678026" LOG_EFFECT_SIZE="0.11449518780916923" MODIFIED="2012-09-17 17:34:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6889538660032697" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="126" WEIGHT="85.7338189351991" Z="0.4002751552212418">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="4.732881687161078" CI_START="0.35798491589407766" EFFECT_SIZE="1.3016528925619835" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6751256480861412" LOG_CI_START="-0.4461352724678026" LOG_EFFECT_SIZE="0.11449518780916923" MODIFIED="2012-09-17 17:34:24 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.658634215064458" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="121" TOTAL_2="126" VAR="0.4337990292535747" WEIGHT="85.7338189351991"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5007192549331494" CI_END="10.040068161596247" CI_START="0.6486231365704898" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.551905269079569" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="33.36528489837057" I2_Q="28.33456046587591" ID="CMP-065.04" LOG_CI_END="1.0017366612257976" LOG_CI_START="-0.18800756397990892" LOG_EFFECT_SIZE="0.40686454862294436" METHOD="MH" MODIFIED="2012-09-17 17:35:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2205610998512979" P_Q="0.23750007652486171" P_Z="0.18007531027246293" Q="1.3953727298691048" RANDOM="YES" SCALE="463.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3707229585841368" TOTALS="YES" TOTAL_1="157" TOTAL_2="154" WEIGHT="100.0" Z="1.340523189762471">
<NAME>Skin irritation</NAME>
<GROUP_LABEL_1>Cryotherapy + imiquimod</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy + vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryo + imiquimod</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cryo + vehicle</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1258518839771" CI_START="0.49741738210426456" DF="0" EFFECT_SIZE="1.596774193548387" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-065.04.01" LOG_CI_END="0.7097660527064391" LOG_CI_START="-0.30327904250784704" LOG_EFFECT_SIZE="0.203243505099296" MODIFIED="2012-09-17 17:35:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.43160935040606074" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="33" WEIGHT="67.38250240464887" Z="0.7864407062788087">
<NAME>5% imiquimod</NAME>
<DICH_DATA CI_END="5.1258518839771" CI_START="0.49741738210426456" EFFECT_SIZE="1.596774193548387" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7097660527064391" LOG_CI_START="-0.30327904250784704" LOG_EFFECT_SIZE="0.203243505099296" MODIFIED="2012-09-17 17:35:51 +0100" MODIFIED_BY="[Empty name]" ORDER="1184" O_E="0.0" SE="0.5950677035829682" STUDY_ID="STD-Tan-2007" TOTAL_1="31" TOTAL_2="33" VAR="0.35410557184750735" WEIGHT="67.38250240464887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.8285587607045" CI_START="0.8394850734500119" DF="0" EFFECT_SIZE="6.722222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-065.04.02" LOG_CI_END="1.7310127519009102" LOG_CI_START="-0.07598702147462198" LOG_EFFECT_SIZE="0.827512865213144" MODIFIED="2012-09-17 17:35:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07263375497638037" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="32.61749759535113" Z="1.79512519753288">
<NAME>3.75% imiquimod</NAME>
<DICH_DATA CI_END="53.82855876070448" CI_START="0.8394850734500117" EFFECT_SIZE="6.722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7310127519009102" LOG_CI_START="-0.0759870214746221" LOG_EFFECT_SIZE="0.827512865213144" MODIFIED="2012-09-17 17:35:59 +0100" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="1.0614406116739257" STUDY_ID="STD-Jorizzo-2010" TOTAL_1="126" TOTAL_2="121" VAR="1.1266561721107176" WEIGHT="32.61749759535113"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-066" MODIFIED="2012-09-17 20:53:31 +0100" MODIFIED_BY="Maryse Paquet" NO="66">
<NAME>(3% diclofenac in 2.5% hyaluronic acid + ALA-red light PDT) versus (2.5% hyaluronic acid + ALA-red light PDT)</NAME>
<OTHER_OUTCOME COLS="3" ID="CMP-066.01" MODIFIED="2011-12-05 18:20:17 +0000" MODIFIED_BY="Maryse Paquet" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Global Improvement Indices (-2 to 4) at 6 months</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Patient</P>
</TH>
<TH>
<P>Investigator</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-10-03 19:39:45 +0100" MODIFIED_BY="Maryse Paquet" ORDER="729" STUDY_ID="STD-Van-der-Geer-2009">
<TR>
<TD>
<P>Diclofenac in 2.5% hyaluronic acid + ALA-PDT</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>3.4</P>
</TD>
</TR>
<TR>
<TD>
<P>2.5% hyaluronic acid + ALA-PDT</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>2.7</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-066.02" MODIFIED="2011-12-05 18:19:27 +0000" MODIFIED_BY="Maryse Paquet" NO="2" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean reduction of lesion counts</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>At 6 weeks</P>
</TH>
<TH>
<P>At 6 months</P>
</TH>
<TH>
<P>At 12 months</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-10-03 19:40:02 +0100" MODIFIED_BY="Maryse Paquet" ORDER="730" STUDY_ID="STD-Van-der-Geer-2009">
<TR>
<TD>
<P>Diclofenac in 2.5% hyaluronic acid + ALA-PDT</P>
</TD>
<TD>
<P>10.13</P>
</TD>
<TD>
<P>11.56</P>
</TD>
<TD>
<P>12.5</P>
</TD>
</TR>
<TR>
<TD>
<P>2.5% hyaluronic acid + ALA-PDT</P>
</TD>
<TD>
<P>9.9</P>
</TD>
<TD>
<P>10.56</P>
</TD>
<TD>
<P>8.8</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-11-09 12:16:25 +0000" MODIFIED_BY="Maryse Paquet">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-10-02 16:30:38 +0100" MODIFIED_BY="Maryse Paquet" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAcQAAAXMCAYAAAC/Q/xhAACAAElEQVR42uydD2SW3///PyRJkkje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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-11-09 12:16:25 +0000" MODIFIED_BY="Maryse Paquet" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-11-08 16:11:24 +0000" MODIFIED_BY="Maryse Paquet" NO="3" REF_ID="CMP-020.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 15 Imiquimod versus placebo: different concentrations, outcome: 15.1 Participant complete clearance.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-11-08 16:11:24 +0000" MODIFIED_BY="Maryse Paquet" NO="4" REF_ID="CMP-052.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 50 MAL-PDT (red light) versus placebo-PDT (red light), outcome: 50.1 Participant complete clearance.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-08-23 16:28:29 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2012-05-31 09:40:15 +0100" MODIFIED_BY="Liz Doney">
<APPENDIX ID="APP-01" MODIFIED="2012-05-31 09:40:15 +0100" MODIFIED_BY="Liz Doney" NO="1">
<TITLE MODIFIED="2012-05-31 09:38:55 +0100" MODIFIED_BY="Finola M Delamere">CENTRAL (Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-31 09:40:15 +0100" MODIFIED_BY="Liz Doney">
<P>#1 (actinic and keratos*) or (solar and keratos*) or (senile and keratos) or (hyperkeratos*)<BR/>#2 MeSH descriptor Keratosis, Actinic explode all trees<BR/>#3 (#1 OR #2)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-03-29 11:03:58 +0100" MODIFIED_BY="Liz Doney" NO="2">
<TITLE MODIFIED="2011-03-29 10:58:59 +0100" MODIFIED_BY="Liz Doney">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-29 11:03:58 +0100" MODIFIED_BY="Liz Doney">
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. clinical trials as topic.sh.<BR/>6. randomly.ab.<BR/>7. trial.ti.<BR/>8. 1 or 2 or 3 or 4 or 5 or 6 or 7<BR/>9. (animals not (human and animals)).sh.<BR/>10. 8 not 9<BR/>11. actinic keratos$.mp. or exp Keratosis, Actinic/<BR/>12. solar keratos$.mp.<BR/>13. senile keratos$.mp.<BR/>14. hyperkeratos$.mp.<BR/>15. 11 or 12 or 13 or 14<BR/>16. 10 and 15</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-03-29 11:04:44 +0100" MODIFIED_BY="Liz Doney" NO="3">
<TITLE MODIFIED="2011-03-29 10:59:09 +0100" MODIFIED_BY="Liz Doney">EMBASE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-29 11:04:44 +0100" MODIFIED_BY="Liz Doney">
<P>1. random$.mp.<BR/>2. factorial$.mp.<BR/>3. (crossover$ or cross-over$).mp.<BR/>4. placebo$.mp. or PLACEBO/<BR/>5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>7. (assign$ or allocat$).mp.<BR/>8. volunteer$.mp. or VOLUNTEER/<BR/>9. Crossover Procedure/<BR/>10. Double Blind Procedure/<BR/>11. Randomized Controlled Trial/<BR/>12. Single Blind Procedure/<BR/>13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. actinic keratos$.mp. or exp Keratosis, Actinic/<BR/>15. solar keratos$.mp.<BR/>16. senile keratos$.mp.<BR/>17. hyperkeratos$.mp.<BR/>18. 14 or 15 or 16 or 17<BR/>19. 13 and 18</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-08-05 09:46:38 +0100" MODIFIED_BY="Finola M Delamere" NO="4">
<TITLE MODIFIED="2009-08-05 09:46:36 +0100" MODIFIED_BY="Finola M Delamere">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-05 09:46:38 +0100" MODIFIED_BY="Finola M Delamere">
<P>((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Words] and ((actinic$ or solar or senil$) and (keratos$ or queratosis)) or hyperkeratos$ or hiperqueratos$ [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-08-23 16:28:29 +0100" MODIFIED_BY="[Empty name]">

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;75 studies included in quantitative analysis i.e. meta-analyses&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;83 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;12 studies awaiting classification&lt;/p&gt;&lt;p&gt;1 ongoing study&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;150 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;469 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;469 records after duplicates and ongoing studies without results removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;1001 records identified through database searching:&lt;/p&gt;&lt;p&gt;- 311 from trials databases&lt;br&gt;- 690 from the Skin Group Specialised Register, CENTRAL,&lt;br&gt;MEDLINE/PubMed, EMBASE and LILACS&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="160"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;28 additional records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;318 records excluded (non-randomized studies, reviews, and not interventions to cure)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;55 full-text articles excluded, with reasons:&lt;/p&gt;&lt;p&gt;Did not meet review criteria for outcomes: 19&lt;/p&gt;&lt;p&gt;No numerical values, graphical data, ot not enough information: 12&lt;/p&gt;&lt;p&gt;Unacceptable or unclear randomization: 10&lt;/p&gt;&lt;p&gt;Prevention of actinic keratosis lesions: 4&lt;/p&gt;&lt;p&gt;Follow up reports of included studies: 4&lt;/p&gt;&lt;p&gt;Data not separated for actinic keratosis: 3&lt;/p&gt;&lt;p&gt;Terminated studies: 3&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16358_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="16358"><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><CITY>Toronto</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>